0000875320-15-000056.txt : 20151030 0000875320-15-000056.hdr.sgml : 20151030 20151030162350 ACCESSION NUMBER: 0000875320-15-000056 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20150930 FILED AS OF DATE: 20151030 DATE AS OF CHANGE: 20151030 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 151187797 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 10-Q 1 a2015q310-q.htm 10-Q 10-Q
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
________________________________________________________
FORM 10-Q
x
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2015
or
o
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM              TO             
Commission file number 000-19319
____________________________________________
Vertex Pharmaceuticals Incorporated
(Exact name of registrant as specified in its charter)
Massachusetts
04-3039129
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
50 Northern Avenue, Boston, Massachusetts
02210
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code (617) 341-6100
____________________________________________

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes x No o
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes x No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer x
Accelerated filer o
Non-accelerated filer o 
Smaller reporting company o
 
                                       (Do not check if a smaller reporting company)
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x
Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.
Common Stock, par value $0.01 per share
245,717,286
Class
Outstanding at October 23, 2015

 


VERTEX PHARMACEUTICALS INCORPORATED
FORM 10-Q
FOR THE QUARTER ENDED SEPTEMBER 30, 2015

TABLE OF CONTENTS
 
 
Page
 
 
 
Condensed Consolidated Statements of Operations - Three and Nine Months Ended September 30, 2015 and 2014
 
Condensed Consolidated Statements of Comprehensive Loss - Three and Nine Months Ended September 30, 2015 and 2014
 
Condensed Consolidated Balance Sheets - September 30, 2015 and December 31, 2014
 
Condensed Consolidated Statements of Shareholders' Equity and Noncontrolling Interest - Nine Months Ended September 30, 2015 and 2014
 
Condensed Consolidated Statements of Cash Flows - Nine Months Ended September 30, 2015 and 2014
 
 
 
“We,” “us,” “Vertex” and the “Company” as used in this Quarterly Report on Form 10-Q refer to Vertex Pharmaceuticals Incorporated, a Massachusetts corporation, and its subsidiaries.
“Vertex,” “KALYDECO®” and “ORKAMBI®” are registered trademarks of Vertex. Other brands, names and trademarks contained in this Quarterly Report on Form 10-Q are the property of their respective owners.



Part I. Financial Information
Item 1.    Financial Statements
VERTEX PHARMACEUTICALS INCORPORATED
Condensed Consolidated Statements of Operations
(unaudited)
(in thousands, except per share amounts)
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2015
 
2014
 
2015
 
2014
Revenues:
 
 
 
 
 
 
 
Product revenues, net
$
302,511

 
$
137,099

 
$
593,774

 
$
362,879

Royalty revenues
5,759

 
8,386

 
17,628

 
32,134

Collaborative revenues
1,546

 
33,502

 
2,999

 
40,846

Total revenues
309,816

 
178,987

 
614,401

 
435,859

Costs and expenses:
 
 
 
 
 
 
 
Cost of product revenues
30,269

 
10,208

 
55,059

 
28,435

Royalty expenses
1,691

 
3,976

 
6,068

 
18,525

Research and development expenses
246,284

 
190,939

 
685,741

 
654,043

Sales, general and administrative expenses
99,772

 
75,224

 
280,026

 
226,882

Restructuring expenses, net
1,826

 
40,843

 
682

 
46,761

Total costs and expenses
379,842

 
321,190

 
1,027,576

 
974,646

Loss from operations
(70,026
)
 
(142,203
)
 
(413,175
)
 
(538,787
)
Interest expense, net
(21,134
)
 
(20,384
)
 
(63,552
)
 
(51,686
)
Other (expenses) income, net
(1,326
)
 
(3,990
)
 
(5,025
)
 
34,192

Loss from continuing operations before provision for income taxes
(92,486
)
 
(166,577
)
 
(481,752
)
 
(556,281
)
Provision for income taxes
1,330

 
3,419

 
31,760

 
4,915

Loss from continuing operations
(93,816
)
 
(169,996
)
 
(513,512
)
 
(561,196
)
Loss from discontinued operations, net of tax benefit of $0
—

 
(64
)
 
—

 
(703
)
Net loss
(93,816
)
 
(170,060
)
 
(513,512
)
 
(561,899
)
(Income) loss attributable to noncontrolling interest
(1,333
)
 
—

 
30,909

 
—

Net loss attributable to Vertex
$
(95,149
)
 
$
(170,060
)
 
$
(482,603
)
 
$
(561,899
)
 
 
 
 
 
 
 
 
Amounts attributable to Vertex:
 
 
 
 
 
 
 
Loss from continuing operations
(95,149
)
 
(169,996
)
 
(482,603
)
 
(561,196
)
Loss from discontinued operations
—

 
(64
)
 
—

 
(703
)
Net loss attributable to Vertex
(95,149
)
 
(170,060
)
 
(482,603
)
 
(561,899
)
 
 
 
 
 
 
 
 
Amounts per share attributable to Vertex common shareholders:
 
 
 
 
 
 
 
Net loss from continuing operations:
 
 
 
 
 
 
 
Basic
$
(0.39
)
 
$
(0.72
)
 
$
(2.00
)
 
$
(2.40
)
Diluted
$
(0.39
)
 
$
(0.72
)
 
$
(2.00
)
 
$
(2.40
)
Net loss from discontinued operations:
 
 
 
 
 
 
 
Basic
$
—

 
$
—

 
$
—

 
$
—

Diluted
$
—

 
$
—

 
$
—

 
$
—

Net loss:
 
 
 
 
 
 
 
Basic
$
(0.39
)
 
$
(0.72
)
 
$
(2.00
)
 
$
(2.40
)
Diluted
$
(0.39
)
 
$
(0.72
)
 
$
(2.00
)
 
$
(2.40
)
Shares used in per share calculations:
 
 
 
 
 
 
 
Basic
241,969

 
236,137

 
240,749

 
234,207

Diluted
241,969

 
236,137

 
240,749

 
234,207

The accompanying notes are an integral part of these condensed consolidated financial statements.


2

VERTEX PHARMACEUTICALS INCORPORATED
Condensed Consolidated Statements of Comprehensive Loss
(unaudited)
(in thousands)
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2015
 
2014
 
2015
 
2014
Net loss
$
(93,816
)
 
$
(170,060
)
 
$
(513,512
)
 
$
(561,899
)
Changes in other comprehensive loss:
 
 
 
 
 
 
 
Unrealized holding gains (losses) on marketable securities
56

 
(30
)
 
186

 
25

Unrealized gains on foreign currency forward contracts
4,546

 
1,838

 
572

 
1,713

Foreign currency translation adjustment
(1,384
)
 
(624
)
 
(164
)
 
(271
)
Total changes in other comprehensive loss
3,218

 
1,184

 
594

 
1,467

Comprehensive loss
(90,598
)
 
(168,876
)
 
(512,918
)
 
(560,432
)
Comprehensive (income) loss attributable to noncontrolling interest
(1,333
)
 
—

 
30,909

 
—

Comprehensive loss attributable to Vertex
$
(91,931
)
 
$
(168,876
)
 
$
(482,009
)
 
$
(560,432
)
The accompanying notes are an integral part of these condensed consolidated financial statements.


3

VERTEX PHARMACEUTICALS INCORPORATED
Condensed Consolidated Balance Sheets
(unaudited)
(in thousands, except share and per share amounts)
 
September 30,
 
December 31,
 
2015
 
2014
Assets
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
756,250

 
$
625,259

Marketable securities, available for sale
249,580

 
761,847

Restricted cash and cash equivalents (VIE)
75,765

 
8,418

Accounts receivable, net
165,272

 
75,964

Inventories
49,197

 
30,848

Prepaid expenses and other current assets
63,388

 
44,175

Total current assets
1,359,452

 
1,546,511

Property and equipment, net
706,670

 
715,812

Intangible assets
284,340

 
29,000

Goodwill
50,384

 
39,915

Restricted cash
22,086

 
176

Other assets
11,061

 
3,265

Total assets
$
2,433,993

 
$
2,334,679

Liabilities and Shareholders’ Equity
 
 
 
Current liabilities:
 
 
 
Accounts payable
$
78,899

 
$
71,194

Accrued expenses
249,698

 
209,676

Deferred revenues, current portion
14,000

 
17,468

Accrued restructuring expenses, current portion
8,682

 
33,107

Capital lease obligations, current portion
14,153

 
17,806

Senior secured term loan, current portion
—

 
14,206

Other liabilities, current portion
9,527

 
4,797

Total current liabilities
374,959

 
368,254

Deferred revenues, excluding current portion
17,501

 
27,808

Accrued restructuring expenses, excluding current portion
9,122

 
12,748

Capital lease obligations, excluding current portion
39,273

 
39,293

Deferred tax liability
113,860

 
15,044

Fan Pier lease obligation, excluding current portion
472,724

 
473,073

Senior secured term loan, excluding current portion
294,832

 
280,569

Other liabilities, excluding current portion
34,990

 
21,707

Total liabilities
1,357,261

 
1,238,496

Commitments and contingencies


 


Shareholders’ equity:
 
 
 
Preferred stock, $0.01 par value; 1,000,000 shares authorized; none issued and outstanding at September 30, 2015 and December 31, 2014
—

 
—

Common stock, $0.01 par value; 500,000,000 and 300,000,000 shares authorized at September 30, 2015 and December 31, 2014, respectively; 245,646,269 and 241,764,398 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively
2,419

 
2,385

Additional paid-in capital
6,106,270

 
5,777,154

Accumulated other comprehensive income
1,511

 
917

Accumulated deficit
(5,188,053
)
 
(4,705,450
)
Total Vertex shareholders' equity
922,147

 
1,075,006

Noncontrolling interest
154,585

 
21,177

Total shareholders’ equity
1,076,732

 
1,096,183

Total liabilities and shareholders’ equity
$
2,433,993

 
$
2,334,679

The accompanying notes are an integral part of these condensed consolidated financial statements.


4

VERTEX PHARMACEUTICALS INCORPORATED
Condensed Consolidated Statements of Shareholders’ Equity and Noncontrolling Interest
(unaudited)
(in thousands)
 
Common Stock
 
Additional
Paid-in Capital
 
Accumulated
Other
Comprehensive Income (Loss)
 
Accumulated Deficit
 
Total Vertex
Shareholders’ Equity
 
Noncontrolling
Interest
 
Total
Shareholders’ Equity
 
Shares
 
Amount
 
 
 
 
 
 
Balance at December 31, 2013
233,789

 
$
2,320

 
$
5,321,286

 
$
(306
)
 
$
(3,966,895
)
 
$
1,356,405

 
$
—

 
$
1,356,405

Other comprehensive income, net of tax
—

 
—

 
—

 
1,467

 
—

 
1,467

 
—

 
1,467

Net loss
—

 
—

 
—

 
—

 
(561,899
)
 
(561,899
)
 
—

 
(561,899
)
Issuance of common stock under benefit plans
6,449

 
55

 
223,812

 
—

 
—

 
223,867

 
—

 
223,867

Stock-based compensation
—

 
—

 
136,065

 
—

 
—

 
136,065

 
—

 
136,065

Balance at September 30, 2014
240,238

 
$
2,375

 
$
5,681,163

 
$
1,161

 
$
(4,528,794
)
 
$
1,155,905

 
$
—

 
$
1,155,905

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Balance at December 31, 2014
241,764

 
$
2,385

 
$
5,777,154

 
$
917

 
$
(4,705,450
)
 
$
1,075,006

 
$
21,177

 
$
1,096,183

Other comprehensive loss, net of tax
—

 
—

 
—

 
594

 
—

 
594

 
—

 
594

Net loss
—

 
—

 
—

 
—

 
(482,603
)
 
(482,603
)
 
(30,909
)
 
(513,512
)
Issuance of common stock under benefit plans
3,882

 
34

 
139,419

 
—

 
—

 
139,453

 
—

 
139,453

Stock-based compensation
—

 
—

 
189,697

 
—

 
—

 
189,697

 
—

 
189,697

Noncontrolling interest upon consolidation
—

 
—

 
—

 
—

 
—

 
—

 
164,317

 
164,317

Balance at September 30, 2015
245,646

 
$
2,419

 
$
6,106,270

 
$
1,511

 
$
(5,188,053
)
 
$
922,147

 
$
154,585

 
$
1,076,732

The accompanying notes are an integral part of these condensed consolidated financial statements.


5

VERTEX PHARMACEUTICALS INCORPORATED
Condensed Consolidated Statements of Cash Flows
(unaudited)
(in thousands)
 
Nine Months Ended September 30,
 
2015
 
2014
Cash flows from operating activities:
 
 
 
Net loss
$
(513,512
)
 
$
(561,899
)
Adjustments to reconcile net loss to net cash used in operating activities:
 
 
 
Depreciation and amortization expense
46,596

 
46,921

Stock-based compensation expense
186,379

 
135,160

Deferred income taxes
7,793

 
—

Impairment of property and equipment
23

 
978

Other non-cash items, net
(2,899
)
 
7

Changes in operating assets and liabilities:
 
 
 
Accounts receivable, net
(88,735
)
 
(7,315
)
Inventories
(16,127
)
 
(4,901
)
Prepaid expenses and other assets
(23,737
)
 
(19,110
)
Accounts payable
6,283

 
(5,544
)
Accrued expenses and other liabilities
90,320

 
12,210

Accrued restructuring expense
(28,051
)
 
27,249

Deferred revenues
(13,751
)
 
(15,085
)
Net cash used in operating activities
(349,418
)
 
(391,329
)
Cash flows from investing activities:
 
 
 
Purchases of marketable securities
(292,135
)
 
(1,066,772
)
Maturities of marketable securities
804,588

 
1,203,400

Payment for acquisition of variable interest entity
(80,000
)
 
—

Expenditures for property and equipment
(32,775
)
 
(36,525
)
(Increase) decrease in restricted cash and cash equivalents
(21,980
)
 
9

Decrease in restricted cash and cash equivalents (VIE)
14,830

 
—

Decrease (increase) in other assets
(982
)
 
(92
)
Net cash provided by investing activities
391,546

 
100,020

Cash flows from financing activities:
 
 
 
Issuances of common stock under benefit plans
139,689

 
201,274

Payments on capital lease obligations
(16,515
)
 
(17,215
)
Proceeds from capital lease financing
13,386

 
—

Payments on Fan Pier lease obligation
(45,438
)
 
(45,438
)
Proceeds from senior secured term loan
—

 
294,383

Payments returned related to Fan Pier lease obligation
—

 
8,050

Net cash provided by financing activities
91,122

 
441,054

Effect of changes in exchange rates on cash
(2,259
)
 
(481
)
Net increase in cash and cash equivalents
130,991

 
149,264

Cash and cash equivalents—beginning of period
625,259

 
569,299

Cash and cash equivalents—end of period
$
756,250

 
$
718,563

 
 
 
 
Supplemental disclosure of cash flow information:
 
 
 
Cash paid for interest
$
19,074

 
$
2,817

Cash paid for income taxes
$
1,261

 
$
798

Capitalization of costs related to Fan Pier lease obligation
$
—

 
$
25,564

Assets acquired under capital lease
$
—

 
$
8,985

Issuances of common stock exercises from employee benefit plans receivable
$
(236
)
 
$
23,035

The accompanying notes are an integral part of these condensed consolidated financial statements.

6
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)


A. Basis of Presentation and Accounting Policies
Basis of Presentation
The accompanying condensed consolidated financial statements are unaudited and have been prepared by Vertex Pharmaceuticals Incorporated ("Vertex" or the "Company") in accordance with accounting principles generally accepted in the United States of America ("GAAP").
The condensed consolidated financial statements reflect the operations of (i) the Company, (ii) its wholly-owned subsidiaries and (iii) consolidated variable interest entities (VIEs). All material intercompany balances and transactions have been eliminated. The Company operates in one segment, pharmaceuticals.

Certain information and footnote disclosures normally included in the Company's annual financial statements have been condensed or omitted. These interim financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the financial position and results of operations for the interim periods ended September 30, 2015 and 2014.
The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full fiscal year. These interim financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2014, which are contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2014 that was filed with the Securities and Exchange Commission (the “SEC”) on February 13, 2015 (the "2014 Annual Report on Form 10-K").
Use of Estimates and Summary of Significant Accounting Policies
The preparation of condensed consolidated financial statements in accordance with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the amounts of revenues and expenses during the reported periods. Significant estimates in these condensed consolidated financial statements have been made in connection with the calculation of revenues, inventories, research and development expenses, stock-based compensation expense, restructuring expense, the fair value of intangible assets, goodwill, noncontrolling interest, the consolidation of VIEs, leases, the fair value of cash flow hedges and the provision for or benefit from income taxes. The Company bases its estimates on historical experience and various other assumptions, including in certain circumstances future projections that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.
The Company's significant accounting policies are described in Note A, "Nature of Business and Accounting Policies," in the 2014 Annual Report on Form 10-K.
Recent Accounting Pronouncements
For a discussion of recent accounting pronouncements please refer to Note A, “Nature of Business and Accounting Policies—Recent Accounting Pronouncements,” in the 2014 Annual Report on Form 10-K. The Company did not adopt any new accounting pronouncements during the nine months ended September 30, 2015 that had a material effect on its condensed consolidated financial statements.
B.
Product Revenues, Net
The Company sells its products principally to a limited number of specialty pharmacy providers and selected regional wholesalers in North America as well as government-owned and supported customers in international markets (collectively, its “Customers”). The Company's Customers in North America subsequently resell the products to patients and health care providers. The Company recognizes net revenues from product sales upon delivery to the Customer as long as (i) there is persuasive evidence that an arrangement exists between the Company and the Customer, (ii) collectibility is reasonably assured and (iii) the price is fixed or determinable.


7
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

In order to conclude that the price is fixed or determinable, the Company must be able to (i) calculate its gross product revenues from sales to Customers and (ii) reasonably estimate its net product revenues upon delivery to its Customer's locations. The Company calculates gross product revenues based on the price that the Company charges its Customers. The Company estimates its net product revenues by deducting from its gross product revenues (a) trade allowances, such as invoice discounts for prompt payment and Customer fees, (b) estimated government and private payor rebates, chargebacks and discounts, (c) estimated reserves for expected product returns and (d) estimated cost of co-pay assistance programs for patients, as well as other incentives for certain indirect customers. The Company makes significant estimates and judgments that materially affect the Company's recognition of net product revenues. In certain instances, the Company may be unable to reasonably conclude that the price is fixed or determinable at the time of delivery, in which case it defers the recognition of revenues. Once the Company is able to determine that the price is fixed or determinable, it recognizes the revenues associated with the units in which revenue recognition was deferred.
The following table summarizes activity in each of the product revenue allowance and reserve categories for the nine months ended September 30, 2015:
 
Trade
Allowances
 
Rebates,
Chargebacks
and Discounts
 
Product
Returns
 
Other
Incentives
 
Total
 
(in thousands)
Balance at December 31, 2014
$
1,463

 
$
29,102

 
$
4,713

 
$
745

 
$
36,023

Provision related to current period sales
6,120

 
39,533

 
429

 
2,402

 
48,484

Adjustments related to prior period sales
(143
)
 
(12,342
)
 
(993
)
 
(235
)
 
(13,713
)
Credits/payments made
(5,115
)
 
(22,465
)
 
(3,254
)
 
(1,652
)
 
(32,486
)
Balance at September 30, 2015
$
2,325

 
$
33,828

 
$
895

 
$
1,260

 
$
38,308

C.
Collaborative Arrangements
Cystic Fibrosis Foundation Therapeutics Incorporated
In April 2011, the Company entered into an amendment (the “April 2011 Amendment”) to its existing collaboration agreement with Cystic Fibrosis Foundation Therapeutics Incorporated (“CFFT”) pursuant to which CFFT agreed to provide financial support for (i) development activities for VX-661, a compound that targets the processing and trafficking defect of the F508del CFTR proteins discovered under the collaboration, and (ii) additional research and development activities directed at discovering new compounds targeting the processing and trafficking defect of the F508del protein.
Under the April 2011 Amendment, CFFT agreed to provide the Company with up to $75.0 million in funding over approximately five years for research and development activities. The Company retains the right to develop and commercialize KALYDECO (ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor), lumacaftor, VX-661 and any other compounds discovered during the course of the research collaboration with CFFT. The Company recognized no collaborative revenues from this collaboration during the three and nine months ended September 30, 2015 and $2.0 million and $6.5 million of collaborative revenues from this collaboration during the three and nine months ended September 30, 2014, respectively.
In the original agreement, as amended prior to the April 2011 Amendment, the Company agreed to pay CFFT tiered royalties calculated as a percentage, ranging from single digits to sub-teens, of annual net sales of any approved drugs discovered during the research term that ended in 2008, including KALYDECO, ORKAMBI, lumacaftor and VX-661. The April 2011 Amendment provides for a tiered royalty in the same range on net sales of compounds targeting the processing and trafficking defect of F508del CFTR proteins discovered during the research term that began in 2011 and ended in February 2014. In each of the third quarter of 2012 and the first quarter of 2013, CFFT earned a commercial milestone payment of $9.3 million from the Company upon achievement of certain sales levels for KALYDECO. These milestones were reflected in the Company's cost of product revenues. There are no additional commercial milestone payments payable by the Company to CFFT related to sales levels for KALYDECO. The Company also is obligated to make up to two one-time commercial milestone payments to CFFT upon achievement of certain sales levels for ORKAMBI.


8
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

The Company began marketing KALYDECO in the United States and certain countries in the European Union in 2012 and began marketing ORKAMBI in the United States in July 2015. The Company has royalty obligations to CFFT for each compound commercialized pursuant to this collaboration until the expiration of patents covering that compound. The Company has patents in the United States and European Union covering the composition-of-matter of ivacaftor that expire in 2027 and 2025, respectively, subject to potential patent life extensions. The Company has patents in the United States and European Union covering the composition-of-matter of lumacaftor that expire in 2030 and 2026, respectively, subject to potential patent life extensions. CFFT may terminate its funding obligations under the collaboration, as amended, in certain circumstances, in which case there will be a proportional adjustment to the royalty rates and commercial milestone payments for certain compounds. The collaboration also may be terminated by either party for a material breach by the other, subject to notice and cure provisions.
Janssen Pharmaceutica NV
The Company has a collaboration agreement (the “Janssen HCV Agreement”) with Janssen Pharmaceutica NV (“Janssen NV”) for the development, manufacture and commercialization of telaprevir, which Janssen NV began marketing under the brand name INCIVO in certain of its territories in September 2011. Pursuant to the Janssen HCV Agreement, as amended, Janssen NV has a fully-paid license to manufacture and commercialize INCIVO in its territories including Europe, South America, the Middle East, Africa and Australia, subject to the payment of third-party royalties on net sales of INCIVO. In addition to the collaborative revenues, the Company recorded royalty revenues and corresponding royalty expenses related to third-party royalties that Janssen NV remains responsible for based on INCIVO net sales.
During the three and nine months ended September 30, 2015 and 2014, the Company recognized the following revenues attributable to the Janssen NV collaboration:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2015
 
2014
 
2015
 
2014
 
(in thousands)
Royalty revenues (INCIVO)
$
158

 
$
2,284

 
$
1,742

 
$
12,917

Collaborative revenues (telaprevir)
441

 
1,390

 
1,620

 
4,262

  Total revenues attributable to the Janssen NV collaboration
$
599

 
$
3,674

 
$
3,362

 
$
17,179

CRISPR Therapeutics AG
On October 26, 2015, the Company entered into a strategic collaboration, option and license agreement (the "CRISPR Agreement") with CRISPR Therapeutics AG and its affiliates ("CRISPR") to collaborate on the discovery and development of potential new treatments aimed at the underlying genetic causes of human diseases using CRISPR-Cas9 gene editing technology. The Company has the exclusive right to license up to six CRISPR-Cas9-based targets. In connection with the CRISPR Agreement, the Company made an upfront payment to CRISPR of $75.0 million and will make a $30.0 million investment in CRISPR pursuant to a convertible loan agreement.
The Company will fund all of the discovery activities conducted pursuant to the CRISPR Agreement. For potential hemoglobinapathy treatments, including treatments for sickle cell disease, the Company and CRISPR will share equally all research and development costs and worldwide revenues. For other targets that the Company elects to license, the Company would lead all development and global commercialization activities. For each of up to six targets that the Company elects to license, other than hemoglobinapathy targets, CRISPR has the potential to receive up to $420.0 million in development, regulatory and commercial milestones and royalties on net sales.
The Company may terminate the CRISPR Agreement upon 90 days’ notice to CRISPR prior to any product receiving marketing approval or upon 270 days’ notice after such point. The CRISPR Agreement also may be terminated by either party for a material breach by the other, subject to notice and cure provisions. Unless earlier terminated, the CRISPR Agreement will continue in effect until the expiration of the Company's payment obligations under the CRISPR Agreement.


9
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

Variable Interest Entities
The Company has entered into several agreements pursuant to which it has licensed rights to certain drug candidates from third-party collaborators, which has resulted in the consolidation of the third parties' financial statements into the Company's condensed consolidated financial statements as VIEs. In order to account for the fair value of the contingent milestone and royalty payments related to these collaborations under GAAP, the Company uses present-value models based on assumptions regarding the probability of achieving the relevant milestones, estimates regarding the time to develop the drug candidates, estimates of future product sales and the appropriate discount rates. The Company bases its estimate of the probability of achieving the relevant milestones on industry data for similar assets and its own experience. The discount rates used in the valuation model represent a measure of credit risk and market risk associated with settling the liabilities. Significant judgment is used in determining the appropriateness of these assumptions at each reporting period. Changes in these assumptions could have a material effect on the fair value of the contingent milestone and royalty payments. The following collaborations are, or were previously, reflected in the Company's financial statements for being consolidated as VIEs:
Parion Sciences, Inc.
License and Collaboration Agreement

On June 4, 2015, the Company entered into a strategic collaboration and license agreement (the "Parion Agreement") with Parion Sciences, Inc. (“Parion”).  Pursuant to the agreement, the Company is collaborating with Parion to develop investigational epithelial sodium channel (“ENaC”) inhibitors, including VX-371 (formerly P-1037) and P-1055, for the potential treatment of cystic fibrosis, or CF, and other pulmonary diseases.  The Company is leading development activities for VX-371 and P-1055 in CF and other pulmonary diseases and is responsible for all costs, subject to certain exceptions, related to development and commercialization of the compounds.

Pursuant to the Parion Agreement, the Company has worldwide development and commercial rights to Parion’s lead investigational ENaC inhibitors, VX-371 and P-1055, for the potential treatment of CF and all other pulmonary diseases and has the option to select additional compounds discovered in Parion’s research program.  Parion received an $80.0 million up-front payment and has the potential to receive up to an additional (i) $490.0 million in development and regulatory milestone payments for development of ENaC inhibitors in CF, including $360.0 million related to global filing and approval milestones, (ii) $370.0 million in development and regulatory milestones for VX-371 and P-1055 in non-CF pulmonary indications and (iii) $230.0 million in development and regulatory milestones should the Company elect to develop an additional ENaC inhibitor from Parion’s research program. The Company has agreed to pay Parion tiered royalties that range from the low double digits to mid-teens as a percentage of potential sales of licensed products.

The Company may terminate the Parion Agreement upon 90 days’ notice to Parion prior to any licensed product receiving marketing approval or upon 180 days’ notice after such point. If the Company experiences a change of control prior to the initiation of the first Phase 3 clinical trial for a licensed product, Parion may terminate the Parion Agreement upon 30 days’ notice, subject to the Company's right to receive specified royalties on any subsequent commercialization of licensed products. The Parion Agreement also may be terminated by either party for a material breach by the other, subject to notice and cure provisions. Unless earlier terminated, the agreement will continue in effect until the expiration of the Company's royalty obligations, which expire on a country-by-country basis on the later of (i) the date the last-to-expire patent covering a licensed product expires or (ii) ten years after the first commercial sale in the country.

The Company determined that Parion is a VIE based on, among other factors, the significance to Parion of the ENaC inhibitors licensed to the Company pursuant to the Parion Agreement and on the Company's power to direct the activities that most significantly impact the economic performance of Parion.  Accordingly, the Company consolidated Parion's financial statements beginning on June 4, 2015. However, the Company's interests in Parion are limited to those accorded to the Company in the Parion Agreement. In particular, the Company did not acquire any equity interest in Parion, any interest in Parion's cash and cash equivalents or any control over Parion's activities that do not relate to the Parion Agreement.


10
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

Consideration for the Parion Agreement

The Company determined that the fair value of the consideration from the Company to Parion was $255.3 million as of June 4, 2015, which consisted of (i) an $80.0 million up-front payment, (ii) the estimated fair value of the contingent research and development milestones potentially payable by the Company to Parion and (iii) the estimated fair value of potential royalty payments payable by the Company to Parion. The Company valued the contingent milestone and royalty payments using (a) discount rates ranging from 4.1% to 5.9% for the development milestones and (b) a discount rate of 6.6% for royalties. The consideration paid and the preliminary fair value of the contingent milestone and royalty payments payable by the Company pursuant to the agreement are set forth in the table below:
 
June 4, 2015
 
(in thousands)
Up-front payment
$
80,000

Fair value of contingent milestone and royalty payments
175,340

Total
$
255,340

Preliminary Allocation of Assets and Liabilities

For the purposes of the condensed consolidated balance sheets at June 4, 2015 and September 30, 2015, the Company preliminarily allocated the total consideration, which is comprised of the up-front payment and the fair value of the contingent milestone and royalty payments, intangible assets, goodwill, deferred tax liability, net and net other assets and liabilities.

The Company recorded $255.3 million of intangible assets on the Company's condensed consolidated balance sheet for Parion's in-process research and development assets. These in-process research and development assets relate to Parion's pulmonary ENaC platform, including the intellectual property related to VX-371 and P-1055, that are licensed by Parion to the Company. The difference between the preliminary fair value of the consideration and the fair value of Parion's assets (including the fair value of intangible assets) and liabilities was allocated to goodwill.

The following table summarizes the preliminary fair values of the assets and liabilities recorded on the effective date of the agreement:
 
June 4, 2015
 
(in thousands)
Intangible assets
$
255,340

Goodwill
10,468

Deferred tax liability
(91,023
)
Net other assets (liabilities)
(10,468
)
Net assets attributable to noncontrolling interests
$
164,317

BioAxone Biosciences, Inc.
In October 2014, the Company entered into a license and collaboration agreement (the “BioAxone Agreement”) with BioAxone Biosciences, Inc. (“BioAxone”), a privately-held biotechnology company, which resulted in the consolidation of BioAxone as a VIE beginning on October 1, 2014. The Company paid BioAxone initial payments of $10.0 million in the fourth quarter of 2014.
BioAxone has the potential to receive up to $90.0 million in milestones and fees, including development, regulatory and milestone payments and a license continuation fee. In addition, BioAxone would receive royalties and commercial milestones on future net product sales of VX-210, if any. The Company holds an option to purchase BioAxone at a predetermined price. The option expires on the earliest of (a) the day the FDA accepts the Biologics License Application submission for VX-210, (b) the day the Company elects to continue the license instead of exercising the option to purchase BioAxone and (c) March 15, 2018, subject to the Company’s option to extend this date by one year.


11
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

Alios BioPharma, Inc.
In 2011, the Company entered into a license and collaboration agreement (the “Alios Agreement”) with Alios BioPharma, Inc. (“Alios”), which was a privately-held biotechnology company, which resulted in the consolidation of Alios as a VIE through December 31, 2013. Pursuant to the Alios Agreement, the Company and Alios collaborated on the research, development and commercialization of HCV nucleotide analogues discovered by Alios through April 2014. In December 2014, the Alios Agreement terminated in accordance with its terms pursuant to a termination notice delivered by the Company in October 2014. As of September 30, 2014, the Company concluded that it no longer had significant continuing involvement with Alios due to its intent and ability to terminate the Alios Agreement, among other factors; therefore, the operations of Alios are presented as discontinued operations in these condensed consolidated financial statements.
Aggregate VIE Financial Information

The Company did not have any consolidated VIEs for the three and nine months ended September 30, 2014. An aggregate summary of net loss attributable to noncontrolling interest related to the Company's VIEs for the three and nine months ended September 30, 2015 is as follows:
 
Three Months Ended September 30, 2015
 
Nine Months Ended September 30, 2015
 
(in thousands)
Loss attributable to noncontrolling interest before provision for income taxes
$
(1,743
)
 
$
(3,322
)
Provision for income taxes
(777
)
 
(30,367
)
Increase in fair value of contingent milestone and royalty payments
3,853

 
2,780

Net (income) loss attributable to noncontrolling interest
$
1,333

 
$
(30,909
)

During the three and nine months ended September 30, 2015, the fair value of the contingent milestone and royalty payments related to the BioAxone collaboration decreased by $0.6 million and $0.1 million, respectively. During the three and nine months ended September 30, 2015, the fair value of the contingent milestone and royalty payments related to the Parion collaboration increased by $4.5 million and $2.9 million, respectively. The changes in the fair value of the contingent milestone and royalty payments were primarily due to the changes in market interest rates and the time value of money. As of September 30, 2015, the fair value of the contingent milestone and royalty payments related to the BioAxone collaboration and the Parion collaboration was $27.0 million and $178.2 million, respectively.

The following table summarizes items related to the Company's VIEs included in the Company's condensed consolidated balance sheets as of the dates set forth in the table:
 
September 30, 2015
 
December 31, 2014
 
(in thousands)
Restricted cash and cash equivalents (VIE)
$
75,765

 
$
8,418

Prepaid expenses and other current assets
3,057

 
268

Intangible assets
284,340

 
29,000

Goodwill
19,391

 
8,923

Other assets
461

 
42

Accounts payable
1,115

 
189

Accrued expenses and other current liabilities
32,519

 
3,891

Deferred tax liability, net
110,360

 
11,544

Other liabilities
300

 
300

Noncontrolling interest
154,585

 
21,177


The Company has recorded the VIEs' cash and cash equivalents as restricted cash and cash equivalents (VIE) because (i) the Company does not have any interest in or control over the VIEs' cash and cash equivalents and (ii) the Company's agreements with each VIE do not provide for the VIEs' cash and cash equivalents to be used for the development of the assets


12
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

that the Company licensed from the applicable VIE. Assets recorded as a result of consolidating our VIEs' financial condition into the Company's balance sheet do not represent additional assets that could be used to satisfy claims against the Company's general assets.
Outlicense Arrangements
In the ordinary course of the Company's business, the Company has entered into various agreements pursuant to which it has outlicensed rights to certain drug candidates to third-party collaborators. Although the Company does not consider any of these outlicense arrangements to be material, the most notable of these outlicense arrangements is described below. Pursuant to these outlicense arrangements, our collaborators are responsible for all costs related to the continued development of such drug candidates. Depending on the terms of the arrangements, the Company's collaborators may be required to make upfront payments, milestone payments upon the achievement of certain product research and development objectives and/or pay royalties on future sales, if any, of commercial products resulting from the collaboration.

Janssen Pharmaceuticals, Inc.
In June 2014, the Company entered into an agreement (the “Janssen Influenza Agreement”) with Janssen Pharmaceuticals, Inc. (“Janssen Inc.”), which was amended in October 2014 to clarify certain roles and responsibilities of the parties.

Pursuant to the Janssen Influenza Agreement, Janssen Inc. has an exclusive worldwide license to develop and commercialize certain drug candidates for the treatment of influenza, including VX-787. The Company received non-refundable payments of $35.0 million from Janssen Inc. in 2014, which were recorded as collaborative revenue. The Company has the potential to receive development, regulatory and commercial milestone payments as well as royalties on future product sales, if any.
Janssen Inc. is responsible for costs related to the development and commercialization of the compounds. During the three and nine months ended September 30, 2015, the Company recorded reimbursement for these development activities of $4.0 million and $18.7 million, respectively. During the three and nine months ended September 30, 2014, the Company recorded reimbursement for these development activities of $4.3 million. The reimbursements are recorded as a reduction to development expense in the Company's condensed consolidated statements of operations primarily due to the fact that Janssen Inc. directs the activities and selects the suppliers associated with these activities. Janssen Inc. may terminate the Janssen Influenza Agreement, subject to certain exceptions, upon six months' notice.
D.
Earnings Per Share
Basic net loss per share attributable to Vertex common shareholders is based upon the weighted-average number of common shares outstanding during the period, excluding restricted stock and restricted stock units that have been issued but are not yet vested. Diluted net loss per share attributable to Vertex common shareholders is based upon the weighted-average number of common shares outstanding during the period plus additional weighted-average common equivalent shares outstanding during the period when the effect is dilutive.
The Company did not include the securities described in the following table in the computation of the net loss from continuing operations per share attributable to Vertex common shareholder calculations because the effect would have been anti-dilutive during each period:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2015
 
2014
 
2015
 
2014
 
(in thousands)
Stock options
12,025

 
13,097

 
12,025

 
13,097

Unvested restricted stock and restricted stock units
3,367

 
2,672

 
3,367

 
2,672

E.
Fair Value Measurements
The fair value of the Company’s financial assets and liabilities reflects the Company’s estimate of amounts that it would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from sources independent from the Company) and to minimize the use of unobservable inputs (the Company’s assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:
Level 1:
Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.
Level 2:
Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.
Level 3:
Unobservable inputs based on the Company’s assessment of the assumptions that market participants would use in pricing the asset or liability.
The Company’s investment strategy is focused on capital preservation. The Company invests in instruments that meet the credit quality standards outlined in the Company’s investment policy. This policy also limits the amount of credit exposure to any one issue or type of instrument. As of September 30, 2015, the Company’s investments were in money market funds, corporate debt securities and commercial paper.
As of September 30, 2015, all of the Company’s financial assets that were subject to fair value measurements were valued using observable inputs. The Company’s financial assets valued based on Level 1 inputs consisted of money market funds. The Company’s financial assets valued based on Level 2 inputs consisted of corporate debt securities and commercial paper, which consist of investments in highly-rated investment-grade corporations.


13
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

The following table sets forth the Company’s financial assets and liabilities subject to fair value measurements:
 
Fair Value Measurements as of September 30, 2015
 
 
 
Fair Value Hierarchy
 
Total
 
Level 1
 
Level 2
 
Level 3
 
(in thousands)
Financial assets carried at fair value:
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Money market funds
$
340,573

 
$
340,573

 
$
—

 
$
—

Corporate debt securities
25,109

 
—

 
25,109

 
—

Commercial paper
24,000

 
—

 
24,000

 
—

Marketable securities:
 
 
 
 
 
 
 
Corporate debt securities
109,335

 
—

 
109,335

 
—

Commercial paper
140,245

 
—

 
140,245

 
—

Prepaid and other current assets:
 
 
 
 
 
 
 
Foreign currency forward contracts
3,508

 
—

 
3,508

 
—

Other assets:
 
 
 
 
 
 
 
Foreign currency forward contracts
651

 
—

 
651

 
—

Total financial assets
$
643,421


$
340,573

 
$
302,848

 
$
—

Financial liabilities carried at fair value:
 
 
 
 
 
 
 
Other liabilities, current portion:
 
 
 
 
 
 
 
Foreign currency forward contracts
$
(1,552
)
 
$
—

 
$
(1,552
)
 
$
—

Other liabilities, excluding current portion:
 
 
 
 
 
 
 
Foreign currency forward contracts
(24
)
 
—

 
(24
)
 
—

Total financial liabilities
$
(1,576
)
 
$
—

 
$
(1,576
)
 
$
—

The Company's VIEs invested in cash equivalents consisting of money market funds of $75.4 million as of September 30, 2015, which are valued based on Level 1 inputs. These cash equivalents are not included in the table above. The Company’s noncontrolling interest related to VIEs includes the fair value of the contingent milestone and royalty payments, which are valued based on Level 3 inputs. Please refer to Note C, “Collaborative Arrangements,” for further information.
As of September 30, 2015, the fair value and carrying value of the Company's Term Loan was $294.8 million. The fair value of the Company's Term Loan was estimated based on Level 3 inputs computed using the effective interest rate of the Term Loan. The effective interest rate considers the timing and amount of estimated future interest payments as well as current markets rates. Please refer to Note K, "Long-term Obligations" for further information regarding the Company's Term Loan.


14
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

F.
Marketable Securities
A summary of the Company’s cash, cash equivalents and marketable securities is shown below:
 
Amortized Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Fair Value
 
(in thousands)
As of September 30, 2015
 
 
 
 
 
 
 
Cash and cash equivalents:
 
 
 
 
 
 
 
Cash and money market funds
$
707,141

 
$
—

 
$
—

 
$
707,141

Commercial paper
$
25,109

 
$
—

 
$
—

 
$
25,109

Corporate debt securities
$
24,000

 
$
—

 
$
—

 
$
24,000

Total cash and cash equivalents
$
756,250

 
$
—

 
$
—

 
$
756,250

Marketable securities:
 
 
 
 
 
 
 
Commercial paper (due within 1 year)
$
140,131

 
$
114

 
$
—

 
$
140,245

Corporate debt securities (due within 1 year)
109,386

 
28

 
(79
)
 
109,335

Total marketable securities
$
249,517

 
$
142

 
$
(79
)
 
$
249,580

Total cash, cash equivalents and marketable securities
$
1,005,767

 
$
142

 
$
(79
)
 
$
1,005,830

 
 
 
 
 
 
 
 
As of December 31, 2014
 
 
 
 
 
 
 
Cash and cash equivalents:
 
 
 
 
 
 
 
Cash and money market funds
$
625,259

 
$
—

 
$
—

 
$
625,259

Total cash and cash equivalents
$
625,259

 
$
—

 
$
—

 
$
625,259

Marketable securities:
 
 
 
 
 
 
 
Government-sponsored enterprise securities (due within 1 year)
$
463,788

 
$
14

 
$
(52
)
 
$
463,750

Commercial paper (due within 1 year)
51,674

 
72

 
—

 
51,746

Corporate debt securities (due within 1 year)
196,065

 
2

 
(66
)
 
196,001

Corporate debt securities (due after 1 year through 5 years)
50,443

 
—

 
(93
)
 
50,350

Total marketable securities
$
761,970

 
$
88

 
$
(211
)
 
$
761,847

Total cash, cash equivalents and marketable securities
$
1,387,229

 
$
88

 
$
(211
)
 
$
1,387,106

The Company has a limited number of marketable securities in insignificant loss positions as of September 30, 2015, which the Company does not intend to sell and has concluded it will not be required to sell before recovery of the amortized costs for the investment at maturity. There were no charges recorded for other-than-temporary declines in fair value of marketable securities nor gross realized gains or losses recognized in the three and nine months ended September 30, 2015 and 2014.


15
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

G.
Accumulated Other Comprehensive (Loss) Income
A summary of the Company's changes in accumulated other comprehensive (loss) income by component is shown below:
 
Foreign Currency Translation Adjustment
 
Unrealized Holding Gains (Losses) on Marketable Securities
 
Unrealized Gains (Losses) on Foreign Currency Forward Contracts
 
Total
 
(in thousands)
Balance at December 31, 2014
$
(971
)
 
$
(123
)
 
$
2,011

 
$
917

Other comprehensive (loss) income before reclassifications
(164
)
 
186

 
4,072

 
4,094

Amounts reclassified from accumulated other comprehensive loss
—

 
—

 
(3,500
)
 
(3,500
)
Net current period other comprehensive (loss) income
$
(164
)
 
$
186

 
$
572

 
$
594

Balance at September 30, 2015
$
(1,135
)
 
$
63

 
$
2,583

 
$
1,511

 
Foreign Currency Translation Adjustment
 
Unrealized Holding Gains on Marketable Securities
 
Unrealized (Losses) Gains on Foreign Currency Forward Contracts
 
Total
 
(in thousands)
Balance at December 31, 2013
$
(325
)
 
$
42

 
$
(23
)
 
$
(306
)
Other comprehensive (loss) income before reclassifications
(271
)
 
25

 
2,140

 
1,894

Amounts reclassified from accumulated other comprehensive loss
—

 
—

 
(427
)
 
(427
)
Net current period other comprehensive (loss) income
$
(271
)
 
$
25

 
$
1,713

 
$
1,467

Balance at September 30, 2014
$
(596
)
 
$
67

 
$
1,690

 
$
1,161

H.
Hedging
The Company maintains a hedging program intended to mitigate the effect of changes in foreign exchange rates for a portion of the Company’s forecasted product revenues denominated in certain foreign currencies. The program includes foreign currency forward contracts that are designated as cash flow hedges under GAAP having contractual durations from one to eighteen months. To date, the existence of operational sites in countries outside the United States has limited the degree to which the Company has sought to hedge its revenues in certain foreign currencies.
The Company formally documents the relationship between foreign currency forward contracts (hedging instruments) and forecasted product revenues (hedged items), as well as the Company's risk management objective and strategy for undertaking various hedging activities, which includes matching all foreign currency forward contracts that are designated as cash flow hedges to forecasted transactions. The Company also formally assesses, both at the hedge’s inception and on an ongoing basis, whether the foreign currency forward contracts are highly effective in offsetting changes in cash flows of hedged items on a prospective and retrospective basis. If the Company determines that a (i) foreign currency forward contract is not highly effective as a cash flow hedge, (ii) foreign currency forward contract has ceased to be a highly effective hedge or (iii) forecasted transaction is no longer probable of occurring, the Company would discontinue hedge accounting treatment prospectively. The Company measures effectiveness based on the change in fair value of the forward contracts and the fair value of the hypothetical foreign currency forward contracts with terms that match the critical terms of the risk being hedged. As of September 30, 2015, all hedges were determined to be highly effective and the Company has not recorded any ineffectiveness related to the hedging program.
The following table summarizes the notional amount of the Company’s outstanding foreign currency forward contracts designated as cash flow hedges:
 
As of September 30, 2015
 
As of December 31, 2014
Foreign Currency
(in thousands)
Euro
$
106,620

 
$
20,209

British pound sterling
78,861

 
13,515

Australian dollar
25,414

 
—

Total foreign currency forward contracts
$
210,895

 
$
33,724

The following table summarizes the fair value of the Company's outstanding foreign currency forward contracts designated as cash flow hedges under GAAP included on the Company's condensed consolidated balance sheets:
As of September 30, 2015
Assets
 
Liabilities
Classification
 
Fair Value
 
Classification
 
Fair Value
(in thousands)
Prepaid and other current assets
 
$
3,508

 
Other liabilities, current portion
 
$
(1,552
)
Other assets
 
651

 
Other liabilities, excluding current portion
 
(24
)
Total assets
 
$
4,159

 
Total liabilities
 
$
(1,576
)
As of December 31, 2014
Assets
 
Liabilities
Classification
 
Fair Value
 
Classification
 
Fair Value
(in thousands)
Prepaid and other current assets
 
$
2,011

 
Other liabilities, current portion
 
$
—

Total assets
 
$
2,011

 
Total liabilities
 
$
—

The following table summarizes the potential effect of offsetting derivatives by type of financial instrument on the Company's condensed consolidated balance sheets:


16
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

 
As of September 30, 2015
 
Gross Amounts Recognized
 
Gross Amounts Offset
 
Gross Amount Presented
 
Gross Amount Not Offset
 
Legal Offset
Foreign currency forward contracts
(in thousands)
Total assets
$
4,159

 
$
—

 
$
4,159

 
$
(1,576
)
 
$
2,583

Total liabilities
$
(1,576
)
 
$
—

 
$
(1,576
)
 
$
1,576

 
$
—

 
As of December 31, 2014
 
Gross Amounts Recognized
 
Gross Amounts Offset
 
Gross Amount Presented
 
Gross Amount Not Offset
 
Legal Offset
Foreign currency forward contracts
(in thousands)
Total assets
$
2,011

 
$
—

 
$
2,011

 
$
—

 
$
2,011

I. Inventories
Inventories consisted of the following:
 
As of September 30, 2015
 
As of December 31, 2014
 
(in thousands)
Raw materials
$
8,669

 
$
8,506

Work-in-process
34,115

 
20,508

Finished goods
6,413

 
1,834

Total
$
49,197

 
$
30,848

J. Intangible Assets and Goodwill
Intangible Assets
As of September 30, 2015, in-process research and development intangible assets of $284.3 million were recorded on the Company's condensed consolidated balance sheet. The increase of $255.3 million as compared to the $29.0 million recorded as of December 31, 2014 is due to the Company's collaboration with Parion.
In June 2015, in connection with entering into the Parion Agreement, the Company recorded an in-process research and development intangible asset of $255.3 million based on the Company’s estimate of the fair value of Parion’s lead investigational ENaC inhibitors, including VX-371 and P-1055, that were licensed by the Company from Parion. The Company aggregated the fair value of the ENaC inhibitors into a single intangible asset because the phase, nature and risks of development as well as the amount and timing of benefits associated with the assets were similar. In October 2014, the Company recorded an in-process research and development intangible asset of $29.0 million based on the Company’s estimate of the fair value of VX-210, a drug candidate for patients with spinal cord injuries that was licensed by the Company from BioAxone. The Company used discount rates of 7.1% and 7.5% in the present-value models to estimate the fair values of the ENaC inhibitors and VX-210 intangible assets, respectively.
The Company also conducted an evaluation of Parion and BioAxone's other programs at the effective date of the Parion Agreement and BioAxone Agreement, respectively, and determined that market participants would not have ascribed value to those programs because of the stage of development of the assets in each program and uncertainties related to the potential clinical development and commercialization of the programs.
Goodwill
As of September 30, 2015, goodwill of $50.4 million was recorded on the Company's condensed consolidated balance sheet. The Company allocated $10.5 million to goodwill related to the Parion Agreement during the nine months ended September 30, 2015. This goodwill relates to the potential synergies between licensed drug candidates and the Company's CF drugs and drug candidates.  None of the goodwill related to the Parion Agreement is expected to be deductible for income tax purposes. As of December 31, 2014, $39.9 million of goodwill was recorded on the Company’s consolidated balance sheet.
K. Long-term Obligations
Fan Pier Leases
In 2011, the Company entered into two lease agreements, pursuant to which the Company leases approximately 1.1 million square feet of office and laboratory space in two buildings (the “Buildings”) at Fan Pier in Boston, Massachusetts (the “Fan Pier Leases”). The Company commenced lease payments in December 2013, and will make lease payments pursuant to the Fan Pier Leases through December 2028. The Company has an option to extend the term of the Fan Pier Leases for an additional ten years.
Because the Company was involved in the construction project and determined that the Fan Pier Leases did not meet the criteria for “sale-leaseback” treatment upon completion of the Buildings, the Company recorded project construction costs


17
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

incurred by the landlord as an asset and a related financing obligation during the construction period and began depreciating the asset and incurring interest expense related to the financing obligation in 2013. The Company bifurcates its lease payments pursuant to the Fan Pier Leases into (i) a portion that is allocated to the Buildings and (ii) a portion that is allocated to the land on which the Buildings were constructed. The portion of the lease obligations allocated to the land is treated as an operating lease that commenced in 2011.
Property and equipment, net, included $505.6 million and $515.0 million as of September 30, 2015 and December 31, 2014, respectively, related to construction costs for the Buildings. The carrying value of the Company's lease agreement liability for the Buildings was $473.1 million and $473.4 million as of September 30, 2015 and December 31, 2014, respectively.
Term Loan
In July 2014, the Company entered into a credit agreement with the lenders party thereto, and Macquarie US Trading LLC ("Macquarie"), as administrative agent. The credit agreement provides for a $300.0 million senior secured term loan ("Term Loan"). The credit agreement also provides that, subject to satisfaction of certain conditions, the Company may request that the lenders establish an incremental senior secured term loan facility in an aggregate amount not to exceed $200.0 million. The Term Loan initially bore interest at a rate of 7.2% per annum, which will be reduced to 6.2% per annum based on the FDA's approval of ORKAMBI. The Term Loan will bear interest at a rate of LIBOR plus 5.0% per annum during the third year of the term.
The maturity date of all loans under the facilities is July 9, 2017. Interest is payable quarterly and on the maturity date. In October 2015, the Company amended the terms of the credit agreement to provide for, among other things, a modification to the repayment schedule of the loan. As amended, the Company is required to repay principal on the Term Loan in quarterly installments of $75 million from October 1, 2016 through the maturity date. The Company may prepay the Term Loan, in whole or in part, at any time; provided that prepayments prior to the July 9, 2016 are subject to a make-whole premium to ensure Macquarie receives approximately the present value of two years of interest payments over the life of the loan. The Company expects that amending the credit agreement will be accounted for as a debt modification, as opposed to an extinguishment of debt, based on an insignificant change to the present value of the future cash flows relating to the credit agreement.
The Company's obligations under the facilities are unconditionally guaranteed by certain of its domestic subsidiaries. All obligations under the facilities, and the guarantees of those obligations, are secured, subject to certain exceptions, by substantially all of the Company's assets and the assets of all guarantors, including the pledge of all or a portion of the equity interests of certain of its subsidiaries.
The credit agreement requires that the Company maintain, on a quarterly basis, a minimum level of KALYDECO net revenues. Further, the credit agreement includes negative covenants, subject to exceptions, restricting or limiting the Company's ability and the ability of its subsidiaries to, among other things, incur additional indebtedness, grant liens, engage in certain investment, acquisition and disposition transactions, pay dividends, repurchase capital stock and enter into transactions with affiliates. The credit agreement also contains customary representations and warranties, affirmative covenants and events of default, including payment defaults, breach of representations and warranties, covenant defaults and cross defaults. If an event of default occurs, the administrative agent would be entitled to take various actions, including the acceleration of amounts due under outstanding loans. There have been no events of default as of or during the period ended September 30, 2015.
Based on the Company's evaluation of the Term Loan, the Company determined that the Term Loan contains several embedded derivatives. These embedded derivatives are clearly and closely related to the host instrument because they relate to the Company's credit risk; therefore, they do not require bifurcation from the host instrument, the Term Loan.
The Company incurred $5.3 million in fees paid to Macquarie that were recorded as a discount on the Term Loan and are being recorded as interest expense using the effective interest method over the term of the loan in the Company’s condensed consolidated statements of operations. As of September 30, 2015, the unamortized discount associated with the Term Loan that was embedded in the senior secured term loan caption on the Company’s condensed consolidated balance sheet was $5.2 million.


18
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

L. Stock-based Compensation Expense
The Company issues stock options, restricted stock and restricted stock units with service conditions, which are generally the vesting periods of the awards. The Company also has issued, to certain members of senior management, restricted stock and restricted stock units that vest upon the earlier of the satisfaction of (i) a performance condition or (ii) a service condition and stock options that vest upon the earlier of the satisfaction of (a) performance conditions or (b) a service condition. In addition, the Company issued pursuant to a retention program restricted stock awards to certain members of senior management that will vest upon the satisfaction of both (i) a performance condition and (ii) a service condition. The Company also issues shares pursuant to an employee stock purchase plan ("ESPP").
In the second quarter of 2015, the Company’s shareholders approved an amendment and restatement of the 2013 Stock and Option Plan that, among other things, increased the number of shares of common stock available for issuance under the plan by 7,800,000 shares, plus the number of shares that remained available for issuance under our 2006 Stock and Option Plan, which rolled-over into the 2013 Stock and Option Plan.
During the three and nine months ended September 30, 2015 and 2014, the Company recognized the following stock-based compensation expense included in loss from continuing operations:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2015
 
2014
 
2015
 
2014
 
(in thousands)
Stock-based compensation expense by type of award:
 
 
 
 
 
 
 
Stock options
$
39,074

 
$
26,291

 
$
105,720

 
$
78,403

Restricted stock and restricted stock units
26,203

 
18,418

 
78,274

 
51,431

ESPP share issuances
1,738

 
1,883

 
5,703

 
6,231

Less stock-based compensation expense capitalized to inventories
(1,281
)
 
(456
)
 
(3,318
)
 
(905
)
Total stock-based compensation included in costs and expenses
$
65,734

 
$
46,136

 
$
186,379

 
$
135,160

 
 
 
 
 
 
 


Stock-based compensation expense by line item:
 
 
 
 
 
 
 
Research and development expenses
$
44,701

 
$
31,131

 
$
124,550

 
$
91,284

Sales, general and administrative expenses
21,033

 
15,005

 
61,829

 
43,876

Total stock-based compensation included in costs and expenses
$
65,734

 
$
46,136

 
$
186,379

 
$
135,160

The following table sets forth the Company's unrecognized stock-based compensation expense, net of estimated forfeitures, by type of award and the weighted-average period over which that expense is expected to be recognized:
 
As of September 30, 2015
 
Unrecognized Expense,
Net of
Estimated Forfeitures
 
Weighted-average
Recognition
Period
 
(in thousands)
 
(in years)
Type of award:
 
 
 
Stock options
$
197,031

 
2.30
Restricted stock and restricted stock units
$
190,786

 
2.73
ESPP share issuances
$
1,885

 
0.44


19
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

The following table summarizes information about stock options outstanding and exercisable at September 30, 2015:
 
 
Options Outstanding
 
Options Exercisable
Range of Exercise Prices
 
Number
Outstanding
 
Weighted-average
Remaining
Contractual Life
 
Weighted-average
Exercise Price
 
Number
Exercisable
 
Weighted-average
Exercise Price
 
 
(in thousands)
 
(in years)
 
(per share)
 
(in thousands)
 
(per share)
$18.93–$20.00
 
138

 
2.35
 
$
18.93

 
138

 
$
18.93

$20.01–$40.00
 
2,499

 
3.81
 
$
34.56

 
2,284

 
$
34.36

$40.01–$60.00
 
2,593

 
6.80
 
$
48.27

 
1,458

 
$
49.52

$60.01–$80.00
 
1,567

 
8.31
 
$
75.94

 
551

 
$
74.95

$80.01–$100.00
 
1,932

 
8.28
 
$
90.27

 
638

 
$
87.16

$100.01–$120.00
 
1,791

 
9.32
 
$
109.24

 
201

 
$
109.22

$120.01–$134.69
 
1,505

 
9.78
 
$
131.21

 
168

 
$
127.52

Total
 
12,025

 
7.31
 
$
74.90

 
5,438

 
$
53.98

M. Other Arrangements
Sale of HIV Protease Inhibitor Royalty Stream
In 2008, the Company sold to a third party its rights to receive royalty payments from GlaxoSmithKline plc, net of royalty amounts to be earned by and due to a third party, for a one-time cash payment of $160.0 million. These royalty payments relate to net sales of HIV protease inhibitors, which had been developed pursuant to a collaboration agreement between the Company and GlaxoSmithKline plc. As of September 30, 2015, the Company had $31.2 million in deferred revenues related to the one-time cash payment, which it is recognizing over the life of the collaboration agreement with GlaxoSmithKline plc based on the units-of-revenue method. In addition, the Company continues to recognize royalty revenues equal to the amount of the third-party subroyalty and an offsetting royalty expense for the third-party subroyalty payment.
Other income (expense), net
In April 2014, the Company received a one-time cash payment of $36.7 million from its landlord pursuant to the Fan Pier Leases.  This payment related to bonds issued pursuant to an Infrastructure Development Assistance Agreement between The Commonwealth of Massachusetts and the Company’s landlord.  The bonds were issued in connection with the landlord’s contribution to infrastructure improvements and also were dependent upon employment levels at the Company through the bond issuance date.  The Company accounted for the cash payment as a government grant as it was provided in part related to the Company’s employment level in Massachusetts. Such grants are recognized as income in the period in which the conditions of the grant are met and there is reasonable assurance that the grant will be received, provided it is not subject to refund. In the second quarter of 2014, the Company recorded $36.7 million as a credit to other income (expense), net in its consolidated statements of operations because the Company’s employment obligations related to these funds were satisfied as of the date of issuance of the bonds and the payment received was not subject to refund.
N. Income Taxes
The Company is subject to U.S. federal, state, and foreign income taxes. For the three and nine months ended September 30, 2015, the Company recorded a provision for income taxes of $1.3 million and $31.8 million, respectively. The provision for income taxes recorded in the three and nine months ended September 30, 2015 included $0.8 million and $30.4 million, respectively, related to the Company's VIE's income tax provision. The VIE's income tax provision for the nine months ended September 30, 2015 primarily related to the income tax effect on the $80.0 million up-front payment received by Parion from the Company in June 2015. The Company has no liability for taxes payable by Parion and the income tax provision and related liability have been allocated to noncontrolling interest (VIE). For the three and nine months ended September 30,


20
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

2014, the Company recorded a provision for income taxes of $3.4 million and $4.9 million, respectively, related to state income taxes and income earned in various foreign jurisdictions.
As of September 30, 2015 and December 31, 2014, the Company had unrecognized tax benefits of $0.9 million. The Company recognizes interest and penalties related to income taxes as a component of income tax expense. As of September 30, 2015, no interest and penalties have been accrued. The Company does not expect that its unrecognized tax benefits will materially increase within the next twelve months. The Company did not recognize any material interest or penalties related to uncertain tax positions as of September 30, 2015 and December 31, 2014. In 2015, it is reasonably possible that the Company will reduce the balance of its unrecognized tax benefits by approximately $0.5 million due to the application of statute of limitations and settlements with taxing authorities, all of which would reduce the Company’s effective tax rate.
The Company continues to maintain a valuation allowance against certain deferred tax assets where it is more likely than not that the deferred tax asset will not be realized because of its extended history of annual losses.
The Company files U.S. federal income tax returns and income tax returns in various state, local and foreign jurisdictions. The Company is no longer subject to any tax assessment from an income tax examination in the United States before 2011 or any other major taxing jurisdiction for years before 2009, except where the Company has net operating losses or tax credit carryforwards that originated before 2009. The Company currently is under examination by the Internal Revenue Service for the year ended December 31, 2011 and in Canada, Pennsylvania, Delaware, New York and Texas for varying periods including the years ended December 31, 2011 through 2013. No adjustments have been reported. The Company is not under examination by any other jurisdictions for any tax year. The Company concluded audits with Massachusetts and Revenue Quebec during 2015 and the Canada Revenue Agency and Revenue Quebec during 2014 with no material adjustments.
The Company currently intends to reinvest the total amount of its unremitted earnings. At September 30, 2015, foreign earnings, which were not significant, have been retained indefinitely by foreign subsidiary companies for reinvestment; therefore, no provision has been made for income taxes that would be payable upon the distribution of such earnings, and it would not be practicable to determine the amount of the related unrecognized deferred income tax liability. Upon repatriation of those earnings, in the form of dividends or otherwise, the Company would be subject to U.S. federal income taxes (subject to an adjustment for foreign tax credits) and withholding taxes payable to the various foreign countries.
O. Restructuring Liabilities
2003 Kendall Restructuring
In 2003, the Company adopted a plan to restructure its operations to coincide with its increasing internal emphasis on advancing drug candidates through clinical development to commercialization. The restructuring liability relates to specialized laboratory and office space that is leased to the Company pursuant to a 15-year lease that terminates in 2018. The Company has not used more than 50% of this space since it adopted the plan to restructure its operations in 2003. This unused laboratory and office space currently is subleased to third parties.
The activities related to the restructuring liability for the three and nine months ended September 30, 2015 and 2014 were as follows:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2015
 
2014
 
2015
 
2014
 
(in thousands)
Liability, beginning of the period
$
9,924

 
$
14,936

 
$
11,596

 
$
19,115

Cash payments
(3,975
)
 
(4,249
)
 
(10,544
)
 
(12,071
)
Cash received from subleases
2,919

 
2,689

 
8,194

 
8,067

Restructuring expense (income)
146

 
(464
)
 
(232
)
 
(2,199
)
Liability, end of the period
$
9,014

 
$
12,912

 
$
9,014

 
$
12,912



21
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)


Fan Pier Move Restructuring
In connection with the relocation of its Massachusetts operations to Fan Pier in Boston, Massachusetts, which commenced in 2013, the Company is incurring restructuring charges related to its remaining lease obligations at its facilities in Cambridge, Massachusetts. The majority of these restructuring charges were recorded in the third quarter of 2014 upon decommissioning three facilities in Cambridge. During the first quarter of 2015, the Company terminated two of these lease agreements resulting in a credit to restructuring expense equal to the difference between the Company’s estimated future cash flows related to its lease obligations for these facilities and the termination payment paid to the Company’s landlord on the effective date of the termination. The third major facility included in this restructuring activity is 120,000 square feet of the Kendall Square Facility that the Company continued to use for its operations following its 2003 Kendall Restructuring. The rentable square footage in this portion of the Kendall Square Facility was subleased to a third party in February 2015. The Company will continue to incur charges through April 2018 related to the difference between the Company’s estimated future cash flows related to this portion of the Kendall Square Facility, which include an estimate for sublease income to be received from the Company's sublessee and its actual cash flows. The Company discounted the estimated cash flows related to this restructuring activity at a discount rate of 9%.
The activities related to the restructuring liability for the three and nine months ended September 30, 2015 and 2014 were as follows:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2015
 
2014
 
2015
 
2014
 
(in thousands)
Liability, beginning of the period
$
9,017

 
$
3,256

 
$
33,390

 
$
797

Cash payments
(3,070
)
 
(2,266
)
 
(25,421
)
 
(6,643
)
Cash received from subleases
1,820

 
—

 
1,820

 
—

Restructuring expense (income)
51

 
39,752

 
(1,971
)
 
46,588

Liability, end of the period
$
7,818

 
$
40,742

 
$
7,818

 
$
40,742

Other Restructuring Activities
The Company has incurred several other restructuring activities that are unrelated to its 2003 Kendall Restructuring and the Fan Pier Move Restructuring. In October 2013, the Company adopted a restructuring plan that included (i) a workforce reduction primarily related to the commercial support of INCIVEK following the continued and rapid decline in the number of patients being treated with INCIVEK as new medicines for the treatment of HCV infection neared approval and (ii) the write-off of certain assets. This action resulted from the Company's decision to focus its investment on future opportunities in cystic fibrosis and other research and development programs.
The activities related to the Company's other restructuring liabilities for the three and nine months ended September 30, 2015 and 2014 were as follows:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2015
 
2014
 
2015
 
2014
 
(in thousands)
Liability, beginning of the period
$
902

 
$
792

 
$
869

 
$
8,441

Cash payments
(1,559
)
 
(399
)
 
(2,782
)
 
(8,865
)
Restructuring expense
1,629

 
1,555

 
2,885

 
2,372

Liability, end of the period
$
972

 
$
1,948

 
$
972

 
$
1,948



22
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

P. Commitments and Contingencies
Financing Arrangements
As of September 30, 2015, the Company had irrevocable stand-by letters of credit outstanding that were issued in connection with property leases and other similar agreements totaling $21.9 million that are cash collateralized. The cash used to support these letters of credit is included in restricted cash, as of September 30, 2015, on the Company's condensed consolidated balance sheet.
Litigation
On May 28, 2014, a purported shareholder class action Local No. 8 IBEW Retirement Plan & Trust v. Vertex Pharmaceuticals Incorporated, et al. was filed in the United States District Court for the District of Massachusetts, naming the Company and certain of the Company's current and former officers and directors as defendants. The lawsuit alleged that the Company made material misrepresentations and/or omissions of material fact in the Company's disclosures during the period from May 7, 2012 through May 29, 2012, all in violation of Section 10(b) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder. The purported class consists of all persons (excluding defendants) who purchased the Company’s common stock between May 7, 2012 and May 29, 2012. The plaintiffs seek unspecified monetary damages, costs and attorneys’ fees as well as disgorgement of the proceeds from certain individual defendants’ sales of the Company’s stock. On October 8, 2014, the Court approved Local No. 8 IBEW Retirement Fund as lead plaintiff, and Scott and Scott LLP as lead counsel for the plaintiff and the putative class. On February 23, 2015, the Company filed a reply to the plaintiffs’ opposition to its motion to dismiss.  The court heard oral argument on the motion to dismiss on March 6, 2015 and took the motion under advisement. On September 30, 2015, the court granted the Company's motion to dismiss. On October 15, 2015, the plaintiff filed a notice of appeal. The Company believes the claims to be without merit and intend to vigorously defend the litigation. As of September 30, 2015, the Company has not recorded any reserves for this purported class action.
Guaranties and Indemnifications
As permitted under Massachusetts law, the Company’s Articles of Organization and By-laws provide that the Company will indemnify certain of its officers and directors for certain claims asserted against them in connection with their service as an officer or director. The maximum potential amount of future payments that the Company could be required to make under these indemnification provisions is unlimited. However, the Company has purchased directors’ and officers’ liability insurance policies that could reduce its monetary exposure and enable it to recover a portion of any future amounts paid. No indemnification claims currently are outstanding, and the Company believes the estimated fair value of these indemnification arrangements is minimal.
The Company customarily agrees in the ordinary course of its business to indemnification provisions in agreements with clinical trial investigators and sites in its drug development programs, sponsored research agreements with academic and not-for-profit institutions, various comparable agreements involving parties performing services for the Company, and its real estate leases. The Company also customarily agrees to certain indemnification provisions in its drug discovery, development and commercialization collaboration agreements. With respect to the Company’s clinical trials and sponsored research agreements, these indemnification provisions typically apply to any claim asserted against the investigator or the investigator’s institution relating to personal injury or property damage, violations of law or certain breaches of the Company’s contractual obligations arising out of the research or clinical testing of the Company’s compounds or drug candidates. With respect to lease agreements, the indemnification provisions typically apply to claims asserted against the landlord relating to personal injury or property damage caused by the Company, to violations of law by the Company or to certain breaches of the Company’s contractual obligations. The indemnification provisions appearing in the Company’s collaboration agreements are similar to those for the other agreements discussed above, but in addition provide some limited indemnification for its collaborator in the event of third-party claims alleging infringement of intellectual property rights. In each of the cases above, the indemnification obligation generally survives the termination of the agreement for some extended period, although the Company believes the obligation typically has the most relevance during the contract term and for a short period of time thereafter. The maximum potential amount of future payments that the Company could be required to make under these provisions is generally unlimited. The Company has purchased insurance policies covering personal injury, property damage and general liability that reduce its exposure for indemnification and would enable it in many cases


23
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

to recover all or a portion of any future amounts paid. The Company has never paid any material amounts to defend lawsuits or settle claims related to these indemnification provisions. Accordingly, the Company believes the estimated fair value of these indemnification arrangements is minimal.
Other Contingencies
The Company has certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues a reserve for contingent liabilities when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. There were no material contingent liabilities accrued as of September 30, 2015 or December 31, 2014.


24

Item 2.     Management's Discussion and Analysis of Financial Condition and Results of Operations
OVERVIEW
We are in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. We use precision medicine approaches with the goal of creating transformative medicines for patients in specialty markets. Our business is focused on developing and commercializing therapies for the treatment of cystic fibrosis, or CF, and advancing our research and early-stage development programs in other indications, while maintaining our financial strength.
We market KALYDECO (ivacaftor) for the treatment of certain patients with CF who have specific genetic mutations in their cystic fibrosis transmembrane conductance regulator, or CFTR, gene. In July 2015, we began marketing ORKAMBI (lumacaftor in combination with ivacaftor) in the United States for the treatment of patients with CF twelve years of age and older who have two copies (homozygous) of the F508del mutation in their CFTR gene, which is the most prevalent form of CF. We also are seeking approval to market lumacaftor in combination with ivacaftor for this patient population in Europe, Canada and Australia.
Cystic Fibrosis
Ivacaftor
KALYDECO was approved in 2012 in the United States and European Union as a treatment for patients with CF six years of age and older who have the G551D mutation in their CFTR gene. Our KALYDECO net product revenues have been increasing over the last several years due to the increased number of patients who are being treated with KALYDECO in the United States and ex-U.S. markets as we have expanded the label for KALYDECO and obtained reimbursement for additional patients eligible for treatment with KALYDECO in ex-U.S markets.
In September 2015, the European Union Committee for Medicinal Products for Human Use, or CHMP, issued positive opinions recommending approval of KALYDECO for patients with CF two to five years of age who have one of nine gating mutations in their CFTR gene and in patients with CF 18 years of age and older who have the R117H mutation in their CFTR gene. The CHMP's opinions will be reviewed by the European Commission, which has the authority to approve medicines for the European Union. In Europe, we believe there are approximately 125 patients with CF two to five years of age with one of the nine gating mutations included in the opinion and approximately 250 patients with CF 18 years of age and old with the R117H mutation in their CFTR gene.
We have submitted a supplemental New Drug Application, or sNDA, for KALYDECO for patients with CF two years of age and older who have one of 23 residual function mutations to the United States Food and Drug Administration, or FDA. A target review date for the sNDA of February 6, 2016 was set under the Prescription Drug User Fee Act for the FDA's decision on the sNDA. The sNDA was based on preclinical data for ivacaftor in the 23 residual function mutations, the established clinical profile of KALYDECO and on previously reported data from an exploratory Phase 2a clinical trial in 24 patients with residual function mutations. Nineteen of the patients in this clinical trial had one of the 23 residual function mutations included in the sNDA. We believe more than 1,500 patients with CF two years of age and older in the United States have the mutations represented in the sNDA.
In the first quarter of 2016, we plan to commence a clinical trial for ivacaftor in patients with CF less than two years of age to evaluate the effect of ivacaftor on markers of CF disease in young children. The clinical trial will utilize a weight-based dose of ivacaftor granules that can be mixed in soft foods or liquids.
Lumacaftor in Combination with Ivacaftor
In July 2015, the FDA approved ORKAMBI for the treatment of patients with CF twelve years of age and older who are homozygous for the F508del mutation in their CFTR gene. In the third quarter of 2015, we began marketing ORKAMBI in the United States and recognized our first net product revenues from ORKAMBI. Our future ORKAMBI net product revenues in the United States will reflect the number of patients for whom ORKAMBI is prescribed, the level of rebates, chargebacks, discounts and other adjustments to our ORKAMBI gross product revenues and patient adherence to the recommended treatment regimen. We believe that there currently are approximately 8,500 patients in the United States who are eligible for treatment with ORKAMBI and that as of September 30, 2015 more than 3,000 patients in the United States have started treatment with ORKAMBI.
We submitted a Marketing Authorization Application, or MAA, for ORKAMBI for the treatment of patients with CF twelve years of age and older who are homozygous for the F508del mutation in their CFTR gene to the European Medicines Agency, or EMA, in November 2014. In September 2015, the CHMP issued a positive opinion recommending approval of the MAA. The CHMP's opinion will be reviewed by the European Commission, which has the authority to approve medicines for


25

the European Union. We believe that there are approximately 12,000 patients with CF twelve years of age and older who are homozygous for the F508del mutation in Europe.
We are conducting two Phase 3 clinical trials to evaluate lumacaftor in combination with ivacaftor for the treatment of patients with CF six to eleven years of age who are homozygous for the F508del mutation in their CFTR gene. The first clinical trial is fully enrolled and if successful, will be used to support an sNDA to the FDA in the first half of 2016. Enrollment is ongoing in the second clinical trial, which is required to support approval of lumacaftor in combination with ivacaftor in this patient population in the European Union.
VX-661 in Combination with Ivacaftor
In the first quarter of 2015, we initiated a Phase 3 development program for VX-661 in combination with ivacaftor in multiple CF patient populations who have at least one copy of the F508del mutation. These clinical trials are enrolling patients with CF with the following mutations:
•
Two copies of the F508del in their CFTR gene;
•
One copy of the F508del mutation in their CFTR gene and a second mutation in their CFTR gene that results in a gating defect in the CFTR protein;
•
One copy of the F508del mutation in their CFTR gene and a second mutation in their CFTR gene that results in residual CFTR function; and
•
One copy of the F508del mutation in their CFTR gene and a second mutation that results in minimal CFTR function.
We expect to enroll more than 1,000 patients with CF in this Phase 3 development program. In mid-2016, we expect to complete enrollment in the first three of these clinical trials and the first part of the fourth clinical trial.
ENaC Inhibition
In June 2015, we entered into a collaboration with Parion Sciences, Inc., or Parion, to develop investigational epithelial sodium channel, or ENaC, inhibitors, including VX-371 (formerly P-1037), for the potential treatment of CF and other pulmonary diseases. VX-371 is currently being evaluated in an exploratory Phase 2a clinical trial in approximately 120 patients with CF with any mutation in their CFTR gene, including those who have mutations not expected to respond to ivacaftor alone. We expect data from this clinical trial in mid-2016. We expect to initiate a Phase 2a clinical trial of VX-371 in early 2016, that evaluates the addition of VX-371 to treatment with ORKAMBI for patients with CF who are homozygous for the F508del mutation in their CFTR gene.
Next-generation CFTR Corrector Compounds
We are developing two next-generation CFTR corrector compounds, VX-152 and VX-440, that we plan to evaluate as part of combination treatment regimens. We initiated the first Phase 1 clinical trial in healthy volunteers of a next-generation corrector compound in October 2015 and plan to initiate the first Phase 1 clinical trial in healthy volunteers of the second next-generation corrector compound in November 2015. If these clinical trials are successful, we plan to initiate Phase 2 clinical trials of VX-152 or VX-440 in combination with VX-661 and/or ivacaftor in the second half of 2016. In human bronchial epithelial, or HBE, cells with two copies of the F508del mutation in the CFTR gene, as well as in HBE cells with one copy of the F508del mutation in the CFTR gene and a second mutation that results in minimal CFTR function, the triple combinations (VX-152/VX-661/ivacaftor and VX-440/VX-661/ivacaftor) resulted in chloride transport (measured as a percent of normal) that was approximately three-fold greater than the use of a lumacaftor/ivacaftor combination in these cells.
Research and Early-Stage Development
We are engaged in a number of other research and early-stage development programs, including in the areas of oncology and pain.
Oncology
We are conducting two Phase 1 clinical trials of VX-970, a protein kinase inhibitor of ATR, dosed intravenously in combination with commonly used DNA-damaging chemotherapies across a range of solid tumor types, including triple negative breast cancer and non-small cell lung cancer. Data from a Phase 1 safety and pharmacokinetics clinical trial demonstrated that treatment with VX-970 was generally well-tolerated, both alone and in combination with the chemotherapy drug carboplatin, and there was preliminary evidence of anti-tumor activity. We also have entered into a cooperative research and development agreement with the National Cancer Institute to evaluate VX-970 across other types of cancers. The first clinical trial conducted under the agreement is ongoing, and six additional clinical trials are planned. We are also in Phase 1


26

development of VX-803, a second ATR inhibitor, alone and in combination with chemotherapy. We expect to initiate Phase 1 clinical development of VX-984, a third oncology drug candidate, alone and in combination with chemotherapy, in early 2016.
Pain
We are developing VX-150 and VX-241, two drug candidates for the treatment of pain. By the end of 2015, we expect to initiate a Phase 2 clinical trial to evaluate VX-150 in approximately 100 patients with symptomatic osteoarthritis of the knee. We expect to begin clinical development of VX-241 in the first half of 2016.
We plan to continue investing in our research programs and fostering scientific innovation in order to identify and develop transformative medicines. We believe that pursuing research in diverse areas allows us to balance the risks inherent in drug development and may provide drug candidates that will form our pipeline in future years.
CRISPR Collaboration
In October 2015, we entered into an agreement with CRISPR Therapeutics AG, or CRISPR, to collaborate on the discovery and development of potential new treatments aimed at the underlying genetic causes of human diseases using CRISPR-Cas9 gene editing technology. We and CRISPR will focus the initial discovery efforts on genes known to cause and contribute to cystic fibrosis and sickle cell disease. We have the exclusive rights to license up to six CRISPR-Cas9-based targets. In connection with this collaboration agreement, we made an upfront payment to CRISPR of $75.0 million and will provide a $30.0 million investment in CRISPR, which is a private company.
We will fund all of the discovery activities, which will be conducted primarily by CRISPR. For potential hemoglobinapathy treatments, including treatments for sickle cell disease, we will share equally all research and development costs and worldwide revenues with CRISPR, and CRISPR would lead the commercialization efforts in the United States. For other targets that we elect to license, we would lead all development and global commercialization activities, and CRISPR would be entitled to development, regulatory and sales milestones and royalties on net sales.
HCV Infection
Prior to 2014, we recognized significant net product revenues based on sales of INCIVEK (telaprevir), a product for the treatment of genotype 1 HCV infection that we marketed in North America. In October 2013, in response to declining sales of INCIVEK and increased competition, we reduced our focus on marketing INCIVEK and eliminated the U.S. field-based sales force that had been promoting INCIVEK. We have withdrawn INCIVEK from the market in the United States, and we expect to wind-down any remaining activities relating to the field of HCV infection in 2015.
In the fourth quarter of 2014, we terminated our collaboration with Alios BioPharma, Inc., or Alios, related to the development of HCV nucleotide analogues. Our financial statements reflect the activities related to Alios as discontinued operations.
Drug Discovery and Development
Discovery and development of a new pharmaceutical product is a difficult and lengthy process that requires significant financial resources along with extensive technical and regulatory expertise and can take 10 to 15 years or more. Potential drug candidates are subjected to rigorous evaluations, driven in part by stringent regulatory considerations, designed to generate information concerning efficacy, side-effects, proper dosage levels and a variety of other physical and chemical characteristics that are important in determining whether a drug candidate should be approved for marketing as a pharmaceutical product. Most chemical compounds that are investigated as potential drug candidates never progress into development, and most drug candidates that do advance into development never receive marketing approval. Because our investments in drug candidates are subject to considerable risks, we closely monitor the results of our discovery, research, clinical trials and nonclinical studies and frequently evaluate our drug development programs in light of new data and scientific, business and commercial insights, with the objective of balancing risk and potential. This process can result in abrupt changes in focus and priorities as new information becomes available and as we gain additional understanding of our ongoing programs and potential new programs, as well as those of our competitors.
If we believe that data from a completed registration program support approval of a drug candidate, we submit an NDA to the FDA requesting approval to market the drug candidate in the United States and seek analogous approvals from comparable regulatory authorities in foreign jurisdictions. To obtain approval, we must, among other things, demonstrate with evidence gathered in nonclinical studies and well-controlled clinical trials that the drug candidate is safe and effective for the disease it is intended to treat and that the manufacturing facilities, processes and controls for the manufacture of the drug candidate are adequate. The FDA and foreign regulatory authorities have substantial discretion in deciding whether or not a drug candidate should be granted approval based on the benefits and risks of the drug candidate in the treatment of a particular disease, and


27

could delay, limit or deny regulatory approval. If regulatory delays are significant or regulatory approval is limited or denied altogether, our financial results and the commercial prospects for the drug candidate involved will be harmed.
Regulatory Compliance
Our marketing of pharmaceutical products is subject to extensive and complex laws and regulations. We have a corporate compliance program designed to actively identify, prevent and mitigate risk through the implementation of compliance policies and systems, and through the promotion of a culture of compliance. Among other laws, regulations and standards, we are subject to various U.S. federal and state laws, and comparable foreign laws pertaining to health care fraud and abuse, including anti-kickback and false claims statutes, and laws prohibiting the promotion of drugs for unapproved or off-label uses. Anti-kickback laws make it illegal for a prescription drug manufacturer to solicit, offer, receive or pay any remuneration to induce the referral of business, including the purchase or prescription of a particular drug. False claims laws prohibit anyone from presenting for payment to third-party payors, including Medicare and Medicaid, claims for reimbursed drugs or services that are false or fraudulent, claims for items or services not provided as claimed, or claims for medically unnecessary items or services. We expect to continue to devote substantial resources to maintain, administer and expand these compliance programs globally.
Reimbursement
Sales of our products depend, to a large degree, on the extent to which our products are covered by third-party payors, such as government health programs, commercial insurance and managed health care organizations. We dedicate substantial management and other resources in order to obtain and maintain appropriate levels of reimbursement for our products from third-party payors, including governmental organizations in the United States and ex-U.S. markets. Following the FDA's July 2015 approval of ORKAMBI in the United States, we are engaging in discussions with numerous commercial insurers and managed health care organizations, along with government health programs that are typically managed by authorities in the individual states. If ORKAMBI is approved in Europe and other foreign countries, we will need to focus on obtaining and maintaining government reimbursement for ORKAMBI on a country-by-country basis, because in many foreign countries patients are unable to access prescription pharmaceutical products that are not reimbursed by their governments. Consistent with our experience with KALYDECO when it was first approved, we expect reimbursement discussions in ex-U.S. markets may take a significant period of time following obtaining any marketing approvals for ORKAMBI in ex-U.S. markets.


28

RESULTS OF OPERATIONS
 
Three Months Ended September 30,
 
Increase/(Decrease)
 
Nine Months Ended September 30,
 
Increase/(Decrease)
 
2015
 
2014
 
$
 
%
 
2015
 
2014
 
$
 
%
 
(in thousands)
 
 
 
(in thousands)
 
 
Revenues
$
309,816

 
$
178,987

 
$
130,829

 
73
 %
 
$
614,401

 
$
435,859

 
$
178,542

 
41
 %
Operating costs and expenses
379,842

 
321,190

 
58,652

 
18
 %
 
1,027,576

 
974,646

 
52,930

 
5
 %
Other items, net
(25,123
)
 
(27,857
)
 
2,734

 
10
 %
 
(69,428
)
 
(23,112
)
 
$
(46,316
)
 
(200
)%
Net loss attributable to Vertex
$
(95,149
)
 
$
(170,060
)
 
$
(74,911
)
 
(44
)%
 
$
(482,603
)
 
$
(561,899
)
 
$
(79,296
)
 
(14
)%
Net Loss Attributable to Vertex
Net loss attributable to Vertex was $95.1 million in the third quarter of 2015 compared to a net loss attributable to Vertex of $170.1 million in the third quarter of 2014. Our revenues increased in the third quarter of 2015 as compared to the third quarter of 2014 due to net product revenues from ORKAMBI, which was approved by the FDA in July 2015, and increased KALYDECO net product revenues, partially offset by decreased collaborative revenues. Our operating costs and expenses increased in the third quarter of 2015 as compared to the third quarter of 2014 primarily due to increases in research and development expenses, sales, general and administrative expenses and cost of product revenues, partially offset by decreased restructuring expenses. In the near term, we expect net loss (income) attributable to Vertex will be dependent on expected increases in ORKAMBI net product revenues.
Net loss attributable to Vertex was $482.6 million in the nine months ended September 30, 2015 compared to a net loss attributable to Vertex of $561.9 million in the nine months ended September 30, 2014. Our revenues increased in the nine months ended September 30, 2015 as compared to the nine months ended September 30, 2014 due to net product revenues from ORKAMBI and increased KALYDECO net product revenues, partially offset by decreased royalty revenues and collaborative revenues. Our operating costs and expenses increased in the nine months ended September 30, 2015 as compared to the nine months ended September 30, 2014, primarily due to increases in research and development expenses, sales, general and administrative expenses and cost of product revenues, partially offset by decreased restructuring expenses and royalty expenses. The change in other items, net in the nine months ended September 30, 2015 as compared to the nine months ended September 30, 2014 was principally due to a $36.7 million credit to other income (expense) recorded in the nine months ended September 30, 2014 related to a one-time payment received in connection with our headquarters lease for which there was no corresponding credit in the nine months ended September 30, 2015.

Diluted Net Loss Per Share Attributable to Vertex Common Shareholders
Diluted net loss per share attributable to Vertex common shareholders was $0.39 in the third quarter of 2015 as compared to a diluted net loss per share attributable to Vertex common shareholders of $0.72 in the third quarter of 2014. Diluted net loss per share attributable to Vertex common shareholders was $2.00 in the nine months ended September 30, 2015 as compared to a diluted net loss per share attributable to Vertex common shareholders of $2.40 in the nine months ended September 30, 2014.


29

Revenues
 
Three Months Ended September 30,
 
Increase/(Decrease)
 
Nine Months Ended September 30,
 
Increase/(Decrease)
 
2015
 
2014
 
$
 
%
 
2015
 
2014
 
$
 
%
 
(in thousands)
 
 
 
(in thousands)
 
 
Product revenues, net
$
302,511

 
$
137,099

 
$
165,412

 
121
 %
 
$
593,774

 
$
362,879

 
$
230,895

 
64
 %
Royalty revenues
5,759

 
8,386

 
(2,627
)
 
(31
)%
 
17,628

 
32,134

 
(14,506
)
 
(45
)%
Collaborative revenues
1,546

 
33,502

 
(31,956
)
 
(95
)%
 
2,999

 
40,846

 
(37,847
)
 
(93
)%
Total revenues
$
309,816

 
$
178,987

 
$
130,829

 
73
 %
 
$
614,401

 
$
435,859

 
$
178,542

 
41
 %
Product Revenues, Net
 
Three Months Ended September 30,
 
Increase/(Decrease)
 
Nine Months Ended September 30,
 
Increase/(Decrease)
 
2015
 
2014
 
$
 
%
 
2015
 
2014
 
$
 
%
 
(in thousands)
 
 
 
(in thousands)
 
 
KALYDECO
$
165,929

 
$
126,801

 
$
39,128

 
31
 %
 
$
450,991

 
$
339,371

 
$
111,620

 
33
 %
ORKAMBI
130,767

 
—

 
N/A

 
N/A

 
130,767

 
—

 
N/A

 
N/A

INCIVEK
5,815

 
10,298

 
(4,483
)
 
(44
)%
 
12,016

 
23,508

 
(11,492
)
 
(49
)%
Total product revenues, net
$
302,511

 
$
137,099

 
$
165,412

 
121
 %
 
$
593,774

 
$
362,879

 
$
230,895

 
64
 %
Our total net product revenues increased in the third quarter and the nine months ended September 30, 2015 as compared to the third quarter and the nine months ended September 30, 2014 due to net product revenues from ORKAMBI, which was approved by the FDA in July 2015, and increased KALYDECO net product revenues.
KALYDECO net product revenues were $165.9 million in the third quarter of 2015, including $70.9 million of net product revenues from international markets. The increase in KALYDECO net product revenues in the third quarter and the nine months ended September 30, 2015, as compared to the third quarter and the nine months ended September 30, 2014, was primarily due to additional patients being treated with KALYDECO as we completed reimbursement discussions in various jurisdictions and increased the number of patients eligible to receive KALYDECO through multiple label expansions that were approved by regulatory authorities in the United States and Europe during 2014 and 2015.
Our ORKAMBI net product revenues in the United Sates increased on a monthly basis during the third quarter of 2015 as patients initiated treatment following approval in early July 2015. We expect ORKAMBI revenues to increase in the fourth quarter of 2015 as compared to the third quarter of 2015 as additional patients initiate treatment with ORKAMBI. If approved in the fourth quarter of 2015, we expect to recognize our first ex-U.S. ORKAMBI net product revenues in the first half of 2016. Initially, we expect these revenues will be primarily from Germany due to the time it will take to complete the reimbursement discussions in other European countries.
We have withdrawn INCIVEK from the market in the United States. We may continue to recognize small incremental INCIVEK revenues over the next several quarters as we adjust our INCIVEK reserves for rebates, chargebacks and discounts.
Royalty Revenues
Our royalty revenues were $5.8 million and $17.6 million in the third quarter and the nine months ended September 30, 2015, respectively, as compared to $8.4 million and $32.1 million in the third quarter and the nine months ended September 30, 2014, respectively. Since the beginning of 2014, our royalty revenues have consisted of (i) revenues related to a cash payment we received in 2008 when we sold our rights to certain HIV royalties and (ii) revenues related to certain third-party royalties payable by our collaborators on sales of HIV and HCV drugs that also result in corresponding royalty expenses. The decreased royalty revenues in the third quarter and the nine months ended September 30, 2015 as compared to the third quarter and the nine months ended September 30, 2014 were primarily due to the continued decline in net sales of INCIVO (telaprevir) by our collaborator Janssen NV.
Collaborative Revenues
Our collaborative revenues were $1.5 million and $3.0 million in the third quarter and the nine months ended September 30, 2015, respectively, as compared to $33.5 million and $40.8 million in the third quarter and the nine months ended September 30, 2014, respectively. The decrease during the third quarter and the nine months ended September 30, 2015 as


30

compared to the third quarter and the nine months ended September 30, 2014 was primarily attributable to a one-time $30.0 million payment we received in July 2014 from Janssen Pharmaceuticals, Inc.
Operating Costs and Expenses
 
Three Months Ended September 30,
 
Increase/(Decrease)
 
Nine Months Ended September 30,
 
Increase/(Decrease)
 
2015
 
2014
 
$
 
%
 
2015
 
2014
 
$
 
%
 
(in thousands)
 
 
 
(in thousands)
 
 
Cost of product revenues
$
30,269

 
$
10,208

 
$
20,061

 
197
 %
 
$
55,059

 
$
28,435

 
$
26,624

 
94
 %
Royalty expenses
1,691

 
3,976

 
(2,285
)
 
(57
)%
 
6,068

 
18,525

 
(12,457
)
 
(67
)%
Research and development expenses
246,284

 
190,939

 
55,345

 
29
 %
 
685,741

 
654,043

 
31,698

 
5
 %
Sales, general and administrative expenses
99,772

 
75,224

 
24,548

 
33
 %
 
280,026

 
226,882

 
53,144

 
23
 %
Restructuring expenses, net
1,826

 
40,843

 
(39,017
)
 
(96
)%
 
682

 
46,761

 
(46,079
)
 
(99
)%
Total costs and expenses
$
379,842

 
$
321,190

 
$
58,652

 
18
 %
 
$
1,027,576

 
$
974,646

 
$
52,930

 
5
 %
Cost of Product Revenues
Our cost of product revenues includes the cost of producing inventories that corresponded to product revenues for the reporting period, plus the third-party royalties payable on our net sales of our products. Pursuant to our agreement with Cystic Fibrosis Foundation Therapeutics Incorporated, or CFFT, our tiered third-party royalties on sales of KALYDECO and ORKAMBI, calculated as a percentage of net sales, range from the single digits to the sub-teens. Our cost of product revenues increased in the third quarter and the nine months ended September 30, 2015 as compared to the third quarter and the nine months ended September 30, 2014 due to increased net product revenues. We expect our cost of product revenues to continue to increase due to increased net product revenues, together with an expected increase in the third-party royalty rate payable to CFFT as we pay royalties at the top end of the royalty range, and the expected payment of an aggregate of $27.8 million of commercial milestones to CFFT by early 2016 based on sales of ORKAMBI.
Royalty Expenses
Royalty expenses include third-party royalties payable upon net sales of telaprevir by our collaborators in their territories and expenses related to a subroyalty payable to a third party on net sales of an HIV protease inhibitor sold by GlaxoSmithKline. Royalty expenses do not include royalties we pay to CFFT on sales of KALYDECO and ORKAMBI, which instead are included in cost of product revenues. Royalty expenses in the third quarter of 2015 decreased by $2.3 million, or 57%, as compared to the third quarter of 2014 and decreased by $12.5 million, or 67%, in the nine months ended September 30, 2015 as compared to the nine months ended September 30, 2014, primarily as a result of decreased INCIVO (telaprevir) sales by our collaborator Janssen NV.
Research and Development Expenses
 
Three Months Ended September 30,
 
Increase/(Decrease)
 
Nine Months Ended September 30,
 
Increase/(Decrease)
 
2015
 
2014
 
$
 
%
 
2015
 
2014
 
$
 
%
 
(in thousands)
 
 
 
(in thousands)
 
 
Research expenses
$
69,342

 
$
63,460

 
$
5,882

 
9
%
 
$
200,099

 
$
195,825

 
$
4,274

 
2
%
Development expenses
176,942

 
127,479

 
49,463

 
39
%
 
485,642

 
458,218

 
27,424

 
6
%
Total research and development expenses
$
246,284

 
$
190,939

 
$
55,345

 
29
%
 
$
685,741

 
$
654,043

 
$
31,698

 
5
%
Our research and development expenses include internal and external costs incurred for research and development of our drugs and drug candidates. We do not assign our internal costs, such as salary and benefits, stock-based compensation expense, laboratory supplies and other direct expenses and infrastructure costs, to individual drugs or drug candidates, because the employees within our research and development groups typically are deployed across multiple research and development programs. These internal costs are significantly greater than our external costs, such as the costs of services provided to us by clinical research organizations and other outsourced research, which we allocate by individual program. All research and development costs for our drugs and drug candidates are expensed as incurred.
Since January 1, 2012, we have incurred $3.2 billion in research and development expenses associated with drug discovery and development. The successful development of our drug candidates is highly uncertain and subject to a number


31

of risks. In addition, the duration of clinical trials may vary substantially according to the type, complexity and novelty of the drug candidate and the disease indication being targeted. The FDA and comparable agencies in foreign countries impose substantial requirements on the introduction of therapeutic pharmaceutical products, typically requiring lengthy and detailed laboratory and clinical testing procedures, sampling activities and other costly and time-consuming procedures. Data obtained from nonclinical and clinical activities at any step in the testing process may be adverse and lead to discontinuation or redirection of development activities. Data obtained from these activities also are susceptible to varying interpretations, which could delay, limit or prevent regulatory approval. The duration and cost of discovery, nonclinical studies and clinical trials may vary significantly over the life of a project and are difficult to predict. Therefore, accurate and meaningful estimates of the ultimate costs to bring our drug candidates to market are not available.
In 2014 and the nine months ended September 30, 2015, costs related to our CF programs represented the largest portion of our development costs. Any estimates regarding development and regulatory timelines for our drug candidates are highly subjective and subject to change. Obtaining regulatory approval can be a lengthy, time-consuming and uncertain process. We have submitted an MAA to the EMA for lumacaftor in combination with ivacaftor. If we are successful in obtaining marketing approval from the European Commission in the fourth quarter of 2015, we currently do not expect to recognize revenues from ORKAMBI in Europe until the first half of 2016. We cannot make a meaningful estimate when, if ever, our other clinical development programs will generate revenues and cash flows.
Research Expenses
 
Three Months Ended September 30,
 
Increase/(Decrease)
 
Nine Months Ended September 30,
 
Increase/(Decrease)
 
2015
 
2014
 
$
 
%
 
2015
 
2014
 
$
 
%
 
(in thousands)
 
 
 
(in thousands)
 
 
Research Expenses:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Salary and benefits
$
21,542

 
$
21,575

 
$
(33
)
 
—
 %
 
$
61,796

 
$
63,017

 
$
(1,221
)
 
(2
)%
Stock-based compensation expense
16,342

 
11,523

 
4,819

 
42
 %
 
43,199

 
32,414

 
10,785

 
33
 %
Laboratory supplies and other direct expenses
8,755

 
7,988

 
767

 
10
 %
 
28,339

 
27,963

 
376

 
1
 %
Outsourced services
4,788

 
2,895

 
1,893

 
65
 %
 
14,293

 
12,229

 
2,064

 
17
 %
Infrastructure costs
17,915

 
19,479

 
(1,564
)
 
(8
)%
 
52,472

 
60,202

 
(7,730
)
 
(13
)%
Total research expenses
$
69,342

 
$
63,460

 
$
5,882

 
9
 %
 
$
200,099

 
$
195,825

 
$
4,274

 
2
 %
We maintain a substantial investment in research activities. Our research expenses increased by 9% in the third quarter of 2015 as compared to the third quarter of 2014 and were consistent in the nine months ended September 30, 2015 as compared to the nine months ended September 30, 2014. We expect to continue to invest in our research programs with a focus on identifying drug candidates for specialty markets.
Development Expenses
 
Three Months Ended September 30,
 
Increase/(Decrease)
 
Nine Months Ended September 30,
 
Increase/(Decrease)
 
2015
 
2014
 
$
 
%
 
2015
 
2014
 
$
 
%
 
(in thousands)
 
 
 
(in thousands)
 
 
Development Expenses:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Salary and benefits
$
42,101

 
$
40,571

 
$
1,530

 
4
 %
 
$
123,723

 
$
121,411

 
$
2,312

 
2
 %
Stock-based compensation expense
28,359

 
19,608

 
8,751

 
45
 %
 
81,351

 
58,870

 
22,481

 
38
 %
Laboratory supplies and other direct expenses
6,696

 
5,392

 
1,304

 
24
 %
 
22,113

 
25,040

 
(2,927
)
 
(12
)%
Outsourced services
70,927

 
32,483

 
38,444

 
118
 %
 
177,324

 
156,018

 
21,306

 
14
 %
Drug supply costs
2,977

 
2,253

 
724

 
32
 %
 
7,262

 
6,777

 
485

 
7
 %
Infrastructure costs
25,882

 
27,172

 
(1,290
)
 
(5
)%
 
73,869

 
90,102

 
(16,233
)
 
(18
)%
Total development expenses
$
176,942

 
$
127,479

 
$
49,463

 
39
 %
 
$
485,642

 
$
458,218

 
$
27,424

 
6
 %
Our development expenses increased by $49.5 million or 39% in the third quarter of 2015 as compared to the third quarter of 2014, primarily due to an increase in outsourced services related to ongoing clinical trials, including our Phase 3 development program for VX-661 in combination with ivacaftor and an increase in stock-based compensation expense. Our


32

development expenses increased by $27.4 million, or 6%, in the nine months ended September 30, 2015 as compared to the nine months ended September 30, 2014, primarily due to an increase in outsourced services and an increase in stock-based compensation expense, partially offset by a reduction in infrastructure costs. The increase in outsourced services expenses in the nine months ended September 30, 2015 as compared to the nine months ended September 30, 2014 was primarily due to the increase in clinical trial expenses. The decrease in infrastructure costs in the nine months ended September 30, 2015 as compared to the nine months ended September 30, 2014 was primarily attributable to the relocation of our corporate headquarters in Massachusetts from Cambridge to Boston in the nine months ended September 30, 2014.
Sales, General and Administrative Expenses
 
Three Months Ended September 30,
 
Increase/(Decrease)
 
Nine Months Ended September 30,
 
Increase/(Decrease)
 
2015
 
2014
 
$
 
%
 
2015
 
2014
 
$
 
%
 
(in thousands)
 
 
 
(in thousands)
 
 
Sales, general and administrative expenses
$
99,772

 
$
75,224

 
$
24,548

 
33
%
 
$
280,026

 
$
226,882

 
$
53,144

 
23
%
Sales, general and administrative expenses increased by 33% in the third quarter of 2015 as compared to the third quarter of 2014 and increased by 23% in the nine months ended September 30, 2015 as compared to the nine months ended September 30, 2014, primarily due to increased investment in commercial support for KALYDECO and ORKAMBI and costs incurred to prepare for the potential launch of ORKAMBI in ex-U.S. markets.
Restructuring Expense, Net
We recorded restructuring expenses of $1.8 million in the third quarter of 2015 as compared to restructuring expenses of $40.8 million in the third quarter of 2014 and recorded restructuring expenses of $0.7 million in the nine months ended September 30, 2015 as compared to restructuring expenses of $46.8 million in the nine months ended September 30, 2014. Our restructuring expenses in the third quarter and the nine months ended September 30, 2015 and 2014 primarily relate to adjustments to our restructuring liability resulting from the relocation of our corporate headquarters to Boston, Massachusetts and the early termination of our leases in Cambridge, Massachusetts.
Other Items
Interest Expense, Net
Interest expense, net was $21.1 million and $63.6 million in the third quarter and the nine months ended September 30, 2015, respectively, compared to $20.4 million and $51.7 million in the third quarter and the nine months ended September 30, 2014, respectively. During the fourth quarter of 2015, we expect to incur approximately $15 million of interest expense associated with the leases for our corporate headquarters and approximately $5 million of interest expense related to the credit agreement that we entered into in July 2014.
Other (Expense) Income, Net
Other (expense) income, net was an expense of $1.3 million in the third quarter and an expense of $5.0 million in the nine months ended September 30, 2015, compared to expense of $4.0 million and income of $34.2 million in the third quarter and the nine months ended September 30, 2014, respectively. Other income (expense), net in the nine months ended September 30, 2014 was primarily due to a credit of $36.7 million related to a one-time cash payment in the second quarter of 2014 from our landlord pursuant to leases for our corporate headquarters.
Income Taxes
We recorded a provision for income taxes of $1.3 million and $31.8 million in the third quarter and the nine months ended September 30, 2015, respectively, compared to $3.4 million and $4.9 million in the third quarter and the nine months ended September 30, 2014, respectively. The provision for income taxes in the nine months ended September 30, 2015 was principally due to the consolidation of Parion as a VIE into our condensed consolidated financial statements in the second quarter of 2015. The provision for income taxes in the third quarter and nine months ended September 30, 2014 related to state income taxes and income earned in various foreign jurisdictions.
Discontinued Operations, Net of Tax
Our loss from discontinued operations was $0.1 million and $0.7 million in the third quarter and the nine months ended September 30, 2014, respectively, related to Alios, a variable interest entity that we consolidated from June 2011 through


33

December 2013. As of September 30, 2014, we concluded that we no longer had significant continuing involvement with Alios. As a result, the effect of the Alios collaboration is presented as discontinued operations in our condensed consolidated statements of operations.
LIQUIDITY AND CAPITAL RESOURCES
As of September 30, 2015, we had cash, cash equivalents and marketable securities of $1.01 billion, which represented a decrease of $11 million from $1.02 billion as of June 30, 2015 and a decrease of $381 million from $1.39 billion as of December 31, 2014.
In the third quarter of 2015, we maintained our cash, cash equivalents and marketable securities balance due to increased cash receipts in the third quarter of 2015 from product sales together with $51.8 million in cash we received from issuances of common stock pursuant to our employee benefit plans balancing cash expenditures in the third quarter of 2015 related to, among other things, research and development expenses and sales, general and administrative expenses.
The decrease in our cash, cash equivalents and marketable securities during the nine months ended September 30, 2015 was primarily due to cash expenditures we made during the nine months ended September 30, 2015 related to, among other things, research and development expenses and sales, general and administrative expenses and an $80 million payment made in connection with entering into a collaboration agreement with Parion, partially offset by cash receipts from product sales and $139.7 million in cash we received from issuances of common stock pursuant to our employee benefit plans. We also incurred $35.9 million in costs for capital expenditures including net cash flows from capital leases during the nine months ended September 30, 2015.
Our future cash flows will be substantially dependent on continued revenue from KALYDECO, increasing ORKAMBI sales in the United States and on obtaining approval and government reimbursement for ORKAMBI in ex-U.S. markets.
Sources of Liquidity
We intend to rely on our existing cash, cash equivalents and marketable securities together with cash flows from product sales as our primary source of liquidity. In the near-term, we expect cash flows from product revenues to increase due to sales of ORKAMBI in the United States. If we are successful in obtaining marketing approval for ORKAMBI from the European Commission in the fourth quarter of 2015, we currently do not expect to recognize revenues from ORKAMBI in Europe until the first half of 2016. Initially, we expect these revenues will be primarily from Germany due to the time it will take to complete the reimbursement discussions in other European countries.
We have borrowed $300.0 million under a credit agreement that we entered into in July 2014 and, subject to certain conditions, we may request up to an additional $200.0 million pursuant to that credit agreement. In recent periods, we also have received significant proceeds from the issuance of common stock under our employee benefit plans, but the amount and timing of future proceeds from employee benefits plans is uncertain. Other possible sources of liquidity include strategic collaborative agreements that include research and/or development funding, commercial debt, public and private offerings of our equity and debt securities, development milestones and royalties on sales of products, software and equipment leases, strategic sales of assets or businesses and financial transactions. Negative covenants in our credit agreement may prohibit or limit our ability to access these sources of liquidity.
Future Capital Requirements
We incur substantial operating expenses to conduct research and development activities and operate our organization. In October 2015, we entered into an amendment to our credit agreement to, among other things, modify the repayment schedule of the loan. Under the terms of the credit agreement, we were previously required to repay the principal amount on the $300.0 million we borrowed in July 2014 in installments of $15 million on each of November 1, 2015, January 1, 2016, April 1, 2016 and July 1, 2016 and in installments of $60 million on each of October 1, 2016, January 1, 2017, April 1, 2017 and July 9, 2017. As amended, our first principal payment will be in the fourth quarter of 2016 with us repaying $75 million on each of October 1, 2016, January 1, 2017, April 1, 2017 and July 9, 2017. We also have substantial facility and capital lease obligations, including leases for two buildings in Boston, Massachusetts that continue through 2028. In addition, we have entered into certain collaboration agreements with third parties that include the funding of certain research, development and commercialization efforts with the potential for future milestone and royalty payments by us upon the achievement of pre-established developmental and regulatory targets.


34

We expect that cash flows from KALYDECO and ORKAMBI, together with our current cash, cash equivalents and marketable securities will be sufficient to fund our operations for at least the next twelve months. The adequacy of our available funds to meet our future operating and capital requirements will depend on many factors, including the amounts of future revenues generated by KALYDECO and ORKAMBI and the potential introduction of one or more of our other drug candidates to the market, the level of our business development activities and the number, breadth, cost and prospects of our research and development programs.
Financing Strategy
In July 2014, we borrowed $300.0 million pursuant to a credit agreement. In addition, subject to certain conditions, we may request that the lenders loan us up to an additional $200.0 million under the credit agreement. We may raise additional capital through public offerings or private placements of our securities or securing new collaborative agreements or other methods of financing. We will continue to manage our capital structure and will consider all financing opportunities, whenever they may occur, that could strengthen our long-term liquidity profile. There can be no assurance that any such financing opportunities will be available on acceptable terms, if at all.
CONTRACTUAL COMMITMENTS AND OBLIGATIONS
Our commitments and obligations were reported in our Annual Report on Form 10-K for the year ended December 31, 2014, which was filed with the Securities and Exchange Commission, or SEC, on February 13, 2015. There have been no material changes from the contractual commitments and obligations previously disclosed in that Annual Report on Form 10-K, except that:
•
in the second quarter of 2015, we entered into a collaboration agreement with Parion pursuant to which Parion is eligible to receive milestone and royalty payments, including up to $490 million in development and regulatory milestone payments for the development of VX-371 (formerly P-1037) and/or P-1055 in CF;
•
in the fourth quarter of 2015, we entered into a collaboration agreement with CRISPR pursuant to which CRISPR is eligible to receive milestone and royalty payments, including up to $420 million in development, regulatory and commercial milestone payments for each of up to six targets pursuant to the collaboration; and
•
in the fourth quarter of 2015, we entered into an amendment to our credit agreement to, among other things, modify the repayment schedule of the loan. As amended, our first principal payment will be in the fourth quarter of 2016 with us repaying $75 million on each of October 1, 2016, January 1, 2017, April 1, 2017 and July 9, 2017.
CRITICAL ACCOUNTING POLICIES AND ESTIMATES
Our discussion and analysis of our financial condition and results of operations is based upon our condensed consolidated financial statements prepared in accordance with generally accepted accounting principles in the United States. The preparation of these financial statements requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reported periods. These items are monitored and analyzed by management for changes in facts and circumstances, and material changes in these estimates could occur in the future. Changes in estimates are reflected in reported results for the period in which the change occurs. We base our estimates on historical experience and various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ from our estimates if past experience or other assumptions do not turn out to be substantially accurate. During the nine months ended September 30, 2015, there were no material changes to our critical accounting policies as reported in our Annual Report on Form 10-K for the year ended December 31, 2014, which was filed with the SEC on February 13, 2015.
RECENT ACCOUNTING PRONOUNCEMENTS
For a discussion of recent accounting pronouncements please refer to Note A, “Nature of Business and Accounting Policies—Recent Accounting Pronouncements,” in the 2014 Annual Report on Form 10-K. There were no new accounting pronouncements adopted during the nine months ended September 30, 2015 that had a material effect on our financial statements.
Item 3.    Quantitative and Qualitative Disclosures About Market Risk
As part of our investment portfolio, we own financial instruments that are sensitive to market risks. The investment portfolio is used to preserve our capital until it is required to fund operations, including our research and development activities. None of these market risk-sensitive instruments are held for trading purposes.
Interest Rate Risk
As of September 30, 2015, we invest our cash in a variety of financial instruments, principally money market funds, investment-grade corporate bonds and commercial paper. These investments are denominated in U.S. dollars. All of our interest-bearing securities are subject to interest rate risk and could decline in value if interest rates fluctuate. Substantially all of our investment portfolio consists of marketable securities with active secondary or resale markets to help ensure portfolio liquidity, and we have implemented guidelines limiting the term-to-maturity of our investment instruments. Due to the conservative nature of these instruments, we do not believe that we have a material exposure to interest rate risk.
Foreign Exchange Market Risk
As a result of our foreign operations, we face exposure to movements in foreign currency exchange rates, primarily the Euro, Swiss Franc, British Pound, Australian Dollar and Canadian Dollar against the U.S. dollar. The current exposures arise primarily from cash, accounts receivable, intercompany receivables, payables and inventories. Both positive and negative affects to our net revenues from international product sales from movements in foreign currency exchange rates are partially mitigated by the natural, opposite affect that foreign currency exchange rates have on our international operating costs and expenses.
We maintain a foreign currency management program with the objective of reducing the impact of exchange rate fluctuations on our operating results and forecasted revenues and expenses denominated in foreign currencies.
Item 4.    Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Our chief executive officer and chief financial officer, after evaluating the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this Quarterly Report on Form 10-Q, have concluded that, based on such evaluation, as of September 30, 2015 our disclosure controls and procedures were effective and designed to provide reasonable assurance that the information required to be disclosed is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms. In designing and evaluating our disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.
Changes in Internal Controls Over Financial Reporting
No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934, as amended) occurred during the three months ended September 30, 2015 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
PART II. Other Information
Item 1.     Legal Proceedings
Local No. 8 IBEW Retirement Plan & Trust v. Vertex Pharmaceuticals Incorporated, et al.
On May 28, 2014, a purported shareholder class action Local No. 8 IBEW Retirement Plan & Trust v. Vertex Pharmaceuticals Incorporated, et al. was filed in the United States District Court for the District of Massachusetts, naming us and certain of our current and former officers and directors as defendants. The lawsuit alleged that we made material misrepresentations and/or omissions of material fact in our disclosures during the period from May 7, 2012 through May 29, 2012, all in violation of Section 10(b) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder. The purported class consists of all persons (excluding defendants) who purchased our common stock between May 7, 2012 and May 29, 2012. The plaintiffs seek unspecified monetary damages, costs and attorneys’ fees as well as disgorgement of the proceeds from certain individual defendants’ sales of our stock. On October 8, 2014, the Court approved Local No. 8 IBEW Retirement Fund as lead plaintiff, and Scott and Scott LLP as lead counsel for the plaintiff and the putative class. We filed a motion to dismiss the complaint on December 8, 2014 and the plaintiffs filed their opposition to our motion to dismiss on January 22, 2015. On February 23, 2015, we filed a reply to the plaintiffs’ opposition to our motion to dismiss.  The court heard oral argument on our motion to dismiss on March 6, 2015 and took the motion under advisement. On September 30, 2015, the court granted our motion to dismiss. On October 15, 2015, the plaintiff filed a notice of appeal. We believe the claims to be without merit and intend to vigorously defend the litigation.
DOJ Subpoena
In the third quarter of 2015, we received a subpoena from the United States Department of Justice related to our marketed medicines. This subpoena requests documents relating primarily to our Good Laboratory Practices in a bioanalytical laboratory. We are in the process of responding to the subpoena and intend to cooperate.
Item 1A. Risk Factors
Information regarding risk factors appears in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2014, which was filed with the SEC on February 13, 2015. There have been no material changes from the risk factors previously disclosed in that Annual Report on Form 10-K.

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q and, in particular, our Management’s Discussion and Analysis of Financial Condition and Results of Operations set forth in Part I-Item 2, contain or incorporate a number of forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding:
•
our expectations regarding the amount of, timing of and trends with respect to our revenues, costs and expenses and other gains and losses, including those related to net product revenues from KALYDECO and ORKAMBI;
•
our expectations regarding clinical trials, development timelines and regulatory authority filings and submissions for ivacaftor, lumacaftor, VX-661, VX-371 (formerly P-1037), VX-152, VX-440, VX-970, VX-803, VX-984, VX-150 and VX-241, as well as the sNDA for KALYDECO for patients with CF two years of age and older who have one of 23 residual function mutations;
•
our expectations regarding planned clinical trials for next-generation correctors based upon pre-clinical data;
•
expectations regarding potential marketing approvals for drug candidates in ex-U.S. markets, including drug candidates that have received a positive opinion from the CHMP;
•
our ability to successfully market KALYDECO and ORKAMBI or any of our other drug candidates for which we obtain regulatory approval;
•
our expectations regarding the timing and structure of clinical trials of our drugs and drug candidates, including ivacaftor, lumacaftor, VX-661, VX-371 (formerly P-1037), VX-152, VX-440, VX-970, VX-803, VX-984, VX-150 and VX-241, and the expected timing of our receipt of data from our ongoing and planned clinical trials;


35

•
the data that will be generated by ongoing and planned clinical trials and the ability to use that data to advance compounds, continue development or support regulatory filings;
•
our beliefs regarding the support provided by clinical trials and preclinical and nonclinical studies of our drug candidates for further investigation, clinical trials or potential use as a treatment;
•
our plan to continue investing in our research and development programs and our strategy to develop our drug candidates, alone or with third party-collaborators;
•
the establishment, development and maintenance of collaborative relationships;
•
potential business development activities;
•
our ability to use our research programs to identify and develop new drug candidates to address serious diseases and significant unmet medical needs; and
•
our liquidity and our expectations regarding the possibility of raising additional capital.
Any or all of our forward-looking statements in this Quarterly Report on Form 10-Q may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many factors mentioned in this Quarterly Report on Form 10-Q will be important in determining future results. Consequently, no forward-looking statement can be guaranteed. Actual future results may vary materially from expected results. We also provide a cautionary discussion of risks and uncertainties under “Risk Factors” in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2014, which was filed with the SEC on February 13, 2015. These are factors and uncertainties that we think could cause our actual results to differ materially from expected results. Other factors and uncertainties besides those listed there could also adversely affect us.
Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “intends,” “expects” and similar expressions are intended to identify forward-looking statements. There are a number of factors and uncertainties that could cause actual events or results to differ materially from those indicated by such forward-looking statements, many of which are beyond our control. In addition, the forward-looking statements contained herein represent our estimate only as of the date of this filing and should not be relied upon as representing our estimate as of any subsequent date. While we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking statements.
Item 2.     Unregistered Sales of Equity Securities and Use of Proceeds
Issuer Repurchases of Equity Securities
The table set forth below shows all repurchases of securities by us during the three months ended September 30, 2015:
Period
 
Total Number
of Shares Purchased
Average Price
Paid per Share
Total Number of Shares
Purchased as Part of
Publicly Announced
Plans or Programs
Maximum Number of
Shares that May Yet
be Purchased Under
the Plans or Programs
July 1, 2015 to July 31, 2015
33,518
$0.01
—
—
August 1, 2015 to August 31, 2015
56,800
$0.01
—
—
September 1, 2015 to September 30, 2015
32,027
$0.01
—
—
The repurchases were made under the terms of our Amended and Restated 2006 Stock and Option Plan and our Amended and Restated 2013 Stock and Option Plan. Under these plans, we award shares of restricted stock to our employees that typically are subject to a lapsing right of repurchase by us. We may exercise this right of repurchase if a restricted stock recipient’s service to us is terminated. If we exercise this right, we are required to repay the purchase price paid by or on behalf of the recipient for the repurchased restricted shares, which typically is the par value per share of $0.01. Repurchased shares are returned and are available for future awards under the terms of our Amended and Restated 2013 Stock and Option Plan.
Item 5.     Other Information
On October 26, 2015, we entered into a strategic collaboration, option and license agreement, or the CRISPR Agreement, with CRISPR Therapeutics AG and its affiliates to collaborate on the discovery and development of potential new treatments aimed at the underlying genetic causes of human diseases using CRISPR-Cas9 gene editing technology. Detailed information on the CRISPR Agreement is set forth in Note C of Part 1-Item 1 of this Quarterly Report on Form 10-Q under the heading "CRISPR Therapeutics AG."

Item 6.    Exhibits
Exhibit Number
Exhibit Description
10.1
2015 Amendments to Credit Agreement, dated as of July 9, 2014, among Vertex Pharmaceuticals Incorporated, Macquarie US Trading LLC and the other lenders party thereto.
31.1
Certification of the Chief Executive Officer under Section 302 of the Sarbanes-Oxley Act of 2002.
31.2
Certification of the Chief Financial Officer under Section 302 of the Sarbanes-Oxley Act of 2002.
32.1
Certification of the Chief Executive Officer and the Chief Financial Officer under Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS
XBRL Instance
101.SCH
XBRL Taxonomy Extension Schema
101.CAL
XBRL Taxonomy Extension Calculation
101.LAB
XBRL Taxonomy Extension Labels
101.PRE
XBRL Taxonomy Extension Presentation
101.DEF
XBRL Taxonomy Extension Definition




36

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
Vertex Pharmaceuticals Incorporated
 
 
 
October 30, 2015
By:
/s/ Ian F. Smith
 
 
Ian F. Smith
 
 
Executive Vice President and Chief Financial Officer
(principal financial officer and
duly authorized officer)



37
 EX-10.1 2 a2015q310-q_exhibit101.htm EXHIBIT 10.1 Exhibit

October 1, 2015

Macquarie US Trading LLC
125 West 55 Street
New York, NY 10019
Attention: Arvind Admal (Arvind.Admal@macquarie.com)
David Anekstein (David.Anekstein@macquarie.com)


RE:
Amortization Grid

Ladies and Gentlemen:

Reference is made to that certain Credit Agreement, dated as of July 9, 2014 (as amended, supplemented, amended and restated or as otherwise modified from time to time, the “Credit Agreement”), among Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (the “Borrower”), the lenders from time to time party thereto, and Macquarie US Trading LLC, as Administrative Agent. Capitalized terms not otherwise defined herein shall have the meanings ascribed to them in the Credit Agreement.
The Borrower hereby requests that the amortization grid set forth in Section 2.04 of the Credit Agreement be amended and restated in its entirety to read as follows:
Date
Amount
Closing Date to October 31, 2015
$0.00
November 1, 2015
$15,000,000
January 1, 2016
$15,000,000
April 1, 2016
$15,000,000
July 1, 2016
$15,000,000
October 1, 2016
$60,000,000
January 1, 2017
$60,000,000
April 1, 2017
$60,000,000
Maturity Date
$60,000,000

In connection with such request, the Borrower certifies as follows:
(a)    The Borrower has the corporate or other organizational power and authority to execute, deliver and perform the terms and provisions of this letter agreement (the “Letter”) and has taken all necessary corporate action to authorize the execution, delivery and performance by it of this Letter. The Borrower has duly executed and delivered the Letter, and the Letter constitutes its legal, valid and binding obligation enforceable in accordance with its terms,

EAST\107271627.1

except to the extent that the enforceability thereof may be limited by applicable bankruptcy, insolvency, moratorium and other similar laws affecting secured parties generally and principles of equity.
(b)    The execution, delivery and performance by the Borrower of this Letter, has been duly authorized by all necessary corporate or other organizational action, and does not and will not (a) contravene the terms of its Organization Documents; (b) conflict with or result in any breach or contravention of, or the creation of any Lien under, or require any payment to be made under (i) any Material Contract to which the Borrower is a party or affecting the Borrower or the properties of the Borrower or any of its Subsidiaries or (ii) any order, injunction, writ or decree of any Governmental Authority or any arbitral award to which the Borrower or its property is subject; or (c) violate any applicable Law.
(c)    No Default has occurred and is continuing or would result from the consummation of the transactions contemplated by this Agreement or any other Loan Document.
Except as expressly set forth herein, this Letter shall not by implication or otherwise limit, impair, constitute a waiver of or otherwise affect the rights and remedies of the Lenders or the Administrative Agent under the Credit Agreement or any other Loan Document, and shall not alter, modify, amend or in any way affect any of the terms, conditions, obligations, covenants or agreements contained in the Credit Agreement or any other provision of the Credit Agreement or of any other Loan Document, all of which are ratified and affirmed in all respects and shall continue in full force and effect. Nothing herein shall be deemed to entitle the Borrower to a consent to, or a waiver, amendment, modification or other change of, any of the terms, conditions, obligations, covenants or agreements contained in the Credit Agreement or any other Loan Document in similar or different circumstances.
This Letter shall constitute a “Loan Document” for all purposes of the Credit Agreement and the other Loan Documents. THIS LETTER SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK. This Letter may be executed in counterparts (and by different parties hereto on different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract. Delivery of any executed counterpart of a signature page of this Letter by telecopy or email transmission (including by “.pdf” or “.tif” electronic format) shall be effective as delivery of a manually executed counterpart of this Letter.
By executing below, the signatories hereto agree to the amendment set forth herein.

EAST\107271627.1


Sincerely,
Vertex Pharmaceuticals Incorporated
 
 
/s/ Jeffrey Leiden
By:
Jeffrey Leiden
Title:
Chief Executive Officer
 
 
/s/ Ian Smith
By:
Ian Smith
Title:
Chief Financial Officer
 
 
ACKNOWLEDGED AND AGREED:
MACQUARIE US TRADING LLC, as Administrative Agent
 
 
/s/ Joshua Karlin
By:
Joshua Karlin
Title:
Authorized Signatory
 
 
/s/ Anita Chiu
By:
Anita Chiu
Title:
Associate Director
 
 
MACQUARIE CAF LLC
 
 
/s/ D. Price/ A. Hennedige
By:
D. Price/ A. Hennedige
Title:
Authorized Signatories
 
 
APPOLLO CREDIT FUNDING I LTD
 
 
By:
Apollo ST Fund Management LLC, its collateral manager
 
 
/s/ Joseph Moroney
By:
Joseph Moroney

Title:
Authorized Signatory
 
 
 
 

EAST\107271627.1


APPOLLO LINCOLN FIXED INCOME FUND, L.P.
 
 
By:
Apollo Lincoln Fixed Income Management LLC, its collateral manager
 
 
/s/ Joseph Glatt
By:
Joseph Glatt

Title:
Vice President
 
 
APPOLLO TR OPPRTUNISTIC, LTD.
 
 
By:
Apollo Total Return Master Fund, L.P., its member Appollo Total Return Advisors, L.P., its General Partner Apollo Total Return Advisors GP, LLC, its General Partner
 
 
/s/ Joseph Glatt
By:
Joseph Glatt

Title:
Vice President
 
 
MIDCAP FUNDING V TRUST (formerly known as MidCap Funding V, LLC
 
 
By:
Apollo Capital Management, L.P., its investment manager
 
 
By:
Apollo Capital Management, GP, LLC, its general partner
 
 
/s/ Howard Widra
By:
Howard Widra

Title:
Authorized Signatory

EAST\107271627.1

HIGHBRIDGE AIGUILLES ROUGES SECTOR B INVESTMENT FUND, L.P.
 
 
By:
Highbridge Principal Strategies, LLC
 
 
/s/ Vikas Keswani
By:
Vikas Keswani

Title:
Managing Director
 
 
APOLLO ALTERNATIVE CREDIT ABSOLUTE RETURN FUND L.P.
 
 
By:
Apollo Alternative Credit Absolute Return Management LLC, its Investment Manager
 
 
/s/ Joseph Glatt
By:
Joseph Glatt

Title:
Vice President




EAST\107271627.1
EXECUTION COPY

SECOND AMENDMENT TO CREDIT AGREEMENT
SECOND AMENDMENT TO CREDIT AGREEMENT (this “Amendment”), dated as of October 23, 2015 (the “Amendment Effective Date”), to the CREDIT AGREEMENT, dated as of July 9, 2014 (as the same may be amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “Credit Agreement”), among Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (the “Borrower”), the lenders from time to time party thereto (collectively, the “Lenders” and individually each a “Lender”), the guarantors party thereto from time to time (the “Guarantors”) and Macquarie US Trading LLC, as Administrative Agent (the “Administrative Agent’).
W I T N E S S E T H:
WHEREAS, pursuant to the Credit Agreement, the Lenders have agreed to make, and have made certain loans and extensions for credit to the Borrower;
WHEREAS, the Borrower has requested that certain provisions of the Credit Agreement be amended as set forth herein;
WHEREAS, the Administrative Agent and Lenders are willing to agree to such amendments, in each case on the terms set forth herein; and
WHEREAS, the Lenders that execute and deliver this Amendment constitute all of the Lenders.
NOW THEREFORE, in consideration of the premises and mutual covenants hereinafter set forth, the parties hereto agree as follows:

SECTION 1.Defined Terms; References. Unless otherwise defined herein, terms defined in the Credit Agreement and used herein shall have the meanings given to them in the Credit Agreement. Each reference to (x) “hereof”, “hereunder”, “herein” and “hereby” and each other similar reference and each reference to “this Agreement” and each other similar reference contained in the Credit Agreement and (y) “thereof”, “thereunder”, “therein” and “thereby” and each other similar reference and each reference to the Credit Agreement and each other similar reference contained in the other Loan Documents shall, in each case, as of the Amendment Effective Date, refer to the Credit Agreement as amended hereby.
SECTION 2.    Amendments to the Credit Agreement. The Credit Agreement is, effective as of the Amendment Effective Date, hereby amended as follows:
2.1.     The defined term “Kalydeco Product US and Foreign Revenue” in Section 1.01 of the Credit Agreement is amended and restated in its entirety to read as follows:
“Kalydeco Product US and Foreign Revenue” means, with respect to any date of determination, total revenue from sales of the Kalydeco Product derived from customers located in the United States and in other jurisdictions over the trailing twelve month period ending on such date of determination, which revenue, if consisting of currency other than US Dollars, will be calculated using the foreign

EAST\110676466.2

exchange rates prevailing as of the date of determination (or, in the event Kalydeco Product US and Foreign Revenue is less than $400,000,000, but greater than $300,000,000, the Borrower may use the foreign currency exchange rates for the relevant currencies that were in effect on the Closing Date to the extent such exchange rates are obtained from the same source as the rates used in producing the most recent financial statements delivered under clauses (a) and (b) of Section 6.01).”
2.2.     Section 2.04 of the Credit Agreement is amended so that the amortization grid set forth therein is amended and restated in its entirety to read as follows:
Date
Amount
Closing Date to September 30, 2016
$0.00
October 1, 2016
$75,000,000
January 1, 2017
$75,000,000
April 1, 2017
$75,000,000
Maturity Date
$75,000,000
2.3.     Section 2.11(a) of the Credit Agreement is amended and restated in its entirety to read as follows:
“On and after the period ending six months following the Closing Date, the Borrower may by written notice to the Administrative Agent elect to request that Macquarie CAF LLC establish one or more new term loan commitments (each, an “Incremental Commitment”), in a minimum amount of at least $50,000,000, but which Incremental Commitments shall not exceed $200,000,000 in the aggregate. Each such notice shall specify the date (the “Increase Effective Date”) on which the Borrower proposes that the Incremental Commitment shall be effective, which shall be a date not less than 10 Business Days after the date on which such notice is delivered to the Administrative Agent. Notwithstanding anything contained herein to the contrary, the establishment of the Incremental Commitment shall be made in the sole discretion of the Administrative Agent.”
2.4.     Section 6.02(a)(ii) of the Credit Agreement is amended and restated in its entirety to read as follows:
“(ii) revenue from sales of the Kalydeco Product derived from customers located outside of the United States over the trailing twelve month period ending on such date of determination, which revenue, if consisting of currency other than US Dollars, will be calculated using the foreign exchange rates prevailing as of the date of determination (or, in the event Kalydeco Product US and Foreign Revenue is less than $400,000,000, but greater than $300,000,000, the Borrower may use the foreign

EAST\110676466.2    

currency exchange rates for the relevant currencies that were in effect on the Closing Date to the extent such exchange rates are obtained from the same source as the rates used in producing the most recent financial statements delivered under clauses (a) and (b) of Section 6.01),”
2.5.     Section 7.02(c) of the Credit Agreement is amended and restated in its entirety to read as follows:
(c)    Investments by the Borrower and its Subsidiaries in their respective Subsidiaries outstanding on the date hereof, (ii) additional Investments by the Borrower and its Subsidiaries in Loan Parties (other than Holdings), (iii) additional Investments by Subsidiaries of the Borrower that are not Loan Parties in other Subsidiaries that are not Loan Parties and (iv) so long as no Event of Default has occurred and is continuing or would result from such Investment, additional Investments by the Loan Parties in Subsidiaries that are not Loan Parties, but only with respect to this clause (iv) to the extent that the Borrower and its Subsidiaries maintain in the aggregate at least $450,000,000 in cash and/or Cash Equivalents (the “Non-Loan Party Investment Required Cash”) (which value will be determined on a daily basis) immediately after giving effect to each such Investment (provided that (x) Non-Loan Party Investment Required Cash as used in this Section shall be increased by the amount of any advance of Incremental Loans and shall be reduced by any payments made under Section 2.03(a) or Section 2.04 and (y) Cystic Fibrosis Drug Franchise Assets may not be invested in non-Loan Party Subsidiaries under this Section 7.02(c));
2.6.     Section 7.03(e) of the Credit Agreement is amended and restated in its entirety to read as follows:
(e)    Indebtedness in respect of capital leases (other than capitalized real estate leases), Synthetic Lease Obligations and purchase money obligations for fixed or capital assets within the limitations set forth in Section 7.01(i); provided, however, that the aggregate amount of all such Indebtedness shall not exceed at any time outstanding $35,000,000 for the 2015 calendar year, $65,000,000 for the 2016 calendar year and $95,000,000 for the 2017 calendar year (for the avoidance of doubt, any of such Indebtedness which is listed on Schedule 7.03 shall not count toward the calculation of such baskets) .
2.7.     Section 7.06 of the Credit Agreement is hereby amended to remove the period at the end of Section 7.06(f), to insert “; and” at end of Section 7.06(f), and add the following section (g) immediately after Section 7.06(f):
“(g) the Borrower may, either directly or indirectly, repurchase shares of its stock from its stockholders (“Share Buyback”), but only to the extent that the Borrower and its Subsidiaries maintain in the aggregate at least $450,000,000 in cash and/or Cash Equivalents (the “Share Buyback Required Cash”) (which value will be determined on a daily basis) immediately after giving effect to the Share Buyback payment; provided that Share Buyback Required Cash as used in this Section shall be increased by the amount of any advance of Incremental Loans and shall be reduced by any payments made under Section 2.03(a) or Section 2.04.

EAST\110676466.2    

2.8.    Schedules 1.01, 5.05, 5.08 and 5.13 are hereby amended in their entirety to read as set forth on Exhibit A hereto.
SECTION 3.    Effectiveness. This Amendment shall become effective as of the date first written above when (i) the Administrative Agent (or its counsel) shall have received duly executed and completed counterparts hereof (in the form provided and specified by the Administrative Agent) that, when taken together, bear the signatures of each Loan Party, the Administrative Agent and each of the Lenders; and (ii) the representations and warranties set forth in Section 4 of this Amendment are true and correct in all material respects.
SECTION 4.     Representations and Warranties. To induce the other parties hereto to enter into this Amendment, each Loan Party represents and warrants to each of the Lenders and the Administrative Agent that:
4.1.     Each of the representations and warranties made by any of the Loan Parties in the Loan Documents (other than the representation and warranty set forth in Section 5.18(a) of the Credit Agreement and other than representations and warranties contained in the Collateral Documents that refer to schedules to such Collateral Documents) is true and correct in all material respects (except any such representation and warranty which is qualified by materiality, which is correct and accurate in all respects) on and as of the Amendment Effective Date as if made on such date; provided if any such representation and warranty is expressly made only as of a prior date, such representation and warranty is true as of such prior date. No Default or Event of Default exists or is continuing under any of the Loan Documents.
4.2.     The execution, delivery and performance by each Loan Party of this Amendment, and the consummation of the transactions contemplated hereby, are within their respective corporate, limited liability company or other powers, have been duly authorized by all necessary respective corporate, limited liability company or other organizational action, and do not and will not (i) violate the certificate of formation, certificate of incorporation or other constitutive documents or operating agreement, bylaws or other organizational document of any Loan Party, or (ii) violate any law, statute, rule or regulation applicable to such party in any material respect; and
4.3.     This Amendment has been duly executed and delivered by each of the Loan Parties party hereto, and constitutes a legal, valid and binding obligation of each such Loan Party, enforceable against it in accordance with its terms, subject to (i) the effects of bankruptcy, insolvency, moratorium, reorganization, fraudulent conveyance or other similar laws affecting creditors’ rights generally, (ii) general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law) and (iii) implied covenants of good faith and fair dealing.
SECTION 5.    Effect of Amendment.
5.1.     Except as expressly set forth herein, this Amendment shall not by implication or otherwise limit, impair, constitute a waiver of or otherwise affect the rights and remedies of the Lenders or the Administrative Agent under the Credit Agreement or any other Loan Document, and shall not alter, modify, amend or in any way affect any of the terms, conditions, obligations, covenants or agreements contained in the Credit Agreement or any other provision of the Credit Agreement or of any other Loan Document, all of which are ratified and affirmed in all respects and

EAST\110676466.2    

shall continue in full force and effect. Nothing herein shall be deemed to entitle the Borrower to a consent to, or a waiver, amendment, modification or other change of, any of the terms, conditions, obligations, covenants or agreements contained in the Credit Agreement or any other Loan Document in similar or different circumstances.
5.2.     Each Loan Party agrees that (a) all of its obligations, liabilities and indebtedness under any Loan Document to which it is a party, including, if applicable, its guarantee of the Obligations, shall remain in full force and effect on a continuous basis after giving effect to this Amendment and (b) all of the Liens and security interests created and arising under such Loan Documents shall remain in full force and effect on a continuous basis, and the perfected status and priority of each such Lien and security interest shall continue in full force and effect on a continuous basis, unimpaired, uninterrupted and undischarged, after giving effect to this Amendment as collateral security for its Obligations under the Credit Agreement and for its guarantees in the other Loan Documents.
5.3.     On and after the Amendment Effective Date, each reference in the Credit Agreement to “this Agreement”, “hereunder”, “hereof”, “herein”, or words of like import, and each reference to the Credit Agreement in any other Loan Document shall be deemed a reference to the Credit Agreement as amended hereby. This Amendment shall constitute a “Loan Document” for all purposes of the Credit Agreement and the other Loan Documents.
SECTION 6.    General.
6.1.     GOVERNING LAW. THIS AMENDMENT SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK.
6.2.     Costs and Expenses. The Borrower agrees to reimburse the Administrative Agent for its reasonable out-of-pocket costs and expenses incurred in connection with the preparation, negotiation and execution of this Amendment, including, without limitation, the reasonable out-of-pocket fees, charges and disbursements of counsel to the Administrative Agent.
6.3.     Counterparts. This Amendment may be executed in counterparts (and by different parties hereto on different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract. Delivery of any executed counterpart of a signature page of this Amendment by telecopy or email transmission (including by “.pdf” or “.tif” electronic format) shall be effective as delivery of a manually executed counterpart of this Amendment.
6.4.     Headings. The headings of this Amendment are used for convenience of reference only, are not part of this Amendment and shall not affect the construction of, or be taken into consideration in interpreting, this Amendment.
[remainder of page intentionally left blank]

EAST\110676466.2    
EXECUTION COPY

IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed and delivered by their duly authorized officers as of the date first above written.
VERTEX PHARMACEUTICALS INCORPORATED, as Borrower


By: /s/ Ian Smith
Name: Ian Smith
Title: Chief Financial Officer

VERTEX PHARMACEUTICALS (SAN DIEGO) LLC, as a Guarantor
By: /s/ Ian Smith
Name: Ian Smith
Title: Treasurer
VERTEX PHARMACEUTICALS (DELAWARE) LLC, as a Guarantor
By: /s/ Ian Smith
Name: Ian Smith
Title: Treasurer
VERTEX PHARMACEUTICALS (DISTRIBUTION) INCORPORATED, as a Guarantor
By: /s/ Ian Smith
Name: Ian Smith
Title: Treasurer
VERTEX PHARMACEUTICALS (PUERTO RICO) LLC, as a Guarantor
By: /s/ Ian Smith
Name: Ian Smith
Title: Treasurer
VERTEX HOLDINGS, INC., as a Guarantor
By: /s/ Ian Smith
Name: Ian Smith    
Title: Treasurer



EAST\110676466.2

MACQUARIE US TRADING LLC, as Administrative Agent
 
 
/s/ Joshua Karlin
By:
Joshua Karlin
Title:
Authorized Signatory
 
 
/s/ Anita Chiu
By:
Anita Chiu
Title:
Associate Director
 
 
MACQUARIE CAF LLC
 
 
/s/ D. Price/ G. Scarpa
By:
D. Price/ G. Scarpa
Title:
Authorized Signatories
 
 
APPOLLO CREDIT FUNDING I LTD
 
 
By:
Apollo ST Fund Management LLC, its collateral manager
 
 
/s/ Joseph Moroney
By:
Joseph Moroney

Title:
Authorized Signatory
 
 
 
 


EAST\110676466.2    

APPOLLO LINCOLN FIXED INCOME FUND, L.P.
 
 
By:
Apollo Lincoln Fixed Income Management LLC, its collateral manager
 
 
/s/ Joseph Glatt
By:
Joseph Glatt

Title:
Vice President
 
 
APPOLLO TR OPPRTUNISTIC, LTD.
 
 
By:
Apollo Total Return Master Fund, L.P., its member
 
 
By:
Appollo Total Return Advisors, L.P., its General Partner
 
 
By:
Apollo Total Return Advisors GP, LLC, its General Partner
 
 
/s/ Joseph Glatt
By:
Joseph Glatt

Title:
Vice President
 
 
MIDCAP FUNDING V TRUST (formerly known as MidCap Funding V, LLC
 
 
By:
Apollo Capital Management, L.P., its investment manager
 
 
By:
Apollo Capital Management, GP, LLC, its general partner
 
 
/s/ Howard Widra
By:
Howard Widra

Title:
Authorized Signatory

EAST\110676466.2    

HIGHBRIDGE AIGUILLES ROUGES SECTOR B INVESTMENT FUND, L.P.
 
 
By:
Highbridge Principal Strategies, LLC
 
 
/s/ Vikas Keswani
By:
Vikas Keswani

Title:
Managing Director
 
 
APOLLO ALTERNATIVE CREDIT ABSOLUTE RETURN FUND L.P.
 
 
By:
Apollo Alternative Credit Absolute Return Management LLC, its Investment Manager
 
 
/s/ Joseph Glatt
By:
Joseph Glatt

Title:
Vice President


EAST\110676466.2    
 EX-31.1 3 a2015q310-q_exhibit311.htm EXHIBIT 31.1 Exhibit


Exhibit 31.1
CERTIFICATION
I, Jeffrey M. Leiden, certify that:
1.
I have reviewed this Quarterly Report on Form 10-Q of Vertex Pharmaceuticals Incorporated;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)
evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)
disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date:
October 30, 2015
/s/ Jeffrey M. Leiden
 
 
 
 
 
Jeffrey M. Leiden
 
 
Chief Executive Officer and President




 EX-31.2 4 a2015q310-q_exhibit312.htm EXHIBIT 31.2 Exhibit


Exhibit 31.2
CERTIFICATION
I, Ian F. Smith, certify that:
1.
I have reviewed this Quarterly Report on Form 10-Q of Vertex Pharmaceuticals Incorporated;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)
evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)
disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date:
October 30, 2015
/s/ Ian F. Smith
 
 
 
 
 
Ian F. Smith
 
 
Executive Vice President and Chief Financial Officer



 EX-31.2 5 a2015q310-q_exhibit321.htm EXHIBIT 31.2 Exhibit


Exhibit 32.1
SECTION 906 CEO/CFO CERTIFICATION
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) each of the undersigned officers of Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (the “Company”), does hereby certify, to such officer’s knowledge, that the Quarterly Report on Form 10-Q for the quarter ended September 30, 2015 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date:
October 30, 2015
 
 
 
/s/ Jeffrey M. Leiden
 
 
 
 
 
Jeffrey M. Leiden
 
 
Chief Executive Officer and President
 
 
 
Date:
October 30, 2015
 
 
 
/s/ Ian F. Smith
 
 
 
 
 
Ian F. Smith
 
 
Executive Vice President and Chief Financial Officer
A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.
 





 EX-101.INS 6 vrtx-20150930.xml XBRL INSTANCE DOCUMENT 0000875320 2015-01-01 2015-09-30 0000875320 2015-10-23 0000875320 2014-07-01 2014-09-30 0000875320 2014-01-01 2014-09-30 0000875320 2015-07-01 2015-09-30 0000875320 2015-09-30 0000875320 2014-12-31 0000875320 us-gaap:ParentMember 2015-01-01 2015-09-30 0000875320 us-gaap:CommonStockMember 2014-09-30 0000875320 us-gaap:NoncontrollingInterestMember 2015-01-01 2015-09-30 0000875320 us-gaap:CommonStockMember 2013-12-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2013-12-31 0000875320 us-gaap:CommonStockMember 2015-01-01 2015-09-30 0000875320 us-gaap:RetainedEarningsMember 2013-12-31 0000875320 us-gaap:CommonStockMember 2015-09-30 0000875320 us-gaap:ParentMember 2013-12-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2014-01-01 2014-09-30 0000875320 us-gaap:NoncontrollingInterestMember 2015-09-30 0000875320 us-gaap:AdditionalPaidInCapitalMember 2014-09-30 0000875320 us-gaap:CommonStockMember 2014-12-31 0000875320 us-gaap:CommonStockMember 2014-01-01 2014-09-30 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-09-30 0000875320 us-gaap:ParentMember 2014-01-01 2014-09-30 0000875320 us-gaap:NoncontrollingInterestMember 2014-01-01 2014-09-30 0000875320 us-gaap:RetainedEarningsMember 2015-09-30 0000875320 us-gaap:ParentMember 2014-09-30 0000875320 us-gaap:RetainedEarningsMember 2015-01-01 2015-09-30 0000875320 us-gaap:NoncontrollingInterestMember 2014-09-30 0000875320 us-gaap:AdditionalPaidInCapitalMember 2015-01-01 2015-09-30 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-01-01 2015-09-30 0000875320 us-gaap:AdditionalPaidInCapitalMember 2014-12-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2015-09-30 0000875320 us-gaap:RetainedEarningsMember 2014-01-01 2014-09-30 0000875320 us-gaap:ParentMember 2015-09-30 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2014-09-30 0000875320 us-gaap:ParentMember 2014-12-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2014-01-01 2014-09-30 0000875320 us-gaap:RetainedEarningsMember 2014-12-31 0000875320 us-gaap:NoncontrollingInterestMember 2013-12-31 0000875320 2014-09-30 0000875320 us-gaap:NoncontrollingInterestMember 2014-12-31 0000875320 2013-12-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2013-12-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2014-12-31 0000875320 us-gaap:RetainedEarningsMember 2014-09-30 0000875320 vrtx:RebatesChargebacksAndDiscountsMember 2015-01-01 2015-09-30 0000875320 vrtx:CopayMitigationRebatesMember 2015-01-01 2015-09-30 0000875320 us-gaap:AllowanceForSalesReturnsMember 2015-01-01 2015-09-30 0000875320 vrtx:RebatesChargebacksAndDiscountsMember 2014-12-31 0000875320 us-gaap:AllowanceForTradeReceivablesMember 2015-01-01 2015-09-30 0000875320 us-gaap:AllowanceForSalesReturnsMember 2014-12-31 0000875320 us-gaap:AllowanceForTradeReceivablesMember 2014-12-31 0000875320 vrtx:CopayMitigationRebatesMember 2014-12-31 0000875320 vrtx:RebatesChargebacksAndDiscountsMember 2015-09-30 0000875320 vrtx:CopayMitigationRebatesMember 2015-09-30 0000875320 us-gaap:AllowanceForTradeReceivablesMember 2015-09-30 0000875320 us-gaap:AllowanceForSalesReturnsMember 2015-09-30 0000875320 vrtx:JanssenCollaborativeAgreementMember 2014-07-01 2014-09-30 0000875320 vrtx:JanssenCollaborativeAgreementMember 2014-01-01 2014-09-30 0000875320 vrtx:JanssenCollaborativeAgreementMember 2015-01-01 2015-09-30 0000875320 vrtx:JanssenCollaborativeAgreementMember 2015-07-01 2015-09-30 0000875320 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2015-01-01 2015-09-30 0000875320 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2015-07-01 2015-09-30 0000875320 vrtx:ParionSciencesIncMember 2015-06-04 2015-06-04 0000875320 vrtx:ParionSciencesIncMember 2015-06-04 0000875320 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2014-12-31 0000875320 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2015-09-30 0000875320 us-gaap:SubsequentEventMember vrtx:CRISPRTherapeuticsMember 2015-10-26 0000875320 2015-06-04 0000875320 vrtx:ParionSciencesIncMember 2015-09-30 0000875320 vrtx:BioAxoneBiosciencesIncMember 2015-07-01 2015-09-30 0000875320 vrtx:CysticFibrosisFoundationTherapeuticsIncorporatedAgreementMember 2011-04-01 2011-04-30 0000875320 vrtx:ParionSciencesIncMember vrtx:EnacInhibitorsinCfMember 2015-06-04 2015-06-04 0000875320 vrtx:CysticFibrosisFoundationTherapeuticsIncorporatedAgreementMember 2014-07-01 2014-09-30 0000875320 vrtx:BioAxoneBiosciencesIncMember 2014-10-01 2014-10-31 0000875320 us-gaap:SubsequentEventMember vrtx:CRISPRTherapeuticsMember 2015-10-26 2015-10-26 0000875320 vrtx:BioAxoneBiosciencesIncMember 2015-01-01 2015-09-30 0000875320 vrtx:CysticFibrosisFoundationTherapeuticsIncorporatedAgreementMember 2015-01-01 2015-09-30 0000875320 vrtx:ParionSciencesIncMember 2015-01-01 2015-09-30 0000875320 vrtx:BioAxoneBiosciencesIncMember 2015-09-30 0000875320 vrtx:CysticFibrosisFoundationTherapeuticsIncorporatedAgreementMember 2014-01-01 2014-09-30 0000875320 vrtx:CysticFibrosisFoundationTherapeuticsIncorporatedAgreementMember 2012-07-01 2012-09-30 0000875320 vrtx:ParionSciencesIncMember 2015-07-01 2015-09-30 0000875320 vrtx:JanssenCollaborativeAgreementMember 2014-01-01 2014-12-31 0000875320 vrtx:ParionSciencesIncMember vrtx:EnacInhibitorsinNonCfMember 2015-06-04 2015-06-04 0000875320 vrtx:BioAxoneBiosciencesIncMember 2014-10-01 2014-12-31 0000875320 vrtx:ParionSciencesIncMember vrtx:AdditionalEnacInhibitorsMember 2015-06-04 2015-06-04 0000875320 vrtx:CysticFibrosisFoundationTherapeuticsIncorporatedAgreementMember 2015-07-01 2015-09-30 0000875320 vrtx:CysticFibrosisFoundationTherapeuticsIncorporatedAgreementMember 2013-01-01 2013-03-31 0000875320 us-gaap:RestrictedStockMember 2015-01-01 2015-09-30 0000875320 us-gaap:RestrictedStockMember 2014-07-01 2014-09-30 0000875320 us-gaap:RestrictedStockMember 2014-01-01 2014-09-30 0000875320 us-gaap:EmployeeStockOptionMember 2014-07-01 2014-09-30 0000875320 us-gaap:EmployeeStockOptionMember 2014-01-01 2014-09-30 0000875320 us-gaap:RestrictedStockMember 2015-07-01 2015-09-30 0000875320 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-09-30 0000875320 us-gaap:EmployeeStockOptionMember 2015-07-01 2015-09-30 0000875320 us-gaap:FairValueInputsLevel3Member 2015-09-30 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:VariableInterestEntityPrimaryBeneficiaryMember vrtx:BioAxoneBiosciencesIncMember 2015-09-30 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2015-09-30 0000875320 us-gaap:FairValueMeasurementsRecurringMember 2015-09-30 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2015-09-30 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2015-09-30 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2015-09-30 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2015-09-30 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2015-09-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2015-09-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2015-09-30 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2015-09-30 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2015-09-30 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2015-09-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2015-09-30 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2015-09-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2015-09-30 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2015-09-30 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2015-09-30 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2015-09-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2015-09-30 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2015-09-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2015-09-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2015-09-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherAssetsMember us-gaap:FairValueMeasurementsRecurringMember 2015-09-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2015-09-30 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2015-09-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2015-09-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2015-09-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2015-09-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2015-09-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2015-09-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2015-09-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueMeasurementsRecurringMember 2015-09-30 0000875320 us-gaap:CashAndCashEquivalentsMember 2014-12-31 0000875320 vrtx:CorporateDebtSecuritiesDueWithinOneYearMember 2015-09-30 0000875320 us-gaap:CommercialPaperMember 2014-12-31 0000875320 us-gaap:AvailableforsaleSecuritiesMember 2015-09-30 0000875320 vrtx:CashAndMoneyMarketFundsMember 2014-12-31 0000875320 us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2015-09-30 0000875320 us-gaap:AvailableforsaleSecuritiesMember 2014-12-31 0000875320 us-gaap:CorporateDebtSecuritiesMember 2015-09-30 0000875320 vrtx:CorporateDebtSecuritiesDueWithinOneYearMember 2014-12-31 0000875320 us-gaap:CommercialPaperMember 2015-09-30 0000875320 vrtx:CorporateDebtSecuritiesDueAfterOneYearThroughFiveYearsMember 2014-12-31 0000875320 us-gaap:CashAndCashEquivalentsMember 2015-09-30 0000875320 vrtx:U.S.GovernmentSponsoredEnterprisesDebtSecuritiesDueWithinOneYearMember 2014-12-31 0000875320 vrtx:CashAndMoneyMarketFundsMember 2015-09-30 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2013-12-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2014-01-01 2014-09-30 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2014-01-01 2014-09-30 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2013-12-31 0000875320 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2014-09-30 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2014-09-30 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2014-09-30 0000875320 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2014-01-01 2014-09-30 0000875320 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2013-12-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2015-09-30 0000875320 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2015-01-01 2015-09-30 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2015-01-01 2015-09-30 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2015-01-01 2015-09-30 0000875320 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2014-12-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2014-12-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2014-12-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2015-09-30 0000875320 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2015-09-30 0000875320 currency:EUR us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2014-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2014-12-31 0000875320 currency:EUR us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2015-09-30 0000875320 currency:GBP us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2015-09-30 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2015-09-30 0000875320 currency:GBP us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2014-12-31 0000875320 currency:AUD us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2014-12-31 0000875320 currency:AUD us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2015-09-30 0000875320 us-gaap:OtherAssetsMember 2015-09-30 0000875320 us-gaap:OtherNoncurrentLiabilitiesMember 2015-09-30 0000875320 us-gaap:OtherCurrentLiabilitiesMember 2015-09-30 0000875320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2015-09-30 0000875320 us-gaap:OtherCurrentLiabilitiesMember 2014-12-31 0000875320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2014-12-31 0000875320 us-gaap:IndefinitelivedIntangibleAssetsMember us-gaap:VariableInterestEntityPrimaryBeneficiaryMember vrtx:BioAxoneBiosciencesIncMember 2014-10-01 2014-10-31 0000875320 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember vrtx:BioAxoneBiosciencesIncMember 2014-10-31 0000875320 us-gaap:IndefinitelivedIntangibleAssetsMember us-gaap:VariableInterestEntityPrimaryBeneficiaryMember vrtx:ParionSciencesIncMember 2014-10-01 2014-10-31 0000875320 us-gaap:SeniorLoansMember us-gaap:SubsequentEventMember 2015-10-01 2015-10-31 0000875320 us-gaap:SeniorLoansMember 2014-07-31 0000875320 us-gaap:SecuredDebtMember 2014-07-31 0000875320 2011-01-01 2011-12-31 0000875320 us-gaap:BuildingMember 2014-12-31 0000875320 us-gaap:SeniorLoansMember 2015-09-30 0000875320 us-gaap:SeniorLoansMember us-gaap:MinimumMember us-gaap:LondonInterbankOfferedRateLIBORMember 2014-07-01 2014-07-31 0000875320 us-gaap:BuildingMember 2015-09-30 0000875320 2011-12-31 0000875320 us-gaap:SeniorLoansMember 2014-07-01 2014-07-31 0000875320 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-09-30 0000875320 us-gaap:ResearchAndDevelopmentExpenseMember 2014-01-01 2014-09-30 0000875320 vrtx:EmployeeStockPurchasePlanMember 2014-01-01 2014-09-30 0000875320 us-gaap:EmployeeStockOptionMember 2014-07-01 2014-09-30 0000875320 vrtx:EmployeeRestrictedStockOptionMember 2014-01-01 2014-09-30 0000875320 vrtx:EmployeeRestrictedStockOptionMember 2014-07-01 2014-09-30 0000875320 vrtx:SellingGeneralAndAdministrativeExpenseMember 2015-01-01 2015-09-30 0000875320 vrtx:SellingGeneralAndAdministrativeExpenseMember 2015-07-01 2015-09-30 0000875320 vrtx:EmployeeRestrictedStockOptionMember 2015-01-01 2015-09-30 0000875320 vrtx:EmployeeStockPurchasePlanMember 2015-07-01 2015-09-30 0000875320 vrtx:EmployeeStockPurchasePlanMember 2015-01-01 2015-09-30 0000875320 us-gaap:ResearchAndDevelopmentExpenseMember 2015-07-01 2015-09-30 0000875320 vrtx:EmployeeStockPurchasePlanMember 2014-07-01 2014-09-30 0000875320 us-gaap:EmployeeStockOptionMember 2015-07-01 2015-09-30 0000875320 us-gaap:OtherRestructuringMember 2015-01-01 2015-09-30 0000875320 vrtx:KendallRestructuringMember 2015-01-01 2015-09-30 0000875320 vrtx:FanPierMoveMember 2015-01-01 2015-09-30 0000875320 vrtx:SellingGeneralAndAdministrativeExpenseMember 2014-07-01 2014-09-30 0000875320 us-gaap:EmployeeStockOptionMember 2014-01-01 2014-09-30 0000875320 vrtx:SellingGeneralAndAdministrativeExpenseMember 2014-01-01 2014-09-30 0000875320 us-gaap:ResearchAndDevelopmentExpenseMember 2015-01-01 2015-09-30 0000875320 us-gaap:ResearchAndDevelopmentExpenseMember 2014-07-01 2014-09-30 0000875320 vrtx:EmployeeRestrictedStockOptionMember 2015-07-01 2015-09-30 0000875320 vrtx:EmployeeRestrictedStockOptionMember 2015-09-30 0000875320 us-gaap:EmployeeStockOptionMember 2015-09-30 0000875320 vrtx:EmployeeStockPurchasePlanMember 2015-09-30 0000875320 vrtx:ExercisePriceRangefromDollars80.01toDollars100.00Member 2015-09-30 0000875320 vrtx:ExercisePriceRangefromDollars60.01toDollars80.00Member 2015-09-30 0000875320 vrtx:ExercisePriceRangefromDollars80.01toDollars100.00Member 2015-01-01 2015-09-30 0000875320 vrtx:ExercisePriceRangeFromDollars120.01toDollars134.69Member 2015-09-30 0000875320 vrtx:ExercisePriceRangefromDollars100.01toDollars120.00Member 2015-09-30 0000875320 vrtx:ExercisePriceRangefromDollars40.01toDollars60.00Member 2015-09-30 0000875320 vrtx:ExercisePriceRangefromDollars40.01toDollars60.00Member 2015-01-01 2015-09-30 0000875320 vrtx:ExercisePriceRangefromDollars100.01toDollars120.00Member 2015-01-01 2015-09-30 0000875320 vrtx:ExercisePriceRangefromDollars20.01toDollars40.00Member 2015-09-30 0000875320 vrtx:ExercisePriceRangeFromDollars18.93toDollars20.00Member 2015-09-30 0000875320 vrtx:ExercisePriceRangefromDollars20.01toDollars40.00Member 2015-01-01 2015-09-30 0000875320 vrtx:ExercisePriceRangeFromDollars18.93toDollars20.00Member 2015-01-01 2015-09-30 0000875320 vrtx:ExercisePriceRangeFromDollars120.01toDollars134.69Member 2015-01-01 2015-09-30 0000875320 vrtx:ExercisePriceRangefromDollars60.01toDollars80.00Member 2015-01-01 2015-09-30 0000875320 vrtx:StockandOptionPlan2013Member 2015-04-01 2015-06-30 0000875320 2014-04-01 2014-06-30 0000875320 2008-01-01 2008-12-31 0000875320 2014-04-01 2014-04-30 0000875320 vrtx:KendallRestructuringMember 2015-06-30 0000875320 vrtx:KendallRestructuringMember 2014-09-30 0000875320 vrtx:KendallRestructuringMember 2014-12-31 0000875320 vrtx:KendallRestructuringMember 2014-07-01 2014-09-30 0000875320 vrtx:KendallRestructuringMember 2015-07-01 2015-09-30 0000875320 vrtx:KendallRestructuringMember 2014-01-01 2014-09-30 0000875320 vrtx:KendallRestructuringMember 2015-09-30 0000875320 vrtx:KendallRestructuringMember 2013-12-31 0000875320 vrtx:KendallRestructuringMember 2014-06-30 0000875320 vrtx:FanPierMoveMember 2015-06-30 0000875320 vrtx:FanPierMoveMember 2015-07-01 2015-09-30 0000875320 vrtx:FanPierMoveMember 2014-07-01 2014-09-30 0000875320 vrtx:FanPierMoveMember 2014-01-01 2014-09-30 0000875320 vrtx:FanPierMoveMember 2014-06-30 0000875320 vrtx:FanPierMoveMember 2015-09-30 0000875320 vrtx:FanPierMoveMember 2013-12-31 0000875320 vrtx:FanPierMoveMember 2014-09-30 0000875320 vrtx:FanPierMoveMember 2014-12-31 0000875320 vrtx:KendallRestructuringMember 2003-01-01 2003-12-31 0000875320 vrtx:FanPierMoveMember 2015-03-31 0000875320 vrtx:FanPierMoveMember 2015-01-01 2015-03-31 0000875320 us-gaap:OtherRestructuringMember 2014-06-30 0000875320 us-gaap:OtherRestructuringMember 2015-07-01 2015-09-30 0000875320 us-gaap:OtherRestructuringMember 2014-09-30 0000875320 us-gaap:OtherRestructuringMember 2013-12-31 0000875320 us-gaap:OtherRestructuringMember 2015-06-30 0000875320 us-gaap:OtherRestructuringMember 2015-09-30 0000875320 us-gaap:OtherRestructuringMember 2014-07-01 2014-09-30 0000875320 us-gaap:OtherRestructuringMember 2014-01-01 2014-09-30 0000875320 us-gaap:OtherRestructuringMember 2014-12-31 xbrli:shares vrtx:lease utreg:sqft iso4217:USD xbrli:shares vrtx:segment vrtx:target vrtx:payment xbrli:pure vrtx:building iso4217:USD vrtx:facility false --12-31 Q3 2015 2015-09-30 10-Q 0000875320 245717286 Large Accelerated Filer VERTEX PHARMACEUTICALS INC / MA 0 20209000 13515000 33724000 25414000 106620000 78861000 210895000 71194000 189000 78899000 1115000 75964000 165272000 209676000 3891000 249698000 32519000 -306000 -23000 42000 -325000 1161000 1690000 67000 -596000 917000 2011000 -123000 -971000 1511000 2583000 63000 -1135000 5777154000 6106270000 136065000 136065000 136065000 189697000 189697000 189697000 46136000 31131000 15005000 135160000 91284000 43876000 65734000 44701000 21033000 186379000 124550000 61829000 13097000 2672000 13097000 2672000 12025000 3367000 12025000 3367000 1100000 120000 978000 23000 2334679000 2433993000 1546511000 1359452000 340573000 302848000 0 643421000 761847000 249580000 255340000 3853000 -600000 4500000 2780000 -100000 2900000 27000000 178200000 175340000 164317000 17806000 14153000 8985000 0 39293000 39273000 569299000 718563000 625259000 756250000 0 0 340573000 24000000 25109000 0 0 0 0 24000000 25109000 340573000 149264000 130991000 0.01 0.01 300000000 500000000 241764398 245646269 241764398 245646269 2385000 2419000 -168876000 -560432000 -91931000 -482009000 0 0 1333000 -30909000 -168876000 -560432000 -90598000 -512918000 23035000 -236000 10208000 28435000 30269000 55059000 321190000 974646000 379842000 1027576000 0.05 300000000 0.072 0.062 75000000 5200000 5300000 17468000 14000000 27808000 17501000 15044000 11544000 113860000 110360000 91023000 46921000 46596000 0 1576000 2011000 4159000 2011000 4159000 2011000 2583000 1576000 0 1576000 1576000 3976000 18525000 1691000 6068000 0 0 0 0 -0.72 -2.40 -0.39 -2.00 -0.72 -2.40 -0.39 -2.00 -481000 -2259000 456000 905000 1281000 3318000 197031000 190786000 1885000 P2Y3M18D P2Y8M23D P5M9D 0.075 0.071 0 1576000 0 1576000 2011000 2011000 651000 3508000 0 651000 0 651000 0 -1552000 0 -1552000 0 -24000 0 -24000 0 3508000 0 3508000 0 0 1552000 24000 39915000 8923000 50384000 19391000 10468000 -169996000 -561196000 -95149000 -482603000 -166577000 -556281000 -92486000 -1743000 -481752000 -3322000 -169996000 -561196000 -93816000 -513512000 -0.72 -2.40 -0.39 -2.00 -0.72 -2.40 -0.39 -2.00 -64000 -703000 0 0 -64000 -703000 0 0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3419000 4915000 1330000 777000 800000 31760000 30367000 30400000 798000 1261000 -5544000 6283000 7315000 88735000 12210000 90320000 -15085000 -13751000 4901000 16127000 0 7793000 19110000 23737000 -9000 21980000 0 -14830000 -20384000 -51686000 -21134000 -63552000 2817000 19074000 1834000 6413000 30848000 49197000 8506000 8669000 20508000 34115000 1238496000 1357261000 2334679000 2433993000 368254000 374959000 200000000 294800000 0 0 140245000 109335000 0 0 140245000 109335000 21177000 21177000 154585000 154585000 441054000 91122000 100020000 391546000 -391329000 -349418000 -170060000 -561899000 -95149000 -482603000 0 0 1333000 1333000 -30909000 30909000 25564000 0 164317000 164317000 0 1 -142203000 -538787000 -70026000 -413175000 3265000 42000 11061000 461000 1894000 2140000 25000 -271000 4094000 4072000 186000 -164000 -624000 -271000 -1384000 -164000 1184000 1467000 1713000 25000 1467000 -271000 1467000 3218000 594000 572000 186000 594000 -164000 594000 1838000 1713000 4546000 572000 -30000 25000 56000 186000 29000000 29000000 284340000 284340000 255340000 4797000 9527000 21707000 300000 34990000 300000 -7000 2899000 36700000 36700000 -3990000 34192000 -1326000 -5025000 92000 982000 399000 2266000 4249000 8865000 6643000 12071000 1559000 3070000 3975000 2782000 25421000 10544000 17215000 16515000 1066772000 292135000 0 80000000 36525000 32775000 0.01 0.01 1000000 1000000 0 0 0 0 0 0 44175000 268000 63388000 3057000 201274000 139689000 0 13386000 8050000 0 294383000 0 1203400000 804588000 -170060000 -561899000 0 -561899000 -561899000 -93816000 -513512000 -30909000 -482603000 -482603000 715812000 515000000 706670000 505600000 427000 427000 0 0 3500000 3500000 0 0 4300000 4300000 4000000 18700000 45438000 45438000 190939000 654043000 246284000 685741000 21900000 8418000 8418000 75765000 75765000 176000 22086000 40843000 1555000 39752000 -464000 46761000 2372000 46588000 -2199000 1826000 1629000 51000 146000 682000 2885000 -1971000 -232000 8441000 797000 19115000 792000 3256000 14936000 1948000 40742000 12912000 869000 33390000 11596000 902000 9017000 9924000 972000 7818000 9014000 33107000 8682000 12748000 9122000 27249000 -28051000 -4705450000 -5188053000 178987000 3674000 435859000 17179000 309816000 599000 614401000 3362000 8386000 2284000 32134000 12917000 5759000 158000 17628000 1742000 137099000 362879000 302511000 593774000 75224000 226882000 99772000 280026000 280569000 294832000 14206000 0 135160000 186379000 7800000 120.01 18.93 100.01 20.01 40.01 60.01 80.01 5438000 168000 138000 201000 2284000 1458000 551000 638000 12025000 1505000 138000 1791000 2499000 2593000 1567000 1932000 134.69 20.00 120 40 60 80 100 26291000 18418000 1883000 78403000 51431000 6231000 39074000 26203000 1738000 105720000 78274000 5703000 53.98 127.52 18.93 109.22 34.36 49.52 74.95 87.16 74.90 131.21 18.93 109.24 34.56 48.27 75.94 90.27 P7Y3M22D P9Y9M11D P2Y4M6D P9Y3M26D P3Y9M22D P6Y9M18D P8Y3M22D P8Y3M11D 233789000 240238000 241764000 245646000 6449000 3882000 223867000 223812000 55000 223867000 139453000 139419000 34000 139453000 1075006000 922147000 1356405000 -306000 5321286000 2320000 0 1356405000 -3966895000 1155905000 1161000 5681163000 2375000 0 1155905000 -4528794000 1096183000 917000 5777154000 2385000 21177000 1075006000 -4705450000 1076732000 1511000 6106270000 2419000 154585000 922147000 -5188053000 900000 900000 -13713000 -993000 -143000 -235000 -12342000 36023000 4713000 1463000 745000 29102000 38308000 895000 2325000 1260000 33828000 236137000 234207000 241969000 240749000 236137000 234207000 241969000 240749000 0.066 0.059 0.041 1387106000 761847000 625259000 51746000 625259000 50350000 196001000 463750000 1005830000 249580000 756250000 25109000 140245000 24000000 707141000 109335000 1387229000 761970000 625259000 51674000 625259000 50443000 196065000 463788000 1005767000 249517000 756250000 25109000 140131000 24000000 707141000 109386000 88000 88000 0 72000 0 0 2000 14000 142000 142000 0 0 114000 0 0 28000 211000 211000 0 0 0 93000 66000 52000 79000 79000 0 0 0 0 0 79000 P30D 230000000 490000000 370000000 420000000 30000000.0 9300000 9300000 P90D P90D 360000000 75000000 6 P180D P270D P10Y P6M 80000000 75000000.0 10000000 35000000 P1Y 33502000 2000000 1390000 40846000 6500000 4262000 1546000 0 441000 2999000 0 1620000 473073000 472724000 473400000 473100000 P2Y 31200000 0 0 0 2 2 0.09 P15Y 90000000.0 2 2 P5Y P10Y 10468000 160000000 0 2689000 0 8067000 1820000 2919000 1820000 8194000 0.5 3 500000 48484000 429000 6120000 2402000 39533000 32486000 3254000 5115000 1652000 22465000 75400000 29000000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements are unaudited and have been prepared by Vertex Pharmaceuticals Incorporated ("Vertex" or the "Company") in accordance with accounting principles generally accepted in the United States of America ("GAAP"). </font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The condensed consolidated financial statements reflect the operations of (i) the Company, (ii) its wholly-owned subsidiaries and (iii) consolidated variable interest entities (VIEs). All material intercompany balances and transactions have been eliminated. The Company operates in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">one</font><font style="font-family:inherit;font-size:10pt;"> segment, pharmaceuticals.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain information and footnote disclosures normally included in the Company's annual financial statements have been condensed or omitted. These interim financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the financial position and results of operations for the interim periods ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full fiscal year. These interim financial statements should be read in conjunction with the audited financial statements for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, which are contained in the Company's Annual Report on Form&#160;10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;"> that was filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on </font><font style="font-family:inherit;font-size:10pt;">February&#160;13, 2015</font><font style="font-family:inherit;font-size:10pt;"> (the "2014 Annual Report on Form&#160;10-K").</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Marketable Securities</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of the Company&#8217;s cash, cash equivalents and marketable securities is shown below:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="53%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross <br clear="none"/>Unrealized <br clear="none"/>Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross <br clear="none"/>Unrealized <br clear="none"/>Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of September 30, 2015</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash and cash equivalents:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash and money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">707,141</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">707,141</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">25,109</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">25,109</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">24,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">24,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">756,250</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">756,250</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Marketable securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Commercial paper (due within 1 year)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">140,131</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">114</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">140,245</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities (due within 1 year)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">109,386</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(79</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">109,335</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">249,517</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">142</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(79</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">249,580</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total cash, cash equivalents and marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,005,767</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">142</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(79</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,005,830</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2014</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash and cash equivalents:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash and money market funds</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">625,259</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">625,259</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">625,259</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">625,259</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Marketable securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Government-sponsored enterprise securities (due within 1&#160;year)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">463,788</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(52</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">463,750</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Commercial paper (due within 1 year)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">51,674</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">72</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">51,746</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities (due within 1 year)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">196,065</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(66</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">196,001</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities (due after 1 year through 5 years)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">50,443</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">50,350</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">761,970</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">88</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(211</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">761,847</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total cash, cash equivalents and marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,387,229</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">88</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(211</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,387,106</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has a limited number of marketable securities in insignificant loss positions as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, which the Company does not intend to sell and has concluded it will not be required to sell before recovery of the amortized costs for the investment at maturity. There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> charges recorded for other-than-temporary declines in fair value of marketable securities nor gross realized gains or losses recognized in </font><font style="font-family:inherit;font-size:10pt;">the three and nine months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Collaborative Arrangements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cystic Fibrosis Foundation Therapeutics Incorporated</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2011, the Company entered into an amendment (the &#8220;April 2011 Amendment&#8221;) to its existing collaboration agreement with Cystic Fibrosis Foundation Therapeutics Incorporated (&#8220;CFFT&#8221;) pursuant to which CFFT agreed to provide financial support for (i)&#160;development activities for VX-661, a compound that targets the processing and trafficking defect of the F508del CFTR proteins discovered under the collaboration, and (ii)&#160;additional research and development activities directed at discovering new compounds targeting the processing and trafficking defect of the F508del protein. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the April 2011 Amendment, CFFT agreed to provide the Company with up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$75.0 million</font><font style="font-family:inherit;font-size:10pt;"> in funding over approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">five</font><font style="font-family:inherit;font-size:10pt;"> years for research and development activities. The Company retains the right to develop and commercialize KALYDECO (ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor), lumacaftor, VX-661 and any other compounds discovered during the course of the research collaboration with CFFT. The Company recognized no collaborative revenues from this collaboration during </font><font style="font-family:inherit;font-size:10pt;">the three and nine months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$6.5 million</font><font style="font-family:inherit;font-size:10pt;"> of collaborative revenues from this collaboration during </font><font style="font-family:inherit;font-size:10pt;">the three and nine months ended September 30, 2014</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the original agreement, as amended prior to the April 2011 Amendment, the Company agreed to pay CFFT tiered royalties calculated as a percentage, ranging from single digits to sub-teens, of annual net sales of any approved drugs discovered during the research term that ended in 2008, including KALYDECO, ORKAMBI, lumacaftor and VX-661. The April 2011 Amendment provides for a tiered royalty in the same range on net sales of compounds targeting the processing and trafficking defect of F508del CFTR proteins discovered during the research term that began in 2011 and ended in February 2014. In each of the third quarter of 2012 and the first quarter of 2013, CFFT earned a commercial milestone payment of </font><font style="font-family:inherit;font-size:10pt;">$9.3 million</font><font style="font-family:inherit;font-size:10pt;"> from the Company upon achievement of certain sales levels for KALYDECO. These milestones were reflected in the Company's cost of product revenues. There are no additional commercial milestone payments payable by the Company to CFFT related to sales levels for KALYDECO. The Company also is obligated to make up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">two</font><font style="font-family:inherit;font-size:10pt;"> one-time commercial milestone payments to CFFT upon achievement of certain sales levels for ORKAMBI. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company began marketing KALYDECO in the United States and certain countries in the European Union in 2012 and began marketing ORKAMBI in the United States in July 2015. The Company has royalty obligations to CFFT for each compound commercialized pursuant to this collaboration until the expiration of patents covering that compound. The Company has patents in the United States and European Union covering the composition-of-matter of ivacaftor that expire in 2027 and 2025, respectively, subject to potential patent life extensions. The Company has patents in the United States and European Union covering the composition-of-matter of lumacaftor that expire in 2030 and 2026, respectively, subject to potential patent life extensions. CFFT may terminate its funding obligations under the collaboration, as amended, in certain circumstances, in which case there will be a proportional adjustment to the royalty rates and commercial milestone payments for certain compounds. The collaboration also may be terminated by either party for a material breach by the other, subject to notice and cure provisions.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Janssen Pharmaceutica&#160;NV</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has a collaboration agreement (the &#8220;Janssen HCV Agreement&#8221;) with Janssen Pharmaceutica NV (&#8220;Janssen NV&#8221;) for the development, manufacture and commercialization of telaprevir, which Janssen NV began marketing under the brand name INCIVO in certain of its territories in September 2011. Pursuant to the Janssen HCV Agreement, as amended, Janssen NV has a fully-paid license to manufacture and commercialize INCIVO in its territories including Europe, South America, the Middle East, Africa and Australia, subject to the payment of third-party royalties on net sales of INCIVO. In addition to the collaborative revenues, the Company recorded royalty revenues and corresponding royalty expenses related to third-party royalties that Janssen NV remains responsible for based on INCIVO net sales. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During </font><font style="font-family:inherit;font-size:10pt;">the three and nine months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized the following revenues attributable to the Janssen NV collaboration:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="57%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Royalty revenues (INCIVO)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">158</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,284</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,742</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,917</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Collaborative revenues (telaprevir)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">441</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,390</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,620</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,262</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;Total revenues attributable to the Janssen NV collaboration</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">599</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,674</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,362</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">17,179</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">CRISPR Therapeutics AG</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 26, 2015, the Company entered into a strategic collaboration, option and license agreement (the "CRISPR Agreement") with CRISPR Therapeutics AG and its affiliates ("CRISPR") to collaborate on the discovery and development of potential new treatments aimed at the underlying genetic causes of human diseases using CRISPR-Cas9 gene editing technology. The Company has the exclusive right to license up to </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> CRISPR-Cas9-based targets. In connection with the CRISPR Agreement, the Company made an upfront payment to CRISPR of </font><font style="font-family:inherit;font-size:10pt;">$75.0 million</font><font style="font-family:inherit;font-size:10pt;"> and will make a </font><font style="font-family:inherit;font-size:10pt;">$30.0 million</font><font style="font-family:inherit;font-size:10pt;"> investment in CRISPR pursuant to a convertible loan agreement. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company will fund all of the discovery activities conducted pursuant to the CRISPR Agreement. For potential hemoglobinapathy treatments, including treatments for sickle cell disease, the Company and CRISPR will share equally all research and development costs and worldwide revenues. For other targets that the Company elects to license, the Company would lead all development and global commercialization activities. For each of up to </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> targets that the Company elects to license, other than hemoglobinapathy targets, CRISPR has the potential to receive up to </font><font style="font-family:inherit;font-size:10pt;">$420.0 million</font><font style="font-family:inherit;font-size:10pt;"> in development, regulatory and commercial milestones and royalties on net sales. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company may terminate the CRISPR Agreement upon </font><font style="font-family:inherit;font-size:10pt;">90</font><font style="font-family:inherit;font-size:10pt;"> days&#8217; notice to CRISPR prior to any product receiving marketing approval or upon </font><font style="font-family:inherit;font-size:10pt;">270</font><font style="font-family:inherit;font-size:10pt;"> days&#8217; notice after such point. The CRISPR Agreement also may be terminated by either party for a material breach by the other, subject to notice and cure provisions. Unless earlier terminated, the CRISPR Agreement will continue in effect until the expiration of the Company's payment obligations under the CRISPR Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Variable Interest Entities</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has entered into several agreements pursuant to which it has licensed rights to certain drug candidates from third-party collaborators, which has resulted in the consolidation of the third parties' financial statements into the Company's condensed consolidated financial statements as VIEs. In order to account for </font><font style="font-family:inherit;font-size:10pt;">the fair value of the contingent milestone and royalty payments</font><font style="font-family:inherit;font-size:10pt;"> related to these collaborations under GAAP, the Company uses present-value models based on assumptions regarding the probability of achieving the relevant milestones, estimates regarding the time to develop the drug candidates, estimates of future product sales and the appropriate discount rates. The Company bases its estimate of the probability of achieving the relevant milestones on industry data for similar assets and its own experience. The discount rates used in the valuation model represent a measure of credit risk and market risk associated with settling the liabilities. Significant judgment is used in determining the appropriateness of these assumptions at each reporting period. Changes in these assumptions could have a material effect on the fair value of the contingent milestone and royalty payments. The following collaborations are, or were previously, reflected in the Company's financial statements for being consolidated as VIEs:</font></div><div style="line-height:120%;padding-top:15px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Parion Sciences,&#160;Inc.</font></div><div style="line-height:120%;padding-top:15px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">License and Collaboration Agreement</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 4, 2015, the Company entered into a strategic collaboration and license agreement (the "Parion Agreement") with Parion Sciences, Inc. (&#8220;Parion&#8221;).&#160; Pursuant to the agreement, the Company is collaborating with Parion to develop investigational epithelial sodium channel (&#8220;ENaC&#8221;) inhibitors, including VX-371 (formerly P-1037) and P-1055, for the potential treatment of cystic fibrosis, or CF, and other pulmonary diseases.&#160; The Company is leading development activities for VX-371 and P-1055 in CF and other pulmonary diseases and is responsible for all costs, subject to certain exceptions, related to development and commercialization of the compounds.</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the Parion Agreement, the Company has worldwide development and commercial rights to Parion&#8217;s lead investigational ENaC inhibitors, VX-371 and P-1055, for the potential treatment of CF and all other pulmonary diseases and has the option to select additional compounds discovered in Parion&#8217;s research program.&#160; Parion received an </font><font style="font-family:inherit;font-size:10pt;">$80.0 million</font><font style="font-family:inherit;font-size:10pt;"> up-front payment and has the potential to receive up to an additional (i) </font><font style="font-family:inherit;font-size:10pt;">$490.0 million</font><font style="font-family:inherit;font-size:10pt;"> in development and regulatory milestone payments for development of ENaC inhibitors in CF, including </font><font style="font-family:inherit;font-size:10pt;">$360.0 million</font><font style="font-family:inherit;font-size:10pt;"> related to global filing and approval milestones, (ii) </font><font style="font-family:inherit;font-size:10pt;">$370.0 million</font><font style="font-family:inherit;font-size:10pt;"> in development and regulatory milestones for VX-371 and P-1055 in non-CF pulmonary indications and (iii)&#160;</font><font style="font-family:inherit;font-size:10pt;">$230.0 million</font><font style="font-family:inherit;font-size:10pt;"> in development and regulatory milestones should the Company elect to develop an additional ENaC inhibitor from Parion&#8217;s research program. The Company has agreed to pay Parion tiered royalties that range from the low double digits to mid-teens as a percentage of potential sales of licensed products.</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company may terminate the Parion Agreement upon </font><font style="font-family:inherit;font-size:10pt;">90</font><font style="font-family:inherit;font-size:10pt;"> days&#8217; notice to Parion prior to any licensed product receiving marketing approval or upon </font><font style="font-family:inherit;font-size:10pt;">180</font><font style="font-family:inherit;font-size:10pt;"> days&#8217; notice after such point. If the Company experiences a change of control prior to the initiation of the first Phase 3 clinical trial for a licensed product, Parion may terminate the Parion Agreement upon </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;"> days&#8217; notice, subject to the Company's right to receive specified royalties on any subsequent commercialization of licensed products. The Parion Agreement also may be terminated by either party for a material breach by the other, subject to notice and cure provisions. Unless earlier terminated, the agreement will continue in effect until the expiration of the Company's royalty obligations, which expire on a country-by-country basis on the later of (i)&#160;the date the last-to-expire patent covering a licensed product expires or (ii)&#160;</font><font style="font-family:inherit;font-size:10pt;">ten</font><font style="font-family:inherit;font-size:10pt;"> years after the first commercial sale in the country.</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company determined that Parion is a VIE based on, among other factors, the significance to Parion of the ENaC inhibitors licensed to the Company pursuant to the Parion Agreement and on the Company's power to direct the activities that most significantly impact the economic performance of Parion. &#160;Accordingly, the Company consolidated Parion's financial statements beginning on June&#160;4, 2015. However, the Company's interests in Parion are limited to those accorded to the Company in the Parion Agreement. In particular, the Company did not acquire any equity interest in Parion, any interest in Parion's cash and cash equivalents or any control over Parion's activities that do not relate to the Parion Agreement.</font></div><div style="line-height:120%;padding-top:15px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Consideration for the Parion Agreement</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company determined that the fair value of the consideration from the Company to Parion was </font><font style="font-family:inherit;font-size:10pt;">$255.3 million</font><font style="font-family:inherit;font-size:10pt;"> as of June 4, 2015, which consisted of (i)&#160;an </font><font style="font-family:inherit;font-size:10pt;">$80.0 million</font><font style="font-family:inherit;font-size:10pt;"> up-front payment, (ii)&#160;the estimated fair value of the contingent research and development milestones potentially payable by the Company to Parion and (iii)&#160;the estimated fair value of potential royalty payments payable by the Company to Parion. The Company valued the contingent milestone and royalty payments using (a)&#160;discount rates ranging from </font><font style="font-family:inherit;font-size:10pt;">4.1%</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">5.9%</font><font style="font-family:inherit;font-size:10pt;"> for the development milestones and (b)&#160;a discount rate of </font><font style="font-family:inherit;font-size:10pt;">6.6%</font><font style="font-family:inherit;font-size:10pt;"> for royalties. The consideration paid and the preliminary fair value of the contingent milestone and royalty payments payable by the Company pursuant to the agreement are set forth in the table below:</font></div><div style="line-height:120%;text-align:center;text-indent:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:63.49206349206349%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="78%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="20%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">June 4, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Up-front payment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">80,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Fair value of contingent milestone and royalty payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">175,340</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">255,340</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:15px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Preliminary Allocation of Assets and Liabilities</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the purposes of the condensed consolidated balance sheets at June&#160;4, 2015 and </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the Company preliminarily allocated the total consideration, which is comprised of the up-front payment and the fair value of the contingent milestone and royalty payments, intangible assets, goodwill, deferred tax liability, net and net other assets and liabilities. </font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recorded </font><font style="font-family:inherit;font-size:10pt;">$255.3 million</font><font style="font-family:inherit;font-size:10pt;"> of intangible assets on the Company's condensed consolidated balance sheet for Parion's in-process research and development assets. These in-process research and development assets relate to Parion's pulmonary ENaC platform, including the intellectual property related to VX-371 and P-1055, that are licensed by Parion to the Company. The difference between the preliminary fair value of the consideration and the fair value of Parion's assets (including the fair value of intangible assets) and liabilities was allocated to goodwill. </font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the preliminary fair values of the assets and liabilities recorded on the effective date of the agreement:</font></div><div style="line-height:120%;text-align:center;text-indent:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:63.49206349206349%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="78%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="20%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">June 4, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">255,340</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10,468</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Deferred tax liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(91,023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net other assets (liabilities)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(10,468</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net assets attributable to noncontrolling interests</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;text-indent:12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">164,317</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:16px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">BioAxone Biosciences, Inc.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2014, the Company entered into a license and collaboration agreement (the &#8220;BioAxone Agreement&#8221;) with BioAxone Biosciences, Inc. (&#8220;BioAxone&#8221;), a privately-held biotechnology company, which resulted in the consolidation of BioAxone as a VIE beginning on October 1, 2014. The Company paid BioAxone initial payments of </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;"> in the fourth quarter of 2014. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BioAxone has the potential to receive up to </font><font style="font-family:inherit;font-size:10pt;">$90.0 million</font><font style="font-family:inherit;font-size:10pt;"> in milestones and fees, including development, regulatory and milestone payments and a license continuation fee. In addition, BioAxone would receive royalties and commercial milestones on future net product sales of VX-210, if any. The Company holds an option to purchase BioAxone at a predetermined price. The option expires on the earliest of (a) the day the FDA accepts the Biologics License Application submission for VX-210, (b) the day the Company elects to continue the license instead of exercising the option to purchase BioAxone and (c) March 15, 2018, subject to the Company&#8217;s option to extend this date by </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> year. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Alios BioPharma,&#160;Inc.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2011, the Company entered into a license and collaboration agreement (the &#8220;Alios Agreement&#8221;) with Alios BioPharma,&#160;Inc. (&#8220;Alios&#8221;), which was a privately-held biotechnology company, which resulted in the consolidation of Alios as a VIE through December 31, 2013. Pursuant to the Alios Agreement, the Company and Alios collaborated on the research, development and commercialization of HCV nucleotide analogues discovered by Alios through April 2014. In December 2014, the Alios Agreement terminated in accordance with its terms pursuant to a termination notice delivered by the Company in October 2014. As of September 30, 2014, the Company concluded that it no longer had significant continuing involvement with Alios due to its intent and ability to terminate the Alios Agreement, among other factors; therefore, the operations of Alios are presented as discontinued operations in these </font><font style="font-family:inherit;font-size:10pt;">condensed consolidated financial statements</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:15px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Aggregate VIE Financial Information</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company did not have any consolidated VIEs for </font><font style="font-family:inherit;font-size:10pt;">the three and nine months ended September 30, 2014</font><font style="font-family:inherit;font-size:10pt;">. An aggregate summary of net loss attributable to noncontrolling interest related to the Company's VIEs for </font><font style="font-family:inherit;font-size:10pt;">the three and nine months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> is as follows:</font></div><div style="line-height:120%;text-align:center;text-indent:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.42857142857143%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="61%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="17%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="17%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Loss attributable to noncontrolling interest before provision for income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,743</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,322</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Provision for income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(777</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(30,367</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Increase in fair value of contingent milestone and royalty payments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,853</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,780</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net (income) loss attributable to noncontrolling interest</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,333</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(30,909</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During </font><font style="font-family:inherit;font-size:10pt;">the three and nine months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">the fair value of the contingent milestone and royalty payments</font><font style="font-family:inherit;font-size:10pt;"> related to the BioAxone collaboration decreased by </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. During </font><font style="font-family:inherit;font-size:10pt;">the three and nine months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">the fair value of the contingent milestone and royalty payments</font><font style="font-family:inherit;font-size:10pt;"> related to the Parion collaboration increased by </font><font style="font-family:inherit;font-size:10pt;">$4.5 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$2.9 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. The changes in </font><font style="font-family:inherit;font-size:10pt;">the fair value of the contingent milestone and royalty payments</font><font style="font-family:inherit;font-size:10pt;"> were primarily due to the changes in market interest rates and the time value of money. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the fair value of the contingent milestone and royalty payments related to the BioAxone collaboration and the Parion collaboration was </font><font style="font-family:inherit;font-size:10pt;">$27.0 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$178.2 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes items related to the Company's VIEs included in the Company's condensed consolidated balance sheets as of the dates set forth in the table:</font></div><div style="line-height:120%;text-align:center;text-indent:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.42857142857143%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="65%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">September 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restricted cash and cash equivalents (VIE)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">75,765</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,418</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,057</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">268</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">284,340</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">29,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">19,391</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,923</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">461</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,115</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">189</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accrued expenses and other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">32,519</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,891</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Deferred tax liability, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">110,360</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,544</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Noncontrolling interest</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">154,585</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">21,177</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has recorded the VIEs' cash and cash equivalents as restricted cash and cash equivalents (VIE) because (i)&#160;the Company does not have any interest in or control over the VIEs' cash and cash equivalents and (ii)&#160;the Company's agreements with each VIE do not provide for the VIEs' cash and cash equivalents to be used for the development of the assets that the Company licensed from the applicable VIE. Assets recorded as a result of consolidating our VIEs' financial condition into the Company's balance sheet do not represent additional assets that could be used to satisfy claims against the Company's general assets. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Outlicense Arrangements</font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the ordinary course of the Company's business, the Company has entered into various agreements pursuant to which it has outlicensed rights to certain drug candidates to third-party collaborators. Although the Company does not consider any of these outlicense arrangements to be material, the most notable of these outlicense arrangements is described below. Pursuant to these outlicense arrangements, our collaborators are responsible for all costs related to the continued development of such drug candidates. Depending on the terms of the arrangements, the Company's collaborators may be required to make upfront payments, milestone payments upon the achievement of certain product research and development objectives and/or pay royalties on future sales, if any, of commercial products resulting from the collaboration. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Janssen Pharmaceuticals, Inc.</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2014, the Company entered into an agreement (the &#8220;Janssen Influenza Agreement&#8221;) with Janssen Pharmaceuticals, Inc. (&#8220;Janssen Inc.&#8221;), which was amended in October 2014 to clarify certain roles and responsibilities of the parties. </font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the Janssen Influenza Agreement, Janssen Inc. has an exclusive worldwide license to develop and commercialize certain drug candidates for the treatment of influenza, including VX-787. The Company received non-refundable payments of </font><font style="font-family:inherit;font-size:10pt;">$35.0 million</font><font style="font-family:inherit;font-size:10pt;"> from Janssen Inc. in 2014, which were recorded as collaborative revenue. The Company has the potential to receive development, regulatory and commercial milestone payments as well as royalties on future product sales, if any. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Janssen Inc. is responsible for costs related to the development and commercialization of the compounds. During </font><font style="font-family:inherit;font-size:10pt;">the three and nine months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded reimbursement for these development activities of </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$18.7 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. During </font><font style="font-family:inherit;font-size:10pt;">the three and nine months ended September 30, 2014</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded reimbursement for these development activities of </font><font style="font-family:inherit;font-size:10pt;">$4.3 million</font><font style="font-family:inherit;font-size:10pt;">. The reimbursements are recorded as a reduction to development expense in the Company's </font><font style="font-family:inherit;font-size:10pt;">condensed consolidated statements of operations</font><font style="font-family:inherit;font-size:10pt;"> primarily due to the fact that Janssen Inc. directs the activities and selects the suppliers associated with these activities. Janssen Inc. may terminate the Janssen Influenza Agreement, subject to certain exceptions, upon </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> months' notice.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commitments and Contingencies</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financing Arrangements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the Company had irrevocable stand-by letters of credit outstanding that were issued in connection with property leases and other similar agreements totaling </font><font style="font-family:inherit;font-size:10pt;">$21.9 million</font><font style="font-family:inherit;font-size:10pt;"> that are cash collateralized. The cash used to support these letters of credit is included in restricted cash, as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, on the Company's condensed consolidated balance sheet.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Litigation</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 28, 2014, a purported shareholder class action </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Local No. 8 IBEW Retirement Plan &amp; Trust v. Vertex Pharmaceuticals Incorporated, et al.</font><font style="font-family:inherit;font-size:10pt;"> was filed in the United States District Court for the District of Massachusetts, naming the Company and certain of the Company's current and former officers and directors as defendants. The lawsuit alleged that the Company made material misrepresentations and/or omissions of material fact in the Company's disclosures during the period from May 7, 2012 through May 29, 2012, all in violation of Section 10(b) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder. The purported class consists of all persons (excluding defendants) who purchased the Company&#8217;s common stock between May 7, 2012 and May 29, 2012. The plaintiffs seek unspecified monetary damages, costs and attorneys&#8217; fees as well as disgorgement of the proceeds from certain individual defendants&#8217; sales of the Company&#8217;s stock. On October 8, 2014, the Court approved Local No. 8 IBEW Retirement Fund as lead plaintiff, and Scott and Scott LLP as lead counsel for the plaintiff and the putative class. On February 23, 2015, the Company filed a reply to the plaintiffs&#8217; opposition to its motion to dismiss.&#160; The court heard oral argument on the motion to dismiss on March 6, 2015 and took the motion under advisement. On September 30, 2015, the court granted the Company's motion to dismiss. On October 15, 2015, the plaintiff filed a notice of appeal. The Company believes the claims to be without merit and intend to vigorously defend the litigation. </font><font style="font-family:inherit;font-size:10pt;">As of September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the Company has not recorded any reserves for this purported class action.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Guaranties and Indemnifications</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As permitted under Massachusetts law, the Company&#8217;s Articles of Organization and By-laws provide that the Company will indemnify certain of its officers and directors for certain claims asserted against them in connection with their service as an officer or director. The maximum potential amount of future payments that the Company could be required to make under these indemnification provisions is unlimited. However, the Company has purchased directors&#8217; and officers&#8217; liability insurance policies that could reduce its monetary exposure and enable it to recover a portion of any future amounts paid. No indemnification claims currently are outstanding, and the Company believes the estimated fair value of these indemnification arrangements is minimal.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company customarily agrees in the ordinary course of its business to indemnification provisions in agreements with clinical trial investigators and sites in its drug development programs, sponsored research agreements with academic and not-for-profit institutions, various comparable agreements involving parties performing services for the Company, and its real estate leases. The Company also customarily agrees to certain indemnification provisions in its drug discovery, development and commercialization collaboration agreements. With respect to the Company&#8217;s clinical trials and sponsored research agreements, these indemnification provisions typically apply to any claim asserted against the investigator or the investigator&#8217;s institution relating to personal injury or property damage, violations of law or certain breaches of the Company&#8217;s contractual obligations arising out of the research or clinical testing of the Company&#8217;s compounds or drug candidates. With respect to lease agreements, the indemnification provisions typically apply to claims asserted against the landlord relating to personal injury or property damage caused by the Company, to violations of law by the Company or to certain breaches of the Company&#8217;s contractual obligations. The indemnification provisions appearing in the Company&#8217;s collaboration agreements are similar to those for the other agreements discussed above, but in addition provide some limited indemnification for its collaborator in the event of third-party claims alleging infringement of intellectual property rights. In each of the cases above, the indemnification obligation generally survives the termination of the agreement for some extended period, although the Company believes the obligation typically has the most relevance during the contract term and for a short period of time thereafter. The maximum potential amount of future payments that the Company could be required to make under these provisions is generally unlimited. The Company has purchased insurance policies covering personal injury, property damage and general liability that reduce its exposure for indemnification and would enable it in many cases to recover all or a portion of any future amounts paid. The Company has never paid any material amounts to defend lawsuits or settle claims related to these indemnification provisions. Accordingly, the Company believes the estimated fair value of these indemnification arrangements is minimal.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Contingencies</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues a reserve for contingent liabilities when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> material contingent liabilities accrued as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> or </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated Other Comprehensive (Loss) Income</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of the Company's changes in accumulated other comprehensive (loss) income by component is shown below:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="41%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Foreign Currency Translation Adjustment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized Holding Gains (Losses) on Marketable Securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Foreign Currency Forward Contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(971</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(123</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,011</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">917</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other comprehensive (loss) income before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(164</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">186</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,072</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,094</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Amounts reclassified from accumulated other comprehensive loss</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net current period other comprehensive (loss) income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(164</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">186</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">572</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">594</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at September 30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,135</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">63</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,583</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,511</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="41%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Foreign Currency Translation Adjustment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized Holding Gains on Marketable Securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized (Losses) Gains on Foreign Currency Forward Contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at December 31, 2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(325</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(23</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(306</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other comprehensive (loss) income before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(271</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">25</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,140</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,894</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Amounts reclassified from accumulated other comprehensive loss</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(427</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(427</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net current period other comprehensive (loss) income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(271</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">25</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,713</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,467</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at September 30, 2014</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(596</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">67</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,690</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,161</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Long-term Obligations</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fan Pier Leases</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2011, the Company entered into </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> lease agreements, pursuant to which the Company leases approximately </font><font style="font-family:inherit;font-size:10pt;">1.1 million</font><font style="font-family:inherit;font-size:10pt;"> square feet of office and laboratory space in </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> buildings (the &#8220;Buildings&#8221;) at Fan Pier in Boston, Massachusetts (the &#8220;Fan Pier Leases&#8221;). The Company commenced lease payments in December 2013, and will make lease payments pursuant to the Fan Pier Leases through December 2028. The Company has an option to extend the term of the Fan Pier Leases for an additional </font><font style="font-family:inherit;font-size:10pt;">ten years</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because the Company was involved in the construction project and determined that the Fan Pier Leases did not meet the criteria for &#8220;sale-leaseback&#8221; treatment upon completion of the Buildings, the Company recorded project construction costs incurred by the landlord as an asset and a related financing obligation during the construction period and began depreciating the asset and incurring interest expense related to the financing obligation in 2013. The Company bifurcates its lease payments pursuant to the Fan Pier Leases into (i)&#160;a portion that is allocated to the Buildings and (ii)&#160;a portion that is allocated to the land on which the Buildings were constructed. The portion of the lease obligations allocated to the land is treated as an operating lease that commenced in 2011.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net, included </font><font style="font-family:inherit;font-size:10pt;">$505.6 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$515.0 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, respectively, related to construction costs for the Buildings. The carrying value of the Company's lease agreement liability for the Buildings was </font><font style="font-family:inherit;font-size:10pt;">$473.1 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$473.4 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Term Loan</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2014, the Company entered into a credit agreement with the lenders party thereto, and Macquarie US Trading LLC ("Macquarie"), as administrative agent. The credit agreement provides for a </font><font style="font-family:inherit;font-size:10pt;">$300.0 million</font><font style="font-family:inherit;font-size:10pt;"> senior secured term loan ("Term Loan"). The credit agreement also provides that, subject to satisfaction of certain conditions, the Company may request that the lenders establish an incremental senior secured term loan facility in an aggregate amount not to exceed </font><font style="font-family:inherit;font-size:10pt;">$200.0 million</font><font style="font-family:inherit;font-size:10pt;">. The Term Loan initially bore interest at a rate of </font><font style="font-family:inherit;font-size:10pt;">7.2%</font><font style="font-family:inherit;font-size:10pt;"> per annum, which will be reduced to </font><font style="font-family:inherit;font-size:10pt;">6.2%</font><font style="font-family:inherit;font-size:10pt;"> per annum based on the FDA's approval of ORKAMBI. The Term Loan will bear interest at a rate of LIBOR plus </font><font style="font-family:inherit;font-size:10pt;">5.0%</font><font style="font-family:inherit;font-size:10pt;"> per annum during the third year of the term.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The maturity date of all loans under the facilities is July 9, 2017. Interest is payable quarterly and on the maturity date. In October 2015, the Company amended the terms of the credit agreement to provide for, among other things, a modification to the repayment schedule of the loan. As amended, the Company is required to repay principal on the Term Loan in quarterly installments of </font><font style="font-family:inherit;font-size:10pt;">$75 million</font><font style="font-family:inherit;font-size:10pt;"> from October 1, 2016 through the maturity date. The Company may prepay the Term Loan, in whole or in part, at any time; provided that prepayments prior to the July 9, 2016 are subject to a make-whole premium to ensure Macquarie receives approximately the present value of </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> years of interest payments over the life of the loan. The Company expects that amending the credit agreement will be accounted for as a debt modification, as opposed to an extinguishment of debt, based on an insignificant change to the present value of the future cash flows relating to the credit agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's obligations under the facilities are unconditionally guaranteed by certain of its domestic subsidiaries. All obligations under the facilities, and the guarantees of those obligations, are secured, subject to certain exceptions, by substantially all of the Company's assets and the assets of all guarantors, including the pledge of all or a portion of the equity interests of certain of its subsidiaries. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> The credit agreement requires that the Company maintain, on a quarterly basis, a minimum level of KALYDECO net revenues. Further, the credit agreement includes negative covenants, subject to exceptions, restricting or limiting the Company's ability and the ability of its subsidiaries to, among other things, incur additional indebtedness, grant liens, engage in certain investment, acquisition and disposition transactions, pay dividends, repurchase capital stock and enter into transactions with affiliates. The credit agreement also contains customary representations and warranties, affirmative covenants and events of default, including payment defaults, breach of representations and warranties, covenant defaults and cross defaults. If an event of default occurs, the administrative agent would be entitled to take various actions, including the acceleration of amounts due under outstanding loans. There have been no events of default as of or during the period ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on the Company's evaluation of the Term Loan, the Company determined that the Term Loan contains several embedded derivatives. These embedded derivatives are clearly and closely related to the host instrument because they relate to the Company's credit risk; therefore, they do not require bifurcation from the host instrument, the Term Loan.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company incurred </font><font style="font-family:inherit;font-size:10pt;">$5.3 million</font><font style="font-family:inherit;font-size:10pt;"> in fees paid to Macquarie that were recorded as a discount on the Term Loan and are being recorded as interest expense using the effective interest method over the term of the loan in the Company&#8217;s </font><font style="font-family:inherit;font-size:10pt;">condensed consolidated statements of operations</font><font style="font-family:inherit;font-size:10pt;">. </font><font style="font-family:inherit;font-size:10pt;">As of September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the unamortized discount associated with the Term Loan that was embedded in the senior secured term loan caption on the Company&#8217;s condensed consolidated balance sheet was </font><font style="font-family:inherit;font-size:10pt;">$5.2 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Hedging</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company maintains a hedging program intended to mitigate the effect of changes in foreign exchange rates for a portion of the Company&#8217;s forecasted product revenues denominated in certain foreign currencies. The program includes foreign currency forward contracts that are designated as cash flow hedges under GAAP having contractual durations from one to eighteen months. To date, the existence of operational sites in countries outside the United States has limited the degree to which the Company has sought to hedge its revenues in certain foreign currencies.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company formally documents the relationship between foreign currency forward contracts (hedging instruments) and forecasted product revenues (hedged items), as well as the Company's risk management objective and strategy for undertaking various hedging activities, which includes matching all foreign currency forward contracts that are designated as cash flow hedges to forecasted transactions. The Company also formally assesses, both at the hedge&#8217;s inception and on an ongoing basis, whether the foreign currency forward contracts are highly effective in offsetting changes in cash flows of hedged items on a prospective and retrospective basis. If the Company determines that a (i) foreign currency forward contract is not highly effective as a cash flow hedge, (ii) foreign currency forward contract has ceased to be a highly effective hedge or (iii) forecasted transaction is no longer probable of occurring, the Company would discontinue hedge accounting treatment prospectively. The Company measures effectiveness based on the change in fair value of the forward contracts and the fair value of the hypothetical foreign currency forward contracts with terms that match the critical terms of the risk being hedged. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, all hedges were determined to be highly effective and the Company has not recorded any ineffectiveness related to the hedging program.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the notional amount of the Company&#8217;s outstanding foreign currency forward contracts designated as cash flow hedges:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:84.52380952380952%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="47%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="24%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="24%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of September 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Foreign Currency</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Euro</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">106,620</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">20,209</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">British pound sterling</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">78,861</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">13,515</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Australian dollar</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">25,414</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">210,895</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">33,724</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the fair value of the Company's outstanding foreign currency forward contracts designated as cash flow hedges under GAAP included on the Company's condensed consolidated balance sheets:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.84126984126983%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td width="35%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="36%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of September 30, 2015</font></div></td></tr><tr><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Liabilities</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Classification</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Classification</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Prepaid and other current assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,508</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities, current portion</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,552</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">651</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities, excluding current portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(24</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,159</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,576</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.84126984126983%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td width="35%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="36%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2014</font></div></td></tr><tr><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Liabilities</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Classification</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Classification</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Prepaid and other current assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,011</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities, current portion</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,011</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the potential effect of offsetting derivatives by type of financial instrument on the Company's condensed consolidated balance sheets:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.03174603174604%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td width="36%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of September 30, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Amounts Recognized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Amounts Offset</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Amount Presented</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Amount Not Offset</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Legal Offset</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Foreign currency forward contracts</font></div></td><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,159</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,159</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,576</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,583</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,576</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,576</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,576</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.03174603174604%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td width="36%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Amounts Recognized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Amounts Offset</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Amount Presented</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Amount Not Offset</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Legal Offset</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Foreign currency forward contracts</font></div></td><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,011</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,011</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,011</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock-based Compensation Expense</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company issues stock options, restricted stock and restricted stock units with service conditions, which are generally the vesting periods of the awards. The Company also has issued, to certain members of senior management, restricted stock and restricted stock units that vest upon the earlier of the satisfaction of (i) a performance condition or (ii) a service condition and stock options that vest upon the earlier of the satisfaction of (a) performance conditions or (b) a service condition. In addition, the Company issued pursuant to a retention program restricted stock awards to certain members of senior management that will vest upon the satisfaction of both (i) a performance condition and (ii) a service condition. The Company also issues shares pursuant to an employee stock purchase plan ("ESPP").</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the second quarter of 2015, the Company&#8217;s shareholders approved an amendment and restatement of the 2013 Stock and Option Plan that, among other things, increased the number of shares of common stock available for issuance under the plan by </font><font style="font-family:inherit;font-size:10pt;">7,800,000</font><font style="font-family:inherit;font-size:10pt;"> shares, plus the number of shares that remained available for issuance under our 2006 Stock and Option Plan, which rolled-over into the 2013 Stock and Option Plan.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During </font><font style="font-family:inherit;font-size:10pt;">the three and nine months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized the following stock-based compensation expense included in loss from continuing operations:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="53%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stock-based compensation expense by type of award:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">39,074</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">26,291</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">105,720</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">78,403</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restricted stock and restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">26,203</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18,418</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">78,274</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">51,431</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">ESPP share issuances</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,738</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,883</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,703</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,231</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Less stock-based compensation expense capitalized to inventories</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,281</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(456</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,318</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(905</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total stock-based compensation included in costs and expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">65,734</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">46,136</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">186,379</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">135,160</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stock-based compensation expense by line item:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Research and development expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">44,701</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">31,131</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">124,550</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">91,284</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Sales, general and administrative expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">21,033</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">15,005</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">61,829</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">43,876</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total stock-based compensation included in costs and expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">65,734</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">46,136</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">186,379</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">135,160</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the Company's unrecognized stock-based compensation expense, net of estimated forfeitures, by type of award and the weighted-average period over which that expense is expected to be recognized:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:80.55555555555556%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td width="49%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="23%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="25%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of September&#160;30, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Unrecognized Expense,<br clear="none"/>Net of <br clear="none"/>Estimated Forfeitures</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-average <br clear="none"/>Recognition <br clear="none"/>Period</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in years)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Type of award:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">197,031</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.30</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restricted stock and restricted stock units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">190,786</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.73</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">ESPP share issuances</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,885</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.44</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes information about stock options outstanding and exercisable at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.28571428571429%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="16%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Options Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Options Exercisable</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Range of Exercise Prices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number <br clear="none"/>Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-average <br clear="none"/>Remaining <br clear="none"/>Contractual Life</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-average <br clear="none"/>Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number <br clear="none"/>Exercisable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-average <br clear="none"/>Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(per share)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(per share)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;padding-left:13px;text-align:center;text-indent:-14px;vertical-align:top;">$18.93&#8211;$20.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">138</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">138</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$20.01&#8211;$40.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,499</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.81</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">34.56</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,284</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">34.36</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$40.01&#8211;$60.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,593</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6.80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">48.27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,458</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">49.52</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$60.01&#8211;$80.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,567</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8.31</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">75.94</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">551</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">74.95</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$80.01&#8211;$100.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,932</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8.28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">90.27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">638</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">87.16</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$100.01&#8211;$120.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,791</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9.32</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">109.24</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">201</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">109.22</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;padding-left:13px;text-align:center;text-indent:-14px;vertical-align:top;">$120.01&#8211;$134.69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,505</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9.78</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">131.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">168</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">127.52</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,025</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7.31</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">74.90</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,438</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">53.98</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Earnings Per Share</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net loss per share attributable to Vertex common shareholders is based upon the weighted-average number of common shares outstanding during the period, excluding restricted stock and restricted stock units that have been issued but are not yet vested. Diluted net loss per share attributable to Vertex common shareholders is based upon the weighted-average number of common shares outstanding during the period plus additional weighted-average common equivalent shares outstanding during the period when the effect is dilutive. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company did not include the securities described in the following table in the computation of the net loss from continuing operations per share attributable to Vertex common shareholder calculations because the effect would have been anti-dilutive during each period:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="57%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stock options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,025</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">13,097</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,025</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">13,097</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Unvested restricted stock and restricted stock units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,367</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,672</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,367</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,672</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the Company&#8217;s financial assets and liabilities reflects the Company&#8217;s estimate of amounts that it would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from sources independent from the Company) and to minimize the use of unobservable inputs (the Company&#8217;s assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:88.4920634920635%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td width="12%" rowspan="1" colspan="1"></td><td width="88%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;1:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;2:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Observable inputs other than Level&#160;1 inputs. Examples of Level&#160;2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;3:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unobservable inputs based on the Company&#8217;s assessment of the assumptions that market participants would use in pricing the asset or liability.</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s investment strategy is focused on capital preservation. The Company invests in instruments that meet the credit quality standards outlined in the Company&#8217;s investment policy. This policy also limits the amount of credit exposure to any one issue or type of instrument. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the Company&#8217;s investments were in money market funds, corporate debt securities and commercial paper.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, all of the Company&#8217;s financial assets that were subject to fair value measurements were valued using observable inputs. The Company&#8217;s financial assets valued based on Level&#160;1 inputs consisted of money market funds. The Company&#8217;s financial assets valued based on Level 2 inputs consisted of corporate debt securities and commercial paper, which consist of investments in highly-rated investment-grade corporations. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the Company&#8217;s financial assets and liabilities subject to fair value measurements:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="49%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value Measurements as of September 30, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;border-top:1px solid #000000;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value Hierarchy</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level&#160;1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level&#160;3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Financial assets carried at fair value:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash equivalents:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">340,573</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">340,573</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">25,109</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">25,109</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">24,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">24,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Marketable securities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">109,335</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">109,335</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">140,245</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">140,245</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Prepaid and other current assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency forward contracts</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,508</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,508</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency forward contracts</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">651</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">651</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total financial assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">643,421</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">340,573</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">302,848</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Financial liabilities carried at fair value:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities, current portion:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,552</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,552</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities, excluding current portion:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency forward contracts</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(24</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(24</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total financial liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,576</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,576</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's VIEs invested in cash equivalents consisting of money market funds of </font><font style="font-family:inherit;font-size:10pt;">$75.4 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, which are valued based on Level 1 inputs. These cash equivalents are not included in the table above. The Company&#8217;s noncontrolling interest related to VIEs includes </font><font style="font-family:inherit;font-size:10pt;">the fair value of the contingent milestone and royalty payments</font><font style="font-family:inherit;font-size:10pt;">, which are valued based on Level 3 inputs. Please refer to Note C, &#8220;Collaborative Arrangements,&#8221; for further information.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the fair value and carrying value of the Company's Term Loan was </font><font style="font-family:inherit;font-size:10pt;">$294.8 million</font><font style="font-family:inherit;font-size:10pt;">. The fair value of the Company's Term Loan was estimated based on Level 3 inputs computed using the effective interest rate of the Term Loan. The effective interest rate considers the timing and amount of estimated future interest payments as well as current markets rates. Please refer to Note K, "Long-term Obligations" for further information regarding the Company's Term Loan.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intangible Assets and Goodwill</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Intangible Assets</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, in-process research and development intangible assets of </font><font style="font-family:inherit;font-size:10pt;">$284.3 million</font><font style="font-family:inherit;font-size:10pt;"> were recorded on the Company's condensed consolidated balance sheet. The increase of </font><font style="font-family:inherit;font-size:10pt;">$255.3 million</font><font style="font-family:inherit;font-size:10pt;"> as compared to the </font><font style="font-family:inherit;font-size:10pt;">$29.0 million</font><font style="font-family:inherit;font-size:10pt;"> recorded as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;"> is due to the Company's collaboration with Parion.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2015, in connection with entering into the Parion Agreement, the Company recorded an in-process research and development intangible asset of </font><font style="font-family:inherit;font-size:10pt;">$255.3 million</font><font style="font-family:inherit;font-size:10pt;"> based on the Company&#8217;s estimate of the fair value of Parion&#8217;s lead investigational ENaC inhibitors, including VX-371 and P-1055, that were licensed by the Company from Parion. The Company aggregated the fair value of the ENaC inhibitors into a single intangible asset because the phase, nature and risks of development as well as the amount and timing of benefits associated with the assets were similar. In October 2014, the Company recorded an in-process research and development intangible asset of </font><font style="font-family:inherit;font-size:10pt;">$29.0 million</font><font style="font-family:inherit;font-size:10pt;"> based on the Company&#8217;s estimate of the fair value of VX-210, a drug candidate for patients with spinal cord injuries that was licensed by the Company from BioAxone. The Company used discount rates of </font><font style="font-family:inherit;font-size:10pt;">7.1%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">7.5%</font><font style="font-family:inherit;font-size:10pt;"> in the present-value models to estimate the fair values of the ENaC inhibitors and VX-210 intangible assets, respectively. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company also conducted an evaluation of Parion and BioAxone's other programs at the effective date of the Parion Agreement and BioAxone Agreement, respectively, and determined that market participants would not have ascribed value to those programs because of the stage of development of the assets in each program and uncertainties related to the potential clinical development and commercialization of the programs. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Goodwill</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, goodwill of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$50.4 million</font><font style="font-family:inherit;font-size:10pt;"> was recorded on the Company's condensed consolidated balance sheet. The Company allocated </font><font style="font-family:inherit;font-size:10pt;">$10.5 million</font><font style="font-family:inherit;font-size:10pt;"> to goodwill related to the Parion Agreement during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">. This goodwill relates to the potential synergies between licensed drug candidates and the Company's CF drugs and drug candidates.&#160; None of the goodwill related to the Parion Agreement is expected to be deductible for income tax purposes. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$39.9 million</font><font style="font-family:inherit;font-size:10pt;"> of goodwill was recorded on the Company&#8217;s consolidated balance sheet.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is subject to U.S. federal, state, and foreign income taxes. For </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">the three and nine months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded a </font><font style="font-family:inherit;font-size:10pt;">provision for income taxes</font><font style="font-family:inherit;font-size:10pt;"> of </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$31.8 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. The provision for income taxes recorded in </font><font style="font-family:inherit;font-size:10pt;">the three and nine months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> included </font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$30.4 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, related to the Company's VIE's income tax provision. The VIE's income tax provision for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> primarily related to the income tax effect on the </font><font style="font-family:inherit;font-size:10pt;">$80.0 million</font><font style="font-family:inherit;font-size:10pt;"> up-front payment received by Parion from the Company in June 2015. The Company has no liability for taxes payable by Parion and the income tax provision and related liability have been allocated to noncontrolling interest (VIE). For </font><font style="font-family:inherit;font-size:10pt;">the three and nine months ended September 30, 2014</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded a </font><font style="font-family:inherit;font-size:10pt;">provision for income taxes</font><font style="font-family:inherit;font-size:10pt;"> of </font><font style="font-family:inherit;font-size:10pt;">$3.4 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$4.9 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, related to state income taxes and income earned in various foreign jurisdictions. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, the Company had unrecognized tax benefits of </font><font style="font-family:inherit;font-size:10pt;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;">. The Company recognizes interest and penalties related to income taxes as a component of income tax expense. </font><font style="font-family:inherit;font-size:10pt;">As of September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, no interest and penalties have been accrued. The Company does not expect that its unrecognized tax benefits will materially increase within the next twelve months. The Company did not recognize any material interest or penalties related to uncertain tax positions as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">. In 2015, it is reasonably possible that the Company will reduce the balance of its unrecognized tax benefits by approximately </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;"> due to the application of statute of limitations and settlements with taxing authorities, all of which would reduce the Company&#8217;s effective tax rate.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company continues to maintain a valuation allowance against certain deferred tax assets where it is more likely than not that the deferred tax asset will not be realized because of its extended history of annual losses. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company files U.S. federal income tax returns and income tax returns in various state, local and foreign jurisdictions. The Company is no longer subject to any tax assessment from an income tax examination in the United States before 2011 or any other major taxing jurisdiction for years before 2009, except where the Company has net operating losses or tax credit carryforwards that originated before 2009. The Company currently is under examination by the Internal Revenue Service for the year ended December 31, 2011 and in Canada, Pennsylvania, Delaware, New York and Texas for varying periods including the years ended December 31, 2011 through 2013. No adjustments have been reported. The Company is not under examination by any other jurisdictions for any tax year. The Company concluded audits with Massachusetts and Revenue Quebec during 2015 and the Canada Revenue Agency and Revenue Quebec during 2014 with no material adjustments.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company currently intends to reinvest the total amount of its unremitted earnings. At </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, foreign earnings, which were not significant, have been retained indefinitely by foreign subsidiary companies for reinvestment; therefore, no provision has been made for income taxes that would be payable upon the distribution of such earnings, and it would not be practicable to determine the amount of the related unrecognized deferred income tax liability. Upon repatriation of those earnings, in the form of dividends or otherwise, the Company would be subject to U.S. federal income taxes (subject to an adjustment for foreign tax credits) and withholding taxes payable to the various foreign countries.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Inventories</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories consisted of the following:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:84.52380952380952%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="47%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="24%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="24%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of September 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,669</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,506</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Work-in-process</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">34,115</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">20,508</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,413</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,834</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">49,197</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">30,848</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For a discussion of recent accounting pronouncements please refer to Note&#160;A, &#8220;Nature of Business and Accounting Policies&#8212;Recent Accounting Pronouncements,&#8221; in the </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;"> Annual Report on Form&#160;10-K. The Company did not adopt any new accounting pronouncements during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> that had a material effect on its condensed consolidated financial statements.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis of Presentation and Accounting Policies</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements are unaudited and have been prepared by Vertex Pharmaceuticals Incorporated ("Vertex" or the "Company") in accordance with accounting principles generally accepted in the United States of America ("GAAP"). </font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The condensed consolidated financial statements reflect the operations of (i) the Company, (ii) its wholly-owned subsidiaries and (iii) consolidated variable interest entities (VIEs). All material intercompany balances and transactions have been eliminated. The Company operates in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">one</font><font style="font-family:inherit;font-size:10pt;"> segment, pharmaceuticals.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain information and footnote disclosures normally included in the Company's annual financial statements have been condensed or omitted. These interim financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the financial position and results of operations for the interim periods ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full fiscal year. These interim financial statements should be read in conjunction with the audited financial statements for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, which are contained in the Company's Annual Report on Form&#160;10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;"> that was filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on </font><font style="font-family:inherit;font-size:10pt;">February&#160;13, 2015</font><font style="font-family:inherit;font-size:10pt;"> (the "2014 Annual Report on Form&#160;10-K").</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates and Summary of Significant Accounting Policies</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of condensed consolidated financial statements in accordance with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the amounts of revenues and expenses during the reported periods. Significant estimates in these condensed consolidated financial statements have been made in connection with the calculation of revenues, inventories, research and development expenses, stock-based compensation expense, restructuring expense, the fair value of intangible assets, goodwill, noncontrolling interest, the consolidation of VIEs, leases, the fair value of cash flow hedges and the provision for or benefit from income taxes. The Company bases its estimates on historical experience and various other assumptions, including in certain circumstances future projections that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</font></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's significant accounting policies are described in Note&#160;A, "Nature of Business and Accounting Policies," in the </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;"> Annual Report on Form&#160;10-K.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For a discussion of recent accounting pronouncements please refer to Note&#160;A, &#8220;Nature of Business and Accounting Policies&#8212;Recent Accounting Pronouncements,&#8221; in the </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;"> Annual Report on Form&#160;10-K. The Company did not adopt any new accounting pronouncements during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> that had a material effect on its condensed consolidated financial statements.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Arrangements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Sale of HIV Protease Inhibitor Royalty Stream</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2008, the Company sold to a third party its rights to receive royalty payments from GlaxoSmithKline&#160;plc, net of royalty amounts to be earned by and due to a third party, for a one-time cash payment of </font><font style="font-family:inherit;font-size:10pt;">$160.0 million</font><font style="font-family:inherit;font-size:10pt;">. These royalty payments relate to net sales of HIV protease inhibitors, which had been developed pursuant to a collaboration agreement between the Company and GlaxoSmithKline&#160;plc. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the Company had </font><font style="font-family:inherit;font-size:10pt;">$31.2 million</font><font style="font-family:inherit;font-size:10pt;"> in deferred revenues related to the one-time cash payment, which it is recognizing over the life of the collaboration agreement with GlaxoSmithKline&#160;plc based on the units-of-revenue method. In addition, the Company continues to recognize royalty revenues equal to the amount of the third-party subroyalty and an offsetting royalty expense for the third-party subroyalty payment.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other income (expense), net</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2014, the Company received a one-time cash payment of </font><font style="font-family:inherit;font-size:10pt;">$36.7 million</font><font style="font-family:inherit;font-size:10pt;"> from its landlord pursuant to the Fan Pier Leases.&#160; This payment related to bonds issued pursuant to an Infrastructure Development Assistance Agreement between The Commonwealth of Massachusetts and the Company&#8217;s landlord.&#160; The bonds were issued in connection with the landlord&#8217;s contribution to infrastructure improvements and also were dependent upon employment levels at the Company through the bond issuance date.&#160; The Company accounted for the cash payment as a government grant as it was provided in part related to the Company&#8217;s employment level in Massachusetts. Such grants are recognized as income in the period in which the conditions of the grant are met and there is reasonable assurance that the grant will be received, provided it is not subject to refund. In the second quarter of 2014, the Company recorded </font><font style="font-family:inherit;font-size:10pt;">$36.7 million</font><font style="font-family:inherit;font-size:10pt;"> as a credit to other income (expense), net in its </font><font style="font-family:inherit;font-size:10pt;">consolidated statements of operations because the Company&#8217;s employment obligations related to these funds were satisfied as of the date of issuance of the bonds and the payment received was not subject to refund.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restructuring Liabilities</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">2003 Kendall Restructuring</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2003, the Company adopted a plan to restructure its operations to coincide with its increasing internal emphasis on advancing drug candidates through clinical development to commercialization. The restructuring liability relates to specialized laboratory and office space that is leased to the Company pursuant to a </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">15</font><font style="font-family:inherit;font-size:10pt;">-year lease that terminates in 2018. The Company has not used more than </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;"> of this space since it adopted the plan to restructure its operations in 2003. This unused laboratory and office space currently is subleased to third parties. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The activities related to the restructuring liability for </font><font style="font-family:inherit;font-size:10pt;">the three and nine months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;"> were as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="57%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Liability, beginning of the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,924</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14,936</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,596</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">19,115</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,975</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4,249</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(10,544</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(12,071</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash received from subleases</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,919</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,689</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,194</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,067</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restructuring expense (income)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">146</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(464</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(232</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,199</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Liability, end of the period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,014</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,912</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,014</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,912</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fan Pier Move Restructuring</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the relocation of its Massachusetts operations to Fan Pier in Boston, Massachusetts, which commenced in 2013, the Company is incurring restructuring charges related to its remaining lease obligations at its facilities in Cambridge, Massachusetts. The majority of these restructuring charges were recorded in the third quarter of 2014 upon decommissioning </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> facilities in Cambridge. During the first quarter of 2015, the Company terminated </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> of these lease agreements resulting in a credit to restructuring expense equal to the difference between the Company&#8217;s estimated future cash flows related to its lease obligations for these facilities and the termination payment paid to the Company&#8217;s landlord on the effective date of the termination. The third major facility included in this restructuring activity is </font><font style="font-family:inherit;font-size:10pt;">120,000</font><font style="font-family:inherit;font-size:10pt;"> square feet of the </font><font style="font-family:inherit;font-size:10pt;">Kendall Square Facility</font><font style="font-family:inherit;font-size:10pt;"> that the Company continued to use for its operations following its </font><font style="font-family:inherit;font-size:10pt;">2003 Kendall Restructuring</font><font style="font-family:inherit;font-size:10pt;">. The rentable square footage in this portion of the </font><font style="font-family:inherit;font-size:10pt;">Kendall Square Facility</font><font style="font-family:inherit;font-size:10pt;"> was subleased to a third party in February 2015. The Company will continue to incur charges through April 2018 related to the difference between the Company&#8217;s estimated future cash flows related to this portion of the </font><font style="font-family:inherit;font-size:10pt;">Kendall Square Facility</font><font style="font-family:inherit;font-size:10pt;">, which include an estimate for sublease income to be received from the Company's sublessee and its actual cash flows. The Company discounted the estimated cash flows related to this restructuring activity at a discount rate of </font><font style="font-family:inherit;font-size:10pt;">9%</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The activities related to the restructuring liability for </font><font style="font-family:inherit;font-size:10pt;">the three and nine months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;"> were as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="57%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Liability, beginning of the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,256</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">33,390</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">797</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,070</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,266</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(25,421</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(6,643</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash received from subleases</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,820</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,820</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restructuring expense (income)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">51</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">39,752</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,971</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">46,588</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Liability, end of the period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,818</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">40,742</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,818</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">40,742</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Restructuring Activities</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has incurred several other restructuring activities that are unrelated to its </font><font style="font-family:inherit;font-size:10pt;">2003 Kendall Restructuring</font><font style="font-family:inherit;font-size:10pt;"> and the </font><font style="font-family:inherit;font-size:10pt;">Fan Pier Move Restructuring</font><font style="font-family:inherit;font-size:10pt;">. In October 2013, the Company adopted a restructuring plan that included (i) a workforce reduction primarily related to the commercial support of INCIVEK following the continued and rapid decline in the number of patients being treated with INCIVEK as new medicines for the treatment of HCV infection neared approval and (ii) the write-off of certain assets. This action resulted from the Company's decision to focus its investment on future opportunities in cystic fibrosis and other research and development programs.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The activities related to the Company's other restructuring liabilities for </font><font style="font-family:inherit;font-size:10pt;">the three and nine months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;"> were as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="57%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Liability, beginning of the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">902</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">792</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">869</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,441</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,559</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(399</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,782</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(8,865</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restructuring expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,629</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,555</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,885</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,372</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Liability, end of the period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">972</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,948</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">972</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,948</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of the Company's changes in accumulated other comprehensive (loss) income by component is shown below:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="41%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Foreign Currency Translation Adjustment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized Holding Gains (Losses) on Marketable Securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Foreign Currency Forward Contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(971</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(123</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,011</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">917</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other comprehensive (loss) income before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(164</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">186</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,072</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,094</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Amounts reclassified from accumulated other comprehensive loss</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net current period other comprehensive (loss) income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(164</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">186</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">572</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">594</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at September 30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,135</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">63</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,583</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,511</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="41%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Foreign Currency Translation Adjustment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized Holding Gains on Marketable Securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized (Losses) Gains on Foreign Currency Forward Contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at December 31, 2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(325</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(23</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(306</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other comprehensive (loss) income before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(271</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">25</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,140</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,894</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Amounts reclassified from accumulated other comprehensive loss</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(427</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(427</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net current period other comprehensive (loss) income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(271</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">25</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,713</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,467</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at September 30, 2014</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(596</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">67</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,690</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,161</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company did not include the securities described in the following table in the computation of the net loss from continuing operations per share attributable to Vertex common shareholder calculations because the effect would have been anti-dilutive during each period:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="57%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stock options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,025</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">13,097</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,025</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">13,097</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Unvested restricted stock and restricted stock units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,367</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,672</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,367</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,672</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of the Company&#8217;s cash, cash equivalents and marketable securities is shown below:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="53%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross <br clear="none"/>Unrealized <br clear="none"/>Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross <br clear="none"/>Unrealized <br clear="none"/>Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of September 30, 2015</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash and cash equivalents:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash and money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">707,141</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">707,141</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">25,109</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">25,109</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">24,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">24,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">756,250</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">756,250</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Marketable securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Commercial paper (due within 1 year)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">140,131</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">114</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">140,245</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities (due within 1 year)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">109,386</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(79</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">109,335</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">249,517</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">142</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(79</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">249,580</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total cash, cash equivalents and marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,005,767</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">142</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(79</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,005,830</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2014</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash and cash equivalents:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash and money market funds</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">625,259</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">625,259</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">625,259</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">625,259</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Marketable securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Government-sponsored enterprise securities (due within 1&#160;year)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">463,788</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(52</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">463,750</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Commercial paper (due within 1 year)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">51,674</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">72</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">51,746</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities (due within 1 year)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">196,065</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(66</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">196,001</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities (due after 1 year through 5 years)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">50,443</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">50,350</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">761,970</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">88</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(211</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">761,847</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total cash, cash equivalents and marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,387,229</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">88</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(211</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,387,106</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During </font><font style="font-family:inherit;font-size:10pt;">the three and nine months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized the following stock-based compensation expense included in loss from continuing operations:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="53%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stock-based compensation expense by type of award:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">39,074</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">26,291</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">105,720</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">78,403</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restricted stock and restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">26,203</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18,418</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">78,274</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">51,431</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">ESPP share issuances</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,738</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,883</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,703</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,231</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Less stock-based compensation expense capitalized to inventories</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,281</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(456</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,318</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(905</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total stock-based compensation included in costs and expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">65,734</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">46,136</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">186,379</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">135,160</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stock-based compensation expense by line item:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Research and development expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">44,701</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">31,131</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">124,550</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">91,284</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Sales, general and administrative expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">21,033</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">15,005</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">61,829</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">43,876</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total stock-based compensation included in costs and expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">65,734</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">46,136</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">186,379</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">135,160</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the Company&#8217;s financial assets and liabilities subject to fair value measurements:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="49%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value Measurements as of September 30, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;border-top:1px solid #000000;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value Hierarchy</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level&#160;1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level&#160;3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Financial assets carried at fair value:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash equivalents:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">340,573</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">340,573</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">25,109</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">25,109</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">24,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">24,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Marketable securities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">109,335</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">109,335</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">140,245</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">140,245</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Prepaid and other current assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency forward contracts</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,508</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,508</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency forward contracts</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">651</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">651</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total financial assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">643,421</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">340,573</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">302,848</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Financial liabilities carried at fair value:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities, current portion:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,552</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,552</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities, excluding current portion:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency forward contracts</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(24</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(24</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total financial liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,576</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,576</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the fair value of the Company's outstanding foreign currency forward contracts designated as cash flow hedges under GAAP included on the Company's condensed consolidated balance sheets:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.84126984126983%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td width="35%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="36%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of September 30, 2015</font></div></td></tr><tr><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Liabilities</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Classification</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Classification</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Prepaid and other current assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,508</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities, current portion</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,552</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">651</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities, excluding current portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(24</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,159</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,576</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.84126984126983%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td width="35%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="36%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2014</font></div></td></tr><tr><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Liabilities</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Classification</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Classification</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Prepaid and other current assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,011</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities, current portion</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,011</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories consisted of the following:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:84.52380952380952%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="47%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="24%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="24%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of September 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,669</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,506</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Work-in-process</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">34,115</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">20,508</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,413</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,834</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">49,197</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">30,848</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the notional amount of the Company&#8217;s outstanding foreign currency forward contracts designated as cash flow hedges:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:84.52380952380952%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="47%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="24%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="24%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of September 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Foreign Currency</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Euro</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">106,620</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">20,209</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">British pound sterling</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">78,861</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">13,515</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Australian dollar</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">25,414</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">210,895</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">33,724</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the preliminary fair values of the assets and liabilities recorded on the effective date of the agreement:</font></div><div style="line-height:120%;text-align:center;text-indent:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:63.49206349206349%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="78%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="20%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">June 4, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">255,340</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10,468</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Deferred tax liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(91,023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net other assets (liabilities)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(10,468</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net assets attributable to noncontrolling interests</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;text-indent:12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">164,317</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The activities related to the restructuring liability for </font><font style="font-family:inherit;font-size:10pt;">the three and nine months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;"> were as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="57%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Liability, beginning of the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,256</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">33,390</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">797</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,070</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,266</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(25,421</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(6,643</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash received from subleases</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,820</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,820</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restructuring expense (income)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">51</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">39,752</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,971</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">46,588</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Liability, end of the period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,818</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">40,742</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,818</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">40,742</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The activities related to the Company's other restructuring liabilities for </font><font style="font-family:inherit;font-size:10pt;">the three and nine months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;"> were as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="57%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Liability, beginning of the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">902</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">792</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">869</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,441</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,559</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(399</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,782</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(8,865</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restructuring expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,629</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,555</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,885</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,372</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Liability, end of the period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">972</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,948</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">972</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,948</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The activities related to the restructuring liability for </font><font style="font-family:inherit;font-size:10pt;">the three and nine months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;"> were as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="57%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Liability, beginning of the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,924</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14,936</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,596</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">19,115</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,975</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4,249</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(10,544</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(12,071</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash received from subleases</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,919</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,689</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,194</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,067</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restructuring expense (income)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">146</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(464</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(232</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,199</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:1px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Liability, end of the period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,014</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,912</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,014</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,912</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes information about stock options outstanding and exercisable at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.28571428571429%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="16%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Options Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Options Exercisable</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Range of Exercise Prices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number <br clear="none"/>Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-average <br clear="none"/>Remaining <br clear="none"/>Contractual Life</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-average <br clear="none"/>Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number <br clear="none"/>Exercisable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-average <br clear="none"/>Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(per share)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(per share)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;padding-left:13px;text-align:center;text-indent:-14px;vertical-align:top;">$18.93&#8211;$20.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">138</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">138</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$20.01&#8211;$40.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,499</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.81</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">34.56</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,284</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">34.36</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$40.01&#8211;$60.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,593</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6.80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">48.27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,458</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">49.52</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$60.01&#8211;$80.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,567</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8.31</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">75.94</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">551</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">74.95</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$80.01&#8211;$100.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,932</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8.28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">90.27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">638</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">87.16</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$100.01&#8211;$120.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,791</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9.32</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">109.24</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">201</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">109.22</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;padding-left:13px;text-align:center;text-indent:-14px;vertical-align:top;">$120.01&#8211;$134.69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,505</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9.78</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">131.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">168</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">127.52</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,025</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7.31</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">74.90</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,438</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">53.98</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates and Summary of Significant Accounting Policies</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of condensed consolidated financial statements in accordance with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the amounts of revenues and expenses during the reported periods. Significant estimates in these condensed consolidated financial statements have been made in connection with the calculation of revenues, inventories, research and development expenses, stock-based compensation expense, restructuring expense, the fair value of intangible assets, goodwill, noncontrolling interest, the consolidation of VIEs, leases, the fair value of cash flow hedges and the provision for or benefit from income taxes. The Company bases its estimates on historical experience and various other assumptions, including in certain circumstances future projections that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</font></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's significant accounting policies are described in Note&#160;A, "Nature of Business and Accounting Policies," in the </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;"> Annual Report on Form&#160;10-K.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the potential effect of offsetting derivatives by type of financial instrument on the Company's condensed consolidated balance sheets:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.03174603174604%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td width="36%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of September 30, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Amounts Recognized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Amounts Offset</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Amount Presented</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Amount Not Offset</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Legal Offset</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Foreign currency forward contracts</font></div></td><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,159</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,159</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,576</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,583</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,576</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,576</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,576</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.03174603174604%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td width="36%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Amounts Recognized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Amounts Offset</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Amount Presented</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Amount Not Offset</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Legal Offset</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Foreign currency forward contracts</font></div></td><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,011</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,011</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,011</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consideration paid and the preliminary fair value of the contingent milestone and royalty payments payable by the Company pursuant to the agreement are set forth in the table below:</font></div><div style="line-height:120%;text-align:center;text-indent:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:63.49206349206349%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="78%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="20%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">June 4, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Up-front payment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">80,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Fair value of contingent milestone and royalty payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">175,340</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">255,340</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Product Revenues, Net </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company sells its products principally to a limited number of specialty pharmacy providers and selected regional wholesalers in North America as well as government-owned and supported customers in international markets (collectively, its &#8220;Customers&#8221;). The Company's Customers in North America subsequently resell the products to patients and health care providers. The Company recognizes net revenues from product sales upon delivery to the Customer as long as (i)&#160;there is persuasive evidence that an arrangement exists between the Company and the Customer, (ii)&#160;collectibility is reasonably assured and (iii)&#160;the price is fixed or determinable. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In order to conclude that the price is fixed or determinable, the Company must be able to (i)&#160;calculate its gross product revenues from sales to Customers and (ii)&#160;reasonably estimate its net product revenues upon delivery to its Customer's locations. The Company calculates gross product revenues based on the price that the Company charges its Customers. The Company estimates its net product revenues by deducting from its gross product revenues (a)&#160;trade allowances, such as invoice discounts for prompt payment and Customer fees, (b)&#160;estimated government and private payor rebates, chargebacks and discounts, (c)&#160;estimated reserves for expected product returns and (d)&#160;estimated cost of co-pay assistance programs for patients, as well as other incentives for certain indirect customers. The Company makes significant estimates and judgments that materially affect the Company's recognition of net product revenues. In certain instances, the Company may be unable to reasonably conclude that the price is fixed or determinable at the time of delivery, in which case it defers the recognition of revenues. Once the Company is able to determine that the price is fixed or determinable, it recognizes the revenues associated with the units in which revenue recognition was deferred.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes activity in each of the product revenue allowance and reserve categories for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">: </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td width="39%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Trade <br clear="none"/>Allowances</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Rebates, <br clear="none"/>Chargebacks <br clear="none"/>and Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Product <br clear="none"/>Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Other <br clear="none"/>Incentives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,463</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">29,102</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,713</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">745</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">36,023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Provision related to current period sales</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,120</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">39,533</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">429</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,402</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">48,484</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Adjustments related to prior period sales</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(143</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(12,342</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(993</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(235</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(13,713</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Credits/payments made</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(5,115</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(22,465</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,254</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,652</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(32,486</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at September 30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,325</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">33,828</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">895</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,260</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">38,308</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company did not have any consolidated VIEs for </font><font style="font-family:inherit;font-size:10pt;">the three and nine months ended September 30, 2014</font><font style="font-family:inherit;font-size:10pt;">. An aggregate summary of net loss attributable to noncontrolling interest related to the Company's VIEs for </font><font style="font-family:inherit;font-size:10pt;">the three and nine months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> is as follows:</font></div><div style="line-height:120%;text-align:center;text-indent:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.42857142857143%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="61%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="17%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="17%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Loss attributable to noncontrolling interest before provision for income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,743</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,322</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Provision for income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(777</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(30,367</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Increase in fair value of contingent milestone and royalty payments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,853</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,780</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net (income) loss attributable to noncontrolling interest</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,333</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(30,909</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes items related to the Company's VIEs included in the Company's condensed consolidated balance sheets as of the dates set forth in the table:</font></div><div style="line-height:120%;text-align:center;text-indent:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.42857142857143%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="65%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">September 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restricted cash and cash equivalents (VIE)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">75,765</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,418</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,057</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">268</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">284,340</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">29,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">19,391</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,923</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">461</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,115</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">189</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accrued expenses and other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">32,519</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,891</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Deferred tax liability, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">110,360</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,544</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Noncontrolling interest</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">154,585</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">21,177</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During </font><font style="font-family:inherit;font-size:10pt;">the three and nine months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized the following revenues attributable to the Janssen NV collaboration:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="57%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Royalty revenues (INCIVO)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">158</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,284</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,742</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,917</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Collaborative revenues (telaprevir)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">441</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,390</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,620</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,262</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;&#160;Total revenues attributable to the Janssen NV collaboration</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">599</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,674</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,362</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">17,179</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes activity in each of the product revenue allowance and reserve categories for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">: </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td width="39%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Trade <br clear="none"/>Allowances</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Rebates, <br clear="none"/>Chargebacks <br clear="none"/>and Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Product <br clear="none"/>Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Other <br clear="none"/>Incentives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,463</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">29,102</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,713</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">745</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">36,023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Provision related to current period sales</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,120</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">39,533</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">429</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,402</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">48,484</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-12px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Adjustments related to prior period sales</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(143</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(12,342</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(993</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(235</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(13,713</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Credits/payments made</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(5,115</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(22,465</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,254</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,652</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(32,486</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at September 30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,325</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">33,828</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">895</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,260</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">38,308</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the Company's unrecognized stock-based compensation expense, net of estimated forfeitures, by type of award and the weighted-average period over which that expense is expected to be recognized:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:80.55555555555556%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td width="49%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="23%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="25%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of September&#160;30, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Unrecognized Expense,<br clear="none"/>Net of <br clear="none"/>Estimated Forfeitures</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-average <br clear="none"/>Recognition <br clear="none"/>Period</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in years)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Type of award:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">197,031</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.30</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restricted stock and restricted stock units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">190,786</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.73</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">ESPP share issuances</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,885</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.44</font></div></td></tr></table></div></div></div> EX-101.SCH 7 vrtx-20150930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2108100 - Disclosure - Accumulated Other Comprehensive (Loss) Income link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - Accumulated Other Comprehensive (Loss) Income (Details) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - Accumulated Other Comprehensive (Loss) Income (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Basis of Presentation and Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2401402 - Disclosure - Basis of Presentation and Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - Basis of Presentation and Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Collaborative Arrangements link:presentationLink link:calculationLink link:definitionLink 2404403 - Disclosure - Collaborative Arrangements (Details) link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - Collaborative Arrangements Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Collaborative Arrangements (Tables) link:presentationLink link:calculationLink link:definitionLink 2122100 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2422401 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1003501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1006000 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Condensed Consolidated Statements of Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - Condensed Consolidated Statements of Operations (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Condensed Consolidated Statements of Shareholders' Equity and Noncontrolling Interest link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Earnings Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - Hedging link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - Hedging (Details) link:presentationLink link:calculationLink link:definitionLink 2310301 - Disclosure - Hedging (Tables) link:presentationLink link:calculationLink link:definitionLink 2119100 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2419401 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2113100 - Disclosure - Intangible Assets and Goodwill link:presentationLink link:calculationLink link:definitionLink 2413401 - Disclosure - Intangible Assets and Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 2412402 - Disclosure - Inventories - Schedule of Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 2312301 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - Long-term Obligations link:presentationLink link:calculationLink link:definitionLink 2415401 - Disclosure - Long-term Obligations - Fan Pier Leases (Details) link:presentationLink link:calculationLink link:definitionLink 2415402 - Disclosure - Long-term Obligations - Term Loan (Details) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Marketable Securities link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - Marketable Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 2118100 - Disclosure - Other Arrangements link:presentationLink link:calculationLink link:definitionLink 2418401 - Disclosure - Other Arrangements (Details) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Product Revenues, Net link:presentationLink link:calculationLink link:definitionLink 2402402 - Disclosure - Product Revenues, Net (Details) link:presentationLink link:calculationLink link:definitionLink 2302301 - Disclosure - Product Revenues, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 2120100 - Disclosure - Restructuring Liabilities link:presentationLink link:calculationLink link:definitionLink 2420402 - Disclosure - Restructuring Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2420403 - Disclosure - Restructuring Liabilities (Details 2) link:presentationLink link:calculationLink link:definitionLink 2320301 - Disclosure - Restructuring Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 2116100 - Disclosure - Stock-based Compensation Expense link:presentationLink link:calculationLink link:definitionLink 2416402 - Disclosure - Stock-based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2416403 - Disclosure - Stock-based Compensation Expense (Details 2) link:presentationLink link:calculationLink link:definitionLink 2316301 - Disclosure - Stock-based Compensation Expense (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 vrtx-20150930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 vrtx-20150930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 vrtx-20150930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Earnings Per Share [Abstract] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Stock options Employee Stock Option [Member] Unvested restricted stock and restricted stock units Restricted Stock [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Goodwill and Intangible Assets Disclosure [Abstract] Intangible Assets and Goodwill Goodwill and Intangible Assets Disclosure [Text Block] Restructuring and Related Activities [Abstract] Restructuring Liabilities Restructuring and Related Activities Disclosure [Text Block] Earnings Per Share Earnings Per Share [Text Block] Derivative Instruments and Hedging Activities Disclosure [Abstract] Schedule of Cash Flow Hedging Instruments Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block] Schedule of Foreign Exchange Contracts Schedule of Foreign Exchange Contracts, Statement of Financial Position [Table Text Block] Derivatives Offsetting Derivatives Offsetting [Table Text Block] [Table Text Block] for Derivatives Offsetting [Table] Accounting Policies [Abstract] Basis of Presentation and Accounting Policies Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Commitments and Contingencies Disclosure [Abstract] Restricted cash and cash equivalents Restricted Cash and Cash Equivalents Statement of Stockholders' Equity [Abstract] Statement [Table] Statement [Table] Statement, Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Total Vertex Shareholders’ Equity Parent [Member] Common Stock Common Stock [Member] Additional Paid-in Capital Additional Paid-in Capital [Member] Accumulated Deficit Retained Earnings [Member] Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Noncontrolling Interest Noncontrolling Interest [Member] Statement Statement [Line Items] Increase (Decrease) in Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Balance (shares) Shares, Outstanding Balance Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Other comprehensive income (loss), net of tax Other Comprehensive Income (Loss), Net of Tax Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Issuance of common stock under benefit plans (shares) Stock Issued During Period, Shares, Employee Benefit Plan Issuance of common stock under benefit plans Stock Issued During Period, Value, Employee Benefit Plan Stock-based compensation Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Noncontrolling interest upon consolidation Noncontrolling Interest, Increase from Business Combination Balance (shares) Balance Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Stock-based compensation expense by line item Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Unrecognized stock-based compensation expense, net of estimated forfeitures Schedule of Unrecognized Share-based Compensation Expense [Table Text Block] Disclosure as of the latest balance-sheet date presented of the total compensation cost related to outstanding, nonvested share-based compensation awards not yet recognized, net of estimated forfeitures, and the weighted average period over which those unrecognized costs are expected to be reported. Stock options outstanding and exercisable Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block] Collaborative Arrangements Collaborative Arrangements Collaborative Arrangements Collaborative Arrangement Disclosure [Text Block] Product Revenues [Abstract] Product Revenues [Abstract] Product Revenues, Net Product Revenues Disclosure [Text Block] Product Revenues Disclosure [Text Block] Inventory Disclosure [Abstract] Inventories Inventory Disclosure [Text Block] Schedule of Collaborative Arrangement Agreements [Table] Schedule of Collaborative Arrangement Agreements [Table] A schedule reflecting significant collaboration agreements in which the entity is a participant. Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Drug Candidate [Axis] Drug Candidate [Axis] Potential drug candidate that milestone payments are based upon Drug Candidate [Domain] Drug Candidate [Domain] [Domain] for Potential drug candidate that milestone payments are based upon Additional Enac Inhibitors Additional Enac Inhibitors [Member] Additional ENaC Inhibitors Enac Inhibitors in Non Cf Enac Inhibitors in Non Cf [Member] ENaC Inhibitors in Non-CF ENaC Inhibitors in CF Enac Inhibitors in Cf [Member] ENaC Inhibitors in CF Collaborative Arrangements by Agreement [Axis] Collaborative Arrangements by Agreement [Axis] Significant terms of collaboration arrangements, by individual agreement. Collaborative Arrangement Agreement [Domain] Collaborative Arrangement Agreement [Domain] Listing of significant collaboration agreements. BioAxone Biosciences Inc BioAxone Biosciences Inc [Member] BioAxone Biosciences Inc [Member] Parion Sciences, Inc Parion Sciences, Inc [Member] Parion Sciences, Inc Cystic Fibrosis Foundation Therapeutics Incorporated Cystic Fibrosis Foundation Therapeutics Incorporated Agreement [Member] Collaboration agreement entered into with Cystic Fibrosis Foundation Therapeutics Inc., for the development, manufacture and commercialization of a product of the entity. CRISPR Therapeutics CRISPRTherapeutics [Member] CRISPR Therapeutics AG collaboration. Janssen Janssen Collaborative Agreement [Member] Collaboration agreement entered into with Janssen Pharmaceutical, N.V. for the development, manufacture and commercialization of a product of the entity. Schedule of Collaborative Arrangement Agreements [Line Items] Schedule of Collaborative Arrangement Agreements [Line Items] -- None. No documentation exists for this element. -- Collaborative funding Collaborative Arrangement Research Development Funding This element represents the funding under collaborative agreement 2011 amendment for research and development. Number of years over which funding will be made (in years) Number of Years over which Research Development Funding will be Made This element represents the number of years over which research and development funding will be made as per the collaboration agreement 2011 amendment. Collaborative revenues Collaborative Revenues The aggregate revenue from collaborative revenues. It includes the revenues earned by the entity from nonrefundable, up-front license fees; net reimbursements of research and/or development efforts, including manufacturing services; and milestone payments. Milestone payment made Collaborative Arrangement, Milestone Payment Made Represents the milestone payment made. Number of commercial milestone payments for achievement of certain sales levels for corrector compound such as VX-809 or VX-661 (in payments) Number of Commercial Milestone Payments for Achievement of Certain Sales Levels for Corrector Compound Represents the milestone payments to be made upon achievement of certain sales levels for a corrector compound. Up-front payment Collaborative Arrangement Up-front License Fee The amount of the up-front license fee paid by the entity pursuant to a collaborative arrangement. Investment in collaborative partner, pursuant to convertible loan agreement Collaborative Arrangement, Investment in Collaborative Partner, Amount Collaborative Arrangement, Investment in Collaborative Partner, Amount Right to license, number of targets (up to) Collaborative Arrangement, Right to License, Number of Targets Collaborative Arrangement, Right to License, Number of Targets Collaborative arrangement development and regulatory potential milestone payments maximum Collaborative Arrangement Development And Regulatory Potential Milestone Payments Maximum Represents the potential milestone amount to be paid by the entity under the collaboration agreement if drug candidates are approved and commercialized. Collaborative arrangement regulatory potential milestone payments maximum, global filling and approval Collaborative Arrangement Regulatory Potential Milestone Payments Maximum Represents the potential milestone amount to be paid by the entity under the collaboration agreement if drug candidates are commercialized. Prior to marketing approval, time period of notice required to terminate (in days) Collaborative Arrangement, Prior to Marketing Approval, Time Period of Notice Required to Terminate Collaborative Arrangement, Prior to Marketing Approval, Time Period of Notice Required to Terminate Subsequent to marketing approval, time period of notice required to terminate (in days) Collaborative Arrangement, Subsequent to Marketing Approval, Time Period of Notice Required to Terminate Collaborative Arrangement, Subsequent to Marketing Approval, Time Period of Notice Required to Terminate Change of control prior to clinical trial, time period of notice required to terminate (in days) Collaborative Arrangement, Change of Control Prior to Clinical Trial, Time Period of Notice Required to Terminate Collaborative Arrangement, Change of Control Prior to Clinical Trial, Time Period of Notice Required to Terminate Term of agreement following first commercial sale (in years) Collaborative Arrangement, Term of Agreement Following First Commercial Sale Collaborative Arrangement, Term of Agreement Following First Commercial Sale Business combination, consideration transferred Business Combination, Consideration Transferred Development milestones discount rate low end of range (percentage) Business Acquisition Contingent Consideration Development Milestones Discount Rate Low End Of Range The low end of the range of discount rates used to estimate the fair value of the contingent consideration related to development milestones in a business combination. Development milestones discount rate high end of range (percentage) Business Acquisition Contingent Consideration Development Milestones Discount Rate High End Of Range The high end of the range of discount rates used to estimate the fair value of the contingent consideration related to development milestones in a business combination. Commercial milestones and royalties discount rate (percentage) Business Acquisition Contingent Consideration Commercial Milestones And Royalties Discount Rate The discount rate used to estimate the fair value of the contingent consideration related to commercial milestones and royalties in a business combination. Intangible assets Other Indefinite-lived Intangible Assets License fees and milestone payments (up to) Maximum license fees and milestone payments Maximum license fees and milestone payments Purchase option, term of extension of expiration date (in years) Collaborative Arrangements, Purchase Option, Term of Extension of Expiration Date Collaborative Arrangements, Purchase Option, Term of Extension of Expiration Date Increase (decrease) in fair value of contingent milestone and royalty payments Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Contingent consideration, liability Business Combination, Contingent Consideration, Liability Reimbursement revenue Reimbursement Revenue Time period of notice required to terminate (in months) Collaborative Arrangement, Time Period of Notice Required to Terminate Collaborative Arrangement, Time Period of Notice Required to Terminate Cash and Cash Equivalents [Abstract] Marketable Securities Cash, Cash Equivalents, and Marketable Securities [Text Block] Schedule of Indefinite-Lived Intangible Assets by Major Class [Table] Schedule of Indefinite-Lived Intangible Assets [Table] Asset Class [Axis] Asset Class [Axis] Asset Class [Domain] Asset Class [Domain] Indefinite-lived Intangible Assets Indefinite-lived Intangible Assets [Member] Variable Interest Entities [Axis] Variable Interest Entities [Axis] Variable Interest Entity, Classification [Domain] Variable Interest Entity, Classification [Domain] Variable Interest Entity, Primary Beneficiary Variable Interest Entity, Primary Beneficiary [Member] Indefinite-Lived Intangible Assets [Line Items] Indefinite-lived Intangible Assets [Line Items] In-process research and development intangible asset Variable Interest Entity, Consolidated, Carrying Amount, In-Process Research and Development Intangible Asset Variable Interest Entity, Consolidated, Carrying Amount, In-Process Research and Development Intangible Asset Fair value inputs, discount rate (percent) Fair Value Inputs, Discount Rate Goodwill Goodwill Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Axis] Exercise Price Range [Axis] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain] $18.93–$20.00 Exercise Price Range From Dollars 18.93 to Dollars 20.00 [Member] Represents the range of exercise prices from $18.93 to $20.00 per share for the purpose of disclosing shares potentially issuable under outstanding stock options, as well as other option information. $20.01–$40.00 Exercise Price Range from Dollars 20.01 to Dollars 40.00 [Member] Represents the range of exercise prices from $20.01 to $40.00 per share for the purpose of disclosing shares potentially issuable under outstanding stock options, as well as other option information. $40.01–$60.00 Exercise Price Range from Dollars 40.01 to Dollars 60.00 [Member] Represents the range of exercise prices from $40.01 to $60.00 per share for the purpose of disclosing shares potentially issuable under outstanding stock options, as well as other option information. $60.01–$80.00 Exercise Price Range from Dollars 60.01 to Dollars 80.00 [Member] Represents the range of exercise prices from $60.01 to $80.00 per share for the purpose of disclosing shares potentially issuable under outstanding stock options, as well as other option information. $80.01–$100.00 Exercise Price Range from Dollars 80.01 to Dollars 100.00 [Member] Represents the range of exercise prices from $80.01 to $100.00 per share for the purpose of disclosing shares potentially issuable under outstanding stock options, as well as other option information. $100.01–$120.00 Exercise Price Range from Dollars 100.01 to Dollars 120.00 [Member] Represents the range of exercise prices from $100.01 to $120.00 per share for the purpose of disclosing shares potentially issuable under outstanding stock options, as well as other option information. $120.01–$134.69 Exercise Price Range From Dollars 120.01 to Dollars 134.69 [Member] Represents the range of exercise prices from $120.01 to $134.69 per share for the purpose of disclosing shares potentially issuable under outstanding stock options, as well as other option information. Share-based Compensation Arrangement by Share-based Payment Award Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Exercise price, low end of range (usd per share) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit Exercise price, high end of range (usd per share) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit Exercise price range, options outstanding (in shares) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options Exercise price range, options outstanding, weighted-average remaining contractual life (in years) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term Exercise price range, options outstanding, weighted-average exercise price (in dollars per share) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price Exercise price range, options exercisable (in shares) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options Exercise price range, options exercisable, weighted-average exercise price (in dollars per share) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price Fair Value Disclosures [Abstract] Fair Value Measurements Fair Value Disclosures [Text Block] Valuation and Qualifying Accounts Disclosure [Table] Valuation and Qualifying Accounts Disclosure [Table] Valuation Allowances and Reserves Type [Axis] Valuation Allowances and Reserves Type [Axis] Valuation Allowances and Reserves [Domain] Valuation Allowances and Reserves [Domain] Trade Allowances Allowance for Trade Receivables [Member] Rebates, Chargebacks and Discounts Rebates Chargebacks and Discounts [Member] A valuation allowance for amounts due to the entity for rebates, chargebacks and discounts in the normal course of business that are expected to be uncollectible. Product Returns Allowance for Sales Returns [Member] Other Incentives Copay Mitigation Rebates [Member] A valuation allowance for amounts due to the entity for copay mitigation rebates in the normal course of business that are expected to be uncollectible. Valuation and Qualifying Accounts Disclosure [Line Items] Valuation and Qualifying Accounts Disclosure [Line Items] Product Revenue Allowance and Reserve [Roll Forward] Movement in Valuation Allowances and Reserves [Roll Forward] Balance at December 31, 2014 Valuation Allowances and Reserves, Balance Provision related to current period sales Valuation Allowances and Reserves Provision Total of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs, charged to product revenues. Adjustments related to prior period sales Valuation Allowances and Reserves, Adjustments Credits/payments made Valuation Allowances and Reserves, Sales Credits or Payments, Current Represents the credits or payments to allowances and reserves. Balance at September 30, 2015 Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Prepaid and other current assets Prepaid Expenses and Other Current Assets [Member] Other Assets Other Assets [Member] Other liabilities, current portion Other Current Liabilities [Member] Other liabilities, excluding current portion Other Noncurrent Liabilities [Member] Derivative Instrument [Axis] Derivative Instrument [Axis] Derivative Contract [Domain] Derivative Contract [Domain] Foreign currency forward contracts Foreign Exchange Forward [Member] Fair Value by Measurement Frequency [Axis] Measurement Frequency [Axis] Fair Value, Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Recurring basis Fair Value, Measurements, Recurring [Member] Fair Value, Hierarchy [Axis] Fair Value, Hierarchy [Axis] Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Level 1 Fair Value, Inputs, Level 1 [Member] Level 2 Fair Value, Inputs, Level 2 [Member] Level 3 Fair Value, Inputs, Level 3 [Member] Investment Type [Axis] Investment Type [Axis] Investment Type Categorization [Domain] Investments [Domain] Money market funds Money Market Funds [Member] Corporate debt securities Corporate Debt Securities [Member] Commercial paper Commercial Paper [Member] Fair value of financial assets and liabilities Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Financial assets carried at fair value: Assets, Fair Value Disclosure [Abstract] Cash equivalents: Cash and Cash Equivalents, Fair Value Disclosure Marketable securities: Marketable Securities Foreign currency forward contracts Foreign Currency Cash Flow Hedge Derivative at Fair Value, Net Total financial assets Assets, Fair Value Disclosure Total financial liabilities Financial Liabilities Fair Value Disclosure Cash and cash equivalents Variable Interest Entity, Consolidated, Carrying Amount, Cash and Cash Equivalents Variable Interest Entity, Consolidated, Carrying Amount, Cash and Cash Equivalents Term loan fair value Loans Payable, Fair Value Disclosure Financial assets subject to fair value measurements (excluding restricted cash and cash equivalents (Alios)) Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Restructuring Plan [Axis] Restructuring Plan [Axis] Restructuring Plan [Domain] Restructuring Plan [Domain] Kendall Restructuring Kendall Restructuring [Member] Kendall Restructuring [Member] Fan Pier Move Restructuring Fan Pier Move [Member] Fan Pier Move [Member] Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Lease term (in years) Lease Term Total length of time of a real estate lease, stated in years. Restructuring and related activities, leased office space, maximum percentage used - not more than Restructuring and Related Activities, Leased Office Space, Maximum Percentage Used Maximum of percentage used of leased office space. Number of facilities decommissioned Restructuring and Related Activities, Number of Facilities Decommissioned Restructuring and Related Activities, Number of Facilities Decommissioned Number of leases terminated Number Of Lease Terminated Number Of Lease Terminated Area of real estate property (in square feet) Area of Real Estate Property Discount rate related to leases (percent) Lease Restructuring Liability Accrual Discount Rate The credit-adjusted risk-free discount rate applied to the undiscounted amount of projected cash inflows and/or outflows to arrive at the present value of the lease restructuring liability recorded as of the balance sheet date. Income Statement [Abstract] Tax effect of discontinued operations Discontinued Operation, Tax Effect of Discontinued Operation Stock-based Compensation Expense Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Document and Entity Information [Abstract] Document and Entity Information [Abstract] Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Document Type Document Type Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Equity [Abstract] Accumulated Other Comprehensive (Loss) Income Comprehensive Income (Loss) Note [Text Block] Basis of Presentation Basis of Presentation and Significant Accounting Policies [Text Block] Use of Estimates and Summary of Significant Accounting Policies Use of Estimates, Policy [Policy Text Block] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Schedule of Cash, Cash Equivalents and Available-for-sale Securities [Table] Schedule of Cash, Cash Equivalents and Available-for-sale Securities [Table] Schedule of the cash and cash equivalents and available-for-sale investments held by the entity. Schedule of Cash, Cash Equivalents and Available-for-sale Securities Types of Financial Instruments [Axis] Schedule of Cash, Cash Equivalents and Available-for-sale Securities Types of Financial Instruments [Axis] This element represents a number of concepts which capture the categories of financial instruments classified as cash and cash equivalents and available-for-sale investments. Types of Financial Instruments [Domain] Types of Financial Instruments [Domain] Provides general categories of financial instruments included as cash, cash equivalents and available-for-sale investments. Total cash and cash equivalents Cash and Cash Equivalents [Member] Cash and money market funds Cash and Money Market Funds [Member] Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time. Corporate Debt Securities Total marketable securities Available-for-sale Securities [Member] Government-sponsored enterprise securities (due within 1 year) U.S. Government Sponsored Enterprises Debt Securities, Due Within One Year [Member] U.S. Government Sponsored Enterprises Debt Securities, Due Within One Year [Member] Commercial paper (due within 1 year) Commercial Paper, Not Included with Cash and Cash Equivalents [Member] Corporate debt securities (due within 1 year) Corporate Debt Securities, Due Within One Year [Member] Corporate Debt Securities, Due Within One Year [Member] Corporate debt securities (due after 1 year through 5 years) Corporate Debt Securities, Due After One Year Through Five Years [Member] Corporate Debt Securities, Due After One Year Through Five Years [Member] Summary of cash, cash equivalents and marketable securities Schedule of Cash, Cash Equivalents and Available-for-sale Securities [Line Items] -- None. No documentation exists for this element. -- Amortized Cost Cash, Cash Equivalents, Available-for-sale Securities, Amortized Cost This item represents the cost of cash and cash equivalents and debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any. Gross Unrealized Gains Cash, Cash Equivalents, Available-for-sale Securities, Gross Unrealized Gain This item represents the gross unrealized gains for cash, cash equivalents and securities which are categorized neither as held-to-maturity nor trading securities. Such gross unrealized gains are the excess of the fair value over the carrying value as of the reporting date. Gross Unrealized Losses Cash, Cash Equivalents, Available-for-sale Securities, Unrealized Loss, Gross This item represents the gross unrealized losses for cash, cash equivalents and securities which are categorized neither as held-to-maturity nor trading securities. Such gross unrealized losses are the excess of the carrying value over the fair value as of the reporting date. Fair Value Cash, Cash Equivalents and Available-for-sale Securities, Fair Value This item represents the fair value of cash, cash equivalents and debt and equity securities, which are categorized neither as held-to-maturity nor trading. Schedule of product revenue allowances and reserve categories Schedule of Valuation and Qualifying Accounts [Table Text Block] Tabular disclosure of product revenues allowances and reserve accounts (their beginning and ending balances, as well as reconciliation by type of activity during the period). Other Restructuring Other Restructuring [Member] Activity related to the restructuring liability Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Recognized Collaborative Revenue [Abstract] Recognized Collaborative Revenue [Abstract] -- None. No documentation exists for this element. -- Royalty revenues Royalty Revenue Total revenues Revenues Fair value of contingent milestone and royalty payments Business Combination, Liabilities Arising from Contingencies, Amount Recognized Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract] Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract] Restricted cash and cash equivalents (VIE) Restricted Cash and Cash Equivalents, Current Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Deferred tax liability Deferred Tax Liabilities, Net, Noncurrent Net other assets (liabilities) Other Liabilities (Assets), Net Other Liabilities (Assets), Net Other assets Other Assets, Noncurrent Accounts payable Accounts Payable, Current Accrued expenses Accrued Liabilities, Current Other liabilities, excluding current portion Other Liabilities, Noncurrent Noncontrolling interest Stockholders' Equity Attributable to Noncontrolling Interest Net assets attributable to noncontrolling interests Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Loss attributable to noncontrolling interest before provision for income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest Provision for income taxes Income Tax Expense (Benefit) Increase in fair value of contingent milestone and royalty payments Net (income) loss attributable to noncontrolling interest Net Income (Loss) Attributable to Noncontrolling Interest Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] Stock and Option Plan 2013 [Member] Stock and Option Plan 2013 [Member] Stock and Option Plan 2013 [Member] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis] Income Statement Location [Axis] Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain] Income Statement Location [Domain] Research and development expenses Research and Development Expense [Member] Sales, general and administrative expenses Selling General and Administrative Expense [Member] The allocation (or location) of expense to (in) selling, general and administrative expense. Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Award Type and Plan Name [Axis] Award Type [Axis] Award Type [Domain] Equity Award [Domain] Stock options Restricted stock and restricted stock units Employee Restricted Stock Option [Member] An arrangement whereby certain members of senior management are entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. ESPP share issuances Employee Stock Purchase Plan [Member] Employee Stock Purchase Plan [Member] Stock-based compensation expense: Share-based Compensation Allocation [Abstract] -- None. No documentation exists for this element. -- Stock-based compensation expense by type of award: Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost Less stock-based compensation expense capitalized to inventories Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Capitalized Amount Total stock-based compensation included in costs and expenses Allocated Share-based Compensation Expense Type of award: Employee Service Share-based Compensation, Aggregate Disclosures [Abstract] Unrecognized Expense, Net of Estimated Forfeitures Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized Weighted-average recognition period (in years) Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Number of additional shares authorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Hedging Derivative Instruments and Hedging Activities Disclosure [Text Block] Statement of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization expense Depreciation, Depletion and Amortization Stock-based compensation expense Share-based Compensation Deferred income taxes Increase (Decrease) in Other Deferred Liability Impairment of property and equipment Asset Impairment Charges Other non-cash items, net Other Noncash Income (Expense) Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Accounts receivable, net Increase (Decrease) in Accounts Receivable Inventories Increase (Decrease) in Inventories Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Accounts payable Increase (Decrease) in Accounts Payable Accrued expenses and other liabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Accrued restructuring expense Restructuring Reserve, Period Increase (Decrease) Deferred revenues Increase (Decrease) in Deferred Revenue Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchases of marketable securities Payments to Acquire Available-for-sale Securities Maturities of marketable securities Proceeds from Sale and Maturity of Available-for-sale Securities Payment for acquisition of variable interest entity Payments to Acquire Intangible Assets Expenditures for property and equipment Payments to Acquire Property, Plant, and Equipment (Increase) decrease in restricted cash and cash equivalents Increase (Decrease) in Restricted Cash Decrease in restricted cash and cash equivalents (VIE) Increase (Decrease) in Restricted Cash and Investments Decrease (increase) in other assets Payments for (Proceeds from) Other Investing Activities Net cash provided by investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Issuances of common stock under benefit plans Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options Payments on capital lease obligations Payments of Financing Costs Proceeds from capital lease financing Proceeds from Long-term Capital Lease Obligations Payments on Fan Pier lease obligation Repayments of Long-term Capital Lease Obligations Proceeds from senior secured term loan Proceeds from (Repayments of) Secured Debt Payments returned related to Fan Pier lease obligation Proceeds from (Payments for) Other Financing Activities Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Effect of changes in exchange rates on cash Effect of Exchange Rate on Cash and Cash Equivalents Net increase in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Cash and cash equivalents—beginning of period Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents—end of period Supplemental disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Cash paid for interest Interest Paid Cash paid for income taxes Income Taxes Paid Capitalization of costs related to Fan Pier lease obligation Noncash or Part Noncash Acquisition, Fixed Assets Acquired Assets acquired under capital lease Capital Lease Obligations Incurred Issuances of common stock exercises from employee benefit plans receivable Conversion of Stock, Amount Issued Income Tax Disclosure [Abstract] Provision for income taxes Unrecognized tax benefits Unrecognized Tax Benefits Estimated reduction in unrecognized tax benefits in next fiscal year Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations and Settlements with Taxing Authorities, Estimated in Next Fiscal Year Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations and Settlements with Taxing Authorities, Estimated in Next Fiscal Year Schedule of Inventories by Type Schedule of Inventory, Current [Table Text Block] Revenues: Revenues [Abstract] Product revenues, net Sales Revenue, Goods, Net Costs and expenses: Costs and Expenses [Abstract] Cost of product revenues Cost of Goods Sold Royalty expenses Direct Operating Cost, Royalty Expense Research and development expenses Research and Development Expense Sales, general and administrative expenses Selling, General and Administrative Expense Restructuring expenses, net Restructuring Charges Total costs and expenses Costs and Expenses Loss from operations Operating Income (Loss) Interest expense, net Interest Income (Expense), Net Other (expenses) income, net Other Nonoperating Income (Expense) Loss from continuing operations before provision for income taxes Loss from continuing operations Income (Loss) from Continuing Operations, Including Portion Attributable to Noncontrolling Interest Loss from discontinued operations, net of tax benefit of $0 Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Net loss (Income) loss attributable to noncontrolling interest Net loss attributable to Vertex Net Income (Loss) Attributable to Parent Loss from continuing operations Income (Loss) from Continuing Operations Attributable to Parent Loss from discontinued operations Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent Net loss from continuing operations: Income (Loss) from Operations before Extraordinary Items, Per Basic and Diluted Share [Abstract] Net loss per share from continuing operations, basic (usd per share) Income (Loss) from Continuing Operations, Per Basic Share Net loss per share from continuing operations, diluted (usd per share) Income (Loss) from Continuing Operations, Per Diluted Share Net loss from discontinued operations: Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share [Abstract] Net loss from discontinued operations, basic (usd per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share Net loss from discontinued operations, diluted (usd per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share Net loss: Basic (usd per share) Earnings Per Share, Basic Diluted (usd per share) Earnings Per Share, Diluted Shares used in per share calculations: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Derivative [Table] Derivative [Table] Hedging Designation [Axis] Hedging Designation [Axis] Hedging Designation [Domain] Hedging Designation [Domain] Designated as hedging instrument Designated as Hedging Instrument [Member] Other assets Currency [Axis] Currency [Axis] All Currencies [Domain] All Currencies [Domain] Euro Euro Member Countries, Euro British pound sterling United Kingdom, Pounds Australian dollar Australia, Dollars Foreign Currency Forward Contract Hedging Relationship [Axis] Hedging Relationship [Axis] Hedging Relationship [Domain] Hedging Relationship [Domain] Cash Flow Hedging Cash Flow Hedging [Member] Derivative [Line Items] Derivative [Line Items] Notional amount of foreign currency forward contract Derivative, Notional Amount Foreign Currency Cash Flow Hedge Derivative at Fair Value [Abstract] Foreign Currency Cash Flow Hedge Derivative at Fair Value, Net [Abstract] Fair Value - assets Foreign Currency Cash Flow Hedge Asset at Fair Value Fair Value - liabilities Foreign Currency Cash Flow Hedge Liability at Fair Value Offsetting Derivative Assets [Abstract] Offsetting Derivative Assets [Abstract] Gross Amounts Recognized Derivative Asset, Fair Value, Gross Asset Gross Amounts Offset Derivative Asset Fair Value Gross Asset Collateral And Other Set Off Against Gross Assets Subject To Offsetting Enforceable Master Netting Arrangement Or Similar Agreement Derivative, Asset Fair Value, Gross Asset, Collateral And Other Set Off Against Gross Assets Subject To Offsetting Enforceable Master Netting Arrangement Or Similar Agreement Gross Amount Presented Derivative Asset Gross Amount Not Offset Derivative Asset, Not Offset, Policy Election Deduction Legal Offset Derivative Asset, Fair Value, Amount Offset Against Collateral Offsetting Derivative Liabilities [Abstract] Offsetting Derivative Liabilities [Abstract] Gross Amounts Recognized Derivative Liability, Fair Value, Gross Liability Gross Amounts Offset Derivative Liability Fair Value Gross Liability Collateral And Other Set Off Against Gross Assets Subject To Offsetting Enforceable Master Netting Arrangement Or Similar Agreement Derivative Liability, Fair Value, Gross Liability, Collateral and Other Set Off Against Gross Assets Subject to Offsetting Enforceable Master Netting Arrangement or Similar Agreement Gross Amount Presented Derivative Liability Gross Amount Not Offset Derivative Liability, Not Offset, Policy Election Deduction Legal Offset Derivative Liability, Fair Value, Amount Offset Against Collateral Statement of Financial Position [Abstract] Assets Assets [Abstract] Current assets: Assets, Current [Abstract] Cash and cash equivalents Marketable securities, available for sale Available-for-sale Securities, Current Accounts receivable, net Accounts Receivable, Net, Current Inventories Inventory, Net Prepaid expenses and other current assets Total current assets Assets, Current Property and equipment, net Property, Plant and Equipment, Net Restricted cash Restricted Cash and Cash Equivalents, Noncurrent Other assets Total assets Assets Liabilities and Shareholders’ Equity Liabilities and Equity [Abstract] Current liabilities: Liabilities, Current [Abstract] Deferred revenues, current portion Deferred Revenue, Current Accrued restructuring expenses, current portion Restructuring Reserve, Current Capital lease obligations, current portion Capital Lease Obligations, Current Senior secured term loan, current portion Senior Notes, Current Other liabilities, current portion Other Liabilities, Current Total current liabilities Liabilities, Current Deferred revenues, excluding current portion Deferred Revenue, Noncurrent Accrued restructuring expenses, excluding current portion Restructuring Reserve, Noncurrent Capital lease obligations, excluding current portion Capital Lease Obligations, Noncurrent Deferred tax liability Fan Pier lease obligation, excluding current portion Construction Financing Obligation, Noncurrent Represents the noncurrent portion of a lease liability recorded as a result of capitalizing the landlord's costs of constructing facilities associated with building leases. Senior secured term loan, excluding current portion Senior Notes, Noncurrent Total liabilities Liabilities Commitments and contingencies Commitments and Contingencies Shareholders’ equity: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Preferred stock, $0.01 par value; 1,000,000 shares authorized; none issued and outstanding at September 30, 2015 and December 31, 2014 Preferred Stock, Value, Issued Common stock, $0.01 par value; 500,000,000 and 300,000,000 shares authorized at September 30, 2015 and December 31, 2014, respectively; 245,646,269 and 241,764,398 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital, Common Stock Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated deficit Retained Earnings (Accumulated Deficit) Total Vertex shareholders' equity Stockholders' Equity Attributable to Parent Total shareholders’ equity Total liabilities and shareholders’ equity Liabilities and Equity Long-term Debt and Capital Lease Obligations [Abstract] Long-term Obligations Debt Disclosure [Text Block] Number of operating segments Number of Operating Segments Accumulated Other Comprehensive (Loss) Income Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Other Income and Expenses [Abstract] Sale of HIV Protease Inhibitor Royalty Stream Sale of HIV Protease Inhibitor Royalty Stream Gross proceeds from sale of royalty rights receivable from GlaxoSmithKline Proceeds from Sale of Royalty Rights The cash inflow from the sale of the entity's right to receive future royalty payments. Deferred revenue royalty purchase agreement Deferred Revenue Royalty Purchase Agreement This element represents the carrying value of deferred revenue recorded with regard to agreement to sell rights to receive royalty payments, as on the balance sheet date. Other nonoperating income Other Nonoperating Income Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Potential gross common equivalent shares Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Preferred stock, par value (usd per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, shares authorized Preferred Stock, Shares Authorized Preferred stock, shares issued Preferred Stock, Shares Issued Preferred stock, shares outstanding Preferred Stock, Shares Outstanding Common stock, par value (usd per share) Common Stock, Par or Stated Value Per Share Common stock, shares authorized Common Stock, Shares Authorized Common stock, shares issued Common Stock, Shares, Issued Common stock, shares outstanding Common Stock, Shares, Outstanding Summary of cash, cash equivalents and marketable securities Cash, Cash Equivalents and Investments [Table Text Block] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum Minimum [Member] Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Senior Secured Term Loan Facility Secured Debt [Member] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Senior Secured Term Loan Senior Loans [Member] Variable Rate [Axis] Variable Rate [Axis] Variable Rate [Domain] Variable Rate [Domain] LIBOR London Interbank Offered Rate (LIBOR) [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Face amount of term loan Debt Instrument, Face Amount Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Interest rate, stated percentage Debt Instrument, Interest Rate, Stated Percentage Contingent interest rate (percent) Debt Instrument, Interest Rate, Stated Percentage Rate Range, Minimum Basis spread on variable rate (percent) Debt Instrument, Basis Spread on Variable Rate Amount of principal repayment on quarterly installment payments from October 1, 2016 through maturity Debt Instrument, Periodic Payment, Principal Debt instrument, repayment provision, period over which present value of interest payments is determined (in years) Debt Instrument, Repayment Provision, Period Over Which Present Value of Interest Payments is Determined Debt Instrument, Repayment Provision, Period Over Which Present Value of Interest Payments is Determined Unamortized discount on term loan Debt Instrument, Unamortized Discount Raw materials Inventory, Raw Materials, Net of Reserves Work-in-process Inventory, Work in Process, Net of Reserves Finished goods Inventory, Finished Goods, Net of Reserves Total Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Building Building [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Number of leases Lease Agreement, Number of Leases Represents the number of leases entered by the reporting entity. Number of buildings under lease agreement Lease Agreements Number of Buildings Represents number of buildings under lease agreements. Optional term of lease agreement (in years) Optional Term of Lease Agreement Represents additional period to extend term of lease agreement. Construction financing lease obligation, current and noncurrent Construction financing lease obligation, current and noncurrent Represents the current noncurrent portion of a lease liability recorded as a result of capitalizing the landlord's costs of constructing facilities associated with building leases. Other Arrangements Other Nonoperating Income and Expense [Text Block] Foreign Currency Translation Adjustment Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Unrealized Holding Gains (Losses) on Marketable Securities Accumulated Net Investment Gain (Loss) Attributable to Parent [Member] Unrealized Gains (Losses) on Foreign Currency Forward Contracts Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent [Member] Statement [Line Items] Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] Balance at balance sheet date Other comprehensive (loss) income before reclassifications Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Amounts reclassified from accumulated other comprehensive loss Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Total changes in other comprehensive loss Balance at balance sheet date Income Taxes Income Tax Disclosure [Text Block] Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract] Changes in other comprehensive loss: Other Comprehensive Income (Loss), Net of Tax [Abstract] Unrealized holding gains (losses) on marketable securities Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax Unrealized gains on foreign currency forward contracts Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Net of Tax Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Comprehensive loss Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Comprehensive (income) loss attributable to noncontrolling interest Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Comprehensive loss attributable to Vertex Comprehensive Income (Loss), Net of Tax, Attributable to Parent Restructuring activities Restructuring Reserve [Roll Forward] Liability, beginning of the period Restructuring Reserve Cash payments Payments for Restructuring Cash received from subleases Restructuring Reserve Settled with Cash Receipt from Sublease Amount of cash received in the period to fully or partially offset a specified, previously accrued type of restructuring cost. Restructuring expense (income) Liability, end of the period Schedule of Recognized Collaborative Revenue Schedule of Recognized Collaborative Revenue [Table Text Block] This element represents the revenues related to the collaboration recognized by the entity during the period. Fair Value Of Consideration Transferred Fair Value Of Consideration Transferred [Table Text Block] [Table Text Block] for Fair Value Of Consideration Transferred [Table] Schedule of Recognized Identified Assets Acquired and Liabilities Assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Schedule of Collaborative Arrangement Activity Net Loss Attributable to Noncontrolling Interest Schedule of Collaborative Arrangement Activity Net Loss Attributable to Noncontrolling Interest [Table Text Block] Represents the summary of activity related to the Alios Collaboration. Schedule Of Collaborative Arrangement Summary Of Items Related To Variable Interest Entities Schedule Of Collaborative Arrangement Summary Of Items Related To Variable Interest Entities [Table Text Block] Represents details pertaining to Variable Interest Entities assets and liabilities included in the company's condensed consolidated balance sheets. EX-101.PRE 11 vrtx-20150930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 R39.htm IDEA: XBRL DOCUMENT v3.3.0.814
Collaborative Arrangements (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended
Jun. 04, 2015
Sep. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
Dec. 31, 2014
Recognized Collaborative Revenue [Abstract]            
Royalty revenues   $ 5,759 $ 8,386 $ 17,628 $ 32,134  
Collaborative revenues   1,546 33,502 2,999 40,846  
Total revenues   309,816 178,987 614,401 435,859  
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]            
Restricted cash and cash equivalents (VIE)   75,765   75,765   $ 8,418
Prepaid expenses and other current assets   63,388   63,388   44,175
Intangible assets   284,340   284,340   29,000
Goodwill   50,384   50,384   39,915
Deferred tax liability   (113,860)   (113,860)   (15,044)
Other assets   11,061   11,061   3,265
Accounts payable   78,899   78,899   71,194
Accrued expenses   249,698   249,698   209,676
Other liabilities, excluding current portion   34,990   34,990   21,707
Noncontrolling interest   154,585   154,585   21,177
Loss attributable to noncontrolling interest before provision for income taxes   (92,486) (166,577) (481,752) (556,281)  
Provision for income taxes   (1,330) (3,419) (31,760) (4,915)  
Net (income) loss attributable to noncontrolling interest   1,333 0 (30,909) 0  
Janssen            
Recognized Collaborative Revenue [Abstract]            
Royalty revenues   158 2,284 1,742 12,917  
Collaborative revenues   441 1,390 1,620 4,262  
Total revenues   599 $ 3,674 3,362 $ 17,179  
Up-front payment           35,000
Parion Sciences, Inc            
Recognized Collaborative Revenue [Abstract]            
Up-front payment $ 80,000          
Fair value of contingent milestone and royalty payments 175,340          
Business combination, consideration transferred 255,340          
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]            
Intangible assets 255,340          
Goodwill 10,468          
Deferred tax liability (91,023)          
Net other assets (liabilities) (10,468)          
Net assets attributable to noncontrolling interests $ 164,317          
Provision for income taxes   (800)   (30,400)    
Increase in fair value of contingent milestone and royalty payments   (4,500)   (2,900)    
Variable Interest Entity, Primary Beneficiary            
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]            
Restricted cash and cash equivalents (VIE)   75,765   75,765   8,418
Prepaid expenses and other current assets   3,057   3,057   268
Intangible assets   284,340   284,340   29,000
Goodwill   19,391   19,391   8,923
Deferred tax liability   (110,360)   (110,360)   (11,544)
Other assets   461   461   42
Accounts payable   1,115   1,115   189
Accrued expenses   32,519   32,519   3,891
Other liabilities, excluding current portion   300   300   300
Noncontrolling interest   154,585   154,585   $ 21,177
Loss attributable to noncontrolling interest before provision for income taxes   (1,743)   (3,322)    
Provision for income taxes   (777)   (30,367)    
Increase in fair value of contingent milestone and royalty payments   (3,853)   (2,780)    
Net (income) loss attributable to noncontrolling interest   $ 1,333   $ 30,909    
XML 13 R54.htm IDEA: XBRL DOCUMENT v3.3.0.814
Restructuring Liabilities (Details 2) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
Restructuring activities        
Restructuring expense (income) $ 1,826 $ 40,843 $ 682 $ 46,761
Kendall Restructuring        
Restructuring activities        
Liability, beginning of the period 9,924 14,936 11,596 19,115
Cash payments (3,975) (4,249) (10,544) (12,071)
Cash received from subleases 2,919 2,689 8,194 8,067
Restructuring expense (income) 146 (464) (232) (2,199)
Liability, end of the period 9,014 12,912 9,014 12,912
Fan Pier Move Restructuring        
Restructuring activities        
Liability, beginning of the period 9,017 3,256 33,390 797
Cash payments (3,070) (2,266) (25,421) (6,643)
Cash received from subleases 1,820 0 1,820 0
Restructuring expense (income) 51 39,752 (1,971) 46,588
Liability, end of the period 7,818 40,742 7,818 40,742
Other Restructuring        
Restructuring activities        
Liability, beginning of the period 902 792 869 8,441
Cash payments (1,559) (399) (2,782) (8,865)
Restructuring expense (income) 1,629 1,555 2,885 2,372
Liability, end of the period $ 972 $ 1,948 $ 972 $ 1,948
XML 14 R48.htm IDEA: XBRL DOCUMENT v3.3.0.814
Long-term Obligations - Term Loan (Details) - USD ($)
 1 Months Ended
Oct. 31, 2015
Jul. 31, 2014
Sep. 30, 2015
Senior Secured Term Loan      
Debt Instrument [Line Items]      
Face amount of term loan   $ 300,000,000  
Interest rate, stated percentage   7.20%  
Contingent interest rate (percent)   6.20%  
Unamortized discount on term loan   $ 5,300,000 $ 5,200,000
Senior Secured Term Loan Facility      
Debt Instrument [Line Items]      
Maximum borrowing capacity   $ 200,000,000  
Minimum | Senior Secured Term Loan | LIBOR      
Debt Instrument [Line Items]      
Basis spread on variable rate (percent)   5.00%  
Subsequent Event | Senior Secured Term Loan      
Debt Instrument [Line Items]      
Amount of principal repayment on quarterly installment payments from October 1, 2016 through maturity $ 75,000,000    
Debt instrument, repayment provision, period over which present value of interest payments is determined (in years) 2 years    
EXCEL 15 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0````(`%>#7DIG[_Y"G.=G88X[+J4_+?&(MM3U;'VGD:SRWV@Y%Y6VOO!M#H9-[+M MV!UDG;O5RK34N?;!YBUURJ7I4XY7LSL=THVV.07;#6P*[#]Y7>+L8PI&'TAW ML2=*=JAC>AHH'JN_C[Q4OJ*5?AC2NPH_W[LZT#"MB;WQSZ6N=SE+S+\MJQR- M;ZIPN/%OG1E;AN;']6\[ROD_7LO!3=S:X2KH1W-08'NR,95C;;49CXWJT87- M#^5):%^A-!8Z??_3T*=@9-/AA$B\JP\!TH<$Z4.!]-&`]'$&TL=G MD#Z^@/3Q%:0/OD!I!$54CD(J1S&5HZ#*453E**QR%%QW8OG*\M"_V/Z'D4X$G1H>)%]2-F M`Q+M*;V"^GH`A3&^.R6:E((C-Z."N[_8_`)02P,$%`````@`5X->1WW\E?;Y M`0``DB$``!H```!X;"]??'G=.SR:OI]7;6E#*L0\J9-IR;?]$/JIKN[?CPU M9;H<]V%H-J_-/@6MZV48+^=4CP\?9R^>M^MJ?-Y*M?C9C/M4UM7O?GS-;4HE MA_-);J8%IMMO0_K.\OUN=]BDIW[SZY2Z\D5%^+=`%>:#=#Y(*4$V'V24()\/ MBOI M61L];'/T5J"WAM';P-Z&T=O`WH;1V\#>AM';P-Z&T=O`WH; M1V\'>CM';P=Z.T=O!WH[1V\'>CMIKQMM=G/T=J"W<_1VH+=S]':@MW/T=J"W M<_1VH+=S](Y`[\C1.P*](T?O"/2.'+TCT#MR](Y`[TAZ5XE>5G+TCA=ZY[89 MT_:EC(=NGZ]=\]]P6'2!=RYOQW3]E/-4V'"A=9E62N%\O/K?_3SU;TCX]/G% MXSM02P,$%`````@`5X->1]K(E(Q&`P``P`T``!````!D;V-0&ULO5=;;]HP%/XK%D^=-!H*I=LJ&HE"NU;J!176/1OG$"P<&]D.H_OU.W$* M#:V3$A[&`SC'YSO7SR>F)TWK?*35$K3E8,@Z$=*1X$ALTAH>88 M523NSI1.J,5''0=J-N,,AHJE"4@;M%NMLP#6%F0$47.Y-=H(>YF7_G(I.*.6 M*QG>09LLTY/V<0L_VQ)LY+EMH!&7\8AR;<+>RIZO@%FE7]NTLH=V M*5(L:[IYGF!\ID&FU$"VO&BLJ.94V@8Q_"\^MANYVUSJUF)IK`Y_*[TPL%6Z)9%W>*:GX;=KM/`U:YFL,TL?"W;3MZ99,*M`/,X&U%M_U,I7$Z;0G2[ MC4+V&Q.$RHA<28MT)+S"4UW!`U(R,-!OODNN*:U6=,I5X,LB!* MF25/L`*9@OE*'L"61"0$G2J-5E=`^EIG)SNC@_&J7U$MDZH78.E4`'D=ASAGO9J8;YJDPI7LT7-5_*A7]X4)X(7=*QDT+.B&/ M4\%CURN_\;%5;-',3FCDTL`<\LY>K;.U%Y,G_6F3;B53"9`)79+5B)1\[_E%;RJ/<57UN=/RCMH0;0RPR M%_7)\4"UKDVH8G3X!``!I`P``$0```&1O8U!R;W!S+V-O&ULS9--3\,P#(;_"NJ] M2]O!#E77`R!.3$)B",0M)-X6UGPH\=3UWY-Y7.%K?XZ48\&[G&X))P:`!#08#RR99.LV4^*XM9 M>5V\'R8[\S<:UOT0_];QR2!M%Q4V<.%N22-IN?1)(`E!>.5067,1CC#?Q`0+ MNX]/$'@YJ!?29=M"UUHO0TWW:XP.+R>N;&U]=TS]B,Y>5?T%4$L#!!0````( M`%>#7D>97)PC$`8``)PG```3````>&PO=&AE;64O=&AE;64Q+GAM;.U:6W/: M.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X?A1%8C6QY9)&$?[]'-A#+E@WM MDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@V2_;UKNW+][@5S(D$4$P&:>O M\,`*I4Q>M5II`,,X?+&A`T%116F]?(+3E'S/X%/F7/Z3H= M,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1TDB`@LE]E`6Z2?:CTQ4(,@T[ M.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP'`3@4;N>PIWT;+^D00FTHVG0 M9-CVVJZ1IJJ-4T_3]WW?ZYMHG`J-6T_3:W?=TXZ)QJW0>`V^\4^'PZZ)QJO0 M=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@`%AP=M;,T@.67BGZ=90:V1V[W4%< M\%CN.8D1_L;%!-9ITAF6-$9RG9`%#@`WQ-%,4'RO0;:*X,*2TER0UL\IM5`: M")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']IJP&G[;N;SY/\<^CDGZ>3UTU" MSG"\+`GQ^R-;88 MC'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZY!$XM4D-,A,_")V&F&I0'`*D M"3&6H8;XM,:L$>`3?;>^",C?C8CWJV^:/5>A6$G:A/@01AKBG'/F<]%L^P>E M1M'V5;SOX%^9PU"AR1 M&QT"9QNS1B&$:;OP'J\DCIJMPA$K0CYB&38:CFED)O816:I^JAS0^J!XR"@7Q MN1X^Y7IX"C>6QKQ0KH)[`?_1VC?"J_B"P#E_+GW/I>^Y]#VATK\>WZV22$KYI9+2,6 MD$N!LT$DN/R+RO`JQ`GH9%LE"0AMNZ5/U2I77Y:^Y*+@\6^3I MKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KTL@'37[ M]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K34I!OP_GIQ7@:XCG9!+E]F%=M MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.'>7M?F&>5QE`T%&ULK"0L1K=@ MN-?Q+!3@9&`MH`>#KU$"\E)58#%;Q@,KD*)\3(Q%Z'#GEUQ?X]&2X]NF9;5N MKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^:CVT%4[/_EFMR)\,$4X6"Q)( M8Y07IDJB\QE3ON>;G*YZ(G;ZEW?!8/+]<,E'#^4[YU_T74.N?O;= MX_INDSM(3)QYQ1$!=$4"(Y4U#VT%SU&\Z.9 MX!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83+$.D?L%]BHJ`$:MBOKJO3_DE MG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL'?!^2!F.,6_0T7X\48JVFL:W& MVC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5`Y3_;U`UH]@TT')$%7C&9MC:C MY$X*/-S^[PVPPL2.X>V+OP%02P,$%`````@`5X->1Y."IL1N`@``0@P```T` M``!X;"]S='EL97,N>&ULS5==:]LP%/TK0AFCA1';"4G;U3:,0F#0E4'SL+T0O[`3EQ`XCJ]9!(/Y M#'HO)QW[AWGUW(!Z?H3Z'J\Q/:"Y/_='W5<'R!LMFJJ5-0B\?MV"_[+>`?&- M(?::(XO#7/#NY";0`7%8/8,UHMH_,.ZIH$("I4M#*[`(1PP[CSM$22*)`7/$ M"-TZ>&(`6TV-'R-<2)O;91CF&?M=)EDD$?2;W\O3)1V[']"HFTPF?4"[*#S)D)F6.XR!["%XI#B7.D` M28J5&94HC72AE&#:R`@J!$?44+81C:%I4TSIHWEW?^1[W)L<.!]SQCX$1D5K MZHUHS*X,[*9Z?3;'W:>=GL0+-ODN@8Y&94FW7R@I.,-.K(,6HGDZ1A\TY.;J&'FB58+NQG\?62IE?'C\R^G7`@\WVKY@0);[`YIM6>K;3YN4J; MWIRK,G,%.5MIU^*L!F3O6@]%-]YIIUZTU M9[;I&K6=52C1%_J]+)HLPSFJJ?I.UD+9R0AV]KV1'\QW7LL=100[^QO.2,W< MI;'[UQ#_!E!+`P04````"`!7@UY'YLE6(9@$``"Y$0``#P```'AL+W=OV?)),W3=-HSVK]]U>HA(+"](&09]3>UE*M9,DZ$;**[UB8J?RFC^N!=L]-V M0ZQ$K+4/<=%VM_MGK:VN]8^VW706MN[AH_/ZA[-1FD7IG3'=4^V-[B%Z0_AY MA=H8=3GX8Y2K+^U,S)+IF(#?=-`K;73\/DNZ8Z/:GHQ^ZTHW_+^.A.T&YWF* MA;25N+*1*&)N^\FCH6G;0'^>5]V+_9FF`S^O)OU0(>C"V4K9H"I!1\$97=&H M5&(1Z8=>`*`40.FQH`Q`&8"R8T$Y@'(`Y7\,.I=&VE()`!4`*HX%30$T!=#T MV*Z=`N@40*?'@EX#Z#6`7K\$G=5()\Z>SJIWI>E:P#T!D!O7H+N MO*N:,HHOZINRC0I_BT\JHH9C]'#,=ML$JWGLO[:8U,`:D#&QF=+Z2 MWE(X!W&GO%ALI5?X-"H\81R^EMJ+K](T2MPJ&1K_L@$H[X2Q]U;Z>T61;I18 MJ++Q.FHU`*"T$\9:&O>F;DPWGY_CEKIQX6I*Q%N:;QH91*&V$\;;CZK:T&#@ M(RCHA#%T;FGZ(J6Y8:-1QPGCXYS,L9LVA8GW(5"^ZA3ZX%SUH(U!$OHX882\ M<79S0LFY%I]71F_ZE0L!Z.&$$7$177E_LI)]<-2TJH5>ZJO']A@3&BJ9,DKV MP[]'Q1153!D5Y[9TM1)+^3@8RW201QD)O]!ZZ2F4R!V[$3=:=HO$<$)2U#!E MDVA=Z]BUN9L*2A.1<,J6OX%0QY31\6""2`M$H8XIHR.;(L2K91LLX2\DH:4I MFT?WY8H.AR@T-V7,?9DPV!:AMBFC[9[,\4]@7)(%V@S'"G7.V,)@;V1\DMXC"I7.&*4/!=GE8&W/ M4.F,49H+,J9W.0J=,T+OC;(>AB@4.F>$WA-E7*O0[YSQ^V"8Y5CYYJAZSJC^ M,\RX=@S*749NC+,3L:!]7=50]TC1[@ZB4.ZHZE,TP=1!:;O`@TOV!W=@:I&O$+48$M7/&VL M?^VE*[765E7MEX;0O8:VZF7[^8%^^JU"7K2E9GM^ZRIZ=_O=(!'KQI@+NO;9 MWCC9[:Y[\O,'AW?_`5!+`P04````"`!7@UY')4VY)T`"``".!P``&````'AL M+W=O/*!LG=>$2*\C[;I^,ZOA.BW M0<#+BK28/]&>=/+D0EF+A5RR:\![1O!9D]HF@&&8!"VN.[_(]=XK*W)Z$TW= MD5?F\5O;8O;O0!HZ['S@/S;>ZFLEU$90Y,',.]N6-"]H^*+[7 MXH]QK#L]#N-)A"::FP`G`IP)"'Y+0!,!S000Z4A'SW1N>F1DQYI>K2@Q\8%V(C$+1`[!6*+GAH"(R+6B$XCLC1& M,'2K)$Z5Q%+)#!4;L7$+I$Z!U*(#,U,)'W^$I^87:M.^Z=J)"/L'XJ+Y0*(CT*GZ0OE6R.\Z(A%Z&FJ9RS ML5V,"T'[1_>;6W#Q'U!+`P04````"`!7@UY'"%E<1?`%``"U'P``&````'AL M+W=OHGR?V>[/E[O?_1O%15._FU MW>R:^^E+V[[>S6;-PTNU+9O;^K7:I?\\U?MMV::?^^=9\[JORL<^:+N9&:6R MV;9<[Z:+>7_MZWXQK]_:S7I7?=U/FK?MMMS_FU>;^OU^JJ#]5 M70W5IGIHNQ1E^OA9+:O-ILN41OYG2/HY9A=X^OTC^V\]W53^][*IEO7F[_5C M^Y*J5=/)8_54OFW:;_7[[]7`P74)'^I-T_^=/+PU;;W]")E.MN6OP^=ZUW^^ M'_X3U!"&`\P08(X!QW%P``T!]!E@+P;8(<#^WQ'<$.#8"+,#]W[F5F5;+N;[ M^GVR/RSW:]GM*GWGTMH\=!?[I>C_E^:N25=_+HR9SWYV>09(?H"84PB=0U82 MHH^(61K_6(1!1>1&CG`^P!(@+*OA:I+B8I*S,@G.%?7Q=!KO<+R%\;:/MZ?Q M&9OK`\3WD%T/(66"E!1$ZQ M_;F2*!/YFA829%4X&?",E8>LO&3%1LF]+%C%H#DO"=,^Q,!6?B5AF;96L5U= M2)@E%]S(/@R06Q#W*"D<'V%\%'-#K,P\@KDQ&=_($J6546SWK"3*.<5OBD*B M3$A3@WEUNH@:O9+,1*=7LN@L\N8#4!0]OTP$M MQ?DFK0^_59<0IX@WHQ7"9>2[F6&GVC2:XB@%&4 M^Q3`DBT2*PCSS'EN?!#0AK1'Q0H" MH'-)G\::#78O6MH7KDBY!LZ$2'&*P.6D.>?\`"I9<<7929B->D3D#?8O1OH7 MWA]S(]W$321I6Q$N&9T8N8E!0*?):7&T1,`LM>:16]!@)V.DD^'2E1OI*/CB M`9%]!5@(2!*9%]A7D'F!))%YN=17 ML'DQTKQ8[M`&C+_45R0$])6K>0J49[RO8+=BO#CIVS"2`3L"`QP!]SL#)IQ6 MJFZY+5IB&#][K0;8&6_1D4`J(T9A$EF4N$E,Y!J ME!EA%T!*K+H;L4B$)9:DQ'(WEM-UB;T.65V'%!,->Z%89)9NYZMT*IQIEA<:),KOK(V9RP%I`\N3I^-B=YB#3I0".> MVR(<99H_T%C!?,IS!2E@/FO4&$.L522UBC\ESDF>(3%#@(,,43[$$.4##&,;YR^F>Z?)KN?Z;JG!]96^*P[ODS_3+^:O MY7/U9[E_7N^:R?>Z;>MM_[[SJ:[;*I6O;E/A+U7Y>/RQJ9[:[JM/W_>'M\J' M'VW]^O&2_/BF?O$?4$L#!!0````(`%>#7D&PO M=V]R:W-H965T&ULC53;#`S`3O3/G0F MDX?V68;E,M&%2,*D?U])8(P)M?N"I-4YNV=7R\8]%^^R!E#.)R5,[MQ:J7:+ MD,QKH%@^\!:8OBFYH%CIHZB0;`7@PI(H08'G/2**&^8FL;6]BB3FG2(-@U?A MR(Y2+/ZD0'B_.@'+G/OO;0V00%O"K@5[. M]H[1?N3\W1Q^%#O7,Q*`0*Z,!ZR7$V1`B'&D`W^,/B\A#7&^/WM_L=EJ]4/D=U.H6HOU7*>`$G=$O?'^.XPI;(S#G!-IOT[>2<7IF>(Z%'\.:\/LV@\W MW[R1MDX(1D(P$:8XZX1P)(070G23$(V$Z'\C;$;"9A$!#;G;RNVQPDDL>.^( MX;5;;)K*WV[TV^3&:)_"WNG:26T])8]>C$[&SPA)!T@P@P3A-63_%>)/"*3C M3R*"-1%I\#7"=8!L!1$M--QU:W^D6:TRH\L/YKS%Q+3 M`?)D(2\8\J48&:=AL-S8/IO84_] M;>:OV/=ZF`S__L5]$K>X@I]85`V3SI$KW?6V-TO.%6CAWH/N]EJ/N^E`H%1F M^Z3W8I@`PT'Q]CS/IJ&:_`502P,$%`````@`5X->1X;VKRG[`@``H0L``!@` M``!X;"]W;W)K" M:!!$_SL#'P08_0"4(!LG81,A*!GG],@F))Y-2=X7:"%4)$((=_!ME\&N0F M38;6BED]F];JCCY"]9'51Q-]!$SD/9)8I+'(0\92$H-R(!A)]+L?@IH@'">, M$U@9C(M)FF6X/8[:XVYY.*Z/47WLE"<&OO,>X9,\.2R-BSPP6!:7(2F(LW$9 M>L=-@KI)7#<)<),X4T0\@GY`8M M(8&BR=:YL63.0.RC'CJF$O`.Y`-S4[HLY!GTA7$D3M,$;-0U!NHO308KM4'! M.(P8O6/RSLE%7),$FB38?F0,>G0Q^,E`$!9F80:]?1;IUA5Z%#X1ZKJBT!5% M3@F2,0)M(1R^=`@8I;J9=.PA(+ITP:3_J$5[L)U?YVWEN5'FC)B,CMWEDVTN MP7A.9BN"C*]--VK[G8_PR_FI.(CO17LHF\Y[D4IW3;:WV4NIA,X_?-0+<]3] M\OA0B;TRMXF^;_L.LG]0\G1MB,>N?/D74$L#!!0````(`%>#7D>T7WJN%@4` M`*09```8````>&PO=V]R:W-H965T&ULA9E-C^)&$(;_"N*> MI:NJ/T<,4G`4)8=(JSTD9\_@&=`")MBS;/Y]VH:9F*KJS05L\U;WVU]/5YOE MI3U_[;9-T\^^'_;'[G&^[?O3PV+1/6^;0]U]:D_-,?_RTIX/=9]OSZ^+[G1N MZLT8=-@OT!B_.-2[XWRU')]]/J^6[5N_WQV;S^=9]W8XU.=_ULV^O3S.8?[^ MX,ON==L/#Q:KY>(C;K,[-,=NUQYGY^;E;WS>/>O;TW5[/=#2;GFOV^%_E?G$#B]?B_]U[&YV?Y3 MW355N_]KM^FWV:V9SS;-2_VV[[^TE]^:6QO<4.!SN^_&S]GS6]>WA_>0^>Q0 M?[]^[X[C]^7Z2S2W,#T`;P'X$0#VAP%T"R`6L+@Z&]OU2]W7J^6YO'HX=-?Z66];EI]]6@9:+;T,Y-\GZ*L&)!.\5E50$^R%9Y/H_ M3*!J`L=XFL8[/9[4>!KC[33>LT9<)6&4'&]5>'2&M43*L@A=TMU8U8V5;@)S M6.^ODQPD3(@7S3W#4<#9=5B@PF<+]WH_,8))`C!S)(U`(8#]R-E!'Z M4N?H0`9)9+Z.UR!ABY;R0!`WI`B)K`^%'0MT,H,7.W`LE:#C%"1/$^:Y2\C)[O!Y6B(@)32%-0ARI*J"8.592P!`N.+PI- M%J(I#!<6M%YBI*GB?,4)2A3SIRX':FR(95&2N8*YTO%!1RI*I/)%O$9)RIP9&4YX189Y[I26EHY3 ME)DNI]P:90Z;`,724A)B#*7L$G4VHV0S<*:L4K(A$(GDA8)8G5G*1S(Y*8:('O.YJ*8NFEDXY54K`* MG&(D>>GS;$!Q-%6$+H1\.BV`C'2TDH)6X"`C#9G<>J6H$I1FGXY54K`*@F$2 MES\YB!E/?//1E#889UUA(ED=K59!*W".68G,A`B6+U)%EQ>I,Z4*#@%"8?"L#E>KP!4XQZR2WYK@@]B!5&'R$`N[HM7A:A4D M@GB]*E_CZL=G3:@>GQ>3]^FG^K7YHSZ_[H[=[*GM^_8POD!_:=N^R86:3[F- MVZ;>?-SLFY=^N`SY^GS]$^%ZT[>G]_]$/OZ86?T+4$L#!!0````(`%>#7D?X MT&PO=V]R:W-H965T&ULC97;CILP M$(9?!?$`BSE#1)":5%5[46FU%^VUDS@!K<'4=L+V[6L;0L&,DLU%\.'_9[[! M:%STC+^+BA#I?#2T%5NWDK+;>)XX5J3!XH5UI%4[9\8;+-647SS1<8)/QM10 M+T`H\1IZDLE]8)7%M[D M.]4-:47-6H>3\];]XF_V/M(2H_A5DU[,QHZ&/S#VKB<_3EL7:09"R5'J$%@] M;F1/*-615.8_8]#_.;5Q/KY'_V;*5?@'+,B>T=_U25:*%KG.B9SQE(I@(DB`"D"XP\7%#D<(`0#A"9`-`\0(*N,09,936LTZ`7Y M5B5/1`N4"$2)`!0KRV[0Q+,L/C(_B^:Y;@$4@T`Q`&0=X"Y>);)1'BD6$`D( MD0`0H061/(5XI%A`I"!$"D!$%D3ZF:_DB6B!DH$H&8`26RC9JMH8(?`[62O# ME7(!E8-0.0"56%#Y*E40Q4F4!$EN04%*/TVB,,]@*-UOH1:%`*S4[E'HTUR@ M%`;S9FVTPQ?R$_-+W0KGP*3JR*9OGAF31(5%+RI@I6[*:4+)6>IAJL9\N#N& MB63=_2J<[N/R'U!+`P04````"`!7@UY'[OAC.28$``#H$P``&````'AL+W=O ML_MEE>1J7U67^%A2GW,7;QBA-`LZ8#M+X'HON>CXCU-X_S?F4NR\\L8QI\W?AS>]F5](YA.@JO=]I"Z8W'( MCJ/<[5[&?\#SFO,::8B?!W'M[T_ORR;=:OBO<>'F6?+W85ONJ]&R\6CK=O%[4O[( MSFO7YJ!JAYLL*9K/T>:]*+/TTV0\2N/?E^_#L?D^7_ZQK#6C#7AKP*\&P.\: MB-9`7`V$O&L@6P/Y%4'<-5"M@;H:<'/70+<&^LO@?M*F-3!7`ZGO&MC6P'Y% M:)(.+NUHFAG%93R=Y-EYE%]FX"FN)SH\VVJZ;.J;S>QH_JO:651W/Z;`[23X MJ!VUS.S"\`X3=IDYP0C692**@2ZSH!C>9984([K,BF)DEUE3C+HR056W:_$X M63S>.)`=!QHE?6%4PQP;A@MA;$C'$60<0<0QJ$D7QMS$J9+1DBG4J(%5O[$*.K**=*"( M=J#U,%->VT%JU+/Y$&CU`.J,5Y/CU=YX)5H*,^T%>5(:;(B7^4!N.9!;^UQ/ M*PV9F?$[(?&N8[P06LJ>Y6?)*):(@O:MF?67.1?6Z_@P+++^ND(K94%[`DXG M%I*)A41B:+.=A?[T$YIIO*T,PQ8/L];Z=`C MCT"$PHNGA3I9@5*AM_<.!:,6[.Z^!A>3<*>T!="H%DL"?)**6Q.B5%;D"#6: M[&N"ZEFV0`LG$,HIO2(0TBG!:-D3BM9.(,13:MQ!X:?-PFK#$KB#%&@4PQH5 M`:6?UNN@[TX98T!)W$$??)*&*:D8[J!/AF!P`WV(`Y@>50%:1^%_""G02@I# MI!1\!51XXLZ'0*L'4'?$M);"`#$%2OVJIRS@>-`$*"W7S%O``\$U!0H6LAZ] M`UI688BN@B^LPMH>_0%:66&(M((O==4DD#18\OZ*LCK:\P M1&"!T$0;ZA`_.@SD%H^Y[LF&UEA.:2P^;.<&AV;1^[*H[:EJN M.277Z#@;<5^]N*R.0+HG5,_9CY(PO'6U4.>TQ8PV^$@[)\"0N(4O[F_XOSM<"Q& MKUE99FGS/F*79:6K?+)O5:/V+MY>+Q*W*^N?IOJ=7UY$72[*[/3Y7NWZ]:<&?X-'`.QBZ(]%%CLH3UK$R4QUK92 M24FVW[Z2[#C.\!%[L2WYD7Q#BC\.J>5;T_[HGNJZG_W<[P[=S?RI[Y^O%XON M[JG>5]V7YKD^#/\\-.V^ZH?+]G'1/;=U=3\5VN\6;(Q?[*OM8;Y:3O>^MJME M\]+OMH?Z:SOK7O;[JOUO7>^:MYLYS=]O?-L^/O7CC<5JN3B7N]_NZT.W;0ZS MMGZXF=_2]<;Z43(I_M[6;]W%[]EH_GO3_!@O_KR_F9O10[VK[_JQBFKX>JTW M]6XWUC2T_.^ITH\VQX*7O]]K_WT*=[#_O>KJ3;/[9WO?/PUNS7QV7S]4+[O^ M6_/V1WV*P8T5WC6[;OJ?D4 M1,&BA178J0)[48&UJA..DC!)#I/DRI$XTK$@G:>8$O;CH!\'`F)<@8<5^"P@ M@E).4&R(8Q\`;;B=!.!':< MLA.S=D)(J@,WN:C@(T$?"?A0O;].61.L7>22%"+V,0(-,<``)T%#P&3M7/'E M8WUT`V2A8*8`)`+/?BD>")Q;XBP>_2"M3YI/X<08Q.EX@"X(N8(AS">2S%#, M("MY0^2)@S8$=#:9PH0DS#O*@4D(`U95SMK"B$`8H`8+ZS$\.QV2$C3:4RXBYV#\8H@0HZDD;RODX3%+C M2#O*=1S8%M8HPAPE`%+/VE$.R2N2D#M".F=B::)AI!)@JM?K'N7$O!*;+$7M M"0D3"1?ZB3%>V>1$\X6GD3$4F4!<>LTZB3X/_K!49TQ#0C+>AU#(,1ASEG/. MDMNUC`%#HS%&3UR@*[G!G&7`61^U M&\!/X1"R84,Z[[@P11ASEG/.DM?H9X!0IJ07K0W0E>8&QBP#S`:-60;\M%$R M,[FL-%H8L0P0&S1B&2`VQ6Q'@U2EV87QR@"O0>.5?&M!S/2. M]"2%NL"EA%$P6060-6BR"B"F2-1##V2%49?"[AH@-6BD"DI+G16-^5_K/EO" M7!7`U:"Y*CDO-3*`A--@IO1,8Z0*0&JVX9`DNR03(;"WL?P5P5P%7-[[4`7HI) M2:>M2&<3E]([P5P5D+;J;OK:_IBJ0L'.E.6$Q5"V`JDX`UO;74`62 MF(J/#8:J!5#-#B=.HD\GORQZ-08J%B/:S^+B_'Y?MX_3>XUN=M>\'/KQI/SB M[OG=R2V/Y__J_IJN-\@?PT#1]/;@T M7X;N>JJK^_/%KG[HQY]A^-T>WX,<+_KF^?VUSOG=TNI_4$L#!!0````(`%># M7D?E5T[0H`$``+$#```8````>&PO=V]R:W-H965T&UL?5/; M;MP@$/T5Q`<$FW72=N6UE$T5)0^5HCRTSZP]OBC`.(#7R=\'L-=Q6[E-3V0%OG^CUCMFQ!"7N%/6A_4Z-1PGG3-,SV!D0504HR MGB0W3(E.TR*/OB=3Y#@XV6EX,L0.2@GS?@2)XX&F].)X[IK6!0;4%)!+0;IGG%\@+F$ZT!8HK1Q M)>5@':H+A!(EWJ:]TW$?IYOL9H9M`_@,X`O@:Q*%3XFBS._"B2(W.!(SM;87 MX073/?>-*(,SUAWOO%#KO>S^2,)6/55@FC@ZEI0XZ#BH*^\RG;<\ MOLEG>)'WHH$?PC2=MN2$SK]L['^-Z,!+2:ZN*6G]_UD,";4+QR_^;*:1F@R' M_>6#++^T^`!02P,$%`````@`5X->1T[O@`.@`0``L0,``!D```!X;"]W;W)K M&UL?5/!;MP@$/T5Q`<$+^M-TY774C95U1XJ13FT M9]8>VRC`N(#7Z=\7L-=Q6ZL78(9Y;]X,0S&B?74=@"=O6AEWHIWW_9$Q5W6@ MA;O#'DRX:=!JX8-I6^9Z"Z).(*T8S[)[IH4TM"R2[]F6!0Y>20//EKA!:V%_ MG4'A>*([>G.\R+;ST<'*@BVX6FHP3J(A%IH3?=P=SWF,2`'?)8QN=291^P7Q M-1I?ZQ/-H@104/G((,)VA2=0*A*%Q#]GSO>4$;@^W]@_IVJ#^HMP\(3JAZQ] M%\1FE-30B$'Y%QR_P%S"(1)6J%Q:234XC_H&H42+MVF7)NWC=,,?9M@V@,\` MO@`>LB1\2I1D?A)>E(7%D=BIM;V(+[@[\M"(*CI3W>DN"'7!>RUW'_."72/1 M''.>8O@Z9HE@@7U)P;=2G/D_<+X-WV\JW"?X_@^%AVV"?),@3P3Y?TO1F@R/_>V#++^T_`U02P,$%`````@`5X->1XS< M([&@`0``L0,``!D```!X;"]W;W)K&UL?5/!;MP@ M$/T5Q`<$+[OIIBNOI6RBJCU4BG)HSZP]ME&`<0"OT[\O8*_CM&XOP`SSWKP9 MAGQ`^^):`$_>M#+N2%OONP-CKFQ!"W>#'9AP4Z/5P@?3-LQU%D250%HQGF6? MF!;2T")/OB=;Y-A[)0T\6>)ZK87]=0*%PY%NZ-7Q+)O61P M>=17""5:O(V[-&D?QAN^GV#K`#X!^`RXRY+P,5&2^2B\*'*+`[%C:SL17W!S MX*$1972FNM-=$.J"]U)L/N]S=HE$4\QIC.'+F#F"!?8Y!5]+<>)_P?DZ?+NJ M<)O@VW\H_$"P6R78)8+=?TMB0:^"]M(X\@9?7C9U/\:T4.0DMW<4M*&_S,;"FH?C_MPMN-(C8;'[OI! MYE]:_`902P,$%`````@`5X->1[I2@.B@`0``L0,``!D```!X;"]W;W)K&UL?5/!;N,@$/T5Q`<4AZ3=;>18:EI5W<-*50^[9V*/ M;51@7,!Q]^\7L.-:K=4+,,.\-V^&(1_0OKH6P)-WK8P[T-;[;L^8*UO0PEUA M!R;9-/ZZ&!%SF9<)348)]$0"_6!WFWVQUV,2`%_)`QN<291^PGQ-1J_ MJ@/-H@104/K((,)VAGM0*A*%Q&\3YT?*"%R>+^R/J=J@_B0AT:4T9GJ3G=!J`O><[&YO1\6+-W.? M`0``L0,``!D```!X;"]W;W)K&UL?5/!;MP@$/T5 MQ`<$+W;::N6UE$U5M8=*40[MF;7'-@HP+N!U^O<%['6FS?#4$YH M7UP/X,FK5L:=:._]<&3,U3UHX>YP`!-N6K1:^&#:CKG!@F@22"O&L^P#TT(: M6I7)]V2K$D>OI($G2]RHM;"_SZ!P.M$#O3F>9=?[Z&!5R59<(S48)]$0"^V) M/AR.YR)&I(`?$B:W.9.H_8+X$HUOS8EF40(HJ'UD$&&[PB,H%8E"XE\+YUO* M"-R>;^Q?4K5!_44X>$3U4S:^#V(S2AIHQ:C\,TY?82GA/A+6J%Q:23TZC_H& MH42+UWF7)NW3?),7"VP?P!<`7P&?LB1\3I1D?A9>5*7%B=BYM8.(+W@X\M"( M.CI3W>DN"'7!>ZUXQDMVC41+S'F.X9N8PQK!`ON:@N^E./-_X'P?GN\JS!,\ M?Z-(Q?TX653_UM$#T%*=G=/21_^SVHH:'T\?@QG.X_4;'@<;A]D_:75 M'U!+`P04````"`!7@UY'0U@D1Z$!``"Q`P``&0```'AL+W=O9?=,"VEHD2??LRUR[+V2!IXM<;W6POX^@\+A1#?T MYGB13>NC@Q4YFW&5U&"<1$,LU"?ZL#F>=S$B!?R4,+C%F43M%\37:'RO3C2+ M$D!!Z2.#"-L5'D&I2!02OTV<'RDC<'F^L3^E:H/ZBW#PB.J7K'P;Q&:45%"+ M7OD7'+[!5,(^$I:H7%I)V3N/^@:A1(OW<9#9/F?72#3%G,<8OHC9 MS!$LL,\I^%J*,_\'SM?AVU6%VP3??E)XOTZP6R78)8+=?TMJK! M-FET'"FQ-VE0%]YY.A]X>I./\"+O1`,_A&VD<>2"/KQLZG^-Z"%(R>[VE+3A M_\R&@MK'XR&<[3A2H^&QNWV0^9<6?P!02P,$%`````@`5X->1S:O&E"A`0`` ML0,``!D```!X;"]W;W)K&UL?5/!;MP@$/T5Y`\( M-NNDZ#+MQ\'$'B>$BRY.)X%FWG@H.6!5UPM5"@K4!-##2'Y"[; M'_,0$0->!(QV=29!^PGQ-1B_ZD.2!@D@H7*!@?OM#/<@92#RB=]FSJ^4`;@^ M7]A_Q&J]^A.W<(_RMZA=Y\6F":FAX8-TSSC^A+F$ZT!8H;1Q)=5@':H+)"&* MOT^[T'$?IYO\9H9M`]@,8`O@-HW"IT11Y@-WO"P,CL1,K>UY>,%LSWPCJN", M=<<[+]1Z[[EDZ6U!SX%HCCE.,6P5DRT1U+,O*=A6BB/[!\ZVX;M-A;L(W_VA M\/LV0;Y)D$>"_+\E;L1DZ5])Z*JG"DP;1\>2"@<=!W7E7:;SCL4W^0HOBYZW M\,A-*[0E)W3^96/_&T0'7DIZ=9V0SO^?Q9#0N'#\YL]F&JG)<-A?/LCR2\M/ M4$L#!!0````(`%>#7D?])RE_GP$``+$#```9````>&PO=V]R:W-H965T6_>#$,QHGUS'8`G[UH9=Z2=]_V!,5=UH(6[PQY,N&G0 M:N&#:5OF>@NB3B"M&,^R!Z:%-+0LDN_%E@4.7DD#+Y:X06MA?YY`X7BD.;TZ M7F7;^>A@9<$67"TU&"?1$`O-D3[EA],^1J2`;Q)&MSJ3J/V,^!:-+_619E$" M**A\9!!AN\`S*!6)0N(?,^)QAVP`^`_@">,R2\"E1 MDOE1>%$6%D=BI];V(KY@?N"A$55TIKK371#J@O=2\CPOV"42S3&G*8:O8FX1 M++`O*?A6BA/_"\ZWX;M-A;L$W_VF\!\$^TV"?2+8_[?$K9C='TG8JJ<:;)M& MQY$*!Y,&=>5=IO.)IS>YA9=%+UKX*FPKC2-G].%E4_\;1`]!2G9W3TD7_L]B M*&A\/'X(9SN-U&1X[*\?9/FEY2]02P,$%`````@`5X->1YX"J6JA`0``KP,` M`!D```!X;"]W;W)K&UL?5/!;N0@#/T5E`\H"9/9 MK4:92)U6J]W#2E4/[9E)G`05<`IDTOY]@632:!OM!;#Q>WXVIAC1O-H.P)%W M);4])IUS_8%26W6@N+W!'K2_:=`H[KQI6FI[`[R.("4I2],?5'&AD[*(OD=3 M%C@X*30\&F('I;CY.('$\9ADR=7Q)-K.!0Y!RD#D$[_-G%\I`W!]OK+_ MBM5Z]6=NX1[EBZA=Y\6F":FAX8-T3SC^AKF$?2"L4-JXDFJP#M45DA#%WZ== MZ+B/T\V.S;!M`)L!;`'93;OXA/2K_"RZ'D+?[EI MA;;DC,Z_:^Q^@^C`2TEO]@GI_.]9#`F-"\>?_FRF@9H,A_WU>RQ_M/P$4$L# M!!0````(`%>#7D<9]E5WH0$``+$#```9````>&PO=V]R:W-H965T*D4YM&?6'MLHP+B`U^G? M%[#7<5NK%V"&>6_>#$,QHGUS'8`G[UH9=Z*=]_V1,5=UH(6[PQY,N&G0:N&# M:5OF>@NB3B"M&,^R>Z:%-+0LDN_%E@4.7DD#+Y:X06MA?YU!X7BB.;TY7F7; M^>A@9<$67"TU&"?1$`O-B3[EQ_,^1J2`[Q)&MSJ3J/V"^!:-K_6)9E$"**A\ M9!!AN\(S*!6)0N*?,^='R@AYT%X2ZX+V6/+\OV#42S3'G*8:O8O(E@@7V M)07?2G'F_\#Y-GRWJ7"7X+L_%#YL$^PW"?:)8/_?$K=B'O]*PE8]U6#;-#J. M5#B8-*@K[S*=3SR]R4=X6?2BA6_"MM(XPU[%:JQ=@AGEOW@Q#,:)]=1V`)^]: M&7>BG??]D3%7=:"%N\,>3+AIT&KA@VE;YGH+HDX@K1C/LGNFA32T+)+OV98% M#EY)`\^6N$%K87^?0>%XHCF].5YDV_GH8&7!%EPM-1@GT1`+S8D^Y,?S/D:D M@)\21K_UB691`BBH?&008;O"(R@5B4+BMYGS(V4$KL\W]J=4 M;5!_$0X>4?V2M>^"V(R2&AHQ*/^"XS>82SA$P@J52RNI!N=1WR"4:/$^[=*D M?9QN#O$ MNN"]ECS_4K!K))ICSE,,7\7D2P0+[$L*OI7BS/^!\VWX;E/A+L%W:SC/M@GV MFP3[1+#_;XD;,?SO(MFJIQILFT;'D0H'DP9UY5VF\X&G-_D(+XM>M/!#V%8: M1R[HP\NF_C>('H*4[.Y`21?^SV(H:'P\?@IG.XW49'CL;Q]D^:7E'U!+`P04 M````"`!7@UY'1;\1`*`!``"Q`P``&0```'AL+W=O05HQGV1W30AI:%LGW:LL"!Z^D@5=+W*"UL+].H'`\TAV].MYDV_GH M8&7!%EPM-1@GT1`+S9$^[`ZG/$:D@.\21KC9?Z2+,H`114/C*( ML%W@$92*1"'QSYGS,V4$KL]7]J=4;5!_%@X>4?V0M>^"V(R2&AHQ*/^&XS/, M)=Q&P@J52RNI!N=17R&4:/$Q[=*D?9QN[O,9M@W@,X`O@"]9$CXE2C*_"B_* MPN)([-3:7L07W!UX:$05G:GN=!>$NN"]E)SS@ETBT1QSFF+X*F:W1+#`OJ3@ M6RE._!\XWX;O-Q7N$WS_A\+]-D&^29`G@OR_)6[%Y'\E8:N>:K!M&AU'*AQ, M&M25=YG.!Y[>Y#.\+'K1PC=A6VD<.:,/+YOZWR!Z"%*RFUM*NO!_%D-!X^/Q M/ISM-%*3X;&_?I#EEY:_`5!+`P04````"`!7@UY'$R!\3Z`!``"Q`P``&0`` M`'AL+W=O9?=,"VEHD2??LRUR[+V2 M!IXM<;W6POX^@\+A1#?TYGB13>NC@Q4YFW&5U&"<1$,LU"?ZL#F>=S$B!?R4 M,+C%F43M%\37:'RO3C2+$D!!Z2.#"-L5'D&I2!02OTV<'RDC<'F^L3^E:H/Z MBW#PB.J7K'P;Q&:45%"+7OD7'+[!5,(^$I:H7%I)V3N/^@:A1(OW<9!\G[-K))IBSF,,7\1LY@@6V.<4?"W%F?\#Y^OP[:K";8)O/RF\7R?8K1+L M$L'NOR6NQ1S^2L(6/=5@FS0ZCI38FS2H"^\\G0\\O)%WHH$?PC;2.')! M'UXV];]&]!"D9'=[2MKP?V9#0>WC\1#.=ARIT?#8W3[(_$N+/U!+`P04```` M"`!7@UY'L@Q:$:$!``"Q`P``&0```'AL+W=OMC#O2SOO^P)BK.M#"W6`/)MPT:+7PP;0M<[T% M42>05HQGV2>FA32T+)+OR98%#EY)`T^6N$%K87^?0.%XI#MZ=3S+MO/1P-TD^$NN"]E)S?%>P2B>:8TQ3#5S&[)8(%]B4%WTIQ MXO_`^38\WU28)WC^0>&7;8+])L$^$>S_6^)&3)[]E82M>JK!MFET'*EP,&E0 M5]YE.N]Y>I/W\++H10L_A&VE<>2,/KQLZG^#Z"%(R6YN*>G"_UD,!8V/Q\_A M;*>1F@R/_?6#++^T_`-02P,$%`````@`5X->1\5YSDJ?`0``L0,``!D```!X M;"]W;W)K&UL?5/!;MP@$/T5Q`<$+W;::.6UE$T5 MI8=*40[MF;7'-@IX7,#K].\+V.MU$Z<78(9Y;]X,0SZB>;4M@"-O6G7V0%OG M^CUCMFQ!"WN#/73^ID:CA?.F:9CM#8@J@K1B/$F^,"UD1XL\^IY-D>/@E.S@ MV1`[:"W,GR,H'`]T1R^.%]FT+CA8D;,%5TD-G978$0/U@=[O]LA!?<[;EO1!FYXYX5:[ST7 M/-WE[!R(YICC%,-7,=<(YMF7%'PKQ9%_@/-M>+JI,(WP]!^%GQ!DFP19),C^ M6^)63/HN"5OU5(-IXNA84N+0Q4%=>9?IO.?Q3:[A1=Z+!GX(T\C.DA,Z_[*Q M_S6B`R\EN;FEI/7_9S$4U"XPUW%;JQ=@ MAGEOW@Q#,:)]=1V`)^]:&7>BG??]D3%7=:"%N\,>3+AIT&KA@VE;YGH+HDX@ MK1C/LGNFA32T+)+OV98%#EY)`\^6N$%K87^=0>%XHCMZ<[S(MO/1P8Q(`3\DC&YU)E'[!?$U&M_J$\VB!%!0^<@@PG:%1U`J M$H7$;S/G1\H(7)]O[%]2M4']13AX1/53UKX+8C-*:FC$H/P+CE]A+N$0"2M4 M+JVD&IQ'?8-0HL7[M$N3]G&Z.?`9M@W@,X`O@,]9$CXE2C*?A!=E87$D=FIM M+^(+[HX\-***SE1WN@M"7?!>2[[/"W:-1'/,>8KAJYC=$L$"^Y*";Z4X\W_@ M?!N^WU2X3_#]'PH/VP3Y)D&>"/+_EK@5<_]7$K;JJ0;;IM%QI,+!I$%=>9?I M?$B/R#["RZ(7+7P7MI7&D0OZ\+*I_PVBAR`ENSM0TH7_LQ@*&A^/G\+93B,U M&1[[VP=9?FGY&U!+`P04````"`!7@UY'1X`%";X!``![!```&0```'AL+W=O MI7G4+8-"[X)W>1ZTQ_0YC7;8@ MJ+Z2/71VIY9*4&.7JL&Z5T`K3Q(ZC370.O+"F-2Z`BQPOO(H)Z#23'5)0[Z.[S>Z0.80'_&,PZM4!0&J=`[7"">^#<"5GCMUGSR](1U_.S^J.OUF9_I!KN)?_/ M*M/:9.,(55#3@9L7.3[!7,+6"9:2:_]%Y:"-%&=*A`1]GT;6^7&<=K)TIH4) M9":0A7`3^\0G(Y_F`S6TR)4BI(]K`7ZH:UFETE,;>47^3:BD-V%3B*UMP:U^"9<&A-FYZ M;>=J:HYI861_;O7EO2D^`5!+`P04````"`!7@UY'>B-,\:,!``"Q`P``&0`` M`'AL+W=OL.E-JR!<7M#7:@_4V-1G'G3=-0VQG@500I25F:[JGB0B=%'GW/ILBQ=U)H M>#;$]DIQ\^\$$H=CLDFNCA?1M"XX:)'3&5<)!=H*U,1`?4QN-X=3%B)BP!\! M@UV<2=!^1GP-QE-U3-(@`224+C!POUW@#J0,1#[QV\3YD3(`E^;)J0"FK>2_>"PR-,)>P"88G2QI64O76HKI"$*/X^[D+'?1AO M]FR"K0/8!&`SX&<:A8^)HLQ[[GB1&QR(&5O;\?""FP/SC2B#,]8=[[Q0Z[V7 M@F593B^!:(HYC3%L$;.9(ZAGGU.PM10G]@W.UN';587;"-\NL__:K1-DJP19 M),@^E;C[4N):S/Y+$KKHJ0+3Q-&QI,1>QT%=>.?IO(V/2#_"B[SC#?SFIA': MDC,Z_[*Q_S6B`R\EO=DEI/7_9S8DU"XZ7/8&-.?"-%%`X+I!]E#9W!%!7H0@JD_%^!R/(>[\!YX;>O& MN`#),[+PRE9`IUO9!0JJ<_BT.UV.#N$!/UL8]6H>N-RO4KZYQ??R'$8N!>!0 M&*?`['"#9^#<"5GCW[/FAZ4CKN=W]:^^6IO]E6EXEOQ76YK&)AN%00D5&[AY ME>,WF$M(G&`AN?;?H!BTD>)."0/!WJ>Q[?PX3CO':*;A!#H3Z(9`)B.?YA=F M6)XI.09J.MJ>N1OK_UR` MJOUSUD$AA\XWCU5TZ1A/U+^3#WB>]:R&'TS5;:>#JS3VM?DW44EIP*82/=BK M:VQ/6Q8<*N.FJ9VKZ9E/"R/[>]-:.F?^%U!+`P04````"`!7@UY'ER1.1J,! M``"Q`P``&0```'AL+W=OPUW%37X`9YKUY,PS%B.;5 M=@".O"FI[3'IG.L/E-JJ`\7M#?:@_4V#1G'G3=-2VQO@=00I25F:WE+%A4[* M(OJ>3%G@X*30\&2('93BYOT$$L=CDB57Q[-H.Q<&4AX@8\")@M*LS"=K/B*_!^%T?DS1(``F5"PS<;Q=X`"D#D4_\=^;\3!F` MZ_.5_6>LUJL_;)J0&AH^2/>,XR^82]@'P@JEC2NI!NM072$) M4?QMVH6.^SC=Y-D,VP:P&<`6P%T:A4^)HLP?W/&R,#@2,[6VY^$%LP/SC:B" M,]8=[[Q0Z[V7DNWO"GH)1'/,:8IAJYALB:">?4G!ME*<_BFWR& MET7/6WCDIA7:DC,Z_[*Q_PVB`R\EO=DGI//_9S$D-"XPXWBSO@`SS'OS9ACR`>V':P$\^=3*N`-MO>_VC+FR!2W<'79@ MPDV-5@L?3-LPUUD050)IQ7B6/3`MI*%%GGQOMLBQ]TH:>+/$]5H+^_<("H<# MW="+XUTVK8\.5N1LQE52@W$2#;%0'^C39G_I/PL$SJM^R\FT0FU%2 M02UZY=]Q>(6IA/M(6*)R:25E[SSJ"X02+3['79JT#^/-8S;!U@%\`O`;`!L3 M)9G?A1=%;G$@=FQM)^(+;O8\-**,SE1WN@M"7?">"_ZPR=DY$DTQQS&&+V*N M$2RPSRGX6HHC_P_.U^';587;!-\NX=EVG6"W2K!+!+M_2N0W):[%W"9ABYYJ ML$T:'4=*[$T:U(5WGLXGGM[D&E[DG6C@I["--(Z73?VO$3T$*=G=/25M M^#^SH:#V\?@MG.TX4J/AL;M\D/F7%E]02P,$%`````@`5X->1Q,OHM.A`0`` ML0,``!D```!X;"]W;W)K&UL;5/!CML@$/T5Q`:]>3,,Q8CVU74` MGKQI9=R9=M[W)\9LMB#J!M&(\RXY,"VEH623? MLRT+'+R2!IXM<8/6POZY@,+Q3'?T[GB1;>>C@Y4%6W"UU&"<1$,L-&?ZN#M= M\AB1`GY*&-WJ3*+V*^)K-+[79YI%":"@\I%!A.T&3Z!4)`J)?\^<[RDC<'V^ MLW]-U0;U5^'@"=4O6?LNB,THJ:$1@_(O.'Z#N81#)*Q0N;22:G`>]1U"B19O MTRY-VL?IYIC-L&T`GP%\`7Q.`#8E2C*_""_*PN)([-3:7L07W)UX:$05G:GN M=!>$NN"]E?R8%^P6B>:8RQ3#5S&[)8(%]B4%WTIQX?_!^39\OZEPG^#[-3P[ M;A/DFP1Y(LC_*?'PH<2MF(])V*JG&FR;1L>1"@>3!G7E7:;SD:0\OBUZT M\$/85AI'KNC#RZ;^-X@>@I3LX4!)%_[/8BAH?#Q^"F<[C=1D>.SO'V3YI>5? M4$L#!!0````(`%>#7D?3!(-FI`$``+$#```9````>&PO=V]R:W-H965T0/*`ZY-!LYEIJNJMV'2E4?=I^)/;91@7$! MQ^W?+^#8=;-^`6:8<^;,,&0]FC?;`#CRH:2VQZ1QKCU0:HL&%+=WV(+V-Q4: MQ9TW34UM:X"7$:0D96FZHXH+G>19]+V8/,/.2:'AQ1#;*<7-YPDD]L=DE8R. M5U$W+CAHGM$)5PH%V@K4Q$!U3!Y6A],F1,2`/P)Z.SN3H/V,^!:,W^4Q28,$ MD%"XP,#]=H%'D#(0^<3O5\ZOE`$X/X_L3[%:K_[,+3RB_"M*UWBQ:4)*J'@G MW2OVO^!:PC80%BAM7$G168=JA"1$\8]A%SKN_7"S'6'+`'8%L`FP3Z/P(5&4 M^9,[GF<&>V*&UK8\O.#JP'PCBN",=<<[+]1Z[R5GN_N,7@+1->8TQ+!9S&J* MH)Y]2L&64IS8?W"V#%\O*EQ'^'H.3W\L$VP6"3:18/.-8']3XD+,;G^3A,YZ MJL#4<70L*;#3<5!GWFDZ'UA\DZ_P/&MY#<_T0`O#$8S6J.?.XGI=[]XKD^)*E/`3A4UBM0-YSA`3CW0L[X8];\MO3$ M]?RB_ABJ==F?J($'Q?^RVG8NV31!-31TX/95C4\PE[#S@I7B)GQ1-1BKQ(62 M($$_IY'),([33GXWT^($,A/(0KA+0^*344CS-[6T++0:D9Z.MJ?^#V9[X@ZB M\L%0=]ASB1H7/9:,<<)0U:8;$%@I[Y8D)C%D?Q')W'Z)IKA)M`W M:WKV@\`V*K`-`MNUP&UZ56(,\T.1NZC)+B)`KDQBF$W<)(^:Y!&![95)#+.[ M,L&KVR%`MZ$)#*K4($/+K:)+G]V3<+N^X671TQ;^4-TR:=!)67='PTUJE++@ M4DEO7,&=>PF6!8?&^NFMF^NI.::%5?VEU9?WIOP"4$L#!!0````(`%>#7D=) MYXEZHP$``+$#```9````>&PO=V]R:W-H965T]#^ID&CN/.F::GM#?`Z@I2D+$WO MJ.)")V41?2^F+'!P4FAX,<0.2G'SYP02QV.2)5?'JV@[%QRT+.B"JX4";05J M8J`Y)@_9X92'B!CP)F"TJS,)VL^('\'X61^3-$@`"94+#-QO%W@$*0.13_Q[ MYOQ*&8#K\Y7]*5;KU9^YA4>4[Z)VG1>;)J2&A@_2O>+X#',)MX&P0FGC2JK! M.E172$(4_YQVH>,^3C<[-L.V`6P&L`5PGT;A4Z(H\P=WO"P,CL1,K>UY>,'L MP'PCJN",=<<[+]1Z[Z5D^[N"7@+1''.:8M@J)ELBJ&=?4K"M%"?V'YQMPW>; M"G<1OEO#LWR;(-\DR"-!_D^)^V\E;L7]/YMII";# M87_](,LO+?\"4$L#!!0````(`%>#7D>7$KYWO@$``'L$```9````>&PO=V]R M:W-H965TE>S,*6FM[8^4FK(% MQ0.)Z237(+O(JFM3Y`BYPNO$HHZ(S`CFBH3\G3YGC./"(`?@D8S6I.?.X7 MQ#>_^%&=DM2G`!)*ZQ6X&Z[P#%)Z(6?\9];\L/3$]?RF_BU4Z[*_<`//*'^+ MRK8NV30A%=1\D/85Q^\PE[#W@B5*$[ZD'(Q%=:,D1/'W:11=&,=IYY#-M#B! MS02V$![3D/AD%-+\RBTO%/\`4$L#!!0````(`%>#7D=_\RR\YP$``,8%```9```` M>&PO=V]R:W-H965T;!3R534`VGOCK%-' MO]&Z/P2!*AK@5#V('CJS4PG)J39+60>JET!+1^(L(&&X"SAM.S_/7.Q9YID8 M-&L[>):>&CBG\M\)F!B/?N1?`R]MW6@;"/(L6'AERZ%3K>@\"=71?XP.I\A! M'.)W"Z-:S3UK_BS$JUW\+(]^:#T`@T);"6J&"SP!8U;)9/X[B[[GM,3U_*K^ MW95K[)^I@B?!_K2E;HS;T/=*J.C`](L8?\!.T$R0F4`60A(ZXU,B9_,;U33/I!@].9UM3^TOC`[$'$1A@ZYN MMV>,*A.]Y"399<'%"LV8TX0A*TRT(`*COJ0@6(H3^4(G.'V#.MPX>OS!X1X7 MB%&!V`EL/@@DN,`6%=@B#M)/9X1@TA!/LD.3[!"!&\>\1P7V]Y>9H`+)'64B MF/3&WTS1)"DBL,$%[&O";FQX?Z'1C4L?W5$J!DKC3WF"U3OC(&O73I17B*%S MW6L575K6(W'O]!V>9SVMX1>5==LI[RRT>>WN359":#!>P@=SO1K35)<%@TK; MZ=[,Y=1FIH46_;5K+JT[_P]02P,$%`````@`5X->1S'!Z5.F`0``L0,``!D` M``!X;"]W;W)K&UL;5/+;MLP$/P50A\0RO0CL"$+ MB%,4[:%`D$-[IJ651(3DJB1EI7]?/F1%:74AN*VP?L0?N=!HWBSH>FI;8WP.M(4I*R/#]0Q87.RB+F7DQ9X."D MT/!BB!V4XN;/!22.YVR3W1.OHNU<2-"RH#.O%@JT%:B)@>: M_95;>$;Y2]2N\V;SC-30\$&Z5QR_P=3"/@A6*&T<2358A^I.R8CB[VD6.LYC MVMD?)MHZ@4T$-A-8,IX*19M?N.-E87`D)AUMS\,-;D[,'T05DK'ON.>-6I^] ME>RX+^@M"$V82\*P!68S(ZA7GTNPM1(7]A^='0_K`MM5C]LHL%W6/[)U@=VJ MP"X*[#XY>/RGR8391XQ>;9(NSE2!:>/3L:3"0<>'NLC.K_.)Q3OY@)=%SUOX MP4TKM"57=/YFX_DWB`Z\D?S!>^C\_YD#"8T+RT>_-NE)I1U$Q3LY=`P``I0\``!D```!X;"]W;W)K&ULE9=?;YLP%,6_"N*]!5_SMTHB-9VF[6%2M8?MF29.@@HX`])T MWW[&T)38QU*F2@7,]3V^R?G%OHNS;%^[@Q"]]UY73;?T#WU_?`B";G,0=='= MRZ-HU)N=;.NB5X_M/NB.K2BV>E)=!12&25`79>.O%GKLN5TMY*FORD8\MUYW MJNNB_;L6E3PO?>9_#/PL]X=^&`A6B^`R;UO6HNE*V7BMV"W]1_:PYLD0HB-^ ME>+Z]8?$O4KX.#]^W2S\F'%(6ZO(DG455#)J7\9TKZJ3E,G-]_ M9/^JRU7+?RDZ\22KW^6V/ZC5AKZW%;OB5/4_Y?F;F&J(AX0;677ZO[RT=?S^";FTS0\@:8)=)E`X\)'(;W,+T5?K!:M/'OM^-D>B^$K M9`^D/HC-,*CKUN_40CLU^K:B/%L$;T.B*68]QM`LAETB`I7](D%(8DW6=,IS MG(##-7*=@,\2\##$"2*8(-()HJL$S"ARC$EU3#/&)"%Q+!-#F1C(D"$SQL0S MF2A3?U@F@3()D.&&3&+)W#&>,D9E@FAS(YD'&L<^`8L1+>;D3FP(W=8,4I:%XMBQ+'=\<@=(^,;C#C%#07 M2ABY*L)P,GZ#':>@:S]&KHHPQ`Q1;/IQ"KH2BAF+'4J88X9`-AW);)*)DTL( MD\P0RJDC!8:4I?_A2AYSAUD(HTKA M#:Z<@JY=23QR%$48:4)(F[XD&^D[HBAQ^(4PU(2@-HU)-M2<9^3XK21,-2&J M72DPKQ3=[DS"(!("T70F@2W5N=,1!I$0B*8QR=Y4(W(<9`C32FA/M6P)-M4\ M=Q6$F2;$M&5*FVFU>\>.PPAAI@DQ;7G29CK+'=[GF&B.B'8=(S&IG-WN2(X) MY(A`TY'<)C"-7-4ZCKR(/].0W-Y5*7+])'-,*4>[JNE(#G95XJZ*,,L8(9M.14]#\O,\H,&MVDC MZ3;L,WRU.!9[\:-H]V73>2^R5\V<;KEV4O9"+2:\5P4?5,]\>:C$KA]N4W7? MCEWD^-#+XT=3?.G,5_\`4$L#!!0````(`%>#7D?;,+MI*04``.4=```9```` M>&PO=V]R:W-H965T5MDFK3X5NVS;_.>Y*#=IW?PL7X)J5V;ILC/:Y($2 M(@PVZ7H[G<^Z:]_+^:QXK?/U-OM>3JK7S28M_UQE>;&_G,KI\<*/]*?=;:OSKY/VL$_%L7/]L?M\G(J MVC%D>?94MR[2YN,M6V1YWGIJ(O_JG;[';`W/OQ^]7W?I-L-_3*ML4>3_KI?U MJAFMF$Z6V7/ZFM<_BOU-UN=@6X=/15YU?R=/KU5=;(XFT\DF_7WX7&^[S_WA M/['HS;"!Z@W4R4!%@P:Z-]#O!G+0P/0&9JR![0WL6(.P-PC'&D2]0336(.X- MXK$&26^0C#5HY_PPW2MLKE16/5.&^O=K71_;-9S%5S]6VNI9@%;ZVG7G-UT"A'(UW- M`FF4J_F,--K5?$$:XVJNJ48EB:OYBOQ85W.#-*&KN46:R-5\0YK8U=PAC3?F M^Q'C>1C.*V@F^S3C"L^XZCSH]"=!W-^_[UTKP^2J)-L.XFT)A3" M6UHW5*>U%8H([ZBPF?.$Z.ZISHC8C>RD:'"*AJ2HE;_DD4;A*!9'L<"#5Q`+ MI#$X2HBCA,"#5PH+I`EQE`A'B8B'V*_;@\2>SV%LM!%D%K]&8+:%H,*[T2X? M1KATTHQQFC&X41'VD&`/R?CZ:[<="&T!1A'[!!2T!L50QI+;(B2(EOALER1: M,AR-P9-4-)H6?C0DDDP@AF*28DQK;\NZ[D7G"^RO$"U$))1#Z3/@D8`J6ONC M,G391[`^QBC=<3&HDH!#FN&09$`DPP\L?08SDG*&+/V%I,4>#R]&IMHE*'?M MLQ.*&'A*!@HR`3XB/Q`2Q3B08M"A`#JT5\P+)#+,K5,,-12@AO&W4"AB]E#% M]3.`!<;?17N1@W]KO8W"#<=@0U%L^!O=0E$8_%\T!@<*X<"'E*)%;BRB`1#V MFR`S*@8&"L'`AU0O.@\FHUC!<8V1NB-C$*-`(V,83"D&,2H:CRG%@$,!)A@/ M'%]ZT?FBC.P0IA1##P7`8$(_&A(QK8MFZ*$I&&CK+\ADDJZ?2A3:H97&J'(R^U6@RY'@X%_&R%T1\7`32.X)?Y=4O1V,F&X$QWHA2PW M5`95VGS@8,F`15.PT/5%86&,!$=+`!6=H$5F::,<*BJ\1Y%5J/A)92"ET6G+ M2_.A%SE'XT$X:`9G&G1,5OHWE79,!E7D#1*B"K@#0AE'0'D_PJ6;*,-<#9AK ME3\L)-),(`:W&I#4,IN,84AJQ/AJ,0RR#$"6];O37N3`00\VPX9AD0$LLDR? M:QC0&/V!M+EG,Z`GHFG35D='PVDS3#*@V;',OFF8BC*S8)HZ#!"PB$1EQ=3Q!9LV_X9_0J)0K\;"\Y>S^S2E^PA+5_6VVKR6-1UL>E> MQSP719TU#L6G9N2K+%V>?N39<]U^C9KOY>$MY.%'7>R.+U5/;W;G_P%02P,$ M%`````@`5X->1TJ8\3$]!@``G2,``!D```!X;"]W;W)K&ULE5K!DP0H2CM)9AK;47OHS,X>VK,V41+/VE9J*YOM MWU>2E:P$/";J);;E1Q(@B?<`Q!YPNIP_UO73Y^7R=/M8 M[HO3I^JI/#3?W%?'?5$W'X\/R]/3L2SNND'[W=(9DRSWQ?8PO[KHGGTY7EU4 MS_5N>RB_'&>GY_V^./Y[7>ZJE\NYG;\^^+I]>*S;!\NKB^7;N+OMOCR_V<^YYQ;2(?[:EB^GP?M9:_RWJOK>?OCC[G)N6AO*77E;MU,4SQM@^=T!U`^@J0.X'\!3!_A^@)\Z(.D')%,'A'Y`$`.6Y]WMSF9=U,75Q;%Z MF1W/%^JI:.^M_1R:T[]M'W:'W7W7G,ZI>?KCBA*Z6/YH)^HQUV>,&V%XC%EI MC!LCU@`A)ME\.,G-QY/D&A)^09;-9KSMB(,[XKKQ-/+6XPD(3D#=!#RT,8C= M.D-"!SET$!]\)C9,@U)*$[%E&F1#XE*Q;1I%SE)D6QAZQ=HKL-1KDL$QMTHT%LTL&"(Z\\],IKK\0J*Z\--EEJI5\:9D.:I>+D M-QJ66&9CA6L:QN33P149^99`WQ)PD2.;$^`$06U.D$<>E)W!AT&XG)V>A,J# MON]L4VQP"@U.E<&IV-A5JO>?*!5N;2:AE?L]%9A#H#<<85^+5=257K,B(.L2:RT?!(L!S!R,26T M6`JMUL+,2*M)LT.:2K+?3(/E"&9M%MMLK'56BUVF+@J0*,Z23%+)1%R.<"9+ M0H2Q+=8SJP7-&I6K`4GC3![,9AHL!S!G@PD1N[%6V43;;16G)"C!\))[-A-Q M.<`Y:T/,KBP1$;Z"&#$5L4[@C6YK9$.`AS'I0'+L-4Z3(G,=:S6SL8] MDNYIE`HL#5DT.:61^>V[4XTK&2S43@MUDVM'IL"BZ>ST&J<%B67HK`'(DB)DA$J<#`BT MH$M[(N&BL)$'9F>RP8;(C61PP+IM$"2 M/+/<`>7ST2S984ES6M(H5G([K"TN_(_@P\3M-'$K?Z][T*CT,G%_,8)9J&$*:84?@,;_?<(2Y74BJ]M> M7B>RL.TU$9?WN&$&\T[;RV-E]%H9==O+H]9WD)GZ!L&(7"3*/!8]KT5/951> M"]4BJ-X:0I$9>C>V!RN:UXJF,RJO)6A!J5<;!&`NI+&[AI7*:Z72/2X/:FS5 MX]H`U+A_=;9G.?@1PE/Q4/Y9'!^VA]/L6U77U;[[U<%]5=5E,Z7YU#CW6!9W M;Q]VY7W=O@W-^^/YUR/G#W7U]/ICF+=?Y%S]!U!+`P04````"`!7@UY'HIV, M;"D"```+!P``&0```'AL+W=O6)[1LVCJ%K\QAY\)0>S?!C>T7[N^>PV\UZ=*J`#(,S#R#C7! M+:]IZS!\7+NO_FJ7*H0&_*YQSR=K1WG?4_JA-C\/:]=3%G"#2Z$4D'Q<\!8W MC1*2B?\.FK>4BCA=7]6_ZVJE^SWB>$N;/_5!5-*LYSH'?$3G1KS3_@<>2HB4 M8$D;KG^=\LP%)5>*ZQ#T:9YUJY^]>9-Z`\U.@`,!CH0QCYT0#(3@1@B_)(0# M(7PV0S00HD4&8&K7G2N00'G&:.\P<]H=4A^5OXKDV90JJ(]"OY.]XS)ZR8,D MS,!%"0V8C<'`"08&TMH]TIH5%EL+BRV%I7:!Q"J0/-_:U"J0/M':]*[0((@7H.T]",;)XE,L MGE':/5`R18')7YU@=M)#ECLE/;="-602'>?X*U2C8A'?^*NM;XD73.-FP8?A5HF?_E_4$L#!!0````(`%>#7D&PO=V]R:W-H M965TV(.O[FP#713%.VA0)!#>U;6 MVK41R7(E[3K]]]6'O7',=PKR8ELR.<,A]7!>BER?F_9;MR_+?O&]KH[=9KGO M^]/#:M4][^^IP+#^WB^ZUKHOVW\>R:LZ;)2VO-[X<7O;]>&.U7:_>Z^T.=7GL M#LUQT9;/F^4O]/!(9,8R4Y&_#N6YN_F]&%O_M6F^C1=_[#9+,3:BK,JG?K11 M#%]OY:>RJD93@^M_+E9_.!TKWOZ^6O]MBG=H_]>B*S\UU=^'7;\?FBN6BUWY M7+Q6_9?F_'MY"6)JX5-3==/GXNFUZYOZ6F6YJ(OO\_?A.'V?YW^\N%3#%>2E M@GRO(.>&SXZF9OY:],5VW3;G13MW[JD8QY`>Y-`13^/-*>[IOZ&AW7#W;:M< M6*_>1D.7,H]S&7E31H8?95:#_7NKJ;ZZ;:07V("& M!O1D0/]D@.ZBG,NXFS;*H+U@_!CHQP`_$ANPT(!-C]1!`PZT0-U%.I$HJB M55H8QSSHA$DA"5PYQ@2&A3)H(8P+(5ZB@'44L#0DF(F!,#"$B/'WGDSD:?"C M%/<@8+3(`E=<:S%A6S(U$W-P_L9="R=V*^9(@>P4F?TK,E_09`6-P)`(G"C@&A_&B,#,* M,!/A>2F4X@5CI4#J"ISVPE@IF=ZCBM%O")?['E7)N"B,BT)9*^K1.&MQ7C!1 M"F2LH!D3F"B5H?(4)D6EZ#P5"STEI->><86)4BE23V5I/87!4P"\P&0BC:G2 M&6I/8V1TBMK3L=KCO&"J-$A6@>DNC:G2..D,H:6<$ M,QM;S).-LY06C)JUF"<;TL-U&!87PQ*'ZY)A<1@6AV!A\I_#L+@,6!R&Q<6P M@%AC6/BA=9@7%_.B!:,P'8;!9606AV%P<68!X29G%L>\]4:\,)+/81)<1F9Q MF`079Q80:YQ9K.%>O6-3@\9L%GJ#"/6?"Q"HNC] M@^!U1JP8!(^R0A1KO'KA1Q;3X@$MQ#45H^`SEBZ>V=M!22&*-EZZ<%XP+1[0 M0DQW!0Q"R%CM!PQ"0$GA/M80K_8_D#&,+`B8EP!X(>T8,`HA0T4%C$)(45$A5E'_-[:8F`"((49&!6:G,T-&D>#V M.E.$U+54PO"28'9$!<"&V(U99J]39*@I$LQNITC14]=2/XVR9`:(!+,K*@`[ MQ"@J$LR&I\C05"28K4R1HJJNI9+&F=GP%``AXO:C!;/E*3*D%0EF-U.DB*MK MJ;1QYDX,$*"(&'U%[)F!#(5%W&D`1RV/CFB^!```MAL``!D```!X;"]W;W)K&UL ME9E;D]HX$(7_"L7[Q+JT+#/%4+7CK:W=AU2E\I`\>T`,5&S,VIXA^^\C&P\+ MTI$C7KB8(_E8ZO[GNOG1[HSI9C^K\M`^S7===WQ,DG:],U71?JJ/YF!_ MV=9-573V:_.:M,?&%)MA4%4F@K$TJ8K]8;Y:#L>^-*ME_=:5^X/YTLS:MZHJ MFO^>35F?GN9\_G'@Z_YUU_4'DM4RN8S;["MS:/?U8=:8[=/\#_Z8IZR7#(IO M>W-JKS[/>O,O=?VC__+/YFG.>@^F-.NNGZ*P;^\F-V79SV3/_.\XZ?_G[`=> M?_Z8_:_A5U^WV^ZG77+YK.-V19O9?>U/OUMQFM0_83KNFR'U]GZ MK>WJZF/(?%85/\_O^\/P?CK_DLIQ&!X@Q@'B,H#3Y``Y#I#.@.3L;+BN/XNN M6"V;^C1KSIMQ+/H]YX_2KMRZ/S@LU/";O;+6'GU?D6#+Y+V?:-0\GS7B2B-N M%;FOT'21)-;`Q86`+L0P7EZ?(55X`@DGD,,$=',9W+F,LT8/FL.@X8PIG6KG M8H!.9EJ(!39$T!`!0\ZJ/9\UZOI$Y*ZLK\DR[$-!'PKXD(X/Y9WC02\<'T`C M.,=.4N@D!4[(<9+Z*V*W*)-.1.9`9[>(LQ0;TM"0!H8"09?!";+XJ%W`"181 M4;OP+E6K5"AW17R9%0D5B-F>;`@&+")J1]'UJ5PSDY);(P$J\8BP'4631J8D MMT8PF+B(B-I1]-L]`KK)3<*HXXAU@<#G&$Z]^O=&IB2W1C"@>!83O5GD)OFZ MR4W"R..(>1I/(3"E!(N/7H'Y(A!?W.@5/CR$XLR],P*9XFFP_@D40(@S;NP* MGQ]NR`")%@$G&"\"X<4-WE$TZ61*_ MO`F<16)F2%39N,$D_;)E8M4D1HM$:`DP4F(8R'O:H4`_%-40^2DJ:&$3PVV( M?)U.^4*'%@;GLXQIB61,3P1$H:9(XE26,6V1C.F+D"C8&$E,!1G3&DF_*NDW M*W.Y"W1VLS(*W&,EIHP$E)&A_<;XD'>T1Q*S048T2+GTV4"IU*&((`P(BFA] M<)TH(C&)B>_HGA0@;LX88101-^2DU\L]"NG`OM,$4",#"4"! M/TONZ$<(9S3%]"/D)RLGQH-N<;I23)]!X"^*8*S@'*28-H*B>P3":4HQ/0+Y M=WF[<()">X33F4`ZRT!<*YRFZH[:7^$45#&UO_)3T%:5,DN=%$*Z1E5]CG:`)N`$)[.*J?Z57P^`/PR!*`T4W`IC0<5T`*-(.SLEE>L' M5!9VIU@@]U7@[U2`&2D#4V!\J#MZ`(7)H")Z@%SY9%",*&06TT%%]`"YBNX! M%`:#BN@!'=O92 M=UU=#8]4MG7=&3LE^V1-[TRQN7PIS;;K/VK[N3D_5CI_Z>KCQU.RRZ.ZU2]0 M2P,$%`````@`5X->1UV+0BC(`P``FQ(``!D```!X;"]W;W)K&ULE5A-DYI`$/TKE'<7NOD2R[5J%5+)(56I')(SJZ-2`<;`N";_ M/GRM"].-DHO`\+K[=<_TB4O*DUR\:TPRDN6 MQ<7?C4CE]7D&L_>![\GQI.H!<[TR;W;[)!-YF?8"RPB#&M(@?B3B M6O;NC9K\JY2_ZH957,0J=BIVD5<7=[$5J1I[:F*_+MS^A&S-NS?OWO_ MU*1;T7^-2[&5Z<]DKTX56VMF[,4AOJ3JN[Q^%ET.;NUP)].R^35VEU+)[-UD M9F3QG_::Y,WUVKY96)T9;X"=`=X,;G%X`[LSL#\,G+L&3F?@3(W@=@:N%L%L M36*=KK/<;VJ8.E6<[.K!YNI:-Y5M2NKT;>U8SLK\ZUVU&$V M+09[&+2'D)!"X(8P*P(W%LBQV""-,`RP91`:S?"AD^BNDP%-FRV6W=C;@V*Y MO`.'=>`T#IR!`T]+H\7X#29O,`'X6B(4,[(Q5!8:%8]$F=NN96E<&)2#/L_%9[GXA(L7:-W@D]K;"!K? M+04!+/0%ZQ.Z+BDOQ8#CC:2T8%-:/%YSFP6-X@)H.3$@\#10.,53],#3(*F` M32I@D@IX!_7_!"=\UO1FAA'MA`GMW($&BS+P]8IP*!O'Z+`B^@(XH:<[T"`0 M>/JJXU#HC\P0\&()]H2^[D#]0'I3WX4,B?"B"U1U]:8..\RCLC"H\;+PP@N< M\NK]"%15YP"]Y=EV)`=S`[(")SF+'CD;)L=+.3!:[HS-%J_`X/]'7_**!Q,D M+P0J0G/0]S41@W)PA`RO5,!)%>G*@/D7]70N%#2F$,AK'EH36K(#W6O)NY`A M$5XYD2HG:4FDDDAKPH!&:\*K)G*JJ?N2K3FGRX7Z_.\5%\C8MCDI?&JU1*9LU7_4%*)2KR MUE,U(R<1[V\/J3BH^M:O[HOV[*1]4/+\?A1T.X]:_P-02P,$%`````@`5X-> M1^(IMR>%`P``C!$``!D```!X;"]W;W)K&ULE5A- MC]HP$/TK4>Z[\=AQ$E:`5*BJ]E!IM8?VG`4#T28Q3<*R_??-UU*PGQ%<(`EO M9MZ,_68N;OFF;_%`3U:J>*M'[4>U6VOVQT5:1->UMM M@WI?J73=&Q5YP!F+@B+-2G\^[9\]5_.I/C1Y5JKGRJL/19%6?Q93_[G M@Y=LNVNZ!\%\&ISLUEFARCK3I5>ISG_F)WA^?6G]V]]NBW]U[162YW_ MSM;-KF7+?&^M-NDA;U[T\;L:?)KY7I!_#=U;VW\?A MEX2-9MB`CP;\9$#A50,Q&@C#(!B8]7E]39MT/JWTT:N&Q=BGW9K3DV@KM^H> M]H7J?VLSJ]NG[_,PY-/@O7,T8A8#AI]A#,321L3A"1*T!$XL.&3!>WMQP4)@ M!P(Z$+V#\,)!:)`<,'&/*8)8_$XEB@'$G75A#N&/)*H,3X7'$I4 MF@<.`'-L$XY5S&T5)['#`U8H#^^H")8>!]*S=@FWI1=)U_)CY7%;><1CV%I_>\P^>%XY@M[J@+EHT`@\VNBSW8B$41-\^&`,<9 M9Q,'(ZQ"@09@XG"!!2:B.^J"!2;0W++J8A^&XR2)R"R+#2,AR44(RU4`N4I7 M9;$2Q>3VLH18B2$ZJ9IE&4$7KW8R)/,%$,#,H1&GFUQMFNXR;J^KX<^"X:;1^\__/DY_P,S_`5!+ M`P04````"`!7@UY'7=]%K^P!``!6!0``&0```'AL+W=OPUKH_`J"*FK54/8F>=6:G$K*E MVBSE%:A>,EHZ4LM!!"$!+6VZ,$M=[%EFJ;AIWG3L60;JUK94_CTS+H93B,)' MX*6YUMH&0):"F5M4([I`LNH4?D''G%B$`_QJV*`6\\!ZOPCQ:A<_RE,( MK07&6:&M`C7#G>6,:'Y"-!&BF8#B M3PEX(N`5`8S.7%U?J:99*L40R/$L>FJ/'!VQZ5QA@ZY1;L]4IDSTGL4$IN!N MA2;,><1$"TST'I%O$;MXA@!C8'81>5U$CH^7&=`'`M@K@)U`_*X,M"ICQ.P< MIG.8/2&'524>4`*)WTKLM1)[K*SZ=1XQR2(+CA%*5EZVJ`@F<.\WDWC-)!XS M>&4FV:0A,5J!\BT([?$'1T2\5LC&"HI6W3^33??C`SKL5EZV*`SW\;HO8'$% M>GIE/ZF\-IT*+D*;V^3^^4H(S8PB?#*%U>:1FQ><5=I.=V8NQWL_+K3H'Z_8 M_)1F_P!02P,$%`````@`5X->1R,S>[2_`@``)PL``!D```!X;"]W;W)K&ULE5;;A,)@_MLV++ M-A-`+I+C].\K"4PP6NKXQ8!\SN[1KHYF\Y-HW^2><^5]U%4C%_Y>J<-]$,CU MGM=,WHD#;_0_6]'63.G/=A?(0\O9QI+J*L!A&`/=%C_SSPDNYVRNS$!1Y,/`V9,#<0B M?I7\)$?OGA'_*L2;^?BQ6?BAT<`KOE8F!-./=[[D564BZK6G-)Q:R[29&":[&K15YF3 M!H4D3N$LYIZ#C!NZ!4VBF1`SWD=?+RD"G?V`\/7SWF/HM0,/X>9//((-C*+K M9[['7-0_BS(TU>/"T@S/E1B^#I!['\PW&C8QHC=T"?8>W7#@( M-BE*W$S)7`C8IBB]8;^P!9'K09*@Z7XA$(;S8-B#V/4@F?,@ACV(;_`@ACV( M70^ZNP5!T_LW&$T--6]W=EZ3WEH<&SL>CE:'F?#!CH3!)[S(#VS'?[)V5S;2 M>Q5*SRYVPM@*H;C6$M[I$[W74^OP4?&M,J^)?F^[.:[[4.)P'DN'V;CX!U!+ M`P04````"`!7@UY'_8,BF%("``#!!P``&0```'AL+W=O&.N%45X7_WM&3MUD7N M8^.UN.92;X`T`0/O7%2T%@6K'4XO6W>'-D?D:8A!_"IH*T;WC@Y_8NQ-+WZ< MMR[4&6A),ZDEB+KL) MWD#P/R?X/<$?"![ZE(![`IX10%>*:<212)(FG+4.[]Y>0_2?!&VP:G6F-TUG MS3/5"J%V[RF.@@3Q:!:&IR6&*\]7J*.2XQ M/@KL07QKM;X1\"=!8KL`M@I@(X`G`K.4^PX3&$S=56*W"*P6P=(BAC.+#H/0 MR`.MD-TEM+J$%AP21Q]MMF^;F@)A)]( M/#D@T->_&63]_'?(^_]+ZC'C]@%0`!=]`:,#L*+\:B:)<#)VJ\W@ M&NT.TVIGAA7X@*=)0Z[T)^'7HA;.B4EU#)O#\L*8I"H.7*D7E*MY.BQ*>I'Z M-E+WO)LPW4*RYC$PAZF=_@-02P,$%`````@`5X->1_F*E3B``@``4PD``!D` M``!X;"]W;W)K&ULE5;;CILP$/T5Q`.(O*`U$2^LI8UZ- MO47K/8HUQ"!^E;03D[&EG3\P]JXG/XX;V]4^T(KF4E,0]?B@&:TJS:24_PRD M-TUM.!U?V;^9<)7[!R)HQJK?Y5$6REO7MH[T1"Z5?&/==SK$$&C"G%7"_%OY M14A67TULJR:?_;-LS+/KW\3N8`8;X,$`CP:C#FS@#0;>SXQ^R4&PVYX8*R>,??O)&*8P`<)?$/@W1&L M8((`)`B6'JS<62)Z3&0PC<%X[O"#I4)0*@2DT$P*PCS(:`2*1`"!-Q.!,#XL M$H,B,4`P.Z)9O$A:X-VGK#]!``X_2>T*=&@%.!3"!/J;`U6=^_\G"3TH7`1X M,2N8;`!-X\7/#Q,"*WB+,*#VH'807'W(^T+,1@N7*5K6 M:>"B!Q1P^:'P"]'"Q866E1.X>/YMCA8['`5/-Q@N,K2LLL#UYF(0:%[+SJ3U MU)2?30\75LXNC=0?[\GJ>$_88MVZ9NL[M,[Z;G^C29.6G.E/PL]E(ZP#DZHQ MFO9U8DQ2Y:/[HO:N4#><<5+1D]3#2(UYW_/[B63M]0HSWJ/2?U!+`P04```` M"`!7@UY'L^?8D>$#```S$@``&0```'AL+W=OF4N39Z7^5GGUI2C2ZK]G MG9OKXX(OWA>^9\=3TRWXZY4_V>VS0I=U9DJOTH?'Q1-?)@(Z2:_X)]/7^N;8 MZY)_->9G=_+7_G'!NAQTKG=-YR)M?][TB\[SSE,;^=_1Z4?,SO#V^-U[TI?; MIO^:UOK%Y#^R?7-JLV4+;Z\/Z25OOIOKGWJL078.=R:O^__>[E(WIG@W67A% M^FOXS`8[PCS`BZV0+)QK-H27`.7YVT#) MITYFI0BRH:*W%[-$%>T@(!T$O8-@YB!"=V30J%Y3]IH_.$0<]8-0!1(U;4N( MA.`H8$*HXILYF94ER;(D45:,RAHT\B9**)5`]W!CJX*0"UR7K>)1*!0*F1`R M(7G(Z-)"LK30*DTH1V\4Z4#=/S,1Z2"RF\L9:FYD52IBIG!S;16$$*/)VMHJ MSJ0"%#*Q92H*F*`KB\G*8KLUW(&6[@E"$8X1S0&,.&97%"LF<.&C3KEU\Y0< MT.5$2A92*9$#19S$ZA,'PH5C,CF-,_X%GG$::)P@FC6=HP@-'D--V1`R'@48 M5UMN\TI%@(<](;RU+7;>3!IL7'YA1&F`<)L@Q(B&Q(@R%6'PC3KEULU3HI'$ MU3TC2HE<<6AR<0I=KOFB$<$)1KA&%&A&`,4(/*)`,$()-'H;2A5%N'-@SEO5/!T:22#N&$U2%#GB MT-P"FUO"\>P"&@U`H,$YF30:@$"#]=X$-AJ"0#'\/DC(!.?6,PX(@$`@)7ZZ M$^[B]BW4\8@"FC-@(T2X/-`$@>@+3:8)`O$]38ZMM@!G`C^A"!F7#']3;0E9 MR"/`KZ>$+!"1SES*ILOS9G7:[WCJMSO0^C-?;CBQON7+9-C-^'"_7IW3H_X[ MK8Y967NOIFD_R_N/YX,QC6[S9P]MYB>=[J>37!^:[E"UQ]6PIS&<-.;\OD4S M[1.M_P=02P,$%`````@`5X->1S6-!N0:!0``+AT``!D```!X;"]W;W)K&ULE=G9;N,V%`;@5Q'\`%JX20P<`\D417M18#`7[;5B MTPM&BRO)\?3MJX5Q)/(_&$TN8EL^XA$E?CX4M;W7S??V;$P7_"B+JGW>G+ON M^A1%[?YLRKP-ZZNI^F^.=5/F7?^Q.47MM3'Y8=RI+"(6QRHJ\TNUV6W';5^; MW;:^=<6E,E^;H+V59=[\]VJ*^OZ\238?&[Y=3N=NV!#MMM%CO\.E-%5[J:N@ M,PX_S]1^N_C]WM#_\M;\V7NOCG_RW;:I[T$SG=MK/ES"Y(GU)V(_;!S[/7[7'VC;;WW?299LH_>A M(1OS.L6P6$P( M=0DX"H_=%*3G0S(+-94)XGM)&,C$W$Q34#K+Q*AS@HDF?`4Q&[0P1HV1!$M. M$&77&`KBU&G#E!/DU&5F@[*5%PA[3A!H5Y<-6G?F,.($*79]V:"U/<*0$R"9 M"Z()C#31ZXDQK)3%*XC9(+T8^"'UZ\@P9H8PN\1LT)R8((@Q+)D!R1XQ&S0? M*$QH323"EAFR[!I#09RHE@Q;9LBR:\P&S4^2YSJ$N;,`&>R">R49;^`##MEJ)IZR+2'3-#(..;,$6<7 MF0V:(U,$,HXM9#9J/2)&% MC,J$.7/$V47&P31;2**2<:R9(\TN,N[79J%#2=UW8,X<<*;*+L=.>;H>&<=. M.:JG+C(;I!=#GT:&.7/$V4.F/609@4Q@RP)8]N_'8G^D2$4,28$U"Z3918:" M.%$Q!<8L$&87F0U:W)7)4!,%1F#.`G%VD0E_GBTE,1($<<>,,+O&A%^;A_M, M8A8@L&8!-%,S(X&9"O4+"P28J4#EU#5F@_1BY/?&?GY?+;!L@62[WFS0W%N? MDG?7":$S^8$LN62+:W!`*"!''B)(8M$6P7G`V:#T\=DU5-8MH2 MT7;!27_6K:@Z(3%LB6"[X*1?I[,T3(AIG\2T):`MJ,M,+'3)]>`D-BM1:77! MV2"]'/ID59/8MD2V764V:*&,6@.16+-$*UBN,ANT4)9JJD.8LT2=*6)E&I%VG2G_YC?I[WX5,>%2F+1" MBUDN->6O22'QH3#';GB;]N^; MZ7'>]*&KKQ]/)Q^/2'?_`U!+`P04````"`!7@UY'74KN:PH"``#M!0``&0`` M`'AL+W=OVT#YW9V8?VF9@;=1;$`L;MOR^@,<:PNWT1N9QS[N$"-^NY>)45@$)OC#9R MZU5*M1O?ET4%C,@5;Z'1*R/EF8T]BSSC MG:)U`\\"R8XQ(O[N@/)^ZX7>)?!2EY4R`3_/_(EWK!DTLN8-$G#:>@_AYBDU M"`OX54,O9__(>#]P_FHF/XY;+S`6@$*AC`+1PQGV0*D1THG_C)K7E(8X_[^H M?[.[U>X/1,*>T]_U457:;."A(YQ(1]4+[[_#N(7$"!:<2OM%12<59Q>*AQAY M&\:ZL6,_K*PO-#=WA.X$D7B]\N#!?%D9J<8J3--ZDBSN!R[U)$F72U/]S/48,:?77X&HK1M1Z*"=XUML'T\ M5WB>M:2$GT24=2/1@2O]!.U#.7&N0)L)5KHTE>Z]TX3"29E?W4R0&-K1,%&\ MO337J1Y5Z57X[`@``]`<``!D```!X;"]W;W)K M&ULC57=H/X#&C'%FFS;9O=B93B^V MUR0AT:F*"R1VWWX!C35"&V_DQW,.YSLPD+:4O?.<$.%\5&7-5VXN1+/T/+[/ M287Y`VU(+?\<*:NPD$-V\GC#"#YH4E5ZH>]'7H6+VLU2/??"LI2>15G4Y(4Y M_%Q5F/U[)"5M5V[@7B=>BU,NU(27I=[`.Q05J7E!:X>1X\K]$2RWB4)HP)^" MM'S4=Y3W':7O:O#KL')]98&49"^4`I;-A:Q)62HAN?#?7O-S244<]Z_J&UVM M=+_#G*QI^58<1"[-^JYS($=\+L4K;7^2O@2D!/>TY/KK[,]NV[?Y$24^S$\*>$`Z$`'Y+`#T!S"7`G@#G$E!/0',)44^(YA+BGA!/"%Z7 MKMZ;)RQPEC+:.JP[3PU6QS98QG+W]VI2;[;^)W>'R]E+AA!,O8L2ZC&/'28< M84`TP:Q-3'B+>+(@)B+/=T4V]T6V)B3^A'@RC"&1T)I(J/E@7&WHVP6`50!H M`3@2@,$DK0X2:TBM(0$`_B0P$P1@D$PBLX"".)I(;4P43`)D+PI:BX)&40BA M254=!HU62?R)D^<9F"TTW(XQ-V:1U2RRF(TF9I%A!!EFO\?<&(FL1B+#"`!? M',;8*A#//XP+J\#B_F%<&'$OC"1,#/#A5UDD5B>)F46XF-PTBRS[E7J!H(VUS=V M>.BS_U!+`P04````"`!7@UY'[00Q]6,"``!="```&0```'AL+W=OEAWX^\BA:UFZ5V[55D*3^KLJC9JW#DN:JH M^+MA)6]7+G(O"V_%*5=FPN;&%C)]LI(4/WX8%M6ED9).__I1:^>AC@>7]2_V>WJ\'=4 MLBTO?Q<'E>MH?=\E/;7V9^EXM6%XCH5_>R>16V? M;?)00]H1P(*#H2P+I">1*B&TNN[W;S#U31;-4 M\-81W>=NJ#E5:$GTM]F;1?LI[#N=.ZE7/S)"XM3[,$(]9M-A\`B#@UO(\STD MC*,!X^D0AC@P%,<&WPD0DMR:;"',8A((@(G\6\P+A$%PL`&8M,`*!..$)`DL M$(("H14(;R+`DR@[#+&8VF(0\GW8A8`NY,X%)S$L$($"T>/[C$&!&-CG].A` MF!`V24"3!!`@$Q,(,W,^%Z#)XCZ7BYDS8QH35&G^X]E$,\6*@&U,JG7;@\8' M)YAQ`4MQC3#@DDQ[`KYSP3,N<`VAX/\UL.E!-T6`9VH`P:6&H%I;3'T`4#SU M\48]M6+B9&\SZ>SYN5:FG8Q6AQMS;;O^9'V#EMONWKO*9&E#3^PG%:>BELZ. M*]WQ;5\^MW<-63F6WD;J%EI=7?FS.EE;>[_RK*B>%J>Z/B]]O]J=;)Y4C^YL MB^:?@ROSI&X>RZ-?G4N;[#NC//-Y$"@_3])BL5YU;=_*]3W7;X*]7_LUNG^:VJ%)7>*4]/"V>V3+FHD4ZXI_4 M7JN[>Z\=_*MS/]N'O_9/BZ`=@\WLKFY=),WES6YMEK6>FI[_'9Q^]-D:WM^_ M>_^CD]L,_S6I[-9E/])]?6I&&RR\O3TDEZS^[JY_VD&#;!WN7%9UO][N4M4N M?S=9>'GRJ[^F17>]]O^H<#"C#?A@P&\&MWYH@W`P"#\,Q*<&8C`0ENWIE_[K/23NKV%(V[V;7-G:OHONOB5W5M+ZM9<16_EOK M:&`V/,?#CQFP'<1L&I46PX[F'B3JFZ$.IN0+AP)`(M(!O!5-*PY@0GE2D)MZ> M)%5)I(KKB':@2`=J?EPCTD%$Q!5,CTW/R#NAQL`YM,40$R8$T7\A*"8-H&*" M,@U'Z]*D+DWHDD"71MT\A`926X(27!@@C*!8(`6(4DQA/(@F)HTAI1E"&HC@ MQJ!^N&%@S%L"4AH*PY!F!LHBH$!-3.2V^E#I-)BQP@=H/,O@"B>@!Z%@SJ,H M'L(U3E+,F`EI$Y6"$=(B*(WA518PN,H(BC5OED-Q9 MB?G,Z.+`?J,Z,+H\,*H^P#PV0"`J$0PQID(N82*CJ#`T`0PQQB(SM3#H&L%P MD<"I;(#&N2R(`JB-P#A72!R%2<$95$=P2MT5T[$^NH0Q-2.?#=!HJFJ.Y&$J M@-+F.(H_=30619=51M55E,UPG9,,2L),6Z/0@L?8`S-P/QH3F%!2ZPEM=&EE M5&U%Z0Q7ND@S#=5A2@210.KF.(N_=#861Q=7AJLK-Q,3FM.5C`?STQFG*P:G M*@9,9YQ*\FCWCZ'(P/@2D%9@(Q!3D!!3'RMTL>"X6.!<-D#CN2PEW+U06&C@ M]H6B>(3V\A2FM9K8XR\B$Z$)27RE&:&ALAFNXJ]<]<+\NP_ZW);'[BBE\G;N4M3M*KUK MO1W7///V0`"T;]ARRXCV%[:,^\.8#_?KU3DYVK^3\I@6E??JZMKEW6'!P;G: M-H,/'IOW<;+)_O:0V4/=WD;-?=D?R?0/M3N_GS#=CKG6_P-02P,$%`````@` M5X->1]BG^V&)`0``.P,``!D```!X;"]W;W)K&UL M;5/;3N,P$/T5RQ]0)PZ!;95&HB`$#TB(A]UG-YDT%KX$VVW@[_$ES8:J+_', M^)PSQV.G&K7YL#V`0U]2*+O%O7/#AA#;]""97>D!E-_IM)',^=0MSC'Y\([/_0N%$A=D9G7 M<@G*ZT_0O+2;G$6+("`Q@4%YI<3/(`0 M0<@W_IPT_[<,Q&5\5G^*I_7N]\S"@Q;_>.MZ;S;#J(6.'85[U^,S3$'\5.?_I?X!4$L#!!0````(`%># M7D>NGG>$NFL``!F_`0`4````>&POMRVUB6 M+OC[S%,@'*I)*0)B$N#=U5T12MG.=*73=MO.K.[HF!\0"4FH)`$60%I61?ZH M=SC]YT2<>8EYA'F4>I)9MWW%!DC)SNSNB8JH2E,DL*]KK[VNW_JGIME%GS;K MLOGG)[>[W?;IUU\WR]M\DS6#:IN7\,MU56^R'?Q9WWS=;.L\6S6W>;[;K+]. MA\/IUYNL*)]$^[+XRSZ_K/;E[I^?3.;#)W_XIZ;XPS_M_O"L6NXW>;F+LG(5 M/2]WQ>X^>EERFT551N=1?-/7^_^\$]?XSO\WB+ZH2IWMPV\L\I7_J_O M\^T@&@WC*!TF$__'-\O=($I'X1\/C>??+ZZ:79TM=_^7_Z8\_"Z_*?`):.)U MMLG]IWYZ_N[#\W^-WGYW\>Z'B\OG/WYX>7GQZGWT\O5E]'7TPT5'HY?^YR7] M1Y?PWDU5M_IYE=4W>72Q7.;P%#RSXN<[5_'#_;;5?S(\_Y?.%][F=5&M.L>N M-O;_^!__HW?W['5X`5^VZ,=_4OH-/OLO(_^;"WAUQ:^OLQO_U^MLW;1&KG:R MVFR`C-[OJN7/:#MZL]\U.R"XHFRU=5G!EI<-+#1\:JIUL:)5?[^#?W`` M351=1V^VN!E`G@V]\ MZD.U@YWL;J.!U<)CG7_:XI*VQXJ/X'INO3%W#54N]K:"1=;4E M:NEZX7VVQI6YR_51PD7EYEJUE:)WQ MJFFBZ[K:1)6F*_^9E^4N!^K2,PIV^&9W"ZSD5/5S!K2WK#;A9TVG2R#!HMSC M=$S_T54./#C'G?E8-,B(X4]I+]IEG]JS>'OTDP>Z[GY\!:R#WX`3:5Z@^2$9 M06\P[C*_+NC/DZ'?U&MX;@W-^=^?OJ3AGM&/4;;;U<75?I==K6$&5516)79; MPYG`D1:R%5V-M][_*:]W^:<'3ZNS_>ZE:QTP_0X\P@RJY^TXNLJ:8AF=[IN5 M>>'L,]M<%>L]DOF\Q:Q` M?4)%N`'YY\!T0D8 M%,BW)"7";$AX[1@BZ"TW!:Y3N*UOJVIU5ZS7!U8O+#KV32'\FZ**=9%=%6O: MRQ9IZ.7?9O>X]H'?:^327?+QL_PZAUY6EDJCUG/+O+*KQ;I#6#_P^F6V+7#* MZSQK\JBZ6A?VL5#[[A$I;UYA'+ MEW]2E\UG+N31#?4LZ=%MZ(F@G*\FW+*8O,C*Z&V!B^EU]8">NK?QZ"8"&WKT MN[RU/5N*1HUBQ_()L4&2=$";7;8?1F/BTV:;+?-_?@*73)/7'_,G?XB"HB3> M^'G=_/UO_XO8T.X^8%U0F]"P1>5D.!@F<++K"%CP/O]]E,3#X1#_KPPBV7YW M"SP5Y(#?XWV81T73($T1!S6&&+CQHO?Y%L2N*U@X94NDI^!>DF^[[B8V\G0- M:<(#HD%A>R/K[]8@'S*.&`_&%B1.N+;7][^/TO$DGHZG<3I=T`OI.(EGTW$\ M6LRU>>BS)^]VVCJQJU6!-`4$A!?6.=SW2SY[@;.]WZ"2D*^"TA$+-GUOK4#3 M7A8=LA<++#QMH:NOA*I:NM)Q4A*WVP0)]>`1HK4\[MWCA*JV1G,2?=UA/#?J M"XC[+XH2VBG0!EHUQ0$C=^N\:;(^I!NVWFQ1^K%O,,D>^W359UNUC^G1,W%? M.SB-X./A.00?[9W`$=KB>X?BGQ.)$?5U*7"?94(F0N\]@3YG?]Y!],9.WL-3 MW@I/N3S,4YZ%N8/]"%^2/3KR`4[QLH-3J*-Z*M8+9*^V/X:U\D<]U[6E?0WW/M=Q^43[+:S/ M4A_S1\RUY2WKF&OKN>.,4JCZOEA7=P\P1N$KU_2*[6Y`\0.EB0[M3=M8&K1# M@`H-"U:`_EDJ>RG:.>`SZ>+*%'E4T\]R.`MP$[(M!WTP&Q2(_\I?B)9Q+"5V M/:^UACZ7Q,L-"$NUNJ&W07T\?*!!HCVGF1>P-V$_D&V&,\M"ZC3UT*<[]]@= MP@JYKTQ;+_0H%+UZWD&%,F3[/D@-AXBS*#_"8`Y0T-M]O;S-<)JP;4=9)7_( M=O++T:^\S>Z),M`PE2V!'$1J@_<_9G5!;VNVD9/;V6_B.:XD7*)[O-ZQG>-( M[%3=-V<@:\O-`\M9'V$)"]CV'O1^V)*F6T&SI[G_^@A2$P.Y$E?0Y]5]<',/ M$<0UR\W]!*'NN.8QEYQL-%FJEUT&BX#Q;IGG*^66$(2VRW&V;)/:IR"PJ MRN-IO=,6_?>__<=5?E.4)3DIKU'G**JV5M#S>H[H3-H:2.GJ1J4CT1`I/)P"+N3"0@:( M!,?GR:'WXP]C_BFOEP7R;:+E?+-=5_=Y[@FRQES?EJ2:@EI]BQ8M6&\M0HBQ MF1UIZR)@$/M#X)$>#?Q!747AIS_<@M"W1&DE*^_)`*@EO*4MX5UKTT!C9#WT MY^[+;`_7AQB.;K./N%1Y":<1Q(.:3Z.H>V]!&-UDRWQ/=HF&]*EZ6W'PV.D3 M?NI)!)0#3#MZD)\',=8KTA&O2MVM_2WS'`+$L&R`/)N5-3,^AY_1Z,5 MW?'8VH]EH0556H6+#1R490;]?GMQ\?;)V8"6XB&SK_/K-3(0;-X*3X&V3XLS M^E9F$,,7\$T![]R!*K:^/Z_ND-LU^ZNF6!59K8Q`\!@\Y_3<<8WC&W@--C#N MB_4:I`7X%<='C\EV1E\HDO(^S^IC]B1J0"]2_(<5*R$#?*:-!2B=HK/_?UO__O]\\N__^W_IIB&%_E5O4=" M2R12F1]Z0EUU#Q5YVH\-[>)SD&@W=)JQV_?[S0:;0XM@<5,6U[#?H$2$+@TD M*>;DUCU]/(L,,&[DMK#+=%4WULE#>MID/\.V"#O)G3&#!+_?;(7R<'4SEMZ8 M/G'N.2GI>[%!A)58CL)TQ1_EH-IUOL.]X#35B7C`&L3,?)%ZS>B4>NH$7T8K MUFV=*Z%>D3$`A0"S?=#(;='@6B*[Q(G#JI(= MKN2KO]HW1H55!R"6RY-GJ0_,LJB7^PTZ"/#*O]ZC2H^C_7.^M,Z-=>*NX.Z' M'5.L'+69JB1A@R5H6C>[49`U8)/H1N0;84EL>U7`6:QY_KO;"JA1SQ"D`TNW M,B>ZSM5%R^Q7T[MJ65@RDS_^Q7P;OH.5S&F-?RY!C'+6&#AW8QT36T94#`U[ M7N7-LBZNN.?7**%LD1<9V7MJP1D9N+X^]X#G!M'#\+4!D/C2Z&&^CH MJ=JTO@(-$.6*;%5M,7_F'B2,NYX)69P/%.`\VG#N0:?00Y1\"Y)"9B1?%6!9 MTAE[`#\E[@\HJM0<_NMG%(@UAT<06Z$&&V9B1N.[9:@G2R!#ZM0 M@)CF!N1YJ5Y$V<8_NY=VJ^[04%4"F0'&L[ZG.P>&*#`?4WD?N%8->UQ6P"YA56@[2%R4X>)Z MK2LRG"O-K\90$F1>S3XC=UJ.`T#&SK(+B$5UC7Q1KLH"31]7^>X.+V5+%-67 MCNI+5$FUMAQGA'UIYGU/-T4M6\8:):]4L:1171>?6&E:Y6B9*XCC#T`9A^]6 MS$_0CX+*&8_V\-NQ,^8-C!7O$Q4?BFNBA(F<".&FIB!]+[5&C(>TX/":H0:9 MR)D]27674'NX?:W66GN&3ZI&O\(M6[(FXU*%'FGG,%F2J4IK8?0ZZ59N,3NN MA8F_Q'W`-Z'QNK\"J<3 MR^2OLN7/1N"F/J&YI=VQG>,U107!G#U5+^O%_=B#^2 M92V^F_!0&G7%,#SA0$HD#=$`'4PS/!'$O`.7H4R$EC@Y<=8Y>>A15MH.S(JD M"'6`8B.#++*(W'T.YX'H_G(#5:5C.K)=AL/*1V.Z?)>!2=P3]I M/!JG^&FQH"_2T82^']$XSZ)+V"[8VZ^WRH5$FNSI)$X2>C"%`4SITRA.)V-Z M-YY.J,D1_#:?1LXB!98=5B<>I;0SN'#?#&AQ4NG0_QZ'H^&\W:$A)V? M>F&N^0.9K/:3T>4]L)5E]**X`EY?H)8`&IDVV-?9EJROG@4=&,4%K.D:AY^X M'"(G71CU'10E0?K02C'1&,]F?Y.(D&87]`WK4:,B\J7,68NC0/6K< MIR@7OGCQ@;K;[E%F8G,0GUK\B?L1JB%ASI;D62RE0X6RAFV%,-X_^OFG?SV? M3F%M,C)$X."$]^"%M6O4849C*)E[V6Q^#;S^9_P;&05[#/'!%Y/A'-@C#/## M.WQKEV,J$5UV'W/CAV+K@[5HL1%H,A.^UFE(L:;`EQ,'`JM^<%RH7*D)-3(9 MI4\]>#HRDT'THQY^B#CBKHVQZ8Z(8K_%GT]FD\$PVA3K-5(#<*OK/<<7XR2B M;`NO?Z*;=(W>VX]L8.5=.V)I?,E^1VE==$$4-[<[OF[H18E*WVS0S4=)8-'W M%Z_^[=GSRS>P)Q^S97:]J^JS.'KS[ON+'[YY&9VN]QOYEDUEFZN"M1V>GOV. M>3066F/C)?I3=)`=[Y)%)Y;V"W)2W=B&=YZX>^CXJ,'J=^@SJ'O;KUAY\LI( M4S1>F]88=K>PI33NHZXG?/`DM?:6OI@.)OH+DM1^D]&@@=\.02?IB9P]0`8% M'C/-L$@H)#Y((B=>1:+7A:G=T<`B)#BC@@.`,^JUB-6U!'>*(-ST:,AFDPO*AGQ'TG?W?&(^(O74 M^YLN M&9(:6'1:@1QU*&=>G\7##K+C_G6YRF^RDM96>B M?:?US4OGW*&6:T\'57]<'4M2[)^%.9;KID+E02)%^%WR*?$5M+NKT)5]3KI- M_]C4(!ZTMG)N/+,_T15;Q>QC%@Y,H,M)V?-19R9U01Y]OL?0/&CMQU+N4$UJ M?B_J\@IV`E_^<;\F#]/2,+B01GYR;=.6(;P&^CM9? M-MR!ME\8GR)HZK3L6J*A(ZDZ:8]1/=^YAMY26>WFW"P[XL^KZW.0.>1HZIM< M."4.,>=E3F?B:$\G[@V#%I:K/Y-J#[=!A<,B3S\-,%H7USC5'0;5MRQ-O]Y$ M++[=FLEHJ&8R_:R9$#V@Y4'T7+G][8I(.G&-EW7M<%NZ@I"4;+ MB7BY#Z*W#I?*H^!RN.1I#8V7&.-<[L\IUG$-6U8V.=\VW1.WQ]L>I!+#^,#' MT?MJ;_P?+'[^4*Q6<%\^S]"I?7'-/AMT[NW1\;0N,H>42'`R,@2)*>=,E$9* M]24P'B')..H>5VV%17A7,$85I%Y9,I\3Z`"_(<.IF$/4'G*6?>&'!TN\S-J( M.M^0FL>--H6":-`&>EEO/<-!].RSU!S1,/P9B]*U7(9-<#`)YZ@^ MA;.,H[*QU[S!O,;!]OQ.@Z6!FD^><="'6(M.>:$P22>9S,GRE<[93C@;HWDP M2>-%,HO"V&O`5?1)/HO&XP1>&RV&\-]I.HS&<3I-(Q>/[4%K`MU/%@NTM\73 MV9C^'4UI4+,XF2VBRW5M6Z^KFOBW2L'0'[(P8XF!(PUT8Z@1E(XHK%.:BTY-=:]Y@N#<#@756O5W=H'C1:(XZ>K6+&_.JY M42E^H;'(QQW:'84?K3%D%,?AF`:A4UP,1PM5PH=M-WRA5!K8%$.;#QF1S.$6 M=K^]!=Q.K%90'1"S:YRXF.-9$4/I.'6)T!6MZOP&S4J5<(*0-,M+'K[D?7^F M+;^'B(PU8.#FJ^R>)Q:36>M9D%I MP61[=%IOJT*?(G]0O[WP_6.YQE@JH/,UIJ283N/PLM%143!OY"]D!W"7!NR: M6K3<%M2BVHS@)Y4EH#/WGZLL`9\].]=>`Y15VU;1)N"`*7;THM#[BEDZ'0$E M=:,)$NX2D.M6=)LILZZ6XB581&0V)CN6L8&N\X^9/7($ M`M+A#&Y+9#*SG"AT?;F[;K\,G9GX4RN.2H="(RL`QI'M3$0*J^B'8F8ME_N# MID9Q@7"S@IAWCZ'W5M.Q@M'=.'`5;H)&3S4@%3"A M7K:6FJ)!>?V:W"$;M!%E%"%!MA0,T"2WO!.^VWZ-PW\IG#P8B/F9A\:/Q_". M#(@A,=XE9+`6D5_&0D;44C_"(T7K#OW#TI6\&R<)RM6O% MA56RN[!X@F1.WZA(T'R+=_&:%KM:%?L-Y=F6<$!P(,]?9YS@4I2WQ57!%X.1 M4G_ZU_/1+(E.,:4,M9;H[7DR',W.:#GP\P164S%F2YI2PBT=.(Y&N)9H!"*6 MRQ>QA3NPW:]![T?7CM)\7/Y3-"1=LJ.I+ZH`QVI&1NK"B]Y^F->T;1?96G"Y M' MPQ9Y(`$XF]]:QH,;+&M,*E7?.BNI6U1Y$GPXR<_Q5;4]\[#DUC2TGB-1A@.U M:"+`HZ,_.IG;TOM^>^XJH_9P>I2`K+3'AE$M)^-%MUH@<69:,^@P;'MF`V\' MF&KM0W@RFMI]6A0GJA7:+\0IJZ5[6YR@()>3T>P1(^\Y6@AL`EMO-ENE+%:E M#A;&?M/1H_J59,26UN<&D=C[XRXDB[^]=-.RV#L!!8JU^B$%I(RRYUP[@3%! M:57MKYP(@DVQX@@"/_3`-19IJZ\6[54X_2$MT6<6/5JB/.IHB7Y_QZF+R?P( M=?'EM;MQ6HHCMPAG6TK67UVMW<"/`F-"O=1=]-Z_11R7:!0M@=@I46M'<@YK ME_Y<8C7C8U=MY,^J9<6W`H:5-4UQ"TH!N2YR3]VGG!*=,A&^#SHVO37(_W*Z M=O:%E.R`HUNIIN(PQ944-_S]^=7]N7PDT/Y&";C($VL[ZW^E]GN=-;OS774N MK8DG5;MPV[0C_38113)B/>>SPOCR-P!D1!8`:$42!0<]S_@!+@2-=% M[<$>L*,/\--=2H2%WN(*_8/H.YC`1Z1_=UXJ0;4Q8@;%T*A$+UHDS*;D%.KV M^ZM(1@RREF``FMNMR$"IX*H()]A+>Q82I]_FIL0^4:3 MDZD20Y*9,;![]0JF???4H5/?(?RCKZ6<1'/&H'[AYL0?/8%D-HE'XZ'X?4\B M.#GT]UMK@2[6*@6/\'B,">Z5!;[P0FF`^WI;B:]2UC)DW!7$FZAA)&2,%[#G M3>@7;7>YRR+-)A;LX,)1"JGNI'"610'JT).99`,"9KQ>%\(BZ%]12N[!"=+A)*D3OC2DGV>3JUQHUI9]P./ZAF=UPM'AQ7@AC]R2SZIJ@N/B%+ M@`^-:]9]:46Z$`A_CY%Y;1FM#P4)ZBX#$8(]PSFU7L478@K2I$3A]?WY;8XX M3T5E(DBBI4))4UF:!UR"NN],*S"V[*W60K(=77Y&M[5N@!7^M;FV,$`D\8Q& M=$:J/=ZK;A@_-*U;.L:O[]OO/"F$\ZW-V>SS^@?L>V2#T_LK2K&(M7GN1/3% M9MP<0:$&:FP(W:$%V!Z[]NQT96U*`D:8`LE'!66I>):N:HV88Z5EA]T*2JZU MJ3NBE]R2WRDKF)N2-[6>+-R`+`686S`7NV'+Y)?D&]ZZ9QNZVKO8WMZW\Z%';-^)- MJ!T?Q0]887OZHE(R27R+D M)#TA`&(-@E.WC1>L)MZ"\;8)^U("TN,*%*V,O9;! M16`A27PJ=IA1A.`J\`;B_=C0"U953T2W6'^T$I%YPJM]KO*7\4Z5A5=W.&ZN M8Y]M;7/`'/9[?+*F"K2QG&0;^5-HC!W2&`+`?N2.DH^/@V^#M;RYP?`,R MLJG:8ELA4#U8P!L'O%&.O4<`\00R#48K0!=V% MC*/3V6Q&X`;#>#3%3R\M>.KK1VKQHW@^&45I/)L/27Q]5$5)"B,?C48TD6&\ M&"Y@=(^/PP]A]3W,N.(1FKYWO11DP9,GSG8R'$S=_.;A(-%?^#G'_X4F)_JF M.S6%7,Y3&UN9VI++O>B<&MF_G)"@SQJMA.X4&[:U"+_>N9U(G)1A%#J5BU88 M(]-T][#`^7WG9?/;48\:77#]V98\\U/FD]E\D/:N?(]J334^#O#0;LCE(ZUI M6DOG,,^PP?%I:-W;(#1^3LK1A1\0I682SZ8(Q3*/Q\D\.KH"*C"TX606I:"/ MMVT`Z7Q,%H!T099/8PA8Q*-%`ETM0-^WBY%&XVD2C=/(+R(*[`Y1:)+Y(NHI M>1(HCQF-TGB2+)#M0H=ARP,;\I($V?P0_HTGXW'4JNB(=03I_UTEA)+).)[, M)U$*8X6+P]'2,LO<@KN*M/-5SZYP&.^QNW>54]*)CY$>K2I"![>$%-OOA%F9 MMD/IJ'$IE!67UJU89Q(5R4^-2N&7(5^#:]=JY1-HXZ#V M/66LCB(A0=<#91C76T(*#"L[,/F\H2DBE8,MH#U`X]Z23ZBEYW:_'1-A.?,3#-^. MZ$7_)C+:CW0H'(J2L0&/;I92!U59\D9F7^3V6.4L!6!&[?Q(!RW M#+02L*A1=`[U%\9_,,%+'6Z'BNPU!#((/WU-B(1>\JV8TLA\IHQFL:I)(L8W MC7'*AUZ[.7E=+<&B(T5\;1F*R2Q^R$K5?LZ/SQM>V8=@TLQRT MS#T;C;ABFP[H`*[A#"-[D:6O*Y5-H"E0W7PJ/X"S1;ISO0,3B2-[>!R85UJY MC"8`ULKX[H:5ZLR.4:JL'-84XR"K'/,*20&X-BP1W:2 M(Q&+,S-&#AGKQ6?@%W._!%.]PYF>08/W0Q/6+"NV`>H,G1/'W&R,S.[DVD'5 M09;TF*#IS]7LVGGR>;&YPMN-AB&4T>1=T>:XM^.6WC`?S+ZX+AK*0-O_2ZY!M%VC7&QD_%:STIC1=XYK]^XV MM_WT)'SB2@!3"A<**#1*L5WNTJW4L`M80+2O9[/=NU67](IS\4/C*[!YP,,W MPRZ+TFAEUIKJGI_=EG$11-]A/9W7[@O$CBS#V//;-*AW6SGHYV MV6;6LO79CE.C)7<&GEP;!F^_:2>DJLH^RF=ET8`6USJJ[%#PMFLC(#VAZ'R# MZKA=\UEG9[,9+3KS)($9RT:8BF\ZI$B,J1P>7,!L=KK`T<8L'1GX@C`<_%!' M[-"NZ5A&5Y9H\OQGSE/)/A4;%)7QUSVK^-45HF7+X89#W42G,F;*VJVNI&87 M8V>"6KJD>:](8R21Q`OBY0`FRHHI6[WMRT!__E8[F;)7P/FBV^HNN)*\\8QB M'EZ),]^2:RTA:)DU*I+W.I^759^F0=VG@T"=:@3MR>#CH4GJ^L270?3\4[;92L2,M*#>4C?A M7XY89"]]W5UBFIG;RA$;8QPNJLZ:2#7@ M6_=YVK.\K_8DO-&.7$%]6O`]DEM-I'1=+?43;D/*W&"1 M,C''T8#18DK2!R?V(R(.4AS)15F]$FMBN\"@/SHJ3D43P*(Q]`=G75$FB*@= M=,58,`*@"'$-.\FIHW@V%$:I?NK]5J(YU9@/^L3"8Q,7'1(%>M;T645U.(XT MB#L(:E<[6W#S-/UM!L).[Q`L6*3>^YDK*^*8+"W(XJ$;^_ZGYR31@%,'6B3; M)IM6E]*`IFWW,+O)'NU5>G0':;"#ARVYEY#")&'VML#RWZ_OS6F*!U&_G M-U1R0O56:/#2E@M2>-'N]N&RU>$=?!IUB799%RE9+WRG[U-.0U`;I]976)DO M*[_PQ[W,ZAI3+('RS#B?1I>>)^@IRNC>[B-C=$SN2GK,?/R!QB`[I)I\VM,;M!^/1A-ZV?[=#ZK)RP7;[7IYC*`>IE*=\O*67T#O@D>_:R)>D1D^&S1,X_EX+KMC2,&FVPYZ:'EA8U,LA1%JCQH^A?Y, MJ%2)(A3OBT!'QI;QF"Y/4ZR0@DV;3_ZJV0O`(YI-O2%:7U@\ST0?B&*)>HWO M1!4&12PZQ$45=-_8R[X+WB6FQ&\_ZU8I)&W/L<@\?L`$'RA0`3PS!K&[(^+: M["B,YK,C40Y/=*0G^C94,?*2*D9VEZ&A\H\H,UYC]#M5S=+2\$-B;-AM7M<$ M/1E2Q8%$/B`0_RM$4.3HF,5X,/>,QIV:?.MUD[S8L2!B,-)B@;'?X!HXD4:J M+]T##Z;K:>76;51PDL;'T`*"_)BKS8()M$]-Y+]*9_2Z7U^+^6(.$)")V4?]D5 M)/+4_!3@;2?1;#B+DW'B2`;FV]8=?*(D`O=Y^;+[DC]1(H+W'G_)'+\[T`7C MKJ9Q.O%?5]]VRAS>Z$_1X8(*.:QJ0HD)!#P,5W`RPB5(J$09MZTDC.XYA5HC M`68^C=)Y=#K#<%,ET?`4PZ2!Z["()\F,ND6`87Y7OI_;"_0@FL/XU^$00];: M3?,O\]%0B*H=)_=HFIH".:03GT;4MXL:$(3Q@7,-X/!ZQG$5E[>"+T61X@"IGTR1>S/#0 MT;*SSZ'*T7P6I^FBU33_D@RG@=("[3+$'9R6+"96N@:[OZ1> M18\"%YM2W^VH*4KC6`F"UUJC:9FTD4)08?!A+_*'WI#0>_0V$_*RLD;I>X!C M!91!T;+2<#U/G-Z]JGA#]@6LM2757K4/^UI!&Y^C^0^NXPU2#<*2Y0@BQ,OC MRC/A52RA(:[W6N=28H5"Z\CT535-KHN(_M424Q^);-^ZZB^6R_U&BEBQTH$; M4N>W6`4$1)]3S'J@5(-JTW8>,ZI(]WW_H-8[Y0!T_9M8\T131^S`&& MY\.RC?5J^Y56_R]$;[O4>MMC2G^>+F9\R$^3E--+TA@K7IU$B/#_YO":Z0/$ MC@D-O'::3%%W3.#>!7D"F"_\=S%&"6O/6\.;17Q#"061+#1(/`D`MZ M\@=,2/&*D1[>\1,US!,:Z$DTF:548&!\L!HH:+@)52&%2Y!JIX),,")F.8'E M^VQJ.89(-'GH5WX%(N%$G91GRL)*JO*0AG@7?@Z-I$1\T'@*DBV6B)A_01(9 MIY0"Q?\\ECQ2.1XIEWKELKA8+W?62R$LK"S8`L*"7CQ=#.G?9)KXO.^[?(5X M-?[7SW)*>,6!O;3<#=X#Y=5[]DW.99-X0J9670KOPLVH=RP M$BM;$%ZG$]^`-FC#;Z^%_O)/@JU7ZQ#'3)F@@G9]>`^$%;?4(UJ6S M4U6(T[5KQ])0)6;@8E>Y/FSPTIXM>!X>57"_)#Y=(Z0BKDINHW*C-U\0@JD- M!`)9[54@"1$K&FHP`YM":/)2[ET89$7N=#:+4!W=7/#'="@*)G@64IK-E'W# M&!M54=6M#,9X[`(31K&,&!UFHMG]>/@&!5$RM-/$R%.OU_N(-59MD=T`T:16 MU5*[PG(V<>%"W!9;'6EPQ#:<*N*S?&OLKN^C#WJ+1+U\TYPYQ=U=N8"0M3=9 MF=WD;CPV1^XIGR`2*VWT+ON9+52<+Z`&9\+V--2/(C40")>W],QZ_27I#CTB M9@5L5W>@XJ'>%':RXC"O@-6IL`YJ4MQZ$B2HO=7[,?'`J[$%R M#&)`V]>(8$X'QC`+/4VN.&/M(B,MPDZKT%4)-MI9WXC#W0/XU#`1:G$IL>C@ MT%':HV0C?_!G$M\9ZY[C MA"B<`>-O0I50K#1SZ4=*&#AU7^QU7GL0'>)\:\R`"33>\>L+IV]I,$(S/HET M(E[=WF_Q1N9@A".(C2.@*!%$`@9VPNJ6*"H1,*N=)D+'GW'=F=8..J#E])%: M9^,'TEZV2:5U>MBZC54LL]<1/+'*'HM%P2C7"0-H:QNEP$7V#&]D@F.^>.'1>DR]E M-H_GTP0C%"?8J2IW5\(UM,;XEW02CZ%7RVUUC)L-D5WF"Q3S1J-XEHZ/6?L^ M'\07771;]-!NJ$]AC:CL_ MG=Q;=.X^Q`\JGDTF#SV,<9QH6VB'@[.+Q/_3EH[5]:.6SAP([^W0C)7;]A!^ MFT[X,0J!==VOM`;3$"2,!"(9/[(1];X\.;/C1JF3[XQAS/WA#0W7^1(77N!: MG*]?`S^7QU_E-S!\^>,8I[J[LT'*4U9U]9?E16?S0B]I!GSO_(E_Z*+<_T:K MI$Q3XJ=J_^5KNR]+N&6(BK"NS`?UJ#(.!#[5>/7..^'@.M]@AIQX!]!G!) MKZ.3=&YGH;D9CX_B0RRJ*2@5[L.'AR:$LMI(>R?IPBFG83+>@H13-'9N6BC' M68?E*X1E*\5W$HGM*MX*ZZ%)MV714N\(0`\WE[A>PDHNTMU=\L,UU!&K48 MH@\7T-8Q>8@B0`H)1YS`\U>@<%Q+2H:?C*A.!@?2G83(96X.-=UH9#?LS59>A$03DC]*W!`K.`G3M0Q4YB5E9GUH?5L$SQ\!:7+Z@A_BG%L;(:R12V9NC)PJ#Q@STY4Z; MA5::2_8%RB\9?06:_F\XJ)LAQ%G=W=5Q"&.!K8G#N#VV`VL MI>(;%H[Z1#QV?1\E%E!?@P#..>(A*[55U2#2F#'W<&ED2TXLAB%<[0MRTC8& M%5M]0[`GP+KTW."5;RJ,UXVC'X#!`&/9HU9L7O56@8LPVD>1>`?LXTJFKN-! M"Q?5=<1,U%0N]Q[WZT3XR]^"ODV'Z3Q0E:P,`0LS&(\Z.7[3*HO/Y)2;&D:# MZ!M+U-&FZXQBPQ&_U<'NW=6"``&[26DBH7LC-`254V[E9Q6D;M'@8!\PY_:< MENPJ6_Z,0<[&-DX9]BBWKW.;>>M=[Q"*U!B=@7,H$7"$?6TAY,))7:U1(N$5 M9N&(T;L5]Q%K">4KJ4-D\UAW>=BYC2U<@5B*R)4@>J#`YR;+X0,\%B<\70%J M>)PO.`3&C1EY-7J+ZWV])!:,TN8#29$..Y7(T78KSJ+V:@PXFV"@W8YX:RW. M+L,O3#LD_^K51`\!>91=OS7/R"[%'>X#.B3*<^"BDD\0&^ND,J<-G0[>/*Y=9%!`@8Q41 MIQ=/P$`/Q/5[/-Q*S&TUR)'_X]G(XM@T2_SJB,2/8V8YL#(%2%>&&^)@T03) MN+3KSHD:M48)IVZD!!Z*SOFN8N;\`U;8`O$ACWY\C\%`I(B^>G49G3[1/SUA M[W6VPM1T\D>37^DF5X7O6SU+?K**L#@9#>VB`J!O8#E#BA_$C<2IKG&JIT_T MM)^<=31-^H)N'VG509IAA#]Q3UHH:!I=T&.-B&E#2=;-SK!JM5[P90;GB8*/ MV8:"0T!YKVL&T+,D@Y<,4*8@IT7W189/M]02"VF>I,ZZ\(S-SDO=!]C[J\K. MOR#_L4KZF`W2WQ%"2%:6^XW&RBHHB)0!BOBP3)T'7;7VQ;.+KQJKE.5U].;= M]Q<_?//2'Y*TF]4=HWGU\ILW[QBO!8Z\W9]U+Q`8(02N5.RJUN#0 MX8E+JUQ-K(XN=1YXPZ=C0>=HAM8!!<=ID$ZE(,;Z7D44[/R>?*N"5P-;8;ZI ML9KZ3CYY6LGY0/LN-CN&;N/5G*&:;=PLPIS1I<+5EYKE+6R;`=Q84SK/A8:> M:]6]ML.'J1E,0B]105VKV=I49:T'NCE@A0TDVVSB`K*Y94JF6B8+K.`'[UAM M>2A.[S$C(U1KBBTHN`!@3#2$-=B*3?Y[M7XB.FWUNC1N&51KVZ=<6,QP@8SD MS7/N"%K88%EO/'!'!FE)'6*)CI"`;0K]H+!^FXJ(0U=;U.164ID91&%H>@_L2]D4 M\*W8G/S,CWV7D`FEWK86`(\>YX)9,3(<585SJ(+3<*:/IAM+0@D>:=S+?:D9 M-C'`&]@N&&'.\JEBZ@+FL@)5EDJH8RW98E7@SA*PZ?I@9['6QW4/J1BY0?2"<_WB\`'0`6PE7J(H=&`Z1)F57MUYM]X\0S^13E!S^&$[;U!) M=WKM%0Q+>W4B$I4";)RT%%N%1'B?*SBF#/9[4U,Z29'CJ/+R)N-@)+4/)F4C MYBJGG''"ZF/1J`P4)ZHN)F3658'LD9`M@#>JNCP*),2`8)%X*&8*&X6&Q,+L M&HNBLXFI6\Y"!R@%X"[WT"ZE-6C09:N0^1U!W+1[/1W7+K/+K M;+_>V82M[C[Y"<\0EV:&QP]UJ;K1+[.%DUR_ZBN*R"/CLN:%]`-'JHE0&))P MQ;X+;!AM?;NU:%-HSM"(S6IWW'.*Y9S6JN:=!;^%SC+F178H#LDX*F/'X+*5 M57O=1+<`ZFY#VO78,K\).#+@*+CF=N^VMD]]R*AAQ`I-*@T6$<:X"^A_A8.Q M8BU4*GOH-V*PRS46R1((UC7PX/6]K_+?5H2UKL,S++^4>C;@BV3R1B^57QKG MWL");U1S12VVJV@7T01'T1K,D?CBR?.):!2\>0FU#@.-IX&;\TMN6M#1$3 MO2Z[;F+H'S8#HB8Z9L2RX2W>K9*ZRX\RE@Y=50JW-R;;%9FYR.[06E_3IV1^3(HD;CSM:? M'N4$]*VO950-3+-%/8K`&0_6F25(`YOMNKK/>4U)VU<,@<4EXTJ[-DF=4^[8'%%A6>JO::\MO>:7M\PSWJ[%I;7*8=* MG21LPB0\*PA<@[7+#7_,BG6F'8$-KLT MNZ!G,^AE;Q=8HB$=#J?A>>HRB=4:1*USNIET#%#W\GP.YKE.+&X[323BD'1& M'6_:6/QU:?-7`_IM\'@.8/O^AK"Z?2.V0F#I6#_UD'A/HM$B'LXP>S"=QNF" M\"\0*X*BXF?S>#P2;@R$C200N.3)!Z/D@A/G>`=*])I,,5Q M-,<8PODH@G[A76AAA"!I37-X1T0YXLVL2/=2,92G29S.$TK(G$PY<7>48"'D MT\5PHD.Q.WNP]YH]$*3JJ$)*)]$41CL:$S9$G(RFG-$;CV882YF,)G$R'1ZU M/YB/3UE(3W&AP\%,5K?C,2P2888E"J\D'<<30D59X)3'T7NN3J#+W:!,Z2I` MNKTTB8>C$19Y'<*B(*)#NHC&HW@^F_XF"_3A]EA(OZ_0SF,=W4.DP86J7+BC MJK[."S1SL27'.1G:8M#"(%?9N\BQE!,OLRH!M$(RS"A[HG5_M"?S7(WY3W[G MWH''/P7-XT/_N4X6,]C:)$H'H^C"^.HQG"%\SF(W"A_:$#NPD&@[&!]-6 M;+0G1B]V!25;5V8*HDK%#'46S(5_*A=$@Q6<]+OJN^?6^^_([`F+)%_FT5M& MHGW-]UQKN5M?=#W8O2^G&M7]K/64]1.6S5B,_OZW_WF2#@=P%2?`!6&O*.L; M?Z$OU&=Z)L&'Q_1P&H\7BV@TF#-XX``87$I'G_["LS96+TSEA0DT,QW,D4V, MYX-TACGEDSD%;`\F:43/T0MS'DX\F98@B<_D['#>(=PLXQI-)/18-&* M2>=<%AMY+OR$(($@D3Y7;*Y;6VNW2HP9J?&[ES^ATWU'ONF7*M0R>B<(>^_1 MC;_A(*7AW,,N!^E3JB&3LXT]OY1/K74+<0^$E>^76>?JO<;4.Z^IZMG MNUYJ7JG>T(#RQ,^`KDNVS].]Q,&/S@!B\0=797Y.!3')C:!,?^A^2J8MAV@3 M&*$Q\^"(=%5W7+"M6C`[QIKY,59F)J.:W)DMK:>K8K@*ZG-<@I@=T%ZC8P&, M:3`G2)RV@6BEBBGJ+'+/^!5:(3*TFZB:-VN7KFOV5IK^2U"HKKTO]HFY= M4X\YV(`LX$#RU"0J\E3>/F."AXF9TN4M'8'+)O31]&AJ%3ZBLT4!2"J^ZD#H MD<+;E@8M>KBJ$$$MI+Y309XZX]@8-#`]LX3$BP9SAD@ANVA1N*C/H#+=Y;!" M9'YWHP2]^%5.=)"YL/K-XV)`;AY<1XD(]9JRPG%M$W&)%^X,B@VIT09HA)1[ M28%6-17(J,`Z/4?QX+1U=+C:--N%C6,U"FK;C^VZ7NGTV-M+9MH;#28G/A^T M5['%4+NRQ=/=4?F6TPF\<>,[SM(/HO=8A9#Z,,6H1#0DTR]1KXKK9W&TL"/* M;%.11!3S@&LZQFIO:>,0R:NIRDRB^/TW\;-DJ M=.84-JFB6C3)R?=\9M39,H==V,M=UK64[30V6H(/6&V]^[=C4^),6Y[1V![) MCX/W@^@Z7Z$6&?/*QAH=!?,J[0KP`\RV?(R5IBO-IZ\\/4D4=JY;R7?NO+,. MW8?;WGKWNMO'0=B9(,FA-08>E9T[T1/RZ*JZ/[U\_E43V<'\:NP\E>[?-3\[ M:N"F"ITW%*MIE6?-*T.2OY[0?GON5#(UE`W2HF0O^`5Q<(UUDF`[ZAMQ1]P@ M3=HA%?)EVE6'*K@*K.#RE$QS5EDL.X2V"SJ;*D8_DK`["Q@>)&PGV)3B3ZT4 MC1X*H@/J-BD^&,E1*=[Y5`!=:+Y3NQ\,2M564J8*\\3'HP]7\\4-61%FZ#\M;:KL4.' M9(C:@^Y3JT@RCO&2`%R*&K&&[P@3VA./`Z];4J>C,:E@*Z!=$ZF!?.F.4?ZD MAKDNXZM42&Q:Y<^R3$=KOZDHF?AG#G/,2@Y)5HO??MO#J14CNI7$B$O.63?P M/:@JE)V$!L>R1'V.X5\]?#:L&.#(#?9)K'.0^$N'*]E?6ZQ)9`UDT6M'XO!X ME2>[&,@J.V04-0.9M)2`8FS'TN42&6'^B;Z.2^9"W@FF)&9,4&@>ECPBV723 M_9DO*:0;>WS$W3FN5+\\7,02U"9[M_-O/S3$F+P-AMCE]I543"D/@F0A#CH@ MU1M!++2Z\FB/X5G67-V-/';VI"4[B**L,>;MG5@!WHLK5HD5%-W--.$SA$1V M-KK,RFR5Q=';O"R;^_7'K"S@KV?`?V#,L*^O\[OHWZJ:S=`?8!2<3P"[?V_' M#[A15[R273TKW8_S@U[#MFO,4YN)USE&5/I<7/29X**8C79H3Q+-F+1P:*V# M+A)A!C-0S*6M<*M5_I=]#B=/A7UIEDO408NIG[RXT67C.E\>8-(&\[>I>-ZBC.1E'&18F\%D=B5^.52]\56C5/:4I7)VT7F))EMU!NN]7HSGZ0^XZB[V%9471P'V.K_LA+0UE5VQWK!A024K%S M3IG(4'0VE@S*C\,LD!7+C/2[2)%:?2DI4!/A/`I&MUQ]E'Q*/V]=<4HA<824X4ZH.ISYSKK-*G5QKZ$I[;5Q+/C"4<[J" MK)1&7;J\D9S&0"XQ\7=LG<0DDH\FP]_Q`4&K!PVD0812/+5J/W343/^.%+RG M8M'=E]11WXR=NQC.BSUSY531\?M6Q7=/2>_:@^O'66)TO`PQ9KJ441K]C6)9 MU/D!I?8J!VFF%!P9R^9Y$BWB13JFXASQ@D,*DAA1K]%I34!5EY85M\&8C\5L M0C$@<3K&DB>GR3">C,?T*8V'!+9-[VC#!1?VE3V!HQPOD@66DYXOHGF<+,;P MW^%TYIUJY98X959X!@.<0J<$]7Z:CE+Z!][&(5@3S"";RJA#2+RN).(REX.``J:JHYM*/&KEKYE\;Y=43<$*H]"3 M]P]U(I.P[.0\LUYM9PBBH+FYJ@N"R/4LZGAP2#*7Y`\VXH9'X49H:PL@'D3/ M@LVW_RK'F1<-"A$LG>+IZ!B9$\!V7=3-KC?.T#"S%>6EZ:'[8!0XE_UZQPS? M,9G704LCZ&@8"L%GGG>?-8,[,R=^UJ>F2M<*Y_9K-$MTDJ\9$N8`?VI6[U]_S3 M"]5ZR\RA='TVN(C+TKLX3-@,QU>)UNL:ZCH M='`N'2^8H(Q>Y%?U'L7JMHF6K`8:Y9DMU74B@;K&^T:Y7,D4M:3 M[)E=!XE2:K:#`X;S7_PN^H?$$+I."8XR3B=3QEH>45V,V6+6EA:&LR%?U2F5 MW3I%9.>4@DBG\70\.B0L8/PD%\`UGPX("I,$0W!GDQ0#5KDVSG@:3^;S0W+" M+)XG%+\UC&=4)L7[@B,?W-XMM<87D'5NDTKS8J-'D``UC!UG]'K700\;4U=` MGPSC9^QWJDKNT+8JEM[P>4XVN*OJGX&\EX*9(+D/'6XOH^S`KFZ1M^"ZOWQ] M^?*GY]_;48ZWN<7@R=F4;8N5JJ^EA`@33J^!`3FS2P&UD(BFFB?SWUVT@8M\ M214%]*G4\$`8"W7Y$\90B(Q7Y@3PJ1$>=!(%OG>'P$/GH'G8><)L.A9=1=(S M6)8(\SF8$IM+J"C$(%0;L?C_Q[QM2.=^@?^="XCO&`MVNFP-`E!_H8I6P,NHBK7U5ZM&*PK1 M.Q/XV22(=@=4;14ZDX*7TV=(@%-MI8!LM=CR29I8CE;-K$G4H#C!'3)Y M-,TH'"7X82_RH&)]2O/PIU`TCC!M!9)S&VHJ/!(Q\52BDW>@-1D^!9#J/ M):@H8Z3#FL)_3(961,6\%(=[1:ZDU]4@FD MHV<%+P],>E_O-#O27_N1>`B_N_&0#3AOVB`]>&NH,/K94[:A*P?-30+?NH*9 M+AG,E1+G\6[6CH!U=M?LT>:U7N&TC;_QJMQZ(2T^;K MYZ^IVHV_ZRM]8)M`KCO=0KC),]KC5&L5M/$,#9.R7Q:=AD6UUL:-]W)TDB$F M3,I*6=7LGJM"81>\\LEB-&80+`7!0V9@!.E)AE?G&"%3;?9K#;=%4;[,@LB8UH0= M>WV-"?LY)G60&9;"U;!.[X[*@&8;T!L)84$E[F0[()`ROV^@<\YGMT">8;MN MJOK&26DD!.9\I9+@-/H%>12H/)F>*C:I8[G]>=($!WBLE="G3S8_BH=&)UOV MG>,76+0E$WANO0Z\H^^7U6YG?7KUZJU^%+6H)E_KDZE?-7%[^YT`7^`^TV"- MBCR*`V8_9W9ZF/1"*`/S*O-M07#A09!T:$NL7X5 M'+>UG=B":<@5A"DO%$1G2ZVM]BSP@FC]05`FY7_U1BY9%T^($?.L,HF\9 M[$>9OU["BF]*JR`EC&*+QJL=^_IP/US3+'#G=A[R!:)4RW%Z4]]DI8)ZQCZ^ MN3]'EJ[1RL+Q-X6,I(6YU'%QX$PUY![O`BH2-&45J0*=;#I"PHM:YW0+-B5W M0U@GTHDRVGXB@"&#P6P`XOCTK>09LJA4+X\Y7],TXHE`PML=1@9P4/H66= M\TL/!!8WLZ5I#%-"`"G_D"L4(M3(29IME,@`APX$8(;QK M3\_>SM(6CHD8M9MS)Z%RJHJ#PKK7A3`)@0R=I2'U-(Y,?7FCRWI]94L0G3:@ M`)/26>W.X11AY8+K@B%GBMU>(#64-,3PQHRF18U`A*%#6.I\K MH^?*HJH0!"[='3$F@2@1(:3^]A98"!#]:VQ6"DV26-<\/@*7OB-="0;W)UP\ MB7,->07NW\G=2\U-OL M`.JQ:$@$^.<]QM751M%CZ2PV@BTQ>F#JD<6$&44K+%+916(='UI=4(0`WIHZ MSD06"YO6RRI`+L&F-U0=@G,K/V`55N*=S#4@*$I#L0*/A0\,HAF(0T+4I%$M@>X'U-![4 M?8-K`(U]!%J[VI.6IA+]M/30H#-$E?KU!ZT\6F90C/U)M\1'K2N8##VUEZAJ M\@2O<:):KT`!#G[C-=.;QIFM9!=6R'$[-EF@6,7C#]&5A1QN@(K@3OU8J*O, M=D4JM"*=.D=N(0J=5T&PK)ZBXHF2Y\UM]QUI=6U(^E;*Y6P0<@PH-O_(R6D. ML#I7,Y<^Y1*DQDD**5ER^E58M6HD87XB;2K2\KFE,0Y%=)(IY7;6@UYB!?@H,:Z& M!CJ&)MDEW:93F%4@`<.W<7_#\7[7JE*BH?P+4XGYK3I^I^K3V5'M'-<9NVTX M'I?"N3LLO*8DIY6SR0Y%BID6OYH)!R;`:"ED<81Y-CI]PD\]4<+9$R&:)V=T MU=&9(7XDPKI>(`'91@W;\#A$_=SNNHR\L`H7:(A89M`O5LW5./0GFL<%GS3[E>!>46>LVX!FQ;H6UCYK\AD$.MNXN M#J)+K758T#%T&58[4*-RQWQ`HJN^*PXU,'^CZ@U4Q"^M5<"MJ8%5TJ'W-+ZPBT M*6@C"DQ)=7&]7^/>-:B9Z$R+`WN"$I,6:#+E5_OSOO0B(Q6G";9Q1,K+.++A M,`4J-T2"%TR"[W*.*2@QJ703)6[APJ\#3_#OB1[^KGT`?F(0PX<"U0!72-F&[C7HI\K&'BG3$CLL+&A@+-.(N:J5]L MQ4H>1-G20,8[8@&#AEMXLI;\T/6.9/Q9`9(/6`-C_+-&IZ%<'(@W2W'14Q(^ M,'!VRBP-GXOF8=>B8=$DBW6`C@![6.Z-(U`-.8XL4,"X.^Y$S2H^`EDN&&'+ M@KW%7UKERMZA5D?G@U1R+^2[4E0XBC&ZQBH"%.>%DF\/_))]6 M$&L<"`?'\<+UL7:-M7V8-$6)H&0FPHG#JI92PT[9,,788`Z`C9]N`>4OBWJY MWS!B3:,U5"YD9LZ-=>*,,E,Y8K>-<>HTBHH1F1+4?<-:+D>@JE@G2H]2,P39 M@_@GU^8T)YH"Q.D:5R$/0N^JY6YP%E3":(U_+D%(\XMFV%4Z;`E4,;2,<'!4 MZ5%H]S7*/Q=Q].0UU^B%K?]&*TEA.3]^HH9W@+\',JF6N<=IZZJL,'T\B)-V MZ'F"4LB4]4F?5'K)D;^=E[9L1JPQ^PWW7BT!W&G'+\+?__8?AT878RF^(U$'EJNE`X"AAAE1BPWJ!R"@7,L.VUM,BP"QD6J=-(&\W-W MT>D'/%EMS?"]5<-H*V\JQ#"=O-XH>90T&B]@#'6E"\EW+7V>_ M'=T^#!/E*95+P[#4*SS\<:06B`T?##+HA>M](^%*L$]MV0WCW\;3$6+L+N*$ M8O;&\2P9$3HA`CZ.IO$P'6$_PJGM4G@2VR.#(:1>,4\Y/& MT.YX'H_G0+:63F&UQ$66G'9.$XIIQE2HT9A"`A>+$:43JC)$?PVQVAJ:Y$"RWZ"X87IA$.T MYX0C.5\0'&:<3C%@>S2/1\-`%*$VB,.>.[%[QY#P.Y-=Z[8DIZ$%[O^;H5$; MF6O'><9V,NP?0?,&M3!Z_9/K$?AM@E/?^0A_IQ3"_.8,=XM`114::2*QZ92[ M-O.6V+R^`RH%L?UC49]%&,":4(P^!J`.X:BD4P7M^:@U0=C/Q8)2`*:$=#V* M1U,:U"Q.9@M_AU^@6/43B55OL'Q#V10K5>SE`UH\.`<[Q,J6SL-B_U52F)A% M4+OWK:^V4+]!"(T=VD>(E_D`F18,DDU%/M:@5>Z'JEOM!%!9);=Q&R#\WCUE M+*:QT@/=G?[1QW>"0\FI42]=B*?X*[,W.P;Y``32\3SU73O=>F7H68;7++Y8=3E73&]._[B]]Q<&LE"G? MG@R!Z<[APK&@78QOY'21T*UR1M>Y%LJQK5-KW)P2B^WP@VIVW@'K4%8("GHZ MCD?)K&\'.YFTRDBYI[Y?(:;^A=?S:[=G508RM*^^/$:*H^3B&:$(-:G')06@ M2>S"+O[9&,L$`K=038`C5ZX7^^W120M%\[!,!7KIJ!O!ST]XR%0%DZ8']^P$ MY849"2,GA-2?HNCPMON%T]EL1L+%$)@Y?GJI8+2P'-,C>1/('9-1A.D10Y:! M59+6@S86;[W1:$03&<:+X2+JED#>])T-9?>"AU["=C0:G>)#!1>46/%U6=3G M8L5_(,,KJ.5^8NRVK!\3O:]@Q911JNFXCYZ&R*XM3?NRB)M\P+%&^`%-=D`# M+`DBD!\!F<>SZ83S9)(Y^JWHDM86+9-;H4/JF1V.XN%D%J7`)=N<&20=XLL@ MW./%:-CS`J28!+I:`!=^8_/?\30!J5TIHN923TB<3N8+_(G<@3TCL^\>$+$G MR0+I%SH,WP<,F9HD>%Z&!)LP'LNHG)9@!OC_UQW$G4S&\013@6"LLQ;/?RXP M,]%;:):J6W4*X6]UE,(-U?.3<'>S:U*!YA@^KY)ZD90:8Q!W[":[P#&0K]'( MMW<]+)J;=U=XB328?XLSB'=21?#;.2G&2.E"THHZS_$)%N@@='R^*M9[%B3$ MX(BJ,.MQOV&9&5VP0?#U03<<+F;>7S]2_%L>*"Z1=5><&!$+3T$Z3^W//8+Y M#\#I]_4!->^%-G[(L;.`B:P;8N.T93(UZJ,8R\6ZJ)JS5M]!IANL:T)17=?^ M4'WA\O#0GT9=Z],94F"]\%T!9%TO;^]%+G]%0-6)_)O*OR.?,%I+C-AT!(R\ ML\;YE!,2K75[B@298V1,_3/>!110B+4KAO%D-G(^80HU__=2N?:Y2+)UT--) MG,`UBP]9'R]-+N\VP\.:CHE!TV/FXP\T!MDAU>33GMZ@?;C?)YSF;7UN]9?` M)-*Q/&A]5M=.UVWS%.V,C'%%WR_)(4Q%:E2`&!Z:R7!.S9E/]B5S5"/324(O MJG]Y\UO4>!)-QR-*A'?V:)C&C(G/#'='F:HG$+FS:?_%6S%X!'-)MZ0S1?^)S#(D?+M]MIRC(* M"*=>MC@4$MDF1.)^4Q>V-M,*.WU@XX1K=5O=E=',L;_2E"X@JJ<$+A!62@@P,LA*UQ"+UTW; M3?,O\]%0B*JM5SR:IJ9`#NG$IQ'U[>'-[G^_8[._U;4ISDWF0XY2^I;"*@]L M'!9E&X&>2\63D`I.A6G2UT!C1Q'3)"&+*HAM..8):O#3AU+08AH/025+HU-" M7*&_A\FA5BCL61J)5';P1)7@F@SC\7C$7)K\&?#%:#(\0)6S*0*PX*&C93E- MDX26!+^?CV>?0Y6C^2Q.TT6K:?XE&4Y;S'BYW&_VK).K>-O-%M0(T`91$SA% M^\N9JDC5=3MTL714W(V;.[/Z$G'$[6M-?8GYY>K>0EKWN;RZ0"_5!4H&;GMU1CG.:%1DE.8`WLBC M=XHU*B?T*OL_@;V/B.XGL'R?32W'$(DF#_W*KT`D;.Q+>:9\[Z3*ECE$MO8Y M-)(2\:4(OP*W-")+?4$2&:=D1N5_'DL>J1R/E-VU[-I&G_>LET+XWEFP*,QW M=CPE;"X@FVGB<[/O\A4E#1WCUJ4;^P5&0ZFW7I88LQ6,6CG")512AKN34N.+ MR#:NR_5A16*58^@/[5+6M**W>@J'=LDO+;+VR/?YOJYP:8=3C;3F![&.$ZT M;-VA;G>=D_^TI6.9X:BE,Z?*>SLTXX`1X1DP[X_D4&JB-[J(XF-O8 M6>7>CY`*[.>!7+&"=E^3`N>4:XP[?5@><3W[;LOL3L=R-N20G`J`WP0$QC]5 M]<_G17E.&$NP\J,Q>0;AQD;N^P)+N<.L*)8<@P''('"!6#@:ZZB:\2).%@1[ M.D0;;6M1K!#W2SO$_;F")^U:S8<4M/_/BYT[%,+O>+0/^/E^0Q?;@87=]5=\ M'RU`A429.IW&Z8(K:4]`R"*PVWD\'HX>5`<>6X%7$G:50P,I-#X!J7Z4A(O" M@^`_FE-A^%$$_<*[T,((?4A-98&]C6"1RJ23*()N.060:DEV!`BBQ8#CFC$CB.R46K3`1&Z5Q<@GK M]M(D'HY&"+8UA$5!DU6ZB,:C>`XWQ&^P0*U$+KMNS>&,&JD_;F6H5_5USFG6 MC_>M?N55D_N\<<2M,ZBC.^]RA*C(5^<98B??Z#P0@A)0F2#9SK"?QJ0Y:J1Q M&67/W>(LZG,UYC_YG7NL!?\4P^B'?@X"5P8041*E@]'P0;P"7QW&,_0$#&:C M,'LX(=8PB8:#<5OM(IRFUPP*W=JVUA==#W;O[ZF.23EK/67]=)+, M!XO1W__V/T_2X6`XA#,\QSTGZPW^0E^HS_1,@@^/Z>$T'B\6T6@P9V_P`%BR MBO:&OY`[C-4+4WEA`LU,!W-D;./Y()VA;8C"Q,>+`6B(]!R],.?AQ)/I+)H/ MB"?.)H,%W#L3^CP>H.U@KAY/AO+\8I3"\Y0SL!AB!U.:P'PV2&`\]!B_(/.- M9W`_+@8CB@(?+@8IW%51 M4&$+)EE'Y!Y7.B!T(O]1?^`?%8O,%^TXKD[P_W\0TS^*682*6?AT$:AM\3#2 M^4?U@/_NU0,>B'3T#&N)K@,&C7P[T*LJB#3^,Z]U%0]3F5<>;2DG'[1"4>-5ZX+'8;"_Z@#TL^06D#!:\UD/$B&OWM4-[>@.A[?#ZA:[7ZL M2#"K&Y,_5;0Z[>MB.IBVN_BFJ"X^8586?&B6A"A"6&XMHY*7C>K__@KT:[Q[ MN'P!1F3I?"]SG^VWP(7:7%5@*L4T$#,")YJ"$/Q3057`Y59(=B\E=1K5VV^/ M0]/:W@5)4CM=Y?SI[#/RU=H[I5]T,I'C;FWM+6*VE-%[6?0XM.IOB6$3W!'& MVI"M1,I-Q8Q$:H!)!=^W[)9;Y>J#)?+S"41*-!UMF6H/U<>,;^&Q%C:P-" MO9'$:!JV?57><&$[NU=B$EZ('WR&$90]S#"6`>9H>`W!^"UO$;1((1PK\"/& MWU@C#Y?B"E7-E00TQ#8#CH+J\-._GL^'"X1N@D_3:4+34IV<1;]TL4,!1&@+ M.\7F"D%6:4QU&.?BPP,IFO6A-KN7']JR(>-,P[H]+[,E4,9M<540!O\OT3%, MR247"ZNV!3Q?YS<8#8=UN$TT0V"S!#ZYE=+H#8\@F,KH\OK(@3Y_G5UZ[U^^ M^.Q)/G!2<72SKJXH287S.!T[NC3-IUE5E@YBV"1?LWPI%F>BK7:?9\:;/G`"P&.1Z.!,9@ MS;2[TR^;X=]BH8]-KP]FA7Z^[-2/D1%Z^H%`&9VBX)>3_SHP`>X1P:J@-(!O M"/H/KJNZ)0F&4K>M`\#)V.J?7AN&[6%K\7T8D$YG=LNRL0N:;)"7;D)V>VB] MS5JY%[G3K)?GG:MF32(WWF0\Q=:6/R:S^>@,YB/-0T>FVP8E2&*QYJ$`=Q)$ MXBLTK+6:"":&'GK*.D('^@.^W=P\6Z;[S@<_:Y[IEYAG^AGS'!W]X&?-<_0EYCDZ M8IX'XYE_.2;>\Y?H`%\YW,9O-+#N@_EK=]@Z(;]VARU296/UQ9?. M?,G&.UR+7Z;QCI7N#?[_DNO_*W1T:%=^S2X[]NK7[/*8'>Q.7?G5]O)+=_F@ M7?W5.C]F?W^USEL[_2!M"IKI#S0XNMH;_*^=N^&G3!Y_BM-EN M#28L^W?B'`1E^3"D0H\#*BBJ&'GH&!D7P<.H]T+YJF+IAHQ4H[Q^R3\?'.#@I9>2Y"W.:Q^1G!P[C M9R1F=\G'!U+DV\:*Q^(K]+3T&+@%OSF=P_U@,FGUY:9XX^%7N8BXY9:II=O$ M:3UTWF'28+$M[(")&=H^@*SNO_SGNK.\9D[O7^Y1)Y6M9?ZW,ON/F M:IN8NR=\2+GQGW_F)%O?"OE8::6_'*9"5'=]/(!V/WHB?;$=K]LX```-KS`%^K;3N<\C[IR01_.C9ST3?]'+WLS8,6UTC?; M(];XLA<&"U*#RCY\J(D32]HZRW;P5WLL*Q!PL<[A^2N*$&X/KN^P?"D)NCTL MG1C;6<[)K[S4,[5UQ]1^Z0)9[IS`,3Y=RU]5E-L]EH0*1T^U!+%9*`KL5YG' ML1LQ&TS:(WI5E3?G%#WUQBH]?A[IL/]7'%[>Y?2(H^O=__O_X%<_H+,Z(&(E M:2])VW&(";9%\>Q7^V(="BEY*X6&82W6F80,/`>]AB75XOVNFG*1& MY=TYHLA_M3M:!JM@4(PWN7;9OX-Q\M2`J75MS"\4)U^5\F?;GQT>81?ID`/K M%3JP`NROCZ.UG/!_W*^[V=W[O,3X+A*&$65=]=HF,-"I#)Y0+Y&\R):Y#1JD M7'$!MB]E`8`\8B[71-7T))"R??324*BF]AP7=GO=/&4::N;',M,6!_1*]>?O/F75O_ M0_-.LZ7ZGS!Z7?>V?T4F@V%[10(A,<<2RX7>>ZDJ3&5L5'09C`L//TI<]R02 M9>LU_6!BR%!U!)JN\/PSX4ZUSK[!\F>!52,*-1)6;/6H0S3B0)*R%)MU"A@R M&>GQ%`B`Q+%?B*[6R3+2<(#=8>2)QT7==$7^'\K;;[EX/Q>M(&QT>F3N_4-G MTT:):`VG]]=P@KF87)[KI/@7W]Q2M4&XMP_+(>&E^])&$P7."__T`)*STR168B)"7H)MOO M;JLZ9!TX^E!%Z=E1(3QVYL1)]+6\$R[(0`$YH<[MU`F@2_NYM\*,+I`*6RNO M\N6W-<6<8B-Q,&7?"MWM&MQ6T4ASK?9`7ESBE=?D]1+==]D<4SGX;3 M-$Q@GS&PW'V70LI);[:"F5H#Z^_0AC[X_'6U6OM2P_=`"_K'$P<2;/;-ZNC5 MB4.9,_T-*,8R5OL^#6Z[!Z?@_SR25A8'J,<#66C)=7XS'8S4@U[P?YX?2`_L&@-J&.5?0"'KH86!T8DX0!'Q05WZ:MV\EQ+Z;"EE]:/ MEBK;KGR)X$!(G=^]_`DK9>U(&=.1YKI(X_L=2,"ML'8V`Y,9)5^)E-E(@RK. MM,9CVTA^.#$&>NS;=?:I>K\I=K??(^)1>\Q2?DA59]5AJRK%JC/0FQ<;]$:3 M9\O>E[:V1#Z9#UP*[,$2HR/F8)4D*8G=9G):Y($)B?H+#>^[WLB+*`M(Y`SM'S::SE!&_94C[+N-&6M9$< M2*WLR5GJ2-5QUY$%0':NF;1_*9B.3/P:;YH&E$S@[9(58:G7T1Z?.J=J4AOT M\^UNVZK<9!C2#8W()BO,I:M3F&!>"H/^R.*:>G7GGZZ;9_>'_`U!+`0(4`Q0````(`%># M7D7!E M&UL4$L!`A0#%`````@`5X->1TAU!>[%````*P(```L````````````` M`(`!*0(``%]R96QS+RYR96QS4$L!`A0#%`````@`5X->1WW\E?;Y`0``DB$` M`!H``````````````(`!%P,``'AL+U]R96QS+W=O1]K(E(Q&`P``P`T``!```````````````(`!2`4` M`&1O8U!R;W!S+V%P<"YX;6Q02P$"%`,4````"`!7@UY'&&&>G3X!``!I`P`` M$0``````````````@`&\"```9&]C4')O<',O8V]R92YX;6Q02P$"%`,4```` M"`!7@UY'F5R<(Q`&``"<)P``$P``````````````@`$I"@``>&PO=&AE;64O M=&AE;64Q+GAM;%!+`0(4`Q0````(`%>#7D>3@J;$;@(``$(,```-```````` M``````"``6H0``!X;"]S='EL97,N>&UL4$L!`A0#%`````@`5X->1^;)5B&8 M!```N1$```\``````````````(`!`Q,``'AL+W=O#7D&PO=V]R:W-H965T&UL M4$L!`A0#%`````@`5X->1R(P6:GK`0``8`4``!@``````````````(`!9"`` M`'AL+W=O#7D>&]J\I M^P(``*$+```8``````````````"``84B``!X;"]W;W)K&PO=V]R:W-H965T&UL4$L!`A0#%`````@`5X-> M1_C1S8@L`@``FP<``!@``````````````(`!`BL``'AL+W=O#7D?N^&,Y)@0``.@3```8```````` M``````"``60M``!X;"]W;W)K&PO=V]R:W-H M965T&UL4$L!`A0#%`````@`5X->1^573M"@`0``L0,``!@` M`````````````(`!)C<``'AL+W=O#7D=.[X`#H`$``+$#```9``````````````"``?PX``!X;"]W M;W)K&UL4$L!`A0#%`````@`5X->1XS<([&@`0`` ML0,``!D``````````````(`!TSH``'AL+W=O&PO=V]R:W-H965T#7D?% MBS=SGP$``+$#```9``````````````"``8$^``!X;"]W;W)K&UL4$L!`A0#%`````@`5X->1T-8)$>A`0``L0,``!D````````` M`````(`!5T```'AL+W=O&PO=V]R:W-H M965T#7D?])RE_GP$``+$#```9 M``````````````"``0=$``!X;"]W;W)K&UL4$L! M`A0#%`````@`5X->1YX"J6JA`0``KP,``!D``````````````(`!W44``'AL M+W=O&PO=V]R:W-H965T#7D='9^ZAH`$``+$#```9``````````````"` M`8U)``!X;"]W;W)K&UL4$L!`A0#%`````@`5X-> M1T6_$0"@`0``L0,``!D``````````````(`!9$L``'AL+W=O&PO=V]R:W-H965T#7D>R#%H1H0$``+$#```9``````````````"``1)/``!X;"]W;W)K M&UL4$L!`A0#%`````@`5X->1\5YSDJ?`0``L0,` M`!D``````````````(`!ZE```'AL+W=O&PO=V]R:W-H965T#7D='@`4) MO@$``'L$```9``````````````"``9=4``!X;"]W;W)K&UL4$L!`A0#%`````@`5X->1WHC3/&C`0``L0,``!D````````````` M`(`!C%8``'AL+W=O&PO=V]R:W-H965T M#7D>7)$Y&HP$``+$#```9```` M``````````"``7-:``!X;"]W;W)K&UL4$L!`A0# M%`````@`5X->1]00!PB>`0``L0,``!D``````````````(`!35P``'AL+W=O M&PO=V]R:W-H965T#7D?3!(-FI`$``+$#```9``````````````"``?I? M``!X;"]W;W)K&UL4$L!`A0#%`````@`5X->1^5W M^/&]`0``>P0``!D``````````````(`!U6$``'AL+W=O>)>J,!``"Q`P``&0`````````` M````@`')8P``>&PO=V]R:W-H965T#7D>7$KYWO@$``'L$```9``````````````"``:-E``!X;"]W;W)K&UL4$L!`A0#%`````@`5X->1W_S++SG`0``Q@4``!D` M`````````````(`!F&<``'AL+W=O&PO M=V]R:W-H965T#7D=1,4[.70,` M`*4/```9``````````````"``9-K``!X;"]W;W)K&UL4$L!`A0#%`````@`5X->1]LPNVDI!0``Y1T``!D``````````````(`! M)V\``'AL+W=O&PO=V]R:W-H965T#7D>BG8QL*0(```L'```9```````` M``````"``?MZ``!X;"]W;W)K&UL4$L!`A0#%``` M``@`5X->1S0>@_FS!0``*B<``!D``````````````(`!6WT``'AL+W=O&PO=V]R:W-H965T#7D==BT(HR`,``)L2```9``````````````"``3J(``!X M;"]W;W)K&UL4$L!`A0#%`````@`5X->1^(IMR>% M`P``C!$``!D``````````````(`!.8P``'AL+W=O&PO=V]R:W-H965T# M7D&UL4$L!`A0#%`````@`5X->1_V#(IA2`@``P0<``!D````` M`````````(`!#I4``'AL+W=O&PO=V]R M:W-H965T#7D>SY]B1X0,``#,2 M```9``````````````"``4Z:``!X;"]W;W)K&UL M4$L!`A0#%`````@`5X->1S6-!N0:!0``+AT``!D``````````````(`!9IX` M`'AL+W=O&PO=V]R:W-H965T#7D>5>E5^.P(``/0'```9```````````` M``"``?BE``!X;"]W;W)K&UL4$L!`A0#%`````@` M5X->1^T$,?5C`@``70@``!D``````````````(`!:J@``'AL+W=O&PO=V]R:W-H965T#7D?8I_MAB0$``#L#```9``````````````"``3>O``!X;"]W M;W)K&UL4$L!`A0#%`````@`5X->1ZZ>=X2Z:P`` M&;\!`!0``````````````(`!][```'AL+W-H87)E9%-T&UL4$L% 3!@````!``$`` XML 16 R55.htm IDEA: XBRL DOCUMENT v3.3.0.814
Commitments and Contingencies (Details)
$ in Millions
Sep. 30, 2015
USD ($)
Commitments and Contingencies Disclosure [Abstract]  
Restricted cash and cash equivalents $ 21.9
XML 17 R46.htm IDEA: XBRL DOCUMENT v3.3.0.814
Intangible Assets and Goodwill (Details) - USD ($)
$ in Thousands
 1 Months Ended
Oct. 31, 2014
Sep. 30, 2015
Jun. 04, 2015
Dec. 31, 2014
Indefinite-Lived Intangible Assets [Line Items]        
Intangible assets   $ 284,340   $ 29,000
Goodwill   50,384   39,915
Parion Sciences, Inc        
Indefinite-Lived Intangible Assets [Line Items]        
Intangible assets     $ 255,340  
Goodwill     $ 10,468  
Variable Interest Entity, Primary Beneficiary        
Indefinite-Lived Intangible Assets [Line Items]        
Intangible assets   284,340   29,000
Goodwill   $ 19,391   $ 8,923
Variable Interest Entity, Primary Beneficiary | BioAxone Biosciences Inc        
Indefinite-Lived Intangible Assets [Line Items]        
In-process research and development intangible asset $ 29,000      
Indefinite-lived Intangible Assets | Variable Interest Entity, Primary Beneficiary | Parion Sciences, Inc        
Indefinite-Lived Intangible Assets [Line Items]        
Fair value inputs, discount rate (percent) 7.10%      
Indefinite-lived Intangible Assets | Variable Interest Entity, Primary Beneficiary | BioAxone Biosciences Inc        
Indefinite-Lived Intangible Assets [Line Items]        
Fair value inputs, discount rate (percent) 7.50%      
XML 18 R33.htm IDEA: XBRL DOCUMENT v3.3.0.814
Inventories (Tables)
 9 Months Ended
Sep. 30, 2015
Inventory Disclosure [Abstract]  
Schedule of Inventories by Type
Inventories consisted of the following:
 
As of September 30, 2015
 
As of December 31, 2014
 
(in thousands)
Raw materials
$
8,669

 
$
8,506

Work-in-process
34,115

 
20,508

Finished goods
6,413

 
1,834

Total
$
49,197

 
$
30,848
XML 19 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 20 R25.htm IDEA: XBRL DOCUMENT v3.3.0.814
Basis of Presentation and Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2015
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying condensed consolidated financial statements are unaudited and have been prepared by Vertex Pharmaceuticals Incorporated ("Vertex" or the "Company") in accordance with accounting principles generally accepted in the United States of America ("GAAP").
The condensed consolidated financial statements reflect the operations of (i) the Company, (ii) its wholly-owned subsidiaries and (iii) consolidated variable interest entities (VIEs). All material intercompany balances and transactions have been eliminated. The Company operates in one segment, pharmaceuticals.

Certain information and footnote disclosures normally included in the Company's annual financial statements have been condensed or omitted. These interim financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the financial position and results of operations for the interim periods ended September 30, 2015 and 2014.
The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full fiscal year. These interim financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2014, which are contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2014 that was filed with the Securities and Exchange Commission (the “SEC”) on February 13, 2015 (the "2014 Annual Report on Form 10-K").
Use of Estimates and Summary of Significant Accounting Policies
Use of Estimates and Summary of Significant Accounting Policies
The preparation of condensed consolidated financial statements in accordance with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the amounts of revenues and expenses during the reported periods. Significant estimates in these condensed consolidated financial statements have been made in connection with the calculation of revenues, inventories, research and development expenses, stock-based compensation expense, restructuring expense, the fair value of intangible assets, goodwill, noncontrolling interest, the consolidation of VIEs, leases, the fair value of cash flow hedges and the provision for or benefit from income taxes. The Company bases its estimates on historical experience and various other assumptions, including in certain circumstances future projections that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.
The Company's significant accounting policies are described in Note A, "Nature of Business and Accounting Policies," in the 2014 Annual Report on Form 10-K.
Recent Accounting Pronouncements
Recent Accounting Pronouncements
For a discussion of recent accounting pronouncements please refer to Note A, “Nature of Business and Accounting Policies—Recent Accounting Pronouncements,” in the 2014 Annual Report on Form 10-K. The Company did not adopt any new accounting pronouncements during the nine months ended September 30, 2015 that had a material effect on its condensed consolidated financial statements.
XML 21 R50.htm IDEA: XBRL DOCUMENT v3.3.0.814
Stock-based Compensation Expense (Details 2)
shares in Thousands
 9 Months Ended
Sep. 30, 2015
$ / shares
shares
Share-based Compensation Arrangement by Share-based Payment Award  
Exercise price range, options outstanding (in shares) | shares 12,025
Exercise price range, options outstanding, weighted-average remaining contractual life (in years) 7 years 3 months 22 days
Exercise price range, options outstanding, weighted-average exercise price (in dollars per share) $ 74.90
Exercise price range, options exercisable (in shares) | shares 5,438
Exercise price range, options exercisable, weighted-average exercise price (in dollars per share) $ 53.98
$18.93–$20.00  
Share-based Compensation Arrangement by Share-based Payment Award  
Exercise price, low end of range (usd per share) 18.93
Exercise price, high end of range (usd per share) $ 20.00
Exercise price range, options outstanding (in shares) | shares 138
Exercise price range, options outstanding, weighted-average remaining contractual life (in years) 2 years 4 months 6 days
Exercise price range, options outstanding, weighted-average exercise price (in dollars per share) $ 18.93
Exercise price range, options exercisable (in shares) | shares 138
Exercise price range, options exercisable, weighted-average exercise price (in dollars per share) $ 18.93
$20.01–$40.00  
Share-based Compensation Arrangement by Share-based Payment Award  
Exercise price, low end of range (usd per share) 20.01
Exercise price, high end of range (usd per share) $ 40
Exercise price range, options outstanding (in shares) | shares 2,499
Exercise price range, options outstanding, weighted-average remaining contractual life (in years) 3 years 9 months 22 days
Exercise price range, options outstanding, weighted-average exercise price (in dollars per share) $ 34.56
Exercise price range, options exercisable (in shares) | shares 2,284
Exercise price range, options exercisable, weighted-average exercise price (in dollars per share) $ 34.36
$40.01–$60.00  
Share-based Compensation Arrangement by Share-based Payment Award  
Exercise price, low end of range (usd per share) 40.01
Exercise price, high end of range (usd per share) $ 60
Exercise price range, options outstanding (in shares) | shares 2,593
Exercise price range, options outstanding, weighted-average remaining contractual life (in years) 6 years 9 months 18 days
Exercise price range, options outstanding, weighted-average exercise price (in dollars per share) $ 48.27
Exercise price range, options exercisable (in shares) | shares 1,458
Exercise price range, options exercisable, weighted-average exercise price (in dollars per share) $ 49.52
$60.01–$80.00  
Share-based Compensation Arrangement by Share-based Payment Award  
Exercise price, low end of range (usd per share) 60.01
Exercise price, high end of range (usd per share) $ 80
Exercise price range, options outstanding (in shares) | shares 1,567
Exercise price range, options outstanding, weighted-average remaining contractual life (in years) 8 years 3 months 22 days
Exercise price range, options outstanding, weighted-average exercise price (in dollars per share) $ 75.94
Exercise price range, options exercisable (in shares) | shares 551
Exercise price range, options exercisable, weighted-average exercise price (in dollars per share) $ 74.95
$80.01–$100.00  
Share-based Compensation Arrangement by Share-based Payment Award  
Exercise price, low end of range (usd per share) 80.01
Exercise price, high end of range (usd per share) $ 100
Exercise price range, options outstanding (in shares) | shares 1,932
Exercise price range, options outstanding, weighted-average remaining contractual life (in years) 8 years 3 months 11 days
Exercise price range, options outstanding, weighted-average exercise price (in dollars per share) $ 90.27
Exercise price range, options exercisable (in shares) | shares 638
Exercise price range, options exercisable, weighted-average exercise price (in dollars per share) $ 87.16
$100.01–$120.00  
Share-based Compensation Arrangement by Share-based Payment Award  
Exercise price, low end of range (usd per share) 100.01
Exercise price, high end of range (usd per share) $ 120
Exercise price range, options outstanding (in shares) | shares 1,791
Exercise price range, options outstanding, weighted-average remaining contractual life (in years) 9 years 3 months 26 days
Exercise price range, options outstanding, weighted-average exercise price (in dollars per share) $ 109.24
Exercise price range, options exercisable (in shares) | shares 201
Exercise price range, options exercisable, weighted-average exercise price (in dollars per share) $ 109.22
$120.01–$134.69  
Share-based Compensation Arrangement by Share-based Payment Award  
Exercise price, low end of range (usd per share) 120.01
Exercise price, high end of range (usd per share) $ 134.69
Exercise price range, options outstanding (in shares) | shares 1,505
Exercise price range, options outstanding, weighted-average remaining contractual life (in years) 9 years 9 months 11 days
Exercise price range, options outstanding, weighted-average exercise price (in dollars per share) $ 131.21
Exercise price range, options exercisable (in shares) | shares 168
Exercise price range, options exercisable, weighted-average exercise price (in dollars per share) $ 127.52
XML 22 R42.htm IDEA: XBRL DOCUMENT v3.3.0.814
Marketable Securities (Details) - USD ($)
$ in Thousands
Sep. 30, 2015
Dec. 31, 2014
Summary of cash, cash equivalents and marketable securities    
Amortized Cost $ 1,005,767 $ 1,387,229
Gross Unrealized Gains 142 88
Gross Unrealized Losses (79) (211)
Fair Value 1,005,830 1,387,106
Total cash and cash equivalents    
Summary of cash, cash equivalents and marketable securities    
Amortized Cost 756,250 625,259
Gross Unrealized Gains 0 0
Gross Unrealized Losses 0 0
Fair Value 756,250 625,259
Cash and money market funds    
Summary of cash, cash equivalents and marketable securities    
Amortized Cost 707,141 625,259
Gross Unrealized Gains 0 0
Gross Unrealized Losses 0 0
Fair Value 707,141 625,259
Commercial paper    
Summary of cash, cash equivalents and marketable securities    
Amortized Cost 25,109 51,674
Gross Unrealized Gains 0 72
Gross Unrealized Losses 0 0
Fair Value 25,109 51,746
Corporate Debt Securities    
Summary of cash, cash equivalents and marketable securities    
Amortized Cost 24,000  
Gross Unrealized Gains 0  
Gross Unrealized Losses 0  
Fair Value 24,000  
Total marketable securities    
Summary of cash, cash equivalents and marketable securities    
Amortized Cost 249,517 761,970
Gross Unrealized Gains 142 88
Gross Unrealized Losses (79) (211)
Fair Value 249,580 761,847
Government-sponsored enterprise securities (due within 1 year)    
Summary of cash, cash equivalents and marketable securities    
Amortized Cost   463,788
Gross Unrealized Gains   14
Gross Unrealized Losses   (52)
Fair Value   463,750
Commercial paper (due within 1 year)    
Summary of cash, cash equivalents and marketable securities    
Amortized Cost 140,131  
Gross Unrealized Gains 114  
Gross Unrealized Losses 0  
Fair Value 140,245  
Corporate debt securities (due within 1 year)    
Summary of cash, cash equivalents and marketable securities    
Amortized Cost 109,386 196,065
Gross Unrealized Gains 28 2
Gross Unrealized Losses (79) (66)
Fair Value $ 109,335 196,001
Corporate debt securities (due after 1 year through 5 years)    
Summary of cash, cash equivalents and marketable securities    
Amortized Cost   50,443
Gross Unrealized Gains   0
Gross Unrealized Losses   (93)
Fair Value   $ 50,350
XML 23 R37.htm IDEA: XBRL DOCUMENT v3.3.0.814
Product Revenues, Net (Details)
$ in Thousands
 9 Months Ended
Sep. 30, 2015
USD ($)
Product Revenue Allowance and Reserve [Roll Forward]  
Balance at December 31, 2014 $ 36,023
Provision related to current period sales 48,484
Adjustments related to prior period sales (13,713)
Credits/payments made (32,486)
Balance at September 30, 2015 38,308
Trade Allowances  
Product Revenue Allowance and Reserve [Roll Forward]  
Balance at December 31, 2014 1,463
Provision related to current period sales 6,120
Adjustments related to prior period sales (143)
Credits/payments made (5,115)
Balance at September 30, 2015 2,325
Rebates, Chargebacks and Discounts  
Product Revenue Allowance and Reserve [Roll Forward]  
Balance at December 31, 2014 29,102
Provision related to current period sales 39,533
Adjustments related to prior period sales (12,342)
Credits/payments made (22,465)
Balance at September 30, 2015 33,828
Product Returns  
Product Revenue Allowance and Reserve [Roll Forward]  
Balance at December 31, 2014 4,713
Provision related to current period sales 429
Adjustments related to prior period sales (993)
Credits/payments made (3,254)
Balance at September 30, 2015 895
Other Incentives  
Product Revenue Allowance and Reserve [Roll Forward]  
Balance at December 31, 2014 745
Provision related to current period sales 2,402
Adjustments related to prior period sales (235)
Credits/payments made (1,652)
Balance at September 30, 2015 $ 1,260
XML 24 R52.htm IDEA: XBRL DOCUMENT v3.3.0.814
Income Taxes (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Jun. 04, 2015
Sep. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
Dec. 31, 2014
Schedule of Collaborative Arrangement Agreements [Line Items]            
Provision for income taxes   $ 1,330 $ 3,419 $ 31,760 $ 4,915  
Unrecognized tax benefits   900   900   $ 900
Estimated reduction in unrecognized tax benefits in next fiscal year   500   500    
Parion Sciences, Inc            
Schedule of Collaborative Arrangement Agreements [Line Items]            
Provision for income taxes   $ 800   $ 30,400    
Up-front payment $ 80,000          
XML 25 R47.htm IDEA: XBRL DOCUMENT v3.3.0.814
Long-term Obligations - Fan Pier Leases (Details)
$ in Thousands, ft² in Millions
 12 Months Ended
Dec. 31, 2011
ft²
lease
building
Sep. 30, 2015
USD ($)
Dec. 31, 2014
USD ($)
Property, Plant and Equipment [Line Items]      
Number of leases | lease 2    
Area of real estate property (in square feet) | ft² 1.1    
Number of buildings under lease agreement | building 2    
Optional term of lease agreement (in years) 10 years    
Property and equipment, net   $ 706,670 $ 715,812
Construction financing lease obligation, current and noncurrent   473,100 473,400
Building      
Property, Plant and Equipment [Line Items]      
Property and equipment, net   $ 505,600 $ 515,000
XML 26 R9.htm IDEA: XBRL DOCUMENT v3.3.0.814
Basis of Presentation and Accounting Policies
 9 Months Ended
Sep. 30, 2015
Accounting Policies [Abstract]  
Basis of Presentation and Accounting Policies
Basis of Presentation and Accounting Policies
Basis of Presentation
The accompanying condensed consolidated financial statements are unaudited and have been prepared by Vertex Pharmaceuticals Incorporated ("Vertex" or the "Company") in accordance with accounting principles generally accepted in the United States of America ("GAAP").
The condensed consolidated financial statements reflect the operations of (i) the Company, (ii) its wholly-owned subsidiaries and (iii) consolidated variable interest entities (VIEs). All material intercompany balances and transactions have been eliminated. The Company operates in one segment, pharmaceuticals.

Certain information and footnote disclosures normally included in the Company's annual financial statements have been condensed or omitted. These interim financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the financial position and results of operations for the interim periods ended September 30, 2015 and 2014.
The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full fiscal year. These interim financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2014, which are contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2014 that was filed with the Securities and Exchange Commission (the “SEC”) on February 13, 2015 (the "2014 Annual Report on Form 10-K").
Use of Estimates and Summary of Significant Accounting Policies
The preparation of condensed consolidated financial statements in accordance with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the amounts of revenues and expenses during the reported periods. Significant estimates in these condensed consolidated financial statements have been made in connection with the calculation of revenues, inventories, research and development expenses, stock-based compensation expense, restructuring expense, the fair value of intangible assets, goodwill, noncontrolling interest, the consolidation of VIEs, leases, the fair value of cash flow hedges and the provision for or benefit from income taxes. The Company bases its estimates on historical experience and various other assumptions, including in certain circumstances future projections that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.
The Company's significant accounting policies are described in Note A, "Nature of Business and Accounting Policies," in the 2014 Annual Report on Form 10-K.
Recent Accounting Pronouncements
For a discussion of recent accounting pronouncements please refer to Note A, “Nature of Business and Accounting Policies—Recent Accounting Pronouncements,” in the 2014 Annual Report on Form 10-K. The Company did not adopt any new accounting pronouncements during the nine months ended September 30, 2015 that had a material effect on its condensed consolidated financial statements.
XML 27 R43.htm IDEA: XBRL DOCUMENT v3.3.0.814
Accumulated Other Comprehensive (Loss) Income (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]        
Balance at balance sheet date     $ 917 $ (306)
Other comprehensive (loss) income before reclassifications     4,094 1,894
Amounts reclassified from accumulated other comprehensive loss     (3,500) (427)
Total changes in other comprehensive loss $ 3,218 $ 1,184 594 1,467
Balance at balance sheet date 1,511 1,161 1,511 1,161
Foreign Currency Translation Adjustment        
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]        
Balance at balance sheet date     (971) (325)
Other comprehensive (loss) income before reclassifications     (164) (271)
Amounts reclassified from accumulated other comprehensive loss     0 0
Total changes in other comprehensive loss     (164) (271)
Balance at balance sheet date (1,135) (596) (1,135) (596)
Unrealized Holding Gains (Losses) on Marketable Securities        
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]        
Balance at balance sheet date     (123) 42
Other comprehensive (loss) income before reclassifications     186 25
Amounts reclassified from accumulated other comprehensive loss     0 0
Total changes in other comprehensive loss     186 25
Balance at balance sheet date 63 67 63 67
Unrealized Gains (Losses) on Foreign Currency Forward Contracts        
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]        
Balance at balance sheet date     2,011 (23)
Other comprehensive (loss) income before reclassifications     4,072 2,140
Amounts reclassified from accumulated other comprehensive loss     (3,500) (427)
Total changes in other comprehensive loss     572 1,713
Balance at balance sheet date $ 2,583 $ 1,690 $ 2,583 $ 1,690
XML 28 R29.htm IDEA: XBRL DOCUMENT v3.3.0.814
Fair Value Measurements (Tables)
 9 Months Ended
Sep. 30, 2015
Fair Value Disclosures [Abstract]  
Financial assets subject to fair value measurements (excluding restricted cash and cash equivalents (Alios))
The following table sets forth the Company’s financial assets and liabilities subject to fair value measurements:
 
Fair Value Measurements as of September 30, 2015
 
 
 
Fair Value Hierarchy
 
Total
 
Level 1
 
Level 2
 
Level 3
 
(in thousands)
Financial assets carried at fair value:
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Money market funds
$
340,573

 
$
340,573

 
$
—

 
$
—

Corporate debt securities
25,109

 
—

 
25,109

 
—

Commercial paper
24,000

 
—

 
24,000

 
—

Marketable securities:
 
 
 
 
 
 
 
Corporate debt securities
109,335

 
—

 
109,335

 
—

Commercial paper
140,245

 
—

 
140,245

 
—

Prepaid and other current assets:
 
 
 
 
 
 
 
Foreign currency forward contracts
3,508

 
—

 
3,508

 
—

Other assets:
 
 
 
 
 
 
 
Foreign currency forward contracts
651

 
—

 
651

 
—

Total financial assets
$
643,421


$
340,573

 
$
302,848

 
$
—

Financial liabilities carried at fair value:
 
 
 
 
 
 
 
Other liabilities, current portion:
 
 
 
 
 
 
 
Foreign currency forward contracts
$
(1,552
)
 
$
—

 
$
(1,552
)
 
$
—

Other liabilities, excluding current portion:
 
 
 
 
 
 
 
Foreign currency forward contracts
(24
)
 
—

 
(24
)
 
—

Total financial liabilities
$
(1,576
)
 
$
—

 
$
(1,576
)
 
$
—
XML 29 R28.htm IDEA: XBRL DOCUMENT v3.3.0.814
Earnings Per Share (Tables)
 9 Months Ended
Sep. 30, 2015
Earnings Per Share [Abstract]  
Potential gross common equivalent shares
The Company did not include the securities described in the following table in the computation of the net loss from continuing operations per share attributable to Vertex common shareholder calculations because the effect would have been anti-dilutive during each period:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2015
 
2014
 
2015
 
2014
 
(in thousands)
Stock options
12,025

 
13,097

 
12,025

 
13,097

Unvested restricted stock and restricted stock units
3,367

 
2,672

 
3,367

 
2,672
XML 30 R44.htm IDEA: XBRL DOCUMENT v3.3.0.814
Hedging (Details) - USD ($)
$ in Thousands
Sep. 30, 2015
Dec. 31, 2014
Foreign Currency Cash Flow Hedge Derivative at Fair Value [Abstract]    
Fair Value - assets   $ 2,011
Fair Value - liabilities   0
Offsetting Derivative Assets [Abstract]    
Gross Amounts Recognized $ 4,159 2,011
Gross Amounts Offset 0 0
Gross Amount Presented 4,159 2,011
Gross Amount Not Offset (1,576) 0
Legal Offset 2,583 2,011
Offsetting Derivative Liabilities [Abstract]    
Gross Amounts Recognized (1,576)  
Gross Amounts Offset 0  
Gross Amount Presented (1,576)  
Gross Amount Not Offset 1,576  
Legal Offset 0  
Prepaid and other current assets    
Foreign Currency Cash Flow Hedge Derivative at Fair Value [Abstract]    
Fair Value - assets 3,508 2,011
Other liabilities, current portion    
Foreign Currency Cash Flow Hedge Derivative at Fair Value [Abstract]    
Fair Value - liabilities (1,552) 0
Other assets    
Foreign Currency Cash Flow Hedge Derivative at Fair Value [Abstract]    
Fair Value - assets 651  
Other liabilities, excluding current portion    
Foreign Currency Cash Flow Hedge Derivative at Fair Value [Abstract]    
Fair Value - liabilities (24)  
Designated as hedging instrument | Foreign Currency Forward Contract | Cash Flow Hedging    
Derivative [Line Items]    
Notional amount of foreign currency forward contract 210,895 33,724
Designated as hedging instrument | Euro | Foreign Currency Forward Contract | Cash Flow Hedging    
Derivative [Line Items]    
Notional amount of foreign currency forward contract 106,620 20,209
Designated as hedging instrument | British pound sterling | Foreign Currency Forward Contract | Cash Flow Hedging    
Derivative [Line Items]    
Notional amount of foreign currency forward contract 78,861 13,515
Designated as hedging instrument | Australian dollar | Foreign Currency Forward Contract | Cash Flow Hedging    
Derivative [Line Items]    
Notional amount of foreign currency forward contract $ 25,414 $ 0
XML 31 R30.htm IDEA: XBRL DOCUMENT v3.3.0.814
Marketable Securities (Tables)
 9 Months Ended
Sep. 30, 2015
Cash and Cash Equivalents [Abstract]  
Summary of cash, cash equivalents and marketable securities
A summary of the Company’s cash, cash equivalents and marketable securities is shown below:
 
Amortized Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Fair Value
 
(in thousands)
As of September 30, 2015
 
 
 
 
 
 
 
Cash and cash equivalents:
 
 
 
 
 
 
 
Cash and money market funds
$
707,141

 
$
—

 
$
—

 
$
707,141

Commercial paper
$
25,109

 
$
—

 
$
—

 
$
25,109

Corporate debt securities
$
24,000

 
$
—

 
$
—

 
$
24,000

Total cash and cash equivalents
$
756,250

 
$
—

 
$
—

 
$
756,250

Marketable securities:
 
 
 
 
 
 
 
Commercial paper (due within 1 year)
$
140,131

 
$
114

 
$
—

 
$
140,245

Corporate debt securities (due within 1 year)
109,386

 
28

 
(79
)
 
109,335

Total marketable securities
$
249,517

 
$
142

 
$
(79
)
 
$
249,580

Total cash, cash equivalents and marketable securities
$
1,005,767

 
$
142

 
$
(79
)
 
$
1,005,830

 
 
 
 
 
 
 
 
As of December 31, 2014
 
 
 
 
 
 
 
Cash and cash equivalents:
 
 
 
 
 
 
 
Cash and money market funds
$
625,259

 
$
—

 
$
—

 
$
625,259

Total cash and cash equivalents
$
625,259

 
$
—

 
$
—

 
$
625,259

Marketable securities:
 
 
 
 
 
 
 
Government-sponsored enterprise securities (due within 1 year)
$
463,788

 
$
14

 
$
(52
)
 
$
463,750

Commercial paper (due within 1 year)
51,674

 
72

 
—

 
51,746

Corporate debt securities (due within 1 year)
196,065

 
2

 
(66
)
 
196,001

Corporate debt securities (due after 1 year through 5 years)
50,443

 
—

 
(93
)
 
50,350

Total marketable securities
$
761,970

 
$
88

 
$
(211
)
 
$
761,847

Total cash, cash equivalents and marketable securities
$
1,387,229

 
$
88

 
$
(211
)
 
$
1,387,106
XML 32 R31.htm IDEA: XBRL DOCUMENT v3.3.0.814
Accumulated Other Comprehensive (Loss) Income (Tables)
 9 Months Ended
Sep. 30, 2015
Equity [Abstract]  
Accumulated Other Comprehensive (Loss) Income
A summary of the Company's changes in accumulated other comprehensive (loss) income by component is shown below:
 
Foreign Currency Translation Adjustment
 
Unrealized Holding Gains (Losses) on Marketable Securities
 
Unrealized Gains (Losses) on Foreign Currency Forward Contracts
 
Total
 
(in thousands)
Balance at December 31, 2014
$
(971
)
 
$
(123
)
 
$
2,011

 
$
917

Other comprehensive (loss) income before reclassifications
(164
)
 
186

 
4,072

 
4,094

Amounts reclassified from accumulated other comprehensive loss
—

 
—

 
(3,500
)
 
(3,500
)
Net current period other comprehensive (loss) income
$
(164
)
 
$
186

 
$
572

 
$
594

Balance at September 30, 2015
$
(1,135
)
 
$
63

 
$
2,583

 
$
1,511


 
Foreign Currency Translation Adjustment
 
Unrealized Holding Gains on Marketable Securities
 
Unrealized (Losses) Gains on Foreign Currency Forward Contracts
 
Total
 
(in thousands)
Balance at December 31, 2013
$
(325
)
 
$
42

 
$
(23
)
 
$
(306
)
Other comprehensive (loss) income before reclassifications
(271
)
 
25

 
2,140

 
1,894

Amounts reclassified from accumulated other comprehensive loss
—

 
—

 
(427
)
 
(427
)
Net current period other comprehensive (loss) income
$
(271
)
 
$
25

 
$
1,713

 
$
1,467

Balance at September 30, 2014
$
(596
)
 
$
67

 
$
1,690

 
$
1,161
XML 33 R8.htm IDEA: XBRL DOCUMENT v3.3.0.814
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Cash flows from operating activities:    
Net loss $ (513,512) $ (561,899)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization expense 46,596 46,921
Stock-based compensation expense 186,379 135,160
Deferred income taxes 7,793 0
Impairment of property and equipment 23 978
Other non-cash items, net (2,899) 7
Changes in operating assets and liabilities:    
Accounts receivable, net (88,735) (7,315)
Inventories (16,127) (4,901)
Prepaid expenses and other assets (23,737) (19,110)
Accounts payable 6,283 (5,544)
Accrued expenses and other liabilities 90,320 12,210
Accrued restructuring expense (28,051) 27,249
Deferred revenues (13,751) (15,085)
Net cash used in operating activities (349,418) (391,329)
Cash flows from investing activities:    
Purchases of marketable securities (292,135) (1,066,772)
Maturities of marketable securities 804,588 1,203,400
Payment for acquisition of variable interest entity (80,000) 0
Expenditures for property and equipment (32,775) (36,525)
(Increase) decrease in restricted cash and cash equivalents (21,980) 9
Decrease in restricted cash and cash equivalents (VIE) 14,830 0
Decrease (increase) in other assets (982) (92)
Net cash provided by investing activities 391,546 100,020
Cash flows from financing activities:    
Issuances of common stock under benefit plans 139,689 201,274
Payments on capital lease obligations (16,515) (17,215)
Proceeds from capital lease financing 13,386 0
Payments on Fan Pier lease obligation (45,438) (45,438)
Proceeds from senior secured term loan 0 294,383
Payments returned related to Fan Pier lease obligation 0 8,050
Net cash provided by financing activities 91,122 441,054
Effect of changes in exchange rates on cash (2,259) (481)
Net increase in cash and cash equivalents 130,991 149,264
Cash and cash equivalents—beginning of period 625,259 569,299
Cash and cash equivalents—end of period 756,250 718,563
Supplemental disclosure of cash flow information:    
Cash paid for interest 19,074 2,817
Cash paid for income taxes 1,261 798
Capitalization of costs related to Fan Pier lease obligation 0 25,564
Assets acquired under capital lease 0 8,985
Issuances of common stock exercises from employee benefit plans receivable $ (236) $ 23,035
XML 34 R32.htm IDEA: XBRL DOCUMENT v3.3.0.814
Hedging (Tables)
 9 Months Ended
Sep. 30, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Cash Flow Hedging Instruments
The following table summarizes the notional amount of the Company’s outstanding foreign currency forward contracts designated as cash flow hedges:
 
As of September 30, 2015
 
As of December 31, 2014
Foreign Currency
(in thousands)
Euro
$
106,620

 
$
20,209

British pound sterling
78,861

 
13,515

Australian dollar
25,414

 
—

Total foreign currency forward contracts
$
210,895

 
$
33,724
Schedule of Foreign Exchange Contracts
The following table summarizes the fair value of the Company's outstanding foreign currency forward contracts designated as cash flow hedges under GAAP included on the Company's condensed consolidated balance sheets:
As of September 30, 2015
Assets
 
Liabilities
Classification
 
Fair Value
 
Classification
 
Fair Value
(in thousands)
Prepaid and other current assets
 
$
3,508

 
Other liabilities, current portion
 
$
(1,552
)
Other assets
 
651

 
Other liabilities, excluding current portion
 
(24
)
Total assets
 
$
4,159

 
Total liabilities
 
$
(1,576
)
As of December 31, 2014
Assets
 
Liabilities
Classification
 
Fair Value
 
Classification
 
Fair Value
(in thousands)
Prepaid and other current assets
 
$
2,011

 
Other liabilities, current portion
 
$
—

Total assets
 
$
2,011

 
Total liabilities
 
$
—
Derivatives Offsetting
The following table summarizes the potential effect of offsetting derivatives by type of financial instrument on the Company's condensed consolidated balance sheets:
 
As of September 30, 2015
 
Gross Amounts Recognized
 
Gross Amounts Offset
 
Gross Amount Presented
 
Gross Amount Not Offset
 
Legal Offset
Foreign currency forward contracts
(in thousands)
Total assets
$
4,159

 
$
—

 
$
4,159

 
$
(1,576
)
 
$
2,583

Total liabilities
$
(1,576
)
 
$
—

 
$
(1,576
)
 
$
1,576

 
$
—

 
As of December 31, 2014
 
Gross Amounts Recognized
 
Gross Amounts Offset
 
Gross Amount Presented
 
Gross Amount Not Offset
 
Legal Offset
Foreign currency forward contracts
(in thousands)
Total assets
$
2,011

 
$
—

 
$
2,011

 
$
—

 
$
2,011
XML 35 R40.htm IDEA: XBRL DOCUMENT v3.3.0.814
Earnings Per Share (Details) - shares
shares in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
Stock options        
Antidilutive Securities Excluded from Computation of Earnings Per Share        
Antidilutive securities excluded from computation of earnings per share (in shares) 12,025 13,097 12,025 13,097
Unvested restricted stock and restricted stock units        
Antidilutive Securities Excluded from Computation of Earnings Per Share        
Antidilutive securities excluded from computation of earnings per share (in shares) 3,367 2,672 3,367 2,672
XML 36 R53.htm IDEA: XBRL DOCUMENT v3.3.0.814
Restructuring Liabilities (Details)
ft² in Thousands
 3 Months Ended 12 Months Ended
Mar. 31, 2015
ft²
lease
Sep. 30, 2014
facility
Dec. 31, 2003
Dec. 31, 2011
ft²
Restructuring Cost and Reserve [Line Items]        
Area of real estate property (in square feet)       1,100
Kendall Restructuring        
Restructuring Cost and Reserve [Line Items]        
Lease term (in years)     15 years  
Restructuring and related activities, leased office space, maximum percentage used - not more than     50.00%  
Fan Pier Move Restructuring        
Restructuring Cost and Reserve [Line Items]        
Number of facilities decommissioned | facility   3    
Number of leases terminated | lease 2      
Area of real estate property (in square feet) 120      
Discount rate related to leases (percent) 9.00%      
XML 37 R2.htm IDEA: XBRL DOCUMENT v3.3.0.814
Condensed Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
Revenues:        
Product revenues, net $ 302,511 $ 137,099 $ 593,774 $ 362,879
Royalty revenues 5,759 8,386 17,628 32,134
Collaborative revenues 1,546 33,502 2,999 40,846
Total revenues 309,816 178,987 614,401 435,859
Costs and expenses:        
Cost of product revenues 30,269 10,208 55,059 28,435
Royalty expenses 1,691 3,976 6,068 18,525
Research and development expenses 246,284 190,939 685,741 654,043
Sales, general and administrative expenses 99,772 75,224 280,026 226,882
Restructuring expenses, net 1,826 40,843 682 46,761
Total costs and expenses 379,842 321,190 1,027,576 974,646
Loss from operations (70,026) (142,203) (413,175) (538,787)
Interest expense, net (21,134) (20,384) (63,552) (51,686)
Other (expenses) income, net (1,326) (3,990) (5,025) 34,192
Loss from continuing operations before provision for income taxes (92,486) (166,577) (481,752) (556,281)
Provision for income taxes 1,330 3,419 31,760 4,915
Loss from continuing operations (93,816) (169,996) (513,512) (561,196)
Loss from discontinued operations, net of tax benefit of $0 0 (64) 0 (703)
Net loss (93,816) (170,060) (513,512) (561,899)
(Income) loss attributable to noncontrolling interest (1,333) 0 30,909 0
Net loss attributable to Vertex (95,149) (170,060) (482,603) (561,899)
Loss from continuing operations (95,149) (169,996) (482,603) (561,196)
Loss from discontinued operations $ 0 $ (64) $ 0 $ (703)
Net loss from continuing operations:        
Net loss per share from continuing operations, basic (usd per share) $ (0.39) $ (0.72) $ (2.00) $ (2.40)
Net loss per share from continuing operations, diluted (usd per share) (0.39) (0.72) (2.00) (2.40)
Net loss from discontinued operations:        
Net loss from discontinued operations, basic (usd per share) 0.00 0.00 0.00 0.00
Net loss from discontinued operations, diluted (usd per share) 0.00 0.00 0.00 0.00
Net loss:        
Basic (usd per share) (0.39) (0.72) (2.00) (2.40)
Diluted (usd per share) $ (0.39) $ (0.72) $ (2.00) $ (2.40)
Shares used in per share calculations:        
Basic (in shares) 241,969 236,137 240,749 234,207
Diluted (in shares) 241,969 236,137 240,749 234,207
XML 38 R45.htm IDEA: XBRL DOCUMENT v3.3.0.814
Inventories - Schedule of Inventories (Details) - USD ($)
$ in Thousands
Sep. 30, 2015
Dec. 31, 2014
Inventory Disclosure [Abstract]    
Raw materials $ 8,669 $ 8,506
Work-in-process 34,115 20,508
Finished goods 6,413 1,834
Total $ 49,197 $ 30,848
XML 39 R6.htm IDEA: XBRL DOCUMENT v3.3.0.814
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Sep. 30, 2015
Dec. 31, 2014
Statement of Financial Position [Abstract]    
Preferred stock, par value (usd per share) $ 0.01 $ 0.01
Preferred stock, shares authorized 1,000,000 1,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value (usd per share) $ 0.01 $ 0.01
Common stock, shares authorized 500,000,000 300,000,000
Common stock, shares issued 245,646,269 241,764,398
Common stock, shares outstanding 245,646,269 241,764,398
XML 40 R35.htm IDEA: XBRL DOCUMENT v3.3.0.814
Restructuring Liabilities (Tables)
 9 Months Ended
Sep. 30, 2015
Kendall Restructuring  
Restructuring Cost and Reserve [Line Items]  
Activity related to the restructuring liability
The activities related to the restructuring liability for the three and nine months ended September 30, 2015 and 2014 were as follows:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2015
 
2014
 
2015
 
2014
 
(in thousands)
Liability, beginning of the period
$
9,924

 
$
14,936

 
$
11,596

 
$
19,115

Cash payments
(3,975
)
 
(4,249
)
 
(10,544
)
 
(12,071
)
Cash received from subleases
2,919

 
2,689

 
8,194

 
8,067

Restructuring expense (income)
146

 
(464
)
 
(232
)
 
(2,199
)
Liability, end of the period
$
9,014

 
$
12,912

 
$
9,014

 
$
12,912
Fan Pier Move Restructuring  
Restructuring Cost and Reserve [Line Items]  
Activity related to the restructuring liability
The activities related to the restructuring liability for the three and nine months ended September 30, 2015 and 2014 were as follows:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2015
 
2014
 
2015
 
2014
 
(in thousands)
Liability, beginning of the period
$
9,017

 
$
3,256

 
$
33,390

 
$
797

Cash payments
(3,070
)
 
(2,266
)
 
(25,421
)
 
(6,643
)
Cash received from subleases
1,820

 
—

 
1,820

 
—

Restructuring expense (income)
51

 
39,752

 
(1,971
)
 
46,588

Liability, end of the period
$
7,818

 
$
40,742

 
$
7,818

 
$
40,742
Other Restructuring  
Restructuring Cost and Reserve [Line Items]  
Activity related to the restructuring liability
The activities related to the Company's other restructuring liabilities for the three and nine months ended September 30, 2015 and 2014 were as follows:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2015
 
2014
 
2015
 
2014
 
(in thousands)
Liability, beginning of the period
$
902

 
$
792

 
$
869

 
$
8,441

Cash payments
(1,559
)
 
(399
)
 
(2,782
)
 
(8,865
)
Restructuring expense
1,629

 
1,555

 
2,885

 
2,372

Liability, end of the period
$
972

 
$
1,948

 
$
972

 
$
1,948
XML 41 R22.htm IDEA: XBRL DOCUMENT v3.3.0.814
Income Taxes
 9 Months Ended
Sep. 30, 2015
Income Tax Disclosure [Abstract]  
Income Taxes
Income Taxes
The Company is subject to U.S. federal, state, and foreign income taxes. For the three and nine months ended September 30, 2015, the Company recorded a provision for income taxes of $1.3 million and $31.8 million, respectively. The provision for income taxes recorded in the three and nine months ended September 30, 2015 included $0.8 million and $30.4 million, respectively, related to the Company's VIE's income tax provision. The VIE's income tax provision for the nine months ended September 30, 2015 primarily related to the income tax effect on the $80.0 million up-front payment received by Parion from the Company in June 2015. The Company has no liability for taxes payable by Parion and the income tax provision and related liability have been allocated to noncontrolling interest (VIE). For the three and nine months ended September 30, 2014, the Company recorded a provision for income taxes of $3.4 million and $4.9 million, respectively, related to state income taxes and income earned in various foreign jurisdictions.
As of September 30, 2015 and December 31, 2014, the Company had unrecognized tax benefits of $0.9 million. The Company recognizes interest and penalties related to income taxes as a component of income tax expense. As of September 30, 2015, no interest and penalties have been accrued. The Company does not expect that its unrecognized tax benefits will materially increase within the next twelve months. The Company did not recognize any material interest or penalties related to uncertain tax positions as of September 30, 2015 and December 31, 2014. In 2015, it is reasonably possible that the Company will reduce the balance of its unrecognized tax benefits by approximately $0.5 million due to the application of statute of limitations and settlements with taxing authorities, all of which would reduce the Company’s effective tax rate.
The Company continues to maintain a valuation allowance against certain deferred tax assets where it is more likely than not that the deferred tax asset will not be realized because of its extended history of annual losses.
The Company files U.S. federal income tax returns and income tax returns in various state, local and foreign jurisdictions. The Company is no longer subject to any tax assessment from an income tax examination in the United States before 2011 or any other major taxing jurisdiction for years before 2009, except where the Company has net operating losses or tax credit carryforwards that originated before 2009. The Company currently is under examination by the Internal Revenue Service for the year ended December 31, 2011 and in Canada, Pennsylvania, Delaware, New York and Texas for varying periods including the years ended December 31, 2011 through 2013. No adjustments have been reported. The Company is not under examination by any other jurisdictions for any tax year. The Company concluded audits with Massachusetts and Revenue Quebec during 2015 and the Canada Revenue Agency and Revenue Quebec during 2014 with no material adjustments.
The Company currently intends to reinvest the total amount of its unremitted earnings. At September 30, 2015, foreign earnings, which were not significant, have been retained indefinitely by foreign subsidiary companies for reinvestment; therefore, no provision has been made for income taxes that would be payable upon the distribution of such earnings, and it would not be practicable to determine the amount of the related unrecognized deferred income tax liability. Upon repatriation of those earnings, in the form of dividends or otherwise, the Company would be subject to U.S. federal income taxes (subject to an adjustment for foreign tax credits) and withholding taxes payable to the various foreign countries.
XML 42 R36.htm IDEA: XBRL DOCUMENT v3.3.0.814
Basis of Presentation and Accounting Policies (Details)
 9 Months Ended
Sep. 30, 2015
segment
Accounting Policies [Abstract]  
Number of operating segments 1
XML 43 R24.htm IDEA: XBRL DOCUMENT v3.3.0.814
Commitments and Contingencies
 9 Months Ended
Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies
Commitments and Contingencies
Financing Arrangements
As of September 30, 2015, the Company had irrevocable stand-by letters of credit outstanding that were issued in connection with property leases and other similar agreements totaling $21.9 million that are cash collateralized. The cash used to support these letters of credit is included in restricted cash, as of September 30, 2015, on the Company's condensed consolidated balance sheet.
Litigation
On May 28, 2014, a purported shareholder class action Local No. 8 IBEW Retirement Plan & Trust v. Vertex Pharmaceuticals Incorporated, et al. was filed in the United States District Court for the District of Massachusetts, naming the Company and certain of the Company's current and former officers and directors as defendants. The lawsuit alleged that the Company made material misrepresentations and/or omissions of material fact in the Company's disclosures during the period from May 7, 2012 through May 29, 2012, all in violation of Section 10(b) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder. The purported class consists of all persons (excluding defendants) who purchased the Company’s common stock between May 7, 2012 and May 29, 2012. The plaintiffs seek unspecified monetary damages, costs and attorneys’ fees as well as disgorgement of the proceeds from certain individual defendants’ sales of the Company’s stock. On October 8, 2014, the Court approved Local No. 8 IBEW Retirement Fund as lead plaintiff, and Scott and Scott LLP as lead counsel for the plaintiff and the putative class. On February 23, 2015, the Company filed a reply to the plaintiffs’ opposition to its motion to dismiss.  The court heard oral argument on the motion to dismiss on March 6, 2015 and took the motion under advisement. On September 30, 2015, the court granted the Company's motion to dismiss. On October 15, 2015, the plaintiff filed a notice of appeal. The Company believes the claims to be without merit and intend to vigorously defend the litigation. As of September 30, 2015, the Company has not recorded any reserves for this purported class action.
Guaranties and Indemnifications
As permitted under Massachusetts law, the Company’s Articles of Organization and By-laws provide that the Company will indemnify certain of its officers and directors for certain claims asserted against them in connection with their service as an officer or director. The maximum potential amount of future payments that the Company could be required to make under these indemnification provisions is unlimited. However, the Company has purchased directors’ and officers’ liability insurance policies that could reduce its monetary exposure and enable it to recover a portion of any future amounts paid. No indemnification claims currently are outstanding, and the Company believes the estimated fair value of these indemnification arrangements is minimal.
The Company customarily agrees in the ordinary course of its business to indemnification provisions in agreements with clinical trial investigators and sites in its drug development programs, sponsored research agreements with academic and not-for-profit institutions, various comparable agreements involving parties performing services for the Company, and its real estate leases. The Company also customarily agrees to certain indemnification provisions in its drug discovery, development and commercialization collaboration agreements. With respect to the Company’s clinical trials and sponsored research agreements, these indemnification provisions typically apply to any claim asserted against the investigator or the investigator’s institution relating to personal injury or property damage, violations of law or certain breaches of the Company’s contractual obligations arising out of the research or clinical testing of the Company’s compounds or drug candidates. With respect to lease agreements, the indemnification provisions typically apply to claims asserted against the landlord relating to personal injury or property damage caused by the Company, to violations of law by the Company or to certain breaches of the Company’s contractual obligations. The indemnification provisions appearing in the Company’s collaboration agreements are similar to those for the other agreements discussed above, but in addition provide some limited indemnification for its collaborator in the event of third-party claims alleging infringement of intellectual property rights. In each of the cases above, the indemnification obligation generally survives the termination of the agreement for some extended period, although the Company believes the obligation typically has the most relevance during the contract term and for a short period of time thereafter. The maximum potential amount of future payments that the Company could be required to make under these provisions is generally unlimited. The Company has purchased insurance policies covering personal injury, property damage and general liability that reduce its exposure for indemnification and would enable it in many cases to recover all or a portion of any future amounts paid. The Company has never paid any material amounts to defend lawsuits or settle claims related to these indemnification provisions. Accordingly, the Company believes the estimated fair value of these indemnification arrangements is minimal.
Other Contingencies
The Company has certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues a reserve for contingent liabilities when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. There were no material contingent liabilities accrued as of September 30, 2015 or December 31, 2014.
XML 44 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 45 R7.htm IDEA: XBRL DOCUMENT v3.3.0.814
Condensed Consolidated Statements of Shareholders' Equity and Noncontrolling Interest - USD ($)
shares in Thousands, $ in Thousands
Total
Total Vertex Shareholders’ Equity
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Accumulated Other Comprehensive Income (Loss)
Noncontrolling Interest
Balance (shares) at Dec. 31, 2013     233,789        
Balance at Dec. 31, 2013 $ 1,356,405 $ 1,356,405 $ 2,320 $ 5,321,286 $ (3,966,895) $ (306) $ 0
Increase (Decrease) in Stockholders' Equity              
Other comprehensive income (loss), net of tax 1,467 1,467       1,467  
Net loss (561,899) (561,899)     (561,899)   0
Issuance of common stock under benefit plans (shares)     6,449        
Issuance of common stock under benefit plans 223,867 223,867 $ 55 223,812      
Stock-based compensation 136,065 136,065   136,065      
Balance (shares) at Sep. 30, 2014     240,238        
Balance at Sep. 30, 2014 1,155,905 1,155,905 $ 2,375 5,681,163 (4,528,794) 1,161 0
Balance (shares) at Dec. 31, 2014     241,764        
Balance at Dec. 31, 2014 1,096,183 1,075,006 $ 2,385 5,777,154 (4,705,450) 917 21,177
Increase (Decrease) in Stockholders' Equity              
Other comprehensive income (loss), net of tax 594 594       594  
Net loss (513,512) (482,603)     (482,603)   (30,909)
Issuance of common stock under benefit plans (shares)     3,882        
Issuance of common stock under benefit plans 139,453 139,453 $ 34 139,419      
Stock-based compensation 189,697 189,697   189,697      
Noncontrolling interest upon consolidation 164,317 0         164,317
Balance (shares) at Sep. 30, 2015     245,646        
Balance at Sep. 30, 2015 $ 1,076,732 $ 922,147 $ 2,419 $ 6,106,270 $ (5,188,053) $ 1,511 $ 154,585
XML 46 R3.htm IDEA: XBRL DOCUMENT v3.3.0.814
Condensed Consolidated Statements of Operations (Parenthetical) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
Income Statement [Abstract]        
Tax effect of discontinued operations $ 0 $ 0 $ 0 $ 0
XML 47 R17.htm IDEA: XBRL DOCUMENT v3.3.0.814
Inventories
 9 Months Ended
Sep. 30, 2015
Inventory Disclosure [Abstract]  
Inventories
Inventories
Inventories consisted of the following:
 
As of September 30, 2015
 
As of December 31, 2014
 
(in thousands)
Raw materials
$
8,669

 
$
8,506

Work-in-process
34,115

 
20,508

Finished goods
6,413

 
1,834

Total
$
49,197

 
$
30,848
XML 48 R1.htm IDEA: XBRL DOCUMENT v3.3.0.814
Document and Entity Information - shares
 9 Months Ended
Sep. 30, 2015
Oct. 23, 2015
Document and Entity Information [Abstract]    
Entity Registrant Name VERTEX PHARMACEUTICALS INC / MA  
Entity Central Index Key 0000875320  
Current Fiscal Year End Date --12-31  
Entity Filer Category Large Accelerated Filer  
Document Type 10-Q  
Document Period End Date Sep. 30, 2015  
Document Fiscal Year Focus 2015  
Document Fiscal Period Focus Q3  
Amendment Flag false  
Entity Common Stock, Shares Outstanding   245,717,286
XML 49 R18.htm IDEA: XBRL DOCUMENT v3.3.0.814
Intangible Assets and Goodwill
 9 Months Ended
Sep. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets and Goodwill
Intangible Assets and Goodwill
Intangible Assets
As of September 30, 2015, in-process research and development intangible assets of $284.3 million were recorded on the Company's condensed consolidated balance sheet. The increase of $255.3 million as compared to the $29.0 million recorded as of December 31, 2014 is due to the Company's collaboration with Parion.
In June 2015, in connection with entering into the Parion Agreement, the Company recorded an in-process research and development intangible asset of $255.3 million based on the Company’s estimate of the fair value of Parion’s lead investigational ENaC inhibitors, including VX-371 and P-1055, that were licensed by the Company from Parion. The Company aggregated the fair value of the ENaC inhibitors into a single intangible asset because the phase, nature and risks of development as well as the amount and timing of benefits associated with the assets were similar. In October 2014, the Company recorded an in-process research and development intangible asset of $29.0 million based on the Company’s estimate of the fair value of VX-210, a drug candidate for patients with spinal cord injuries that was licensed by the Company from BioAxone. The Company used discount rates of 7.1% and 7.5% in the present-value models to estimate the fair values of the ENaC inhibitors and VX-210 intangible assets, respectively.
The Company also conducted an evaluation of Parion and BioAxone's other programs at the effective date of the Parion Agreement and BioAxone Agreement, respectively, and determined that market participants would not have ascribed value to those programs because of the stage of development of the assets in each program and uncertainties related to the potential clinical development and commercialization of the programs.
Goodwill
As of September 30, 2015, goodwill of $50.4 million was recorded on the Company's condensed consolidated balance sheet. The Company allocated $10.5 million to goodwill related to the Parion Agreement during the nine months ended September 30, 2015. This goodwill relates to the potential synergies between licensed drug candidates and the Company's CF drugs and drug candidates.  None of the goodwill related to the Parion Agreement is expected to be deductible for income tax purposes. As of December 31, 2014, $39.9 million of goodwill was recorded on the Company’s consolidated balance sheet.
XML 50 R4.htm IDEA: XBRL DOCUMENT v3.3.0.814
Condensed Consolidated Statements of Comprehensive Loss - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]        
Net loss $ (93,816) $ (170,060) $ (513,512) $ (561,899)
Changes in other comprehensive loss:        
Unrealized holding gains (losses) on marketable securities 56 (30) 186 25
Unrealized gains on foreign currency forward contracts 4,546 1,838 572 1,713
Foreign currency translation adjustment (1,384) (624) (164) (271)
Total changes in other comprehensive loss 3,218 1,184 594 1,467
Comprehensive loss (90,598) (168,876) (512,918) (560,432)
Comprehensive (income) loss attributable to noncontrolling interest (1,333) 0 30,909 0
Comprehensive loss attributable to Vertex $ (91,931) $ (168,876) $ (482,009) $ (560,432)
XML 51 R12.htm IDEA: XBRL DOCUMENT v3.3.0.814
Earnings Per Share
 9 Months Ended
Sep. 30, 2015
Earnings Per Share [Abstract]  
Earnings Per Share
Earnings Per Share
Basic net loss per share attributable to Vertex common shareholders is based upon the weighted-average number of common shares outstanding during the period, excluding restricted stock and restricted stock units that have been issued but are not yet vested. Diluted net loss per share attributable to Vertex common shareholders is based upon the weighted-average number of common shares outstanding during the period plus additional weighted-average common equivalent shares outstanding during the period when the effect is dilutive.
The Company did not include the securities described in the following table in the computation of the net loss from continuing operations per share attributable to Vertex common shareholder calculations because the effect would have been anti-dilutive during each period:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2015
 
2014
 
2015
 
2014
 
(in thousands)
Stock options
12,025

 
13,097

 
12,025

 
13,097

Unvested restricted stock and restricted stock units
3,367

 
2,672

 
3,367

 
2,672
XML 52 R11.htm IDEA: XBRL DOCUMENT v3.3.0.814
Collaborative Arrangements
 9 Months Ended
Sep. 30, 2015
Collaborative Arrangements  
Collaborative Arrangements
Collaborative Arrangements
Cystic Fibrosis Foundation Therapeutics Incorporated
In April 2011, the Company entered into an amendment (the “April 2011 Amendment”) to its existing collaboration agreement with Cystic Fibrosis Foundation Therapeutics Incorporated (“CFFT”) pursuant to which CFFT agreed to provide financial support for (i) development activities for VX-661, a compound that targets the processing and trafficking defect of the F508del CFTR proteins discovered under the collaboration, and (ii) additional research and development activities directed at discovering new compounds targeting the processing and trafficking defect of the F508del protein.
Under the April 2011 Amendment, CFFT agreed to provide the Company with up to $75.0 million in funding over approximately five years for research and development activities. The Company retains the right to develop and commercialize KALYDECO (ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor), lumacaftor, VX-661 and any other compounds discovered during the course of the research collaboration with CFFT. The Company recognized no collaborative revenues from this collaboration during the three and nine months ended September 30, 2015 and $2.0 million and $6.5 million of collaborative revenues from this collaboration during the three and nine months ended September 30, 2014, respectively.
In the original agreement, as amended prior to the April 2011 Amendment, the Company agreed to pay CFFT tiered royalties calculated as a percentage, ranging from single digits to sub-teens, of annual net sales of any approved drugs discovered during the research term that ended in 2008, including KALYDECO, ORKAMBI, lumacaftor and VX-661. The April 2011 Amendment provides for a tiered royalty in the same range on net sales of compounds targeting the processing and trafficking defect of F508del CFTR proteins discovered during the research term that began in 2011 and ended in February 2014. In each of the third quarter of 2012 and the first quarter of 2013, CFFT earned a commercial milestone payment of $9.3 million from the Company upon achievement of certain sales levels for KALYDECO. These milestones were reflected in the Company's cost of product revenues. There are no additional commercial milestone payments payable by the Company to CFFT related to sales levels for KALYDECO. The Company also is obligated to make up to two one-time commercial milestone payments to CFFT upon achievement of certain sales levels for ORKAMBI.
The Company began marketing KALYDECO in the United States and certain countries in the European Union in 2012 and began marketing ORKAMBI in the United States in July 2015. The Company has royalty obligations to CFFT for each compound commercialized pursuant to this collaboration until the expiration of patents covering that compound. The Company has patents in the United States and European Union covering the composition-of-matter of ivacaftor that expire in 2027 and 2025, respectively, subject to potential patent life extensions. The Company has patents in the United States and European Union covering the composition-of-matter of lumacaftor that expire in 2030 and 2026, respectively, subject to potential patent life extensions. CFFT may terminate its funding obligations under the collaboration, as amended, in certain circumstances, in which case there will be a proportional adjustment to the royalty rates and commercial milestone payments for certain compounds. The collaboration also may be terminated by either party for a material breach by the other, subject to notice and cure provisions.
Janssen Pharmaceutica NV
The Company has a collaboration agreement (the “Janssen HCV Agreement”) with Janssen Pharmaceutica NV (“Janssen NV”) for the development, manufacture and commercialization of telaprevir, which Janssen NV began marketing under the brand name INCIVO in certain of its territories in September 2011. Pursuant to the Janssen HCV Agreement, as amended, Janssen NV has a fully-paid license to manufacture and commercialize INCIVO in its territories including Europe, South America, the Middle East, Africa and Australia, subject to the payment of third-party royalties on net sales of INCIVO. In addition to the collaborative revenues, the Company recorded royalty revenues and corresponding royalty expenses related to third-party royalties that Janssen NV remains responsible for based on INCIVO net sales.
During the three and nine months ended September 30, 2015 and 2014, the Company recognized the following revenues attributable to the Janssen NV collaboration:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2015
 
2014
 
2015
 
2014
 
(in thousands)
Royalty revenues (INCIVO)
$
158

 
$
2,284

 
$
1,742

 
$
12,917

Collaborative revenues (telaprevir)
441

 
1,390

 
1,620

 
4,262

  Total revenues attributable to the Janssen NV collaboration
$
599

 
$
3,674

 
$
3,362

 
$
17,179


CRISPR Therapeutics AG
On October 26, 2015, the Company entered into a strategic collaboration, option and license agreement (the "CRISPR Agreement") with CRISPR Therapeutics AG and its affiliates ("CRISPR") to collaborate on the discovery and development of potential new treatments aimed at the underlying genetic causes of human diseases using CRISPR-Cas9 gene editing technology. The Company has the exclusive right to license up to six CRISPR-Cas9-based targets. In connection with the CRISPR Agreement, the Company made an upfront payment to CRISPR of $75.0 million and will make a $30.0 million investment in CRISPR pursuant to a convertible loan agreement.
The Company will fund all of the discovery activities conducted pursuant to the CRISPR Agreement. For potential hemoglobinapathy treatments, including treatments for sickle cell disease, the Company and CRISPR will share equally all research and development costs and worldwide revenues. For other targets that the Company elects to license, the Company would lead all development and global commercialization activities. For each of up to six targets that the Company elects to license, other than hemoglobinapathy targets, CRISPR has the potential to receive up to $420.0 million in development, regulatory and commercial milestones and royalties on net sales.
The Company may terminate the CRISPR Agreement upon 90 days’ notice to CRISPR prior to any product receiving marketing approval or upon 270 days’ notice after such point. The CRISPR Agreement also may be terminated by either party for a material breach by the other, subject to notice and cure provisions. Unless earlier terminated, the CRISPR Agreement will continue in effect until the expiration of the Company's payment obligations under the CRISPR Agreement.
Variable Interest Entities
The Company has entered into several agreements pursuant to which it has licensed rights to certain drug candidates from third-party collaborators, which has resulted in the consolidation of the third parties' financial statements into the Company's condensed consolidated financial statements as VIEs. In order to account for the fair value of the contingent milestone and royalty payments related to these collaborations under GAAP, the Company uses present-value models based on assumptions regarding the probability of achieving the relevant milestones, estimates regarding the time to develop the drug candidates, estimates of future product sales and the appropriate discount rates. The Company bases its estimate of the probability of achieving the relevant milestones on industry data for similar assets and its own experience. The discount rates used in the valuation model represent a measure of credit risk and market risk associated with settling the liabilities. Significant judgment is used in determining the appropriateness of these assumptions at each reporting period. Changes in these assumptions could have a material effect on the fair value of the contingent milestone and royalty payments. The following collaborations are, or were previously, reflected in the Company's financial statements for being consolidated as VIEs:
Parion Sciences, Inc.
License and Collaboration Agreement

On June 4, 2015, the Company entered into a strategic collaboration and license agreement (the "Parion Agreement") with Parion Sciences, Inc. (“Parion”).  Pursuant to the agreement, the Company is collaborating with Parion to develop investigational epithelial sodium channel (“ENaC”) inhibitors, including VX-371 (formerly P-1037) and P-1055, for the potential treatment of cystic fibrosis, or CF, and other pulmonary diseases.  The Company is leading development activities for VX-371 and P-1055 in CF and other pulmonary diseases and is responsible for all costs, subject to certain exceptions, related to development and commercialization of the compounds.

Pursuant to the Parion Agreement, the Company has worldwide development and commercial rights to Parion’s lead investigational ENaC inhibitors, VX-371 and P-1055, for the potential treatment of CF and all other pulmonary diseases and has the option to select additional compounds discovered in Parion’s research program.  Parion received an $80.0 million up-front payment and has the potential to receive up to an additional (i) $490.0 million in development and regulatory milestone payments for development of ENaC inhibitors in CF, including $360.0 million related to global filing and approval milestones, (ii) $370.0 million in development and regulatory milestones for VX-371 and P-1055 in non-CF pulmonary indications and (iii) $230.0 million in development and regulatory milestones should the Company elect to develop an additional ENaC inhibitor from Parion’s research program. The Company has agreed to pay Parion tiered royalties that range from the low double digits to mid-teens as a percentage of potential sales of licensed products.

The Company may terminate the Parion Agreement upon 90 days’ notice to Parion prior to any licensed product receiving marketing approval or upon 180 days’ notice after such point. If the Company experiences a change of control prior to the initiation of the first Phase 3 clinical trial for a licensed product, Parion may terminate the Parion Agreement upon 30 days’ notice, subject to the Company's right to receive specified royalties on any subsequent commercialization of licensed products. The Parion Agreement also may be terminated by either party for a material breach by the other, subject to notice and cure provisions. Unless earlier terminated, the agreement will continue in effect until the expiration of the Company's royalty obligations, which expire on a country-by-country basis on the later of (i) the date the last-to-expire patent covering a licensed product expires or (ii) ten years after the first commercial sale in the country.

The Company determined that Parion is a VIE based on, among other factors, the significance to Parion of the ENaC inhibitors licensed to the Company pursuant to the Parion Agreement and on the Company's power to direct the activities that most significantly impact the economic performance of Parion.  Accordingly, the Company consolidated Parion's financial statements beginning on June 4, 2015. However, the Company's interests in Parion are limited to those accorded to the Company in the Parion Agreement. In particular, the Company did not acquire any equity interest in Parion, any interest in Parion's cash and cash equivalents or any control over Parion's activities that do not relate to the Parion Agreement.
Consideration for the Parion Agreement

The Company determined that the fair value of the consideration from the Company to Parion was $255.3 million as of June 4, 2015, which consisted of (i) an $80.0 million up-front payment, (ii) the estimated fair value of the contingent research and development milestones potentially payable by the Company to Parion and (iii) the estimated fair value of potential royalty payments payable by the Company to Parion. The Company valued the contingent milestone and royalty payments using (a) discount rates ranging from 4.1% to 5.9% for the development milestones and (b) a discount rate of 6.6% for royalties. The consideration paid and the preliminary fair value of the contingent milestone and royalty payments payable by the Company pursuant to the agreement are set forth in the table below:
 
June 4, 2015
 
(in thousands)
Up-front payment
$
80,000

Fair value of contingent milestone and royalty payments
175,340

Total
$
255,340


Preliminary Allocation of Assets and Liabilities

For the purposes of the condensed consolidated balance sheets at June 4, 2015 and September 30, 2015, the Company preliminarily allocated the total consideration, which is comprised of the up-front payment and the fair value of the contingent milestone and royalty payments, intangible assets, goodwill, deferred tax liability, net and net other assets and liabilities.

The Company recorded $255.3 million of intangible assets on the Company's condensed consolidated balance sheet for Parion's in-process research and development assets. These in-process research and development assets relate to Parion's pulmonary ENaC platform, including the intellectual property related to VX-371 and P-1055, that are licensed by Parion to the Company. The difference between the preliminary fair value of the consideration and the fair value of Parion's assets (including the fair value of intangible assets) and liabilities was allocated to goodwill.

The following table summarizes the preliminary fair values of the assets and liabilities recorded on the effective date of the agreement:
 
June 4, 2015
 
(in thousands)
Intangible assets
$
255,340

Goodwill
10,468

Deferred tax liability
(91,023
)
Net other assets (liabilities)
(10,468
)
Net assets attributable to noncontrolling interests
$
164,317


BioAxone Biosciences, Inc.
In October 2014, the Company entered into a license and collaboration agreement (the “BioAxone Agreement”) with BioAxone Biosciences, Inc. (“BioAxone”), a privately-held biotechnology company, which resulted in the consolidation of BioAxone as a VIE beginning on October 1, 2014. The Company paid BioAxone initial payments of $10.0 million in the fourth quarter of 2014.
BioAxone has the potential to receive up to $90.0 million in milestones and fees, including development, regulatory and milestone payments and a license continuation fee. In addition, BioAxone would receive royalties and commercial milestones on future net product sales of VX-210, if any. The Company holds an option to purchase BioAxone at a predetermined price. The option expires on the earliest of (a) the day the FDA accepts the Biologics License Application submission for VX-210, (b) the day the Company elects to continue the license instead of exercising the option to purchase BioAxone and (c) March 15, 2018, subject to the Company’s option to extend this date by one year.
Alios BioPharma, Inc.
In 2011, the Company entered into a license and collaboration agreement (the “Alios Agreement”) with Alios BioPharma, Inc. (“Alios”), which was a privately-held biotechnology company, which resulted in the consolidation of Alios as a VIE through December 31, 2013. Pursuant to the Alios Agreement, the Company and Alios collaborated on the research, development and commercialization of HCV nucleotide analogues discovered by Alios through April 2014. In December 2014, the Alios Agreement terminated in accordance with its terms pursuant to a termination notice delivered by the Company in October 2014. As of September 30, 2014, the Company concluded that it no longer had significant continuing involvement with Alios due to its intent and ability to terminate the Alios Agreement, among other factors; therefore, the operations of Alios are presented as discontinued operations in these condensed consolidated financial statements.
Aggregate VIE Financial Information

The Company did not have any consolidated VIEs for the three and nine months ended September 30, 2014. An aggregate summary of net loss attributable to noncontrolling interest related to the Company's VIEs for the three and nine months ended September 30, 2015 is as follows:
 
Three Months Ended September 30, 2015
 
Nine Months Ended September 30, 2015
 
(in thousands)
Loss attributable to noncontrolling interest before provision for income taxes
$
(1,743
)
 
$
(3,322
)
Provision for income taxes
(777
)
 
(30,367
)
Increase in fair value of contingent milestone and royalty payments
3,853

 
2,780

Net (income) loss attributable to noncontrolling interest
$
1,333

 
$
(30,909
)


During the three and nine months ended September 30, 2015, the fair value of the contingent milestone and royalty payments related to the BioAxone collaboration decreased by $0.6 million and $0.1 million, respectively. During the three and nine months ended September 30, 2015, the fair value of the contingent milestone and royalty payments related to the Parion collaboration increased by $4.5 million and $2.9 million, respectively. The changes in the fair value of the contingent milestone and royalty payments were primarily due to the changes in market interest rates and the time value of money. As of September 30, 2015, the fair value of the contingent milestone and royalty payments related to the BioAxone collaboration and the Parion collaboration was $27.0 million and $178.2 million, respectively.

The following table summarizes items related to the Company's VIEs included in the Company's condensed consolidated balance sheets as of the dates set forth in the table:
 
September 30, 2015
 
December 31, 2014
 
(in thousands)
Restricted cash and cash equivalents (VIE)
$
75,765

 
$
8,418

Prepaid expenses and other current assets
3,057

 
268

Intangible assets
284,340

 
29,000

Goodwill
19,391

 
8,923

Other assets
461

 
42

Accounts payable
1,115

 
189

Accrued expenses and other current liabilities
32,519

 
3,891

Deferred tax liability, net
110,360

 
11,544

Other liabilities
300

 
300

Noncontrolling interest
154,585

 
21,177



The Company has recorded the VIEs' cash and cash equivalents as restricted cash and cash equivalents (VIE) because (i) the Company does not have any interest in or control over the VIEs' cash and cash equivalents and (ii) the Company's agreements with each VIE do not provide for the VIEs' cash and cash equivalents to be used for the development of the assets that the Company licensed from the applicable VIE. Assets recorded as a result of consolidating our VIEs' financial condition into the Company's balance sheet do not represent additional assets that could be used to satisfy claims against the Company's general assets.
Outlicense Arrangements
In the ordinary course of the Company's business, the Company has entered into various agreements pursuant to which it has outlicensed rights to certain drug candidates to third-party collaborators. Although the Company does not consider any of these outlicense arrangements to be material, the most notable of these outlicense arrangements is described below. Pursuant to these outlicense arrangements, our collaborators are responsible for all costs related to the continued development of such drug candidates. Depending on the terms of the arrangements, the Company's collaborators may be required to make upfront payments, milestone payments upon the achievement of certain product research and development objectives and/or pay royalties on future sales, if any, of commercial products resulting from the collaboration.

Janssen Pharmaceuticals, Inc.
In June 2014, the Company entered into an agreement (the “Janssen Influenza Agreement”) with Janssen Pharmaceuticals, Inc. (“Janssen Inc.”), which was amended in October 2014 to clarify certain roles and responsibilities of the parties.

Pursuant to the Janssen Influenza Agreement, Janssen Inc. has an exclusive worldwide license to develop and commercialize certain drug candidates for the treatment of influenza, including VX-787. The Company received non-refundable payments of $35.0 million from Janssen Inc. in 2014, which were recorded as collaborative revenue. The Company has the potential to receive development, regulatory and commercial milestone payments as well as royalties on future product sales, if any.
Janssen Inc. is responsible for costs related to the development and commercialization of the compounds. During the three and nine months ended September 30, 2015, the Company recorded reimbursement for these development activities of $4.0 million and $18.7 million, respectively. During the three and nine months ended September 30, 2014, the Company recorded reimbursement for these development activities of $4.3 million. The reimbursements are recorded as a reduction to development expense in the Company's condensed consolidated statements of operations primarily due to the fact that Janssen Inc. directs the activities and selects the suppliers associated with these activities. Janssen Inc. may terminate the Janssen Influenza Agreement, subject to certain exceptions, upon six months' notice.
XML 53 R23.htm IDEA: XBRL DOCUMENT v3.3.0.814
Restructuring Liabilities
 9 Months Ended
Sep. 30, 2015
Restructuring and Related Activities [Abstract]  
Restructuring Liabilities
Restructuring Liabilities
2003 Kendall Restructuring
In 2003, the Company adopted a plan to restructure its operations to coincide with its increasing internal emphasis on advancing drug candidates through clinical development to commercialization. The restructuring liability relates to specialized laboratory and office space that is leased to the Company pursuant to a 15-year lease that terminates in 2018. The Company has not used more than 50% of this space since it adopted the plan to restructure its operations in 2003. This unused laboratory and office space currently is subleased to third parties.
The activities related to the restructuring liability for the three and nine months ended September 30, 2015 and 2014 were as follows:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2015
 
2014
 
2015
 
2014
 
(in thousands)
Liability, beginning of the period
$
9,924

 
$
14,936

 
$
11,596

 
$
19,115

Cash payments
(3,975
)
 
(4,249
)
 
(10,544
)
 
(12,071
)
Cash received from subleases
2,919

 
2,689

 
8,194

 
8,067

Restructuring expense (income)
146

 
(464
)
 
(232
)
 
(2,199
)
Liability, end of the period
$
9,014

 
$
12,912

 
$
9,014

 
$
12,912



Fan Pier Move Restructuring
In connection with the relocation of its Massachusetts operations to Fan Pier in Boston, Massachusetts, which commenced in 2013, the Company is incurring restructuring charges related to its remaining lease obligations at its facilities in Cambridge, Massachusetts. The majority of these restructuring charges were recorded in the third quarter of 2014 upon decommissioning three facilities in Cambridge. During the first quarter of 2015, the Company terminated two of these lease agreements resulting in a credit to restructuring expense equal to the difference between the Company’s estimated future cash flows related to its lease obligations for these facilities and the termination payment paid to the Company’s landlord on the effective date of the termination. The third major facility included in this restructuring activity is 120,000 square feet of the Kendall Square Facility that the Company continued to use for its operations following its 2003 Kendall Restructuring. The rentable square footage in this portion of the Kendall Square Facility was subleased to a third party in February 2015. The Company will continue to incur charges through April 2018 related to the difference between the Company’s estimated future cash flows related to this portion of the Kendall Square Facility, which include an estimate for sublease income to be received from the Company's sublessee and its actual cash flows. The Company discounted the estimated cash flows related to this restructuring activity at a discount rate of 9%.
The activities related to the restructuring liability for the three and nine months ended September 30, 2015 and 2014 were as follows:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2015
 
2014
 
2015
 
2014
 
(in thousands)
Liability, beginning of the period
$
9,017

 
$
3,256

 
$
33,390

 
$
797

Cash payments
(3,070
)
 
(2,266
)
 
(25,421
)
 
(6,643
)
Cash received from subleases
1,820

 
—

 
1,820

 
—

Restructuring expense (income)
51

 
39,752

 
(1,971
)
 
46,588

Liability, end of the period
$
7,818

 
$
40,742

 
$
7,818

 
$
40,742


Other Restructuring Activities
The Company has incurred several other restructuring activities that are unrelated to its 2003 Kendall Restructuring and the Fan Pier Move Restructuring. In October 2013, the Company adopted a restructuring plan that included (i) a workforce reduction primarily related to the commercial support of INCIVEK following the continued and rapid decline in the number of patients being treated with INCIVEK as new medicines for the treatment of HCV infection neared approval and (ii) the write-off of certain assets. This action resulted from the Company's decision to focus its investment on future opportunities in cystic fibrosis and other research and development programs.
The activities related to the Company's other restructuring liabilities for the three and nine months ended September 30, 2015 and 2014 were as follows:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2015
 
2014
 
2015
 
2014
 
(in thousands)
Liability, beginning of the period
$
902

 
$
792

 
$
869

 
$
8,441

Cash payments
(1,559
)
 
(399
)
 
(2,782
)
 
(8,865
)
Restructuring expense
1,629

 
1,555

 
2,885

 
2,372

Liability, end of the period
$
972

 
$
1,948

 
$
972

 
$
1,948
XML 54 R19.htm IDEA: XBRL DOCUMENT v3.3.0.814
Long-term Obligations
 9 Months Ended
Sep. 30, 2015
Long-term Debt and Capital Lease Obligations [Abstract]  
Long-term Obligations
Long-term Obligations
Fan Pier Leases
In 2011, the Company entered into two lease agreements, pursuant to which the Company leases approximately 1.1 million square feet of office and laboratory space in two buildings (the “Buildings”) at Fan Pier in Boston, Massachusetts (the “Fan Pier Leases”). The Company commenced lease payments in December 2013, and will make lease payments pursuant to the Fan Pier Leases through December 2028. The Company has an option to extend the term of the Fan Pier Leases for an additional ten years.
Because the Company was involved in the construction project and determined that the Fan Pier Leases did not meet the criteria for “sale-leaseback” treatment upon completion of the Buildings, the Company recorded project construction costs incurred by the landlord as an asset and a related financing obligation during the construction period and began depreciating the asset and incurring interest expense related to the financing obligation in 2013. The Company bifurcates its lease payments pursuant to the Fan Pier Leases into (i) a portion that is allocated to the Buildings and (ii) a portion that is allocated to the land on which the Buildings were constructed. The portion of the lease obligations allocated to the land is treated as an operating lease that commenced in 2011.
Property and equipment, net, included $505.6 million and $515.0 million as of September 30, 2015 and December 31, 2014, respectively, related to construction costs for the Buildings. The carrying value of the Company's lease agreement liability for the Buildings was $473.1 million and $473.4 million as of September 30, 2015 and December 31, 2014, respectively.
Term Loan
In July 2014, the Company entered into a credit agreement with the lenders party thereto, and Macquarie US Trading LLC ("Macquarie"), as administrative agent. The credit agreement provides for a $300.0 million senior secured term loan ("Term Loan"). The credit agreement also provides that, subject to satisfaction of certain conditions, the Company may request that the lenders establish an incremental senior secured term loan facility in an aggregate amount not to exceed $200.0 million. The Term Loan initially bore interest at a rate of 7.2% per annum, which will be reduced to 6.2% per annum based on the FDA's approval of ORKAMBI. The Term Loan will bear interest at a rate of LIBOR plus 5.0% per annum during the third year of the term.
The maturity date of all loans under the facilities is July 9, 2017. Interest is payable quarterly and on the maturity date. In October 2015, the Company amended the terms of the credit agreement to provide for, among other things, a modification to the repayment schedule of the loan. As amended, the Company is required to repay principal on the Term Loan in quarterly installments of $75 million from October 1, 2016 through the maturity date. The Company may prepay the Term Loan, in whole or in part, at any time; provided that prepayments prior to the July 9, 2016 are subject to a make-whole premium to ensure Macquarie receives approximately the present value of two years of interest payments over the life of the loan. The Company expects that amending the credit agreement will be accounted for as a debt modification, as opposed to an extinguishment of debt, based on an insignificant change to the present value of the future cash flows relating to the credit agreement.
The Company's obligations under the facilities are unconditionally guaranteed by certain of its domestic subsidiaries. All obligations under the facilities, and the guarantees of those obligations, are secured, subject to certain exceptions, by substantially all of the Company's assets and the assets of all guarantors, including the pledge of all or a portion of the equity interests of certain of its subsidiaries.
The credit agreement requires that the Company maintain, on a quarterly basis, a minimum level of KALYDECO net revenues. Further, the credit agreement includes negative covenants, subject to exceptions, restricting or limiting the Company's ability and the ability of its subsidiaries to, among other things, incur additional indebtedness, grant liens, engage in certain investment, acquisition and disposition transactions, pay dividends, repurchase capital stock and enter into transactions with affiliates. The credit agreement also contains customary representations and warranties, affirmative covenants and events of default, including payment defaults, breach of representations and warranties, covenant defaults and cross defaults. If an event of default occurs, the administrative agent would be entitled to take various actions, including the acceleration of amounts due under outstanding loans. There have been no events of default as of or during the period ended September 30, 2015.
Based on the Company's evaluation of the Term Loan, the Company determined that the Term Loan contains several embedded derivatives. These embedded derivatives are clearly and closely related to the host instrument because they relate to the Company's credit risk; therefore, they do not require bifurcation from the host instrument, the Term Loan.
The Company incurred $5.3 million in fees paid to Macquarie that were recorded as a discount on the Term Loan and are being recorded as interest expense using the effective interest method over the term of the loan in the Company’s condensed consolidated statements of operations. As of September 30, 2015, the unamortized discount associated with the Term Loan that was embedded in the senior secured term loan caption on the Company’s condensed consolidated balance sheet was $5.2 million.
XML 55 R15.htm IDEA: XBRL DOCUMENT v3.3.0.814
Accumulated Other Comprehensive (Loss) Income
 9 Months Ended
Sep. 30, 2015
Equity [Abstract]  
Accumulated Other Comprehensive (Loss) Income
Accumulated Other Comprehensive (Loss) Income
A summary of the Company's changes in accumulated other comprehensive (loss) income by component is shown below:
 
Foreign Currency Translation Adjustment
 
Unrealized Holding Gains (Losses) on Marketable Securities
 
Unrealized Gains (Losses) on Foreign Currency Forward Contracts
 
Total
 
(in thousands)
Balance at December 31, 2014
$
(971
)
 
$
(123
)
 
$
2,011

 
$
917

Other comprehensive (loss) income before reclassifications
(164
)
 
186

 
4,072

 
4,094

Amounts reclassified from accumulated other comprehensive loss
—

 
—

 
(3,500
)
 
(3,500
)
Net current period other comprehensive (loss) income
$
(164
)
 
$
186

 
$
572

 
$
594

Balance at September 30, 2015
$
(1,135
)
 
$
63

 
$
2,583

 
$
1,511


 
Foreign Currency Translation Adjustment
 
Unrealized Holding Gains on Marketable Securities
 
Unrealized (Losses) Gains on Foreign Currency Forward Contracts
 
Total
 
(in thousands)
Balance at December 31, 2013
$
(325
)
 
$
42

 
$
(23
)
 
$
(306
)
Other comprehensive (loss) income before reclassifications
(271
)
 
25

 
2,140

 
1,894

Amounts reclassified from accumulated other comprehensive loss
—

 
—

 
(427
)
 
(427
)
Net current period other comprehensive (loss) income
$
(271
)
 
$
25

 
$
1,713

 
$
1,467

Balance at September 30, 2014
$
(596
)
 
$
67

 
$
1,690

 
$
1,161
XML 56 R13.htm IDEA: XBRL DOCUMENT v3.3.0.814
Fair Value Measurements
 9 Months Ended
Sep. 30, 2015
Fair Value Disclosures [Abstract]  
Fair Value Measurements
Fair Value Measurements
The fair value of the Company’s financial assets and liabilities reflects the Company’s estimate of amounts that it would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from sources independent from the Company) and to minimize the use of unobservable inputs (the Company’s assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:
Level 1:
Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.
Level 2:
Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.
Level 3:
Unobservable inputs based on the Company’s assessment of the assumptions that market participants would use in pricing the asset or liability.
The Company’s investment strategy is focused on capital preservation. The Company invests in instruments that meet the credit quality standards outlined in the Company’s investment policy. This policy also limits the amount of credit exposure to any one issue or type of instrument. As of September 30, 2015, the Company’s investments were in money market funds, corporate debt securities and commercial paper.
As of September 30, 2015, all of the Company’s financial assets that were subject to fair value measurements were valued using observable inputs. The Company’s financial assets valued based on Level 1 inputs consisted of money market funds. The Company’s financial assets valued based on Level 2 inputs consisted of corporate debt securities and commercial paper, which consist of investments in highly-rated investment-grade corporations.
The following table sets forth the Company’s financial assets and liabilities subject to fair value measurements:
 
Fair Value Measurements as of September 30, 2015
 
 
 
Fair Value Hierarchy
 
Total
 
Level 1
 
Level 2
 
Level 3
 
(in thousands)
Financial assets carried at fair value:
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Money market funds
$
340,573

 
$
340,573

 
$
—

 
$
—

Corporate debt securities
25,109

 
—

 
25,109

 
—

Commercial paper
24,000

 
—

 
24,000

 
—

Marketable securities:
 
 
 
 
 
 
 
Corporate debt securities
109,335

 
—

 
109,335

 
—

Commercial paper
140,245

 
—

 
140,245

 
—

Prepaid and other current assets:
 
 
 
 
 
 
 
Foreign currency forward contracts
3,508

 
—

 
3,508

 
—

Other assets:
 
 
 
 
 
 
 
Foreign currency forward contracts
651

 
—

 
651

 
—

Total financial assets
$
643,421


$
340,573

 
$
302,848

 
$
—

Financial liabilities carried at fair value:
 
 
 
 
 
 
 
Other liabilities, current portion:
 
 
 
 
 
 
 
Foreign currency forward contracts
$
(1,552
)
 
$
—

 
$
(1,552
)
 
$
—

Other liabilities, excluding current portion:
 
 
 
 
 
 
 
Foreign currency forward contracts
(24
)
 
—

 
(24
)
 
—

Total financial liabilities
$
(1,576
)
 
$
—

 
$
(1,576
)
 
$
—


The Company's VIEs invested in cash equivalents consisting of money market funds of $75.4 million as of September 30, 2015, which are valued based on Level 1 inputs. These cash equivalents are not included in the table above. The Company’s noncontrolling interest related to VIEs includes the fair value of the contingent milestone and royalty payments, which are valued based on Level 3 inputs. Please refer to Note C, “Collaborative Arrangements,” for further information.
As of September 30, 2015, the fair value and carrying value of the Company's Term Loan was $294.8 million. The fair value of the Company's Term Loan was estimated based on Level 3 inputs computed using the effective interest rate of the Term Loan. The effective interest rate considers the timing and amount of estimated future interest payments as well as current markets rates. Please refer to Note K, "Long-term Obligations" for further information regarding the Company's Term Loan.
XML 57 R14.htm IDEA: XBRL DOCUMENT v3.3.0.814
Marketable Securities
 9 Months Ended
Sep. 30, 2015
Cash and Cash Equivalents [Abstract]  
Marketable Securities
Marketable Securities
A summary of the Company’s cash, cash equivalents and marketable securities is shown below:
 
Amortized Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Fair Value
 
(in thousands)
As of September 30, 2015
 
 
 
 
 
 
 
Cash and cash equivalents:
 
 
 
 
 
 
 
Cash and money market funds
$
707,141

 
$
—

 
$
—

 
$
707,141

Commercial paper
$
25,109

 
$
—

 
$
—

 
$
25,109

Corporate debt securities
$
24,000

 
$
—

 
$
—

 
$
24,000

Total cash and cash equivalents
$
756,250

 
$
—

 
$
—

 
$
756,250

Marketable securities:
 
 
 
 
 
 
 
Commercial paper (due within 1 year)
$
140,131

 
$
114

 
$
—

 
$
140,245

Corporate debt securities (due within 1 year)
109,386

 
28

 
(79
)
 
109,335

Total marketable securities
$
249,517

 
$
142

 
$
(79
)
 
$
249,580

Total cash, cash equivalents and marketable securities
$
1,005,767

 
$
142

 
$
(79
)
 
$
1,005,830

 
 
 
 
 
 
 
 
As of December 31, 2014
 
 
 
 
 
 
 
Cash and cash equivalents:
 
 
 
 
 
 
 
Cash and money market funds
$
625,259

 
$
—

 
$
—

 
$
625,259

Total cash and cash equivalents
$
625,259

 
$
—

 
$
—

 
$
625,259

Marketable securities:
 
 
 
 
 
 
 
Government-sponsored enterprise securities (due within 1 year)
$
463,788

 
$
14

 
$
(52
)
 
$
463,750

Commercial paper (due within 1 year)
51,674

 
72

 
—

 
51,746

Corporate debt securities (due within 1 year)
196,065

 
2

 
(66
)
 
196,001

Corporate debt securities (due after 1 year through 5 years)
50,443

 
—

 
(93
)
 
50,350

Total marketable securities
$
761,970

 
$
88

 
$
(211
)
 
$
761,847

Total cash, cash equivalents and marketable securities
$
1,387,229

 
$
88

 
$
(211
)
 
$
1,387,106


The Company has a limited number of marketable securities in insignificant loss positions as of September 30, 2015, which the Company does not intend to sell and has concluded it will not be required to sell before recovery of the amortized costs for the investment at maturity. There were no charges recorded for other-than-temporary declines in fair value of marketable securities nor gross realized gains or losses recognized in the three and nine months ended September 30, 2015 and 2014.
XML 58 R16.htm IDEA: XBRL DOCUMENT v3.3.0.814
Hedging
 9 Months Ended
Sep. 30, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Hedging
Hedging
The Company maintains a hedging program intended to mitigate the effect of changes in foreign exchange rates for a portion of the Company’s forecasted product revenues denominated in certain foreign currencies. The program includes foreign currency forward contracts that are designated as cash flow hedges under GAAP having contractual durations from one to eighteen months. To date, the existence of operational sites in countries outside the United States has limited the degree to which the Company has sought to hedge its revenues in certain foreign currencies.
The Company formally documents the relationship between foreign currency forward contracts (hedging instruments) and forecasted product revenues (hedged items), as well as the Company's risk management objective and strategy for undertaking various hedging activities, which includes matching all foreign currency forward contracts that are designated as cash flow hedges to forecasted transactions. The Company also formally assesses, both at the hedge’s inception and on an ongoing basis, whether the foreign currency forward contracts are highly effective in offsetting changes in cash flows of hedged items on a prospective and retrospective basis. If the Company determines that a (i) foreign currency forward contract is not highly effective as a cash flow hedge, (ii) foreign currency forward contract has ceased to be a highly effective hedge or (iii) forecasted transaction is no longer probable of occurring, the Company would discontinue hedge accounting treatment prospectively. The Company measures effectiveness based on the change in fair value of the forward contracts and the fair value of the hypothetical foreign currency forward contracts with terms that match the critical terms of the risk being hedged. As of September 30, 2015, all hedges were determined to be highly effective and the Company has not recorded any ineffectiveness related to the hedging program.
The following table summarizes the notional amount of the Company’s outstanding foreign currency forward contracts designated as cash flow hedges:
 
As of September 30, 2015
 
As of December 31, 2014
Foreign Currency
(in thousands)
Euro
$
106,620

 
$
20,209

British pound sterling
78,861

 
13,515

Australian dollar
25,414

 
—

Total foreign currency forward contracts
$
210,895

 
$
33,724


The following table summarizes the fair value of the Company's outstanding foreign currency forward contracts designated as cash flow hedges under GAAP included on the Company's condensed consolidated balance sheets:
As of September 30, 2015
Assets
 
Liabilities
Classification
 
Fair Value
 
Classification
 
Fair Value
(in thousands)
Prepaid and other current assets
 
$
3,508

 
Other liabilities, current portion
 
$
(1,552
)
Other assets
 
651

 
Other liabilities, excluding current portion
 
(24
)
Total assets
 
$
4,159

 
Total liabilities
 
$
(1,576
)
As of December 31, 2014
Assets
 
Liabilities
Classification
 
Fair Value
 
Classification
 
Fair Value
(in thousands)
Prepaid and other current assets
 
$
2,011

 
Other liabilities, current portion
 
$
—

Total assets
 
$
2,011

 
Total liabilities
 
$
—

The following table summarizes the potential effect of offsetting derivatives by type of financial instrument on the Company's condensed consolidated balance sheets:
 
As of September 30, 2015
 
Gross Amounts Recognized
 
Gross Amounts Offset
 
Gross Amount Presented
 
Gross Amount Not Offset
 
Legal Offset
Foreign currency forward contracts
(in thousands)
Total assets
$
4,159

 
$
—

 
$
4,159

 
$
(1,576
)
 
$
2,583

Total liabilities
$
(1,576
)
 
$
—

 
$
(1,576
)
 
$
1,576

 
$
—

 
As of December 31, 2014
 
Gross Amounts Recognized
 
Gross Amounts Offset
 
Gross Amount Presented
 
Gross Amount Not Offset
 
Legal Offset
Foreign currency forward contracts
(in thousands)
Total assets
$
2,011

 
$
—

 
$
2,011

 
$
—

 
$
2,011
XML 59 R34.htm IDEA: XBRL DOCUMENT v3.3.0.814
Stock-based Compensation Expense (Tables)
 9 Months Ended
Sep. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Stock-based compensation expense by line item
During the three and nine months ended September 30, 2015 and 2014, the Company recognized the following stock-based compensation expense included in loss from continuing operations:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2015
 
2014
 
2015
 
2014
 
(in thousands)
Stock-based compensation expense by type of award:
 
 
 
 
 
 
 
Stock options
$
39,074

 
$
26,291

 
$
105,720

 
$
78,403

Restricted stock and restricted stock units
26,203

 
18,418

 
78,274

 
51,431

ESPP share issuances
1,738

 
1,883

 
5,703

 
6,231

Less stock-based compensation expense capitalized to inventories
(1,281
)
 
(456
)
 
(3,318
)
 
(905
)
Total stock-based compensation included in costs and expenses
$
65,734

 
$
46,136

 
$
186,379

 
$
135,160

 
 
 
 
 
 
 


Stock-based compensation expense by line item:
 
 
 
 
 
 
 
Research and development expenses
$
44,701

 
$
31,131

 
$
124,550

 
$
91,284

Sales, general and administrative expenses
21,033

 
15,005

 
61,829

 
43,876

Total stock-based compensation included in costs and expenses
$
65,734

 
$
46,136

 
$
186,379

 
$
135,160
Unrecognized stock-based compensation expense, net of estimated forfeitures
The following table sets forth the Company's unrecognized stock-based compensation expense, net of estimated forfeitures, by type of award and the weighted-average period over which that expense is expected to be recognized:
 
As of September 30, 2015
 
Unrecognized Expense,
Net of
Estimated Forfeitures
 
Weighted-average
Recognition
Period
 
(in thousands)
 
(in years)
Type of award:
 
 
 
Stock options
$
197,031

 
2.30
Restricted stock and restricted stock units
$
190,786

 
2.73
ESPP share issuances
$
1,885

 
0.44
Stock options outstanding and exercisable
The following table summarizes information about stock options outstanding and exercisable at September 30, 2015:
 
 
Options Outstanding
 
Options Exercisable
Range of Exercise Prices
 
Number
Outstanding
 
Weighted-average
Remaining
Contractual Life
 
Weighted-average
Exercise Price
 
Number
Exercisable
 
Weighted-average
Exercise Price
 
 
(in thousands)
 
(in years)
 
(per share)
 
(in thousands)
 
(per share)
$18.93–$20.00
 
138

 
2.35
 
$
18.93

 
138

 
$
18.93

$20.01–$40.00
 
2,499

 
3.81
 
$
34.56

 
2,284

 
$
34.36

$40.01–$60.00
 
2,593

 
6.80
 
$
48.27

 
1,458

 
$
49.52

$60.01–$80.00
 
1,567

 
8.31
 
$
75.94

 
551

 
$
74.95

$80.01–$100.00
 
1,932

 
8.28
 
$
90.27

 
638

 
$
87.16

$100.01–$120.00
 
1,791

 
9.32
 
$
109.24

 
201

 
$
109.22

$120.01–$134.69
 
1,505

 
9.78
 
$
131.21

 
168

 
$
127.52

Total
 
12,025

 
7.31
 
$
74.90

 
5,438

 
$
53.98
XML 60 R51.htm IDEA: XBRL DOCUMENT v3.3.0.814
Other Arrangements (Details) - USD ($)
$ in Millions
 1 Months Ended 3 Months Ended 12 Months Ended
Apr. 30, 2014
Jun. 30, 2014
Dec. 31, 2008
Sep. 30, 2015
Sale of HIV Protease Inhibitor Royalty Stream        
Gross proceeds from sale of royalty rights receivable from GlaxoSmithKline     $ 160.0  
Deferred revenue royalty purchase agreement       $ 31.2
Other nonoperating income $ 36.7 $ 36.7    
XML 61 R21.htm IDEA: XBRL DOCUMENT v3.3.0.814
Other Arrangements
 9 Months Ended
Sep. 30, 2015
Other Income and Expenses [Abstract]  
Other Arrangements
Other Arrangements
Sale of HIV Protease Inhibitor Royalty Stream
In 2008, the Company sold to a third party its rights to receive royalty payments from GlaxoSmithKline plc, net of royalty amounts to be earned by and due to a third party, for a one-time cash payment of $160.0 million. These royalty payments relate to net sales of HIV protease inhibitors, which had been developed pursuant to a collaboration agreement between the Company and GlaxoSmithKline plc. As of September 30, 2015, the Company had $31.2 million in deferred revenues related to the one-time cash payment, which it is recognizing over the life of the collaboration agreement with GlaxoSmithKline plc based on the units-of-revenue method. In addition, the Company continues to recognize royalty revenues equal to the amount of the third-party subroyalty and an offsetting royalty expense for the third-party subroyalty payment.
Other income (expense), net
In April 2014, the Company received a one-time cash payment of $36.7 million from its landlord pursuant to the Fan Pier Leases.  This payment related to bonds issued pursuant to an Infrastructure Development Assistance Agreement between The Commonwealth of Massachusetts and the Company’s landlord.  The bonds were issued in connection with the landlord’s contribution to infrastructure improvements and also were dependent upon employment levels at the Company through the bond issuance date.  The Company accounted for the cash payment as a government grant as it was provided in part related to the Company’s employment level in Massachusetts. Such grants are recognized as income in the period in which the conditions of the grant are met and there is reasonable assurance that the grant will be received, provided it is not subject to refund. In the second quarter of 2014, the Company recorded $36.7 million as a credit to other income (expense), net in its consolidated statements of operations because the Company’s employment obligations related to these funds were satisfied as of the date of issuance of the bonds and the payment received was not subject to refund.
XML 62 R26.htm IDEA: XBRL DOCUMENT v3.3.0.814
Product Revenues, Net (Tables)
 9 Months Ended
Sep. 30, 2015
Product Revenues [Abstract]  
Schedule of product revenue allowances and reserve categories
The following table summarizes activity in each of the product revenue allowance and reserve categories for the nine months ended September 30, 2015:
 
Trade
Allowances
 
Rebates,
Chargebacks
and Discounts
 
Product
Returns
 
Other
Incentives
 
Total
 
(in thousands)
Balance at December 31, 2014
$
1,463

 
$
29,102

 
$
4,713

 
$
745

 
$
36,023

Provision related to current period sales
6,120

 
39,533

 
429

 
2,402

 
48,484

Adjustments related to prior period sales
(143
)
 
(12,342
)
 
(993
)
 
(235
)
 
(13,713
)
Credits/payments made
(5,115
)
 
(22,465
)
 
(3,254
)
 
(1,652
)
 
(32,486
)
Balance at September 30, 2015
$
2,325

 
$
33,828

 
$
895

 
$
1,260

 
$
38,308
XML 63 R49.htm IDEA: XBRL DOCUMENT v3.3.0.814
Stock-based Compensation Expense (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2015
Jun. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
Stock-based compensation expense:          
Less stock-based compensation expense capitalized to inventories $ (1,281)   $ (456) $ (3,318) $ (905)
Total stock-based compensation included in costs and expenses 65,734   46,136 186,379 135,160
Stock options          
Stock-based compensation expense:          
Stock-based compensation expense by type of award: 39,074   26,291 105,720 78,403
Type of award:          
Unrecognized Expense, Net of Estimated Forfeitures 197,031     $ 197,031  
Weighted-average recognition period (in years)       2 years 3 months 18 days  
Restricted stock and restricted stock units          
Stock-based compensation expense:          
Stock-based compensation expense by type of award: 26,203   18,418 $ 78,274 51,431
Type of award:          
Unrecognized Expense, Net of Estimated Forfeitures 190,786     $ 190,786  
Weighted-average recognition period (in years)       2 years 8 months 23 days  
ESPP share issuances          
Stock-based compensation expense:          
Stock-based compensation expense by type of award: 1,738   1,883 $ 5,703 6,231
Type of award:          
Unrecognized Expense, Net of Estimated Forfeitures 1,885     $ 1,885  
Weighted-average recognition period (in years)       5 months 9 days  
Research and development expenses          
Stock-based compensation expense:          
Total stock-based compensation included in costs and expenses 44,701   31,131 $ 124,550 91,284
Sales, general and administrative expenses          
Stock-based compensation expense:          
Total stock-based compensation included in costs and expenses $ 21,033   $ 15,005 $ 61,829 $ 43,876
Stock and Option Plan 2013 [Member]          
Type of award:          
Number of additional shares authorized   7,800,000      
XML 64 R41.htm IDEA: XBRL DOCUMENT v3.3.0.814
Fair Value Measurements (Details)
$ in Thousands
Sep. 30, 2015
USD ($)
Level 3  
Financial assets carried at fair value:  
Term loan fair value $ 294,800
Recurring basis  
Financial assets carried at fair value:  
Total financial assets 643,421
Total financial liabilities (1,576)
Recurring basis | Money market funds  
Financial assets carried at fair value:  
Cash equivalents: 340,573
Recurring basis | Corporate debt securities  
Financial assets carried at fair value:  
Cash equivalents: 25,109
Marketable securities: 109,335
Recurring basis | Commercial paper  
Financial assets carried at fair value:  
Cash equivalents: 24,000
Marketable securities: 140,245
Recurring basis | Level 1  
Financial assets carried at fair value:  
Total financial assets 340,573
Total financial liabilities 0
Recurring basis | Level 1 | Money market funds  
Financial assets carried at fair value:  
Cash equivalents: 340,573
Recurring basis | Level 1 | Corporate debt securities  
Financial assets carried at fair value:  
Cash equivalents: 0
Marketable securities: 0
Recurring basis | Level 1 | Commercial paper  
Financial assets carried at fair value:  
Cash equivalents: 0
Marketable securities: 0
Recurring basis | Level 2  
Financial assets carried at fair value:  
Total financial assets 302,848
Total financial liabilities (1,576)
Recurring basis | Level 2 | Money market funds  
Financial assets carried at fair value:  
Cash equivalents: 0
Recurring basis | Level 2 | Corporate debt securities  
Financial assets carried at fair value:  
Cash equivalents: 25,109
Marketable securities: 109,335
Recurring basis | Level 2 | Commercial paper  
Financial assets carried at fair value:  
Cash equivalents: 24,000
Marketable securities: 140,245
Recurring basis | Level 3  
Financial assets carried at fair value:  
Total financial assets 0
Total financial liabilities 0
Recurring basis | Level 3 | Money market funds  
Financial assets carried at fair value:  
Cash equivalents: 0
Recurring basis | Level 3 | Corporate debt securities  
Financial assets carried at fair value:  
Cash equivalents: 0
Marketable securities: 0
Recurring basis | Level 3 | Commercial paper  
Financial assets carried at fair value:  
Cash equivalents: 0
Marketable securities: 0
Prepaid and other current assets | Foreign currency forward contracts | Recurring basis  
Financial assets carried at fair value:  
Foreign currency forward contracts 3,508
Prepaid and other current assets | Foreign currency forward contracts | Recurring basis | Level 1  
Financial assets carried at fair value:  
Foreign currency forward contracts 0
Prepaid and other current assets | Foreign currency forward contracts | Recurring basis | Level 2  
Financial assets carried at fair value:  
Foreign currency forward contracts 3,508
Prepaid and other current assets | Foreign currency forward contracts | Recurring basis | Level 3  
Financial assets carried at fair value:  
Foreign currency forward contracts 0
Other Assets | Foreign currency forward contracts | Recurring basis  
Financial assets carried at fair value:  
Foreign currency forward contracts 651
Other Assets | Foreign currency forward contracts | Recurring basis | Level 1  
Financial assets carried at fair value:  
Foreign currency forward contracts 0
Other Assets | Foreign currency forward contracts | Recurring basis | Level 2  
Financial assets carried at fair value:  
Foreign currency forward contracts 651
Other Assets | Foreign currency forward contracts | Recurring basis | Level 3  
Financial assets carried at fair value:  
Foreign currency forward contracts 0
Other liabilities, current portion | Foreign currency forward contracts | Recurring basis  
Financial assets carried at fair value:  
Foreign currency forward contracts (1,552)
Other liabilities, current portion | Foreign currency forward contracts | Recurring basis | Level 1  
Financial assets carried at fair value:  
Foreign currency forward contracts 0
Other liabilities, current portion | Foreign currency forward contracts | Recurring basis | Level 2  
Financial assets carried at fair value:  
Foreign currency forward contracts (1,552)
Other liabilities, current portion | Foreign currency forward contracts | Recurring basis | Level 3  
Financial assets carried at fair value:  
Foreign currency forward contracts 0
Other liabilities, excluding current portion | Foreign currency forward contracts | Recurring basis  
Financial assets carried at fair value:  
Foreign currency forward contracts (24)
Other liabilities, excluding current portion | Foreign currency forward contracts | Recurring basis | Level 1  
Financial assets carried at fair value:  
Foreign currency forward contracts 0
Other liabilities, excluding current portion | Foreign currency forward contracts | Recurring basis | Level 2  
Financial assets carried at fair value:  
Foreign currency forward contracts (24)
Other liabilities, excluding current portion | Foreign currency forward contracts | Recurring basis | Level 3  
Financial assets carried at fair value:  
Foreign currency forward contracts 0
Variable Interest Entity, Primary Beneficiary | BioAxone Biosciences Inc | Level 1  
Financial assets carried at fair value:  
Cash and cash equivalents $ 75,400
XML 65 R5.htm IDEA: XBRL DOCUMENT v3.3.0.814
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2015
Dec. 31, 2014
Current assets:    
Cash and cash equivalents $ 756,250 $ 625,259
Marketable securities, available for sale 249,580 761,847
Restricted cash and cash equivalents (VIE) 75,765 8,418
Accounts receivable, net 165,272 75,964
Inventories 49,197 30,848
Prepaid expenses and other current assets 63,388 44,175
Total current assets 1,359,452 1,546,511
Property and equipment, net 706,670 715,812
Intangible assets 284,340 29,000
Goodwill 50,384 39,915
Restricted cash 22,086 176
Other assets 11,061 3,265
Total assets 2,433,993 2,334,679
Current liabilities:    
Accounts payable 78,899 71,194
Accrued expenses 249,698 209,676
Deferred revenues, current portion 14,000 17,468
Accrued restructuring expenses, current portion 8,682 33,107
Capital lease obligations, current portion 14,153 17,806
Senior secured term loan, current portion 0 14,206
Other liabilities, current portion 9,527 4,797
Total current liabilities 374,959 368,254
Deferred revenues, excluding current portion 17,501 27,808
Accrued restructuring expenses, excluding current portion 9,122 12,748
Capital lease obligations, excluding current portion 39,273 39,293
Deferred tax liability 113,860 15,044
Fan Pier lease obligation, excluding current portion 472,724 473,073
Senior secured term loan, excluding current portion 294,832 280,569
Other liabilities, excluding current portion 34,990 21,707
Total liabilities $ 1,357,261 $ 1,238,496
Commitments and contingencies
Shareholders’ equity:    
Preferred stock, $0.01 par value; 1,000,000 shares authorized; none issued and outstanding at September 30, 2015 and December 31, 2014 $ 0 $ 0
Common stock, $0.01 par value; 500,000,000 and 300,000,000 shares authorized at September 30, 2015 and December 31, 2014, respectively; 245,646,269 and 241,764,398 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively 2,419 2,385
Additional paid-in capital 6,106,270 5,777,154
Accumulated other comprehensive income 1,511 917
Accumulated deficit (5,188,053) (4,705,450)
Total Vertex shareholders' equity 922,147 1,075,006
Noncontrolling interest 154,585 21,177
Total shareholders’ equity 1,076,732 1,096,183
Total liabilities and shareholders’ equity $ 2,433,993 $ 2,334,679
XML 66 R10.htm IDEA: XBRL DOCUMENT v3.3.0.814
Product Revenues, Net
 9 Months Ended
Sep. 30, 2015
Product Revenues [Abstract]  
Product Revenues, Net
Product Revenues, Net
The Company sells its products principally to a limited number of specialty pharmacy providers and selected regional wholesalers in North America as well as government-owned and supported customers in international markets (collectively, its “Customers”). The Company's Customers in North America subsequently resell the products to patients and health care providers. The Company recognizes net revenues from product sales upon delivery to the Customer as long as (i) there is persuasive evidence that an arrangement exists between the Company and the Customer, (ii) collectibility is reasonably assured and (iii) the price is fixed or determinable.
In order to conclude that the price is fixed or determinable, the Company must be able to (i) calculate its gross product revenues from sales to Customers and (ii) reasonably estimate its net product revenues upon delivery to its Customer's locations. The Company calculates gross product revenues based on the price that the Company charges its Customers. The Company estimates its net product revenues by deducting from its gross product revenues (a) trade allowances, such as invoice discounts for prompt payment and Customer fees, (b) estimated government and private payor rebates, chargebacks and discounts, (c) estimated reserves for expected product returns and (d) estimated cost of co-pay assistance programs for patients, as well as other incentives for certain indirect customers. The Company makes significant estimates and judgments that materially affect the Company's recognition of net product revenues. In certain instances, the Company may be unable to reasonably conclude that the price is fixed or determinable at the time of delivery, in which case it defers the recognition of revenues. Once the Company is able to determine that the price is fixed or determinable, it recognizes the revenues associated with the units in which revenue recognition was deferred.
The following table summarizes activity in each of the product revenue allowance and reserve categories for the nine months ended September 30, 2015:
 
Trade
Allowances
 
Rebates,
Chargebacks
and Discounts
 
Product
Returns
 
Other
Incentives
 
Total
 
(in thousands)
Balance at December 31, 2014
$
1,463

 
$
29,102

 
$
4,713

 
$
745

 
$
36,023

Provision related to current period sales
6,120

 
39,533

 
429

 
2,402

 
48,484

Adjustments related to prior period sales
(143
)
 
(12,342
)
 
(993
)
 
(235
)
 
(13,713
)
Credits/payments made
(5,115
)
 
(22,465
)
 
(3,254
)
 
(1,652
)
 
(32,486
)
Balance at September 30, 2015
$
2,325

 
$
33,828

 
$
895

 
$
1,260

 
$
38,308
XML 67 R27.htm IDEA: XBRL DOCUMENT v3.3.0.814
Collaborative Arrangements (Tables)
 9 Months Ended
Sep. 30, 2015
Collaborative Arrangements  
Schedule of Recognized Collaborative Revenue
During the three and nine months ended September 30, 2015 and 2014, the Company recognized the following revenues attributable to the Janssen NV collaboration:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2015
 
2014
 
2015
 
2014
 
(in thousands)
Royalty revenues (INCIVO)
$
158

 
$
2,284

 
$
1,742

 
$
12,917

Collaborative revenues (telaprevir)
441

 
1,390

 
1,620

 
4,262

  Total revenues attributable to the Janssen NV collaboration
$
599

 
$
3,674

 
$
3,362

 
$
17,179
Fair Value Of Consideration Transferred
The consideration paid and the preliminary fair value of the contingent milestone and royalty payments payable by the Company pursuant to the agreement are set forth in the table below:
 
June 4, 2015
 
(in thousands)
Up-front payment
$
80,000

Fair value of contingent milestone and royalty payments
175,340

Total
$
255,340
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed
The following table summarizes the preliminary fair values of the assets and liabilities recorded on the effective date of the agreement:
 
June 4, 2015
 
(in thousands)
Intangible assets
$
255,340

Goodwill
10,468

Deferred tax liability
(91,023
)
Net other assets (liabilities)
(10,468
)
Net assets attributable to noncontrolling interests
$
164,317
Schedule of Collaborative Arrangement Activity Net Loss Attributable to Noncontrolling Interest
The Company did not have any consolidated VIEs for the three and nine months ended September 30, 2014. An aggregate summary of net loss attributable to noncontrolling interest related to the Company's VIEs for the three and nine months ended September 30, 2015 is as follows:
 
Three Months Ended September 30, 2015
 
Nine Months Ended September 30, 2015
 
(in thousands)
Loss attributable to noncontrolling interest before provision for income taxes
$
(1,743
)
 
$
(3,322
)
Provision for income taxes
(777
)
 
(30,367
)
Increase in fair value of contingent milestone and royalty payments
3,853

 
2,780

Net (income) loss attributable to noncontrolling interest
$
1,333

 
$
(30,909
)
Schedule Of Collaborative Arrangement Summary Of Items Related To Variable Interest Entities
The following table summarizes items related to the Company's VIEs included in the Company's condensed consolidated balance sheets as of the dates set forth in the table:
 
September 30, 2015
 
December 31, 2014
 
(in thousands)
Restricted cash and cash equivalents (VIE)
$
75,765

 
$
8,418

Prepaid expenses and other current assets
3,057

 
268

Intangible assets
284,340

 
29,000

Goodwill
19,391

 
8,923

Other assets
461

 
42

Accounts payable
1,115

 
189

Accrued expenses and other current liabilities
32,519

 
3,891

Deferred tax liability, net
110,360

 
11,544

Other liabilities
300

 
300

Noncontrolling interest
154,585

 
21,177
XML 68 FilingSummary.xml IDEA: XBRL DOCUMENT 3.3.0.814 html 264 275 1 false 73 0 false 11 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://www.vrtx.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - Condensed Consolidated Statements of Operations Sheet http://www.vrtx.com/role/CondensedConsolidatedStatementsOfOperations Condensed Consolidated Statements of Operations Statements 2 false false R3.htm 1001501 - Statement - Condensed Consolidated Statements of Operations (Parenthetical) Sheet http://www.vrtx.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical Condensed Consolidated Statements of Operations (Parenthetical) Statements 3 false false R4.htm 1002000 - Statement - Condensed Consolidated Statements of Comprehensive Loss Sheet http://www.vrtx.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss Condensed Consolidated Statements of Comprehensive Loss Statements 4 false false R5.htm 1003000 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 5 false false R6.htm 1003501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 6 false false R7.htm 1004000 - Statement - Condensed Consolidated Statements of Shareholders' Equity and Noncontrolling Interest Sheet http://www.vrtx.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndNoncontrollingInterest Condensed Consolidated Statements of Shareholders' Equity and Noncontrolling Interest Statements 7 false false R8.htm 1006000 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 8 false false R9.htm 2101100 - Disclosure - Basis of Presentation and Accounting Policies Sheet http://www.vrtx.com/role/BasisOfPresentationAndAccountingPolicies Basis of Presentation and Accounting Policies Notes 9 false false R10.htm 2102100 - Disclosure - Product Revenues, Net Sheet http://www.vrtx.com/role/ProductRevenuesNet Product Revenues, Net Notes 10 false false R11.htm 2104100 - Disclosure - Collaborative Arrangements Sheet http://www.vrtx.com/role/CollaborativeArrangements Collaborative Arrangements Notes 11 false false R12.htm 2105100 - Disclosure - Earnings Per Share Sheet http://www.vrtx.com/role/EarningsPerShare Earnings Per Share Notes 12 false false R13.htm 2106100 - Disclosure - Fair Value Measurements Sheet http://www.vrtx.com/role/FairValueMeasurements Fair Value Measurements Notes 13 false false R14.htm 2107100 - Disclosure - Marketable Securities Sheet http://www.vrtx.com/role/MarketableSecurities Marketable Securities Notes 14 false false R15.htm 2108100 - Disclosure - Accumulated Other Comprehensive (Loss) Income Sheet http://www.vrtx.com/role/AccumulatedOtherComprehensiveLossIncome Accumulated Other Comprehensive (Loss) Income Notes 15 false false R16.htm 2110100 - Disclosure - Hedging Sheet http://www.vrtx.com/role/Hedging Hedging Notes 16 false false R17.htm 2112100 - Disclosure - Inventories Sheet http://www.vrtx.com/role/Inventories Inventories Notes 17 false false R18.htm 2113100 - Disclosure - Intangible Assets and Goodwill Sheet http://www.vrtx.com/role/IntangibleAssetsAndGoodwill Intangible Assets and Goodwill Notes 18 false false R19.htm 2115100 - Disclosure - Long-term Obligations Sheet http://www.vrtx.com/role/LongTermObligations Long-term Obligations Notes 19 false false R20.htm 2116100 - Disclosure - Stock-based Compensation Expense Sheet http://www.vrtx.com/role/StockBasedCompensationExpense Stock-based Compensation Expense Notes 20 false false R21.htm 2118100 - Disclosure - Other Arrangements Sheet http://www.vrtx.com/role/OtherArrangements Other Arrangements Notes 21 false false R22.htm 2119100 - Disclosure - Income Taxes Sheet http://www.vrtx.com/role/IncomeTaxes Income Taxes Notes 22 false false R23.htm 2120100 - Disclosure - Restructuring Liabilities Sheet http://www.vrtx.com/role/RestructuringLiabilities Restructuring Liabilities Notes 23 false false R24.htm 2122100 - Disclosure - Commitments and Contingencies Sheet http://www.vrtx.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 24 false false R25.htm 2201201 - Disclosure - Basis of Presentation and Accounting Policies (Policies) Sheet http://www.vrtx.com/role/BasisOfPresentationAndAccountingPoliciesPolicies Basis of Presentation and Accounting Policies (Policies) Policies http://www.vrtx.com/role/BasisOfPresentationAndAccountingPolicies 25 false false R26.htm 2302301 - Disclosure - Product Revenues, Net (Tables) Sheet http://www.vrtx.com/role/ProductRevenuesNetTables Product Revenues, Net (Tables) Tables http://www.vrtx.com/role/ProductRevenuesNet 26 false false R27.htm 2304301 - Disclosure - Collaborative Arrangements (Tables) Sheet http://www.vrtx.com/role/CollaborativeArrangementsTables Collaborative Arrangements (Tables) Tables http://www.vrtx.com/role/CollaborativeArrangements 27 false false R28.htm 2305301 - Disclosure - Earnings Per Share (Tables) Sheet http://www.vrtx.com/role/EarningsPerShareTables Earnings Per Share (Tables) Tables http://www.vrtx.com/role/EarningsPerShare 28 false false R29.htm 2306301 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.vrtx.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.vrtx.com/role/FairValueMeasurements 29 false false R30.htm 2307301 - Disclosure - Marketable Securities (Tables) Sheet http://www.vrtx.com/role/MarketableSecuritiesTables Marketable Securities (Tables) Tables http://www.vrtx.com/role/MarketableSecurities 30 false false R31.htm 2308301 - Disclosure - Accumulated Other Comprehensive (Loss) Income (Tables) Sheet http://www.vrtx.com/role/AccumulatedOtherComprehensiveLossIncomeTables Accumulated Other Comprehensive (Loss) Income (Tables) Tables http://www.vrtx.com/role/AccumulatedOtherComprehensiveLossIncome 31 false false R32.htm 2310301 - Disclosure - Hedging (Tables) Sheet http://www.vrtx.com/role/HedgingTables Hedging (Tables) Tables http://www.vrtx.com/role/Hedging 32 false false R33.htm 2312301 - Disclosure - Inventories (Tables) Sheet http://www.vrtx.com/role/InventoriesTables Inventories (Tables) Tables http://www.vrtx.com/role/Inventories 33 false false R34.htm 2316301 - Disclosure - Stock-based Compensation Expense (Tables) Sheet http://www.vrtx.com/role/StockBasedCompensationExpenseTables Stock-based Compensation Expense (Tables) Tables http://www.vrtx.com/role/StockBasedCompensationExpense 34 false false R35.htm 2320301 - Disclosure - Restructuring Liabilities (Tables) Sheet http://www.vrtx.com/role/RestructuringLiabilitiesTables Restructuring Liabilities (Tables) Tables http://www.vrtx.com/role/RestructuringLiabilities 35 false false R36.htm 2401402 - Disclosure - Basis of Presentation and Accounting Policies (Details) Sheet http://www.vrtx.com/role/BasisOfPresentationAndAccountingPoliciesDetails Basis of Presentation and Accounting Policies (Details) Details http://www.vrtx.com/role/BasisOfPresentationAndAccountingPoliciesPolicies 36 false false R37.htm 2402402 - Disclosure - Product Revenues, Net (Details) Sheet http://www.vrtx.com/role/ProductRevenuesNetDetails Product Revenues, Net (Details) Details http://www.vrtx.com/role/ProductRevenuesNetTables 37 false false R38.htm 2404402 - Disclosure - Collaborative Arrangements Narrative (Details) Sheet http://www.vrtx.com/role/CollaborativeArrangementsNarrativeDetails Collaborative Arrangements Narrative (Details) Details 38 false false R39.htm 2404403 - Disclosure - Collaborative Arrangements (Details) Sheet http://www.vrtx.com/role/CollaborativeArrangementsDetails Collaborative Arrangements (Details) Details http://www.vrtx.com/role/CollaborativeArrangementsTables 39 false false R40.htm 2405402 - Disclosure - Earnings Per Share (Details) Sheet http://www.vrtx.com/role/EarningsPerShareDetails Earnings Per Share (Details) Details http://www.vrtx.com/role/EarningsPerShareTables 40 false false R41.htm 2406402 - Disclosure - Fair Value Measurements (Details) Sheet http://www.vrtx.com/role/FairValueMeasurementsDetails Fair Value Measurements (Details) Details http://www.vrtx.com/role/FairValueMeasurementsTables 41 false false R42.htm 2407402 - Disclosure - Marketable Securities (Details) Sheet http://www.vrtx.com/role/MarketableSecuritiesDetails Marketable Securities (Details) Details http://www.vrtx.com/role/MarketableSecuritiesTables 42 false false R43.htm 2408402 - Disclosure - Accumulated Other Comprehensive (Loss) Income (Details) Sheet http://www.vrtx.com/role/AccumulatedOtherComprehensiveLossIncomeDetails Accumulated Other Comprehensive (Loss) Income (Details) Details http://www.vrtx.com/role/AccumulatedOtherComprehensiveLossIncomeTables 43 false false R44.htm 2410402 - Disclosure - Hedging (Details) Sheet http://www.vrtx.com/role/HedgingDetails Hedging (Details) Details http://www.vrtx.com/role/HedgingTables 44 false false R45.htm 2412402 - Disclosure - Inventories - Schedule of Inventories (Details) Sheet http://www.vrtx.com/role/InventoriesScheduleOfInventoriesDetails Inventories - Schedule of Inventories (Details) Details 45 false false R46.htm 2413401 - Disclosure - Intangible Assets and Goodwill (Details) Sheet http://www.vrtx.com/role/IntangibleAssetsAndGoodwillDetails Intangible Assets and Goodwill (Details) Details http://www.vrtx.com/role/IntangibleAssetsAndGoodwill 46 false false R47.htm 2415401 - Disclosure - Long-term Obligations - Fan Pier Leases (Details) Sheet http://www.vrtx.com/role/LongTermObligationsFanPierLeasesDetails Long-term Obligations - Fan Pier Leases (Details) Details 47 false false R48.htm 2415402 - Disclosure - Long-term Obligations - Term Loan (Details) Sheet http://www.vrtx.com/role/LongTermObligationsTermLoanDetails Long-term Obligations - Term Loan (Details) Details 48 false false R49.htm 2416402 - Disclosure - Stock-based Compensation Expense (Details) Sheet http://www.vrtx.com/role/StockBasedCompensationExpenseDetails Stock-based Compensation Expense (Details) Details http://www.vrtx.com/role/StockBasedCompensationExpenseTables 49 false false R50.htm 2416403 - Disclosure - Stock-based Compensation Expense (Details 2) Sheet http://www.vrtx.com/role/StockBasedCompensationExpenseDetails2 Stock-based Compensation Expense (Details 2) Details http://www.vrtx.com/role/StockBasedCompensationExpenseTables 50 false false R51.htm 2418401 - Disclosure - Other Arrangements (Details) Sheet http://www.vrtx.com/role/OtherArrangementsDetails Other Arrangements (Details) Details http://www.vrtx.com/role/OtherArrangements 51 false false R52.htm 2419401 - Disclosure - Income Taxes (Details) Sheet http://www.vrtx.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.vrtx.com/role/IncomeTaxes 52 false false R53.htm 2420402 - Disclosure - Restructuring Liabilities (Details) Sheet http://www.vrtx.com/role/RestructuringLiabilitiesDetails Restructuring Liabilities (Details) Details http://www.vrtx.com/role/RestructuringLiabilitiesTables 53 false false R54.htm 2420403 - Disclosure - Restructuring Liabilities (Details 2) Sheet http://www.vrtx.com/role/RestructuringLiabilitiesDetails2 Restructuring Liabilities (Details 2) Details http://www.vrtx.com/role/RestructuringLiabilitiesTables 54 false false R55.htm 2422401 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.vrtx.com/role/CommitmentsAndContingenciesDetails Commitments and Contingencies (Details) Details http://www.vrtx.com/role/CommitmentsAndContingencies 55 false false All Reports Book All Reports In ''Condensed Consolidated Balance Sheets'', column(s) 3, 4 are contained in other reports, so were removed by flow through suppression. In ''Condensed Consolidated Statements of Cash Flows'', column(s) 1, 2 are contained in other reports, so were removed by flow through suppression. vrtx-20150930.xml vrtx-20150930_cal.xml vrtx-20150930_def.xml vrtx-20150930_lab.xml vrtx-20150930_pre.xml vrtx-20150930.xsd true true ZIP 69 0000875320-15-000056-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000875320-15-000056-xbrl.zip M4$L#!!0````(``.#7D??GK%$)VL!`+)"&@`1`!P`=G)T>"TR,#$U,#DS,"YX M;6Q55`D``^71,U;ET3-6=7@+``$$)0X```0Y`0``[%U;=Z.XEGX^L];\ATR> M)Q5NOB2K.V=A8U>[.Y6;J_KRU(N`8FL*@UM`*CZ_?B2,;;"Q8SL&)-BUNJL2 M$$+:^].W+Q+23_]^FSAGKXCXV'-_/I<_2>=GR+4\&[NCG\^_#2_T87"PFA_=SV7'R7/:BE'[01SGZ& MWL@HCMZL<79Y=H<]T$@_@-U7Y`?9C\SO9?0&^YZFR*WE4S]^_/@4/>F1$2TN MJ9=QB<4##G:_[RC-;C^;/EH4=TUL^=EMBFZQ)LGI)KF>ZX:3['?8`;D,9E-T M20M=T%*(8&OYW/L/I1\@Z&5K3YJ7].ZBH(^M["[0&QD=\(,IV5*>WLEX(/0O M1J8Y73[S8OK/44/B&QG*IG>(YR`_\YGH3O9#3`[9#T5WLAX*"!IME=/5);V_ M*/I*@K=427;AD^5-HFJE*U5:E&15V&O#82GY^-$@6Q;N@[/J! MZ5I+<+YM@/F'&I6F5')U&=U=%O7MK(*T6OGRSR^W0VN,)N:J,'Z_\,6R-92= M_O43>]FU']UY0B]GT3J4/[=!G5,Z?53_^FI$KUJ4H3R,@UET97$)V^SB"T;D+&H*2G5C@>+N MX+?S&XG^:;<:JB+]=+G^\/PMEQNOB=\RI8/0LU,OII(@@4%-PLT"@)*\J&!U M+_D$XM_#@&**A5:]?T+: MOJXWF7HN_=77W["_+/5@TN`D^((FSX@4*;SE.$(CUL;YM?E%F[[\;>I@"\?M M.K,Q+3,/*N-V7^_LW?G-HEBR>S]=9M8>-^=RLSU"^ROQB%`/Q`.]//'<8>!9 MWRL+BHT^YHN,U-`_/?,=/?3O/)=51$-#&CJ,!K1*@OSJ4L&N[M:0&M1'#:B! M(VI0<_`*CM.S;MLXH,(SG0<3VP.W:TYQ8#J5U?G._@JM_Z--`PQU,`+9R'A" M@8E=9/=,XE(SZE<6'MD=%9H.XA0!<$'97%!`+N3PD0V9`#%&\2JA#'X=KWX= M=QGUXZ@?,@0%90@*28X?JGW@BS+BP#Q2A/'D"#A^'#E^>4:@*K!!=AB M!"PKG(0.6YIY'XP18<4(&C,=O*(!M9<35%G$[-UWH9V#HTD#`L:J4L71D("` MH8PI11X@/14X6R!QCU8KA^QZ^#A(%?]L#GTD$XG"K`B127/HY; M)`^9Z^(SUWE]"J.)L5L&/YX1@+^,:9OQ'.P@+"(3]^GY^PSI_O4_G:S9)_4$X=;VI.?N" M`SR*GH@%7'$8[>HTP&=/^"Q]E$6IOD>&IH-\RMDA<2N,H:6'LK/G-0/2NH,+ M-DT8FU;\]J$?H)BOQ+31$[(0?C6?G2J;JBR:R>X]4`T8+-X-5B%Q]$DP`0Q3 M-,/PB0V(CXJ/CPI>T0M.JHA.:E[+_(Y%!G!$61S!$1+`D^#,D^`<&Q!YE!!Y MY/B5R.-78V$-',=\]@@5SRO2"3'=4331Y7=F^HB@Z.>5[?C5='T?N>F'%L7$ MP45L$O;K>6Q!]NAZ@8D-OH[S`BB)#:72UQPGDJX`)7&AQ$.Z=75@'D!);"B5 M?HY@YE00P2P\6"R![;&.841%VG5,WZ>:LR)'\_XENC-+.=29#\\>")Z89-9! M+J)/8_JC.#A;.=B'BV7E;A\FE_KR&8"PIB`LFPGG&%1^#5VD'6-5'ZAL/7=H M8<1"[X%KB0.N8RSIENX6BYGFA:0=@IED^=,=$J[\^NVN"9#A$S+I5%,2`#E- M9(+9JK39*GPZ%/!4%SSED`J?PTF[MP*EN?J@)7SVT3\A;5[OE?ZU,2>R=G_> MW6/L6_=I,'QX^CI&Q)RB,,"6@-,J6X2U`E.FM'9B)B?SNDW:!>)7EBZ4YNGQ M&SE8(GR^FI>'P2P"^)<"^)=Y?9IV9*:W@SW]S7,1_=>O"PIV];E^&0WY4=&G M!#M'F>^93ZU('S\3S\=^WPM=.W*JDB:&??5+IJQ&9-=D#NBD0@S*U18=@ M,"HO1%9M?M,@X:AKNC:F"D@L_NNYIC5PQ_@9!Q[QL=M]J38@C[%[^S9E0\3Q M.[?)N%[YOP^N-`*"%9Q@.5BA-$<@B_#!013*0=18M'P0=FCY5;;Q=,9YGAVZ M@`01)(@*L-FI%-$>-CM5GH-U>,"898;4O*Q4.1(\X/`)[O")#T'("=<0,A^8 M0P![5['9A.._9@'K);CUXN4K&`4R9G6%H')@QDSA[NL9<*#J-Y,:&TX-OMT3 M^X.KPPU@:H5G529$[SR8$RU@3C0AYEI.BVJP:DF`D/.CDU)5(,C5@;GI,5QM MS)7!D;LE74.:/#X0@5A8\%B8E\!&?90!@O6$H'I@0$3+JR>V]UD[4.BT(S9V M0B;N(;)"$GW]5T<1"XW<,M/2,G3?C*D5+/9L\0B3P`H`)2[):!91V,#0`&@?$WZ ME<"@OHOL2F!2`*AA02V?4]:W!^B8F[-`'*L;EC[]0S9K$&L]NT2MR4H!; MEAFX5"-^5$`5#W+[]7J%GAW=SA<_!9][<@(TR/%,>0E[S]5QF<@I$2V?9NJ> MN^WU*K?:ICQ6^(),/R21)/HD^A[9FF530J*D_\2,,J%&>XT;!NXKU2PKLO%U M.#7Y$T2HAIT'DW9`Z`&Y36@9HW&'U$XU+#>%OFI'IM0!RSNT`I"L(#).Y?N4 M0YSQ@A`#/0>K:$AHM/+BT0C*Z3L``2,X,ZB#$WID>03AD=M[L\9L7H#^^L,D]O:AJOL^"J*)CE0U M#P1-36SWWJ94"K.@0_2 M:%DU8W^XY-"H>J;=@+VVLU<2?+?8?,9.(HX!P@+"NMZ)$."HFG)41:*B*BU* M@*`(UDF(/1M>MX$'%DLL_.<]EUPW_`L]%2P:_@N/*N\\UX+`$@++G8'E#I!` M;%E3IH(%'J>QRR)%7W5935%5*PRN,5AAB!>JQ%0"D`*L>ZG%R(%U+SQ[SI4: M8(!F/M',:W((YACKD$"!.49>H]LB5B[!UPLBA[8BK%P2>@&&:!Q5D;@6O`H( M:\&KX")G#EX`]UY`L0ENL+KEC^&\/KR":$!D'N#U^RJ(`.K,14`<=2<.&*7\ MCU)>YR!@X`L\\.LYH2(:%PG``K6;JJ_GR('5`]SZ#P6MM(4$A,CNA"`K;2$? M466FRBO2@8\`1*8F7B,=H2=Y@8M.N((+2(1[$BEPN16,WAKN>PG1CZ#L(.:^ MEQ`'`7M!@`3L)29[0>144?8J[-L7("Q!"4N8;U^`HRK*41_SL(!=>&:74MTA M&-?1N-8>M?F!]T,*73MTT/U+U_3'[/_>/R'%DL-Z356COYK880>O4[0,Z=75 M_EIL78!__]+'KNFR#XA6R$L/958GK6BM:G'&6'2X>VYB2GR*M4-.A>%-NY"5 M"U7.Q8[DC+>H^BU[P1DA^@,'8^S>N^@O9`KTP6/>Z(OJ/TAJP'T'<)^HW]D6 M1GJE?G\J,-LM$+:LX<4C?JH&`-LZV-Z3%3#;OE9V[JJ(NR*X&*NZ2TK`<4=; MT3LO&+B6$]K(9NX)Q!='F=H#I`B\"/:XTO:X$API^!;TQ=%@E7>++\P#A#Q+ M9?(LE6`_R+-PG&>I+MOI+P$B\;#].B9>.!KW\6OT*]C>?Z^(N.S&<.JYOD>0W:/-(5."?3J^P4'9CL#-%)]EA9/0H47MK\1T??H3589N_U\X MWS!#'/@L3.'.?B?R=7MUO#!$J#FPCQ'93O6OK\;QH+A#P3>7(-/!_T'V:A^5 MSR9V;SU?('8Y'AY[B2!?H%`PD,"@C9D;*DFF_RTK7=Y+/H%<.U$^23:+.Z5# M"_BF:+[A#D8?MEE`3SS04\YV;!X#JA]"R4()-#.3CD6!B!-% M4V"(A#%$E727`7_"X*\`M[H!)DY0$Y='"MF8(P),7&TH)F7B&@>:N$9.B<6/ M0A!XJ=3$8E5@!'$^#W$^=]!:K$@!"UD+"UG`"I$/H0F,7:EY)@X1`7:+![M5 MT,HR0$E54%+$KF?@J]3%5\ES+?9R<7ZTR5F\&YT5__)W[]M3#KOL9=7D+W30 MF3$94Y$_H;E#X(_Q=.,[@H4N-@^*BZ\NU,@\BN3#*_7J?EQTU0CQX)Y4V_G- M0F_75&\[T7G`&_C9P>\XV*2_J]C`S:D:EPV[UIZ(F#Y\3:=SM>Z;GWH?K552_=YYK;3G6M(KJWM'=.FI_VXFV553]4:?W M5D_O^Y\U6C$0G.B051$0D,/Z[23#;1G?`=F-&?M!CO:;#J3.+:J9*M:)( MZ_XENI,^<3SSX=D#P1.3S#K(I>VP,/TQ?F=\[(#CF,]LSWS:.IT0%LI&42;M MT(B@Z.?59L8=[.EOGHOHO[Z%:=R-_(%K51+2>^GM5*'T,6I?-?4PO7^TS?%! M"_O!)M[>>1=N\F6$M^(1^$#?X+E#D0?[S3#FD"\2]O;6J0W=MMA7$E&F[,]O@NTZ(*506JQQ$&A-[]'(U2-+=%#F?NC'7!N:L M`O-EQLJ3L+)ENC]B?)/JCA]K^VY49#V;+K?[U]>:+1F MLV*W@\[]4[UQ=,!KEXI8O2NEB5,'Y0M%KEZWER8+#6ZIPW#8OO.M/(QEDC[! M6/)B+/-:AD#=26Y]R43WY;SF7C]B543".%?N`G>\E[&+M,[67F]@H#>9.MX, MH6'@6=_OIRR=*QX64EU;@6!KWPK-BY6_[W/&^3\#U_(F:+E]X*UG;7X4\81\ M9!*+'3ILH%?D>)$)B1>PB`>2'5U>06://A?+)*6?W),!GC231+-OJ:'V$%() MFCYB[H=X.%DCDVBFZ)WNU1,2CV!<2C8N1W@:)?,#Y=>`8"M`=I4PD>*('5T$ MG@!H<`$-+EBCL;]+&@%EB!P'NZ//R$7$=*B'IML3[&(JTFB]1S4=TP@_A_2\ MAK%-(\TQ`"0!@700(Q5T[A88J_*-%:<<`R%P>2&P>&P!D*@G2T"6580L*R]\ MLG^H#'Q2GQ`9LJQE9UEYX8PC`V`&,OND^4/5\\5X%]#IWX6&C8S6$ M@0894K$SI+PXI#MG>L$AK=W<+DS@""BX'V,(9JI@UYA)JU:VAV.38(ZM']VUYLP;R9R M?J*KOAX&8X_@_R#[FVLCDH`Y$X;?F?7>$+$PE0WE-[3ZEGZ.D8U[+\2;&&R/ M,>*WI4^2''CQ;[)$?Y7$PTX.LEL@\#CA`3(_C,QF2KAM`.8!P-PJ.Z%QF9%B M`=(4#IMED29W29\2:;:_4H>LI/6A:I^:5P#F76#>3WI"4RT?+D!$#@GI*D"T M!Q#M#ND!-C^,32TEW"8@\P!D;I6=T+CDQCT%:`H'3>Z<4V[`##Z`D#X`=X#F MPVM(APL:8/D`+&^5G=!>`R=9@/:G*W4I6^#8@W(`VV0G-"ZY<0"`,H6C3.Z, M?[E@!IX5F6F9,$"B/!FZZ]DCU] M2A4/:\F>+3X1VM&U8J&@'0B%9CY?=3`H<'N2P_K'#`?)3#N]S*C(I+8X!ZE) M[<,8AY8_^4%J,KAQ@0"#';:\@&S1:M9`:-"I0``UCM#36 M+7,F%#2:@T9//D;96B@U6@L%:2Y>)C$D]<`%7^KI%WS%_I4,([TL_TK-8X4# MU2AD1(0ZXD;-8V"_'PK#T6ABA\=[9\%!T77+C.\7E0$NQ(_4WL^F@);%S["\ M/WT-6A9[2GN_7#=H6>S\]]XSUJ!HF,4&:/`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`_FT'9M' M5B^N(UOWXZ*K1L0!3P+V%VI"@;VN1#%\1?\T%$H.;;DG-9:4I/2;"=1'EIJ. MSW=TDI?>>M^>0&]+O34-2>WK6J13R&M+VB\\168YB24'4GJQ@6'GM&M&J0+)QC0;DLXKO-;)MB@]D"<1I6@;- M>4WVMHVY0?YWH,*8.@I"A+Y5$9VR,3#+ELR\\Z MA_)IQ/CC MI+O>7AK$'5\EM1A9^(=()F+.`#;JFRAL6X1KI:25&]]-Q:&$KOG_C]%\7!]^ MR\]P>G^Q3%[''8L]3D:+Q?C3^&PIM'>?5FGM+>$-OOCJ_9PY,+\*W;3C5X_Y MVSUR]-(;*Q()9\`S3%$ZQS[&Q>B:M$TZ>BS6L(%]'4DQF0QQM98XBI*$-U`V^YI9V%NME1+J6AUAK"87,++`R'<1GHZ+)5F+QF9A.H5T?/D$D MSD7:Q)ZS1]PF>9B2(^@]*_2ZO8UE#U'?SOUV.)N-/5XQ2-U%OM]BC$5$I"!ZR MX@AIB_19I]YJ7'&N22/>*/WM\/+OTWG'7/M7=_YVB;KKRWO^[N.;C4H7FU,4 M)Z%L^VD^FBY6^98__]_+%=/V,$LG3H,D<.9CM2I4 MI+"JSS%$++ZU6-5`L.=C%^P(.L*AD0B(@8%.]MD5ZI&WDYY$"RZQ"9'/NK)3 M\D49K`Y1%U81D;/7)&]J!TI,C6.72.+;8>81SDA9GSCS5)ZTR(A0L$'(TIR2!9G3@D8(%+WW MP005DL[@4NK+7$MB_]X>MKH3LJICF7F$.W*Z",F!D'];#XF$#Z5W1X#M/A]^ M*VP[Q!E%95TL0NBH,>=8V!WU>9K42;2;`5+J!TS4SL_'JZ.N]Z,Q2SJ.OHPO M1I.-0L_[P:%:&1ER+;]-H$UF%)?[7>FBJ#0G6\9:*\W69OI>FHY>PBX?6CB+ M9+L7AH"8NA)5,CU6M0-8E9-+5%8618_S;[RVF7![UH_=*R:B_%% M]V,W_VU\UJV*J3]T9[.?I\MW^<=H)5\HM"C M6AG%0`T7"MS2RD=>TTDP\+ZN8IBR?1O(DG.+Y"7%E!5XI*K`UYOLBB'RJS`. M$L;[T?P.%1\I6BECX:3.*J?(:[=V!DEA>QC]A^.]V>U)2F*?:=%&E"XY"EK$ M=3%O$;DYSY*.D.P?CX%/XDDD%G;@I)U-)Y>8HZE48#^=)C$\` M&'.I-=#D1))IO;FA0;2IV7/S?C*9G55,.7Q!?/Z]?COLB_^VPQ^`TKSR*%4B MYH(!(I/[ZIZDH=DV!:PN]187[D38`ZYE+><5EE[KQ'>SL[:"[4.WZ$;SLU_\ M]#QUOW63V9>E^JP^85_>%(3)T4?CBA>14P(5U^>"H$(3Z#6G`O(%\&9UAWTW MF7`&_I=NVLU'$V://_\\GBZ;HFK%W=TX9*T)&=&YB,IEIQ-)N=YMC;G)+&M5 MD7E&#NV*C,X94K7FWGLEG4>4L;<$F=DW#_5)H'C>Q3R9*8@4K!6..!-3G$-* MIU5?*5U"*4T21E(Y>`&\>3A3"(%Y(XM)+@O('-2-U]?J@YI<4WH#'/6?S9&: MW4'!"01)+'+(/AO(A-B7?`J?7%-+B<;J9Y.V>=J@(+,N&9/C\.@=Y]["^'7- MN;:IL00`!MPO@#==S).90HC6&($A"R^P"$.N/T4&5\I`9Z$" M8YXM8MZ#.0]G"Y`,"4X;%%%6L;#:4.KAM?>Q]:32J>/59WHQ/A]/+BN9/W9G ME_-EC6+^_6QR>=Z=U].8^@Z7%WVIY6@^Y84N^AE`0^TM`PCSR$\)5\-O<$L[ M\^^TWSU'32*YJ'46:"'ULU","Y@VPW`_6D%JL9W8/00# MOU&1+.=_C<^J0E:A[#VSRUF8&$THI&)(R0OJ]TIS-'E`'`JWR^)?D#3^>?(& M$H,5/IBHH]$".=<1N(YHX"!]K#6@F/$PO"Q.(N1>C1OZ%8/^6HTZK)\[M;*OD+'@<0>?&_75Q-$(5.M M#/0E$*?-,A35GS&4HC&U*U2'+'"QZ"[>?OXR&L]KLAM_J;/;!D89[MLB5R2+ M\#&GI+1'X.RV'PHGV4DWAT5DMWH+!\DXB-(]^S8R,Y#RM5T3J98(J`#8UPI2 MS,V^S7;][1T)7=RO&DO:G'6R.K'`I5(8I>NS(VDY>?>B91= M5566K4=G63N6B\+DBH]]19&U)-OI#*`UT0"7AD@YJ!O9+GO)$*TLT:I2K(WK M.0,AV(8YTE21R@&*!KLQ=Q.VBU49K6&2#(:@C2`9^:;PXF\SJ>-C=M9#K%X2K];?_PRZG[N5=?5=W\FY/&NF?>3ME-[Y8 M/B"W9H%LO.7WJPFUR\&D\^[7R_4@FN;9C2=KWSHO\&;R^0XSL%8`%%3*!ZV+ MP'[[Z&S;\WPME(,! M+WW"O-7/Q5MCLQ"^8(K&5H9F[?O>HB*2:XY^GH&GC\L`D5VM&BLR&30.:QSK M/:'TQK>EN*!!#7GHO8SX;32>U%[_,IO_.)IL8-*#0HOS2GI+04BEL_<"!?9M M *:HK>+!L-;"'D?10=2__."$3\4WN;*")PY,ZF+_\U1<32'+0H(./$$?2' MR\5XVBT6C/H_CE=SH>)LNAB?UTF__)=E8?VGCE]X+F\M907-U%\OIQVLH'"< M3?AS9ZM#$S^?UT%72Z7C5.CG>;?\_@8XOQ_-^>U_/!NSXG:+M].S?=MG0A'C M`*^"SX&((*GK`A3(9$.+\XQ9GE1O<.8^:[T#DR[8C"IDW'R+S67'Y:BOM]-5 MSO3NTU=>T@^7N))[]VQ.8:B&SSD()LXX$"XCAYJL^T1-Y=R<^3(FUW>0PH,S M\Z0$>(!]A/',_SZ;=OQUL=-(-K-H0BB1\T:I2@!@]ZUR/Z>AF"2:TI0W*.YB M(J_".7RS]/S.NQ0!A1>"A* M.$\4<_8]V!;)VV:FA[+N58!/Y?6\?E^WXS\GH.EJ$@I50;##:D1:E+^%Q3@_472+H MK3$WC\256YR_[H#ZKMYU^.[C9/SS\F,.V\%!5^>FF:11^TSHDNJ'-M9-N=2D M,&R@6P,/=U-S%.&[MFX4."*7J78$..>,7_=;@B"KVS8SD%N9\?&$LT;5A\_O M?=ZG74JH^3E>0]:V3DCL>QH*E=C,0G#DS%UH[PDZCO@]1X`*M'::=N:%-U)7VX( M.I;\7>HN`N,Z2(%"2IS/2O92_;C1OZBEZ_5+;0G];319=H-> MQ-%\7@?,#+25[ANM:F(($540.4NMD>.97U]=)S(V2F]8M;8FB=^)JH=8QZZQ MC$G70JD$4:*U*16J5[A=&R]X/3#4WAG_4ZU58MX4U_U(1=)>ZCQQZAR?U^OY?P1FO[Q@4J0 MERZUQZX4>7B_6)R(B-X$(;2W$*P+JOI%E,H)8]K^3MC>6GJ5V7.YQV0)O$E% M9P"3L[*9`3N[1RV3(XYW[7FY%'?!4J^R>TPO606%64$BC"2#\65]3XOGO/P; MCFF/7>OU\-XQBUQOZK8*C-"0?7`DEMY1LZ79=L_D55@GX!8+^@"NWEP07:H- M1RS!ZA9!94H"FY#V*K3G](LQ1%-"@)R39M^X\H>:,61JROE.4%HGZKPP MRFP(9-$`3+NC(LPRY8T`6=(+@G8G[G"B$C9FF3%J*XT':Y"8T=%SJ`_4'@N< M+@X[52?!@`ESL]F]>-[=2MOM[[1";9 M:-$`>S\+I!ECN+Z\WY1D=3LQ$DAMW8UX'_H><&%[3FM`F0"E:%&B#&C)H>L+ M2*T;&K2C!6W=M'?XPMA'CE=S'.OK-X^6O[)5O3'!DPI9AN?.1N]#J27:UYO3 M5&_-V"+[3[\OQO\U'4_^^\\7\\ONSW_ZS\/I6&XUWVA["@HRN>@D&EL$0=\$ MBBX8M=WVL9^.Z['8[T?S=_/ED)SSI<[W'9][M_#?_E!N77[%F(I_(:B*AB,H MK?O2`,#MT?W]AW#D_@\A-P2\GZ[CU[&UA7]['2A(9J'18!#21@E%]@T0#/CA M\=>Q_,^%O[SX939OZCWVRT&24"Y%JX+F)Y-,LJPO*56L04.]PD(T,?[K]!Q. M]TZ^LQNOAR2IF'JB92.GPF(]T'$;O3AX3*W"]=2P4D;5P)8?U3:<"2XR#]!H$ M5$A'TON.DY&+T?24^`4)BOH;\UCRIT8,L6[L/L.E!]P!NN42B+7RVMT8)@1L18H7-N? M]]C>*ZNW"T&V/OZ>M.TZ5W7@F)JLM,D`A$#9KY%#5 MW&'6LB?632NE0D6,X#RZ=-,^5W"@(AG=]I#0'?0<1?B&!2@U>/3O6>,J8"2!;N$D#UIJQQ2?R4@.D^AT8PW)&EK@/-C MD;V+W298HA3(>)FUC,&ZN+[;5ZBV$?X-U&+41J>/I=M?7,S''R\O:A7@3[-: M?\/KF,^60Q'[OHE[FT"R15GO+>3DKF"P"<5Z0[Z0Z^\W^#=[5]?"&#Y=7<_;)@ZQ\PG6Z$2)::*SVC-/H'A(/8`P6W-SL>'A MMXT.SVZ?+K=."*[<:B.$=E(UHT.V>.WSYI8@C*7WOUDM2\T MVUG&:(=R1DI=VL.\$!*_*?-T"8^\-@0K"9MGY$@I1,+:XVM0L=8\F@O+G],^ MLS\FUS?SALPYU+YKVKC+#I?THZT;B`8:>?2.T'1TW"D&H19W6PVBP1%",CG. M2'H"[23[NJ6*6F3F*5V!B*4Q$8>+@9QSRR?T07R M#H!NU&8HF+?H>4$P04:3*CT9@!;M"O+E5'/=$11T%LJ(VFD, M&B5(QH?Q3,ZWB8(4?)[6C^1[+,/F`O;LQSP%4"DU4BJII"+1V`#I>?;-(_1\ MD,!X'^\DX+HA'B`H.J9(EG/1&@6!U1!IO!4-H)!(WS3&$[L*V'WR09XSI4(4 M`\MQCH7#Z.>GGTZ_3'_[?5T M=C;]=GJYA%I+G9S=\@];N\W#5[[_ZV9>K7&;_EA6;3'Z^CK#HM6(0::4&,1@ M.3/.88BT_UR2*35P M8&>VT"8R6NZH^1T+V^<)>>3WR59]Y-DY%T..H*,#[Q7]5U';?,!GVT>NP(QD M7B;%5H+V7K4(H9$]D\J*VTR_D)!#I0&RMI&6-Y5XFPNZ=<]R=-FIQ!%E=%%@ MXG5".U`2QEM:8S2L:]05S;X;B-M],$RRO+\EPR%SYETPOO+7,R-:Y%ZN4_@. MXOYV^MDN>:2D;,@];W4&3X%+R\;P&Z_EH5B2A%2E(;DU@A=U_F#$?=6KO7;@T ML'S_'T[ZHUIN=(I.H1QY--Z8$)G(9GANR>W[`N=,/IO%GIV)A_`LDQ0G`C?& M6>=MJO=B2;2SK0FOC0CP-S0%)86T1F6)Z?\O)_,;XMFYNSO.YW^^^?V*`$7Q M6$NM4F!.T&[FM354+"%;IEQ'C*/T>K'VH,>:6PZ7>-G)P2@*V*6)W`H8*D13 M.U98@;:PJQ[7TS_N/*NP]_QR=7MR<4'_\^GJI&6W!2"F9`16L596OO>\FK%24^( M'BD_%)3'&!P($T3`)BT4VHP/]F?4OD_LV",2-'2R.HII:`KG"K(TI#JF/3([ MX;@OUE:Z['$U"SMG.>TCETPG%,YD.=!?>-.KAMN+M"OT?X3X-O1.J7,9;)Q+ M@9-,E,.(8-H("SQ9 MPD4-IX3V;D^^S=E"9U_*"]?GJQ^GE[<_5HZV7O>6&@S3PB!DIR%$QUQ-C5!K MOH1EQ8Y56B?2'A3H8>A78<"<@-XL\2NC1^,&#Z[!FL=8PCV6 M3BOE@5,V$R-Y63V6"Y]4JP&,FMN>0X%N.A:R"Z[,OE+2"`.:TI<*D8-J;[GI MD#([*7!S-N]_^SXYO_\[5S-*1M/%1?F4BZ5?WWAC@+6T+3+G4CB-%JQSM3XU M%]#:B[_;"'@@%;L-HV6^F]*%`YUP$.%;Z2L&!^%CC]G@:%1<6^8?!`5L)57V MVGO')`R%#BGZ9F\=J8K=8ATP,3G+T#&E-,%./9!I>_$G6<;G# M@FVE/8RT'=O2=ZAYXH9,^\P)+M:J%-20;.S8ENUDVU@&W*Y@0>Y8MY282B?I M_*.SH4"C#,.0#Z;'[+GWTFPM<"IY%)_>"]%O.6WKN3 MQ'T/S@DL8+(I.J<-)W`4ALXX1HZRI0?O*G'/BXV(SC-'2#127!8Z.EY3'0W& M;^G%2R6^C]3IK[/Y#(M26'(R6\YVL'EOG^69(%!61AI9*NM3]6X"V;&=QO%! MF45@NHET>U1KS8$)P)3)CED6:!=X8=60,5">'1HZB0]BS!F\O5YUH/KD^H_I MV:0&I\EY*:\GH'LWF>3R\JJ^B3T0[]]5O8PE4I;=(^:,RR,K6`R1C:AU8QCAAOS%C=&F>".8YQ$;WQG',L MYUDM0J``U5`W2CGJR3D:8_UR-:=FH@_X\_3Z_.:W*_J\QU\O/^>7J]O?)[NSWEN!:\RD!P71A`XVOY$=>L[07B%IG< MPB6WL<#QV7E>4%`E^4P_Z7IZ1C_MZ>:.&#)(EK76*MFLK6;#$T1VJBV?(GAD MMCA:WJ"Y[RA_OE\3HKB9?+H\76?J',B93?(1%5I"-#J$>H1GL.VQQ(W9XEPZ M7D/?1;!\=7W_1^7[UD^&W#BN/+PM2BZ%F9<191.=B9G56@U@.8O_^=]/XG?Y M,S?Q&4R\5/G78_>GQYF'IDX5F%)<:&8#_0!II:X5>ZST(<[-;WX6\MW\FYE_ M9=QYP"DV\.P$9S%@*7X)/M>;\$2`3Y/I]<_V..P^8K&MM>(E05O22%(:)I;Q M5LY?NN?EB0MAXN/L?'(QI1\[N9S^,3G_.+NEY&\Z#$);T;GU#(6/AYP%7/C1<_U;''W2&19&-L:(CD=M,$>NP54P MC+;[@OA$VQVEO0\]1&'UI5:6"2,D3%;:X),U((;D(]IV#N2X.N,U6_W05.T= M%HB4DE*9!RVL*;0;JG9J8V';.W(O/ZQQ8L[9&0/*N<2]4L;;(1^6Z-H)GWMQ MR:OKR?3+[*ZIZ^Q'N8_.EU=__GUR_N6^AN]V^(C-ZBN=T#[Z:%4"9VU.+-;# M0V>FV[5NZBLW$6V_.FT`#SY=3[Z=3@?:`#<[/[G]]^3ZODGN,498W5^$Y/G> M:Q\B)M`Z2CL4C0<,38/"L1AJQ2998:BY69YD#Z6D95E*&3V0^@X#E\,UG%;- M-1QEUJ_/''OP&\T@E>%9M)<\V*B\K5?".A?:Q^9*6(^:)0]BJ$SSG MNC'8P]]Z:./]/+WYSV)TO?NQ]2&-?ENRP=5GV5,]\4T`2)MR>602(1IAM(M> M%D)(9(+V$$NFJ75^HA^L6LYW?SAR@&N0E_JN#&"E%#;P6#HZR!^AJFH1B MDRCZ[A2O%'];GBQ8+A,D%5!"E,[/G2+)(*+H%7&^^\-Z?SCPCK:YS!.WH@S( M%+1J_JZE14@)6J3F"?A]1[(^O'B5(;P@"@),A%?\(TB7F*4NHDXH@,\#> M>,=WWW@>WWC!^RZ0*`OQAU+,>*6R'KJ1"NM*RYJLM7@/'R_@(B\&#G1."EC0 MVA-P3#P%;7V=AJB4:8AAWGUC:]\X[$*JQ`%]*H-6A$K:Q(Q#CYB)MF4`?]_K M2];S@:/D;:*%)%SV`@UM]#)3`+@+M1W!H,R-E[R[QTNXQXL!AB!*0ZPM]3)) M<9`J*5>?:G+P[9@%H=Y#R,OXR(LA!F8,"TRDA(66/"L161W"@V6T\GL(V:=[ M'!@T$&`(3&?&E7>@4?!0GV99@K!DF,#[?M_J/>=-@`?M`@>/%@!*[805''0% M#PGC^\X_,D=Y,1AA@]3)&Q$%R\&$TE,_M&NSV,Z@V^B1\MU=WMH#A7;>V*2C MS*5U3N;29%E3UQ3T^QW$@1SEP&5?4<3"ORFM\$H;04&@CFPK1.=-9=/S!H$' MBJMM2YVX,#Y;&[G'Y)-4VD<=`,,D&2K9KC75"F=NFPTWNZH[3 M1IV\9_7;EN0.*$>AE#,XZR5'-5Q.0U@R./KIVFN_MRG"S/8^1B(M%GDW!I>J$,]][+,J*MU MC98';*(^91%R%_U[9'R4DD`2,EG:8<8ZXY@8.AE`NN9I5#-IU(["'-5B4!)O M`FV?+)#^M8E%-8Q!,]JV8R"L'!''/=T`STQ2CHS4B(QB:&%;$,!]KJ,%RQB9 M=A0'&X_B6*K:W=S*GZYN;O+UU==P1VU%6&?@MMI\%IV0(19^,0@ZEY%Y])O* M3F,*Q?J2T;76CDB\UXNU#RVZ)(J8D/8OF"BDY\X'YP>T8TBQ)0-F*1`\NQ9K MV"=XB%QX1NEIF6P%'CB3-3R+R%HMK.;*OH`2W:4`IW+.4I?)00)28%X.!$U+ M"&[+A'=@\K!:^,D%G;9WW_?;Z5]TM$]G5]<4M&H(H]QD\5,*`\XM1;#;?U_1 M5TJGY]>5'$2]-=6TM9.R])^R.4D?Y3#LPEC?,HK0_@*-N*$Y]J;?4=FU.VA6 M8*3=@II9D[W/0F@US!"RL&0FL(8Q6ZQ1<1NEO@Z\^4`*S:1Q^FRO9 M95]3`NG,)=PN(@^>?O5#)8NE!'D9J1R.\N/_8KL>U0[A4/"AA40GLT&/%/4J M;.36QG:'2"E>RTIN,]5^8W03?*!D-0>@5,Z:D)B2=4@Y`GG]?K*';51Y*6OU MQSZI))27$K)G#EE@9ACC%1(VK0[;92FOQEIKD$BVP4J@0XQ+`9XSGRK'HT+I M-2_G3EIC4BRC[Y*) MII()SRDB5I,)+](?OZB&?;ID\,(XIL&6F9;!*>^-KSQEF*7KK.%CNN27UK"S MAM9HC(I%0$[^R8-4NA:JH,OC!^65],H'U_">KWFKG9A31@C.><&T2BXJC/7: M`[RW>]V)C^4\@):=E:1U*Q-8DQ1&\)P%.JRS*(U3KK>2&^_&0VK9WY'"9C`B M*`AH#5,L\=K4K[AVUNQS1QY8R\Y:.DKKBI8N1U40K;>RLMEB9D'O?"L0=_;E[F9AX[WFN57. M4KZ"9,@\M'M]AKW4E?T9[=%^%`DBM4RQP#@MS-4'7ZLXBAC;V M[+)+C\(@ZYCFA5<2G.&!6UX(2E6MS]*,,$5O/.)K-$7/-U)`*,6X25LFG1,Q MF<$47*8>`]O+FV*G?)5%9I@U@,)8S3"!M@MF/.5%KU3I/H9FE*P[BP&<2EF0PBX/&%IDC:]7ZU6*K[FS2HY!0G!,."PDT[*. MV%%6Z%>]XOT=3DC.TF$5DTIE1Y=SJSZ@,>''51C/HWB9_WC7<7#W$+CYJU;F M&7B*)D1*6B0=S+GVD-+B6FBPF2SNW2K4"+*UL#WT9)`V&C.!)1X3R0>BSJ4& M#EXT^:\:E_3N5=@UJ)=0O15)9I&6(3"F MF/I_]JZMNXT;2?\BGX/"K8!'7'3,F4=%:B>>Q7UN6L&RR,@Z5BIY7/F>IEU>/*(-/ M;><0K&@LQ!#ZZF>#KM6?3.CS7N._?YEKK'.T*22M M=-E""(*39NZC/B:V&]&8/.8B=_=OKQ9[;5#=F<6#='$EF36KK%5&Y%`MALD2 MFI+4$O4?I''S^?-HFWAQS^7"W.N2)">2E^S3S"1Q^B#%@25M.:DKZ&&O51&PJAM=?`$2]OT'$G\5(\DW3*.1M&M M0P`'@*Q7$J!V$R-T)+!VP0=)W*1#<.^%S>3Q]3V%Y(F:6.5AS.W"(F6PPD>+Q0AN&6MAVQ(.T'V M&%2?48"!0<%DF9K^PY,2/!'2)GE%&8#YR*W2.H7L^H;)K-KX^YL2UCRKA*?L M06GJ)!L>RR@7$Y4/M8$-E4?;CETOE3N[G0(S"#XH1N5Y0&F="=RI3``DR3I` MH6QD;[OL.-V601('@D!C9$VY!H[N9N`VA0AEY*Q#U[MOV#08;/;##Y_U`%T; MI/HI+Y:+^]^[FS(!8I/V(K71K3[N(NJI82\)G4*(S)+&2E:)%,#5-+2TK=T' MTUS+28J.YV!L0DIDD+,H"9"4E/(B2!-J_0`+O-VZ1F[/:3@8'*,V)FQ5:CM$ M])EL.@@-9#6J[X(LF08M"V;D;E3U^;-G$#4F/P'))N8$V69ZP80YF.B)(A/6 MO'1IP>Z^HBFB?KKZY_=7=*47]/%'7%9Z5XIP9U*:189)R-3WM22ZR`T@-XKM M*OTI@HZF?TS4=.#61B:)_++6@B77+[ZSD-K%=T;K74!Z&/U_NUO]4?#XW75W M?Y2V4"IRY#HX3.@!0^QS-H;KW8:-LO%Q=R#>'B0=S\+8&1#N3^OZ$RQ+*TO0 M-)MZ!CZT"D](:.+`\UAX,1(X)6W#!%.>12L1+]#Z1,)O",9&J+&6,I99:FFASRB&$* ME]V/[\*JNUD\T$>N0U??7_UK\?[QO;];K>[^N5C^%JX^T$]VKL-&N.(OC[>? M!/2I]NT_M)6%_[F,,.UN8O?K0YMO_NZ'_/E-\L%P0V<2+9ETPL:B+S74ANTV MH!6M_?3?YVSOS]>V0.ZNEC7'UP\I_/(;PU],QGL;/?`(Y$HZYRR/T=4X>%+8 M3H_G5NZ6E4RPN"6.[Z]6?W3KXO+U^;VL?[^F8>O]+S\'*O[ZZ4.W]7?"W?OW MW:KL^'Y[]:%;34U>I4I<2E:PNE?2B&":0J:+/XIS3Y0__6L`)!R0$WF+ MF$5&2-K4C3;,V397!Y)QN8U9_SR*T[X*&P1SFN5LA`5":N005;.1?6H'RP&S M0GP-1W+N`?JG?QT*M."*@*\S+GM'UESV$V!4TDTMP9]'<+97$73IQ8/@25S'MC2?]R@N].J2^K#D,T-TY$/SD+1P55Z`8L#!_]**_<+OFR6_ M'F52E@N"\4SH8'*%B0QU:Q@/T<([@]AF1BQ]2%DEZP!B$N"YD;65@6'D37"5 M7LQ.K?[NY\\G[J*JO@G)!*ER"&4KGP[!B%@SIL!0-!GYDPMD/!0>&*K,-7TQ M!'I1],Y@J>9O:XM4Z4H],747=5RY;'?@J.@(R//-FG&L< M2>(Y>DJZHLEK2&`[X:C]J3L94U.5[T*P$+UE&8764?A@^]Z!&%230;!D@?D9 M>=JH].,.*C(+9`@1+<8,7J@$_CDK@FV[%_&S4^ZZ/W4G8VJR12$R)CEQ4U:( M!5>"1K5,T6$[,9_<""7U&9GJJWR/.*FL<+URUWHIG8^!`:^I5DS8KD-Z0UP) M;O?A:H"\DW$U<51DAGV2)@AAZ!JFY$#VT_*$@7:Y@9!6@CD15\]MK?.GQJ-A MWK'@`Y!64$!\U!)D+'!C8'0S8[IY.<\4S*1M3*C.IF"4B73]<]DN19:^0EOK MC6TKO)4&8YNK0EN5R0&[M!H5C2!MO4C&E()[' M:%`:+W.?8"5$*V1+VL!>A#UI.\NH7V39(:%LH/<$MJ0&18^@LA\M;)Y-W!E8 M&U5^-@GR,ZS"&")XCZAZYU:0)KQDUB8>A+(BDS[G9+2LT,;;&*H%-LC:N@H0 M8N3*O1Z#%P6=M1*>''LDW0RE,(G`E_W/7_/B[N%X7UO/A7=[.IW5]_=]7=P/SN(Y]C&?SJ2)_Z1,X8"S6C MD3-K]Z]SI79&WQU`Y>FYG&K53$IB*?<"@D%,,2".^RXWR<;V1YZ"O?:<:ZUY M&:#B'^\7R^[^/MR]_Y5\O_)7YVL`HZW',KZ)9R_(*BI9R\$PJ[8'#K04.Q6X M!Q%Z/E:?RRL>KA[6T;#Z$3_XR7ERC9HK?_Z1'> M9)",N])?K((`IY0,`/W4G=QN(RPGQ'=,O(\`$=U*--K_38FQZK.0.3J<0D>" M^TA?E`&;??:NCF,SG,N63`FDC=0\.I_[_9Y7Z,Y+I`!$8[FR429M#)V^-I5, MC*(-T@BN=V@R=^JF[WN+W\#GK,?A4='.)$!OM$$.H$YR-#V:@ MG$N_>D-_^3^N%LM^=F%WO_AM67[PX^I_'J]N M%^\^K0\R]+`GFWB__K M/NN:K;*?*B0*#BQYWHD;5C9N(\>^;0]BVP7+!PS,MR;1OZZNEO>WZT]Q-_]X MW,AS*O#ERNYX1?C'ALBSRE[6+5,$W6R;)2I&Z^(E.>4*@U"*16;11N$LL21, MG^^(J7'J)/L:%-]![MU9%9_QDF=RG5,6IJQ["[*O'S$BI,;`2(8#>.<;E/,1 MBL\FCT(B=X&\/\=-ZI=N2!8&1C/`3BO]-RG20S0?.@WNOZTYI.(+WPNA[D^>)=0U$Y(P0(JZ8K/Z*!O+C<1 MVT&^;S3?7QZ'\_%:HAK-+GK/$DLJ*1FXDQC<`@F,E](!F]]*E309:<&0]19:N#5ZJ,8>A; M'WD<*(OY2A_?(5"7)P1C3$ZN3(]17LI<`WTZZ8'QIW/PRFO+9J\$9^3KG M7^8RMZP1W(QXRF4)[@@S628D&^64S:E4;:2USGNR!,JTU?QS(B07)*0#[60D MY[5L7K#2(F336QV`P,5)-HE2#BKHO6H$$WKKU<_RO MUY;-7F8R).V"\4`(BI%[#M*IVC,"!D7CK9_M_?W1SL?'IZ`V20A)/96&$P0JQSAICA:2"@*O:SJ8?S\!HB M&NT/B5YH*,C#IV!`N5R;;DASQ@$1[>N>?44BFJK*]RP;]()+\-SE9$1=NJ+( M^K`FCR9W&\B^#1&-HC['1?=[0W] MC>=/>>Y"/Z5"LF"54@[MILY::-L74Y9.TJ%2_9ER.HR1UY/6J&[*)4WM$@?F M(7$!+/2%`)JWC0U[!D6^4F%-:"FIR.,RW`+Y$72G=#91]E/_>#M<3LW545^; ML$:S/$`J/44+(685@]:F%@-+$X-MBKWV]2-.+ZWOEC?=NP41T_TW?0IY3`]7 MR]\6O]YV0_LEIHHW(YEYF2%;XY"<\10]5&./66$[@-#NSA_;N.8[L"XK4$-U;\Z9FW4J`CX$LXA@NCL`_-$$,-CN%& MBJ%JM2_"Q44=?P+#$F<(Y$6J4):`I;[!FPO51N=?0W(;P?&__/*#/M?VS.VQ M'I9EB1P\`VZC$+P6@BLK-+8S_Y4ZC4R.'8_+-T5AUB60RO/(=>0]JABJ$$,[ M$"^>F#^[-Z6C8W(E>E[Z`LA7+0N!.*MCJ;1UKAWY:!4_GM)#&P,RPR`B`',Y M2W(<#3=]M2$Y`VW5)B`;IW:LC'I_@B]*D1B;42J;&3`9HK):\NHG)3^P;T\, M69'3BFCL`B)&[5"61>4^>#K>K%1-K9C45N(*N9X<<7:"+^I,HQS/P M3(<(.93B[8XOF4?PW78/U1:Y&^%R]V&U MN'UQDG5@FF<%*N3`&(G7L;IU1C+O?0.R-]NTAPC>(64VN4^7@>^ZC5N[W+DW M2*Y`P))E#&4$=S_=WK,V?WQ2:L=N\&CEF748@^?2.@'DN4"L:Z>48=JTE6=B M4"^]2-"QM(^.0PO"&(*1*43'R:XG77?/D.O)>>-*"`EV(%AV'MHG8@P^NU(5 M"64BN^'9"=6[S=8&-]":*G8[*<]*^^@>=8L.R>!F%X+*VNGLZZJR'(&W-<&* M#<63]J/][=6G-=+.=ZOU6I+N9ITF?@*\QX]J2TF)0`Q!TAEU@4-G,@5-:(;`\3EX6R__>[Q^6`=I M7E)0/938^NVWMU?++:"Q_NRM7YD*-SANE`V,H'-9-D.@B]?Z=:NPK9D3.Q;O M)3[.R>S:B+;O7]W<>I7+4U9703J4#OG>%"1.EJ1"73S6Y=:J[U9?#X M7]WRYNKV=LYY6J^B36!99`(4:&NQYEZ9`]XN>>;RW`?Z]_/=7FL2LN3H^086 MRG*MZ'LK`:F=/6;,3HOX:W`[\_HJ1?YN-I:CD,Z@QI2?7BBQ+MH)M5I+<1D\ M'G!]DRV56^+_V;NVYCAN7/V+D@(!\/;(Z]:>RHESLCD/^SAKC1-5V9)K)&?7 M_W[!D;LE-4<]%TV/O;5.JN+(DFH`@@0!$/B^6G,JN7C9PH-+;C#CT'?8M5+9 MDMKJ1;VOCSG;1!%TE+2W2%BLA\O5F]K#$HI_7O2T'J3MD?LW2$ZEC'@E;U0[ ME2'#>,N:&KK2$FUK-=^"CB?LWQ!UJ8DL9@/6I\2/Z0*88'MEO5W4(>E%W6_C M0;;&2](I^3R@BT_P8QJH=G>SVIVSTP*Q*=(B9&=APF\H8MJ^6F+$O M/C,N[9&6\[_)5RO*2=9EL$(!GX:!>/&_H6=A:OC9?+JV;]Z-(-3I]NX$BG$O M5FFHQ-&@BE8R$K##S(_<(;IWH!;5[@,W%>5$>?=5F!227&S):^+J)?EP(T(Y M)+\+"$R_1M[?;K]@Q84_5]?OMVQEMYN_K5XFACAD;+$TRD%/VEF2H%KG.#;& M5MS!#J7`&&MWG_L#Y#N?7ON@^Y1.LI4);5*44%4:BW]>SG]/ONA1T6[;O%JM M^7?+0Q"S(.6:E6DX9(TMF^W0XF]D\\$85XK^AX[*(,Q0XZ)/+9QBX1V MY/`L/O>,N3!]`'^E!I++?UQO[C\W9WH?;JY:0^S'#]T#P2$%.(^1),%NS,]- M<9=@',7,T$\DDM&X9T>]*-S9=-IGGJ!CCIFI8D''L;(;.K]K33M0[M&^$.(< MJ]-F_6Z]V:P?.$U_66W>;+8]RU=;,II?UIN__;':Q2XY>4E\#M6G+44R1H?@ M8S$-SF-H4]'0[O'GV@P?(N?E1WB"V'>8:&?19O*&]ER;JEC;N,4C,2IPR8G' MY#_*J;J0-MOOWX5/]W_<;EJ#TI$V*2X8-.BA2OI7JS;%C^533>9I2>IN^TD/ M_!#/]]BL0*^2?=8"4=M&D&R-\S50E:0''^,G]PR9;2G9_WIW]^GH-==MF,/Y M=EF$9`!EG8?78JLDL8)_?L4H?&2"`) M`>`#]3MP'`LRK&I<2NZMKSFN+<1B=*PE$0WL0!)08^L(NZJYSM&6[OCLXV6; M:V_PC`'!:^\=)5.4\WF5M2*[/)_"`)W4MF2H)2JR5 M>!O0JXICP4;5$OL2,D_!00\0Z2PJ?%O-&5:[-OBCHR;Q_YPUC%U)7M:QRQ^, MN_RBS>W1RH9%WNB2#3KGY.-(-&4;>D]7:"9R7T>%;\KN)3R`=OU:)%V:[Q\_ZFYX:UC>?-QBRUU?(YCG%*9BI?\&:@"9E*CUX4> M\Q@;1,ND9+2D0E]SZ?95'#1).&N)P ML:HJEH!AFZ)]V;&,/?%RH\!X4;$#!#ROR=&+ MEGI!K->KL<+^\YMW M9ZR>*PZJG:&4BZ2M8'ALIS)5E.U]`\+#+,,+NATAZS+Z[NN%H\9Z7%QK1G?* M(5HW%-B*-CVG1YN.ZZ+*LZC[[OK^-)*,6+US&T:Y MV6K>@17JR:DN_#I!J-DNVFK;((YX0V:#5'T>7H*X-5#T`.D-7%SA>:2ZQ'%E MR^+=H?6!`$$U+M'0)E$D(SR$&?!2^AT&]9:2*TH,9MK`XZ< MGI7U4@H=>6R-]\5E'ZMA7ZOR(>AQ?#^BV4'_D%GAP.*$EL+V!T8"1)=?UY>%.9U4C]NI9=^,W[^[?/']3,KQ4_7VSG]'=9Y M-M-#;514M]*;A._%.0PC;TZRN8MY'_I#+J'X;'W;2E!;(2IR5GRN*]6/M?<2 M^B#)MJ:02TF]J+F\[%3)M`K(95X52-"BAC`E8%_^DES,G&JN*1!\"X@/@'+[ M4D-\)4)*S=4FJ!$,;B'>V>AA,!THZ^[=GR<#PN<4_N*K\BVA-WJY7BO:4JL/ MR1FOP0[/,[Z4OFKXW1#G`$WFG-ND4`.!-,H;&P8F<`/&J[G:T'_I>I\$G>A4 M!F_(Z4S<..Y,&`JGA8N9XUO_#UWE/6E#H!J"!#[:6*,#Q.1&HC\H!OH!7SVY M6_ZCE^5;\KJ@8TKHJW>>R:?,<9PT4N*+N_SFNR7.XG95@<:-6&(*Q:BBXU`] M9,G";%=A^+[>I[C=*,F3RJI:5R"$I!@>0>^=ZVO2EUGEZP__^+2YVRK_Z_K/ M];)*.4)&$3_(\MTM[YY_DO#C^V+^1G!%/31>4JI)B496G2A@6BS\[7G M[YSB<.Q2[C3M_WYY[5O7;[N96842(,E-/5;]?-0[)DP7TEY_%=LK],29+$8M MKHA+T/1(G.9V<+=.D_/S:?\5;.^]LVT,"$/V$$,%E4=N&D>EFT55;@KA<8#Z MCX]UY^XS<$7DKA1];N6'(%E4&)ZO(:O8,PEJGJ`T'R'=^;3:AX@;N67FA-8E M\#YI<'&(FA7;1;6Z6Z\V;_\(-U=93/G^=ENV.!5J!:JNRA! MN>;,1=Q8H>@H4,"2A^<2OZM9Y8%>[&*BSP[_&9V,:?3BP7IM*CSBP`&'OCW` M.&U9G2[Z_>;ZK00U+6^0GV]_M*CLS]7[=G+VUTN?.E+9Z;5:$=Y2MA1"A(', MF;W(V&T85+YSI//R'"5\N$^KS:8E12?T7<>24[`)*<0J=V'UR@PSF-9G['1Q MK*;NYRCISJ[9-]5.VL#=4@*'-CO+-3,_5M(-]Q#PW]9JSKT1B"J%=?;1I@@U M89"L;F@%J57W3SK:3M`ZOK9JW]1&T;D@U>A3-;*B0OD:=N3VO<@&.6IY_^6&U^?Z%9;2XV"%;"]PP(P"KIB#&9$4"N%-<9@\'U M44TGQLER+@5C42'+/:RLCG)"E,4:8`R!4MXQT:[UCH-T(2V/A*_($JUE5Z(3 M*X8HNF$R8E9YL_E=+&)\J%54Y),FD<06Y%T+YX8*SIXM7SR;G4>=*Y33:DDB5/:-V[ MU86A2N"#Z_DAD.Q26^[L<#!<(6399I+@50X9/0V!N^0?1?U-T4F'(&FM,Q)*J#QB--;^%5`97-`89SY/D"I6 M)A%_N"PFF$D)4Z1L6!O$TJ891KI-U\/5*UYJC\YV MJ$I.9DIUF1J6DOAIXX8.525)1K?)C%O$9R\+6*:,<2/FR.TD_*&^7.DS+W4P9*(GUJ@I0 MLF5/C3)@@'ZPODU^[35!S=_[J@&T).RT9DW:01JQ!8VB35-091@:D35 MDX"J>_1VW!TRRJ:TV0*;,+;KY$P]NIM7:L:_G*XB_Q\NM3N#A^1"S%YNZ<45.V%W*A*O23F0 M\\;$P%#*`.6B$L:N55F)=UU(15IJ=X*E=KU#-LY@Y-AHB(?=*#4/JQ:\`,;N&B^PHZ'%NM"77?2G.\D('[R#-3KG:@RW*5>,5I%1K;?-2 M@_>TAOHX&;U:2,7%[O82,ADY5U;^+06#1C,"/N]"SW-F)I-;4L,CMV>JMEA, MP>=0:F(FJ"/(,]M^7(J()C0IE]7LA.T9@RFJ!E\E^-0HV:H9BN$:1)V^]T5) MVKZ$BGJYR]T1R\G318ZBUK'-A0W03^Q]S%UUR\,B!W"_AD=N3ZJ)*I.WP>M, M)>52\W"YY]SWK'E0BX2>!RIVPN[$&($E7359)5>LAPBC\XQRSW<:>IRI@+]& MP\7N]I1U*8"2[6"6W$@'.[Y&^5R@IVN9JRHOJ>&Q!`\E).5(NQI5(^JV)HV^ MTV73F.5#=ORP4;YT.W'JGT8D1MV_VD?(_=`S_]>;MYO6F9G7#W\>W[&( M):LBWD49R>9KKGED9@2*/>\3VBE1T.'"G4VG/25LDKN/-7HYM([D3'A\I#RM MWO>OP.A@[CWA&*6>3^`_&8'(VW:>8[M@:I$;+;;V1IT:'0[&H5+F_8Y6V!_8 M0@O6)KKL$^K5.LRW>U%5!3UJ"4V4^'Q=AU0'HN$=+'C*B3VF_2-'ZK!M*#\! MY*=20(K@4@2CY9\`0V>X+=SG9 M#(]\&=GO9`R=WL3':CD[W^AM=171URS!.7,._A'%B'L"&9'9Z:D;.D&@2R^[ M1`D:E6I@.:X4GRFG$33?AA[405EE7Z7FOG=SN<'8:?)MO`L;QT(:RF362-[: M8Y;Z*4;.20)=>MUC,HV"7;978Y%6)#?"@"+B8JC=L=9=%\.Q2LX.:C0RTXHZ M9R7A0]+;J^I+S-/`9KHG5L4,T_OI!($NOMMKY5)M-96<+\$YIP>?(-JE MS0"Z@5&+XT&GK.R%*KYF/.1LNE0&N[F.5VD\VP@GB2V3D2#-J8P<['9RX"$A M!(*>G!X5G5FV2UNC876X)#$T:I:#H=F/@X.U84OLJF[;UJ24J[ M,RH\&Q+)?27VH.K:2V2I8I+A?;5&:W?JT];+/T[LLW_G)[>W77@40=<'=8"5/9B#2Y49Y)XF]I+(N' MN"-\(PN32&*7'*<).DO[90R8VD!R@U,/%!C#6!DT2.`^O$=G%Q%TG\0:+UD10A]..1VI.= MI$S[!5UOD1;_LKY9;U;OP\U5N/IP?7-]=_]PC$Z=IZV2NXE;XUBTY!R-`&I` M'F5@"<[Z`2&+N&F.^+&LNR3C90SS2*$E+CUU)F MS^97OH!$_A9"3"E#NTP'S+B2$W:&\7[*GWA9769'Z@DIH3\EO'=Y9.NS MB7N$EG9737JP3U+FYOIV,XRJ_WQ[/TU^]G+<4+O1,Z=88XPL]PV,S9)!A7[^ MUH&>/,7OD.%X&><*:.)TLC&8T$7.(9=LS=CUB(SG6Y(@:`,'(>2/[HF\I0I@:?RK!T0+.SM\5A9"4;A4O@"1)'0X7HGB0 MW+V-'"'93C*-HQV;I*5*/%O2TV;#)/V&&V MM#'E7^O-V^N[]2^;Z[?K7YM/SQ/'*)D[H5@U#C&(*G4*D_7(KOGP M8?OL>I[U_J\WK/O1TVC7MO"PSZR27U,I!"DE:G3<1O+O82B3E54OFK5]U'>K M+F;5=T^L"L^/ZV%V-3%",$%96XUW/H8![(EKY>EK\!.[PO?C>BG#/G?#?(A9 MJVE$::A-E9Q'1K-^=\,6LRL^L:@ZQ:FG@U:XZ`@($FP+R M>%ACT?225?F[52]E5?/,JNZ@LVJK8TFZ"@4(/I&V?NQLC%6[EZQJOEOUW^Q= M6W,;R6[^+_N^3E^!1BJU57VM.!6O?;R[2?DI14NTS1R9\N'%)_[W04N:H<@9 MBJ0DRJ3$!]NR1%+37Z,!?&A5O4]^H>@FG73YT"KF<[R)KBX3L M$',2&0)[IU^3!OF"//)WD(R"4RU>6PGMT*J.NPYF"1]W6?R&$I02B9I?5 M2O;6:9?R)@MKDT[)D`<5(S)E:>[8V;M.JL^] MMB=M??!,=#DO*T2965L[LCIF#^1OI9$6X7LV&9ZKX_5V/IO.!N,ZLO!>?%3Q M^4`466>?F;202Z:=MUQ(ICZMJ(2R^T>SN[*#0?-G4Y5[$%('EAP[LA%H MZ)OFG-8Y#+UDQ8K3-A\5(R7C0H:D!(!P7K&/&IK#++1:2B)^4D9ZVN/'9*20 MZSA6-GTE!1)`3D-3TN)R4JYOEY&>P,DY;?/C4=*435&LIHV6#B+6XNS&QV'W M)_:&'N(,E?=KD8Z*D`:.6D6F) MSC4Q4A@#J;WQ`==KE"W@:9./BY-:$F@,8O1DI6$?3#69GR5Z+?MVF5;3MH]] ME__Z]NU0[[X?F@5J#80Z`ZTD*5@Y>QM+6]P%SZC6@Q^2$:)M*Y`BT/DOP MM*6'PVV6]Q29LJ;L7;+H"M/65'0SV0LCP5K-*W^>C_1Q/5,,SM(=48G"L)*4LB==7HKATK[J3LF5F_ M.E'W64-Z!>2[^>3L"_^:>L@VW1_:XD"&($1V3D?G4]MD$XV`'CA=3YSRZ-#\ ML(_#3L&+9(66*J!48!*(!DHENLT8T=7\^N>,Y8,/.V53.ZTAW/>RQSAB51?D,26K-H(:F7Z1#4)W#+K$O9>3HT-R/91?. M^."B!@F!?T]186'95;=AG+!7'9Z>,9@//NT&,2-B--9@4*BTI::5CXN0.N/+ MD*G3S+M+F16G9:]3E(EZ5J.V]QC88RQZRGAS]2=]XP.=!-Q_WLX^OR% MYZU0F';JB^$U::0BUB(U:_(;8+Q M:=9[V,#_[$O$[6Z';XN$\Y&U/O^!XK3WB2"V=_\8UQ=&2X6OK#K)Q.'+Q#87 MR[(>OY+.W&=U4Y[L>)`P_C\9UNEP8\,?M&@:@[`."X#=S.*U:GERT=S8S3EYZS_N#;F9U/"W<,$6GB+B5!)%%`,N`0-`W"0S-ID M-ZGE*[7:0.U`MN8D,_L,(RA*6E@,`F+0J!W*IL]^;187U^==[3&,4(2AOVL$")&FM7;H*,YB3S!R]S.P0D83G7&Q&3!%A5:GJ]X*4[A7"D\" M<_0"LW,8HRB/05G0[+5$=$6OO3)%^XI.)NGX!6;W,$?(6A5(I"+Q$G%=!_L_?#K8%2?);)L3!C?^>"B#@93ZR=!+2B(2U(X M:3&GE#*BA;9"B]@0I%]^>XWJC@GQG\U,[XIF+%KA:A`A9D*' MIOB28J*F#(@]`FU9%N@#O9'R)`O'+`OKHQ0+BRZ"UD)#2%*K.NJ-#7LC":RR M#4N"^F#>P$D0CDT0MHT^+`+A*#`DK2.8'$6)1NJFO4UF+1&NE`(;B),L'+,L MW!%56&0_@W$ELCK(1NB8&..,#"4="9MQ^#BR%(""6ZW/3L$#8Y MS9+@3O3AV"7A+H*_8`\J0'"L%E*4`I,)N>W:3IK<^K!MRT7\S MBQV9#697=1'Y'_/1[$==Q^68_SM=JC7B;W_EA=4U;*J'$<%G54@$2`1`C*)K M.QN5WA'#2FMT/:U!;R]BUR6:VU&E1UZB@&QD5BX9!\PSI M4'UE:0];XOYV,28?C-/94Y8827K1C`'3GLEU7U-(921"3V730Y9H][B+.@2= M:C%A%<^$$FQNRMQ)IX*]2[1@8)VC\]3@.OHUF@XM-*H// M/I$L)CJL#1IR$DU&?'&V6XIHCH=4*KR*C,"K8TTV8=EA`._7S9#>HC\?.B]I!% MXBU/09N;34=1O:1.3;DF8_6A+>])U(+Z24BZX>!2"N4\CD5R-995#DT[1'0+7>7OVDY M@6P5H/O\2\^P\R/>-6**JOL;K`C(AHL-?'*I(?[%&"56'Y&4DJ9'0>_RA*_' M9Q?S2A?>74ZJ(O&SV63T<3ZK10I_7OY^.:XKF%Q>7/!+7O-:V$^<]?+X]0S. M&I.S%I&C[T-^J,NOPTUQ`)9M8TDX8DG6D4T[-'&`C-)U&J7]JC<*]G/" M]UXVDH)RD)6D>CV'Q;/4-BYVKMV].CZD5I+?\7)@W=Z>@L0@$Q;IV=UPDFS( MC3M>C*,.E$JO]OIYSCCV?_+F[C3%)@6!V5_2*K-3WS*,;V9+1I0X6DE]' MQRM;N]]N/-S;N1H;))4`#!HBB92:\0:L!+%+SZ0$^8+PO9>W$X+7Q46?P!27 M:H)*$&UPF?_J>#O@&-8>=O=<8=TE^"@\'WQELA!:\M>B0".>GD2/MX,OZ/C? MR]M1-3G"&-1DL0J>+R";T`/F;N3RI8"YE;?#,NAB$B15T8JT,J$-?(A45`>\ M%V>1=O1V6.:TL>B-"@E=\-":G]K@W78:O/]JK')(/3'"8P%T?6RGH`6-('*. M2.YJ[ANT%RW&=W2=%`1RM=_]44'QY-Z.):8H09%!JY.TQ&2DO;71KGM\26Z* M"#XG>._E[&`NT0I9LRRL0`>!9)MKX%+N=!^VB.S.'_,!WE]Z3@A18K4H3*9E M]"XW2>W`-MIU_$:EW1%;EB<)[;!%$:A*"$@RH`FQ#3P"0A*=8*ZJ0PA>#J9; M^3P)5=10BHX*G)!U%&G#PFLI3I`SY;5++4:$1@I[)Z/S>N M>I2K3;5^^0VD`(7'?(+WEQ_"R#GA$QMC3](X86-J[Y=U$Q=[DF>>*X[V< MGAQ$G4*G8LI)Z&B#:/H8V!QM3Y""KI*[@[J5UQ,*LM^CI*GW#EK;W";0 M`D:U.G%AR_R19P3BCDY/5DE$\"XE%=@>1:F@*=B5=:Y?Q^GA'[(NV'MTXZ_Q M9'AV^7E<*WK^'/S?3<+4='/DQB[EN!4HIK!I11?8EXEU%NV-#LO:=B(W58'= M7M>:A[C?@ZZZ6[`8>/]\"-K^DT()?;W^M(TFIY=SOE7;;)QNC@V`)H2,=-* MQ4.13=>B3-!-W9!*&[5WK&YZ0>UV&5$K9C6P5DU>F^*-T=*V'9@H=P)G3#'5 M+@?CYJ$>:1E/K%]C"%EKS+ZJ5NN*L[XI,G0EFTX$Q^QFA@X/FQV5JD]4-!5D M9Z\(ZY0QLAGW!CFOMBEG`F+@>/"YOR;--DJONB&8,EOD-@08I ME2J&5*;6Q;;4';WKM'`_;1E/K#@E>HW!4@FDV*!H8LW0*$XF)9U:PM6\QF.# M9D>]*8),!85-03/U-:!\;#K82,RYYP)0'0\^]]>;I)T!0(],JPTC4E`VH1AB M?M.!12H0QP7+@Q2G9B(,R029'24KO0RIG>C%AJ5#8;1VZJ$:9Z6'R>_S^H1O M/Z71Q;S.V;V[!\1-9>[?[J#ZVD+,WCK`(HPK%.K_;NZ%%1+L"S6X#W10*[QK#Q4[MZBDK/EH3`%X1ZGM28Y$_?U4!)J] MK[#SIC"8CLYV/H4Q80!=1#;LT+.8UI!X8ZX#.V4/.H7]S_C(J[MK]X10[&&G MVC5.060_32]F?.>D>EO%;'T"][^Z#:7WVI8:_$+;G_HO_,NY?'YVT]7#=6VP>GU[^5V M.((/ML&8I"G6&>&B*6)11"!C/U*6=D9JQY7L!:S_O/SG0[!BCS%$@86M-K)3 M*BB4JP;/OK' M\&P^&57I+(/1Y*HGPF[Q3XH*,$@34[0BAB!2TRH-:HI"-S'I:D[6==+;PYYS M7TN]9AI_G'T9GL\OAF\_[?KIE;%,WWXJHS&S`58&K\?3V63^M9M1TWS"I\O) M=.D3-D953=+)E)*DSL&&HE1[XVXB=:Z($:2[N7%_V8C7S^0/6OGHC85_3*Z" M"$8Q8<0$:,DTO0!39Z;G+[^!LLK2">W_69C#=X-OP\FF!/S-=)2ZG;/DFA>LA:YCA)="_0;-@D_W@PF?Q_.RGQ\OO$J5RJ32G`46:*5 MR-A.-C]-\Z#_-V!L>#S\,!Y,_OTPN MYY^_E-'W_V?OVIK32);T?YGW,U'7K*H71]1UPF=]T;$].S&/V;R!0`/*. M]]=O5D,WH`*!))"01)`FVX%XIK@K%Q,CX&:;J" M&`N\.""3A"_JF\^2V"")O^K9]WJT$,6NLS?+`V/,N.C`8HB$CT+;^)&&5/8' MP9"/$/K:L?_S]\^__S'&,'"4?_#Y&IGJ>%)=QEPR=CVIIRB&QPB%$06&(M4@Y;ER9^`^3WFTQ3*G<=?B0K)`$,'3M"]"<=H6T^CB-;ET2\A MLKG#>+);/7G>S)UWP+PV1BHEM/*\Z\U-$RN+^IA`[G=&_(&\67#K$@F:!:$3 M(\:$MCV8T+E[>!&E2&`G_2B?)F^V'E74L-Q@-;?T1E_FG#6*HA6)0,KZ(R35 MY&2YW/.A_&$\FY=(5Y?97SU(XQWQ"77;1$Z=$)0$(MI3#FJ5*<@R&QD3A+QF^_*(B%&BK]0Z$9O0A">F MF-:\J]4!6I0<*:*H.%FN_&18'R1.X5%B5&B#7YLU8?,:N<&]31W"LC-I,]*6J^ M[U*;O+S6)HE87-8ZR^+1?"W/4_2<1ZU0`,!$9+:=LYJ_4_9B-4!@!U][#>@? M.;-,.'%6:^WR+!H&1"329I9SH5IAH')F6>O3%TU5HAV/ M)@P5L;\P3PZ M]WIDD:20A)0R]_Z&;G";XJEXH/?)+[\6O._%HTV0CH..C*BD@24%>IYGH\R8 MY,ICD]T9YM>)\R%RS-XG:J16Z)N$$YU4YOF-_ICUX]NE_"&0D:YP)"T,10$ZU+NCVQPWBA[*FV;T"PSTJ/O.>3 MY\L^2A9CT"PW[14V!-/>>A/4Q3))<<;^,+R96"%!)NN=^*X:3RM;EHF=[=`3)J=EHIY';2EXAL]#;M+8G9X)498]TSW/*9];/'<6 M0'-'98J"L1`I)]QRWM7?^T0W]+YZ(3KY$I+5GMA@B.=!!0(*8Y]\1+``'R0K MQVJ?P3\,^V8,[:^)Z`B=YL1[(UUW=Q-,"?P9\T>P[^@,J)BH#1+9!P^.QM#D M[CCGVM/BZN89[&.GKQE7)@6MO*$$$@&&_W==9*4OC?X+\G2GG<=F"=#:!!:L M"CH$_"!2\RS8`,RJ\[-P^&1V])2$!,X:J2PRNMP=?T'JK(`7&?2\K(1VGN6B MN.`^M^>023F14D>KJ2MTGCU_BG'Y)N_P+9OWO5]*6^?J\*!R#]STAJ4>>=,G3ZL9RYU6K2?1>J]29%2TCSRZO%#VI3R#?QA:'9*C MX&+R,06D#)X*VEU0$5R#ELF>0AN(H$_8L5G@M4CAR5AN]@LG5 M9\$D8V.><-#>7`2C;"IJU>1#SYY-FW3I$K8AW3@2@1`V>D36HK9ECA)<_8'X9\\Q2)!V\(P@X!.*?+ MP4?(RHNHYXSY8\@WP>B&4C!@I$G16JY]D\>3#*$FA\DJO1JP#Y'3MD1%Q@13 M-+>XX8R#6[;]B+2XT'N6R"'2V9)Z:Y-..O)`\M@#D,UC$(3P3!RFBNW7`_T1 M,:@/VJ@D4:EUT`Y#T&!;*Z\ETV%Q M^,UXB+^5=X.QLIU,S,9^6(_J?F_X98+8?*FO MJHL*?W`Y'J#EK?O5IPK7@R'';/REFEPAAK?:NX=%*^Z;425:*#?_^:G[:;]- MJN;S)?`7/?QKH\_]NLJS6M#4MQ`OR4NP>="NP,@Q,$4,.&7;H3!H2L1O;RXX M"2V*1][[;I17NH$WDV>^Y9'WX\G/B_$,O[7:>OZB][/!Y7WOG_KJYNHI8)W_ M,$QNOOD\#^`2=[3\G>4`^3CJ]=^.OM=?:USY!K.SWFA=2\&51,7/7>.NXDW&N:/#33*7Y=20D/O9G#/[% M8#FW_>;K%&TO_EK\@?\4@^EN_7Q5+O<3L?_T]O/%IR_?JPG&&C=H\W<:.R$Y MT#;+8;;`GS?N[S5^BZC MSII92`^"[.<4<4KU5V2#]33AHBZ;\22K(*(1:XGN9?<6&TBM7!\-QA,:HI2\ M-90HRJ!MAT44X06PAN^C[YO0.!2&_#_TQ#`,N5>)"-Z"=QJC8D]M;%N*!1F* M8/B8&"ZX[SRNK$??[/7U9/SC-+F_4-808704$C3!&"!T/;BC90*0^YN=W/]1 M&WYZ/$_2ZBYS:4S(J)ABB3.E?>[IJAQAW@4)/DAW"A)YR81Q-ULDCAC%A.8T M/Q0F>1E%.P/,M)/7QF M>[T.,E6"$VL42$&)!VX@+>[[*(+48D-O]#TQW@;+'I#F"7^S\3M\*D;3Q82_ M\>!+GK,[6\^H`&T#6(K.,CC@&L$V1J]-M9LUV_WM M#>P"^BZP=F.]!..%.$KEM?@V,L9S!9.HDA)-?.AYTNTSC/$4;_TRJ)]/9 M\F0N)]B?6,$)^CDT"<"E`F\1/$V[PPVP0+*"D[]W0'B/[>V!U;UU=64<[$-` M^G=O-)U6ZS%HX="61$U$R9U-ADMK0@HNN7:6>LX#9HL`[W?A=1BM^O,Z31"& MA3%.U1/ISK9B"(QEN1...&_S-0]N6DT2*499%$/H_>A3LF\,=F,@()CWL6CHW+*FG3F8@X.[F*HM'I@GF%MB>(>'\'`EXKG3=$/D3Z3XK78'--,;$N=WB_/6[![!.&,J.;:KI) MA>X88.__[#IWE5@7T<%H@K\(G+Q'5WHY64J6RP`-U?&T&[@'7>$HZ*XB-!)Q) MW`?A@M"FG=0IC4/&7I3YRZ/H[!,YK+5K)E%:8$IPH!"0XEC:]I26D)@N;EH) M!@>W8?)N.RL)IU;9:$V*:&=M=&VO<.`N$1!_+P^NUUJV' MVOB=!M81%4"BS[.$1VH=M+5$0)AGY?U<8\QQEGA2RFJM(<:2;&,M,6A#]#)F M]<%N+Z9]9D`>HZPH6&=I/O93#+26$6R8*RL5UICBW)DVEG7OG3=5H/TLG45E MZ.C;QZ_#^ELCL`_C4?]F,JE&]YR/QI1*&-9%Q0FP9+671K5&Q>JRGX'`%ZK5 MFX?[+NL@.[GKFI0SVGCIK?-:2NE\I,N&9\&75T9$/A,4!]O)H/V5887QR;C[ MO<4O]4:7HWN(:)6K`!A&A)"",(:QI@39CMZ1FG@HBJU01&*=K3QLE6;QXX]J\M?WNO_]8E*AJ9C]=YYL.!Z\S5<E5Q;+>6S5J!^!<>L)C+80(-K M45<*_=>;"]:&Y4?#9U4$@PJE>:5CV^^U1A[W'UO:$>7 M'V?H;3]7LX^#@?W6JQ'@Y0NG*+__J?JS+V/\*7Z=CU#B:#">]*M<9_^^-\5W M^3#__HIS^SCY7%_5P][D#L3N<@M20>"&RJ01M$1\"+J[?P>!;>W'<(H[?VER MNU'M:SG^LK[+Y]ZO)A MR>?C*Z06U/F`H9KCOHT&@@Z%I2GE=]&V_/[GI M#4,][><:WD_%@>U<09>L8NUM+H:]T3+42;W115U-WH]_5&5@P]9J09T`XJ50 MEK$0>'`M,8.DV=I(BU&S*]3KWXE9W??>N[F%0L[PWR9/A,]/>O;8XG]5&,\. MAVNO*!A0#$51%(FR(4EE+V@[V^$4PA4MO+]5T1YW[[7.) M2ZOARS*%HCHOC2>V_[U&7M68GH&O)C,T8[F<8?HN5YSE5_@QDJ_^+']R=9TS M%"\B`9(G.0DT$<"C5T)CV";:PZ(\OV'5NBV@6YJ*HR%7"J?3YZ8R8B.T36GZ M8^W)K6+%)%#I7!)*29Z/T71JDV;)8>R^W?1O67>YL:;E4A>*;"]C_*L>#EU5 ME.4_>YWG\KE%\BVC4E'S(*6,R,!U=\@4(D7SU%FGAV]^">#\:+4WS.`N<-Y" MAE9=YM)'N@!1>"XY^G,>+)'=R0JESH2ULJ>[_M;*BC++:9U&GO/4T!ND+AMJ M2-F___P`3U&4@]"+W&L>M.;Y>ILPHO4:5+%83#^@!%^ZC"FW[FFY;0RK^U5U M.4V3\55^KC\.%I%G4RI:.!2B"_:R%@1+"B:`IC8&JEQTAOIN%%<$4H[YNU6% MO6,YRW6OF8BL>Y,?%7+4V7#9$.-3U:_JZUGS5C=?FT=\ZYGN8RW/^CPRFI+5 M5!`0A*/=$3+DFW$N"JV,#%OCVH?MZ3DQN8OZ;)UQ(VPN,$LA$LJ1FJ_D@K46 MQ5DQ`[URE'%"$.W)#O=7FZ"IYX)&26Q@E$>@A#=JHZ3`YVAKHXJ7A\D#U,8S MQ`,50:MH'`=&;-LR3Q+!73EUC:S.A3X5B.01K(U6W'(CC"&09H!RQV2^H8QAII2YHK55'ET:9&;H"=H<>02;0Y,) M$K)7$BD?*IL43*,\$H,U#.1>C/(>T/!LZ M4'IC:PZ+$YD"LE%#J#+>4NF[9(ZB1&U,YLA-D#U\R_?`L+T(A6M?,.50]3$L MKJ?YP&E3P'H@VG@K8)5)62V%XSZR&')>J#U!2MR:54T;S%?Z\[O^X:E0-ZMGT4W4Y/_?$/W4SS!G=`:KLN][UM!H/[/7U ML.[GG._G66]V,\-OO:NOZED3C^8;Z;K$+';U5("*2,I&NMBPK)H2B/6"NY.ZV-+P62 M,_3-^]E\,Z>78\>F&T9C3:;=R>B]RXID()P10SS1>8J3,]:UU=+)Z%A>R#K:/[G&[^WV*T^GN58LF:"A0?$Q&NQK'Q>2T)0S8_[-WY4]J(UGZ MY]V(_1\RF.F>3Z_M7K?;L?.CD))"W4+2ZJ@R\]?O>YF2 M$$<=@`0(7H0/$%(J\^7WOG?DU5*'775XI]<[V9%7(W"XUBVN&L:7F?8=3%U"2W?&-^4=0 M4SFQXPL?@Z*^>*8#AJPM8*!VMZ.UFG6UEZY$;X[Z@\':5!JMD9_`7PFY)((8 M3''E\-@P_\1;TQ&6%\\7TK3AJ%57-;W5@O_;#2T[0'%4WW"BD]YMZGII`A*$ M,`B`?J/P;YA:]@E%Q02LT2^MI`ZW='_2:N:'91K^]-G2N:XW\2?1[ M5+74]AZ8>4%8PSJX/WI]T.HW6]V.WLPF:=WUU;4E#[K6?+59JK80MZ3H-BA8 M6Q<;+K?UN[H&3)0FVT;ZW6`MO&NJ:O/\!+D[E;>:O?ZPWF^I]8$^!)96^_UT M#\=16U?7S[=M-5]-Y163WWZ4WVZWNR,=`*C7N^VNVK]3.^G<.*W=6D_Z:HU6 M\4`,;-29=(K@T(W$3! MR`8MO6!SFW\-H(^"N0QO3!L^[KX:>J,J#]FC0&[7Q`RXW26=1-_7. M6C*WW5R::UQ,3^Z.C`^N&*8*PW3,$PK/#7M^P*F_]S84*,;;UL8/Y9R,W*3< ML^SBNS:>GS*L-YK:$"(#5>^IJ9-W-QQN6+%2WZ>+M^L2T?6)`&_Z1FB'GR?) M/&)),Q"UV_>N$#Q(PA0+F)>V=#=_8=S_SS:?]P88+O&EUP:N]&F%<= M#AI-^)3NU=;J]T>UO__H1+>6_<#":.[P][4)%'D],6:V,[_!G29"]HD_LB_> MS'!OQ6^A_6]^H];]Z+;VXWUTN_*X8[O\>LIQN/0&`JX?;GW#PE'XZ[$71=X, MKOG?;['.UX8#;;QQ^"1ZLER\OJE>MCOE@;WVG/R*M]_8$11ORI*$A)DW87D9 M8_'O\('T7>^@$7NUQW8M*/Q&:\"%@AHDGOLZY&B2;Q7>(6 MWF1#S7RPD^P>*"$P'&>.OW,?RX5GL;3?75%'3&-QT5V]& MO&4[=]HJX$KOL&WZ*.`3AYN1$(+G<[FV7TC@RGXCKB9R5N`"7`$_@SU.@4/G MU]XCIH?#>!S:%K`L<(/H8[@-[EMZ\T/":"!M26F,)S3/KKY]&(8@70;N#<-4 M(.Z[+N]+4,?&AB/<'E%Z!(0=&J:LY0).W+&3B4I0U-=%K9,VPHSIO948;J,-$@>[:Q#"5] MH^?;+M85M!@LIR$='"73=:AE4ENXA&NTD"8-ZX]8[FD,3>'H3H#C!"T-F,$F MX*LC8V<&#$O&%RUJX7NAG+H&HA4OAV:T.D`W%]LEX=3:O?_C8<9-_4VS^P MWU/;[8XZ;.G]@3;$6L>=8LJ"%M'(0+\KN=`YM M=GH0ULPPB93:BX2T4CU4V[HS9RR//QX*_+PJ6[36YXR3W MO*_5:^)[Z!MF^GU[L(,P[VU75M*((R^]$(AJB2N/MA5-X6X0SM@++!Y)0'I+[5.IU<2CLD[?\C+M:$'X)OQ7%+YYV_$*D20`F`)<&8)S' MQ,1$IM?*F#S4/8&)V=< M)^-GILGY9'($N*VF9Y9JH.HKR:EK=3GE5[Q_+\:&LL%"]N0881%$>L!>J(*B MGXRP*LN0A#A"'"'NE`5W,L(BQ%T"XK9W#2_(`Y1S_7`<%\=N5P=TGQ^GW1&< MEXA!"G$)/X0?P@_AYV3E0_BYR/2:ELT@*]NYFGDNGR?3X]@$!'.TD1L<*'BR M?[:1[/,#$"LS+_<5Y%\/%F(^([;BI".P7*!XVO6VHC;4TH6TC^852F+.#DNN M*!%Q>KX$L=$9LE$V6UPK7R&)D8B1B)&(D8B1B)&(D8B1JL)(%+%MQT:5'\@K M/]>4G>G%?,/GP3'3PWOHG58-5CJH$(HF'ZVIJ/5N4:(X%XJA<1(B"B**LN,F M8@MB"V(+8@MB"V(+8HL+9@L*0FBR3<$)D&379&;Q<93;@*JP)-O2PE_=_\XL M#P_OVWGEKU929KG&182 MZ1'I$>D1Z1'I$>D1Z1'I$>F=!.E19'OL9.#AB>X5"KI4J=(W-/CJ188C=S/8 MM*W!25,F,6.U";#=;"E:\W`,>"Y$1\.C1$9$1F<0@A(A$2$1(1$A$2$1(1$A M$2&=-B%1N$:3U`Z2H$,$1X@AQA+A*".YDA$6(NP3$ ME3\^^8JSL?;?].30RQ26]VE@5U;,V:,=36V7J6P./OFK3SXJ8ZN9\]]1YJ!" M*#IF51MU1=4+VSCF7$)2RH\14Q!3+#.%VB"6()8@EB"6H$T;B"V(+8@M"HD^ MM,8VI\%>!%,<<4#L+#,D3VSDL&>J)!.#=J@DWYHR'U^!ZUU%[[1*SRF?BV93 M4KV`I/H%ZYO6(54C52-5.X"J7;4+VTWL12DM8%/EF*:P<29235+-%[U.O;"P M\>Q-(2W\W0%D8UL[31E^18^<8#ZLB"GF M!Q)A\?LE=)6FVCZ8)`L3TRES)V7MB>.(XTZ&X]2&1OQ&_$;\1OQV$B(\Y:S3 M:Z7XZNQ3=:%YM"G01(=$AT2'^X6TG0/N`7@)+E^EUUN?:)X0]P54UG8'%%L& M5C"%2%NM/LT09[G5JJK4ZTVEW3I@\O#2A`> M>Z+O2WM(E2"WJLF*<$6X(EP1KJHB*\(5X>H$MD\\HS)"8X01X@CQ%5"<",1XQ'C$>,1XQ'C$>,1XU%$ M>U9L5X6!U`T%GLH&*1M'6,L!9T&KP6C1UV&E5"D"W""L6-Q;Z6D8C9:NM#N=HF1Q+E$K MI="(*8@IEA[;:HLI(@DB"2*)RR.)JV9A)Y>L:T*5X4&G?!*I$*GL$:,T"]L# M_US*F*=*.MK2C[?88E#O:SC;M'%(.,`O:'BDI%.]8ASKM MG71"(BQ\*6O' M7HFSL"J80BSA",%SX=I=SQ`L%N>%3\%3]$Y;T;3#[3*._" M*.^0F43B.N(ZXCKBNHM(*QYO&EPU4XI$CD2.1(['CGW5>G&[:UR\/YC+,+X3 MF:]-]Q^L8CFA.;;+KZ=#/HYSF; M&B$SF&//[(A;S(UG8QXP;[(Y@\AL%_Z$4$M[`AB$-SM>&#+?"^%GSX620GQV M33*[5/(W[D<<:[,@<;VN,*VNKN]^L4OY"GN<41*%05E>J[IQ!8(RH[8HPV_X,UCS@),P.+Q'ND38S[Q`KQNHGV;HU3P M1<;,`^W]-\?YUV$4,KA)7+?=!QY&>%0(,R*0?80"G[]E#+H*BGG$?PIIM>L5 M4@PSIT9P#\+"!@8H$&R)!TT)KJ.IX5Y#U^&Z1VBYQ4W4`(&=B6$'[,%P8OXT MQ%PH"(@JQ+)!(5!6]P:`CL%U1%OR4H`@_@2%%M(@[(1H&G`N^MJ%"K,9W#8- M&>``WI.AD14*0O&V0DJ"*JWOW[E+06^?)]SD\T_OXO#ZWC#\FX$13O'O<#$$ MT7.MQ>F'OV5=^Q4XK>]XYI]__Z___(^?LN<]QS'&N$;6?N"](##<>XZ*<&>' M)O1W'/#L.=0_),8O?/*^-KK#7O@?_5]?[VK,MN""84;7PY':[:K#7GVD=UJ] MKM8?M/M-M=/7^\V.>C=JU?Z^PLYYL7RU9X"N3_R1??%FQM.NZ'/D7I*)%%\? MY7O&GF.EJXMSLF,YX3T_UK.O<2JR3>+V&SN"XLVD4?,0'!PVLL?``G;(1NBT M&&A?!!L:/H_A]Y!]<,UT<;5575O\P64]/[`=Y!156;)&XJ@HP7%@50P7C`=P MD;`15WA;NDQ3J]\N2F"]]*;L9_7V#9HE&\P-_VZ#;-U[=/-2X(!8C7L@/E$P M[K?%=ND`=I6KSF`T^KKT>C\.PAC=!:B'M+IXBWROL)E^X#W8%F<3VS5@IE^_X%,11R-D M`2NA18=J0_%<6N\E:2JBW"L[7V<$&?X&[0IX"'XD2`#O>J(M%K@2)@H5ZIZ^ M$"OH`C.E+0N35N'UG=J5-.GMNOFIC.[\GO7`)@50G@)97L<$X&,??][7>B9A M51)OB89;Z!T)5-Q@W)#$SNWFVSJ#DARX7HP7@:X58`([&['"#!_:^MT&/Y([ M\X,U;`)&J)CVB/TOA$J_0EVDEYSU:`!N!VHJ]K((V[%ODR=%*6:V5SR\E?W2 M^^]_W0T'GT%C'PS3F$1>\$9AG[_\TOO8_\"NG'B67$4APZ-C8"A!A0(Y^6<6 MMRH)$XG789V$8YQ3W1R+6'&0JK#I`4WR5$^SEB]SM61H`/9:LS.?V/7RSSQ@ M40_Q56M];99;-4`;%7"2C$ACH+*Y7-D M$.#'YP.>DS:`X#RB"#W@.1N=B\R14S`3(_Q%D"+81DPS>,]8RKQ)S!E,8RYM M*-`L"BFX9BQ(QP_D3_R@5"A(..>@VPA"$&$"`"A0P+QO0451`?, M`[]N?!UQ[H8*8L]PW1CJ[7)H.L2.H;PVEP;L`>DQB.^?XLN,(<%-GDE/3S88 MF%JKUSL*?,!T#=Z?TGQ&[7F^%NB3E)VPZB8II?Z#-$S&LE#F^%*L5`A2%R*` M;G&7&[:7Z_:B._J\8,;\WG"E8%1IES)1C?@XB#%3@_H%[0=0<0,>3NP04$!@ ML?^#.R*9&83;-%G1*3KL01BM_*HGGA?4P46`Y"PNDA3!^AO)+WLH)\A`9(B3B(*['K6]%#F\P(^ M<:2;GT`G>39QO.E!H$^ MBIX*N-1EU,_GV[%@"2>$F!)P/0:N2Q^>&7_R`WO3T6-!&4TH\3JR9_P%2:8B MVPH+">=4.=;*][TD$YF^S9-K"N3?73&8\%L$N)#SD5/)@(OK1D$RDH"W#N/` M\SF4!L]X*4%)>EE]2^J3;WP)7/QG[`@.:ZX@%1/W*4DG:!5C%6E/8@<)PLN2 M!DL1@K64O=C@$$&+P%9@E?AWWTXNHO)"Q1`Q6?@NB#A]R89*I@\\*<458>4* MYK)<.0QS[4VN(?1+"#D+41(+B77D4M!:6Q0+'YK++I&"9OH/M#SH!7A8+7FT M%GYBCCW!ML+G$`5YL);D#/9:4_1ZVI36?DT1D)B!XX.V$V,]+C)G67B=`]#3 M":#,]U)$U)B"WP[,>!9&A@OF7OPB]2+;E&Z^&0=<^E)2YA5.5?_3<,.0N^S7J1$` M-D5>U%BD_3Y]*ZIMK96))*WC#QD_E4)>S4VG,OK'X!OKI7S[EH;=T!\Q4):49GWM6;[AQ5'=\KG/@]QWZ.6K?:=3SM-NWT[D)--=^4=WVGKO0;BM+=55RSQBJW"// M&;P]YH2+;VNSN[X*;^BC=(*&ZT[0%G(F'!(.=\;A)_3%]X2>V-2/@,UU M6;Y^NYH3A/+&L)%H\TR@60'TK6<("'V$/N(^0M_YH^_5W$>>XIZ05)O'/:VS M?#A=B:D%7AP:KO7ZDQ(KO0OA<;<<_+(ZEG8EQ[6.NLMMR8O:3V>7A`-M@E#F MC@?-XO:^.O>M#&CWEMUM('',Y7*,IFB=P@)L8AEB&6(98IEU3T9I-S1B&6(9 M8AEBF?)81E.Z:G&'4)P[S53AN-GC)G`&FY=Y7RVFP&^3RLE:NN_QT25G(HM6 MRT:CI$UMS_?H%TK<%Z=-%=,65=&[A9T-3/I`^G#FUD556EI)9VF3?2%].CO[ MTE"T5F&IF'/1ATH/G$LJK85M4TA_<%3M&=P5F%!DOW_]KZLN7'D6/?9CO!_0.AZPIH( M2$.`>\\206UVGS/3W>Z6YUP_W2@!11%N$.!@D5KGU]_,*@`$N$A<"B0`IL-N MBR26JJS,+Y?*RI0?\?)B.ZC/[[]\^ESL/#3Z>ZD3*K5FWD=/^VA%OJ@$V9.% M[%YK^Z1A6<6(/SK68I59?R8K;WKSXH\+53C/$MIEY23/DF*;JVDJ'H5%(;'^ MO.N(RK+GR3/.1`^I^0A$=7M1,93KC=,2CPU=J8EN]Y6.@X[0LCV&AAS8O,-64V%EB$R8X#'%!:G!.+8:9HG&V6^K;,67=/!TOI6N^BCA6S_6$YD2=Z/HL5T"W*47BQ4)AV6R- MP1]),XD<6LS;G0$ML,O!4J7U95X&KK_S@QRL3/C4?W1];,HT8]'D)8X? M.>3!TJRA8WU-BD:FR++0`@5&G;Q;3".<8,,%_D<,4WD1\UG;ETKV=16N M_8P-QW+M&^[2-JFYIG0)#&;XCUTAPAPR%PK2&N='_,:V//U?#6=,FG.*\#PQR*B+:O"JY;)4$JPZ7JYNGV2]WHFR, M31W"&"!HYCL"V>]7K=S!NQ%H__)`.$)L7N0ZB"O92_75O"44!#8F=@#B44C! MB\77K&L+4NSTDQ5'7]E78DG_U=B/^YW!TJ"Y\U[X-V&DW0*%$)::`4.H6@JN M6PA@'>2;LH4K^N`ZD;@Q46:V]$J$?DO;"6`'-/"'/-NQA4>6]N7+2M//G3(_ M"-,V!J+I#0]C-]=?"IA4A%,*K"C;>^&38"7^EF_`B]U:IDD;E]0>RW6H0I*& MHI%]^E3L`K_J=AC*[^]O$Y=%A'<$KEFB&9`07250(ZJC%QK,)Y-&F$09F[=% MF6O%EZQ%BAJX*[0/P*Y?!:<]E>V_CT:?BE:=<'=G:%7"0^4$IKZ-_:.R/@(L M#./I3#X&=#\+I&DK&\@]L`=PV;'#T3CI2N5DS>!<_L3RTP(%E$_$$HL?KF`!TI`GYCF^S'_V1.>'P.&>Q9,Q M%0>**Y-)$"Z,E!ZQ./#^9,E0^8`;@93`/F`!QB-`EL.OXE5262>?P]"W',$C MPF6'\41N.A_7D5.51OH7`#%G[%@XP?_$]J-T*.^)Y19OHNB06M(?T M);2?=S=8D!OPOW2T<$3G/'%]E6`D6G-P^88<<"48M7][!!&X M[AY0$2VVQI/1-"?MC_<)U"XLSQ=+L'BHS[>NWGO6_O;$P:>[QKKX-8V`HN=> MZ$PT[SFTZUP/:E(HC^`?.KC]7S&(>&?WP/:K`>V$FY<"VHM%GO_`8;D7YY3FS(`F!CT"),S=%9<`46^[<13S0*L]4"# MY(=X^X%=%_I:`:6=!T>:=?-@UN__]Z+=-[1S0+(IQLVU3Q=&J]W_7A`._^X" MW=.66+E`1QH#$QKJ)<0P^]AY"/S0"06T7M_IXA$RGC*+W2F,'95H$GO/T^N^ M2!2,1CFB7>VJ!NUB,,FHYV,4H=&[5]\H]?1R:R4F/*X0XSHYIRXUF/DWBTNE MI>?-L<5`V>I^8&G_0=$>KQXR5V_$6)2\10DO"B"Z-?.XZOHES?E11<$W^C]* M=EV2492^@L0M<>R;4I6PLXAWO\;2:10RV<$3OB(:,0O]?)-FT;D>S\#=*Z:3 MQ:+!_'L,V+0`;)*<28C3QJT?-0'.@?+X9CR[*.Y)Y4GU2L"6>7FZG3O?JPKA M#DL.X4I#>![%7=.V\MGGP#C9I1;&S+NI MYXZRU6SWC[6:K^@_`.L+`(TY3`#*@K^7N#QP*1#`^?Z5;+.=2&&6L>.Y(2G" MB?`CE[9T\M934:"+_"[#7YN`X/+^OS#J!/N!?&56FR.0=:&_8X">\+P!//BD M:0*3[3PZ4K%,'?LBXMP3`2Z&;C26/6:/O)CYD+6US&)\2:R$[(OC[Q0M6ANU MVBE*!E_8*5IDL@-N&1F#@V\9O1\7D20+Y8D&Q2*<);P=>$O@NW-*X4V.!PA3 M,/S'3A!&V(`8',\V\#M<80D3#\58[C`MDE=/%^&@K-4NE=!+#7SG$;4L9RJU MP+#/NC-V^,(F,RX&/"3D?\0R)V*%J[4,AQ*QE^A6N2U`IFCO+XV!YO;^TNV; MI+4]DE(3P>C@Y>+AY2+Y$\/E3IA&7=&H"O#IYWE3043N4UYT61A=1/Y%\M@9 M1HAQ6<"K$'BP#!ORRA`1XER]"0*O5\/!+[!&88(,?[7X)ZI'8/ MK';3?0K1P1B,JT3"'03IW]_?9CMM@PUGIU*56Z+WG^6.Y8V2(0ETY%RP2TQI:D/;#MRD$G];M\/QP!\= M3VP*^3(:.W]\$I8%I/T'3.H)(;$X5R?9FP_GH0;<>@&*3IUL6]/'P*R5]%A? M('$B:HN4E7N_8I?9`J^@^%X@K(UX#`_](W9$T_H73+;#+;]T0//QZ)I\S^+W MN"G-0IF0)_[`)X"1(VB"ND%241@""'SSVQ87TQ;:(7%7U_%*<[9.KC&T:O-$ M2Z4AKL7YU@-VF@N::_=7\VN7^JOI0^9(^0P^JJ+H0;=[V5:+'*O$[%WF@Q5! MI=>&,P]C+&[8O_FJA0",>*2]75)`"^AI,$M M.&PJCA>W%FJJX>?\>SVT8=VB(8/79`^6$\/S%3=[WV96=HMGKM]-_O MTH.E8O]^%O)WZ1]+*GX^BWSUO.RP:6=EO<,-ZN^)D?U\UA]\]^8QUN))V^1& M8\?[@$D.\<*:-&TLY7BZ^+34HW"_4IV';BNZ`6E?)V?Y31_S%N*F)-V)+9=. MIU/]BBTXLX&<=XAVH]4KH5)>*8]_+;A(6["A+L?!3J]RNI&OZNW.]2[H^$:O5A+/3L_F?C]X@MU/"7*IBL# M[WH63*N#G5"+ZFAEMA'N*L4^JH6V*:36I!9:539N/^6"V2/7]:TLSV@T/^;Z MZ_Q(ZFNKSAF M-YT%3B@W?D61N%6G0_8\=(RG)B+<0$0TED?#=>W1]VW,Z],UFX]Y$(B::]^R MH]DONBBA@X_#_Y>Y2KECY84CW/7@V7I+7'Z3.>!)5I(27BXCU0%8=(GGEE/. M-D$+L?69Y3`YWL4L\"U,6UV;,R#?)C=)0[[%+;E4J.R%\S,K(OMN!A=@:ENA MZIK(LHZXBP<\8H;YU_Z,8ZYN[B30BE-V(M]%9ITE>7P/+[E#MCE2914;QB"I MF/>M/?#HF7-OL\W>W"[Q:C29IXA).IP7)U>\>&E=OU\$!)&%DT-!/P.;?8IQ M$59LA17S$A-RESJ,IU-8YO_EX2M,D^GQU4@_!YY$E&4>.&;(V[E:)EDZ`.WV MTVX_[?;7-;2\>HN0=OOKNMM/;$E;_;357U9<^OVB6:PJKDI[_8W>ZU<=A:?- M_HHFNI4G3G]/O.M=-%_3]O-;>J4<+.AX;> M,ML'T^!SCBE/IRMFJ@-;TXT2R`^+FTWGN?CCQH1ML(8[5ZOB2,SJI_Y>SV:[ M4)S.AA*9;@=$4>`\Q#(0+HK+>$FI`5'?+JNJH$PY-"/YK<1-_O$)3.EQ!Q_8MMU8"IN&O0.FS+U1%?_*\4??,"T(_@@+1<.53O^@F]OO MKH6*IVGE^4?H&,- MS3LZPO@V>K<;`N?J54 M@%XHN#'FO%#>_[4>?RLJ1(O:R9D\)[4(DW)`G,NZ6VDU77W.T+*+9$JS>?'& M]9T$\8&RUP_F/1;[_0!S_?Y_+TSPP#1GK,T3L[+JN[YKX[-S%<]G<6")2IMS M*8T$`O!QVFWD-%LYB;UEK$VY-0)P[0&5CJ?\X?B0Y<;46;U'V4''_EDQPLC MK#(/P^+?D)AAFC3V*@FP`(OUO?:;2,;#,D@@LX-U!3D+]8_GCP41Y"*;S0EE M]M'#BQIQ0,!6(@18M;&F0/2&73$"I`AQ/3]-6#!EJKOM'-.V`$XTE-L4DEZO M&!2O$[1@5(A+BQ:%M!2>97UNE;:%'%9F5T03\$\>)]H-X"DFUVMM:52T`;L6 M&UPL3'FY\;"\(-=J/EP>0L%H)<6>D5UTQ_QRH"# MPDFZ/&."=%+_?\YFLN49]IF3GN^ M-GI\Q`:+P!$($W<9Z=Y[H@YLM,JNK&3FM/)HP?$*:R;%9F4KP\72NM@$4&U+ M4@!6+I4B.)[8U=.+)M@I%E%I&;]42=((M6[*>S+%7?3/1-O=]<.-0]8+#4US M9U2.3"DUQ]5$$>HP.1.P1_='2LM?D98_[%UVS$&W;R3_MM6EY0_V3,OO[9I> MO_-]_4._L)D3K$F"=WV+MYW@08-[H7=^D^KF=E-U<\"L9>+%D^'%#VCY*&+% MFF!E;0[#](^;,$5'7VK$?^*V7[=QM!Y$%&C>ATKX5@Y<.\5"X=_>*-]"YV;H MW$R:!ZGW.Y2&K"(_LD8@5CDCCR#HA"&HK;=-DR"H,BG:C;*J/JFPD!I["J+? M5Y:9>PKR53UWN'*:O+&BTF[I[1Y)RPD?&%)'PO>>%7`F$O\6RL(=M>I\4P[7 MMO5!MWR?MBEG1FHDD?75=DT1+5/O#ZC*RLGY8R4>$,2#L>?2+_M^JV0C95Q8 MRO%8:@&Q3,":=WHP]'9;G5GQYD'64SBO2@XU81=AUX'"%\/6\.!DVRJ^40/& MVR7X4?&3^'0R8./1W\0!6J!+@]WE64?*8=?5C7Z/7BI*QK!XVB`[&%L\3VAS M&6RSE1UM_6OKLJ?VH+>RCCTP-$/IT/!4>3B3[0EY M(U_`?F'6$2=RIGP^!Q!F_I*=OU4RR,.T)-MC*3;42BG!5@HLGD%7)`Q]U35) MU`FJT1]NW=V:6TFSF0F4FH+,`IE MOS,L)R`?*$9%YS5/YKQF]]#'&0_^PF9.D,X@49^HDD\M->FLYD$)1YRHF*"+ MY9^6JWDT+:N@@MXT'F-..1HA M;OL4<%'8GG^;81!6[O+(BJ16'`2BINFV35J;>CZLK;>ZRDZ'-46"3DE8Z+1D M_I@(=0\E7_H0/;]/[P#6H$.-KIOI*%8W/'HRPC746RV2+7*0-N07:AD_/QPW MU-M#@XP^46;!-B7])44`]>135.=C=P>T<42N$+E">)MIZ(:Z?H1-$0N,7BD&OGSO=S!,I57M1LGX>:YT)H?:(E*U_#,RF8#A"_/G37O^QO\_AAP+@NH/CL1W,NL"3X4AB(& M(CK=VUQT<=WD?9$/L]1B+!V9WF+S)^[Z,WQ)6B]29ES"GRS*5YX$_]J292?' M@3^55\YF\*4HN@BO%C5MQ:W9*L$*,%R#V(V21GY)O4JT>OPX2$8\=CSF60YS M16U+)ZG/O%07LU#A,J5!P&?P`G'LVI:WPF/R4[#\V+6S><-#0WA].'X!,6'. M%(G,'"^,%M[UR#T>9$_:HVKJH@B9*T1(D<3(CWCY.R>"QUORFZ6Z1Q_C*%E+ M;10$6,3X[>Z);V)<60CP7E8K!7X")@E><#F#,*M`G&...(1QA:%>X%G$#%%' M2A12A<5_PM+"<4&T9O#`F,'(X.?GB0,BYD3B1C^CDZT)O2XDR`+-"ARCV4'\ M""(&_"H+K`IV=0+[8L:"Z"57O-@/0A0-%TM-/4ZTE9""D@&2'`A8D7/#2'5^_6 MA>@6)@B_!(T!\82X*=+A<_EG6C<84AP7X"6.@_@)AL;P^GW'/%IB1 MU*[EP32K;ULNYMX MEKP<0-B!8:=C3OD!P-B.+02D$-2O)2&X,+^'_\@JS`+X?P`"P;.34MD.?(GM MN.,H!D*&@-,[*!+Y)Q.>2`@,GE/F.`J4B4#Y$+%[#U`JU9&R2I$+0N2 MQ'-M5&^"Q.]B>$6`(Y1/_"_F@;[PM$\3%DR9Q6-A@\-2OO>LRWK8D("W_Q4# MWV/QQ2*6%G"4>7,(U<[Q,FG$#$RSE9'AO3=V8^[]+]-&Z;795<:/WTNCYE6: M:>R2`0+YT8I\+"6),Q'`[0+VH]Y/!!9,M22W*@.N M9/L@119$B2^QX<,_;AE(8"T\T'\P`.PE$`\FC2T=7"95"YYL::DLA_AO& M-\!X>]V32O_^Z8-TYHN7X(]L`]:.8KU[>^_O*7/__I MI_E]TZDCC+QPY-G7?M+LRH(56'&KB&K`A\]\_//9W0WJJG^V_WU_^J?S7L&H.K]E5G.!BU1V>_+)@9>0*]T:-FU1;. M3E9*<8.L,ROVY+E0:;BL#D_FR"YDI$#X>L9AQ9/N9)0;=)V2J.O1+<[:-;"; MNQRVY@3@COAR[P(TA6=?/+QH+H\BQ%\,N($R0&KP*T#11/@H5CRY%3HP2A;D`\^1C]RARO;YJVDH;O(H9XQZ7NPD M"6\NPET1N,Q.>S[B+]G."F@P/X@2?;5,3:?8UFQAI;5A*/\7?JR[1X$ M/#Y^_0JVQZ.PH>J+61\][3!H:0D&&0 M@SC(G)SYUR#/OP$EF34!D(AP:\6#EPHTG0.R"#TDENC2QEY65=L3N]936!Q_ M/`8S,)#P*JUKL0>%FUIC\/28AUNV`I]<]AS&#M+#Y8\B;V!A5WO*[/E6&L!G MF&TH2WR>P9.?'-_-0C%?$EUCM,X?OD])!5_".X1+^/@(&%&8)&PD%$IC]T;_QU"$G&!&880F]`./ MGCGW"M3!$>>%D"$LX*,?/&9[?&+U`M_BW`[E^J7L"D`%3ID=`R_, MYYY_M(@P+G!U@0!BYC"IC_,=BPR=Y#TH6&R&R1XPM]=`XR[VA"L.QH<])Y!< M]"\68&[NKU]__91=BL5+P!/-I#>[->O(.XLC&<05G"!'>\`1K/BJR^-]63:&PQOB(^8/F%$_))EU=(6JS&0*V]U,L:^*@._N&APD>(O[ M!S(/*`U%B1!P3&KV.IMC?P?9`[Y+(TGO@7&G'N"?M2;,51L; M#9AGAL&L"%=+RF/!A$"=KJ^%TQ'FO2:0^S%X9%ZZDX%$NGJY0(,@2YQ;L@:P M<"UBNB#E2]XH<83>6VEWB.V5Y,HTJ2P,N>"V7';9=)7#"-\[X!P"MZ*TRTW+ MY#684IB^))'^*?OF3.-I;K.,3;'P%`XPW=E*=\"6YI8EPBWGOP@B2Z_-*?*1 M))4T?$",8L\%/S82[M\__&=`H&!9'.=*/Z-1'NV%3YQ0,O]]=BP$@_GGG#KG2C92A3YF&#H@_PG=I303Y)> MDH!8N<"PSHF99<"<[@Y#I386"-&2SU$W/C7(+6 MXLL6L[3`5H:[5QCSM1'GO-:RP(OQD[BY"(2$J?&\(K\/%SC-ZA-VP2NC=B>3K\3UBFS^_90$/![4^!=-1;*/Z@=C/ M23.[%M[%+'`BIHXE=YU\((L?7,`3QACS`.EWHCB)K:?IA[B?"O`MVCO,'P:# M]-TGM*.3S!,$0O1Y\*L$(^8I"`E1)?LY8G,7)LK%OD<2?UHP&L!3]%>M06XC MX'4BSTD%'@Z*%;S][3WD0E9:;KXPNO]!\B4;@EHQX;?H)116,UG`UQ9&?QO. MHI<9/A+),$M,5,&C*.XK`;S`1%JR"OGO"D/.+;S<=A=NH)]X38(E_Q,#PV,> M8!HUE/Z*/G?ZA!H#E:7E5,Q#@'G@KSL5(A4=;!ST2_P'-S'O<-,.)B]RKS._ M)B,>OB(C,\X)KWOM%4E*@-!32SF;BRLK&')Q@;94*Q#)LUU`D2UIK8FD M?U"++T69$L;RXB(4+Q(5;PE:>OEC.AL-+XLQ`R/YP? M&I#AZ=S5*-MQB$2!AST!-S[$(L:1YM=GUE/H3]%Y$/;`TN#Q\0@7^0S<=/"8 M")3P7RYA.EE<#-3(B8YQPID/CEZ,B[NEL4R"E:LH\[*!@.\]>3PB35B1X7<3IB?F#ZI2Y!3*Z@W&;%8G>!8L@ M]^HYDZ=Y4"*/&WB8/PD#*!<^2IE'#"P-AX%=$TXPYIX$EW"@SI3+8`X;1_R` MIF/15)Q3-6\T+J9^S6W%%4:?4#%"'1;E6%^28J1&>F1C;D>*>>3,QF@0WP=_8J%RG#RQ+6%B/[HN^GC%K8*J6ZU/+0B*'VW`^Z-FY MS$5-IU<(]36X.`LL^ M"-$38TED220/@>81T73AGXNS+[84>G%BI'`)6"$2J1A"Q@/@3\;6@@W`+QB2SYX\#?A. MF=I;.#)NB5-$FW!5(0^MM9"&AI_SK_;\`$R/0BT'`Z_)'BS/15K@0237_'S6 M.A.?PQFSTL_;RP,L"7@K[\ M`+[RM&NQ1V6]:/?@FH=)WM#(_D\<"F-T"VH3-Q(W[LJ-__)P)PJ3A+5_P)<8 MP/L[!NJE*<[!`)6I.%^YM,KF"6S$H,2@AV709<9]S"D4O\M$?ER-7\="["^GX<,L\.OR^5L9I>%WLU M@:^2DSXLTM)XM+8V#'U`G5%R/>E]2YS^515MWN2Z325U0-SRI>QI=;LZ- MGO((V2D[%Z3=&RLJQJ"GBDN:HJ!(&DY6&CIZJV^2/)`\D#RD\C"DQNDJ')@- M(R%WS'!=-7A06<9!?1(+:">3=C*KGJ=4#18Y07"@O5N2?\7R7\:YV(;A MPZ8DJCY^=-7M=;]%%,(7PA>R+VIF7W1I[U])=*-"H!)XE@6=/W:G_G4EY`(8[OD%*X$C@2.!8+W`T]>Z`\)'PD?"1\)'P M<<6^IMY56+.%\''#@.8/HGSVJNL/-K`2!.D"59Q@C7) MO*V/'(V.S==3YIZ;U(5OK@1_P>9GWE^M;77_[RYS_]E%Y\ MPQ^B&R>T7#^,@_DU0$$/R?29CW\^N[O!QM'_;/_[_N9,[.?ED@>YZ$;[1@6;5JV[:EV2&/;*_E M7QUS_=5'^>?!5/OX`,/:H!Q$W:8L+G_G1#`$2S[ICGG:)X<'VJ^B"==0K)CWHHGJOMS6'"_RM:6Y[?*:Z-E7\AS-17IK M[#'@''M#A+HVBX,P9O`H&.OSQ+$FA:F(ZT.-S6:!_\V9LHB[+VJF9%P:&ESD M`K>KF5KX1\P"KHTYCS1_#/\=.[B3X=F:RT`QL,@/7C3`?/C2\2JV+`^Q(UHF MA-HY4C\]4F2V?KQ*?\F^,W[\'O=G,A&"R5SY8>1[NO8;"T-F3>*01]'RHQ:% M+O?`2TV[SZTZ*`3@#@M86/++C+T(;L%W9=6.L=*Q+NC[#,NH3=E7OGAYGK=P M,`LC@.]`BS].\L\T!PMCF3!@/T_S9Z*M"3P(Q)G#2_%Y`C5AK5<]>^P'>!\" M!-[)7$5+SCWM!33W,F;M\K3+Y4'5!OJNN,6`TPIP\M4JVF#`>7ZD35&JQ=-@.#`D)M8WQ]PA M<_F%8#^T#G.\K44!9Z(1CA;/8`28L.UR,9B$1%&YK#R_B7A?F!0:IK4FF!7'DT[S,W6OV7&`WRR3 M2Z::XQ,>^",\T>9@N%D.W)58*\]U2OH4"/'>^G_NR3)OY@91D7'('R.2"-9D?7;8<8E;G MSI:WXQ)@:X^Y+IL_\!G(,BXNER^[!<A%K`S_(W9FR`>ZYG'X!_C/C5%>E"#C7[NM[F5/ MK86`HU8T.*-[V5(\N!#Y;^-GO>$>)7YQXOKFK/"D9V;>%4F^$IQC(^@)KG^' MGJD<6Y8*,A?$)"=D.9_YN`N3&A*Y@1IKDE=V>;P.2!K.0!>`V^R^Z'E<7:$< M4$,5\">!&XL%P0NBQ!-S8YZB3H*X?PL7;73-==B#XSH@=DM/%`I7#4MW^FW5 M%KDZ>3EO>0'Q*59WEACSNT5?YU6?+[%L;]?_>T_XK!O\?U_>5B`<# M(YV#UY6#L&1*8$>H MQ8@Z,FXA8<3!R$(H5=%06!M]6//WZ=HZJ%U>1+-95!KPK2L=UH1Q"J^ZA/NT MCU;D)Q'-;A$'V10Q;QYL#%.2+P%PE,$O*AH=D0WC*Z)&`*R8B"XQ;>K;6HH76!*30S5P"G#_,;!2FXR@.S@D%1CN!%%OQ'!@$(+(S0XF0T\WC M58X@#K@K0&,9QU&%4W_M=]4J15%A,%T>:5GVLJCQBL4LQ*ZF@AR"*@5"8*@" MT,]'0HOP.1HCNL`$N"L"0__'="V3R.0L6Z,0"8Q>F%R['`_V--Q]R.E<)D+B M%_)%\(2I`W*,6L[#?=2(0>YF%*0RE1^!X("V7 M$?/4"D4&`AZP?7"Q(\="(0H=VT'AP)C)"-;]K;=)%P*_RUZ18+5?C.7J4DRE MB5JPD=/1H!4Z2ZZ%0>)@(GB@M/10+2T%;$0,/LQ&D'Q,E%@R'C\(TQ!IRN$S ME]N/F;(3WLE")!K175C-4KK"O.F>$*U(J_HRUVJW)M%OX=P)F8,[4`7^IPO1 MS2DVD&='ZEJPSZ<`N2Y_XF+1_GOTZ[]O;J\_8K@:GOS$O5CPUUT$YOG.?;)LPTN5N!8`@=@75UGZF0;-CFV2:)Z&=\DGU>L MK":&E/.1XH'8B&<-' M=>2$XC%R=\X)`3[E9W"TO5!ZCY@Q``H5>`G4HV>+R<[B`+`R1!R<.<(1C#!! M2&P2(.O*L$#^(3(@P,9CF#%N+KWJUF*BD6C8;L7PX"D+T#=-X#C=H,%=:!;@ M;"48P).#Z<)RR0$]I1:/S<2?)CJ4TFY58&65'0VNLD:_R#O$<6#C:*"RO2'*V;QY$5^W`S_V% M3.Y"6/H`Q!I7P<9U!:YQG@1W)KP"LK_J1Z%K1:)CXH)A$B':M@L;TJ"D(^&1 M!+&0OX=Y:D%Z;7KI?)8)6`1.^/5'&4G$SDJZO,GV15`IT1_9-C:21/@4*]ZJ M%Z=?8[;(&]A9AH*BC<_+MEH/#[30&&VU&7,$.\S=(L&18L<^R\20QKX3"@=@ MV<$5B1:XVAS1*'_74D9$'*:`Q<=CN<$POVC*P6RTYRY,/LW(33SI'"]F!:#[ M/RJ*(*'1C,.TQ;8B9C$+:0&4CGCFL2?9!JN217>+;JH9^T@,;JEZ@!JLEC(: M>Z#$P%#^7V[/N0&L;A\38[@]WVV8LX9D)N"$#*:2-5P;LP9;1B+H^K5>LTP/ M21&%<())2^IV:+N7IMIX]JL(MYPUOB81?"%9/`7_]QFPAB//_@>X.B!Q(Y0T MX;#MEE%N#HV[NTYWT#&[-^U^U^Q?W?22C/+;CCDH/Z.\S#W#I"A3@;PRSNIKZ"J)O:$Y.`NW5P1C1`8JJGD8/WI<,D(3B/RT M\2H/>I78XOT6"R.9VF?'UMP;!./%\\$@$G*<2SS&21>XL*5 M(F<#W`0!$6#1SV-=H*?@>K@T32#+@DB"/#R-<_Q]-/J$ACC2*WU&#,88V-R) M)R(,&M\3)I)8?338P5>,)C#*>U^$1B5P\F_@5F`R6D%_H,/F1)*V`DN%QXE> M`4:S\;Y_>0X.\DLD"(T9N<*E30+C-D=_;77^.%X;8K16^,AB8L*YS0C^.I&; MP?ICD?#AHE5J241,`O^N7,&),P.;)7K&==N`?\Y3\9G;KN'WPOAYC;/%7KU!@@,-R%,C'&Q9V!D18(5L5C-?A?\';]S$J M(?T@\9)%&GYPE/PC-\DXGAG";`M#"(O!F*9Q

-&*$,0*QT`5,R8[[NVV/'S2=T ML)9&+TSTA97111;O!@]%M+`X2X+V&.M??H'$$&`^>&;RT.4%E\,#0PYH%R!A M'L1^(**>E61)%SUA&5X1QJ0'=(_3]R2;#<)9R/+(M$;2'D,2=8V%%89I(D/+A\[>1EAM%`<81R$W:3=K'8QA1K+>0PRZH7 M3REL<@HDD,Z4Y#:Y&7FJ:7.ZP*L$:X1CFH^?"'Y=%H=D\?+Z4`8F4N=4^.A% M9EF,CA2MI9HKQ;'O`C`(@1(R&<;3*:B._^52#P%QI$F2I`:]8L?EXY8;C<"RSM7`J$S_G7YU(0_[\N('79`^6U+5`Q2?7_'S6.A.? M\0Q<^GE[D87%`FZ4@V1QY*=?R`H*XIMGQXXF[P:=RZ[9'K2&Z;_?I>>S0>I= M-@OYN_2/)2Z^KX#3;`FO4HJ5Q)N6KR!A[B&O(:KR,J@;QS"IYC1Q MY`$Y,CLGO?:4A9(2R$"Y"I0Y+HS`:"]6J3"4-7A:3?&[Q**\3BS*77B[?]S& MXN6SY;G81?'C$,SPL*2.8\B-%:KY=30V%;?=QL%R[N8!M5#)G6>K4]%KCX)= M5:G)U>KI/5-=U4+J.5P9#*J<-4-LBMA12(9D)&<; MM_6NNG!>4V3DB'YY`W76*,9<&=?!JFVXSQ64(8I[=[:OKPR;7;U35E.R+0C9 M%.$G]_<`FO.$Q35+W3#5L>2IRVP=MG56//#U>N2]DO7RO1]ME"Y7#I`6J&!G;E&P'H9)RX\5HZ8.A,@_D36(U!?'(C2N2E8 MM%$CGH,-K.Z)W\O'&W*UAE1F>N?/U64URY=J*&QRMK?TI/'%!/!U2]+<)/)A MYW+0,,/FWK2Z)W##VS")O=VN2G&W4)8N\W:O)0`]$T74,6.#A5Z+SBE-G M-S"67U?AU<_W:L6_\8=M-I+?ZI^T:>O=UJ!T\6K*]ASA2RD.1'6H=EPU^%&H/G<>E-(S M/9C4("5&)45(BK`,17ANZ-VN>1AJS`6E//HHYI,2O:#31'FUC@W!]@8')G9E MMBUB$ZI1J=>E4[U8.J/M06+FG]+6UF59%L3`S83B\\5Y#/GITU68$6# M`!N<)R@.ZC#'RR@4?GS]6%V4.&XA]'L5H>56WF4->'07 MUW/]$5HZ4TEG*D_U!""=J:0SE:]#=VU[C]!!M[7TIMUF.E))1RKIR!%)-1TY MHB.5E>"V2G$8X=L)V1B52P"G(Y458E12A,U5A&6T9VFZ.JS#\9:^N,QN$<1W@,K[CRQR'F"RQ]>M.AE)OHCC1V/>1;>Y7AA M%,13#))1$Z.*)MSW+EMMH]_I)?]VU"7JDL^.DV0)ECQ@59[ M@MO%1\DY64)W8[AG/_E=B%FI5*2R^GD1"V[(@FN3#TODP(KG'_X]\,-0&TW] MV(M"[3.W_$M+$?/+-`!*^C M@%E;Y0MM[D.7NY]W;-8\Q%F>ZB75EK=-6I7TM<;GU6[*5-5/K55;+[3I2;4U M0IG*V6B$,J>+,I3`3UA#6$-80Q8-H0RA#*%,_5%&48GF30G2Y!8_!$$$001! MV]/"U+N#-ADZ94:-CQ\<+HR@]"(7E3K5U3#$J0^PJ+5MR(2A+7J"AP;!0PG! MW*88&80#A`,G@P-D)I"90/!`\+!FRDK1@0P$0@!"@)HA`#D*FT0CJ;/C,W>W60='-]GK1K#D6?_@]N/P"(C"WX2A2!NG-!R_3`.^#U0Y,KUK:^_ M_.7/?_HI>U#V^\=$H?;L1!,MY,&38W%D/MM)'O(\<:R)!HRJ/7*/!\QU7T3CTB=X M#LQ?F\$`?5ND0^+7#+?&PDM-RP^/N:&O35@HQVGK6N1K%F`4=AN"M&$16)86CQ+NJL"D+@.#]+!X=*'8Q`>9`#X[MSY7F,X M@S&>U?#R,]=@(.>.^'V)*F(0!5KO\F[V_>HWA^+5#RO?#'35WL/[;?E1S[>0 M38BKS>(@C!GP$Q"9`:U$QUIXYRSP'P,V74%2L62;KHF1>!4#I4R.J!D6I^EI?#IS_1?.DSG!KQ8P'-=F+OQX?G;[Y=.GL^\O MZROM[Q,B+%(CD8NDFL&?UG^%.Y+.>^).:XX!07L(=97L`A8*.*9R>H]O&A+Z[8+ M"?OZH-726ZV6DJKI"4@(^!9%"HK\V63\.@.*MWFJ*IR@<^*[+ M[0MT48#4P/BO+U2-V?TF#E"Y*%DI)%(T"0`;D#X>S%4#%HPFH08B``NS0RE.<&QBN#3NU:;1:ZLYI&KT]SVEVVP<^(S:L MRUDVFA_-CXXP5BR8F@VW?^HG&.^%1?2;-(1NEPVA8T:HB>D:RG0?T/C>G^<( M_>BPA&K67.GW$>81JY7":AM7"B!6(U8C5"-6JP6K4?V3@U7@Z99P?+!2['2( M$X)`BRJEGKW>ZZ2]F#QA%#==]LTU^O)6U/_A18M>9APWN,26\>NA_5V!\X#+ M40>)KPRQ:@N5Q''$<<1Q529<98A%''<*'+>]C5@Q4]#,4B'*-`73W,9CA@\: M=B*A/@.,%EL MYD0P1E'SS-<<[PG&X@=..5Z-TO5Z2WQ?7Q'5$GUNZ.:@_$C#,I-N2ZG]^5@= MT38^Q4A!OSH%_2HHG9UNCV239)-DLX*RV=;;!]A;)NDDZ23IW%XZARUE]7)( M-O=U>`\OE"L>>-RJ'+*Q]UK'-E^)V\*>,B*;,G%WE1W=+%8S@BEKMA]C&>Q] MRAEMWJQ^_S53MQ[JNE-M2M/CDU!Y.+"K]]OJ4H#>(J0R*E4YFDC1=8(X@KC* M0%RGIQMM=3$8@CB".((X@K@J09PQZ.GM_I`PCC".,(XPKA(D5(YQ[:X.[$D8 M=[S$%PK<;QZXIS*`5'B2.*[*A*L,L8CCB..(XZJU'7[D+.VR?5[J M]YC`;LR:$_%I*?TE2`M04(GXA_B'^(?XIT+T(?Y1:E=5R*\Y>K%%,&:MB4@+ MM/D3=_W9%%ZD/$5PIWV5H0],92>82"!((&HN$)VV/N@K.[;<%(&H]?[SB@=2 M19N2S@FN6W4Z0/C&L;<]0CTU/5EXZ!HXI;-FE0&"T?PE'"4<)1PM&FX>BAZP6=-([FXK(_1`SHLNKZ@PTL M1S0\PGPQX0)Q#;/UW2*'#U9(>#[D:A8CKOM3^G["M;'O`I##*#1!*RWD40A? M!M%$B^#G:W\*7/#RMU"+O8!;_J/G8)>LMUIJZ9K'(\T?:SR,G"F+X#)XYI@[ M41Q@JLK#BQ:]S#A>P9Y98(MH+K[O69"'VQ<,>)\]:A_XL_;9G[(E M?3UEP:/CR4&R./+3+Z1Q(+YY=NQH\F[0NNSF_]/[+H44@`N7S4+^+OUCB9/G ML\AOEF0PTUNYO[7!=HL8V<]GG>%W;P)8$6.3&XT=[S/;!W[AS@/M;G7C3G78 MR`2=#[?[5F&8@OI>UL,E;PXO@=<>UHWX)"$;9N?:\CFC$'']"Y]%?/K`@SDU MVRU=,UO&QKE&Q(IE5\52S(H;=!!]VQ@WWE"VROGU7WG+YC8Q8-89>Q^D7;/N MY]O,WKF;VSNJ#']B[UG*0'"AE]WS2=ABA-X5P2\ MU=!J\Y#`L>#L-Q+P""FW-;K7,"CYP` MF(\'E5+DCVK`TFX3$:Y&];HJ!H'EG^/$J+KFS]`*/ZK3V+`SX^7-6/E.X;"O MM]25NFG*EAX9\76C3YD'N"_;&V^E-]<>/T2-R"APQ,:JV.T56[3!XI>QYT14 M+9+JGFRFW%IZ?Z`N+;OIA4_(TVB^BU:JGNQO7.:$?+.WJ'G[Y=,G+9RP`'.. MPIAYUG'W]1JFWFJDQ?3!@*JE5-X!J9=&:I3B:5UV-C["3,FZFTYH9;)N/)VR M`*X+-<<;8_JHV,!G#WX<)0Y:$DW4X)LP`A<.;Y:E$WA@.:%X#(NT);)L.<3$ MCDIV]`0A;&[Y@1C0.R1_$N+<(BML%RI1SJ_RG-_AI3GH]HU.\N]07!UF;IJ[T2E!?6"/NQY%4BLIY[U>L1Z:UGO=NYPE!.5I"3P-2OPF7F/(K4N60*N?0J<(X.SJ-;')V9,L?#N-JZ*Z[A!0&SHIBY MVJ_.>&/]1TR].?#244>E3%TT%8AAR5*HI*6P@U-!/$J@6BM0I8`I!4QKUZUB M>RFFL\1-8*J*T:?BQX6K1[#*,=2!RR%4"Z5F8/J*G%/B*-)[I/?JP%0$4Z=T M+B\A;F$,95;*6/.BPF"67[V"G#)[WQA<#MN2WP>F8?SX5[-UV5)7I[@Z2U8Y MO#@K[4(?.LM>'W4F+"=2 M:(0RS5%H51$MLA2KR1^G)%BDODE]$\KL'*T[J:"&2KKL=D4R"%YJ!M]2I20]N5`64E48IS*`&E5[=OZJ(YVY[*KK)XB MJ0Y"@-J;4N9@X])3)`\D#Q63!]*("C1BFS3BWO&;"L6-CQ[8Z2P&=GJ4)%4! M6&[BUI>I=RDL74T.(=$Z-OJK%K;>Y8!0_-BL1ONLC=YG[0PNS3XI-$*9!BFT MBHB6H7>ZE"A520XY)=$B!=YL!3Z\[)J$,J4%VDXPGM9;C*<-*%&JVGA=$2PR M]&Y/F3/1%,@A>:@;?4J4D,&ENM[1Q#B5`=*JVK?U41W][N60$D,(`>J*`*KE MH=M5IB=(&D@:2!_631]V+H?4Q';OZ$V%HL9'#^L,%L,Z1HORI"J`R\W<^QJV M*2I=20XAT3HV_*L/*IGE[S,3J]$VZPEOLPY;E"=%"NWH*--$6[%'Y:2JR1^G M)%BDOANMO@?]2T/9JT,]=&Q_I"V]T@> MCBX/E0UI#2_5A8^)<2H#I%6U<&ND.EK#2Y,2I0@"Z@H!RBLRM,B2(FFHJS20 M0E2B$)79BDV!`,J4VHVEUKRH,)AMVO%`UQ]RMDZ-JO1 MIF^C-WV-MG%I*HL.D$8CF"%CR M+')2'80`-;>ENGI'W0E!D@>2!]*(-=.(W?;ED!!@?;CFAX@]N'SE]2O^_NF' M.+QX9&SV[L8)+=9NRSB]K4?1N&7"0OX%0NY_8F] M3+D7A?=`E"O7M[[^\I<__^FG]%FW+/"`>\)//!"W9%&,,;L]L9=HW!5?NJ[D;G<=CU],N(`YPVQ]]V-)ZRP^/LOW//BN M+1^44DH#4FF"5J\N^6OC7A#903%?34PE'PTSB\&P_7D8^,*Q-(]'&K!1J,U@ M0B%.2&-1%#@/L>!++?*UWT$4^3=@A>G4]^0U$R`(#T+-";4'9"\MGL%/T81K MDF+R1:UX\?8!'^^/"`T+-CZ,P8AZ20+/C`/\/[X=A.+ZM:_R;Y<;B M1[@8QF/!,V&&R)-PT_*7L>=$(3R!1=H$7JT]<.[!\,(8KH"Y:#@QSX^T%YCO M$]S,[4M-NW'<&!]132)H,S<.->02E&OF+C\V>1C_(W:>F,N1!S9Y[O.$RW'R M\9A;$4[`1DHX3_Q2JRT_W\.$$`B9]P+3L<5J.QYR$1>3#;D%E(@<((_-0PM6 M%Y;,D808^RY8/X),8L&3KX&^,V`!)#^N'7Z5L7Z-GOW8M7.LS>#%%^FJI6O,F35)%OF=JG4TS)6)M!L@ M=<%,:RT$]_%S_M6>'TR96[!K#+PF>["DH<5=-[GFY[/6F?@,-H"5?MY>QTQ9 M\.AX'3N:P-5`G&0_&RP/E\U"_B[]8XG5Y^/.;\?,+1:S M8,J\;B(4'B$&\_-9M__=F\90T;!*;ASN>)]QX/MHG'4WB,JXWN^TG`N?8;_#8)M5O0'[;VA<\B+FRJ M=DNGN`OQX2'X\`/8*PK8D#!R3]XTC\";;]"R@MR*P1I"1N*^HW&?LDH7Q'W$ M?81]Q'TUXKZ-L8^,P3U9TC#>X,F]=XM7D..@['0NHM%^'#+/#K\OA[&J6T5" M1%,/FRC^1>PH^3,1C%>E1AIY4$QIIG3C#VG06;"2$H(:*5MMO36DKA659!&2 MK9K+%NDMDBV2+=);QY>MFAW2PK;=[RL2P*=)& M@;63E0=3[_6IU"S)`\D#Z0>2!Y('T@_;>2>[GE-;>[:L<`+MCCG![\R-^?Q8 MV_RLV@:GT#I&MWMK]/N=3FO0&K8Z-W>CCCR%UKN]Z1JM9IU"0VII@ES:;YPA ML<3AOE=7=8\C'X>&W,*IVP";G'G21X1`O[S MX)EX#.C9B2;R.!%SLX$F0_$#;<:T&R8V:6FO5\>@KS*28Z"%:F- M9^=6TU//TU$+.?\:XD&F*?OF3&$-Q:]X5`D>XC^$/'A*SD_-8GC6>3)H&!2# MGR,&C&?+DU.A'P>6F+C-9URPE?PA][KOQ6#P;8ZW]+;86_&^=6L.2;@&WR.'D&/(A1?1F3#59\(&@\O.T&SU MVO+?KKH#8ON>#S/,'<_[#`8E'OBI8_QR?^WV*W_B[MS8-EZ7PTW,S&K0426- M_AG[&,,5P"O5H25.MDJ,!KT/RM7!]4$JY!1N#MX`ET<+]XG;0+&*Z_.7"WQF MZ57PNN>)8TWRBE>^,@/3XLV^9<6!5*MA/!Z#]I#ZB_\1<\]Z$<#[Y+OQ5)SZ MG07^$XQ=3`[UA>.-$=GDL6*I^+U''W\!3>"$E[1W4)KLF21[R_=]7#(M?.![ M9'Y@S47P2BX!8;O]!M^Z6&U@O'B5F3XH/8#_QP;B'8*-Y[)@M7`+D2H^90-( MP#>EKQ`V?EH&0KZ>)*T\26N3I"W?]Z\59GS!^E_CO/`P%-[=W-_,W!G!UNL] M&?260`A2U;-:G^TB!YO%@RH?=5A%<$?L.`N"AV`11/Q1F`MCWXJ3I;+8S(D` M=&8!%\N)2Y&XA:FK+!\B$,CQX#&Q"-$DR\6Y]-RM@-M.!+C&A%DA:K:PP!8% M7%SA+#OK^2(WS)GO.M:+&`$,5'[2F!OZL,93)PF&R&"'*$(C7\N_S42D#6T4 M'++O<5DR!YDC>IG)T$`V>+2O!-@O<G:'*JT=&WEX9Y=UE_?@+0@1SP0(C2%<;UD=F7LV:$.2!+,<-QVR6*L M2CAG[^-"*\A!I=FJG&:T[RFMN\4-,(L%@<-M/`HQW_#:)O5HZST4,[UNEH,NX09WVKV6W+VGO("WUW=:`U5"5M39(KB[B]<`JJ:.W6BT*$U!( MLCI*K"FR17$X$C`2,%)>)%LD6[63+5)>)[B)5/H9J]]$)G!2DCK=0**#5A7> M]V\JCA/_$/\0_Q#_$/]4ASX4\]XCYGW`[)RF^#A&:ZBWVQM7-3]Y_X8""!1` MH``""1@)6!4$C+07"1<)%VFOR@A8['5B[UDOVM@/GEF` M#.=%`;.BVE3Z67%+F25$]6YK0!X8Q27J%)U,HQ%W-$/>#']@\2&EH MS+YIH>\ZMO9_6N(_#?#)>EU#&2R^0:RF^&H4U"`!.VK0@P2-!.WTHH<*-14) M"`E(\P2$PNN'#Z^W#B%4K[/1$9RQ>S]BKC9V/.:)$[$R^%Z.>=,&\\;V8ZP[ MN8]1N'8]D[?AK6594M7ID/@69?=IH5@&(97;$)VVWC%+\GBWH>G=?OOX]"2XK!9<5L[-(X0DA#P*0K9,?=!1EO=) M"$D(20A)"-D@A"Q]_XM032==B#XXIRZYK%@L#AML8B M;$J0RSBN%/@N-J'VNIU;JO0VJS]]Q2_J&Y\IQHL"!S(3*G'@\>LCB&-M5_)OEQC@$VKBJ&F!7B&TK1SCB..(XXKA:$*XRQ"*. M.P6.HXTK*CAXB/B-V5&&@1M2AH([I`Z.5>^)0AVT(T)244_]0OJ#)*7!DD+Z MX_"ADB=J3-WHOO!9Q*V!A?"O[VF_\B?N:@8LSRR.PDM-@S4,^?)2X;V> M'\%UF,O)A`6"Q'2_B`;"%%G"7 M(7-$?LHMXNFA&KKB^.9U.'&Y\!L<"`P"4_#A"3`*8#N->3;`U0MSHQ=MQEZF M..<#T;X]I_TG@`(@?L#'/$":?/`CH*>NI;0T6S]>`PF!V@&+G">NC8*`P53$ M;X=L^#J?:KSSSMF2GBV+^:P\[E0"E070JA7!:#=?,`@7"F0BC7\"D(T!3^ M'WZ*0Z0./@R,`6X)CIR+-CPC?5?VA@0BUETN]`%8%*&$%F>*S\>E8%.P/B)\ MW'QXXSB*@]P34K%%9'[F+O84R\[:2*42BK>L%;3_UK6S7WVT&G&X'Q^`L870 MA&?KQ`D>\,@".Z7""I*^+G#IWS_]$(<7CXS-WMW!.OV.RW3CA);KAS##\![$ MZLKUK:^__.7/?_HIO?+OOF\_`Y^,//N]%P$*.`#$(]%&;7YO=JM`/?CPF8]_ M/KN[0<'Y9_O?]S=GFF/#%\R*+KK#3F=PV[\;F=>=P:#7[MU=C[K&X*I]U>V- M.OWAV2\+&)'GP'MG"JC]@3]KG_TI6^_%[0LQ1?>JL[@1K1)UQ,=G.;X'W[7E M@^:TUB2Q!7^FBU$JO*J9X%[/`MW@(Z`26%PO0 M6`"6LA%T_1E"&F)"\*(+C]GW/+24TAER-'82#TH21,Y9&ST&7+@!>IY,N07W=@*:2@M> M9I]&:[S.U%9,S="B$2PI5[@!K$([B5@DMA]SM=L/[!J^G#@/3N0'H9XXJ;@* MO__?BW;?$%3\=&&TNEVD/HLD`H)FE3#W\%)8DW'@3U-6+7C,&GM\1(-2.,0K M;?:%H4@N8!J:X2Y?7KP';K$8T!-OG4V`6KKF,6$T"W?7";\*&,@S0,YVQKL2 MNQLO3ZQQN/Z!>WSL"$,[]"U'C%=PI[A#ZB=!@1!N<5D`LP3&_FA%/OIMB`R5 M95+EB+LGCP*#F0;8&TRS@_@1/%+/%NI2."0SX%#A\`CBAS,'N15)"13Z3QQ@ M0Q+)C;"8KS+CE>./OOG>0@`'W#NXW@9?0O"`<)V4D;I_:7RG2/T"=R@:4E?1 MD)+0V`PY&'Z6JSGU;>Z&J,>R)2^N=[A.RG&&DA&6#4$=Q60FG6GWY7*9$K71 M?04@=$-?V(FQ%4EHSZ!:$27D7+`)?N.<`'X\!FX;8A*<8FK!S8K:H M-@O/RFO3/'GU!(HP/@#TLZ5X)0%K,``CQW)@_"B1?NS:(EXZ84^X5E;@/,`- MDA6$ZO9#/A]KBM3)Z,*(/?)%:$Y^2P`6>(PS`,?D$6)D,=C/0<2`25#V<[%5 MP8U^!$_!=&H+%A]W@8K`CP$O?SKE`:9<._^;T5IRLAQGR?Q5KH-[$!^]!GYM MLH67[-*)`=NH@<6*O\-MJ$.YOH_)BAQR5G_MME3O!*%^5>+NSN'/]2UQE1JS MQFA==M5.&3`E6[P%G%E"5CL.T@"IDI=[()>X5QA-P'KRD.8E;0K`JL"R@/^Y M,-5P&5+#%X\'CXBZ#SQZYMR;&UQ%PTUJ\R*'7-^)B^1/"Y=?SH5/^X"J*4'D MC:D/P^??4(/):QY`#7)4J\*&0"L2O!E_BOMXW[19',Q`+6&`7&$(K>0`@:Y( M2-K#RZ%:(0$"9LOT"D84W(%7,&++G83M]@<*6POO!4O=7L<8 MM`S3-.\ZU\/.32_92+@S6C<&;23(6(^0.Z#R&Z?:*FV2Y-460$T8/_P'L`:1 MYE^77RZU,;=YP%P=+=J(2_MYG)1%F0./0)P[P**-Y>X-+BD:`SE[T,.=.[>P M(LE7ZRT&L14Y`3P5HS^8]ED7(U$#=V#1/SDAJHJB#EC!B[MBGR+;17FX7E6\ MX*]M0_%6_:(S+XS"]2LU9PIP!I4,X$BL/D\J4K,P+<7KHI)G5'L?BQ&*!7NP MD(WWM[!@[:6,)3-$UO\N&*]^YKL&,W"F8`^[+XM4RQB'."-29(+BCZ'%1?QW,3F%Z'(-( MZ9L_./585O*&V$E(J#M_G(AZ/:`?-/=E@?;KT@#/@?F^W]8&4`IDJGP1TMD( MQD_<*_`J3MZBP<1[)%YP%GM3<3RAE<9C9Q;AU$]J.V/4M.^): MI7#E5C;]\<*62IAQT\F4'CN)"DH!MQ`0M1X]N,X62)]M]BI#AY9B$5Q0;=GX MP[E^P26;<8^YBQLC1>F$_XI4'B"_W&_)VPG?9AC/@YOV[R.

    R%>L#B6O3, MW:=4$R^^UY'[9=E+-/PV?>I\-KCOO6HEL[TO:9_XH2/PLT['--2IN9)A0R9T M)$E*(L2,Z^U[8#>^(.E#$5P6G)/'ER1>;<>6W/I.PYLH:*\R&)BB;`;6SS>Q M;0[O4`5$BG=%R,I,7FCQGEQ>:"0QW=BN0LSQ.J+O*VOR&/`OIY` MI(R/E^^6+(T7/6#&*^Z;HTLVW\Q'[@7"2*=CXH21'[S@]\SS8BQL!K(B@I_- M6)HQ'J@XNH60\8)IK"U$G]&C];U'4*>Y M.#3^EBY8&`KG67C*S"NJ=YBJ)_DG45G_\AS4+5\BL6WWP'$0"'H&ZB!\JLPW MF;+_2-\9A38_0.&EO8"=G[NY-12=8$"1)'P7+3KEF,XVXV@(PN,D?VCR^1IH M51OX5!Q+2DJ))QE>@!./.'K!?-FK%@B4G(5Q!:EB8(>@,.LD,>P]*EI,)/O, MGSB(&=@HP9-C\2P(A#-*O.A4S6B)=C&2M=6NF<=LIFN?N.>%+^X3\QSX=`/: M&@8-*XM&_K_]X*NX_AY&(;P?7']QW@KF[_AV>AHPW3R6I%SW9O#V_?AQ@A_: M,/$/L/#V?^(PDL`ZMWH"CGUWELP>1QH]*\DR7^L"_XDAI]R%@UNDMY]&-1E, M(D7WWX`/F36)$?:E+*2$_F?,`3G2[7+4KO.]8D'/[,K1HR@G_^K-'?DZSY_; M4#F"-$47S%G:0Y`5.@&@0F3PRC-DHI3D_/A8:FB`#D9I02\<9@-8,HKJ823J M&1BF8T]/F(J46V3B$'YUQF!]8/Y:GO-1!XJ8`V@R!]$-"/?PDCT00#-T;`>$ M4!YH\-#$1B9/*8JL\R.2-1`@(]R,>5`*X4N\:,KLQ=2"+!55F"Z@+-,H8SQ+ M(J\V*,?`>8@SBRF&*;Z(?Q>$`NE?^*[$CT+@=W$0ET,.XDL M7TP:WC;1X+5L@86T`L`JM(!V2RNX'EW?&E?=MF'T^W>]F\Z5V;J6:07]UFAD M#"BM0*852"*_52MWBXD.#G\,)IM#6B("LV:2!'D?S7L8WNN-\[99R%YQ@I8X M9;,)BQ16>[$J,G[.OSI)-,B7IC'PFNS!LI2"Q5TWN>;GL]:9^!S.F)5^WIZY MIRP`ZU`.$KQ*/_U"UFL2WSP[=C1Y-^A<=LWVH#5,__TNK?`B#EO-0OXN_6.) M(>:SR!?`SJJ^#%86+M^@A+88V<]GG?YW;]:3*9:\26XT=KS/[!SXA8>^[T`3 MW*XT.G416)*<-YN2*>[W9+Q-RU>0,/>0UQ!UCRI8J]7>QO%TZFM!''E`CEP, M5&S<;(9PN#-KS$NQ[&)^-ZSY8;NC&^JB"4V1)/)'3U8@S!;HG`$) M1&6\ZPVB9-LU,EB(F!U!#=TYGA-.N"V.T9>BA=X*52I=G?TBEJH%N*=WC+8R MFW%7.C9%\,ES/8"*/&%I-?1!6UFC^I.7UCIX@!NT;"H.JE>R-A9=N6_GD MZ]/$"_GD'_CSR!)IZ\`6GP+?\_$0L#C?\@GL6>M%_KM-CGE[V&Z9W4Z_/VP9 MUW?=]FUKT)4YYKW;ZZ[9KT2.N:+UEA_Q\D*9W,\<4U>T.66U(FE?Y81*GQS" MZC),%#2/PS`YSA'(V;+Y;&>%V6JS%9VBYBIH5.C-]D$6UX?'7F%K+"QBCT(0G0=BLWX5:EM#5AY[PLH:;'X0;UYSRHG6%@@>.Q[S+%%<%D^@;G!L M;QE*MT7(`KQ^#!Z9EQ0"O\Y&!A^N6.B$'\>?9'E[^57"[S<<*YW/\*N19^?> MG?#]-EC<&1JFT;TV!D/3&'6O;H;]FZL4B]NWO6[CL'@IPT\06M2[SY%Z+:24 MBP M*_DW[=.$!5-F\5@8F:&&A^^"&18.@LO.S^159UIR5OLLP=NS[U%SX!@#6Q1& M$&>#"W#KP,AF>'S_D7MX"-%]P=\1%.W5!^)AN493H(G%X+U_'XT^G7V_1[&J M@Q\AWF:-0/F[LA8.3P_GX_EOH,"Y\WW^:*<.7\`WXK#WQ`<:7OC/>.(V.UGK M)$7`X#*XKO!F/(\I#H!EI6ZPMK@H][)5)-G(&6-J$(;Z7F=TJ0TRDI!G//R7'SQG+4\ MS9\UKQ:2X4Q7/B,[L>W/'"]Q`L!`8(]9OQ4\#BF M1N%A>5$'0C;RF>45=7I@-1M%6I4J*9H9QJZLJY;#E+3*1CJ%M!2&-%(/)9SU MJ72EKJ95?27P7A0XV(:;TF;N*0\[0B)M4;#JB<^+)JQZIFPBD?642%\QCET4 MVA!+]LR+H;PAC%HX26LA!++U'@KV?\!)F;<\%,4<$O-HY3-6%*91PA&EUUZ< M-X9'9RBMS;$`AQOXUG6EP+P['1:.RO40_(*`*TT?!(K;;]8$N]PC5::.#-V< MBU#`//3RY?8Z%R?Y'@FE9(QW_"&(`>1S%&^K!$(QCS-1KV>#E083N\9NWK]D M3;3;I/V=7-PO\73*9%&T+_.Z-0=W<$L':.G+98;!-N['"M<-_2V`S#]B!ZVJ MN?TB:^)]Y5G%.UX@-@O#>#I+LBS:S29$3?7VOTW1:V$'%M[Y> MR'ZBZ/7!U_*IR27B(5$06Y$D0/;U;CJ518+)QIN!6L3;C_FVE\5BYG#?Y-JG[(XWT)OF+RSBA0(96'%;/VP M^I0HKBC:&N+,@:RB`*1G9X6.9`FWG`CD._GBZB4B8SF!%4]AH84_/8Y%3!^& M^Q]NY20G)W,/X%C#DJ6F458+E2?EY`3A\@]%3QZ62;@6TL2RA!ED.V/<94@* M^8LZ4^D4X99KH01EY\>Y5(M6Z\)ED=9#QO/IH]-FI$($\),T.^"[%ZQ4B63^ MZOG/9;3-/D`).+"0#:_N[FZO1R.S MW^IW!U?MZ[L[N1_9'ADWM]364#Q(D%P;!0$:*^5#<[E:YPMS!7#^X_WOB'^1 M`-WW:6=V6,H7YD8OVI<(;+YI?560*.;?&A2KE()8BL8*#+YU`EOT-W\1T"!2 M[9)2NZ(+E18DA$BZ4X72A/V[R[[Y7Z;@"?TWSGD.O3/7TF6EZW%V:^K7)>%% MV1WG018Y3NKJ%T:B)V%W'X@)QC"7GD;:'DM=^\&>ZEY>66!TB6BR2*WHDP6T M"9DK=UF1^68I\SDI\V5E?Q'%A1>:N(WH[L9!&#,9#<".)J[+'I(@O\:RSL!I MI^+\HB.U7ULV99V!J[(3L=P!1PW?M(U+4VUSB7S[@BSRL=#7;J4PI(R2=NJ0 M]8_1<,$T;7&?ZXQS49G5["+C3J_PAB9C$TD]Y]@#J+CPQQ?)6+4I!Y?6EJU# M$/#P\47J%SH[S/O`I'*239K_@79=VFBC4.=9`,2%A*HP?LC`!6-?:%F/L>PZ M3CW])8F29"'T-0](2%EG#THJYB2P)S(#B`*J(7J:5Y$6/K\+NN( M>*H49#TW]2AMV)$KCA_P<>PE"@:?$G(U$B1DB\ZJ(H'L22<; MO\`<_?4@CJN!D*'DO06?/[?G44P%2!L=;<<]C7#L M2*9+^"C=,\JD*_E>PD2VH;#8&?>9K6.1;>,5&T<1"L&'S_GM&+CXLYSV"+MR MB3VQW=H@#.X,T[@975VW^NW;T76OW>^D:=%W5YU!-=*BCQZ&*!!?^W6^$5EC M"PY\]+;VWZ"A,#>M,,%]97[-"VO^:3GF`D=4D,IK$IHN;NO,.VQ)$Q3"Q_["3])Y+7#=L,X?` M"!X/]N["_A&)?H5QBKV#17MA(6AP*/]>D1M_(5*?Y*:(-"-$*Z!TD@*T?=/-/Q3,IINZSLUVE\H.E@QN7[`=I;H5)CRL5![;W.R(V5!$$"T M?A-S?HU3"JWB0CRH.N>8-`*'G8*4`<3!6\S(,QNI)EZTH=<)W?AH_>D;FW/]>8[0KV8MOS:@Y;%9 MD[K+$:L=CM64U7XE5B-6(U0C5JL$JU$WS$/QG]&E=I@5:]A1]R91Z:;ZBZX] M\$?'\T1*Z3B7('1,14+=Z]16WRVQU.Y0'YKJ>ALTO74)'20M)"V-E!93;_4-DI;-I87VM/?S@K(*`J(,2WK\L12G2"GACRBEICXT ME-E_C8]&4-#S`'JN.:+5&Y!HD6B1:"D7K8%N#"GQB$2+1*L$T6KU^B1:I7EL MV[*#L;=,K7C@<7VUSZO:W6CGLCC>-J&ES853\2$-8P,9?9WLZI/DU*6NO$&L MIL@NQ29)P+;9*>NILS@WI-;&LN@+D'\+6+ODT%^(-JJ/Z6KL`K-[@161KTZQQ0J!,:5,Z4(10E%JXNB M!F;*E.1P$HP2C!*,$HR>`(R2,4HH2BA**$HH2L9H36`T%W+]0?2$677]P0:6 M(]I2(YVC4^VUP2W&TU^'GS+:\&6M=W\#=4-]^-[LP[>J<6_`7=^2'<:QL6<4 M+G0-+O;ARRCN>-J5'T;8.+QP?=KB7#31\RS9'-=L&0O]_QS1P"\.1,)8L<>7 M-6'!8[$1&(XJX%/FB,*6LK=X@EE;/T5MS*)G7\T$L_64?,+2 M3MG(0F'LBI[S,/-\+]]@9?YBH;F][8S'P`G8]B_MN+VVUVX8.5-!F'$LF@"* MIM)H#"\Q]3(K)XVHL17O?*'2QKHIS5%8TR:[,^:\VG`ZZUONRQ&#ED<(>)HW M\UUX4&9=>-,#D3WZ#SEDC9^0KR5+"8@IPZ6AQK&")&?@:Z< M1^FTE3PX[0/[13[_+B&6FD%GG;A3N<.VQ(X72Q["EL_(,0MM)F4#/\'HJMI0 ME]?Q5CP^:['JR29]Z5KY?L0>><9N,S](-54]E@\[7Q>Z=K)M6JY#*E1DL`7X&DV M72$^Z0JE[=QAGKEN]_+P<8YN?TO6-`R3KJ$H98!]J"[F5%M82]L)+7"XTF:Q M\Z../M0;=-/-"O&)&M(2TQV?Z:@A;348D?KI4>M&8K4CLAHUI"56 M(U0C5FL6JU%#6FI(JXJ=J"'M\8[A4D-::JZT.RWP=`$5KSL80YRP.B24.5V4 M:>MFEQI%$LH0RA#*E(@R;;T]7,YE)9@AF"&8(9A118O^D!RF\D(\IQ;)H6:T MQ=O.VWJKKTR)+W-&>3A#-4PY5%MV]-6K\R\H0],"HM26+1"RK#!TI8=^C?+9SF2 M.9(YDCG2<"1M)&VDX:HL<]3V=@=&H[:WZH6WJRP`2EUO*0A*\K64A#;4^]V# MM=DD&2,9.ST9.S?T8?]@>FSKO8MF],TDD221W)RM.CV].QB0VBO;*ZQ0;&;% M`RMS*)9ZTVZ]5NK6@1K9E)E]K@^,DG"6^MA0H%R9;40H2BA:713MM/1^A]J! M$8P2C!*,$HR2,4HH2BA**$HH2L9HPV&T/KUI%P/XKTMX&>U?/T9P=;$9G3;* M&C>5.K'2&U"E;<,F+.V4RD&P.,@4^]I'ZW(Q[X#RXUNF>W/<`'8PG+-7.;)AP'%G8:LV/9K'<6.%,6P%`6FY&)+KN!Y0!/A/$,V_+AML+[ M#]?O?[_][UP;2'EMVC@2"1RP&:"GS2UD_[2MK1>+[@GPB!D#3L*>J0]WYH,Y.=A\ M%VDT]JTX%)SO>$]`?SDH+VUQZ`N2Q5[6#M=Z"4%E:6/G(?!#1S9>S80-AFY- MQ%,1T!V\PS[4`8_:.>Q.BV%+7>I- MTZO84`YB23F(A#&-QIC^D#"&,(8PAC"F/(P9](:$,80QA#&$,>5AC-[IJ*N[ MU'24H>9WU/QN.WJ<&WJWJTR-+W-&>4A#5E=#\J0R[>R?AKZ:Z<.FN=&Q* MH(/"J0?0HB-:'I\$BI/&B\+,U?5:SR%LHP4;R=\(WRK#+X9^K!S MP,+>A'"$<(1PA'!DP1&^$;X1OA&^D057/83;J'7`JK]_^B$.+QX9F[TKY':, M//NSK`4]+ZI_XX26ZX=QP.^!$E>N;WW]Y2]__M-/Z0.^6!-NQR[_.!Y95CR- MQ>VB3C_6D0[XA'NA\\3?>Y8_Y;_Z87B/`\V>)8J4PX?/?/SSV=T-UMOY9_O? M]S=GFF/#%\R*+D;]ULWU;??ZIC7H#GM75YV>>=,U!E?MJ\[0''1Z9[\L+%F> M_&]4#5ZUXI4KUSW2PG@Z9<%+&HF<5^BV)LQ[E)7,V9S\2>%N*[\`VCFL8O@] M%I^'A=`>7L3/P'(P'B?4PHG_[&D/'+73J^RW!:&HY'0E2TYW#EX*V*Q)[6&: M($VPU!=2W:Z3KQLWV(V`@[6%ON[\`+[RM&OL&.19+]I]P+P0[`#LB#*R_Q/+ M)BCD-1,W'H`;_^4%'-[UOV"$_@.^Q(3QOS/'"[5SM/TY&*#`E;^QX"N75MD7 M;H'K\6;W+F)08E#E#+K,F$M8"E\\L\`&C\N+`G!&B4N)2P_!I?=^Q-P=PD!D M5>["@%0-5B%C52C_MY0-@=4$OF(N\RRNL4B[X5;2D<,0O>J.6JN>:AEM*:G' MJV5T/NR77\IH6:#*(U!5C\I7"*$JIQ,)@$X8@`RS30!$`$0`1`!T%``R]99! MU1P)90AE"&5*3+0U^H0QAPLMMHX1Z2D.H;.0071AJCTO^O'M="L^]@.N!=QR M61@Z8R`:[L]2B5GT.GK*(V2G[%R0=F^LJ!B#GBHN:8J"(FDX66GHZ"UU1Z9( M'D@>ZB\/0V665%/DH=P$W9\RA/)@E;&. M+,T2V@:F8:H+")YZ,2R*F!Y`:Y*`DH"2@)*`'EU`S]MZM]4ZNFQ23)+DEN26 MY+:*_\%F4G%]OB?/K);5.4U50>-UZ':`";&5@ZNURN'L!9TG@V5-WZG]G4IY$O78"1P)'`L=Z@:.I M=P>$CX2/A(^$CX2/*_8U]:["FBV$CQL&--?W^SG8P')$>[,3C#FC3C#4"8;Z MB%1GH#1!Z@130S,W&RX5C:=.,,2-%>;&M9U@J`$,\64U^#)K_9(Q)C6`(2ZM M!)=2`YA#,B`U@*$,.G49=(L-8)1M'RF-TA^=CHH#\?4O3'S>-M6EL)WRL>8: M(53E="(!T.D"4$?=$2.J5$000Q!#$+-DXU"+*3)Q"'\(?X[F8[64U6$X:0"B MSC#4&:9T6T%=0]Q3$$F*^)^LJ*@+')Z*@T["T%QAT(V.LOJA)`\D#S67!T,? M4'$8)?X+-89);Z/&,-1W@G9S2&N2@)*`DH"2@-9)0,\[IKH.\-1>@J26I):D MMCE26Y/3!-04ANHRUR'A@#8QE=H,9!H0.#0&'&C;EL2?>L(<&!Z:TQ/&T/OJ M#A=25QA"&#(P&F9@&'JGIRQJTA0$H%/M2OK"*$LIH>JTAS%U3K`Z[7EWJ.ZX M!W6%H8V@BAEC!)T$G25!ISJ[D:IZ$S@2.!(X-@@<#;TW5';$A/"1\)'PD?"Q M4?AH]*@KS,'#F>N[PJSZ^ZF] M2&/"HLGW^)Y[(,J5ZUM??_G+G__TTXIG>9%C.VXW+/"`U<-///@R8<'\\;`V'B[`9S[^^>SN!EM2_[/][_N;,\VQ MX0MF11>]J_[H9M"[-?M7O=[ME7'=[[2[QN"J?=6YNQM=F6>_+"QH?G'>:.ZR MBA_>:G@SF'U;ZN:23T=;R$;;GXGN)UQ#:C+O1;.!R3T_PJPSI+0&ZZB%&?TU MFX=6X#QP6Q,U8;DV]EW063!Z399D3[ZVYHNC^6/QE<*:Z9^*Z-27/,M6(W><`# MMU@AGNU=E9XMU MI,9%I30N,O=L7-3M[]BD95B3+C0TSCJ.LR:9TY7S4K+AOE6&775VD['!D885 MMQRT@/N[@5J\K*)CXD/GR-#S^`O:*`#0DCCWP>;!?> M?(.6%>16=!()&8G[CL9]RK*CB/N(^PC[B/MJQ'T;8Q\9@_LV+C.H<=G^C`6T MJ-(N\JLGVXWV0BSYPE![LOU+A%LN_FS;*M2'VZ.ORAZGJ;<.T+"K*=N4E,91 M5AI'$V6KK;>&ZA)02;9(MHY/N*K(%NDMDBV2+=);QY>M[=VT4_/&_N4]\1!+ M:0?P?X%CX9^A\-#`'U[^,O:<2)G35F,Y;.MM.O=.L=[:5KY0WQ*EUU?6W)?D M@>2AYO)`^H'D@>2!],.FWHF"@S6*#L.L.6MSS<()_N_VC]AY8BZX(N'(L[], M_""ZY\'TO7`CIOAU\>C.!F=K1FVCWQF9YFVW?]TU;T>WO4XW.5O3O^W>WC7^ M;,U("^/IE`4OZ3&8Y*!-UNBC_V.H64!\7?RK\?D:""\-;OW*Y0F.W#$<)]3" MB?_L:0\<$>Y5IMSFQ$J/3JR4<&*EM^^)E78C3SPT_40'S:_>\Z,$HST3C-J4 M\U:X37Q:2E(:3<'.@DML,`W"B/PMXL/C\.'?`SR.(XXCCJDRXRA"+..X4.([2 M;M_*A\"M=+%WN[BA^_H^[8[,>8H\2"XN\0_Q#_$/\4]EZ4/\U7L&,[@J6ZE7M11W52<[_5UXV. MNC8$33^-28&(BM@2A$8-1*,L6]PL7R`)D0B1")$(D0B1")$(D0B1ZH)(Y+&= M6/V<\F--_G3*`\MAKC9C,QX<,SR\A]R9]4"E@Q)!^1GXKFZTAJI(T12(H7T2 M`@H"BK+])D(+0@M""T(+0@M""T*+$T8+00(]`CT"/0(]`CT"/0(]`CT"O$J!'GNVQ@X&'![H-!+0PJ-(+ M&MS[$7-E-8-590TJ#9F$C/4&P'ZWIYO=PR%@4X".MD<)C`B,&N""$B`1(!$@ M$2`1(!$@$2`1(%4;D,A=HR2U`T>G?EO5(;&44IM4!Y9VCI00CCB..(XXKA:$ MJPRQB.-.@>/*WY_P&;?./.1V64 MFFE^19F#$D&USVIT6KK15E8XIBDN*<7'""D(*8I(870()0@E""4():AH`Z$% MH06AA1+OP^QLTPWV))#BB!MBC8R0K"GDL&>H)".#>:@@WY(P'U^`6T.]/>B5 M'E-NBF134%U!4/V$Y8'(J'Z>@E#O6OT#T9)962J,G92U)XPCC"N,AAG=$S"-\(WPC?"MTJ0 ML,I1ITVIN''TJ;ZL>;04:()#@D."P_U@LE7Z_/6%8T38EU`?:DZ MH"@96,,0(I5:78\0C2RU:NBM5E?O]PX8/&SZI@MM(Q1K\0 M(#QVHN];-:1*H%O=:$5\17Q%?$5\51=:$5\17U6@?&*%/,^C[>&*3\]R$1]\ MUY;/&86:/]9NN,6G#SS0VH:NF:VM"F!1"=!27/[J<&SE"$<<1QQ''%<+PE6& M6,1QI\!Q=3C_>]PDONMU_7U+Z:5RBCQ8?:_WZ/0A_B'^(?XA_B'^J2!]FAM= M*[\`9VI<37V/OR3G(;0Q$*:D8Q#+1W>V);E14B9(38H*OT7.71-!JEV-N&=V M=;-;4J+<%D1L2A8(!3H.DOA&:$=HMP/Y2NC40(A'B$>(1XA'B$>(1XA'B$>( M1QYMH]"N#ANI*QY8E0(I*W=8RV%.1:?!Z-#78:E4*P!<0:RF`!WMEA$8$1C5 MS?\D0")`(D`B0")`(D`B0")`JAT@D;MV@A5]CQN=^FU5==Y2LO[I2`KM&]$A M*.(XXCCB..(XXKA*'%+8)8U`Z?[DJOR!PQY/^#NNH3?E^,/,]T(_X+8&GW@P M"YPP;Q9JYW;,M69LR7YP7,]J-U&*IT2W!E?F^MTS`ZO;;>'PQ4T:(I M7BN%T`@I""D*MVU58HI`@D""0.+T0.*\JZQSR;(DU)D]J,LG@0J!RAX^2E=9 M#?RFF!]'W%EK8*CEVI].>6`YS-5F;,:#8D!%VS:.DLW>/&20\*V08(E"VC7T M7E^9B]#XXQH4@%<0@#\5V>JK:P=(,6S/R`15RS^4.T=DN\/`^N9C)I#'MZJ]>E:`K%7%&\I\Q'J5[0H&[^#1M'/$C<&RV: M`!$?)UI7?`QIP^JUV$1+[W3:%)N@N%]U5&!39(L"ZR1@)&!ENFG#\C47^6\D M=&J$;M\"MS412K`HV^K2%*FB+56TW9X'947;Z:K*(>4PIJ+R2,E#\8IE5J?: M214BH?+DMIZA#_LEP>8*2BHC4Y6QD^+2A'&$<97!.'4'[`G>"-X(W@C>*@5O MYZ:A;!]T8S)N%9:J)V]2&@+A(>%A_?`07=I!IT\V7T...SB M%U8-0X@EM!!L"M;NVD-0+9\K3\'3VX.^;IJ'J\K>^$T7VA"ME8E)D'=BD'?( M2")A'6$=81UAW4F$%8^7!E?/D"*!(X$C@>.Q?5^CI:ZZQLG;@[D(XP\B\K7R M^A5___1#'%X\,C9[]\6:<#MV^5QMY-E?)GX0W?-@^MY[XF&$ MG1W">WS5/=#ERO6MK[_\Y<]_^FGY<;?3F>N_E;X%5\G`I/O/QSV=W-V;+ MZ/ZS_>_[FS/-L>$+9D47(_/ZNM]JM^ZN>D.SU6T-KZ]NNL;@JGW5Z0\Z9NOL MEX6ES2_3O3/EH?:!/VN?_2E;#\FYVUW'XQ<3+C2`8;:^6Q1'8Q4>Y4.D9C%" MNC\_W<0!O%];8I]=GA5-.)[.XUP$5SV8JS:%RR:AQF'TMO:%SR(^?>"!UF[I M&JZ'DM>*MREY$@QIN;KC+@_2-:0%LBWS7K0@8U/Q]=@'%GY&JH<1L.G%`[(X M,.N-_PP.\[]'TTOVJ,L]KSV^FH M/[F'\^'V]SPX5?+YJ"7MMH?/(CX]2_7VX+MVL@LM+*+?I"%TNVP(J?)MB.F( MZ3*F^X#&]_X\1^A7=OO,$ACQ#5H>FS57^GV$><1JI;":LFX-Q&K$:H1JQ&J5 M8+6-48T,N#WYS^@>MZ)C^>QT[GA:-/'CD'GVYM7T:IVI?MRT]"]O1?T?7K3H M9<8U?ZRQ9Q;8KX?V=P7.`RY''22^,L2J+502QQ''$<=5F7"5(19QW"EP7!V* MFQVW[K4P!35_)C(XCAD^J$9)RT.U@MYCQJI3'-M#O:6NI6Q3LA0I0D$0<#(0 M8/9T-!'G9(+%+V//B;8)/9Q<&Q(TS]7)9>,/&%*864&8^51D MRP"=9ZBK]D*R1;)%LC6W)TUUD662+9(MDJWTMJZA=]KJZO8T7;9H(_@MAKK] M\NF3%F+!"\T)PYAYUE:%:#<6P)K)F:'WV\K,PZ9($T5%3U@>!@,*$9(\D#PD M=IC>IY`YR0/)0W);3S?5N25-D8XO.B@<>UU/YE8>A]F;A,HO-G`C& M*&J>^9KC/<%8_&"[]AJ'#RL8&XCOZRNBO#ZPH9N#\B,-RTRZ+:7VYV-U1*," MP%72H4V6SDY776U:DDV239)-=;+9UML'V%LFZ23I).G<7CJ'+67U,](ZM%[HCUZ>UV]WU:7`D0M>BFZ M3A!'$%C]UM468CB+C4T M%0AF:@,S;4,WJ(`9P0S!#,%,F6D=9D?O=M6E=1#.$,X0SA#.+-XVQ"HI5.NX MO#C/J85SOC"7A[KVR#T>,%<$=9@]=3PGC`(6.4]\E[A.4ZN.F8;>:E,9O@.H MI(:I[*8*A-'56^K*&Y!`D$#47"!ZACXPE9U@(H$@@:BY0'3:^J"O[-AR4P2B MUOO/*QY(%6U*.B>X;M7I`.$;Q][V"/74]&3AH6O@E,Z:509PBE^7%+\F&"48 M/2J,'KK.#L$HP2C!*,%HPV#TX+5\"$<)1PE'"4>;AJ.'KA=TTCB:B\O^$#&@ MR\KK5_S]TP]Q>/'(V.S=%VO"[=CE'\>WTYGKOW#^A0=/CL6_8-/;*PQ/7N>B MDR/7]2WQU\?Q9V[YCQ[,R/X$,_3ANC`*[X%<5W#-UU_^\N<__;3\ECOF!+\S M-^:C,.11./+L7QWVX+A.Y/#P-\["..#V1P^>'0D:G-3C[96&5\RMV[TQYJ'W@S]IG?\K60W[N=CRR?3'A0L,89NN[18D> MK$"T?(C9+$:8]^>L^PG7QCXLUC.,0A.\H2&]XD6@6/)T'FZQ&07;L:`)7`W$2/`.LM]K4._D"9($ZSB!'>J M&T@N4VZXW;M<\?3HHD?A\RSPQ+[#%*X M9S/N%C?`+!8$#K[2LK8-GX\K$44*B0<4`X0SA#.$,X M0SA#.%-@F(%IF.6+&F$-80UA#6$-88/<#-6 M:1"%`78),S:L=+39U8T6U5(_@!IJF)INJD"4H()(*D@J:BX5I"9(($@@2$W0 MIG/)GLITR@-QDF/&9CPH0]"4$ON8*JFCMUK4#)A"DA528DV1+8K#D8"1@)'R M(MDBV:J=;)'R.L%-I-+/6/TF,H&3DM3I!A(=M*KPOG]3<9SXA_B'^(?XA_BG M.O2AF/<>,>\#9NBT=+.C3(LU198HE':R$D%)L205)!6D)T@B2")( M3]#AB<-FZ'P*^(PYMNC^[D=PF6;%00!O2KIB4/^+8^^B5XA5*T\]ZT<9^\,P"9#@O"I@5U:;2SXI;RBPA MJG=;`_+`*"Y1I[C$846$0A4D*"0HI$M(1$A$2)=0V+MZ8>^/(M1-(6X*_U2= M<,1QQ''$<;4@7&6(11QW"AQ'(>YJAK@?_,#F04I#8_9-"WW7L;7_TQ+_:8!/ MUNL:RF#Q#6(UQ5>CH`8)V%&#'B1H)&BG%SU4J*E(0$A`FB<@%%X_?'B]=0BA M>IV-CN",W?L1<[6QXS%/G(B5P?=RS)LVF#>V'V/=R7V,PK7KF;P-;RW+DJI. MA\2W*+M/"\4R"*G[#3T/P'7'1]T:Q5'+5,ME4Y'@DN"RI)RF M3DOO]MO'IR?!9;7@LG)N'B$D(>11$+)EZH..LKQ/0DA"2$)(0L@&(63I^U^$ MDGL'.RN63&*TRTXFR2*7KL,>'%>46]T,J96GI6F6SF`]E\C\YM'1O^*L2LE2,< M<1QQ''%<+0A7&6(1QYT"Q]4^U%:O%0Q>IVT9>0G]7G4HO)714D]^5F;D4#"54)=0MXZH2Z5DJA9: M(2PE+"4LK2.6D@5+%BRA+J$NH2Y9L$VV8'/!W1\B!G19>?V*OW_Z(0XO'AF; MO?MB3;@=N_SC^(XYP>]8%7`D&IZ,//O7>7#S-\["..#V1^\SQZ01X*HK%CKA M/;[U'DATY?K6UU_^\N<__;3BR3+;Y/:;-6'>([_VDQR3+Q&+^)1[$5R21E0_ M^:&#NW@X&_;-?%A8VOTCWSI2'V@?^K'WVIVP]TN=N=QV/ M7TRX4"R&V?IN49"-54B6#TV;Q_W6!$+5H$'A35IO;(D*W!5:-+%+0?\G!^*YP=3YA9PW\!KL@?+E;*XZR;7 M_'S6.A.?`9:L]//V7`L+_^AX'3N:O!MV+@<=P^P-DW_; MWZ7P"=#HLEG(WZ5_+''T?!;YW:4YI!HKMP4WV*`20_OYK-W][DVT+BJ4Y$;C MT/<=_(4[WM?NU62@!Z+H.@8L\/`KVZ4E)#5NGX"[#&M*[#KQZ5GBV(/OVO(Y MHQ"UQQ<^`^W]`"C?;ND:JN0=S);5%.\2P1<(KK(%'3G2Q&GK..W7[?,9=L@P M.3Q=-W?RRJ?QM1@+.$;X1OA M6^7Q;4^G3PT--X]1'YO`YPZ&[OPX9)X=;KS5U]PR'?-08I9G;"K-,_X4\!D# M;@!Z:[XHV9'6YE#2W^J776KKW9:ZEI?E M+OKQ=R`)7TIQ(*I#M>.JP;>;JQ"CDB(D15CA\J0;4:/)YY)K7XWF0"BOUK$A MV-[@M/>NS';$H]Z]KJ&*14[%!B=1(*S=J?XK,2!A<=D%:O+3)BNPHD&`#1(I2&.5&X<7Z4CE72DLB([',1I=*22CAPU3:KIR!$=J:Q,A(KP MC3B.\*UB^$9'*NE(994SW^A(Y?'AEDZ2G.))$E-O&%+O;,Q*I<` M3D='58A^.3%*1.=&(_4):G+RKE+I#2+/E7I&>'E]SUZ?=;V*QVO]NY+M:;A MU7OO">[V@Y=K&5G;NIG5K3GL71FCH3'HMX>]V^'U[6`DFUGUN[W.X/;0S:P& MAU[3E(*@D$5O*"?$QE!)SZJLR96ZUE"]V:IC#!M0KF''%@:=RZ[9'K2&Z;_J MCBT,]CRUT.D?.%?>[-0EJ;_:$]PN@D?F\Y+DK,U-6FG4[)^>9.R4GK3B(;7J M2D4<21Q9BS,]Q*4;-1(8>-W M_#?-(:G^IO]`[_7453)J^G8_)16ICK<3RIP&RG1;^U=:.164J4-2T7$MG?_Q M@Z_P[(M9X%L\W,;6>;O4[6',;^6-@3JZH2Z:T!1)(G_T9`7";*ELE=44@3BB M=[U!E&R[])R%B-D1U-"=XSGAA-O:H^_;I6BAMT*52E=GOXBE\EX:>L=H*[,9 M=Z5C4P2?/-<#J,@3EE9#'[3W[[=`TEH?#[":R;+EL*"B'%#%Y*UBK$I!\JA9K%PHJ&FT6#Y'WFH+B=\@:J4$TXYX903KNB%E-M(&;B4$TX<>:(<>:"< M\!-+7%E-\>24IW:=6)2[\#9EDE=MK[O&;"INNXT#_YA:B%([:Y/::;1Z>L]L ME4Z1I@2@:".>4L@)9[:GA=G2S1:=5*F.*=[`?+XK^-X))]H,&0/NY8$++]_% M)%>=3%N]A)_^0!_TE)4+;(K844B&9"1G&[?U+AW*J)!?WD"=-8K#*("W,T^S M<9\K*$,43SBQU>SJG2`GDR5*;CR!$8&1ZHSUMMXW2_*D&HQ%2C/6]TH^ M7Y/0_IE;_J,'D[;?HR7EC!UNCT1SIY'U1^P$\,FS?YWWL(#?XBFWMR\[?GUS MU;L==OJ=KMF_ONNU!\.D['BOW[VZ'96>V%ZU)/99P%UGZG@L`+L2.V(_84?L M,$UFEPVV1$?A7`<1+8#E`M&Q-=\3EX&GPBU<=\;ZF?/=/7^X-#9W"W*YBXYC4!\6LJGJU5AV;*!;'>(O-CJQ>7+<^3>>V`*/SIH(AR_.RGE MIM4G-ZW;U=L=RH$]+`(U"GK^[OOVL^-N4[^FJ94;C9;>Z5'E1M+:&_++#1_S M(."V%K%O6:1CIX-4;^ZKJR3G$27L?&CH+5-=<<6WR#+GF/)TNF*F.K`UW2B! M_,`CS8_@YS0$>9Z+/VY,V`9KN'.U*H[$K'[JKY@DFNV\9%[*VH4MK4%R?G44+\[AMH_W<;7+ M:\E=(FF-7D=O&X>KV'AXOJRHB[+_3K627>6U.]9A%,16%`?`Y/"!!T_\ZN7^ M90:_7?MA].:N]/]+GOG_"D_ZY#)O],T)_]]3$'W[?W?,^^3PX#?_B?\FRFGD MMK*-FU'_[K;5O^D,NKW!7:\SN.LG6]EW_=O1U6G4:&.X[9QN2KNB9!HH)-Q] M#O)DG?MTF#VI+7'C+J_'ET23@'.Q/>X!>;0I7#8)->[AWO@&17EV>:UXFY(G MK2S+LM.0GD'?8ZDZF6Q`%>J4;_D;K9:Z37ZCM^D.G55PZ/MH?M48 M9[7G5Y/=_LJE&6]'^> M(_2CG#O5K$F54HG5#L=JRLZM$*L1JQ&J$:M5@M5*JNQ,_+<:*%8,J M>U._[,I/Z>;7BZX]\$?'\W"O)#F^-X.;?/N8BH32UVN3OC[46PKWR)N>O%ZC MI*/*J4-"F=-%F;9N=GN$,H0RA#*$,F46F6D/Z20>P0S!#,%,B=7O%;:!;SK& MU*%\Z'$C.=?8)7C&7K#>TC8'+QI[/JJMM_K*E/@I'(^B4/SI"HNIFSUECC4) M"PE+HX6EJW=,96V+2%I(6IHL+3V]UU%6)N(4A(5Z&RGWBP)N<>>)V]HX\*=: MB.=M6Q=+!-O?[J*]/Q+)2HMDIZ=W!\JJ M6I^*VJOU"=@5#ZS,H5CNV>4L-UDK=.IQ84>O7::L\^UP?&"7A+!6U MID"Y,MN(4)10M+HHVFGI_4Y)41J"48)1@E&"T1.`43)&"44)10E%"47)&*T) MC"IN5+5A,ZDC-:-*?_V('3D+ERRUI>H.;SI7UU=FM]Q$?:J.EY)/?:JHZ/KNM!BVU&V0-[W6!&4*E90I1!C3 M:(SI#PEC"&,(8PACRL.806](&$,80QA#&%,>QNB=CKKJ*$U'&6I112VJMJ/' MN:%WN\K4^#)GE(F[P,N7PKZZ?!C08,O6>J"Y?N2L>F!#HHG'H`+7K2TMKM M*E/()*TDK22M)4JKJ0\&)*TDK22M]9#6=O]@344:+ZUUV/);\<#*I'+7K+HZ M55S;B*;')Z'RI/&R,'-55;53*)Y&\7;"-\*WRN";H0\[!RR_2PA'"$<(1PA' M%ASA&^$;X1OA&UEPU4.XDRKP_11$W_[??W//9J[[>GWOSNU-YWHPNAI=M5HW M_7;[ZFYXE];W-KI7[1.O[[VZGO<+5?.F:MY4S9NJ>5?J/II?-<99[?E1.30J MK+RI+R(^435O8KKC,QU5\ZX&(U(Q4JI[2ZQV1%:C:M[$:H1JQ&K-8C6JYDW5 MO%6Q$U7S/EX*.%7SI@IUN]-BJ`]-9?9MXX^KT.&RDI)Y"&4:C3)&1Q^V>P0S M!#,$,P0SY<&,H7>'!#,$,P0S!#,EPLQ0-]1%:AL/,W4XXT]EO?<),*JO5*P/ M^U11DLJO4OG5#82EHYL=*NQ-PD+"LDG#B);>[2A/Z"!I(6EII+28>JNOK('1 M*4@+[6GOYP4%W.+.$[>U<>!/M1`/S;*0E^(4*27\$:74U(<&M3*DH&>%]%QS M1*LW(-$BT2+1*J$UIC&DQ",2+1*M$D2KU>N3:)7FL6W+#J?24V+4P]UA55H=B?P252MIE#[[J84H2BA:'51U,!,F0-V,2$8)1@E M&"48;1B,DC%**$HH2BA**$K&:$U@M%*=J+Y,6,"O6,CM:W^*B3,L+,N7"![S<8:_8Z.I\.KE]AL/+"?DGP+'XI^9]\C?;%R5:SUE M=H8=\]HTKFXZG=:PW;_K7`UDZZE._\[H]$^B]91L=H1Y2[(]4!A/IPQI'FJ. M-\:60DAOC3WX,3X?*>N+)0@U^":,F(=3$.VSF+K`[_7"\J;55%?:!4]X$:#"_-0;=O=))_APJ[0O7W[`IE=`_= MK>?@+]SUOEY=!MJIRT!KL_357@FJR5V1LET-HT\VW$'M1-!4+-Z,?_$5]P^X(!Q1@`Z#IN_G/[:6X!ET?B:GJ1I^#,]4+0#XQU#%LD2:BU`Q, MWQ"SJXBC2.^1WJL#4Q%,-;Z0P#)Q"V,HLV[`FA<5!K/\ZA7DE%GRQN!RV);\ M/C`-X\>_FJW+5DO9GD)UEJQR>'$XPE6E\UQ[4#IYFI+S3X)5!\%2ID24EWZ_ M;)??XI%83;V=1XU4ZZ/.A.5$"HU0ICD*K2JB199B-?GCE`2+U#>I;T*9G:-U M)Q64D]*%H3,C'TOKJ(RE$5ZKIT]%L,C4.^H*%S<%ZD:?$B6D?3E0WLF7 M&.?H0%I5^[8^JJ/=N>PJZ[Q$JH,0H/:FE#E05M^1Y('D@31B_31BFS3BWO&; M"L6-CQ[8Z2P&=GJ4)%4!6&[BUI>I=RDL74T.(=$Z-OJK%K;>Y8!0_-BL1ONL MC=YG[0PNS3XI-$*9!BFTBHB6H7>ZE"A520XY)=$B!=YL!3Z\[*IK]=%TE*%$ MJ0VDJ[<83QM0HE2U\;HB6&3HW9XR9Z(ID$/R4#?ZE"@A@\LV)4I5F'$:9M_6 M1W7TNY=#2@PA!*@K`JB6AVY7F9X@:2!I('U8-WW8N1PJJQ'1%`2@-*E]A&BP M&-8Q6I0G50%<;N;>U[!-4>E*<@B)UK'A7WU0R2Q_GYE8C;993WB;==BB/"E2 M:$='F2;:BCTJ)U5-_C@EP2+UW6CU/>A?&LI.'38>92A+:@/I$M&S8CQ-:7%V M0NS*;&>HCX[UA[2]1_)P='FH;$AK>*DN?$R,4QD@K:J%6R/5T1I>FI0H11!0 M5PA07I&A198424-=I8$4HA*%J,Q6;`H$4*;4;BRUYD6%P6S3OF^IYKC1[ESV ME!63KM"BU0OB'_S`YD$Z>V/V30M]U[&U_],2_VGD/INA=UOJVH[M2L"F("R) M9AVVN"L3YUZ(U.3!)/T M/^G_K3'([%-MK#)CAB<5&A2WW?L1O672^6T2B*,+1&4C8'TJ MA55IQFF8/5L?W8&E/Y1ED9/J(`2HN2W5U3OJ3@B2/)`\D$:LF4;LMB^'A`#K MPS4_1.S!Y2NO7_'W3S_$X<4C8[-W7ZP)MV.7?QQ_F;"`7[&0V]?^=,:]D$6. M[XEOPU$<3?P`!F__R[-Y\"7RK:\?9_C[)Y=YX=7+[3<>6$[(/P6.Q3\S[Y'? M`]VN7+CNE[_\^4\_I:_[5PAON@TC9\HB'@+I/:3O9S[^^>SNQFP9W7^V_WU_ MWV<*+_G`G[7/_I2MQZ/<[:[C\8L)%_!GF*WO%D7",(L)82IY0G[$R]\Y$3S> MDD\"FFG^6)M3C7FV]B6>3EGP@C]\@7$X8^!R>-G(LOS8BV#`VB]Q.NS0(^8X%@19PK,`R\"W@4_Q)[0$`16QL['O,LA[GP M"OAB"L,)-1_)6UV$/ MCNM$3O(HVPDMUP_C@"?3P;7"$:R[1[X%IXDWX-];T$`7S\.;76H''YK0!0L'UX59#TB;LB6L/G'M`<9OC,^`> M#\B)2RQ624R2N5;L9NN>CEF'Z^&O",`(/\`J`G1:$TE:N,;U9V(]TVGI\&;` MH(L')@?=]^ M=EQ7UP"]<34#WW7Q,0Y&IN'!>KID"562^?S^_A;N!MP78UQ^E<7"B8:FE`;P M_)BL523DP7]R0GS*V`\T^.\#]_C8B;1QX$_AK3!%KD7L&\=50P%",&?>BX84 M@!6#!9BO'SQEXH1(3""WF#F0%84%W_;$8/%CN`A>&^1%`-?`HC@2SYJ0ZP!>.71@; M\`7\E/%\^FC)VXD(X*?GB6,)W@1:I(T\#QGJLUA^%(@[/YC.9VFT+O[[]15>-JF*-HXP?YZ"Z-N[ M&QC%$R``L/S'\1CP`RETCPR?V4H;&$1W[=ON;:O3N1G=C#IMX^ZV>]5*#*+6 M5>OVJA(&4>EL/`:8]9^%PA*($0IS"*X+I=0"JP(#(JA)30TLZF-&BEYE@XKFZF"OLC'#"03.\*\OJ6G$`H?4*?7-O M*KB[K06LP<_YH7@@!M,?`9?RDH_;\^"L(J/ MCB<'R>+(3[^0`0GQS;-C1Y-WP]YEJVWT.[WDW\YW:980^',NFX7\7?K'$GO. M9Y'?Y,[\0+-5SZ*XF-QJ[WMO4ZLMY)-]XX;OQYE3#2\DM"I^/0L5?J#[]KR.2,1!OC" M9^"2/X#CU&[I&IJ:.X0=B05W8<'V$3CP#5H>FR?_'OC@/8Z2*-5G<+#!._U? M;A]SLX?8[T393[KGU6*]9%&$)[:T(L27)\"7VB<,=\,;"12)^0[.?!_\J)*X M2-S74.[[E3\R=TN6JXEG4DIFT&HJWOD!?.5I5AP$W+-><-OPF04B>!T%S(I> MSP_8U8?>Z5C=QA;.L5GS7.QE^7'(/#O\OE3FK-#!SO+RV<21JF1/_9C:A0YV MUB8?L*,;W?)K:#4E4;!&*%,Y&XU0YG11)BO;9Y8O:H0UA#6$-:>+-631$,H0 MRA#*E(LRYX;>[9??!FU98FISN&[C>`Y!$$$00=#VM##U[J!-ADZ94>/C!X<+ M(U@ZVG(AOE$=0,Z=FSLF%#4,<>H#+&IM&S)A:(N>X*%!\%!",+``F0ED)A`\$#RL[Y&E#AW(0"`$(`2H&0*0H[!)-'*SBG-4ZH)*7=3QF'WC MZPC0!&F"%9]@3;:^*F>)4JF+A5(7-]Q**ET8HM+%F^^5I<#Z5QC32M= M4+D!XDTZ[DVL1Y4NB/E.C/FHT@5Q'U6ZJ'#-@-54I$H75.FBRER;2U2F2A=T M7&*+XQ(M0UF7U,8?EZ@1RE3.1B.4.5V4H4H7A#6$-80U9-$0RA#*$,K4'V7( MHB&L(:PAK"&+IFHHLT?;\DT;:E]^`\>+]-*T\Z;<8< M.]>1F+O.U/&P&WFQB7'2^3CM<`TOXF$$W")N#?P7YD8O\*P7V1<:_A")]MB0 M,]>W>!8'8)7`S3V%T&M?=H9FJ]=._U5W"J&SYR&$_N#`"=`F)4`?9Y.7<@\4$_2_8L#C MS@'Z_RU9->0S;,&9#>0\2BU0ZX_]:W8Q#O"VQ*(BUY5!=<'_:X/[8?HQ1AWW\G[4KI>R$61WLA+T7#^,@ZWBZV;'Z(VZ@]9P<-WJ M=CI7H[;1EO'U?K?=O1L=/+ZN:'%7.\()R;249CH,/M)>7>L]JNH<9K\@C=Z' M&)_6'`SORUGB'XYG.3/FNB\8TV<:[AY$W-:\6)S1!ZLRG''+D>;CA`539KW@ M[4_(AZ&P+N&QW,)[`OX(?,E<[7GB@_G)7+S"\;0/8D]@-(5!6DQCH?8,`\'_ M?\08D(,.4!5\YC/\)NR^ZF%N::F"V?KQ.'Y!]9_SX_:6FY8CRMU"[SK^F.-8P?@CY'S$,$.B# MQR!AW'*;):$?T&P&8Q)[)CCX"0=*330+MT,R*A7?",])3IF'F@>\%22CW+SAWYP0)O#`HV?.O<*.3[JQE+Y4AU?EWY72 M7]1Z?\&7!IR%L$8/0#$6(MC(987;%L:(S&>)<8Z=;W"5'\!489%Q^PKP[++& M4O?>TX1JPR4#A+7>5AXZ>*;TCF$ZR?Q\`)3P*^`6R2A7B'D.+8>(P/C@KXG^"QV$R'^:QB%!@`B/1\@'*BX8*H`A5`4F,OE=6< M/&T+`EIR%4Q+A'920=-11SU/'`MU3(CB"3^-49SQZH69Y$;_44+_?+#PXG28 MZ7NW0"@GRFLQ^>I$2H`/?+`7D$.>'5"%^&/LH5AE(T^N+0SW&;A"S`3TQ65] M@1_9=.PC*B"BR#2!,)Z"N2(HQ=!2$7K2TS@#4B2)&0O\-L<5&;Z3H@HK'O%' M/W`2><$;ERBURZ`]7/LI_#`)-0Z$62[TL,M3]QY;XBLF[J!8-ALX1GH_[]`1 MDR_ZPF>1J"@U1ZEV:\TFZBX3>:?)_RP]K';I)3)WQ&BUJE2SJ;Q:,ZOPL8Z9?Z@JV$X<2ARZ M'8=^3F,$ZYCT.A<[6'<-NB$W:4R!>)EX^3B\G.[.K&/3SS)L10Q*#'H[I+9-,F7)BQK#\%8@+ M%T?06T@,OC"*^>?[,M0G/'$68CI]P%V1@H_GCT0+I@@/@SF^+4\";<%S32T` MT=,-D\H_'$`A-4QA-U4>VD.]VU:FC$@@2"!J+A`=2AYK+0V>@=P;*\F^:(A!-2^LJCJ"SY+Z;2MWWD?V?.(QDY8*<`S\#OSTH MW7U7N@I'%,QSHU-^2&V9R\J+.BH.P&Z M"5Y>\(9#4G@A)'4D=25W!R&P?)/?S%`2/DBG>(N5UP&TG M"G_(>B).F5B0M)"TD+1M(2ULW MN\H/M9.PD+`T45@,O==5%G$G82%A:;*PM,$.&_1(6LJ*$%0O7G><$CU9,7IM M;0WZTVH(N.*E=3A=5HL>@:_35GT*:-L\'#>?=M/`&N%LY6P80E%"T>JB:+NM M#\S!\2E,,$HP2C!*,%I3&!T,R10E#"4,)0PE#-V5N(9N]I25P"`4)10E%"44 M/3D4;0_T=HL<^L/`:&Y3Z@?1)7?E]2O^_NF'IR#Z]BYI(/4YZ5:-+V< M/_#H5S\,1U$4.`^Q&->]_\'W+)A0`/<",[['/AP\C.[%C^G+L"\XDOLS'_]\ M=G>#VT7_;/_[_N9,_JNC.X'AC#4;?7&AC&Z'IPVS4&5^VKSG#8 M[O7.?EE8OOQ2O-$/>-7J+_74/GC_[+1%N0W\Z_F1-F%/V`=;-%$77"T.1O_^ M_E:VP5YBG5W>*WJM3P(N&VXO-<1>WM9;SE+:Y;67FC;R-/;X&/!'F%72*OPE M;4,/K!EJ+,=5>!S<*_"5YB2,E3\Q7NQO?V1*J6G"+1K6ATEO]?#=JWBQ(3N M%S^@Y:.(%6N"E0?,J-N/7?O4=)$R.K>)X?RZC:/UP,&9XMHL*[:-OI4#UT[A M-O;MN,U]J?Q_:8G8)1S@Z%.M,BHC4>7=%8*@9D-06V^;5+6M.L=E&F55?5)A M(37V1%J_WU>-TDV6K^JYPY73Y(T5E79+;_=(6NCPI@(2OO>L@+.0@S[2QLP) MM"?FQAQW7-'9AQ%CKRQX"'CZOB3&9-LJOE$# MQMLE^+'3(8$#)/YO<\K@BTP*_SA^'_%I^%FF>=_[O[/`P6>F+[CU(B=R>+CU M"8/K;L?L#GO7W;9Q9[:ZH]OKX8T\8=`U>MW;=O-.&,@LS&F/$ELG#R/P.Q8=0AMXMG%1Z2^F#AA/-(Y+'[8W$G_AQJ(9CA M8S^()ND#Q:@HQ_UDGT&><2\1P?WL\I3)XU)6AUT]':'TE8;Z"A6 M-SQZ,L(UU%LMDBURD#;DE[_[OOWLN"Y9?#\:0[T]-,CH(P>('"`1:1N:RO+K MFR(-Y`*M8Y>/(JA&WL];=.KTE*F8QEMG)%CD]VPJ5N67+&J*5)V\SS.R+%C> M*,3J#>(L"!E[AFZH2R-MBJ"-M;TZW;T[H`VCL@5(E<(;S,-W5#7 MPZ4IXE!^\<6]ZB&N*KSXF5O^HP=DL`NO_,R?N!?SK>LI#CO=7O^V8_2[(^/* MN!ZV#',@ZRGVN]>#:[/T>HH+8M);D"3\?-"2BS=Q@*ITB8-V>98HCRC:0./. MFX=->*>^:,++-VW"N\MKQ=N4/&EEY:1='J3G:T]J0<;#XNMYA\ M[+^8%X;]W6M/+O">LM=9IE8\W76K`'W*4NP(.XC M[B/L(^ZK$?>56U>>6#(WW"Z5D=^?L8`654XV*HS`:"\$TB^,XF;/WG7FDU;I MV:[#^?L/U^]__TAEY:GB\V8Y)E3O^6#L<,(ZD##F=#'&U,V!,@>;4(90AE"& M4&;9DM'[5*:(4(90AE"F3)0Q]:&A+`>Y\3"S?63GU`(XA0SH7!@GXBZ;P4T@5-D@>RCO(W"SM M8N@]4]V)9M(O)$_-UB\=W>PI"\4T11YJO]'S-WM_%TY MX`Y$T&P_QO?OH_G6\L'F.;_[+V\5PTEO$7N?>-.!:*L:>KM#=25>=R:O,MI5 M&<\I@EY2!)TPE##TJ!C:UGM]=?D*A**$HH2BA**GAZ)M=4$`0E%"44)10M&3 M0U&CKQM]-A7N5E7(^YVYL0A,CCS[GS&0:_P"/)>VUMNZ0EYK MU+[M=:]:9F]H=(?79GLTZ,H*>;W;SN!J<.@*><8J1"JU)-Y]H4:;C`F'HJXA M7!=J0"3GR8E>-,?3.+,FFC\6\>)9X-NQ%:5!98WA$YAGR6IX`0]Y\,0UBT7\ MT0\<>-#8#\2-2RRWRZ"7JNTI>>K>8TN0(1%^L6PV\'M2R0[%3KXH*T/DXO/PI\9/7L>EG'L6!1PQ*#'HD!I5M\=:QYWL/1^`\D3E` M''HT@Q6S5S!KY@K=P(B[89;2=UM0\2WCUI.EJH) M;"FIQZQ9TNFU2Z='4[9G:P1#E5-\A#*GBS+F4#=:5!J)8(9@AF"FS%._?8., M&4(90AE"F?)0IM]1UBV#,(8PAC"&,&;IMG9/;YEDRI03,ZY@D4`N'ZC%W*VV'YM:/*BG&^J*;35%Q&AK M[V3EH3W4NVUERH@$@@2BY@+1,96=AR1I(&FHN328>D?=W@[)`\E#S>6A,]`[ MZKI--44@FI;651Q!9\E]-Y6Z[R/[/W$83>'18=Z!GX'?'I3NOBM=A2,*YKG1 M*3^DMLQEY44=%0=@E75LK9#8UE?K-4?J3+U]@+YH)'@D>"1X><$;#DG=D=21 MU!U6ZLQV^>DA)'4D=21U!2.S?9#+-C9L!M)PI_F+$7&9*9,IM3 MY//'\ZYNK*BLMV>(O,FR1ML$IRLLIJEW>B0M)"TD+1M(2ULWN\H/M9.PD+`T M45@,O==5%G$G82%A:;*PM,$.&_1(6LJ*$%0O7G><$CU9,7IM;0UZZA%3@]-E MU"-F10IHVSP<-Y]VBY@:X6SE;!A"44+1ZJ)HNZT/S,'Q*4PP2C!*,$HP6E,8 M'0S)%"4,)0PE#"4,W96XAF[VE)7`(!0E%"44)10].11M#_1VBQSZP\"HNM;9 MV[2^7FZ=[8__Y059\^TO$Q;P!Q9B&^[IC'NA>/#M-_R3;]U%^[K7ZK>ZUU># M6Z/;[8^,*^.J([MH=P:WYO#FT%VT!RNPZ?!-M'DDNEY'$]'W&NG,O)>_A5J< M6P=X$9#X0JP$$'J^%!J7:Z%K'H^PZ38/(V(`6^0]O&C1RXSC M%>R9!;9HOXWODUM^W+Y@(+;LD:?'L5%7:L\3Q\)AL2A]C^:$XD\K.<+]P+7Y M*-^]RNQ;+(S1F[W>/&CMDA=T8F7;54]9\.AX9O7,WMW=4^2S$VI5CY^T\ MY(.S]O\LFM/K^/:SE`!APZ^[YI,PQ0F\*P+>:FBU>33CV&;%;@TPB>.J0)\R M8F:'X;@7`,&RVJWB:>\*[4>\>@S<:,_*/09^GX\'O1ZZV=7:/2"I:R_W%>)+ M(EPC"$>5,-Z"P"\85=?\&5KA1W4:CW[\1^UN:GDS5IXI,NSKK;:A:N)-V8TD M([YN]"GS>-1E>^-DJN;:XZ4KH\\\C`)';*R*W5ZQ11LL?AE[3G14545M^&JD MW%IZ7]W9\,;WX2-/H_DN6JEZLK]Q"4?RS=ZBYNV73Y^T$///-"<,8RQ#0"[: M2;IH^F"@[$C4J:@JTDA5HT^)$M*Z[&Q<6TY5GO'.><(BY=AUO*_OQKX?>7[$ M?X4/VC?Q5>#CM"=1-'OWPP_/S\^7WQX"]](/'G\P6ZWV#_CS#WCA67(]YK3^ M?`:/YJ"$[#/Q[!^6'@Y?__0#/LEYA__"Q_\/4$L#!!0````(``.#7D?SOSI+ M"2$``-!<`0`5`!P`=G)T>"TR,#$U,#DS,%]C86PN>&UL550)``/ET3-6Y=$S M5G5X"P`!!"4.```$.0$``.Q=67,;.9)^WXC]#UK/,RS<1T=[)VQU>U<1=DO1 M[MZ9MPJ<4D53+$V1DNWY]9L@);<.BE6LBY)G7B2*JLQ*?$@@#R2`'__ZY6)V M_?X)O?UT='S\ZJ___9__\>-_(?3W=[]^ M./BI\E<7<;X\.*JC7<9P\+EIKBX._E;5?Y37%J$;JH/UIUDY M_\/913SXLBA_6/CS>&$_5-XN5V\^7RXO?S@\_/SY\^LOKIZ]KNJS0XHQ._Q& M]>03^2]T^QC*7R%"$2.OORS"JP-HWWS1@O_-DS]\R5_<>_XS6SU-C#&'J_]^ M>W11;GH0V)+#OW_\\&G51%3.%TL[]_$58'!P\&-=S>*O,1WDW[__>GR/P76] M_/+:5Q>'^9^';SW@?#7+$)\LSV-]5%U+\N)R!M\=CB3T3W%IR]EB(-D?<)NF M";]9-XM#M>`^LYX->&<7Y>(DG=9Q`<-T-<#>S@-(4EW-ES"P3ZM9Z0EYF=GV5WY=!YCF^'>EL/HHI[:&A`[C\O2VUE_ MN3>R&Z,1GV!67X^1DW1D%^?O9]7G;KAOY32ZZ`\=F_Y->(KCV$TYN8SURM+V M;\-C5M,)?V1GG@[8@GO\IFM&_W&]`]^QF_7I'-YZ7LT"1-P__^.J7'Z%&?Z7 M"F*`^1(X@`QGQ_-E!&]OV;NI'=[5L_FWF0%XS\]@M)9?C^>IJB]6>#@4-9`,+U<[=VT[54Z3WMJS_S\ZNXL=H M%U=UN_AC*]$8`K7LO3:T8XC7KA];D/84[G]C.`--:1+DP6/#O+1E%VU^>A@1 MVG7#QH=["G";7_K2_/H-CP[W\I:=\#1%;U&6$(R6@.S;Q2*N(JO_J:KPN9PU M.A4M2,<3KC5N;3GT%O4:)H>J;A%K;WATN)?G['JXFL63=.?+UF#MQ&8XH=M- M`T\2]!3D0P5S2ZPO3MRL/&L7X&PA&5Z8]W9^6L;Z`]B@UEVY(YOAAI'6_\!#$%]/D5_59?+%@-V&\T(XK2$K`7I",*U&ZK-E#U%6RT: M[9*`?Y)@:$%:]EX374^Q3NLJ7/GEKQ&FS*NX^"4VQLU/4PPN2DN(&@D'%ZR= M$P@;J-Z[L1D M3(';*>H.+#8*Z^W,YQH1(/H`#]T\FJ4;KCQH_>+X91GG(89)7KU1L;Y)L'H_ M2#"K_#UX;]ZZJM)*=N%6-557"W1F[>5AAOTPSI:+VV]6'8$PN:GW^LO-U\5C MN=8R9>G`D)VDW^R76\%FUL79FU<@2+$+>1$5D=8[C4Q0"1$A.;)4*N0Q-R0X M3K$5]QL_R_5N57V+_EY:_RZFJH:QX6=VL2A3N:[`ZPM*`]?">,>YBP)1JPC" M-$D4/7$H*A:]$BY$IYNPNJ.K;VM_4-4AUF]>D5<'GV-Y=KYP!UZ\RQ;O#159T7 MYDYC75:AA58.^9I"&Q.2M1AAQ1C"3$9$G-1(61ZULQR[U%%-Z9]JBEZRGNX9 M[CN*^^/A`^,UOD7;9,N',:G=:BVG??=V>SZ)"&/"T+)T<>27[=-I>G>U*.=Q ML0#M=^5\U2(8[M79O/QG#,-/E@#>1%U)$P'ASB1H-30*'A0GJ'L"6!4H*K7VV+6K31%H$9C!V"B-I;43:&XZ$909QBV72Q(L@ M:3=U8M/XT\]1GT9`?;N>/;'J[`\_^S8'>=!;E3(/2Q MG%?UJE)T7<4*(-[GLJYZ_1B7YU7(116+Y3U_?L.$-J$41<+10K0KD35)H<2I M1U)KBKCW5B0+@]R2K3H_9`#<<9_1R,'0>/%VZWU`H[]N5%QWVYTS49C9&.3< M>M,I><)#0BDHBF+T&L40#9(\8JR(,\3Y_01Q:P&/&OVC>\\5S$0;G:1(QB+WR`0#%";"B8DRAB:Q#5`>2Q1G'BN<-=,\U3*D.GGJRFP6L* M77E[#7-W-E+OJ_J3O5L%UF)R:*(M**5.6,61$50BQ2%H#)9+E+Q/1"D1E.\X M84P3C`^G(V-@-6I_0J>VG&OQ>">RX$3^D;]NKI9[YNVQ37M%K!;<\DQT7":&H1P2RBH(2! M"$DIQ(RB"<.4Z%C':&%*Y[&71HR*UF0VXF8IL(UZ;'R^,,[H*+5!4<(4QZ)P M*`K/$&.4IY0!Y6FU7N'0NTI?^;2`MN&>$) M!^1ELDCX1!%VD2`;@N**P\28V'[6:#;L#-S>P()'A;FD'OHL5]#38!#V$$"H M1*`#0W`>-^[GV&=*?MC.JH8$:F(U;PZ/'S]=Y1A8#09#:;*H^/;0`/@CUM/QP M(8-T@A"*D@\,*9U3OA!'Y6MH-%>*$Z,ZIDFG284,K`.#(#19(FPGK_$)B@(' MC;&Q!)G$+'*"1B1M`O184(XY'A+NN(BJ7J(&#`?3'CS&G38]/:(IN+?:6D\0 M95@B0H)$.*]%!^R\XX([3#OF12 MJC"8/,(M!Y.G%!.,\^@[.@B3QQ&]]&%PF/;H-;;2BT;:;!65Y=PBY;*[#,," M":49?'*.)$LCH1W+,RYYIW3ZWFKWS<33FW MEX%0XU!Y;VGH5T\&2,2XEH1Y&70B/-<2$0HL81BZU)'1W+RF*+7##`, M-ON()]M75VR>VE027OD4CH3MI6Q%P8MQ8BXB.JTH!AK2T(2<2 MDX:0WF/9+I@P#EO/D<8^(DL- M04F!2^]3(N#::Q)M1_.V+VW9K:L>[T0:`**I/)UJWJK?'SY:^,BQ9<#3..F0 M29XAEYQ$(3FGDP^)FH[&91J?9N!.'P"?28JM0B@S.'9V:LMP/+])WMV1?EO5 M52-QH0.)GG-H)H,?4:B0/SF(%IS!SD=K77GVI[C^O77=NSV;(B41',Q/2#D(:(05`45#.,*"*H>IU9@T+G..@T8^^P6: M<%I7UR5@_^[K[XN\Q_OF$-#YV5N_+*^;=I:U9U(8(B.)3L$8239GR3&R.6^) M'18Q2,:4ZEA"-DT(/%ZW5Q-B.M%I':E<9I]K:Y;D]J$"K+71^5":D"Q'!(/) M38(%!/9;28:Q);*C/SN-9HS588]/Z^B.V#3E(N!W^W(%&7R>Q=L;3BZR2JT]P;BPF>]>6DB71D)RTD2\^?@ MICRZ9W!;L2PR?"%D`(TG#=?7+?//,M$FC(8>E/H MQD,["W#DB/^VANIV-6S;4DY;%@4CE#`A)=+!4*0P-8@DG(<(I5X3[)/M.--, MDV692']&Q'.2+%X^W>+XXM*6=8Y1CF`TG&WU>#<3%(1(:3G'2$87D!)"`GHZ MH$2H\H9`E*C-8A M$.!,$)1W#2$A6"1,6A-2QV*G.U6/8][^,9&*#(G@?FS2XW-6=[)'C\D!SZ"Q M$SG)F2^.Y/D^#4("PA0S'!@+470LI%??E>Z,!.9^U.CV]-;M&9BM=(4PABLP MNXAR(Q`S)"(3X4\`,J84G=.F8Y6*_LX5IQ^*^]&8FP->;WVOC0>][J1*;1@6 M"AN#5RD(Y3!R1F`4;01T8E[%9](QV=%1-M^YCHT$[WZMWLV).IU,W@UM88E4 MD0J/HG8$66@I2DS`T%-419:P3%U/823X>W*GQT!R;]KSX!2>VV'P#;-V9]WU M99V7?0%R1U'T.%<&I("H3!%)&N`SE<[SCK?TD>\J';T'H/>U37KG)<+V3`J! M590\UV8'$$8+XQ`->8ZG&!Q5#&X&[GHNVW>5T1X5TOW,>0].$-AI4GM`6WB? MI*&<(V5M0L3XA`P.$D:4240RQ:CO6H[^7:6[QT!R"NUY`I[U59L]5^LW,"F$ MML+!))SAY;GX*2%)"#@/$`OMU?0UI=7-? M[]/7D&U;SF_/I2#$64=BOBV`.60\UBAH\$D%I2RE?,ZBZ9@))7L-&'OW^<,% M_U$QG:@2Q,<85C<$9X%A1'ZTV80OOYZD;GK6C6-!C#9:!XIHRLYFXOD<1S`< MSD=-DM'1IF=]R^!4*C<9O'N9VG:X*::1MG")::HE1]*("!XFL_!^0?*ZI%W4Z$DF!=.2&IK`YQ0B'QF'#>(BGR&8[VA@ M1C@6^E]&\SWJTY"0[B<2O'_ERDZ!X'W20GL33(!1A(5AR$8$PXZ<"IR2U%$99()42(?` M$+:Y4,SE$_"8@7]UW*"TWSJ'L4S@>+CN,:?U[32T/CFM#4P**Y7V%(>\@R]? M?BLMTACGRN<@I,1*!-W1-DZ3(MUW3FL83*?..QPO%E=Y#]Q)6I4Z+WZ?ASQ( M/&!77N<`=W,%='8F%]^V%ZYV'IY4Y\MA[ MY&2D4B=K>>I8:+'7A:K4EA_$<.F%*DWV2OJ%Y5"U:)3@>DA1.>A&#TTA: M;Y#(V.-T>YJOA(9VF9N+RVUCHKEH[<"D$D40Y M*9$+S,`XL1D>`I6^TQBA%CQ'FT.OU_>U?6W,9QA']15^8^JO)"B93L*LET64[R MN#6G!!L"4@`H1_GUZ5F`)$B".!:[@[4K+RIAN3O'USW3W3-]9!$\Z>AV%)#N"=H8U.PG/-U\<#H781@-&&!,9F[IOVK MD^G\`JPU#*PUV.PFYQ16M_GF/^&+FWU.O[A5NIWM-MKW\-@IS32"FT`]L6"S M)*AJRH2&B,M@='#4$.VHZW@'62=(M=J1QL"HULSI\R2ASG:NL^V,&W43Z[S, MN'9$VKL]7S5*$"DU6D_6$`7*I^*$9P38$+1E5IBL#QYU5)]KSRFN>^X)=TV3 MA2(,K/,HH;,BN'(<`Y65Y40YK<>=@[8W?GF9E_3".%<+9NZ>H_*HS(I)4^6" M-V"C+G?N2H!C2D,@PM+H!2-=4VY4>>FZI^-CN33"R`_#MY^G.AJ.,'.P)^KH#YI14"-+Z1E+-U6=OP_=>%FRU= MV.00:W]MR!]_NUO[LIRI0G3OL,D^RN`BBE8;'#B%]F&VB*[6.3/O%'6I8^13 MG5N&BW%T==PKG?6-)/=DI3BG$:FLHT]0N0>LX6SUHV"7"K69X"F04@!#YNQ` M)>[!,*E3M(R[KGE:*MVY7\`X'PC82QWE;2)=M^Y(JY[AW2?"1]WEWB=F$O9P M_,[W&XK$]-(0,"E12$AFD,9E2#S2E*.0FATL>3.8Y_2]S$/F7=?0NRLE5Q]@ MQYFTDVBGL]]U^I26FD0(H[94;54R@HL&QV:CA\@523(&S5+7A!)51$P/E'[I M)3TP@I5\\;=F<3U9AO5$4GRU8VW3FBS(<(;H9@"HZB!Y"E'=:P$Q3,: MRTZ7.!EUP/;07#8LEI7S?VU*UW^;(KVX0V^Y[NR83ILT,:F*C`"SF2%Z))0B&1!EJ1: M042KZ*A%=U=&.5E>5T)W'+S[)N7Y8F.,H.Q(R^=%@=HHK^U6UL6*/J;5E_GQ M\7FU1M%DDAPMCG_.9@U9L`#*&`8B!%=<:3+^> MINC:[T2^?J7Q3EJFB$-301B(.J/EP+6$'%/)E9.U#:/>U,ZFR@M/\,[`U"!M MR2>SW(SQ_7P>BV6VA\R[7F^"4Z)U6Y=46M`ZHDI-T%C,FJ3D`\E,CUI;ZT:B MY_5<^D&FRG*>?W?3U??#Z0^?OMAD):@SVH-.R/S64PV6:`LT>1)BXKCEC;H& M5"]T/AN3_10NA]=*\11W)^?FBO?3>LQV__G+C(\^"*PN*.QR? M2@QRPN%*:KP(4CK*8\EC\6QQ:2Y%#HE)DE#((7=T\N@ M-Z+E<+&C@]\V021AN1;@J75HDM@,.L:$@[&&Q6B\BJ,6U;TRQ!!PU3&[E@G[ M*9$RURBMIO,VN=IA]MC[7:,<#YY(!]D&`IQE!9&1C!:L,.5D$C734==G[)4U M^H:JBLF6VO.R]VF&##TMQ47CU\ELLERM%9O#_'%<`PU'H M@H+,(W6!BN!"Q]QCE6+<^F24P3"KM)$\YO`_7&IQU^N-3P_:!]=@\"GMR(FP2H82* MA`N*4`=2.-S/4T1-,7F6K9*$=8T*KR-+!W%QZ1VSZOZ!9_I3G=Q6HQ+ES,8( MUE(*3G(-5JH$)C@;E$%%-HW[L+<_][P:X%5)://,)?=Z,KU;I7WGP:]\T3C+ M@TVH("9M$W"'"X98H8")X(/W5OMX,,76!<,"-M/H)3!@NZV&:82AW![HE#-: MZ$Z"),%#MDQ+Z7E*\F"XQ)A"`SK1NTMPP)DHCDV8=^6QDUIM1#31"$UP;[$, MI"P5$CW/8!QCW&45@AAU[/?PW#8TGI>/+7N+[3_+754IP*Q;^`)Y\_8MN>'F M^OK*OI7FAMU(9B6WE/%K_E9?C3B^X?!&=I8L.0Q-)-+PX#E0GA`:YCPPYPQX MXQ$ADE24'0_.+Q$PT2\GG"QTAH![;&+HJ:[Z2_IWL=)GGV_P@]7WGH32WCX. M@VP"\R('"AHW?13SQ`&/J"YK1[T.DJB4.E8(J5;'[S(\/3*J7%X2_HPB?+;Z MDE83[.D5B7@_PF'&TFH17^939+_E^CSU:A;WF^I]CN]Z'N[*2,IE5$OG'V=Y MOEAS\1#]/5??:O1QG59N,GTMHK[7KGXM:V>0GMZYR>*?;GJ7/B:WO%ND)[%# M@WBU<.R:G2.RID440NTI!@5!*+D&5`1*\YA,D8[:FNN![J^RBF]0][]`/?SA\>-20>6KO?;^5!3QO%E)[KOX-/DZF;K%U>=%2J^4*![]F$M(A/;1 M4MPWT.:Q/&GP'HFW#HD@4FC7\7B\TIU2?SS_5R16W1WZ`9N?YANY]3,:9>'[ MS32U"0^O4[P+V[;/43+_8&M-)L&&DK51TY"!%T<&;YF&R%AVF1GC$@P!^P@4AG9)#J2@'VZ[01$I'`L$F-!E3^(:I&0"I$G":!X,R0==\H?& M;;UK'07#^M4F1YJT]@ELL**X*%K\G[/@*5&>9*,TZWAD.`J5O&^ZOKKV.L,Y MEH5UYMIIJ+4JE:!:%A4KI90#!"8D"&."\)X[)3H6G:O-2%U(>9KRW16Q,Q7O MMMNG.E'[:(P*]WC&VM`<-?<)E5$M!!@N/*C@[G4WB0J=[UA&JKJ.<@9K_Y7H M4W?/;:?;BUY]5$L-L2QY6P+N&=40K$-;OM4M!4(;-(DQ=-R)QZ%3UY7I`\`] MT/7>YIA]N"N"K1"(@9L?\%KEQ]D*]Y()8K3>AG";*E'H?TRF@]QS[NENT$E^ MPYUQOI@,1:F'YC^%+[@2IKA`MQY>\J;G?AC?#X7//;[6))>T%8&!+@[RH9S3 MI.PY6.M8SC3C4CYX"C'P;'YQ?WPLF]O$3==^"24H>O%M[R7,X8\;I:DT3FA` M513_0>$/0464HHEE8D-0=MP5G+J3\84_R`!8U7%AV@S\7_/%[S_.VFJQR]-9 MY/6O&T,53C`HX+9T+R@IL!H03BB2O376="P!72N@M&\>Z16LJDSRKH3#XXY] MG_SL-"9Y_>M&LD1<0I/"$9Z!6!_!$X=C82*&LCA\&'7"BOZ9I%>P!E(9MV3V M<&KCASDJI6GQ]=9/)Y^?^O8.W,T[-_MYDA8?2H'D(77*'5V7GQ_F;C9@KQ_= MXO?4.B4^U@RLU4\W#>^UO'EN^>59E>FK;]A\Z?+=?%&2-FY51?Q:O"__6QP' M=P;IG=EBXQ-'H2X\9,<2"%\NQJTUF],$80)/!ST)>IAWGB^63T;9GIP\K;/7 M9?;'M-M()U6F$;>^K`U$;BU8*>T]!L[)>'XQY"%.$*H2?WY9R+NEJ#QEG(]# M+'[2[:A[8;D=[3:4:N6,+16PE(!`&$$-2M+-_)4OB07'J&3^.3BN'\1[X[A9 M?!V>AR._4UCMJ`:;A)I;E-&`8=P#CTJ#%TIM9LR4CK2CD]BP.NJH>&PHJ`?2 M<'7BWSM2&[:7JE(;CARE*``#[B0,`%0`<`'9R M='@M,C`Q-3`Y,S!?9&5F+GAM;%54"0`#Y=$S5N71,U9U>`L``00E#@``!#D! M``#D75MSVSB6?M^J_0_>S+/;N)$@NCH[A>N,MYS$ZZ2G9Y]8M`3;W$BDAZ02 M>W_]@I))7UH7BB)I.JGJZL@2<'C.=SX`![?#W_YZ-Y\=?;-9'J?)^W?P%_#N MR":3=!HGU^_?_?[YF'^6IZ?O_OJ?__YOO_W'\?$_Q<79D4HGB[E-BB.9V:BP MTZ/O<7%S],?4YE^/KK)T?O1'FGV-OT7'QP^UCE:?9G'R]3+*[=%='O^:3V[L M/#I+)U&Q?/)-4=S^>G+R_?OW7^XNL]DO:79]@@#`)W6MC27*OXZK8L?E5\<0 M'6/XRUT^?7?D[$OR!O(?2OY:_CHMZ@I/"WLGJQ_KHF7=9Z*_XV59R!@[6?Y: M%\WC=06=4'CRSP]GGY=H',=)7D3)Q+YSEC:52O]YD M]NK]NU*$@PMZ@&%0@O67/<44][?V_;L\GM_.W'_.BGTIUI`53>OW MI>;'*%M]>:B^FP3UI7BS[JYA]8.5G,_C8BG7-0:9+EN"BW`:M*<&5?M3KK'/ MFTHX6-5DZD8B6SXC=QW(M!RF1#0KPY7/-]8V:>Y-)?2NZGF4.<1N;!%/HMGA M>J\5UX<1GUVOOFHCGZYDE-^86?J]'>Y;)?6N^LO`YG`3-DGLVY1/MS9;CK2' MV_!G4<,I?WB#V$-NWV9]OG%/O4EG4S>KU?]:Q,6]ZQH_IBYX3@HGP>EP?9H4 MUH5)Q<&FMGC6@>97LV_W'.UZ^^+^-+E*L_D2[UWF-*E[H'HZRA)G='YNLR4V MNU3:5+YC-1H.ISNJ=:Q4LSAI>ZT#53)1G/TCFBWL!QOEBZQ9X+ZU4A\*-?1> MD[I]J-?,CPVJ'JCT`F;:QRL2N%F<;%#EN>Y74Y)_I:FT^_Q;&=0T:!J?\HUQJVIA(-5 M_>8ZAS1K,$E=4[2[AY?+TM/%S'ZZ>O)E8[#V$M.=TLVZ@8T5#E3D+'5]B\WF MGRYG\76SF<&6*MTK8Z+D/+;9F1N#&KMR3S'=*UW^>99&27M]-T@X4-4/4?;5 M"73T^6PGBRPN&C38;75Z4*9$Y M^:[9)-=G<709SQKU4KOJ]:160V;W]HD7P[*^J[\N'.%J%'E/A5L2,I]9`R@[DYZ[B6D3X6;$74/$6N5C;)) MI>_#QZN&@T35V:#R_)&W5#C:,7-MJ9#[7&YS MI,GQU%Y%BUG14KV-UQ#TE+5+9+6*NQ($B=QV>3.7)F'DJ5.W9U*6SW7WA4VF=KI$$]>VRO7 M"BP?[Q28I9-U&"_QO8KRRR7(B_SX.HIN3\H^Z\3.BKSZ9MF+'0/X<"#Q+P]? MA_4NDK/*GKJ/M1JSZ-+.WK]SCPTW%PY][1N?^@0(3+'[X'E<&2X`X$QJ2<5S MHV;E0:!.;!&F%8@'=9\T@2GDV. MTFQJL_?O8%7KH?GLU=N7)UF[O=D++1IV'^2OM#Z4?AP7#>_^9'>-V_O!.?Q)Q?1+X\G?G@6$Z]A03,!H?$XIP&6`B'(@\`(2.L15WD>&(H6ZR+] M/W/B0.^E`T`T,#D^VN+W)+/1+/X_.RTWX5:J_\WA4L;E^]"DD:A0:8.I6ZQ@&G;!Y?)\LI7O;?"V?8U7V<7%>' M6\J+( MXLO%^)S3QM$;2<`5\ MAP>(?`S2O'-;!U.!?N#Z2!^Z<_KS2M5IG*!E$9TZPK:B(I1$9@!25Q_^&` M8R@"BA^P""CB<%R$Z<7+F_NB'A`<@DW;U!;V*LWLA9W,HCR/K^+5S>DFS#I` M:J@Y$4(2P($!"!E#"1$51A#)=O%V;^'3$"P;#LTA&/=2UW+D;M".Y"(K<3VW M69Q.&U"PR\>$2`L(/4\QAI&/L?O3S:=7*#+CPW8]7V_QUA"D.6WD^<;>[UO]JT[(]#) M9F.[W`>#/GK[1N<0&O0(0L,\`OT^J]U6\I^/N93?A(\'YC<]CU]G=O7@;=O' M[86%&KO8&`NI?"HI1P@;BH0O%/*,)(&0^VXO=V#IIBWE=H)"Z7.$M8\!T=0% M_CH(F'FP4`#%@M?<F`Z(UVR_H?41:7]E27=)?78ETW)>[ELX#JT]7J MPNR.G>PVXD)$!37+T4!Y!'B``.1)7J%`?&G&NXO>K]/3P3']61DVNAWZMTNLX0FU M7MWS+)Y'V;VPB?/=)'8?=^ZP[2,L2-S7(_^&2&FO^B'F,A`!9A0C3PB'D>9^;8L7M-M9 MW7_U>4RA49\`=DJ&6I&-H\X^U4,I?,(9Y0)!Z0M`W0R'5/,:CU,XOGBF)T\U MX4$WX+UE.HPF^'A#+.C`^_\5)7END^<:56ILC!6:5@VIAP4EP'#L869\@A"L M.DOI>DXUCNB@'Z>DO6+5RMOG+C))D\^3V"836RZS;_?PAN(A]%TTY%@OI-`X M0%@%`:TTE8SLO,HRS!YS_U[M!I]6GKRPD_0Z*<\&/K/PX5HZO\R++)H4FQS; MK'9HC&&:@%I4E0G`Z(AIT[9N7V_:'`'-X=%8EG6@4BU6%0V5D M.44A@`5$>3ZCVGAUU\9\-J+>NB?W=0;.,`=\-CKY99'0DYB[P2I@#/@<2\*0 M5X]:!+:\<]/YP9I!6F8[2#J=,?U^:[*T/&$[*5,<&+MQ[[.Q@!!ZC!,$A0!< MN5$*EQ%*'4D0-*:V.^`(W!=^0S1OL>Q>[GZ_(X MV+/<\'Q>'L]X;$-;.H=N'A`23@S7'`D9>&YD$Q+!NAUIHLF(NI9AF/>J^+X2 M,\LLVO'T(3GX\@K;E)R)UJ\:1PH6N4WY2O M;7'_E+?ROD6SY7WQ0D995EZ66Z8+WQJX[R4IQ#1``A"(7#2+@4(".@PJ+`@= MV1VS5V?$G^8$?:(]!//.,WL;Q=.'I&G.@E7BT"5\#WU0``@-,L"G M`1'ES7-*JJ5*)=TOXYA@C)5AW2,\V.V,T^3!=?;,C1'3EZG2M]"J2?40!XHH MJ04+)`QHH``7M=4"\Y%=L1X;KWJ`>`ABO7P!P!KR5$5"+@/7+A37*)`^P;Z' M337_44S3=@3I[?K.V`C2$L8A2*#L:EKR);I[8GOYBJ6=`]:NJJ&"QHW1GC8` M2N!)*0&L8E47OK8\7M1Y,#Y6TG0,;ZNUTV7/]MP\9_J3?.,OUTHW5@B%[PL0 M,,60HC+P?".-KK153O]69/!_=#)T"NI@TA3F?(#L&= M#W&29LLWN3Y_R^P:QKPL&@*A-/7O"!>(YX MWZQ:#M@$7??[9KN>&`:2^+[RD6^(T!M0BY8`K[ M5$(?48J4D5C5`0WS0;M3>YTO7+S"EO)XG3!<0W!6/6PGK6Z*;NN[-]0(`S?! MPN6N`/<)-XP%1.+*-A<1M;MKU?EBQZL1[%#`7N\PUNH\6?'L)-#3VVGRIOQX MFJQ.FY68KJU2#0WW^Y_CZER#$/H0$@)\(IC4&$A&'Q>=I<_:72;J?*UE'`=L M1N"`(9X+S`,)]1RI0/0:"8<;8]6.BYX7NH1#9=9X)K[+C# M,L'MAUXTUDQPGQ>7N?W7PCU*?W/_^^*TW?7:LO4U0J@T$@APQ0V%92)4Y`<5 M($22H=Y`[L>K'9:"CPZJ[?F>UL;?E04PH"@)GV*.%> MF4'.AY5=5)AVES[Z>[?+X?[9[O%6J+0Z'J:RQ;6,DFD\C8I-P_GZ@B&CR@3( MH/+6KV\X80QYE78*DG8^&U?JL7U'\4Z0.MR/VQ-(K2D:8D!X0(CR/,,P1D@; M5O,6&B+&-_P>"O5&CQV$R!A]-YKA\K5=UH&K^'2Z1"J:Z22:G"8W\67LT-S\ M&KT&M4)/E^E3C8$\@&7Z5&1(K3'!?]]6Z,@BTT@`C00T4 M4!*C>=T#$=TN:5X_J1=Z\UU+,#K-Y])Y=EP58)\80)#V.57$62'\RA:-6PZ- M^SMV="%J3P!V2H:.TZ&*P)-8$LD`\0-/^4R4*1M6EDALY$@CW.X]U28O:COP MWC(=QA4TOPT6=.!]$:?\+DVL^S=OFC1U6YU08&.4,)!JZ`GE8A%&ZNY1>FRH MK88N,ZJTZC\PN;6R?P1MEO=I;>EE\9U_/$R?6^@?IF22%ADHKR M@IE6KH=RW.:H'MRP;]H-_F/*CM[J/%+O0+8BRL=%BJ;E)&!,27U;$6

    4USPOUV<_PQ9=0]O+]HB56G8\>'>&;SPLU- MSZ/[Y=];.H%]9(1E%CA%`78@`0V-^RNHCD_X2+0\5SZF7+>=CA<=0'C02"'3 M^=QFDSB:O=3$S6(R/KF)'5?+/UU1FQ4.TL^1*W=6]E-E"9EFF9T4Z?+M]N6T M9]=`TOD#PS(M'$2:,&D!P MSP^XYH`SP;"'@P!Z=52&\-N_I=II=W4H?IVRX?&>:_Q\BG8>945BL]7=L'TI MTDQJB+`2!E#$G*5:!AK!Y23?@/+&.=#M5D'&=/FT4][T`FJW<^GXVF&=/C![ MU7NF5U^B['I]FMCVPD(JN!+(TY#+@+M1'OO`%SX.L`#&&*]=?I,Q707M=D;= M(9:=,N;)7(TGTPM[O9B5CKH_3XN2YVL&W`_173Q?S/=E4^L'A0[Y,GN="#R$ MR@-^#I7JC(HO-&N7#G!,=SP[9=I0.'>\!M@;[_9!(&#*-43?D`#X6D'*?%R' M`8B@EL=A.\_M-1:J]0=MI^0ZS^(T*](/4?;5EM?K^>UMEGZ+9E_BN3VW[L=I M>O4Q+5S7?&%7F7F*](O-YN4]_KUC\X,>%C*I`<`4!%2!`/H8,U,OCC$W-+0C MX`^[3CTDV)U2\O'.SE"\//R)H?`H5AXTOIL024V#`.N@GB0%J.59\S>_%CX: MQ#MEZ"HU2;I,2>)0?VAIT@F,)T[]+.Z)IUT]-_21E)HSX[DY%Y<>AD"Q"CL) M<,N\`S_6$O[KX]XI9TLETJL:*N.*I=_+%_S%65X\+B&62X/[TG(/T:@6< MN"@'!T#00/M,U..*PBTS?_ZPFP?]0;N=7&_W18P2^A!3HJ'V`/()--JKX:=^ MRQ\63``C.W.)#_HLTSYF<=;TH(]F;;7N:?GA=I0#9$0`<;0!X0QPNOI&U>T95Z%-[_#,!*\7YN;?X^O;P8E MY_,'AAB+@`!)*):$D``I7]9QLE*RW:N&X/^S=ZW-;>/(]A_=Q?OQ$<_95,TD MJ61FOZ(4F4FT(XN^HIP=WU]_04JD'5L2)0J$:,]FJA)/0I#LTX=`=Z/1_>KW M,:8"^,CTW+,Y7-6AS_)AMJPK*C^5XW)NGO.T$+]9;*%%D"O!$,0*LS;$P*$0 MPT+7\-7ODDP"[1S688[NC=Y;1J(5$[]"B;GV`G7G-KCC9.#2_)KW1T:$;]!4 MMHN!+[>;?U^+HIJM;FY;/M_M(N6'IJ;31@?E&.4(2^'J"K'$<*S:="NNC!@6 M[T"O?N]B%/32GES_>+^>?Y]5Q8>[QD5IW&%7ES2M#W?6/]XM=JOT@'C:>7T9O=@!@5W>N%+]YBZ7+N$,'<&!F=JNC> M:Z&ZHB)<*S+,%$.O>?=BVAJ8%OL[,9(PN;M;8%I)8K",2$@-C('"MCKC6/!A MY6/0:]ZER(=F#H9]*A:W7^[7U2Y?HCDQ<81"^RX/`G!***"80"YM!)%!U=DF M6`X[QXA>\WY"0KC2;D"-L2-ZXK8;,$QY)2!QQ%+N*-3MY&J0'IC)BU[SGD!V M4)]0*4-+A*:$TZ%&".UK#'OB[>UBVWA)K6ZZ.7>^R/VTX[T>+GMHO$5T!^OG M5>6R*8AVHV?+V6I>?/Y>/`G*9'WHQUG=!_-[L:FWW'.]P>=-_+W!/WZ.L^J[ M7Y;_R2;^3P\O;^_6Q??:=?K1="VYQDL\=B^[[M.O3H7/W^,;?"^7<1VHMFW9 MXN=YO*'/B.N>$Q(1)J"A'W##..68'DS49"6%$IZ7/+]$^MEDFZ2T M4FV_M^:HXJI9&'M:I1P;%[!WSCC&-3%:"E*G^)L6'"*&[HV>38V3ZEA>JM]# M-$D`3`YG\=EK]K;!V'M]<%10Q)E2G#D6366N,7HBEYU>MCN@/+TL`*TT!A(YZ)AWB`ME22L%UC9;\?[3&I]7J\Z:<_]FKTQ?7!B,\8=`+2(&C2D-K+>[DD6!@._:Q%#M,%65: M$'(H];'OP,?9XN;=RLSN%IO9LE?!1\<%:BF%7GH'%#7:<"\P;>4$>F"*4/)M MJ:3*3@E(GB!^75&DN'&S]2KZO8=+3AX?$!1B"@)CK3`>$V_KI,Y6,B/0,"\M M^5Y/4E4G02++QSV?W]_6IUF+FR9MZ*=HU+:3;O^'?NH]@@94.0OJYN4*8XXA M8[:5GU(VS#I+OJ.3]J,?"9P M&SQ3P@`B`'9Q1536$]W*PRD$$^GK-;JVG@?T+L0IB]Y?2![16=[7;_NQ7#<: MV6S6BR_WFSJV^7MY?$]E;[@WQ0,"HU+4G3V$,4ISK.H^>BURRIEAAPA'6W^R M,>P:X&8[B;#'YJHW6M\7FP]??Y_]=81TIPP/5%.$@4>8H+B&&\VB7=]*S>#` MZB6C^3>Y*#4"=%DBDNORZV+S=!]^7SRRNRA@J!`V(-KGQFHM&9&\M=JY)VA8 M'&,TER:7\@<#E&VI>E=5]\6-O5_74UR3$;5=9=WMW;)\*`I=K*)F-A^7LZ,= MV<^\53#&12M?0JVMX!+7_D,;T.?0X6$'#9*GJUUE^1D/QBN2ZE^SY7V1A%.' M[A28J+>%+/5",2-D=$QU&U3B;FC-[N1'U"="J40HYHF[__M^6W:U^KT\$#MN MOI`OLR:AZ?8N+K--&E63TUDM-L7G8OUC,=]E?'XJYN6WK:(;%(Z&[L=]=$!" M>.(X0\@`B1U%B':&HO5BF)^7_.!Z;LY.#/;KA1A;P'U4Q9X#$6?''GON%VK; MDPI11]VPB>N)E:B-O7$$\+`=BN3'U7/3,0>6HR2/VW)^ORL$ZU:;QIG]6JYO M?^).PJ32=I,G?G3-UYGA$<=SQ$=>ER*D-XOE?9V9_[F8Q\6UKDC@_JKC!<5- M38MZ9KK?-'!_^/K\U7\](7$UU2,"HP:2:!H*"2BB6CE-`#>24^LPT+@WI6`D M6[$["'*AH+WILDD?%%A=O=93AAURTCNAD,8MFO';SI53>33=-C]UGAN>U\1\ MLDF^%V*A'_;?H"=%>,2G!N@DUE01AB6E$`O*A&@5H^!`3W[L!.,K57GIS?PZ."5Q`"R3$QEF&O//`<-/*)ZF? M6-IV.G4]S\Q/!%">!-!JLU[,FR.2IZ1T[[T^8,`\8!)9I)'3C&L`NR_&6`8' M*7ZT'??1%)\"G.NM)"=/G@?[MB6]?^`..Z4@``9#H;7RWG:F)X%D8HE"5W=* MKP'Z**&]O8[(&(?6_6RQ;H+FOQ6SZGY=_%2K<.SG7#.\U[W0ME"D6MVTA88B M8W8O>?-A]:EF4;VOMCT?OV[_5\^JQ6/UDB/S0-+G!*:Q4)(9K@VM:Y6HNL@6 MMDX0J92TO9U`IXME7XPOV3."P0@(9S36-BYNQ-GX3>\P9!2S7%FW1\-[5V)- M.0W,)QO>^]=LO:CE:3>)FFV7B(5^,,M952V^+N;MTM)LR/3$[8;<+G@ME%=0 MR";G&B,"9`LEKX_13C$@=P4BE=FASG+R]-G+[A7KH3<68N4GU/[7_;A>W,[6#]O4 MM/DB_M@;=CGO1D'KZ,9IIJ%AW&"-D<"H1<)(FVN=/-%U'D?)IRR"J1#,P:7. MCM`/C271H-9C9!T<$Q3T@AA#-%<>6"\H(K"#,?K[F2)VK\R22H5G5KYLT=J# M3P/('ZOR2U6L?VR_C;O[39U1N)I'5)NO\:F@O0O?6(\,B@,OK>184`\4H9IC MV:++K='3-<,2,.:X8WIMD/]+Y;0H3\[>>T,,SL_7!L\LLAQI;QGBFN$C,>VE8=J3S,9A*^5.9<"FN^@]);+/UG.IY#E MT+B`*;>"`P6XT(A3HRE2W8<`V+!MVM&.1D^3.(G`S4:B^MC(0!X=&1J@$H(Z M2;#0"B(FC'==E(B#@;6>1SMH/4TJIB1-G<*#-."]9CI,QOE^12Q(H'V]*-5?Y:J(?U;S1;&:%]6[ MU?R@/=$[)B#&J!.*>U?W2I8&:-&],R:T-U4HCQL\CAK*<4#*85O:8KWXT0#Q M;E5MULT!WT^+ZL^>78YCPP)1C"H(&"(.20JB=*CUT^L4H&'NR?DVY2NQ$T:` M-"]QZC9;Z]E\\WM\=F^0]]BPP`%S%AF(F?(22\0Q]JV42$VYV40:Y1UD1#*L MWBHS)F-%3)<05]A#*M?%XMO*_35ONOON"F?TQBR.#0L(,\(!10YZC@@C'EG6 M2ND-FE@-VS0*>[Z7DPZ?S$D43Y+Q_;KXW_MH'?7EK)XP.K#ZS`:&'&LN$.+" M0=INBDF,Y;#4F_.KO[TR>R,]LEG9M.^=3]]B/CPZ*$<$D]09C[G23EMF>2NS MIII,UPA)JM%#;$F.W-^#-9,S4*9.EFF0I.HFX'ZSY83A@5+,*>>6`^;@^]'!6L]L)32;B% MBB*F$,2BE3&N^;FJO%U@!B70WR&67(S7M3B!!G$"M:W@"'?0,$L8]UYP8Z'I M<&,8#MLU&C\;,CLGAN%U+4[@09S8C0HDSK-.*:\4H[7%KSSIG`L&Z;!Y8OQ$ MQ^R<&(97#DZ\6_THML77Z\AWCV_T\N+`#!"&>D4T-1II*)'J9C[-T+#8[ODE M[5^9'W0QD/FI86:;XENY7OS?[*2*>/V#@Y,@@,```@3IS#3L#I^O= M7**^HTQ(B-/?@2&3FW1G%9?JB:] MY@@%>L<&"R'F2EAAK:V;.3%*=4=S[R:66S2-FGVI4A/I_/,2,AEL7N M;"RDVB5_7!N/69U[+H\V%>46`5VW9Z6>,V:L[V93/3!S<;R"W:/Q(`$X&9-7 MM\>$YP\U;?VR_,\_BYMOQ6-:I]IT$+TOCJT^0VX7B+(`&&^4\(I:1C'N#H\J M&B?I:=DGXU$F`WA7M5Z&6"T!TSA)>J\I-5`CSI'ISA(IKOS$3FZ/1XY4"&69 M5!:KV:HVLY^8:N?QX<0[!.`%UIP+R8'#D$9P1<=^P=RPL]JC=<0><>H8!:]! M1R[WET,TY:HJEXN;Z,Y%VVB]?JA-]:8Q0#W-S5X83'NXD?#N06)+"<'QEU:, M"6F;]F-;'.(W-"PREJLF368?Z'JXYYBK?BUGJ^KC[*$6[KPYJF=D\!`SZ*VA M#&EKG'70M,4VE#-@6#VV7.5KKN1GI\7T"7_2-1'9N_T]6B>1VOB+\(YWYVMV M"WDT:G\]H>?'GJN#@)P21SRC3AJM/1-,6T0H8'&E`[37VQQ;KK[^&\^N#)@! M324$EF%K.(=0`K23QV*%#A[U'"+_;*H=+;IOJXK^7!.Y[DD) MV3\@6.(]J!NZ86ZTH)AP)"(KJU?Y%"+TU'DPN96,JZL^O]O8= MBQM5[5[[L19"[X[M":.#0(`AB**#1+%QTGJJ:Q`%)D0P0X;%1T?;6KE<=2]L MA-0093Y!EZ"I`C(&<:(=LYX3@*'"1+2+*&1V&`5&;JJ0RA!(A4I6K;^!>O*: M1PTI30U7`'N#@92N1==@Q:=KBR1@3*["\L-`_B^5TZ(\.7/J#3$X/W-SMT8@ MWEKEH=.8$Z>=4P2V*G$,@XFEV5Z?",-;(YR'=`ZNC5/YWC-BF-7&Z2@;\0X) MSEHYA4?##H2]OI8)0QF5$MQL)!K<7P,3ICV17!`B`51`2*([>8C_N[1)N(@L M%P":C2`CM48P'F#AE!7`"(4U8SJZ:#MIX\SUR4X14`8@+@#A=G54Q_Y]OY8]_S'J++]^Z"6R]WK1<8==+".71X`T5AHHQ&C\7>O);&FE4@2QJ;K MYP]33#D:)F]!VY-SA:^GY,S*=7]\.J;,^,]!`\PY!5XI&1<5A2(8M'UCIT"V M;:'C:W4:T)]K\'SY1]?8+_KC,8W%?PZ2>$V@]T;J:%P@;97LG`W@_;""FT6T@T!VZZ-F\:Y9W3<6$85F^5&9.SCZ='B"OL58[0@L-@2SBEW!OFL9&, M"-U!Q^74&EZG4=@Y+3C.P^=:=D+U2P3@U[*J],,N=^A3L6QB@-7WQ=T`"Z+_ MA@$P0PFPTAGDK?)8`DTZ9,3`W9N1&W6,:5LDARQC-N?3-STUG?/EF.#J-$BM MC)74$B.I5K*33S,^X1C;V`K=G_B9#,*W1Y5788!,DB%7V&EYZ\/ MUEN-.(A"48&1-1[Z-H;BC;3##A*.G?][B7[VE%2Y%)7S(TN+I@Y5K6N\^[G6 M,GZBY>W?/N'_^[*6>+;<'H'=H^>>$8%JJ.)WP+&,QI76L*YZW,K$G)R8IE,< M!$N+R%0KIIQ0M^N2VP8>+7%"D<;<"4PM-`1VJ'LKACFMH^4+I3Q`F!&V:Y.K M25EX(LE`,CV_32`F&OH<$&4\4]Y0:%F;H.`I-1.;=/(H_`R678CGM5G5)JP\ M7,ZL?;<*PBNM"#=.>NN$L@"Z-F738V`G-C5-CET),,V2H/;U:_P*-LVYKPZE M;2&)_J6O?W"0!`.E+1<>,"1(_$WC5F)(!YY_&BW',>4"EQR'!P*`Y8H[8(36"#@):6<91L<23&O92JG&@R&W9&@=Y\B!PD_/'MF] MS"_KLJJV^9;E,CJ%Q3I:][LD_\_%)B*COD4(J\WCA=7G^R__+N:;W\M'W-SJ M:[F>%W5T\K=9%>_R?OOW:KVN@]-UU.'#^O/B=K&:?8K:@G3:?;2X.TQ#(K#8:0,*OJ M3NJ=7CS`PZK,C+::9IDZ!R%S!3V_+S=;/#Z6R\7\P2TCO>LC]L7-??/#Z33H MNU,@G#G/B7=08,%E_,]T%HN4?-@".]K!@'PL20S<5.RQ;.U`%%2!<$1C-8X.ID'3GSD#@B<6#B#9:$<\K6W(IH;R69_CDD,Q`]W#/ M'0(@!GN+A$*(16-7(HMA*[N4>EBD8;3Y:FP?\7*$)C`Q==&/X?-/=XO@/2%& M0T&=!AAQ8;P"K?30S/?O,':25F1DN# MN-(`4`)X^S4:*X=5VIW4!CV%Z&2C=5ZM]V$3!0V^9<)(+P6DTYK5!OJ%0(3$LCW2D M4NY3,*Z:$+UB_$+P>P1JW_HW^JXE84]6R9O&!T&1%8@X:R*\.FZ8'H,69R*F M*BK7*XDD-X^K_``.\EMT$KHW#>`MPP/S5$AIJ(\J'>)<`Y(:U-Y3`CDR\TL> MR<2I/G(P#GCO61RF%X,]"2+O2`I&X/ZGHHY@?%ZLRO6BW$35;6^VQZ''@^.6 M>,H(=Y9#1J!WWC0K)T8$ MBSDD5@/,HN6./-(>MT`IC(>Y/_+P?AKE<5S`1MW4?[_V=97J_2W2@GRYUW+H M/4&@3"&/F<78QJW/6^GB1OA`#0=X6,;YZ%[[J6V'7/A-L37\GAKD55_7J_\M MEU%Z'\3VD#]]SXB@(-36<2?=$X M8R_*350L5^NO":"SXGI35I?J^OIJM=BU!=\6VYMM_-/9ZOMJ>Y\K6:R7G\OM M]MY*W?RYVGZ+\Z9;I)OMM^J^A[C;;%??4S.4U?K7:-'ZU6917/VK+/8J&O-: M9=#4PGCL$^0(DCSNWPRI5AE`S[O>G\K%/_4F]ZZ9E,5S^V&]C2BO(G5M0])? MJFKYY^K1GS6JIW7OVT[9(//#^H&8\BP*WO+Y*O7=Q^+?5;TK8WS(3WO,=,%2 M`;U0C'B)%&/02R@I%%H@`53<2=_JJ1T'F<=OLX.HK@Z<;YLH6,-$_"P$=X`: MI!F)WWJ#!L1FJJR3@PTZ\[*YFA"_#'[=.7;W4A)2Q@F)B",JK:3,N`:4"-)4 M&;AO*AB4B^^]FW^]#;1)TFQ_HHY)BD`MA2+*62$44@0`UJ#+K0/S\SF/*#%3 MM4X:!O+_B_*X*,_&7_X32O`IO+'-:73UVFG468*IU_B@G4E-A#QSWEMGO2"P M/['_ASQT?Y"F$ZW^*>G6/SK:LR\W6K;<[2UK?[5!9749[ M/$%U?KG[EZX.*T.F"\PYCHC$0"#I"5#,"-J@(NQDO<'FJ"Q.@..>+?95 MLNXZ#]2W3!,(YDQKXB$6-/[HJ=*B00$(C>:K[^5E^O-2=/DQ_;M*V.S4L/K.*/G>K7VR8*@CCJA').06XY0:EA7X,$HVZJ(,N> M>E@>)OX.G`+29SD[K,JE%.`.<< M)*>$%!)Q!AQ2(-)$.6J_'L30#/U7F3@U)%IN&'CO61QFHWR\(RF83\PDEDI3 M#G6X/>)F7P;/H,XJ5>5^JM:E_'_F[[L/#0F M>,6`E1@Y[B2)RW1"^Q8`:(85A5IR."-$FYEY0WWZ')'%#_^PP/REN. MB?"I`0TR"DJA6G%6:+H6IOV4_DEOXS/@-V@[>-T(,=5Z4UVMEBGFR!1U?9?B MD78II!_6G^HJBO;FHMR4\8W?BO72EK?E576=/J!G).S;4/*^-<1/E".D)1=4 M"*(@4*J]?9%&#I.[;%4U)I&[^<$^Z>WH[I9D8U>;1:+K(I+:YX+SY:B@621* M:1EU-FLMBF>RYJT5CODPIWZV@AF3;FGCP3:%:#R/47Q%#II'@O'2:!+/:899 MZI]&`2`/JX=`=N=`3UOM8E*F#\0H4R3J;=R5JGJ5*<>_G?U'5U#[Q\/AIR.] M.5M]A+-J_?6WLOY^_N5J]?4^,'F:M_AB_6E5UF=EL1E:/&&<#2$>===EO;W[ M=%5$BV"]=/^Y6>V.N;,>`;O=@X,75`MJ;0K-U@8S;(CC1L?C,EH9J+M=6.[P MW+TD]`_,/3Q%L!):2(@5%&EG1"I_"1L$M$-3F0,'0W+'9.3>`-Q1<9IMZ.U> M*O5=:GG:$7+18W1P#$EEN8&6<6:4)33]=@^4U7XJ9^'`:X2QI*#*#=P4ZMA^ M,/HTBNXQ.D2C1`O@F5<.8*Z=,%PW-!.*_/PN&K)PM*^T'(WKJV6?IIY/'PR&,^2]AS3:,R+EK',O&TJ$1,-J8V;S7H[*FVI$8`:Y M)7?F0.N6__4FO??\\MY(V.=4/#0F:(HDHP;',Q4*1ITE$K2G*1+\G3!SN!8Z M-D13?+FJ+HOSRXNRN'*;;;$M&U@.?,/[AD2\A-(:,D15DG8-E#4M7H8-$X!L M/N&,9LA("(WP66\:`6SVEYZ?]LMQ@3NNC,$TKIY8)YP@L#W1*-'#DM6SN66G M^;R/AFD0B\^O[]L"[]P\ET]7M(^]A\8$;X!`3E*K-=<0I>)SM%TS%L.Z`61S MON9B[8@0G50Q__5@/\%#PX*20@"A*7&0>R4`0$0T5!HX4!"R5?[-N(./B-+` M4+#U9EO?U[N(D!;K1=QSJEB?\B[`EE^V'W:H]KT`V#,B MQ`U9.$<-9!%7IZRDD@CHL8Q&%*>P4T2GH*_+P?_*T\$JBE*SM*@S$LRD8,RC M![JHDG`6OORC>?*BV/JQ.,S65__YYLNF_,]-?)6[??`9=/CG]XP(5*4,4Q@W M,2.8-!$4I@4"%BN86FY/E7#[)I_\48Q]?LLS"BY3Z&BOK+339;IW3#`6(LN9 M%QI+2A&7A#;T)7?3#./X1^-8MP0/PN%]\G1V1^VTK)R>A1\CG-]OOG#QX@'"IL[P% MOI5N+J9*%#C9T7DT)-,SN;N,RBN/!YF*1O.HTCE.)`"28=.?,5AT MD-M'(?.S\'UV)^^IV7T"TS95S2N7:5OK-FN?/QL(H`QKRH%V2D%AF*:LH2=B M,UGH7\^2-4>QY+DU>R084S`W71UMR_I[6F0/?_5KCP2@M0==U'.& M73.\/0;L9`?VD8!,S=[.C?KEPP%J8B%Q*NJ8G@/I,!.@H8AI3N9[2`]GS@$N M'X7*S\#OV1W*IV3S272O9;7>58SY4JS_.+^\+*-EF)9\]D&?7W0>T+W&AZC0 M$&4THL0"K3P!6,DF)$L+.+/RL,PDM@8BBP7F+77(Z9GE9N6-*AP,RR1[023V_/*II^EC\5>ZQ]%575=_ MKM9?37$=_^5@CM9;I@D2$X$(E`P"#RSG,NK##0I0#J!?:;($`)H;>,*$&8 M5U%YQZ`Q%!@3:IBEDRUG+:^`C`32H"3&IRNY**^;-52WJ^0&N%_;^6U9__/; M:O'M4]S_XC_OZEM6E\V&^+#P*.:V3%[]*[_=5_;GX<1EG!S)QQYHZ:(FXIQIB M+!604!FHH<;6:68)=;3SA,Z.PKY\W3&F#.N1XS4*NIH6+.&>DS=9(VZ M7DWLG9[%U& M/H)IL9C?S?-E2NCPG,-`ROKU,CP#)Y?AX/ MNQZ,/S`N`"",L%8*DDHA0T.)-`V=4IAA:;S9[I\S"* M3ZX51J!%D-M!Z87Y6F-F>]T'QFE02?\[__X_(]?JMNR M7B>*/E^GCG=UN73I`N"Z7NTZ#_THK?:F_.=J^VVU/E^7_RJ+_>?!B+,'J&G\ MV(Q$0D'`4H)>M.P;'`"860F=\=A:G1K*$R@8OU;;#^O%U-$F(BKD$7"&J M(%%$:4"\;JC"R`T[LK)I,'DVH9R(C2P'ZC)NC`_K^>U;7=U\_>97M[M?N^S7 M(^8,"EK@(:#&"68E\,8XW-`,A1P69YDM.&YJ*1D=P,%>C>=^OKU./M7<=YMJ ML[].]^`90S0BHMI(#(240&^AXY`W]'+/9U)+X;3WBY/!.[HXO?BN?JFKS>;W M=5T65VF-OQQPM!\[;XB6J1"6$D0IB$8EXC)"\4`[$0.S1_(86;,4K0P@YQ>P MQ^6=Q<7N5CR*@+TR;P`P'@*$6J(@(H1&X]?Z5M'3?IB`C:X2O2,!.Q[DT03L M$"1M/_.W2%:O"8,W&G#KK4<$`T8)TX:V&$<0YJ$_S4^DMM[=Y]MO M9:WJ.F5A[#QV4[PC7[OS3W6UO%EL+\K;WT5V9A.S^)Y$Y@0Q"\UJHQ'T6UTLRXMR448C*=D7 MW5$+G8,#I()98#1V@EH:#7,JFWU;:J0GJY/8MQK/F$Q\'KTP-EJ#7!<7Y9=B M6V[,MZ+^&G]<_)$H;%+3.BYZ^HP-F"#+,-WY7)16E%,.6P41N6&Z2+;KX"P< MSP76U!M"\HIL+LKM3=VC?.;A@4%!Z+BDVJ2@+TXU4$PWE'JC9W8;/-E&<#12 M`V^!KXN[CQ'-^T:I#Z+:=E;]8L#!\6?)[M%C?? M1S\B2%-\[!^KV_*^*LMA2"ZJJZLHK'\6]6LU"8Z8+3@OL5$>.`,X=`@#9%M, MD/!3I=F]67!RNTOR8WEZ0T075^E/@RV1A_%!LT@VY(+$#XM;H*%TN-6:A)I9 MT;^LG'V343(,OT$'SN&%M#4V]IT]/8<'"U(+<@.]A-`HK@A!#25.LO,F\L,<`7I,I0*"&(\`EDQS1!OZ,9`STU'GLY$, MQS##9K+3J._+7&[.ZZ8@C[FIZ_+5NC;'3ADL%``2JU%<)R7:KXDNJS9JG(,^^5YWRQOK)FE(, MXJ.8]+FD[C,\2(:D40C\A M]%-4^;MZ=K_V?."2HJ@#>L(E\AYRCH!HP,#4324Y;[IBSL+LYRV$1T!K"DWZ MQ3H[KP'WC`@$&0(X%HXQ;ATF6D+4T):J',[WUOA(7G5Q_BA\?BX9F-WM[SQ8 M/X+Q\U]1)8O'YY,5'';<[Q\1$(*,*<8IU0(KJ(!2CYN>%E.%J/7M%7XLZE4. M5`9QT1?K3ZNR3L;88>:]>#`@B!`FT;[F.)IA`E+_>%!%^VQF72Q&Y=FQ8`QB MU5E9;,K?ROJUY@!/'PA19K"4C,1)=!0>)P0S[7;B[2"M9GE^>;E:E)^OBT7YT/7DL?'`[YO]M;9'FCY([.*&8HVA M@#"&"'+6M4!B,4PVIOEL1Y6-T^"91[)^O4DH5IN`X&N&B+VUX,YHEP$S4-QHD# MQ^G1:21PF*3=H1NY&><%)V/=1@D>H3 MLJEG)(MXM!G#AZ^/T^+U;1KD+G;L>#PX@*`6E#GE%5><8<$S0"C.JF79B<'B MS,/IO!]\JNRE6C:S%'N8S=U]JG7S<;FX:Y9["YKM>B5P9:(Q2J"P3.$H9327 M;);.85AV#>!@U6`&C>'UA%&Y-?AF%/V'NKA8/LSF>8M?JDZSUV1LW4HPU'BJ MI'<80Q>G**M87NL0,++,31NLT,O`=N50L`V213J0;WDQ)YU1PD4I'6U_"[5& M'%F2JEU(`9FFT>G#[O#Q@+-)N!`%)$4:(Z0X0MY0";1BY(BMEC?K%KQOC7K+A,MQJ-1.N'#)).94<>`,,P1*#D0>G9)V9)N* M>]595S!JS+'KZV3:?9V'7@F2$XR%1]$9E4Y)99FSVM7ZA.18LCN1`\%`)A MXXGDU&`A!+>PE!.BBHQ:Z/Q*:&@K/&\>CN,]&O$?INUX)DH#H@3H) MHF2>I5MTC<_2.2K**F[46>=[5'Q/\'1/N&YE^M2L5O.G.]37=R;/!R^`$AI$6\H[9BW5F)&M5%0@599\J9-V'6H]*(.F:H)E[V&=Z:=7,*66 M<6<<90A+S9W%.=.IF3D\29U+>D4!"H0"2/-T5X.B!J03JQLJ:WZL:57%&+1 M[,3*(F$1P1H(F8\#:&Y=F0M?/;W2&O66Z97C4*F=7M'$>*\4<$`XA#0`T3?) MHX-$EWUZU=,K13KK"L;4TBO*JNF=8 M:BA]AZ&Y]5KTCW1;[H>OR=K\'#T`'0?QG^,=NGVM!0V1XX"DLT-4,\TP\(\K M&25ZBD>I>G;Q>H1OD,C,IU4O+8-R?Z?^]7&VRM[]3 MWF_RZ=MLV;P:V$\%4/2/IT>VX7>5@G5MHD7=&X]K#O:SF4/F/GQ\+B$.&(*04"*I<@ISZ+#HFJ)9S4QBQJJ;X ME_G,<@BK)+"WPSL8N7C^8."`&L:M],"S"`HVVN$L"3<8CS=H5::0'5KMA,:4 M]3NZ@-0IU-I#X&)M-^=8`"V$$*L533IN8-.*Y+' M[`RME5=HZ;B4`KX8!HX:7^0_;Z/+T'Q*!T?3$O-;TD!">_]*O.>MX*`20`.H MK-/44$2@TEL9E0*P5@1K8@MS?XB>D#4'I_6][P5$M50>4YB^$:V%ET!LY=2& M$3[>5;P7[;5C1">LSI<;H[,`QD>)DV0DF]C/MU3JI_G>S!=W:=C;(-3!P'F+ MMX,D:?>V,A)[HI%SBHJ\H&IN[DO]?IRIYQ*K,=FWE\Z.H?S6VSG,U3 M1>G+FXCM_6H9A?S>'-+ZT6T$YJ5'QA%I.,5QI8T&5`Z_&`E,F6TY6*JL7]T/ MC5:-V6%C-?TX6/7UV7/!28LLCV:65$@B[PQB)LL!<;6LV<3,RRX85DFQ%>/R M)-GM9>OPPA#=!8H=AU89`S2!\;.-^+(<#M;2PO&:KX7L>!G6'@^H?U&V'W1' M9U5/F*GU&>IN[N:+'TVS#DEMXE$'C>Z=[P1%N?6,>J M[.[-P:SP4=!B(&P[L6/=^<>'Z$9&P9-\[9BQX[4X["P>UO;](*60#(JX=,?^@0,.L>SS M6HC-R(Z6GV"_R)!P5K.0OQR&[,M+R'Y^/.WD@X?LXEXZ"0`Z0PB1J40M,`@: MKW.^SWE66+:Y=T(.Q(JW3.13P%K5,&Z6W].]Z@?`3%M-+Q97M]?_BZ(VR^O% MYF29F=U=KV;S]%=UDZY9;6-6]]MC8$2Z5)!;"8`$]5V^_W&'J]M1V4T8)@X2@QEEG)/.5HBU=$4I=%%4[G M/@ZW:;@VU*.AYOO%[??H(S<;7^O^\R+.SB^-C/>+U;^;U=-\WI6R)7T&%<$D M$6-.)8(02D&EROAB-K;R817Y5,+D"AJ8-,,W%LOZ6JKUG])S^]RDN@,)5E-% MH*(4,@`XPBHNNFM-:`"88&7[,@:;UL_P6^A#+:/(HNU:47/=&W5YN19N-E\_ M=Z\>5M\6RP.+P("]!F:<@H9'3U=SIA3RD0P98Z_HR&Y,.^4QJ-$HH?Z)SY-6 M/!G[$4RJ%:1.Z)3$!3[5*F)QEO)8&L8].7P9T4"H3>H(IF3`$:P48`9SS2W' MR&PQ9`[:6MG:H8]@MJ;*8$@O"08>(84[9Z-@"[1A3&5-O)!WOYL*3,JP_MO>L MF;]8WP>VH]N?^*N3O8\=2:_Z3M=JV\5\/EO>0_%.XM5B^QL"[P`XL%&IJ+7` M&3744<*U1BF`XW4J&K*14RM/:A&OBQ-?2=.+VFCWQ*JO3R-+8X&/(R,EK&K3 M6A`$"82H%0!H'`TT;7#V5B*H38RUI%5.UL+WG+#D'10 M822UI,[&96$K)Y9T$GLMQ\:JOM#NGU7LV M93D!!",K]#`-5O6%=O^L$L]&!D%'6NUN+@CD-!31@I7*<IHL!G28GC90?Y MZ:_-J][@[I]8Z\'\-+8BD[U=>X%BRPA@U@(B,31""/]H1@I/#E[=^":UV*]- MK?[P'L`9?&[[04S>,=G%'=S=7O"..22X)XA82XUDWL*<:+`(E!E9_!?DUB!X M3RZ:]MOBO\UR\]/US?6^+99#=ANH!4@["XD&@BBI+>9Y=>"(X%HYDWI[%8KS MA>/1PN2X_L?=W2FX_J+;X#VQ7B`2T:;0*N(,$AEEA=!(CDJ<&]>[:6%R7,]; MDSX\K.Y7L]O+Z]NKS?,#9<./&4&(?J2"%C*()-.1&=[!QS4525&631GSSK11 M?`&]*>1T1S8+)7\M\;^:ZZMO:2/K]V8YNVI^;Q(3UD4B;M?[:!]F\\_-\@8= M^EA./\(@G5+1GTZ'N2%G0B(CLO/#4^G7*<3'ZGU,DU/8^7ULSU[1S=7U;8)) MSV)S%\WQ)ZQ/,\Q@K#<6$>T($5+'25-Q\V@_"#V)\.$9?G:]:FVR5M_V/VE# MWHFLOMI:.B;*&J'!6=KM7762&36XA>2[QOKJBV M\!PYK&`88##11S&%/->($YFU9(0N"XU5#OA.;Z$95DOUS_FL-V?O*K2V'LK? M_Y;^E?"+O_P?4$L#!!0````(``.#7D=CA##;3<\```.""@`5`!P`=G)T>"TR M,#$U,#DS,%]L86(N>&UL550)``/ET3-6Y=$S5G5X"P`!!"4.```$.0$``.Q= M:V_D.';]'B#_@>D!DEG`GM;[,9G9A41120.][48_=A<8!`591=O:*4M>2>6V M]]>'I*1ZN:I,2J2D#O)ENERC$L\]ESSW\OW+GY[N5^`1EU56Y+^^T7_2W@"< MI\4RRV]_??/U\V7P&;Y[]^9/?_S7?_GEWRXO_Q9^>@^B(EW?X[P&L,1)C9?@ M6U;?@;\N_#7HOP]>TPN+]M?@>;3*LM__YG^YSJI,'BJLI^K]`[? M)^^+-*E9\7=U_?#SV[??OGW[Z>FZ7/U4E+=O#4TSWVY^=?()^M=E]]@E_>I2 M-RY-_:>G:OD&$"/SBI7-44CW^-.+Y[^9[&G=]_VW[/]N'JVR8P^2U^IO__;G M]Y^9G9=97M5)GN(WA`T`&C[*8H4_X1M`__WZZ=U)>/Y;^L3;'-]2RC_B,BN6 MG^NDK-\GUWA%<+"WW97XYO@K5F6Y]P9*D4\ITAU*T0^OO+A^?L"_OJFR^X<5 MX>?M$`-Z(*Y?HE4&C]'PH0_*<[P>OE`VX"^D!6.YD%^^4C;HIK*A?*FB#A^^ M5C9XN9C55HZB3E:2*\>+5YX&O:*/O2>?VB?IZ\_(,"N]%=>=-^.G&N=+O&S$ M<^_=(%O^^H9\6JRKR]LD>5B@I,Q)`*M(3?A\EY0XN*[J,DGKA89\W]4CSPPC M9%J>%NFVZ4+?M$U>@X9+5)YC#8$K6@J491=_=NK)4&9@J)X:N;(*^S9;9: MU]DC_HS3=9G5&:[04[I:DV88$]-A:;"=-:"X`;OV@*U!H+.H2:MW M;*(_.M;BF65GFOLL7,ZGL3/VMI@R3^)H);HNUR5GHL%$OI])#)G*^F(6#5`P M7@W$%CX??T'PE%4+'?EF:`>68_JVK9N>[7A>!SD@?XL$KREQ*HYDDD3M`EP_ MGQ3(WZBAHH%MTKK!%^6^EVHA%O+Z>E%)U%)(\9D0-@?'SB2>S8**8G[M3DJD M^Y#Q-%+>JH?N'5?&,\>>Z M2'^_>J!R^V=\?XW+A>OID>;K)D218\0HUJ`+NP)].PY%Y*Q_*:I'@2@@4#!$ ME:!<#:".UJ#;U9)9/E]23*J9)6SRM*DTD1T=Y.2-%PWB< MB0P--**06;7&';M\G^7X78WOJX5C0]V"T/5\S3;L,$"AI77XM-`,1ARHY`?U M?8Q*CCOD*.#24<87U7A3SF"B\)P9-08P:^;1@17W@KKQ1G%'ST3^Q[=;[DAB M7^+'"C+!?;'.ZX6+3!0$NJ9!4_?",(CC:#-[9^F6,V*$X40T9GBIMJJ$]U0I MW5?*K^,&ZHX77L*'%&@4\G"3(7H+'D^XHO#69UP470 MN_\W(HNHT7+#2B_*N6/*?Q7%\ENV6@7Y\EU>DW:47:]P4%6XKJ*L2E=%M=Y9 MJ1B[>NC",`RM$.I(-[T`:C:!XQF&'NL^XI08N86JDY(.)QM,V2(%#52PQ3K= M`ETA*L_H@AJ7S*3]*S*N&*-6JVC/7_!3'1*"?E^$+M)1&-B!#TG15D30>!V* M$/J62#(HN6C%6=_+YDP;>6>#8`(GFW6),JJ&<&4Z2N$"AG>62KIA]+2'M;U$=.^)(K-*JW3FN1L^2V!\@FOZ):I("6Y7+-*J)-S:!EZX%JZ'EBZ MBRPKLGS(`)#B`\_B74\BKT#%DP]D(=^.`U,C_2DSCB)?-ZT.BP9#5WB>6#8`QA'62CJ.8.)Y1_$>#ACJ%- M@:9KVY'M>Y[N.KX?F'[H-'IO:$Y@A%!H$6#O4A0+Z>!9YP'\\'1 M;9&3R=U)ALXM!1S,ZDR$2X(AKVQ[[TL-MP1%N,P>$SK:_BZGPD@/.*J(+/XW M7MY2@3PBBSNC3[I-"+?"!W'MJUF5(ZDJ7;@19R-3"4$=&0ONVQL*D>EO$ MSID),*GN0+PJOFWT9*<&]#[J0K'+^!1_CMX24_]=1W4VM&L@*OK=CAE@)U)L M#&E/L@#3)6Z2?'`F,HSMY9E$B='-/GE^Q9BT]X@><5'B[#9'3^D=:5H8%CD+ M6]7GFG3(J$XTD,W-:_W!RVE\78&,,>[`S9Q-6YA15AON#*[2, MZ/;9Q9"9"MNF3 MSI+5E8M"@VMQM[3"%$>$'8A@BY$S`LAC]+RJ3T)FWV&?71Z%A%<1M'*V M,G9>%.]!XZ;Z):?@IBC!60_PQSM*!(MB&C&-Q3!>:H[$)>FL3AQKY-M3**I^ MHKN"TI3VA4AY'XM5ENXNL3#LR'9$V MCPTHT*&:;ASZ-$/GMF(,IW4F^9L,2PXW3<@BA[L=796W29[]DPDZ2?DJ4NR2 M_1$F549:]4=2&3O!#]=5EN.JBG"5EAD[WB+(ER\Q;QN_X1ANC"+?#SPM0K9A MN;'=@?9LWQ3IUD^+5'%6QVR@?<%=*]@Y9=@*->)U^W]H$=`T_5A2F7#"CUV9D0,H^Z,I,H-!,RBCDV9\%8"(O[^ZSN M)F;I``@I'>?I\4E9DT3C*#(MUX$!@DZH.UK4)+80N8C[+$6YA:H3LAV<3(OV MD,YB6800DV?D18U'9B(7BHPKQJC4O0]'HS/P%`?Y!_UC3;JL*XIL@<+("W0; M.IKC62C4C1BBKES;L(7N]AAAX[JNZ3@&BGEG9*44IG"J=7<* M=1?A?X`&XW29"!=UYV9%I5(_D]8HV:C#>4P%E(FWR^:F&%_S##N*G0AZT'?= MP$`FZDJAR[Z%%K.(O5KUT3P"(P88W-3 M$D'TIR2C#PGBVM!($3WTJ,A9QXA>M6'&"$'DN*$%0]^C>X-UV!5J>5#L>L%! M)8VE'!===-[BZWMJ>_].SWIXY,B M]7,U$,?IA+R14EAZSL$6^>WL%]&++T6-/ MMS5D!Z$>1?00V+8@7Q.Z'4+\[8J5H@'4#&`*RD$/IOCGI-61)#[OW/$SE3R\ MX..5V>-^W,U$*`88<&06>`@5_(N!E\NLV2'Y,9.B-%B2Q),N9PP;5$B@06IM2D?X67W1E!;6F!X02Z!J/(@[%I MQ9%O!9O2H&<('L?8JPC5`I6FZ_MU<]Y?A&^R-#MST814ZO@D:036Q+2H`[2] MJ6.RF_F.,7-V++%N1`(I(ENDNM9V5=_ADH[OE/@.YQ4[A"@M M[G$+(-3L`$6:[WM68)JNJ3M.U`&P;4=H@%=>J2.*$4,*]J""!BOX\7U1B5]M M)(]ZSF1J$M8%$ZLK^`X$=5UFU^N:[0BM"S#MN`\W;>>R+.G4ST3\%!CV@%L6VYSF19[JZ:5AF%.M=F9'M"8U- M#RI(L1#N8P,=.$')&T8EG\J-QJ*8L)T@<"I1.\?2&1V30NY,I$N.+86"VM=W M]=#[S36;"+E0]Q!"GF]:CJ^37'$S+>?J>KQXQ.5U(;QHB+\`D8:TBT5\K5#? M%4$"9/$)CV*6Q.1F9Y7A^\EN!'[)",]R'W'Z9B(H0RPXM;"G+QG*B_):4RX7EF9%..Z&!9MB:!WW#C#L8H>G'(@F/[+(5 MYT`=7/!C!_@/(,N/;BL0%"7I3N!3K"GY%Y,S`>K!;Q0R:#&/+7F"E)[10U7. MF8E8*C.O&*>.B^9H[/;KG2-9%[$3>%"S/,U$I@.#*+;"KB#7UC5G\8#+K%B2 M2%#6G&F:.U<[ M9.-72=T%V!@! M6BM>S!((#U$JZO/*H/]L/WE4_\Y%L4>V^D5_?`+2^<_G.S$O0FFR\AZ\^C^854\8QSB'!,<'TG%6T"(8MOS]3",/-">-KLM*G83IMU3NH2N&Z0@@?RHZKW M*)]TAPCTEJ?R18]^,6BP@@8L:-!>@&[\L$,,6LB`8IZB!RQ`Z6M]717>F8E6 MJK/O6/]5'9%#=?TH#I`GM0SNK)7V%*'B0CO8-?/6V>'F\$D[[*2WSHY9_T1/^JVR&G_&Y6.6X@;_)YP6MSE["S-E87A> M;"'7,0RH^2:R#C&-&L<=UE]ILP"K6<58G+AEX-AK9H1?>;CNU3_E$?G*< MZJ+"CFET-.%@#S#8[@%N\_'6Z;LV7H"-E:`ULPTL8,?0T;<.JW79F;@SF]HR MDT`U'SY>[(&>"S`9FW>Z16$Q<4!WLPC!?)WES7V*=&#:]CRZ1-^$I/L3^4:W M4-\U-%-HE[4:!*H'F_='2K-NM\KZ@71#TMV[6J3L`!KL#[[8-+TK!`>YCX]7 MLZ'N9CDL59#M55`[J&>QG>@59L_$!;6>FHG8*S:2:V>27$H'+(=U+2?28M^/ M+1C[$8JT8+/NU@UCQVX7IJ%\R3G:(UR"^`JS#HR"I;`S7./)R]],6M<``UY= MXRE&Q=AK/"W-LN+(LR,?::X7N9I/D'6IE&,YPDUI'%CCM;__7Q(XR$%S:>`C M6ZUF2:`8Z=Q2LKU![>IFOS?&3E*`1557V_[:Q^2YN8>MNP.%"%RL1<@(D(N" M,-`@]+S0C*$5NJ[NN;Q[\16C4)=Y[UQ56-SLC>"`%CM@X/='>CH#IKM4:!CA M9R1F)$_.1%K&LK:8I+F(9B7I'5ZN5P13-X71CN0P*.'A>$^P8NXCGZYNVE&> M?Q*P+&`S"[97M$+;#0S#"P+;U\P8F8;F:AU@VQ*\V&0RE!/-'P#\1#]C]&)X.E4OR)7@@KR)E$.^V MC];L@IJ]]IH2$09EVP6N"U!L1T5)&R[R1_)NVMYWJLK>[Q-ZR$9%GJS!,Z9O MZI@]KP`7[-9LBND;SF[OZ/]-'G&9W!+43?I3D#_!M[LLO2./%:0RKG>K;LJ2 M(X*)"4[:@K_&!,!#49(_?^).DVCM8,F/YIL:2WWDU)$RS2K\L22IUR>B M$3O(PR"*/3N.+=VU`I=4:\<(.N1&'.C]>N&3P1VC.PX*AK;:E3^F4+@!3JM& M[Z[X=(X6[9-_%S[NG_R<[HLW)H*MC>VB_*9R-&:R!>$D<%T_@\Y4P&P%S-@Y M]=15^9&KRSYY)9I=WWUZ1DYVXJ>')M";A\6*?"Y*@O$1!V5)2V0CY@O;U6'@ M0QB'Y/4A]`/7=VW="ST=N4X8O+:>;.#;U:G7'B:P"TJD(S:`-X$.UCC\]>LX M]>&1KYMPTNI3Z?]PFN:0UDNPHI!:=X3OFSQ>X+:'O=,3@+9%I$S73!CHODVJ M0.AU$"PM1F(W4`&K1BZ'J.KGM^4Y8; M>K'S6DL=]&YU3;)%!#I(7"M_))(FD&^-05Z_;*L7B7SIU@FC3R5;0SF:0ZHU MV(9"8J49H!S'!"NT(3WV)W1,VS1"QPZ=T.V*=4P'*:K)K)@?(LG"BIX;6_;*OF5Y*"#TU(^>2<+[&43>,,17Z0.6?T?CA- M`O?0D"()H<_;,C?1)C8=UW9@[,0Z-,S(L75'9T4:&C)\[J,)AA2A3J,VJ/8: MS50+R,]P=*;/)H/9F?31I)CRX@X26?0,:4[;)NS"R`N,R(!A:%BF'T2N;W=E MQEIDB]WA-*`@Q3E4ARWC7D(FA[[>JK*KO-LYLL38A'TJTM=,GIUC]9OEDBB@'YAEX7F%4@`0]) M66=I]D!^+6TE*#>GKZW\E.^<.71A%5IW;&6G*A+Y5W*NKRO\CS4I!]'`^X7\ M.GC*JH4>(2,TM"`*8E3"2! M1&A1O2YF'4-V-!M@@087P,#0&A=!(]5*;A;))F9KIQ[9K03N$T'?T?C`W2(C>[/*-,+$*\>D.*6M,FB.!,$Z]^:.% M-+/4M"#(98:21S4EAM:(C^6%B1*R\F)4'9Y#?!0+GV5MTBD?-PXV$L.!9N@D MT/)]P^Y'B72+?+<(_5=+%A,,"`R(Z%92K&01U/;D\D2G(7-01%%XDTL5XRZ. M(/>:&>6`&;K!)^^<3"2K=( M9*>,5EPEL,4GKU,1Q2JQ$@AC$]F>*=S=`JBDN%<7T=QD*J>ZM/BOZBX3$63* M>[QC(R[2Y5WQDC_EB+ZZRZ#M.(&.EB0Z]/1(#Z&16,.05I(0W<`D8AS)>CRZ M8P?#`T=\-$K#RR6!.D]((YU07V>08%4MGDH*_9Z04L87T2-J?TE#HLE))LP? MFWY-HP41IH)P@W!-(SE<)!)(]U3\T>GV5>J89)N+0PK-GHI+-L$^ M4^F.T]LPX=7K#\R^)M8BF%)!J87840J>0CP:/0SFZUH/PT:,@DCH&69;"&KAFT[2/P/3(IJJR62<+03\.MJPCQZ1;=.@ M^FSG_LB`II%F7JSRUWQU2#?'7?W<^_5).;L61H1SKD)8$6\44?\V/LKXPLXP MS(\0,GZ<<.3;(M:4('G"OHC&60X3V?,+XY(HY,J@4% M'%58%A!M9++-%FR^Y'5S2@R%&)*#8M)BRADSM"&%E5B5(PJS320!A8\PLG@2 MY"7\7A89^G^]S#/$1'U7++MU4V`F210DNAOK=A#%<>!;PV&RT/:)3G?QCR(Y M1K_X6"0(#9,12!/[+\F MZD(X4T')Q1A2BIY.5+T&TPKWK7\W5J*9<>*&EAE!)]`3S;4]JQO+T6"LD3<8 M9!Q`LE*WL$"/ZX96I9EY(Q#H*2BCT^9+;#'I,C-M-(T")Z"/<5\YU:0C[`1X MV=IKVLM+C@JRRVU#*7"V4!57[(JW64'](\8 M05GM<`*?K8:DO3_2OM+OE.PZQKK=A=R9DW+(O[J%)^OKE:M)IH"*@3CR6PM9WC&J(+[ MP]VO]P]C!-U@8:3ICNL$B>%#/3:B?K!8AQ11FW4$V>&XP77RQ%.)-S-Q M)&%T"LXHX^,[2&PQCYDVFF`V!7V,4>K]K`/P;Z=O,O@#Q!7[KRH_+U]*2#JW M$:7(*40CPO^1%G6=%:=O0<[$WXI,S;3#($C<&+JF`0-W&->);4BLQR(&DRS- M'40:71%"(8$R3\T>G4AWZ,Z[G7*M4H0P2R'>4S,L>[71^^3^):VVZ;(1DW1S M`W[Y^?>?%5Q<$-!_+8R(])P*$46H/:6D*2ZKA?>7O,CN]MFV7KB>H24PU'P_ MC'3/,*'A#TB2Q"/J,BAQ>,FQB+Z)-(8.&NS2.DE3.(<@ILWO%[HH]]E=(JG! MMQS7L(7'VUM\-"_[&?T7G'P#R+[G-7))&_CR&F2;=ALPN+V=LG/W0-:U8":7 M>17"FV0+6;MXLY+)MWOX(:LS]`TOT3$12P[%*B^>%Y8?NH&)XW`4)1%:_T%C M>*=F.@GYI@()8T^ZIWC=@A*QK96';I+ZV;Q,4U;6KH:P'BX8X06)&EX0L,]X M(F^P1;#'47`"5;9#/]KD$GBIU3T(`/TOJ\:U.^2_XU(0!2@=I.CCJODCCGA5 M[U"\K!NM^:1M6+Y.,>W>90'.4B'HR32/9$>S,!K)PMTO![R8_+;^!QJT_O:: M57_']Z=)GQAK&#$H'O;J#I)>!/!!8\96"+X(*?\J+]R;_0J+-,'Q'$2D7<0Q`PCT'0(AR3`@@[CJ57B MKY]T/5EUJ)B7,N2LT:X9I1#&LRQ\F(XKUI6=%,Y80PU>B"'%?\;=>+MY!K#^ MG*W6^BGX,[C;@[Q8;@ZKK(U(_;\`I`Y%ML+M"T:W#C9?590%"@QX%]?3)KL! MA]TM^FL48#;Y,BMJ-%Z6U?\&B@Q'NWS[=$"/2UN/1F%N'-7^BE:&X\"6K=%: M$;=,:`'A&'=\)=A_INCGON"\!O]$6%95MMSC#]L=WOJ^"'7/U8W8\M&>A M-?C]/V\]S4>/#/[D.'I3S^P'82IISC!I*"J>:L\7UH+HT:KWL;B=`O!TJG2V M@<8X\.4X50;[0&_@)YD##!55M>>"G`0!_74Y%$[QA33$(I)>D!%AA53AKOA1 MG74^WZN0PRC`PJ4J[=Q.X5N$_[9+<"GH2UL)2K)L$4#;\6`,->@'OFF;GJ?W MU[LYIF&2OTX5-Z3D[.6WOA[6R8V(-2`#KQRK;KF4"EIR@X'G#B=`0&?B6L!B M6R[G'.7D+1*1X;#%I5HOFN?Y>9UX=ZCJ0],BMVR"YLE.H:/1TE;I[]BD7:*S MNT.%V";!*I+%.2]I?+'GKGA%\1)_RD^/F-RGU;[(*MC,Y(5A1D&BN8:/0,2A M%QMZ8S3O7E'"D3]M,K`I MT]'.`A&B*\IY'%%O!K\)JSZ?>O/T!^][;[8&J.0M`7%S!J]QGYR4XCV^@$E& M(VT4%>PCG/D^3/B.:R2P':16VY?DRKYVQ?+]P`1H%AQSH, M/:BA!,#1G,`Q/3/0DB2Q3?XC)5S#2PZY#3@<2KOD^6:T_6_?0@0_'7;H)ZB* MSI)>V M*S^W+VPO%)K;HZ@?'7O)UV!5'9[!$JE$ODKW68UT!'WQ;E>5K]GJ7:>AC/^- MKG!?T688\B>%RMG'!-:39"93.8&W`00Y+L^/4#KE)):G.7&DN[YC#M5\PS+X M+S05"6:VS(0R$[D!SYOR"?W(.M]L\"D'+$BM.J4;,=T.!'J8IRHPDW-%I2(S MI!Y"72>D<\4\+OQ\Z<5$&87$'$*&KU7.&J382]8:0Q;1?)G!?967U;[\FE;_ MS/`ME+"+28_Y-KO/T#^NRO4OY3Y?9@_9_QSR*EOMR\>LVN8%>@H6?A@CS[B: MYT::ISNFZ2?#T6'?@_S=H^3"DYP]-."Q[&Q[^$/(OP%[9`$^S8],P*7-HC$" MI16M%?BW]KT=S5;U5?I&MTU])H]SY`[J.%O8&X=A"@Q&`3A,`6P7N!^F0&L: M>!A-@<&Z3^!X`9F'.A-`^&L-^1.!+\?@HIXVZYC&SRKG(1,Q0)*93.D,OESE MU\-3C2"@3\QP`]LU(UM/',.,P]CU/#/VAJV*GN%P)RP38)26!)S.B,4R&2FF`<"TAG%YH/PG&:B><&7V/`[@3:[F=#M*J^2++DL+T=?@&U8>JYP4M&.$80S]Q(Y"#8:VJ6N1 MWX,.-9/_*,1D2&6_[&GL:!L2-):`7;]H6W;&@#VV9L8,:+I9P9$'*3DAA&5# MQVG2V7=ZZ6F! MZ\6.'PR%K,CD/[4B$HSD3`A#;:[A&UZ`KWNT8(WACELVX?XIC,WA)_$;1R(S ME\N$Y2J](X^79`XV@,:(<4,E;(9RWA.0:')A$!O\N4)%(S2I@(RG*5R MM)=B+TE`ET?T#V/VH;Y]3M/=(CC4>9'5-1KM"2<'Z#%!Z46=(S\T?WA$8.MU M5J$,0E^$NJ.;KA7KL:T9CJ4GL3WZPXY/9@;W"%X@@7 M[(]X"05BO7MG*"R4RS]ND!P"5::]5Y!P#7 MMO&J;0QE=%1AV'I81WF]Q+MC']#:[$OY9URLOJT?<(Q8Q(D;ZT80>*:I.YKE M^Q8<=B'"R"7O8#L;0LG*/#ZU-FPVKL&JPPLJ7/U%015D15/1:4(O^&F'`BO. M"I\SJK72?'XF6$!]"AI:;2U3ZTN[)$U^#0]V6:Y%5^1;[O;E5,\TK\)IN#EG_ MZ\OC7#K-YJIL@WZK^8K598G)"Y""IPN)(?<1!%D>O+8,G'W&J+`VG)^$4J6' M>*;LY]_SYY<16M,,/$L++=<,+$&3E$B!: M5T^;`4GT\NPI$+9-A1R(=@;,DP1)G`GL6=#XB?[_-(C2AQ/D08R3YO]8(L3* M@J1,B,LIHE.A"[8^@F-)W^@(>K>QYY MVZJ9\,G>-'CA[J*Z[575PSW+B.3G/V+]*S3YFV=S/GNZ)O`-_1$57?%*EOG1;[/ON2OV>H./3+M@W\,`1W^T&`P0C MAN$/&);RAI^$M0_>[`LE79$W^F)M*B7.4IJ%6]?VI^L7O\ZR&B4!0TK0=Y); MP-BQ79Z#'WT19%- ML"J:@6L`CJ_YND;U'!13K$!FH)IM12&$XSJ!!Z.^);T;0(OH79]JF*77X995AJ7GIU76 M?OH+KMJ?OA(8O0X8=:4>*OUOM,LLU3CF.OBC]I1@?&]X?F;H\HO#TRC6]8I` MLP<.UW%?^]4;,-BKQ,$CX4ZD/K,TWS12I#BJ'"U$)Z7F=IN$&#Q@63@!]*W0 M]!$`/]#"4/>B_KR7:WIN)">>DH\O?6_,Y;?@-V#S8_&:S@FB@Y<<_F4&HL\0 M30:$0B(#O8\^G,A>L^*0+3S-M2U;LTU+ M=_THTCU'AT,UU?0AC;PR#2!9/T\P@:H%1:F8;,212:)TSN@T[Y2NAQ_1)47/ M+E'R@6!Q,:B((O'94`J<4D):AI$U,=-"!R;0TZW8BFPWMO6@SS%#(XCY>ZJ* M@2%9GQXINZ!N4?!X$=0A3(R;.-Z(3.\A02]")F]+*LA7(CJ!3>XS\3W`YN\2 M*J4%J%C7J/PZ0["E1+V^))!+G+J':?T"BQ7^7XP&?4TWN*X#G^I]E2[W"R7G+X>P8$C.LKEM13:R15O3L;I M9?#FG0;>-,IXT1'@#PP;-+CG$$A*:G^@FK(%INAD2W98K:6C)4MNCQ4N6 MT4&;+Y4:_T`DRI4M^Z`,I0DS' MY@<:+,DMBLBO+.O*2>8VI>@F:5[]CG=6!6_-:(U&P.]YO8"^;CNN9>F^;=A^ MY-M.&/<#(@!4^2S[*)*EM$'3"R,&1*N+'/R12>`TU-&I'0UK4I3L*BD?B!8_ MD8KHDP!#2M%SC%5U6H7[FJ7UH?$_U:43W56O6(!O"MV MASWZ9\11OLF;"O`8;51NT[Q80$L/?`]:,(X\#QK0TC2GQ^M&,552.!O(*36O MA<2L>I/[CU(T578=A^;^T&MR55&NW-U_FR$>1OZ^9?WIKDWXECU[!\4_,,/[$TZ(2>W6/Q(K)#[%(!2!;' M'C/H08,>-5NM0(X3R*1R=O[IE).#>BEZR4+?!_(IU1N*J*E<&\L)IS?MYH&S M$2]B>^O27PCFXE^(MK)0+V>_``6-'VT4D.$-1;15CFWG6P/D$MHA!B/((O)6#B=P M9*S3\"]*3R]0/]>"GXY-VM25WRV*"*LLZTC255$D,M1$+^X["-Z:;4--&/B2 M%]G=/MO6B\CV],2#CI7X!G0`;1;17KHU7J['2""4[.GLY%.!^`.4F MQVTP5V%:56]Y\=PV;;DK[JMRF=7U0U9G*6ZG5JQ&%R:=&;)P#,TUC,!W/=OS M+*AK$`X;./S0)Y)K%7!*5_7;70L75!W>9C/]^*ZT_.R2`)K3G'-[^>,(H`+$ M6>H=(^/P<8K6O*YAV`WZ^=O.1/`PGA3CNQG/@\YGFA049X`_T>1@.R2LR"0A M.TLLUQL7TA"5YH`*IY%5H:)4[Q%EW0G:[`XZO0$I<-`8,/#MP(BBR+!-)W"' M9:_I4KU_YAE' M&"AWW^1[DDBV/G)0J\C*3H@IUS8@>$3U",T"&F'B\S840E!K-7)$&8'$N>?W'*HD'[U^,/GO"IP7C?5 M4OGEOMC73\[0Q=]/O_.N.VD:7A*ZF>\AY(:I%^&(1!Y,8T"])`W# M#!`A:9@/E6%MF;X=V\+\ZRW#Z4R=.3N^F[VS//W%WB.G=4GY#6;C,>:3.CO# M*Z:5196^]T:'0^?RVK[KV+S M]WT3J0^'.TM'@XYDA03X'V M#:-Q!C+HIV&&"`")B[,P1`-4FB;!3`E*&M^K2%#/2YU<1_TB@\!X?IHE_H)S MJB5#;UN>NQ0?,WE.>32\_CRG3H&^/*-1&RU<[#Y\)I5Y>Z^\W[`-XSCVJ'Z;;STQBT[NEA5X`X-5-'YU-9M1]P M?ZSNR[K]"-88L"MKUH!4=\7`?7EH+&WSW>Z[LZWK8]O$U)4%Y?%0'_+]IOWM MMD3HKE]G!P77SM=BMV/_+QL35?\39[MOC'YIW?U9M4M)+GZ7NH\,CP8;NHI, MNUC.]W"I)=Y/)RC,.!BA^!,HL0]C"`,2NR[V/)CBU`L'*"%-N';:3-HWG7A; M9$/B]=43KQ[2I1+O['QK2+R?IHFW13U-O+[&Q*LG,$J)=_8`S9%XQZ!U3\^/ MG'AYXL>?>+6.!CL3KUX7KR=>`W1J2+S^&91P`H62*`UAD@'DP00G04;"8(#B M)8&G)_'*VS>=>/UIX@VU)EX%TE43[SQ\ZTZ\_N/$&YI)O`J!T95XYPG0'(EW M#%KW]/Q)$N_%^$DE7O718'WBU>`B=^+51:>&Q!N>08DG4++,B]G=O2@E(6AF MXJ%+LP&*"URNTVE-VC>=>,-IXHVU)EX%TE43[SQ\ZTZ\X>/$&YM)O`J!T95X MYPG0'(EW#%KW]/Q)$N_%^$DE7O718'WBU>`B=^+51:>&Q!N?00'N=/8-,PSB MP(\31%(=?>/'V;=# MKC_]JL1&5_Z=*49S).`Q;OTS]"?)P).8CKO/,?6IGC2L@L!XMY5[EH@U]%OIHEXU$\_% MNNY4W.$^R\4ZNZYTA4=7,IXK3+-T7KFG=/S#]U[QQ5`J'^L8$]8G9"U.#W+6QH[L92O'+8E;P)09_Z9 M#+!`6*U^M=6,QUQOLAHD>YD#&MZ67XNJ^VK[97M8!<2%."/`QV[LHP03+QJ6 M@"/H>W,=):0.U'!RR/7D'_43&6Z,",(D\72H"C0F=/@Y^W=9VOSH'"0%\B#)N-K3QYL MO?Q1\N"CD,V5!V5'RH^8!Z6Y,)D'U0*T3![\]7OR9N:H+_ M%/;_%LT4ZE!LT$-1Y7?%^X*=@=C\."WWARI?'X[Y[F-1?8&K)$,(1P&B!(,H MC!.8QD-G4!1Y+A;.QZ_`)UOR]8WSM7?IKWGGDU,-3CGKDU?.;ONI:)/[]R*O MY'+[*PB+2.Y_!>Z\SMK@F8K@QADX<7I2G)$59T*+PWA9HGQ8?C"\5%XLCY![ MN-I4?KPFVIXK3UX3?IO+E[,_P<7==L]\Q7GS<>L"K%)"4P)]G/E^G."F2$-1 M.BZ)Q)CK5=M7Z9C%A"5$8 M2S9E;IMHF6,G1#ELRRPE/(5]K:9H:HC0#0'KJD"A",^EQ3?U.#T::"P7JN3$[MS0:8 MN[2@^;;Z1[X[%J1[Z?_(?+FMVQV2E1ND+DA"[%(:N6$4DR2#`8AQ#*'G9B^> MA:'%ACD59;"<%I;\/D";^Y76:S1=D1TM[%HB"WI\*0T,/PV/UBP9KGDGC]@O159/2#ZR6F4%8I1&;AK`$,11FD3L%8L`)#Y%<0P;%"+:I=>R M82T;P3KY?N.##+OD5B&(L$G?,L%04P(]?)O1!F%J+RBE&9" M8HER&G*NG&-42ROK;E=^95NR=0/G?5$7U4,C[,V'H6_;>N6AA(29'X64!"1+ M:(:Q-UCWPD!HFU.3R=FT]`2S?:P'H`Y#VDS%&JSR(JI&NJAZSL:WK&PJ46U8 M+Z^1QR646MBW3B'U>'51&C62IDD32,>1E6X<4&B!:MQ"^S/$"*MAADM9`0=I?A0**^B2D?U*$ M<:O?:)*6U<@J"."1NBKTL#DC@81(D0RV:8(B%%@E<9&I\@%!^^+V_Q0U.GGO+IKOES_P9243:[;679OV/,A";V`4.P1A%$0 M!1$8#(ZK-F6,]ZC#?.!&5;98PX18[)U\/O=8%;AEHQ?>OA7295ZA(" M/>P*7#@P.\MREPL@Y^&TUGJ66?(O'=N;8\%N$V#W!K![`0[?VY]6P]A?/PK3 M9@S3=M_^T9Z=_[]SFF]6W94#M\=ZNR]J=IM!?G#RBK6\W1=KUG+4V+EEEPVL MR]VN^&@7812$>K-(40]DJ6\*4X8STKBHWQ_7!Z4$I%-@R-(H7UX895"FL M6V@#D384U4^YXBRH%4BVL)A6\>9*(:U,$E\1G9;W^?=?MH?M79MR>]$<;@KU MHA@D*0RQG]$P"U`QQE,:S M$2>F3"TLYX3+&6IDF4I8C42!"G@V,N>M?-=M,+Z<@M&7PK;4N]=HOU3G:@F5 M#?6M'D=*W:/84)?6V_%6%.!F'O:0'R-$<`I0DE`X%M9)Y)OHU.*W;E6WUEN> M>XSF"HOH;ML2$9'=>M,6C$7[M]YRW"%E+CZ6%.`&'93LY9*EDEN#?RD?V@;V M-_OK>XCOF]3=S!_8)56KC"9>BJB;I6X$,NBYD(SI`,84B:BP"?NSK3X\%/OC M9*=ONO7N_,X0.SUD40DV$A4^$5XZ(&(R/*!E52E'-P1G3(PHL02Q5[389)@L M46.C+I;SC7JMW63].4@K'#:V013[34T>$1>#)!M:V1(3\G/-J3#ILO?GA;,'EGZ<% MEWQ8<#FM.V_;S9=]<6`/27Z7;_?UH?V0==E\P2PUGU+7Q:$]=J@5:O8L/;2O M)&\/K*[8-A^XSJNJ-='^X#^:7^QL-(F-+6,[N;/;YK?;'5LR+^I#?KO;UI^[ MQ[(J[AG\YL$<%\$_'0]L+8A!&/M)VM^][^>353>?K)67QCE#?VF57/?(L6'! M7+M/I<%'3>N$`6W^[U@?VC,*5H!Z08+FPAUB.BS:CAM M3J!,$^=]DR\KF;1I@'8=LP=3C&N?04R`6C6+F."2GDG(!.%5S":D'!.:4U+^Z8 MKGS4,N%0P\+U;"?=L_T$-G^K1@?O/^][=,Z7?'-E46#F<"C/168(@2EY[1KZ M>NRL9!W0WS@]?FO"I&TV,U^XY&8X[X?90-W-0D[!&9^?IB*Y,/TQ/!VXRIW< M%$%/..R?-FCRDW\JH9-8S?L17@@HQ#%U*TKNC]_1"W)#0LX M?NEXS)FIY\XQ[ZKB/M]NLF_L=/`VN;6OMO1%9X>Z;Q,G`4K]R`N]%,?`<_T4 MQEZ/($JB4*@O4*-9X]NR+=)6+\IVXVG8DVVWF$27E77RS:?G"U$M)M@#RP/* MEN[N):L>Z)"B%WJ'D9_%*T)L(!26**T)STKCXUA0*UM[9X8H)#"+$*(T1!&& M,*4>&0P%F`:KAZ*Z+7E%4?SS11[(*13NY[)[!)&,TDFPQ2=H9FD2TZTI/TM) MTQ,^KBB0/'>6"(V"`Z6N820C&[U,G55_W6$2043BR$5N%&,8!2D.(!JUR@V% M#HY4LV2XD.H>E=T)ULVINZVL#OP]5YIX%1";62B5$9ZA-IJN62RI0I>(>DF1 ME`FV29W4G7E.J311)*9:S5QT?!81L+HIEM.R$S1HYNT+72XJF@VF;1$V+/\_IFCZB MN*6-%-7V(6?GMKS9UX>JW?%_OZW_:`\1]U$8(."&T,]@$KB-+3C,'9O_D%`] MIF3(L*2=L#DG<'+W%ZCQR2=?LU$I)EUR+!I1K&L,75$K+<1:HE1Z?"D-C#QI MA4K+?7OM'[ODH#_H.W+#C,`4>"&BB9?`R//H8!.B5.@^*R5#\RG4`$[V4@$U M/D45RC"5T@HEP*)AA7K*$)="*1!KG4*I^')1H90)XN]-*:MB>[?/OJT_L[N! M^Y?F^[H->J$?N0',`(V@'_H4DG"P25-(Q9;%E4P97R'OT?6SP'5[NAK#YZS[ M6`C?':K$+&>/QUR4"K9M]%P.N(:S/)::!%ZCZ5J_A0YV+1$L/;X\[HK01Y!X M,QW^/FD)HE7QSR-[;-MJ+H0!1AZ(/!S%$$9Q!@+0FTX\+TFEVN04[,W6`.?< M?I\V2CDC3+D)H1:N.95L9IK%!$V.4[.-9I>)XFDATT"S+<,]S4AROPX3((LI5Z$<(9)2*+!-`ZPT#F;.NS-V.A[X8F4FU9JX5I0YV:B M6;!PT\"P6=6[3!N/ZFD@W3;5T^'2)=731I>2ZM5C5VU?60:!%P511"(WRX@+ MHPR?%#=)H5`#JQ:#AG7OU.Q^R_J(-8B;.*7RZF:432WR=O8^P5)35`[F!!5. MFGB+)4[>)PZ-4R1,9@H[?OFW;5$U'_#Y^]OBH>&7%9:()B1%*<8@]E#F4A"G M0QM;@B*?ZP(.S29G+/!&=,I35R6.A6>O<]$KKWS\S)J>P%[ABF\.JX-LV]1. MDU>79[+Z2%,KZY[BZ&M+C[A^D*+$3\,8$.JZD+KCC#K)A#9&]5I>9H+;U">3 M);[)XZMOMJL0#(7*<)8XR`JE$-'SU827.!,M#I6YMTTW]3K'4RYJHE!<1=_L M[X^'NE5M,+PJA6E,@\2/"$`!#!$$7CR8;,I8N6)1PHYAA6RQ.$!6\62($]0W MPYS)EWT=L!NGIW#QB>Y3HG@D3(%>VP1+Q95+\J1,CY(8P=ZDZT<92$/BAQ&E M<902D([Z%WI`J/=6QH/^Y4A"!0KHQX[(F3EZ,3'"F M2XP\F\3(DQ(C47HM%B-A5SC$2(X>;C%ZLW\HNB.26?MNUR.2NG$:4.3C(,40 M@P2BL0;#(11J2)/X>,/2O+(E``.(T!1EP4]=U8S@NUGM9"N15 M1L/)(T85B\6E3.EQ:6 M\XGA$KYJ6(XY/FV:@30Q/>KXZA`Y+:2E9F7/4W-%BA2YM$1^5+UX'#ZRI:WH:!4R")$[2P$<92$B"(]\=IGTHA;'0@3=JE@R+ MS@C.V33HG'J$)Z@]BG3R2=!\3(HIT8E$!LPY(5M*D*X2=467]!!LB3QIK+EZ):;_/=N_R^J(8C9WBY*CDJ/%HC-4I./)$8=4IFO7CD M[79?O#D47^I5B+T8)6$:X33(<`@1(MD`$B4DF_OR$7YD<[1M/K0]@^4GY]-V MG^_;9S4_748R.7)P@7M%!&(HN*=G7?CD=P&U7!W#G'):KU[C!21C2'CV&V<- MO26Y8"'G#5Q&(AL"[MS381NADFV]WI4,&;JMV_-T5@0`+T(QB0DA(81I&`1X MK*=I)E3BJELSG2,>9P5V:_V6W7M_<#Z-^>._!).#!I+Y!']>?L5$O,-V]H[$ M"9_S^X!P;D%^D;(K(JN/;DN$4Z-#I:F1*3IOS^O/C;*R_V7_/&Z;Y_?LG8`3 MD)6+*(#4A6'BIPE-8(BCX61O!(-4Z'UU?59-S^\;A$YQ@B@J;1KIY9ST+\*L MX$(`(Y75GNT7$Y@7U&_N]0%>"J^M&6@/@R42:,"QQVL+AJCCW]YM-WC8-7>G MQ=.5CX.(0!='U(8X-W=-DR:X MM7OBZP/'CI293=UG*+FVI:O"H"7RH^;#X^U<=4)$3ZA-^W-9F;K17?GU;\7F MKCB=F(L.H\[]6AQ6/B*NF](4Q10%)`P\;[QQ``7-)%=HK=($`-/334.GV6J. M`N=JX](!$%Q4[+D?\';%&D/LM)"=R5'>S>Q_N@;9`%_F:%PA;J^M#IH,E25* M:M;'YX_8-4FH^I+>R@N:':* M2V,/1U&<1&[F@8``$(\:&(=9L-H7=_FAV'P4*`0UF>9ZT)+N07N"4EJN%+:@ M=5'.6>[-2;-2.MTIMD'=.+F[5L%I9M\2Y=/NUN,ZS0AM+ZKB0W7XMOI' M7FW97/S-OJEJBOKP_]Q=VW+C-K;]%3QVJNP>WB^/X"W5-4F[3[MSIJ;RH&)+ MD,U$(CTDY;3/UQ\`O$BR)1D``8B9J9J.;=G$VFN#:V_<-M*R+=J7N"J;:E.L MB'S$>5V_D)7@;;4K6Y)$YF_F"1>AG;B.8^/_1=#S@C`)H#5`PP+.=`I#)QX= M"QADKGWY:B6#43VUNN:RLL[5*WRJ.Q@`!@M`9\(-.#0"?]>;`3H[;L#959,Y M>G)5+>G5=/0TUM_.HT?H9^G95V&7$$F#J1':!@VE$JD]$6:OX;@KA^"KF%Q= M[SWA'-#\4N5E\R5_(0A/90R9:7MFEL2N9T5)G":I&8=#LVEL1#QS*U/;4CW# M@NHMV&",!UNB.,Y;B1S:D@#/L!-434__<2IMII[`)LVS]?Y?$H^V$$.E0@?5.C/)5"C`+$* M4+-T;X:5ZI,+`>,ZOI])>+F2\=4<7C_AT/65R.-NV>[ZDQ)?T8:."*JF[;`L MG#1(0@A-UW0/&OZ".S$MB>>' MK@6]+'/\T,HRT_#U//\)+6=*#2MH;G`XYL8 M%6WC"CHC5N=2F$1!K5'`WW2UN4YARS/<\"@.)YMSU1Q>,]Y3'2%:V/94_!.5 MJWRS.6IRJ`-EF9X'/=]UH\"&)C0@W*=24/#!LUH^A3Z& MO0R:F.-3G).D,91JDLL>Q_X!32R*[0D099-M??^\Z>?6["60-8=U>!EF5'+[ M$(\L9WGYI4#UK]4S&EHQ+E880R/SK^!2GHX2`4,0#1^*GA@^QA*\[#KA!Y4/[2-:5 MVV)+UY=S4"/\`7X[28W[#4%\`^@W*S!TJ8]3\\*1B'/Y(#]3<\@#!5!7D[H' MC^X="6X^K@G#95L\TQTXM/G5W7I=+-']4[Y$O^8_BNUN^P7A'H2[UP/Z#7^^ M".T4#^&3.'8-Q_,LQTJ3=-1D.V!735V`M.:-))NI^PT9^6C)3?\#3:!#8D=^Z!675@FU58RU_S$L>X=+F90;YGZ.#IZ2KAYMMX(%O M.S-`9P>X[WS;FP+VM@!BS"Q]R1'"YNA3L0`X.`C'O-?O'_[1B?=U(T M<\/`A8%KQ[XQH')\QY47YR=#41SA.WST+H<1(5@=090JZ]-=(R,X:_6*BK"\ M=]O>!)#,V6TRX[!6]XE%8`UNE!28WR-3."1+\]+?(AC+LY8K#$LFF2T`=XW> MK<=!?5$25(O4L,PH<+T49M"'OF<'_C"E:>%!/E,ETDD-:`N6-(5NZ&QD!XU' M;87I8PA].ICC"V@]:7=KL)^NU,@91]S1P9U8-!'AD"T\G+'YG.A/I6@.4C[9 MADIBG^$M2UJCG!R!R3_I;G%BV=:NM7#*)\P#G004 MZ%"!`9;N0J5GV+FP*#V9T)DL1$^WXW654CG$<"PX'R6IP['G%[AS&F0O#++5M,\6Y:`*]83;(,N*0?3NYY'85"]>`!="[M8UMOOICUY">7Q?-G[?K&B&P.GHS\J>G3=&]&2W^LUTY?$P6'&FY,KJB M45>D),Q0XZ4HUYOJ+UHCY!\5'ISMVNY[_!!R[6!W\0!YW!-&B>'O;Z\E/Z1O M8%X0@1'2]>ZP/,/-A11T*ILSR4`GFU')[62ON4_TO4:1XF[]YO6\?J?.21HUIE-X#B[STW6`!^OUY9RHF< MOR/G.KPY(V'78NX)B==',]O\;]+/"<%RU56:_U2NJWI+<8V)?YPY1@K3`&9. M%MB9D?I6OQ:68BS)>W5WY#6D4!9Z>'2G3P<0'"!D&M6J8I=C=E$[RV)SBC+8 M9IN:8R'DW(2<5#+G,`TGUZ!*5;]CU*\5*A9=8U_10T':*-O/^18MH.O"!&:9 MEP2Q%46!'>W;B8V`:7.P\,,5IY/]R[('!0@J1DT29^RRP&LABT_/>7FZD+$U M:/GQH7K^![:2)&L.^8(HC7.0HYUCX(2T3";KRDHR'7\EJ==PZT2,R'WBFT_E M"OWX)WI9N$$:^3;.HQP_=:`/@W&/3QI%;A3P"07OT_4H18\*4%@`X^+6"F[6 M6,5")6%":L'!E32]>$7"1<$0)6PVBB%LP!O)F$8%DV9TUYBW&1ZUY9M_H[Q. MRU5"E@[#T(XA-'V8)#ZT72M.'&=H*X0QTR[I20TH5HX>%^B``8(,)^DKD+#O MLIC&W_L"HH4Z/@T18TV"CISCXHR43*9N!FHRW89*8E_BSD.R8H/J&#?Q4-4O MB]"P#3](4R^P8C\P+=MRC#'=<4R'+POA>[:>'(1B`@,H[@2$DR[6]$,=4T+) M!RM)TC*/(_LOYAUB3,U`)R;!?Y-S3*&!21V&691O^$\6F1E;89J97FH[I."* MX4-_>+X5I.,/#3[SJ@MQ M,H-W7`QW-;$S"+S57U!=5*LAN4AQ:N$%ON=FKAD%D1MDB3TTE'H^TTYZ\:?K M>L\[5"*C!T'6V-]]=80)B@`S5Q+UX(B$=X1!C+`9*82@`2>D8@H57)JQ'Y1D M^"?-(G9="PM3EKHP39S$2X,`CDE'Y#)MK)GR?%VZ<3B(IL@$E(.;.W;M4$F; MH'IP,"91/UX1\8Z"B-(V(PT1-N&$BDRC0T!'.MGJ&@OQV,4VG#2SHL2Q(B\S MK'1H#`8&4Z7$:2UHUI(^O$Y3$RX&>?5$%7G3%(6--^F:K0QJS0RH,G-B,?2D8F,S>2HB"CZ2DJWX>SRY$Q)C1Y1V13/J#O$_;EJT?X`B1<$ MEA7'D>/XL6=EF>&%:=]NYIAVR',L;W)CJE/W)1X*[;H#77?M(UE:/T0,/OQ2 M-0AO.M%L:J.58S[].2:S+P+1?U" M/GCG?>>49%Y:V416(:-\LOF:S)N.)SP([O][/7$\YNB"W`F2.1,!$T5?2>E1 MG"+S&?UU(&UU5>(OE[2@6=/UE^[?@XPU2C(O<;/$=!S/<7W;L8,!1^:PW1VH MK''%0O45D?*U1QIT!)I3B>1SSZ955Z6=3\TPU/-TSTC:>"F]('[*O#,3>51G M7Z6IF_-4CKE?/J+5;D-JV>3-(_D_F>5\SC<$!DXQX7->X%_>H*RJ[_%/[]%R M5],+;KZ1GRZ\U(XB(S*<.(R@&^+\TC,C.TDC+['=-&4Z]J0%B&+I'>#36!VB0R^2VN"T'CGQ&_T"O7)F_M:91?F,FK8K#?>(-BOP_84^"-%US\F% MQ2:;.UNL*;H2E>XU::NW56E'FY+$C1!5)DG79Z^*-H%D84 M.:9O6H9K1&D&ZHHE4WN$ MVMQ`8V>X0M;PW]0/]&0;&ON#Z!TK10/0IKM`H4;]12>X,X!RO+&R#W8-^.NQ M6#[B#.6I)45LN[2%GDDONFZQ'KM%<=`MEIN\:8IUT=V%,B71N696<]F3"O(= M25WG;YX)R6)!4HXDU2ELV=.%-I-JFQ?E(K/`.I1<(4@"O0PIA5YF^5*#>9+*$9_UDBL69[_4U7.QPCP_H!*1 M2G\LD;,HEYO=:A\W;ZX2--^E]USPD^>7.00QB=942CHO[YY=W)5PL'L5_GY% M).M;V"X,+2>!=A"8<>R9F>N&0YNQEW'M5YO4D.J`4K7T73R3D_+NSIU$*=M" MHS8V^8)(/%#X9ECY>X=-^U;<"SQ=VH8K@]Z9K`K*L>7U]EMY!+'EOWV#OU8E M>ODUK_]$;;8K5T.+#C3L"/I)G,21%626[V?>T&(&7:;+RR4THUBFQK=K2^"! M+<4'U@0@3UHVD4J&/%O,N"B MW=%;!#^"3RW(-TVU;Z*B1VK^+(CK<.:<=]L1&M`^YBUN\[F;F!K3[,><''Q" M=8$?NJ1_\1I'479_2^>S=DU;;?'SM_G+\!L@7ZT*@@8_CKYRY%;@O'P!;;&= M?H/O1?^>RZSE=(HY9-62+*FDOS'<)^#JIXK<1)V@[^U^PJAOU#"".$B2,'#\ MU,*AT77">&@T#.)T\8SJ[Q7[`;@I;?%(PB$L=D48X`&"[V#]0/MAK`LT74H! MI=`[EQQ0CC%OSF#)HXCY%1NG9==5W1Q-RP[99^Q:/O12,X6IXR7Q<43!K5,Q$Q M>?94BOHDSX#VMX_W'W^N<&@M2;9]_X33W*I&Y/8R5#_A/!4UQZJ:[-"_<*I< ME'FAFY.)A=AQ:`30-SW?#,#)&:`9;&3V=>!0+XMZ"VV8P@6R&ZVTX MT$?P8;5#=/2!,W\3O&`3?N(9^^GR'\-P>X:NXU->8@#86P!&$\"!#:_SR!N` M[0"=(0!;TI4>%1G&ZW(EQWA_ABX5FQC0ZEJVL;8<;L\-RC5[;@ZC=]TF5]=[ M4?@KXFQ13>:SON1/J/YNQ849AZY&!BFOAQ!%,3]HB<,'1\ MWLD"94`TS"0,V,$3`3\AYSD024J?"\*'E0M.!#HP,)XL&!+:5 M,DT_*6A6]=+D.-N[(JF`EH9'%<6H/@,P@-"1$*PDHKAN\_SR!\Z)?IF MWI%4IJ%L@54ZM:K/K_]2E.A3B[;-(@HM/W,CT[9#:(0FC,UHV,3ON*FKH^8, M.QC%4?>@#.&%4RU3]C;H7N_H]4C=N5BLTRMS",E: M[95S<%J4:/8C(J_1G(4"MU7=%O^'5G'5M(L@,.V$W(5ANHZ9)6;JF_X`Q\_\ M;-&2C78LPV!U&+C"\0B7???;``80-+RG(%3QSC*HG0?EG$/:DS'TYG(`Q1_/ MTDF1&,;\ACSU\*^YVVU:WV[PE?_0"2A*=ZYQ<876#?Y&VGZ_^V`W5X+;Y"M$0 MGB^7-2)VWH"\(S3OOJ-':&[;Q[R\Q3:1P1;.QHOM4U[4?1%8`A9K_0-MHUB3 MXRY23KJ(]8!+QV`4]ZDYQ'L=9KX^0*.%UNG1_C-S@R!Q'60`)[3("`XCY!JM87$^.^ M=C=HB?XG'3=P9/W]=O0CR5JFJ$([1HG``#CVB%`-E;V%=[J^H4\NOMY/OXR-IPH/_YD MA8$JS0Y8.H5(CB"UL\T]4Y!K+&N^H(!B!5G#'@^Y1Y!"7!BF'26.FSC0M!S' MC0POR<8-95'F+TKT0.YX_*8B>1`!Q*1Z8:=Z;["+YQ`$(-_$O'K7R$XBE+E# M9Q+QRF=]5C$OQZG*(E0[4'46L:$OV8S2B![0Z3SB5"XOD&`@10)%.CC"3&!?,"_63+2`C>7Y>_`;/ST,0$0+^G)$?^ MPR'XQ>TQRM84E$1@)K_PA%ZYCIYKS)5LY7O!5@6IO%OL2!O#7<'_L\,1?DTR MR?[2N>Z2FOWMK*>Z M6NV6Y`Z'9U22!'NSJ?[*<;?KY()H3/U\>&&#V#XLN>YAB,KA_<[B(C>V637U^$=H2=S7_"(;@_/MND]=@531+/)HE-YJ\?8V:<^_1 M6';R`XZI.&1_1P]%61+7TIA231>8R%49=VNRSVBO@9%II;[AA*'GN)$7>;:160,4UXF8JN#]/W=7U]PV MCF7_"M_67>5,$?S&O@$@V>NJ3.)*,KNUU0\J6J)C3LNBAZ3<\?[Z!?@EVI$I M``1(9EXZ:4?6/?<`.+BXN`!TVMQ01UY10+ MY$<6H/H7.A7(Q\Y[:0C%W*XA[:#:I5Q?5Q2,[K_D+\F^>FFM;5P3FP1;*+"` M&<:N:X((=U8P1EQ%^9)?K7MZ:-#T*43!H%N4)[YX6B-%@LK>LM,BF3GJ?4W# M2$`KR==*8E59]+F23B,J#.TXV;C$1MCT`PA-#]G$@1:-6]OO=P".>,[B"G^I MD!B('ZYMWNF0E0)N9CA%0`M@VYPJ/A^H4LFP< MY,0H0A8F@4NU!Q,+].@B)^+:ZY\9TASE=:=:H0YJ93QF^[2L:##?;%FV,^Y3 M\E*?[A44H;F:CT_"5MAR8@+8.6`,/+@V!CX8K1,&&^K&*S?J:P"H(\;)DYEU M5`W](RH\<_NN1,/G]CI?=%!-GS].1F]V5-*R^XQETU%9IE6)MO\Z9D6Z0X?= MT(FR/#ZFNT]IU:]SH15#$'HN`,2W`MN.:&C;A[/0Y'HZ>&F,FF>8\V(U2,X- M73,:WXS.N7KR>25LC7_7!O50/(&W--7R$]3J>H**&6NV3C#7/*:BE<0FMEG[ MQ7IGNGEIN#SU+=`L`KD2^OW9MDIWYQ_#0!5IS]XUM=JV'UC8=(!%UW2V&5H8 M4/,=#,='0EE6Q;:U[])U<$=N9[KZ[YM(]`DAY6W`F[Q9CG[1'$_//$G>>1/H MVB#U4_$C5YEI2@0)L3B:+]+3'BL1:FWN_91]TDDCM[#>%NE3DNVB'T_IH4PI MC+KXK1']MJ=NL`E`;,6FYP<.CC'P?<=O38>$_HO8PVPJ+(J,8:D7V%J01MJ@ M;&K@Z^OCC&V#T4AJQ((:JH1N/MVP(;N'5_#;EM`W"I722@[41;53) M^4KT4*E+N;XN*JA[87J?4@.[;\F/04#[B7+2V@U!3!77C6(3$-,EA)B@JP8( M*19+X!H<93:YAN/DFVXZF$:5_)`NH9W.+Y_*S<.IE,3U/%)LPU1`G0)@#TEV M&&>6N$N4C>B;,K97(F[J_,DU=4N1JM5:/5\OSZF0TLZVP9Z'S0"&T`I]$KA> M3.*HLQ92^Z)W>LE;FD?"6(XM;P_]UVFYJ_T)K-`+5A,X'1>P.7B<<*AIF+J\ M:F#]5@O73.0)5)K.0Z)<<:DTF7QEI.^Z_E[EZ'2NUE`LJL"+7&D'DCEIVEHY M30D`@=AT+6S%T`D=&#D^Z8VY#H%BRVPY&]H7UI\'JBQSP%2<-;XX4C]=,BK< MK847BQ7/TC(2($ZC<251X40GSITFG4@)M[)T)^9ODQ>V>=,MH@.(D`6)"T/? M,_W0QLCN*EC#*!`K.I M5IYN1;_0,&#]SH"XT,BRQZTU,Q`G+#*O;FZQOELYY7TI1P:W`*DL_K1,37DNOMT2S\@I878E`J?#DW/)+!3G< M$O7W[)"SRV5O#G1XIV6U,7$8^2Y=[KFF;Y/01F[8U8=3R['0_6'"7ZY9CAB= M^:&BO[YG`I2UL`251YPR/KW1RI:8RGRM\NV?#_F>CJ#R/^J*L.K%0%559'?' MYK7O*C?>L'ESD4TM(O26M1'ID29X)8(CCS]7U-/F.13R>Y[O_LKV^_?J=S1J73TU_A785$^5)1SRNCK:QVDU46"F=.U\0SYX2Y)LCZ)M$&GW'%$/XV/+W/7#5. MOG8]HEW[-"X8`Q^NC?:K:B:NC>A'5214MJEX%2_&394^MJF9Y9=(,[;LR,2[ MQOZUDLEXE=3DZY<'J4F;0FMK^'%Z2.\S&B/XGFD'!`3(`0NS-GXQA( M5,_+FIJGXO16[30GP:C(E*2)Q2G3!RN2[PX#7;6H1BIU-:KZ3^1<5&!Y.E>E MEA/<.*ML4VF9DA3K;VRIZ-_*;-G-H[G-AUTJ?_95N M$?0"-L`#P'%,S\&01+9)H'\JVB<>Q)VJ2:?)%D$M(9!BVDA[0Y$F=%QGA[?O M_$V_NVNN'(J.IA'+J2S:.58B5*NCY7+.907-QBVDG]+J%$X.-Z>^Y:_77:=M M#F!Z08"!#QT[]D/;1TYW+#VR0C\0R:2HMZY[\S.MC*LFUONM?AF<-SDB&!-J M:!:^:''9%A&+(UECO$Y%K'-W59C3D5E"7_NL1.\U.IC/U=5%;^2@O?I3\IBB M'UFYL7RZ8`?`=NZ_&+`P(CQ29*U$4^2PO[VZ0IX`824(\\ M'\+8C+TPCFV"([NSXA-;J(Q,\*OG4X,&D*P>\#(EI@@:2)+6A(O\:%6%QCJ' M+@A2MC)E$$7_CC9(D<#Y;CRK)DP.N\]/;&'(#-*6L]MG*HEIAP``&R,"/#\" M$49.9S`B+M>:;+H5S9I18VNNC:K1&?4@8?@XGF!53>BXGLS+I9BTK(I&D>?7 MYZ)3[MZ'2;1ROFP^PL`9A5;'VAIN@%#C2*ZZ0TGMGGZE?:O.`WYDE++4((LI M(X`"$YL`A1%VB6LY`.'6)$(F@.(E2G)V=,OXX`79Z/%IG[^DJ?$U+9ZS+?WS M(2G2#W=)63^'^,BVDMH23;3?MTXT3\_V!9NW:9'EN_JMV?*:O3[[)66'H8R/ MV4%RK3FID40V9?6WC]3&;`_+Z'`MLS(=(>GB!NTT:E<2G2IQY>Q&K0IZIHI> M&RQ;+H8HMEW`]!;C((9FT!K%Q'.$;JJ89DFS\*D7NU=*)[>.GM@VD]1.0[,H MT[ME5MVC1(EKGB#!ZU8]46?X=$^*(I%'#%+Z87;9=Y@^I_O\B=EN2V3:2!,Z M$8$!(M".'6Q%$7*#+M+$?A@*/P@UDNEW0FD[/4:2BCFD[&YV143 MLU?$#O#U-7;"RU!E[Q!<8FU$V51ROA)]4^K2SV\,**:+,SN9UCNEOZ>'M$C8 M02*T>\P.&7LBACV\_1J`%\/8(I$#B>_:&&*ZGG9;``2:1"!;J=*J[F5OLF,>/Z M7L[!&%2GLB3J\'.W34FV43MUW?QA,.?JX3FQL$>P#?@B=7WTBTU#`ZH6R:"^ MXF$DRI;C:R7QM"3XM_?:3:"`6W#J4879H!J.O6%A.'XY?:8==S6R$[S#[DVU M@6M'/@@1(29V0(P)1>VU6$,,0R"B6XL`U"Q_PT$HER1=IMGXI&[U+2:FF-TU M676;+92%U4'IB/@NVH(KT?!E.8YCXV^"XM(^-].I4K&;0*',E5 M]S*1I&5G[?0PZ\]V'6Q!Q/;"`\\B<>C:<>1W=GT?<5TQK,R8_JV9[C7CLJ]F M*][^\'C(N*^Y4TY*9;+.J*# MD0RR&7\]I$5Z]V)LTZ*B,['Q6.,L63:D3`]97AB/R2%I/TQG=8/=DU;MV7.8 M.>W^VY1E'>GO50^I<7^LCD5Z;93'NW^FVXI]@MVXPE+-I_>"NR'#YJ-K(S$. M1V:PML>BAK+[LMK.BY%0JT;YE&ZS^XP:?:*_2BTDI;%+[[,#_4G[\>1[D=8@ M)Z<^.9KQO8RGRAZPAD2G4G]R34-%9E*KK=W2$?)`@U06B_8V?1+Z7AS&=HP\ MRPUMT^TGTBC@RG(J,:2[VNKK[6TSWHRL+(\)[0I2LY8TCP(SUAP42LY6S135 M86N2O5-F*FDZ)6:I.6B5FZ$FTBNF\N_0<$GAI[*W)G6?[,LY95=#$&=]Q?F4 M1+^UBN[8QMFVVD`80`\$R(*T+YB1&5E>5\@6`IMX_+45JBSJWMQBK=!N5&V' M&UKM/O%_"NWK*Z.9IY1B"88%RRC>W2T\;>K_T>$4JZ!0QK1(]<02C,O-$!\^ ML,M+TK_1_QJOOH'VZZRLROK2P>HA*XUTWRP*C`\?)I=$H M=RK7V25E=B3O1G+=;:K[[FVJ>_AQ=AP!;$P0$<=QH(UM9!(+D!AWIYZCV!.[ M&&I&6`O/3ZS8@GT)2P\DS`/>"6N)%A38DEQ?XZF:^K@+95[]&O-GB7U,)>UP M:?=RWL9>R?;'$IZ?VZE<@GSQ_[S_>FP6W/6K3[J1I*GK$KV[*?- MC8D;SX$1NW0+!:85`=MU0M@5Z$0@=J'$==-+0>72L,G757]DC]Z4ER:C[0D] MRVUGAV?:8_(B$SZ6LUB[\TU1JV[KB1D[5:=+!]X9C7M+;:ZK;22>K?F%NL5* M9K;%:7BO+N$O*V^0I+OS0-O2]HT=(\$01A;9NP1YV0]<$.A>G,U M)C6OA;ZQ)_C>GX2R`WO5N-GPW+(6J_=499]=5]0(?//)`OR+30\]P/=/`+0@ MYRY1YV)NK'9=+?4KD6#57KVM=M=!FN)%P??O11WMAEFYW>?ED?;N/AN&"`X< M.XA"+W8]:T6&(6,+1'MU(]&MZQ.21_-T!8J0_*YFD%?\-UY8`Q&OYQ*$[+^W96KY\HKF_?*ZOL ML8X)X[RX3S-6VJ@ESZ.G?15.*XLWK;;IIO>LV90HS^Q*T,]4Q@OM$B??UC@) MR;31U,E):[_XE28MO43(3&8S-,WRDUR3O:+JW/Z(?0YL0NPB!R#7!9YI^I:- M`M@<)<.FZ06>T(UA*X.N>3K\GS3[_D#]^)`\IT7R/36*$SCCJ@>Y/]=&MS_=HMZL1)OOZA_(;,W#/>&%='9]3MA%>C>' MLBKJXP,E.NS^*]U]SP[?T9;^$X64EJ=4\+?T1X5I4_RYP=`)(A!Z`:*#!$(; MH]!Q08`#$`4F=KGN/)@%B.8IJ\4H."?II9YOTED-ZV*SR@FV,0)M"]L9T(``=@$/CL=4%LQ\0A7AB'A#??,\F&QH"R?X.#!H0,F%$C6VYC M?(RGL5!.!;TK&9=J?'D;3*DCB'M0OS+R:$;&^^IK^#RY;15PRQP6Y([T$/(Z'%1%*MMD^I5B;UYD^ MYB7]N3!NWX:.[R/@6J$%0VQB$]6XD6GZ,!"J!5T&4'M6_C M73$G?V/__,M,2KI;<.PLPEHZSTHFO/7P\?;\PVJ`B>9UGZAF9W4"FOY]G]:9 MZ`,[T%94V?_5/]\$H8T!]CR(G2C$""/HXLZV$R,LEK]58%#SI#;$V+P8-`#7 MG1\3SN*J()HW6SLSQZ)9V1.\:Z,'V+RI-8`X>^+U,FNC"5:%I*]$;M7Z]%/" M5#EA$^LW-FZ(+2N"D1^[MN59`0@BN[/&+E6=7GIQT81F:;MT>Y"2>HG+/$XI M=5!*H9HJA544%0C7`W`3N1(UFNH%URZ\("DB;]87*346ILV?--IC=WN'Z7U: M%.GN8Y;<9?NL>MGX`8H116!'L8LC'T#HQIU]TPUBP>?KU1C5'G`U@-B)?;9( MK)(?P@>'U!',)TZ+<"LF5QU$XZH#^1O+OM0XC9[S'NG\;]-S$3BB:\K;8"5* MI]ZOGQ^OUT$TG^=TE,)P263S!P M?.A#TT;(MWJ#Q.]O_^.3'GD[7,/F]=5]8OK3S/V'_/"A3M9G3;+^D(J*S@0J M^71',X=2TM.0UV]TM!L:+:Z1TWU:!.A=@D8T:#JI*Y$A!8[DJOO;]`5AE_YO M+Y8[Y?Y='(?(#= MMT&JQ-ZQ2NZE5XMST*YFO=BSWT)=;BN6GT:Q5>/4MEB)+.KP[/+*40UY$X03 M;;?L^LWR2_VV7G*W3SD6 M]0T(`A1BBS@^BF$<(61CLS-*?#N<*G0BMK0KW(WT]?$32915,^7LJ90Q+C9G MDJ\!%B'=DB%XM8(EY*IV*0&A7=1:E/V]Y(.'GYO5[F2I4],8LAHX7RNH M%,>N55JX=:,T^3]TH5%F4DP>6H6D5&D[K59CU7IY47PUD*I@H7R;O-01JV,Y MV(0@1BB`(`P"SX%^9QC%IC\ML2AJ37,^L5^U/35XE"V+N=F*26PJ)LKU;RI!WB7@3+435-R(KCJ4Z%'91H);7/1@[^;0,<+\(P M=!TWMF+?]CP8G\)>RQ(ZT:<=C'X99&C/A9N#'145XJBTA29HYU*-HTI:Z^8: M@!S$HJ>MF8\\;3>?^@IP+BK..IISS=JMQ5\>:=='-+?R?TG953K;ZEA0>_1_ MTN(Y;2[Z?(MX8YG(Q1YR$8Q<1(AI!0[L$$1`[`4?A69G4O-BB%CR,(=*LOGD M>B&>Q83Y%4BC1=G?S7Q&MF?67WX21Y160TNL1%-U>)9K[\:3(^0NX_`E?4X/ M1VK8=QU`;4("[1!8$0AQ7\@-3%/H#.]T:YI5L3_;4#1XIH>SPG3*QJLZF502 MD/;"9]+YH@>5,5\Z9^0N/\93(.MGS;<6#D(!3;Q(PP`10)R$2RELAY+=L-CB-'J@'^[SXD-)H1I?.8C7(JH"+(ZHJ8ZV6(F, M:G$M_W_RKK"W;5S+_A4!NUBT0!8@*9&2L)\DDIHM,#,IIGVS>)@/AALKJ;&. M%=AR7_-^_9*R)-M)+.M2I*SL^S3MM,T]]USQ\/+RDG3_*4.%8R8"'1#1P(II%D-35%0;'^6N-<6E1 M35T%HZ>R3B`.0)6M$>\7$!I6M2G?H*X>(9N2Z)H1W"7`CD,V%3%V[>9+81Z% M5O/L]M.Z5,-@J3#4K:O"#YG*JM-88#\(98)E$#:&,Q+*)J?]"E#EP48-TMFO M<.6*_H-4ULWE%M+ M:`_PKM.-?Y$O2.IJS/54--*>0Y?2U(%4F>O>Y_JBKL_JTRR5*,OFKJZ90$IW M*0I\7[>\NV,^U$H"(H02Q!/>428;-/4S#]40`'9XF";XR2+'QJ<'[U%C53OW6]:K/L] M?3V"JU]H^?RA.?T"#TD\UQB+?9N73`5^U!7;UQZ90O4-^2(=43$4-[ M_ESL6AI$E#7A4^*[WYNJ!'KF$QKSQ$]2Q,)4Z-OE(MF65%D&W`BR;-QYWBB` M^N=]^/.3[&BJ'B4B=C3112@<*F05CB/`$U/,4S8'Z*=A6-Z)FIIZ!]36022" M5^99L3FNE58'D][8_I\1%#*)4D8#3FC"A8BSK!5\CL,!]4E;$,9)0%O5_;!< M'XWX`?>,6`\%;+D^*OW#UNRZ./+A9,OH8WU^\ZV&IRLMW'ORV6/U;CLR$]%9 M9^Z=6<>[H=%!6^D,(Q_AA/DTB;A(N(_2MD6`$DH_;;<[93^_O:_>>=S^;;W0 MZ?.=;L3YH?NJWG[^4>^5;=5?6^T6"GKU6NKMD_Z#[8S&&4]Q&(5IF`B:((P3 M6H-..,&@R_*NB]2QI#<.5>VI=\7C8['VMAJ?M].N>=_R=7Z_++TG[<&`3M4K MA+AGB>+=1!=8T#CI>FT\TU'>^U;'M_6NJA^?>S.W:EK8WGBMDU[EI5>[><4. M6>LAZ]E'>[U/92*3UD3(Z.C)O7:(P'7RV_MV'N;%ME3K'E]$.$L)I9D,>)RP M,`IJ>VDL0C&@(`ZV-6J?KIJ-UMY=_8#1JBJ%%]]6RX?Y!;FQ3"^LR.V&TF'5 M;"7WAZ5!A>I*%>N7Y/0H31OS.16%'.S'F6+S0&*,4O1?B_6#&L^/];M1O^HQ M>7L8DC-,4Q;XR!>A#-02@0<,1PV$B$ENFG`/M>LX?3[-LDX5JZV.#$B;!],. M3X+'9'Q(2JMQ_J<*V6/[TET%U;OM,U$XSTLOL-@SR[05BZDHH@O7.C)`N_0! M+D)]:I7Z$@2EU6F2^2$)DB3R*?+CB#00!$F008IGT_SX65\V5ZO-I;[@^D7: M![X@U6(0^JGHZ,0;7I'Z=)0=3D]%`2QVJ*B+6$Q$19VX]NJ65%?T&66?QW"J MD[3Y0N3?RAF**8N)3)A,D4\X"6+4U*93E$C0W5@V[(V:;6[S];+8["\2R!=> M-8A7Q1PJE%9XAJ>98U`\)+W\<**3'[T:HZ=!7C&O/$-;SWQR*.D344"K+G7D MCW;H,E*\H\:RJIGLC1VZ6>C'4F"">,0ED1D-4=`N^WTA0+?HV[;M6@F;H;G) MR]UF7=T>O=+9ISYS:2N%M!X/N$J.'8I!BGG<0]LTS;[5F'!%^>S!9T\IM1F9 M"'RO1_Y.$TZ(SS1'(:"I\10B0F44:UG>ZQ52U6%=:N/;^4U<&^CD-<[W%TGVT>@OY]Z7HUYF'X>2&^`>AJI)KH] M(%O]0O:YK\&)@$*8[)!0)P&9B(BZ\:T8X8L&"NG;ULX\1>6K!)AG7.(HE10A ME`9,GX#(TC2)48@9)`&U:GB$%+0Y`ZLUU-;%*W;)[R>C5^,=)J-GM7)"S^A! MJ.S042<1F8B.NO&M&.&3MJ*CBDOB. MAVK?(+RKH=K;*:.A"J.L]U#]LGMZ6N5Z,V2^T@BR5?&/3^O[8O-8[5VVYS$S MF6693P+U'Y9@3'B*D\8\YR2`U-1LV71<3CN&Z2V6V[M5L=UMJL-L=\V1=+4Z M;'%#SZ!;H[Y?_G(-UF$9S`GAE4AJC-X1R.L=+N_)7HXA M:UZD`-^G"6&JGV8Y(PDF3`T,3^,8_8K+`P4=ZF+$U$0DQ`S[J\LGC0F`7.); M/.9?YS_S;64F2)(PE+Y,_#1+,458OQA9FQ$B26%Z`/O9(TN"!N>5&AW\FET8 M9WV5P1U=4'&HN*F@7$<@3ICHU`@SSB8C$X;P7U]3.X"&_HU>RBLUB&XWG^>; MLOY-.8GF$:<)#(0A-%4,A%'#124)!ATT9<#^\Y% MISKKL?SGO'DFZTZ?-';19>LD.OVDZ]J!@,S8^N@`:U=_6(.@S01/77JXLL.,N=T`HK3;QXH4[/";J/LSE(_#@3*,)-A M&@92/Q\FVIIX2D#=8T-M.=;;>L#.:\KKRYE.[A,`[\@-)+?O7MQXO$)WXKVOKHN*GDL=NM2 M7S^EQ1,GU&<1\F5(D<\)9IRPQFJ(,0*IV#!3CD7L_%V"^<]\<[?G+='-[;2 M=3+5)71V*)Z*SEGRYJ7,V20)7G$3[?Y;6_$/@\07*%4?`]:V29*AOUW8ZG M4X;ZC"5#3J&!M'2>_S\;:W2Q>)AO?QGOE!&:VO;68)Q*F0HHS1( M):4B0V':F-.;3Y!TV]2&XSS[&)8>,TT:#=T0,J:PWW0^!GNPJ?R$.#VAIQ>) MY.UQG^R+>[E7ZX1KO] MZ_QIFQ?WR=/3:GFG5[1?RGFY*]7_^G7YN"SWA8GY>O$E+\M]3\WV'\ORN_JY M^A#OKOQ>;*I3O');+A_UCLMR_7O^L\Q4>C)?_3V?;V8I%9C%."`R('&H-):1 MI'$1$]ZK./H>_7*LK2TP;],0H,^=[JV?'V]'A__W_^L2Z*NUW5KZAM_ZQ<@U^J3>>9ZVVY= M?M5N?%4@4A76_YV1B(:A8G4%.S[]?+WQ)1H?:&/,V$54QQ__J M)OU!1/3/G^:K?%L;^Z4H%MO?\W*6$,PSYH<(Q9ED)&4A1K4MQF,&>J[:R(!C MM?B\*702[&UJDF^\=0X]+6=&7,_,QS5GP"Q'P_%J/#=>A>A&+:K'OM#^+5JZ M,IU3WH&$F(E%FLU(S&?D2H3X-&QQC) M!+"OT="(8WVI<%6UJKQ&!LU+S.GKIS"C,`=3F0-I#:CK92SGZ.GL01S(Z$04 M9[@?K_H.K1`#4I[;^TK?OA2KQ2P.$R5M&4XR*7Q*2.*+M#83TC3-H((#^=DC MZ$QUT="+?,9`;$",]=<85V3!I47S5&'Q-)@KZ,D1%1=DQ(2T":F'$?PW1,.< MAMY:(98;?:'O4[Z9E_6SN'\4S_-5^5RKU2SARHC@88PC3"5'@J*D,1RG_?HE M[%ES7479HVFS%J".6&"SG[*,2R1,:_;8O!9<]7SVC==06P,<67\N$M:A2/;( MGHA&672HL.'V7+>(=[`JU82BP-`4U$;2&W?=>SQR096 MMO<`;[Q?CI@^!7DEJ>M'75?UVR[W$Q$_VUZ]K)"[(`V2Q96;W5VYV^CD\?M\ M\Y!O9XQ$+&$T0"S**!=I%*'6%I%4@I,WN(DQ;,;/O-*EU#M]VNO-<&V&/K M3=M$M,,<_X4]-2`1O36C+67M3VG_6FRW,WTQ;XI0)&7&!,FB%(O65,0##I$- MDY_O6#DTAOVQE&(/KEA#5<.(M7["X9HPF'8\>@$9C\5D\?(7JG4V)E0)U5=29$=CB9DJ MV20)>.&;SLLRY2@OULKR3AF_;522S5/HX%K$?H#BC<>,"#F,!6=I-"?=H2\:[ MULVCU:/WK7)4=VE.Z>ZZ44+3F1I-[P.9B(!-DIHW[^V;&$;;TJK^QFJW4/_K M<[&I'JLKR\WRVZZL#O`6^AD$]8]49%?5;+#W:L8BB0+,"4.^]*,,QR@.&K2( MAM2NBCJ!>%W!-'J@:OPP]EU43SZ"T"7Y4:EO'\6#5][!K1NO=9#DQ`-FOJ@\X7QSP_IZ7 MM_=JYIWY/(A"[),0L2B,,Z%WD=N"KI"QR>70EDP[[RTYS#6+(Z1'LTU5^="G M@X[N9]2__7,XZQGLP:O^^CH0"_UQFD.PR]YP5+T9RD MVMORK5/#K1+86YD_;PJE(-5&FHAQ0J+8SP(>#/Q'HDZAY>1ABO=*?B%*.0E;=IRUQP&F* MHQI(Q(C(9NO\0=\7^!7P+JIU$+T&3+P?,*_P]AXW'_:H/U:#QYN_F,C6IQ/9 MY3?6V8RRZB]-$AJQ#!U^^ONF82C,!F`4XR*(DH@)))$+$4T+"QHC/ M&8/,;["?/-(4]VJ4_IEOROPG]*EB&&G],G]W?,%2>TW5:7K_,D7_/->7'EY3 MR/J*5&\:IRA`_<%WB0N0`HNU]EE&>21#1..`21%&B;XON+$<4AG"VL`&FW/< MAS%V#?PRO;;JV5:9=5.;GH9&7:9R4`VY=QPFHF8V/0+7=H%D.:G3GB9V?^1/ MNN:U?I#J'Y3/,Z7#R(]13)&?1C+(DBQLRA51DG)0B]IXJ$93T3/578YK)\B3E/Q1'!]0,;9)O>$$\K*[1OXL-W,5IN5Z MOGG^5.:/V\_Y)IUOEW?Z(H_E:E?FBR_?YT?OTL;(3QB-HU0F-(OC.`@0;V!2 M%`(/6XR+S?%DTJ[ZSZ?ET'M<1X^>R:PRK<`-GEN.TORZ\_+$(:_RZ,93/GF5 M4_O+C?9N>95?UWZFVUI@>L\YXWT"DYQY1G2_<_X9.PP6RS<-L`K.S`]9&(8T M4#.B"`GFF/'F"&%$**=V:SDPVV/-(@J>MZWDY/Q\,#BH/F<5FDO)MT3UPX6@(C7;E]W@^F,6) M)`$/@@"+(.-9$"=96\["$>?6!1AD?5H2O*ASOQ%$&!8CBS+L+#PNA?@D*9^B M%!^S.E2,C2+TGN38S$$301Y`I=7"?I6D;Y^*[7QU>]]=6[J4U[-8!HPF"C5& M.)6(,T+;O)Y1T/.E$X,^:E7GS#;!L+K.U2FTN)DPT<"[VG&HBS][A_7.0Z^= MB7=0.W(=W8';&5?XS"8Y5TZ''8.-D:L%TK1A2%E`4AX:F4A&,:T+#=1\&(..NV@N*8Q@3@HH)F.5Y.)@%G MH9K>-#"=6APH*O:F`J-8O\_)P,S58=/!`'I[3PAROEDOUP^Z1'BZ^I"A('$F M8Y9@'G."XRS-#KU;:0Q1>V,C(TEY1ZG+R>`]QT?'R!Q,X42&W7`_"LO?UL`! M4^5LLTRFJ2_##+',EY(RD82B,19PC"#'_LPL@(8*_/A?:F$]:TA=OS3%/6NP M!*3!4V4*%:*;_;KQREI380`(#8S'B:H,T(D+$F-"B;&^U$G`+,DX15@I6AH& M*1,LC$5[>CD1!'2PV-2&8XT15I9,Q@2:Z8P+[H8K38WJREI3HP"H#93-B>H- MV(T+BF-&2V_-^9]\^?!=_?SDAUJ%/.2_[QZ_Y9O;^\KT]G97;DNU1E9XVMPJ M18Q2I7TIBB6."H=1VJ*2S*$U$/MWY5XST MN3L2W'VF2;D?9SP(I%K0RC"1..-INQ$<8>!C]79M0\:[T665]<)3*6VELEU/ M:8U!M5U9M<^Q4TV]QOH51*4%#86%Y)T)*-`Y0_4TH7"H=![7RH^QS'!&?)KP M@+%,'T3`DK9/QT9QS$"[EK9M.\Y4V_6T;?$T)WN0?(["\QA)Z30D]!R=TNIR#?+'VJ]^B/_JN]OF/D,I33&2#!?<&4&QX@($E#$ MD/`3(B!2"?W9KJ6PA>/]50'J6`W:X:J?TKFD":9D$(:3`E,>'-B:*\S4R'L`RD^G^$$='V&L9%K*,X> MVG#-ZHXH-""[EQD;R3EV>,`:0^0T,FJ#]2/B_IC1`Q@5;0WI)9GV]KV MI_6VW.STPXN_Y7JI-HL(8@23)"74YS(6V?^1=VY-;MM8'O\JK-JMG9FJ3I87 MD`0V3P0)I%*;L5UN9U[F026KZ;9V9+%74CMV/OT"I$BQU6H*!Q>2G:W$=E]Y M#GXD_@3..0!B*L4/1PCA)$I#4[/[#&?B:A9;=*S:9QM7,I25Q_?G>WW MY6%_-!2AA/)ZN1$B?I#YF"!ZG$,RC#AH3P7XU1W+6',Z_;+V:(ICZ/LL!OJ/ M/K>9]!:#!EPZ7]X`A7)/R!]WNW*[^MY,;1AB*&>8!#E#A;"&2!M(84',&:03 M@"[L^/EO?=&+8L`0J;V>G=&!O8>5P3C1ACZ$`5G08C431=#SO;+PL"CJP.IX M[46VV1SMK,O]<:+A(QIAFM,PB<7?G!)4Y*TM@A*EEZ*1`<>Z(%SR3CY!(PYF MZ(9U8C1J,+T``QO0C7VY^O&^^OJ?;5.E;J#N,ZD9J*<90T`N:(<5?A-KB)TV M5!8?**BFL-_>+Z@?I6GL\RPC?H2S4*A7W%Z;9;Y2^!)T0<>:P1YW%50@E#@H M"H)M!#`!D*WWFA&IEU>/V\-./$4WWC`4^R(@(`QU>@BCN71RD,_GG1K>8/5. M_#-]MR"(4Q1PGA.:T3BD14:2]MH^YPC4B54NZ+@3T]WZL-Y_]A[$(WSG[<45 MQ._=0[NU$AG%;FT;"JQ;_[9=RUC8=].(+(EA/5KE@JZ'\H]RX<)F MO=QZ=]5FL]R!!_$J4%0'[99Y``?I+8H;KZA1C-J11=L'Q^,`-'/IR""?GXVW MP0U6CMWQ:E>N[[?LV^JSN/^E^/3WY>[N&"_,HP*E<9SR/.%13A*$*6MMIB3) M(+$\(T..._[1MW9:^MT[>E?O)2Z7,HT9'QB/@4==[@$+1= MJ",71JKGZ?NE%WQW=0O4PO0SH`][]VN!=US5#$$WF%UW>B]FHIVN6_EB*;5# MJ-`:R+ZY8X22R9I+FN4%B0N4DYAFI#-(DQ24GM>W,HEJ&I5!ZJ!4D\9Q*-I0 MOTDK(9_S&9`X\#8DPW-2@$[,U;/@NE1"..5)K]JJ/&BQA!XV-!', M4$F%$EO5AK@LM M*].YOF-AZ2^SE$XU1R_K3P&*J0W'NM)ZXRUK=^0&%)^.(>$V!B^_4(>$5U=#PG;I#@O/F&!UQ>?&Z_@V M7AFEDIH62_F)CA]+X8EZPG.%R07QL45Q8@&RUHS*[L.EEY)JDS']055Y\B4[ M\.5Z]X_EYK%\4QZZ/>=2),0Q#FF4,AS%19"CH!-'7F!0^;E31\9.:3V=9Y1> M;W"P/'BR"5[=!J4]'R>X;VH#L-G<,IA8:M^MYER5R;;I-,%]/9'I]B[.9+0X M3ELO)T+'`&Q%]NM53#UW%BB/29#Z*,MY(O=U#HK$;WV(XQP40[-JV+6LGW3Z MAZN+\4;`;*[*3@E;5N':UZ<"/"/!/2>I*;#:-^05"*I^VP`":@C0BF#^NEY^ M7&_6A^]]/S#/:(;2G!%>,)P5?L!PZT?D%VRQ+>_E4NH/=K13RP>EWDV:WOW, M73T9W1S]7)VNGJ)J*:V&MV<5Z"O9NT#:*P%D.H; M/7SZ)`3]4&^CTPV-ZZ%7-R0F*/(S6J28^TF(D?B+1JWE("Y`6]I8,.=X$'KR ML#\O;7S4#Q_8P*PFGR,3A@FF,5PW6W!<13:@B!9YST0#;;;H?-<.V[`T$LJ= MI+[]=.;$`OE^D68I\W-,:>@S$L1=S#<6W]3+,!L8=*QU/^_D:=5-P'OOO2]7 MU?UV_\";%8;K+M7;V-TJT\6/I3=K^4^_:= M?G!_^_CQ?\K5X4-UDFVV_52))U_N*OWWI5P6_*;Y>K;;R44GLCKZ[>YV_66] M6>ZR^UU9?V5!$:,DB@.:Q"G-<.!'41IE?> M%J^W8>.]FOIIT=Z+R3M!\005K]D:3W"1CY9W)-/_A;UWA.-]J+S>`+_'QVL` M>4="7@^1]U93_1 M9\,]>PLWV(;@P7IRMK\H/[,2#TS\!P.K/HEW:$8;&WP4I4)$4 M)(^"`"5%AE(_[B(9W(\*R+GLX(N#!IWP`]G[@T[OG?A!`=8@;J!*#!HC<`#+ M;-`UV;2_(:$TQ0="F]UT'NK_BU-W+1"Z>O&F.C3"]J[:K%??V49HG3S1H+Q[ MK#]8H#1A/$69WAU]*F<9!; M"F6>6,L-T*2_7NNPUWD\K<)=XZDN@-;NS#SUT5[SAN73,D:K^9Y&0AKWCN/- MTW!T$6=!YJ,T0P'B21[%F,3'A'O@L,W5]XX'N_]*M1Z8RJTSNZ$O=31 M>#?!9E[I^"YLW.XB&B?'9YAL&@1MF(FR?W4Z5NSKCCYLSW66K54K["A8]94*8[=$$.G40>Q)!.1&/RFBP026CPPCH]:\.Z"3<0[9`H11YT M$,XNS*#5B(%M1'61&"C-]ZLE#EE."U:@P$\2N:]4&F0,MJ[2[/538M-O*JJMG%:SVH-%R.0@D1) M3DD>IAGU_1CY:?="R`O"C4:#+AT;9_3HKL++UOVQFR`;X9XXRIZ]KFHO->`6 MOPPB>^WBZWJ_5R\Z[:K^4;J*NOB&-A M+LAYBF)<8$99CE(:\1SE&8_\2'7D9\66.ZWHW).;^G<.>JV'T]4?J7`;Z/)6 ML<^D1]MM4^7P.07VQ_/]F_PPPR3+(AXF&4)Q4O"HM4("!#JE!WAIQ_/83&=' M8B@=-5UR"`:F0%-OW::\39LFL9F(AZ[WE97'1DL0FITM3QNK$YX'*"812UG& M8I;Z<9BUQD*41G!=@%IP+`]'=XX;E_^7EDZ`H4'DPB4O'=6X\5ID$\O'&9BK M*J(+F7CX[Z.CE3U MXI35DSCMR-U&`=U`;[()?B:=S&J3*G?/J4D.9"%>^)SB@(=I$A0L2:)$GFK3 M&!%3EA"RE1CLRJ!N!B\:J^O,E'N4#5(:"0^KD(P2'5-F-U2S&LJT9B(@FLX/ M93&`"`#OZ>JAW!V^OQ//R$'(D0S8/LBJC7ILD$8$A6&0$4QXC,4=#;MD;)[X MH%/VC`PY?S,WOM5OY+)U3">@8(9334A&(PG3E=:M&Z]VK&;)3BS'GPX,<1H< MT%C`.Q,ALM.69T,8:X"49>I]N3_LUJM#>7M![=+9]0<]1^4RIM;5 MD05.G>&`W#FX$3,1/Q8Y;8S0) M8;N,:EEP+'?-GAZ3A$LN\ACH8&;\9M*7#!MQOB.E!23`L,>"IE$61R@D4D,4DDXVH(0QG+3'HZU.N+ M00M@HY7[MSM1%$]O*E>_C>U7HF/,[S!&%2\!#G!1>:4K3V M"?.53G>U;M3Q.[&_R[,O&L>F*QE61#HS$33[[:H\AZC+"(YQSR.\RA)$`I9WEJ, MT@(4P#4PXUCXVB4;FY.'T*4N)@S!HN82G[:,S6#ER\N(U&1+E^O\A$J[)2]+ MDQDP8OAA+:.]Y7)?OOVX6=_7.Z)WE3YI@A,:Y'F8)!&F*/4+OXN# MXR0');`-3;F>N#7>>1OIGE>=_#/5*U/":I(U(ER8:K5<:\^\MWVNTRC7,*D! M\;*$>";Z9:LUS]9;6X2DON=9N5U7NS?5X;3BD;(T+_(TH)2S+"8L(R%M+>4I M`J6=-2[O6*T:CYIEU&*D):[PQ=M4RZVI6.F`5!,HQPQAHG3$5WLSE0X]!S*@ M/0;T9J(W)BTXW\W-%`:LHN5YX&H1^BQGOH](DJ<4T20MB-_)6)%DX)H6#1NC M5+5L^D%9,VG19JFF+V-@A(E,0_!26'N**J'G:*[5"1G`G(GF&#?C4JV0,1:# M9-HB(CY/XSB,XP3YJ$"HB#J=2RD.()5#&I]AAGT*Z#T\V<665F MGC&;/$T&2H\IPYN)H)BTX&HZ#`A#-PW6JW(40Z.<^`$OJ/B?8DSSN(LI80R+ M[NA;&3\95GY;;1[O9!35:EH,0E8K,^8(JFER;+)%!R_B44^1:2"=B199:,AP MHDP;C5&NK&>5%#F*?5^(HD]B0A+.LRY8A&(,VD#*T-3$&3-;@F4*7#]]YHBU ME0S:M(NF7@0%S*-I$)Z)DMEJC4(V31N2:4*M9SCE">,ABM((BREC5C""VFJG MN$@ST`D`YM:F2ZO9$C4+Q(UR;(Y@6TNS329O5WG!DVT:K&O!C.C9QQ.,MO>GSMY?N1H$ M/@OB*(U1&.$\E@>,M=9S3)4.T[5LTG'/X\NM]VXMDU5G8PSS(89M]L/CC`FQ M`P<;/1^]SLG>J$-MT.$4]5VU>I0;P=2_.$?D3QP$3&$?FI/K]][A<^EM.]_: M)UL>=;<\=H7N-22WII:*>^^?O*`P=K<1/_J7 MO;>J]L**_*&.C_BA3\M5M]APOZ]6:WF>JO?[^O#9^_BXWM2=K;:^_U'YY2?O M0OU*\TGDUR\TV'VY\%IS=&,G?KFY:E7EM#=H%7/]6FWO/Y2[+W69QP*%5.Y9 M$K$B9$5*PS2+VAU+Q%?3`%[-!;O^9.5<+>34]+NR:;^UZ` M0)U2RNN'K= M4:HJK%137$<$+J.P2D>[?F*ZL@FU>@EE2C-1`RW77ZZ0`#9?/5A???FR/LA1 MN-PN08Q\Y!"W%",>83**BC0NLL@/.0_$'QK'[;8Q28@R4`&YB1W7`?J3:\T1 M>7WGH)%X$YR*,?B12$(GQ$\AYFH0W43=7R8T%&^WP'4FVF.E*>&P6W]\K$_4^U#)H:[P2Y`2%[W_92NTH-R?]EC(:!2% M69*%@<^+)(VS/(ZZ\5.:@[9?&=DUUY.O"WM3E76KH#NWC'W+%.=G\[U;P*E= MKR%_.6YS=>-UC?&.K?'ZS?$.E?>T05[;HNDVE[%[1X;FE=/<^IF\"*9J_?EL M=LJ;`#DDJXVQ^(&/D.,)2A,HCSAB#-.VBTR$GE/E>[ M]1_EW4\R_EYZZ_U>%N_51R@]'O8'\8'4F>7!NQ5/:?GE8[GS(O_&DVI0_U11 MKHY?#>JO(O#)#AKW2NUEX?HFP13_='=NF[M3.R0TOR8^_ME4YV@&I-<$Y$ST MTZ@)S\^:,L0!FM17VYX=%#..\X+%(:$8XZ1`I$O(BX$[@LD8^/+.-:SQZ$4! MBQOYJB5,JD_4^_R9I$%4ZT8F$A_*U6']M=Q\_\D+47R3H.0F3$C]"R$*;M($ MW40$MX;,I?*I48T`!>S14(]*.'LFX*$(\3#,0"_/H5R)/FCQFXE2ZOM_(2XW[Y;KNU^VQQK"GOE%$H8))0A'.,QPPCAE11?6R!@BH..[ MS>8+GT;\;KR]18V^4 M?Y79@$I9!#X3W;+9HO/-]VW#4M>VU>KQR^-&UB75"_:%R8==^;G<[L6004R] MJR_EK]5^_Z8\O/WT8?EM@0*?)ES,G$D>H(0S%*%V]7Y""`=%1FW;=JUZ)W?; MTW_[#HM>*SV&*J!M_HIR."%ZH#;VJ#>;A#SQU6N<]?XJW?U;?5JAK,(3/H\M MEC"B0\KIZ-[,149=->]<4YUB!"S;/2S7V_*.+7=;,7O;]]PJRD_KU5KN5DDR M+`R&19BEM&"L8.WQ`@FC&7#IKK&Y$67TKG$)O##7'*F:3(Y,$Z:,K7->ZYWW MUS[;HX-_&WV9[C5D`])GD?=,U,YFBYXMV;4,RR#;OB!IDB=!G(:4(O$OY4D6 MMI9PB@I(.:#&Y4>I"OQ'N3N4WYKH7)=9+74.9M(!J)N_MLK./`?]+.'\;CE% MQ?$S3*#$L#+3F:B020NN)FB!,$:NZ5G0K(@*/^!<[@N5LR3").DFSAPA,V5R MXM(H:K9_L9)G\KZH`]5Y88?R79MMGW?;:B>%'$#HULZC7(08AW'.PXBG11&E M11!1UBW7XAPTGC$V-HH>]-8\U,E$'7UPQ%IMZ#,J9MA`Z/*IDS,[:G)`0:VA MG8DVVFL/\$A)("AU/3LN_RK*CX?Z-/N+NYQT97&8^IGOXS@O$A;Y#+.HP'&` M*0[%+)%RU:2:9:L.^Y]P](=ZH:ATM5EU\-(>0!,>HPC".=1=W=R7N71>1ZT[ M[\HN(0*V#?IX*-;[U:;:/^[*#^6W`]W(="#F\EBC($Y85E`?TS3FG;G`QZ"" M`UT;C@/%IT[;XPW>=%83GYH`CD$.IG2UOIU<\OXIG?)JK\:6LQ?@#.B6*;9XOSSB0B2N=2*M[9EYR$,7U4U)W+1(+=FRK?GT"_#6K9::`D"` M9*8J3ED7]SGG#^"'^X%K^R'R`FIY480\IS%H4^P0*@4==2N&L=,ZQC>1R]XU M4'>^2=)G@I)B_)E'1#D"'?4;O`)?WM7/"($NRC/"H.F2KH1"&@(I==]IG5[>"F_E?F[6D`9`>]>PDH"0,@C"D-J$>1"C"=HP"`@DF4M>#+6A^+^_PF9^I^+I_3_>'YRZ'*TH=-;%//LA+*[-EA M8",?>UYO.XKB]]J:5EL&^^"T[7]__?A/T#L)!B]!YR9H_91)TZI-9HDDK4O( MK9:B59/L8CE2!65Y@V5&5%U#?E3M,94&JZ$,W9C);9;M:LKB;?WH;'[.[^[9 ME-6U;6;%CY(HMF!"2>*2I+<9.[9XZN^IA@Q/_'ZIV)@-/'9.`E[\H.X:7=6U MKJKQE.<]SO)OS82B^;5?]NF/\LM#?KC_;V9+=%:H1WV!/F5.X>7ZDNL7:O>( MZUG6NC>KFA)=QYRJJG497^\SL$WK>Y`7M_OR>RLR3\?=5VO^=_:I^>'Y;W5; MM_DYT[9VLZK]=.`;(WW=?TR?FS6LR0FXWQ'N4J>B2^\U=";:8BD-5$B9SN/L M<;_.X#6KD/>L%X-W59;Q2K-)$IS",;2_!`;&AZW>V`]NR0N%.1)=!PYW) M^?.@QU;4>0K2WE49OFF36Z#76$)IV2W+=B&U:5<]\&ZO)$<-[F-VK=M`_&=&\[5!E=VFUXYW.T!SX%W6V MW_=CK9,.Z;PG^L#?G2B+QO1-RKSLLG]E&"97.JO=!?I&OHM M[3&5!MN`RD+J[V4Q;&:WBTP;Y+K8@U'L4SNBV+%BBE!OSL.^U",1JC8,]U;M M(FIQXI?:'7UE"246H0VKI[+Z?.K2NQN#YI:<7ROSWEKS!"W7M,@\)8RW5I@F`.[?/_$DSE^X8]?-==, MDN;-JVS'ET?XCOU3._&YNNW3`EQG59.T_73+GG@HB*T$>4Y(O!C9OM>>&XV< M&!&A58L%W3/,Y.ORP!U MQB*<<)3J)!QPC`?T`;4KQRMDF=SY"?=%T^)?4&Z&R9OE70EK=48WFT=2KO4-0`$]9Z#;N5+" M5%.6>)4T4X]FE&(319I$K_9EA(U%$TA"._2ISS.EVK;K)+W%*+&$CLYI,+,0 MM?)WGH?0KJ8ZK0P(J8=4*WB2Z%0A24))RKIB.LE&(D`F)7$F4>GJ^#;.)H)6 MXH0Q=BDE_#Y\DC![K=D@B;$_%4TRMA;BT\E301H@)26N.JE,Z:H'5U7;MXK0T=C#&$-L^):$;88(3V",TB#P_C4V=K6AL3T.V=K6Y=JJ^$=5I#NOQF MFB:Y5)CW:A)KVPE/7I1`SPTA<3V:^`-F*?*DM@6FV)F5<5.7P28)*LTTHUI. M8=G2JU\C&HEQ2UG9]?%*/93+G)HHCSJ?^JDLL^?&H9W$`4&(^!Z!@[D`.=/8 M)&AC"2XI+70IBZC((P/Z36?1\F_("JYN395SK0"2#>,]^"C)H@Z>TPDHBG&< M,$/$BGP_\7!L$]+;=`.YQ?9)AI9`D/I:UC1-%6%D2DX=1%IN#6M,)ADVJ:B[ M5D`IQ?(>I=0%4CB-C-/ZGO])AG.Q3<9[-D8[\*S9'XMO6=T>GCY+&$9=BR`* MF4\T#IP@C@(_;CTC=D!"J22R,[AC&'M?GAX>TNJ9GSSE.0T^M)D-CH>-V\L* M[%?^S-H7L^KA[)_R`61S12?&S965FB1=FU+B_P?)62F=N+NF,\.J(@N=$39> M@BLA^)P17SP#/)/84H\3?"SJ0]5LXM!=2);.K&./1A M;$OM6JA\OFE>G]PO.'M5Y.AIW_Q'VKP^/<68:UI*.8CJ4M'8NP5G4HV@<(JP M*V';I!#>>*M@FASB+VNS&I7!'WF]L9$3(#>*$B>`3N1B-W0'`S&FEM0#VL*? M:I@TC2/@#^Z*+$9-ZW[\$DBU_P[/\`?K2=S`^"% M#",(4)-K)1!0=+[446-D]\FJ;)^)-1Z!WB6UR8"*:H+[7V8%DUR7E=3*S%;7*T7&-KC4Y5L) M.Z9$<+Z9-54,18JT0\M-3!!_D=FG2>C%EA6'(8*#K=C%ZAP1-#`W2=0F&FK: MJ=#$@&P3>;+,).0M5829(BGB*JDB&\,H5Y0$$=\D.,8%1JKUOZTTUOA61%SN\0M'X!O@,%/I5I,;09V0UJ>?D$ M]YN-*B>Y\]&IU>QU+#2O>:7'V$ZOLG8KH_\K^ M:3,:0C&)<)(0-J_"(?$0Y$.@SI;MR:4+43)@F"8OMP$_`.Z7VH1'33XQE!A7 M3HXF2J(98(8Z2*!)S M(SY9X-.#NAL\88M?K?4H!"3Y49@A\_ M+S749C4JJLF3PX!@D]BQS#3FM2*"_)"4;X4$D8U@A"%*8L@LE>S*XF/!VN-- M6OQY=7N;\:?\F-U/']'5YV[0$^'$@Q@YODBZ844 M[HK\@HD.*8773V9647HYA?D'!@=!YV$+I)\:)W]>:C(D)-[X"+\U! MO5Z,T2Z9XC6^3WF1?3QD#_4&A2A*$A_;`4)Q`DGLQUYO+O1MJ9O:JC8,@^SL MRAGX@WL&&M>F7=Z34%&,:',(*,UFN+(WB#/"J*ERKH1*D\,8O;ZG*HLB M>6BZS>!#^50<-C"B$;3=)'8)MAWB1FXXD,Y)D-03=P+2QA5^#[;9 M7-G+KQ&K:Z@"'D/R32+/!]!(V;JU*'F.Z@BC1T'05;)')8Y1^"@+(SZY8WB[ MNGUY0O"W]`>_R(#*JBJ_Y\4=3A_93P[/F]CU(L>SX\"VJ$7",$9.?QHYL"&" M4G,\G88-4ZKS"]STCH%MYYGL_$^KVH+3P*6$EIP-\H$3ZP+.SAQ_`+WX@[,` MORN^F2FAA)!C,T,3Y;$2')J)[7R>:$Y`Q4%;,V?-Z@.?J[;)I*\S5LN+0WJ7 M;:@;)HC&C@^I:SD(!]1R>P_.!`<9/_&8B,+C12TEL1)D MFHAL=$RI43P#N.3?:^_3M[=I-Q[TG"B)+>([GDN)BR,2#`"W+*E<%P;=,#P" MQ65Q8-T:7V+*3ZD*?NIP*OLFB,D2T0U7HX5A&+;M9D;C/1O*OI?>8&$`GPNM M!7`[1ZI,K`GBBN(L!16N?UE\E&M+U)'.3'EN,$7N@1+\&V M[^'>?N(Y1!W7$XP:AG/C&:@;UT!9@&_]R0J-A)XBN0J/9U)[(GU;Y;\,RK\X MT[(H9B_K)PQ5#46P2H3JB&L4F-J$4\0CPW->[O+M=?K>Q=`E7VV'K)6^S_/:45^]S] M,QO7UH=TOV]^T/U"#7A=`E?;0WF35<#^`%C;"\#AOBJ?[N[!0WK@:W_-JC7[`\A,.'#G]V`?W@:_>LO!` MR>(#WWF`[(=-A-U+I8STPP+%0'$V1ML-<8*?\@(\9VE5BXZ(EZX:XZ#_"]6* MB1W#$!:X/E:(-C+`0P--;*`+KGM1E56(88WD^J1"'$/\B]2"7;EMC*8'9N<_ MH3:\".@O5"O.AAI<\68`8<6NU0P?S);!&\.-E13ZPL.3M:A0KJHE3II)_J-( M'\KJP%_\)'F];0X"8=?"T/$3#&UL$XH]-^@3BP8065*'<*9;,SPH.7$)[#J? M^+11ST%!)7E5IGVFE9W8L9^JW/NWZ%3O#;V$9WE3M%[E!&]20*-SN^E2"7.- MO\M4,%&?/Z???TM9\\W3??U[=KBZ_25),AYAB&)M91SF.#\B%F M[^/,+'M?M!&8:51\)333&5%IK'JJ\NQ?9?7GQX(-*+=9?68Z="F"ON6Y?NSS M=R'BR+%[TXX32:4KU&'/,-&X9W_/B[\_MKZI,FV*H))0FTE+9:IQ_T!>@,[# MU7#MLFXB8-.@^MK(IB.D2VC3)I<\VVA>Y/5]MONE+'=GIBT(@\@+B<>OXN*` MA"A(>M,63*2R.NNP9YAMO6?@CKNFBK8I>DJB;28IE=$V"-HXN!JR799-A&P: M1%\;V72$=(ELVN22)QNSQD:&R',=$CE6C&W;(6QDB(:1(?6\S:$\I'M)A(E\ ML!2K!A^$6]E7_D^6:D`L?I&6(B/3VIJ$E.^7ZKZ\`.)I1H>WLMF@X3&K#L_7 MK'X<8+'C;V8_GKQ)&]O$]CP2^0Y*<&1Y(;1#C%`<)NP;CESV45U?DO7T%;A[TE23CE[0DM6HN1<&Z9 M-4)PR8;JJ"[JG>2ZCWPVX+1H0&%BN2%*(ARBWK3G M.U(+.3KLK8%Z:GECM:@]D7N&A#;`O67RS0H(IT(^!=G73CZ5D$3)IRR7,/G0 M4[[?Y<5=GY$_#!Q*J>T'<1`YU$$AC7LK4>Q(9D>6RA[[4H@1HB@JMA)XJ'I?:JDVN@9#GX8,CS3R4>03XJ$@1M@-7.PE MO67HR#W'H\'N(XR(S(6M?`A/2==Q#T22!IK$;)5T(QG1&) MCH!4Q1*[1OG7;?+?>(-^)`Q^[-K'M*/`3XL76L,+F M1$+'+*=;,^8%L-G)E/\@/S_\U]1K4 MF#QO4%Z?I&NXC*0GD%)W;5-'>=U;[(?,]29,0HBQZ]N!XY$D2B+/'I8.?4\L M)Z\>2[,A_:9W"3P5K/JT30FDO>OJF%*15YKWAI6=Q/SZA/F#>_/JJ8Q^P[I. MQG\A6G]KS=!_+8P8^"<(NC[X3PGF<@Z=,^?T.UZF\&%#<56 MY"2Q3Q`*D>U0A!U_,.A&0B_43+=B&/Z];^W%SW[X=&PSBDDEI@DK@/[9-)7# M_B#GUT[.LWY@/@TE<#^;EI-1G^YV>2=PER_E4(+LQR$K=I:5=$>[S]*9Y M?P-4V98C?@=2UOVQK^JG?7.A9YL^YH=TG_^;ESO_8&9TMV>_^K<:;,N:6>._ M-,C&?NFV?=(CS]@'U76YS9N,VM_SP_TP<>H6SR;WF:K%=:D_-5[\:^AKS0=9 MSMFB)'>1KU@=KGXO"[ZOD_+Z^K'8E@\9W]OY\9@5=?:5C?,0$^O/#0E#;-E6 ME"0Q&RQ8&-H!;J]W.'9B)UAF-UFC6=,S->XI@%7%LY(W-KS'OLK`T"];_@,=__[5!\X"[H3/M2',(QZ::')I&$JTK+*\KL"X*9WVCZ#$U_!T5E)5.J26PR3"R@MA\@3!\$KP8]^ M`G@X5/G-TZ%Y*>!0@NNT&=\N=%903-819FHNEY7P4G=4I='*K,[)W[/#/XHJ MXU.D;,>O![?V?TGSXE-9UYT?)(F\V*.$!CB);1<%,8Y[/QSJ4[E'!+6;EVG3 M2D\)'GT$OY;M')"[6(.?N)=9_3-/"OE;6OV9M:WZ2[;E3P/DPH=6S)6,-%SG M+Q)US/*T'4<7FS)IB^3G]5)62%\QWNHMJO615W-\EQEL0DA%&OM[^F^_/YKMKO+>M_BD`8DH;$;AJ%/G=BR+-K[%L2! M5+*W61PR/.(](?9K4K\:G;%O?$^K'>#O'%;I5GK18)XB5$'Y"DIO&MY/F=X\ MQ\/]!=QAT'J\:M*KR2],?\.EN\H>P73,H[W$+(*+I]KASS&^/,\?)`$-PL"S MD!NZ["^^#X<90X)#J?=J%3[>,-4'CY:\O_):EI'V.D'#E;2^*1&_L5W,VJ6/$L]/$@=32"S^HA0,[<"V MF#]20R>-=@VWI=..MEW=Q^7#8Y7=9T6=?\OZY?VVZQTR)+(8P!\\BG[,)'L[ M3VO)"(Z(%BH4R8$/\_+"6$9)?3.C&W$IQP8Q!@ID);0T$MKYD,28?"ISUH8= M+]#1DH-SH_=HXU#D$AM[[#\W@JZ-HM#MW(A"!]J;]J`BZR"J@_0D58L',@W[ MW%GA-HY2]N4V`^D!W'1_K>\SUK9W\S\8+"F@V)Q$:U&LI4F;"N_R3,.`C')' M3"[81MEM666?L^T^K>O\-M\VVQ9'EQ+H(80]"UK4,LHP/>KHA> M>7\Z&%OBC(N:UN\=>C%<@BM!^2RAOG4L9A9YA1%_;I"O9@GT/NUR>?SJ)`YO+A`'XPU%6K!K7SF> M<,^FDXCC7(S>AG*YE`_#`Z?]<#_M@DRBTQI7J&41HSO"-(@">((1`CDB!`#,3?&IJ5+B%BHU$!V"7+E,*.;0GE1F!7P8P M"`,$2`33,(-A&?65&5F8A2A1NUAOQD"&4W1#LH>"4SZC.T]_#C MIY^?J*+8P$-+[1XAIVS$8LM85G[+T_'#$'2VN MAL:M96L@&=*G9>C[+6M$0.K^]S,R&!=A%&>L"1R""0I!%$.!#`2!TI4Z%N`8 MWNCE;Z=0_M#XU%67C>8_?%W`/-J?P9X>>UN*2>;K>&8^3),!'>$'FQ)/R*5I M5?9LKW^L8AK*3D7]PQB*>^_[DK'ML63LQ[&XMYM:W+N>QB5,&ULXQK]1V MBYHS:ONCD-X@I=>+N?QS7%,FFT!9UF:)XT1F3P^2]&;9,!I)[PB44$2/U9[^ MSU6D$/L0$$`P"0J4!"0I<"&0)JA4NFAO`7CVB*XG.'9\92B%7HE2Z+NA%'HU ML11Z":OJHK=%#6J2V,X([42Z=\AHJE::Q67&IL2[83%S&E#F+\/&T)*D&WI+ MB-82O+M3Q?N'9KO+O9Z>T28H#_("AQ@"D(:`E'[ZC#:&N5+M]D(0#3-8>,/1R_T+':2M>5::F#FT,"TAI,.Z MK18Y%*'53*X=AGC?)R#LG7R0G@2.<-!BXIL]Z:!H!AVL(P4K@#Y$68PASG!( M2`DAC`6L(L[)A'I#TY#LE!B./=BO?:7Y;YQLO.K,1>W&+FKSIHM:QI2S2 M^=9K7E-:\^QY17A1Y M;Z>H'H5.&_WU8?SA!'U1MX_U:7NV(B`%21%.,M^'`4K\I"!TKXT3'\8Q]:`J M*?^Y8QG.W8_@>2SS]3CE$-5LC9KD8Y+V-6=9,\C8#$SBYZ(U"6WC,YON&(CKNIEN%Z%,T,NP&:K-N(_@;( M_37UW"P#ZMXJ`K<+1EDWJP-;V/RLB_/&&:&5-E+?[),%"JO1$MGL3B('EEN\ M.VRW3]0Y4[)O]YN*O[B[Z^J]5WG=SWK%VX1^\'ZV]>.F.73TXVJU:@_TJQ@& M-D`[F@^KIMO_+DUZ3,FQ$A1F9').4W8`JXG,NK_;_/EY^Y(1[J`@V0A7 M59^.;#7GR7`MPIVFD'GI-)`5?HX@RJ,PQ1"F/LJ!&,LO,J#:-''2(.K)-.7. MB">IM'JWEDVB.9L5DM6HBVM&60:9K)":0N3"LB^KAWI]V-8W=Y33FOL=JP'* MFRW]O&EY\<_G^K'>'>JO_)#"3-KMM0%?.YRFN,[NJVK==G*((P@"A&("9^B8,`QV$"!(H8A%)=@@P-;9@K M&6"/(_9N[KP19N\$M(H_-J!^"89<5O-JY"BI])F\:,`."I2XK#VFL>%+??,G M:FKFDC][]`K-*6ON-88S9P(7R,V@=(V5>:QZU_T%@OUSS39;+$>>=5V][[+5 MOX<-193MUB+=P%H;=1U=#.88XVVZ:[G1^-3N- MR5]CNGX[4[R\F5V(O)W2Q^4OS;>JW3!X M`FO!'KW0'=\99HHKR(LX@DD2L8-0)(+'K9Z?2Q59.@'4UG;IYAH[#B*R?^)" M>H.4WM?&$W(>&5%(JI<'#<\'+?LD=Z;"Q#V2@5E@?(-D>&)HW1RY,T%F;XS6 M];[:;#OVI)O^P:LD]U?G0=7GF5AZ:7N27MKP/E7'D]+LKJ9J]_1+Q]J1K]DY M2]Z8O&NVFS6?;:-+=CL+NZQ91IN^P[(S5]['[LJ2+M1V5C8-=+*K.IWP'^E? M]$WQ%OWQO>IJ^LY_4$L#!!0````(``.#7D?X,:+U['4``-2\!0`5`!P`=G)T M>"TR,#$U,#DS,%]P&UL550)``/ET3-6Y=$S5G5X"P`!!"4.```$.0$` M`.Q=6W/;N))^WZK]#]Z<9\>X@YB:["E<9[WE)-XX<^;L$XN6:)L;F?204F*? M7[^@)"J^Z$)1)*UH\I+($M#LRX=&`V@T?_W[_>WHZ&N<%TF6OGL#WX(W1W$Z MR(9)>OWNS>\7Q_)"GYZ^^?M__ON__?H?Q\?_5)_.CDPVF-S&Z?A(YW$TCH=' MWY+QS=$?P[CX_YMDH_A1?'97___[I]`F!K_GX_NT@NSTI?SR1`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`N7I#=7//'5F;GK9LLW.]LD/;C-2TWJ9^.[)UGF?# MR6#\*?8NV/L7%./?T_;!)K\^2 MZ#(9U?)2F_IUQ%9-8];LWBV3:$AT0.[&^&Y%9$N&:X'U"U(;,WLXS0?,>,XC:_+ MO=ZSZ#)^MG9=UF^4YT^ZE:E%HDPM@FS*_#)J+7+I9XUV&7U.L$5>S^,\R88V M;5FUR\FVSO?%.,I;UO4JPBWR[E<_1=PNUR])MLEO-HY&+?/[@F0[_#8`P_@E MBS4L?_?,MYJW+6FVEQ@X>W)\/X[383R/`9SG6?YM_G4X/R^[]`%(-%@L$$:E)MZ]\8\, MES<,D:9(,@D)5$1#S8D%5`4:"B6L-$0]%694YHUF>:7'SJ1YHMF95C]DX_BS M5Z;R3_RR1KY-74,6!`AIK0CAFB'G`!-V+K$C$(M-$C_&CLP'1UD^C/-W;^"; M(__+59SG\ZEI3>[K%$WC%X,^R@;2.!'@@QV!MR3,!"Y' M7I9.\^CNDZ(.,);U"QG@@A`K!8*&8RX=H::2DZC`'0Y.FAIX%4Y:4&!P\+2C MY;,>U-LSL#[$X]_3/(Y&R;_B87FL/6/]-Z^7,H+FT39QS35D"L MF-"5LC5RM.DK^@5>QZ[SB3%PDU^ET*9/_S\0+=O60 MI-=5+]H'#++G-WVJ^<;^I+7_WX\7T3778BR/[J$_E M>)PGEY-I;LGG;'99P2/_X]7GZ/Y3-AJY+/\6Y<-U_JH^E1!B[0<%5990:Y%V MT@#F=2`Y9!!XA1Q.D+8+`)[[I,X4W/-L^7)_;[:W5[K82IAZ$V,=2J$01CDC MI52&.XP(4M_UC0CO;:G7V;EZ#?BV^9A0,D4E)%)B02`7U#"E%UHTJNDD7W_ML>GD_T>$ M]2M:Z+6]\H[N][O4&`BH.,0",\VPPQ`MYB(&G&F(2[*UGWV1A_$C`K(#E1]V M.$J@MM)JR`/AG.:((8(7@XY#V!!^M%DX^CQ-[$>$8+<6>.V,AV4)G7N>\(`@ MLAQ3(X70H`SZ`66SE!*F$*"OE);T_>Y=3,

    - M(U+-]66DT4UGI#W<#FD*E.?;:KTJO#,/T*Q47$^#_R4;-1S!ZDXAHH8RCAE5 M3F!'A$&!HS!0`4+`$KYQWNLHX,ROHS3YUU3WWRN;^#^6V$9-BB2-B\+$Q2!/ M[E::JX[+Z/2YH9_2N+-&"!D`8RDBW-%*UP$5!Y2CU0;@GD>T>V2:5W<]KYEO MV;8'`HH*8!1!A!DKL1&!GWM*U4.G2]V_C@?Z,"D/"Q>EHM+KB_CZR4W:)4*N M[!,J(G2`(>6*,`=($'AQ*QG]FNN`\J/;,'36C5I??=0>5.!`C*&:!(Z;H,R* M8TQ6'A,0P8*-T7$W4BXWQ45RG4[WYM)QL[A@%[(AEM11)Z"#%F`EI(9:5YHB M(`C^$H._-ERR5]-\'QM:41?H("`<(2/Q M0GT<'E"*1P<8VDF7?:#B0_SMD=AYEOJ/@UFAC*D2'F;_UO%4VY(*F3*.&>H, M)(01RC'!0:4-1X*F&Y][F(O6`;(ZUG9G$4O-RN8;0Y.7M^#+;\*-Y!\!=WV' MD'*HRPU@IQ0/E!:2"SX+\2QG2O+7"3-6\6N28C#*RN*)]:Y5UJ82!IJ2@#H( ML)904,^6"BH]$.`.X$)&6T!X<=.R*R7W/SJ;+?N['Z0H0$X)2SFUP@#'A6)( M>5>'J%/$PHT1;DV.O^\OKV)%7N?QH[JEJR39FE"HF438,@R(Y7[9:H-`N$I" MX%>R!S_\:ILXZU'/?<1F_XCRI&2MJI)MR[K4/G90#_I)RH>/,*<5JS?_D[=$.6T]S;)=J;Q5""T963I#; M=`^U8D0*+A6"FBG`E39D+HFF]FQ,++?9K#"^C85QSB1!VO-JDT210^L<_R^DSANG#!HV0]BD>9-=I69?C M"6/S$NUKTCJVZ!TZYX3U`AC)L9+20D,7 MP,4KSUIK$P@A%9(@J!0H+_LP7,;^BQB=H$/Q&3U&'%WIO@^W4MWAT-GM99+. M,R@6;W^1>>)_OB[OV3]YI[R\+9.QOH^_=3F]K3P@))(X:24JJU'XV5AI!!=C MT!)+_H)KKN:H?57;O!*JR\M,R7#^0O)ID<^9U>%VV%U))K2!U9(%"$-B`B05 M<6RQ`Z:E;(K0[2LK'#A"V[+`*^'P^[@Y'7H=)5?3D\#YBV0'?TX2+XI,AX_' M85%,;J>E&&M<)>GHB:%`3D##RAJ`'`486[\V6JR'!&BZY[5UX89#1_%3=>@/*_\C[\UVA4ZE*.=93G93'1Z:O1URYRMJ(48AX@!0A$ M/GK'P"`%O0XJ71!^0-467QU-+]9/75JJ#]2>Y_%=E`SG+Y?S$LQ>L#I5W[RH MU!JDUN@=*@"A0PXP'A!5UA/GI#HP,=K_TM=BK(\:VON&S_;MTUN1L--T&%\E M:3*.S_SL-'S^0OHUH*S3/<2!(49;)0(-`QX8(-5":H7E`17.WC=,=F">/D#Y M6Y8-OR6CT1K@54U"J0,_IHRT*-",8$:QJU:+1EC>%%Q[M$[:5W`U-$$?`#)S MRWV.[A_)_B%+!QNGV4U=0P.=CRRH=0!J0+76`%;1N0_8&Z<2/]\0WUEAU`QID`@C$"&ZX`RIYVMN#6>_X9X8C_Q MM`%/K=JEMUAMSF`=5[:T?0@E=(`BY;5%#!&6<+V0BQ+=],"&_UPCU(S'=K1( M3Q5=RTWYXCQZ*+6S>7&ZO$,8""F1T%08S@`W6$E<'5`9&S3.)0E^!F>;D-:* M07J"6CZ)'VNA%MJ6]PDU1`*4]6(,QQ@$VGD'7LDGF[^Q3OP$7`W`M6*3WB;2 M;1<&JSN%6#DN*!+2!`1B'@C%W6(!1'GC^VS@)^QJS:AM6*4/W+U/TBQ/Q@_5 M1;TU:'O>-`3*6$Y]G$`!Q]I@21>)]5X^U[@,Z<^3AXT8V]$6>WPR7&WAK%)= M^R?#FYX8!IHP9AABCA@_9UA@3+`8M5(W/F#;/J&L\U=*[!O.]\.D?0R7[\7, MOZEZL-$OGKS6JWAIP'Q?/G8"7]BF563GV]_'X)GOTYM5UAR<]CN#Q]DHQ()T1`-*YD\U%D^MH"?36,[JKSU\NRG"6*CI^DZ3V^ MP*YORH^GZ2R-M-3ITB[5S/2P?8)FZQR$D$%("&!$"6TQT()_/Z#03#2],UQ_ M6^PIW@\%ZOMIOCZ&CH^ROL\B3U\152Z(O43>8OZIUS56GEO3"@$$+`@4Y()X M4QG,):DRK2PRO&F9O3W:='L%,'=MAD>P[*D.YH?EB9]?P',M MH`PP$WY9CQA`FF"[.7NN@Y(#+1?$I($33'`N#(,@,,)YV>824A\$'$`9N+9, MO%M!S.WTW,<,<3&Y+.(_)YY%^]7_\]D_>$/-RQ4]0F@L4@A((QV'Y?L$$0LJ MV8@FAU+3N$.C/W\!6RN*?B40;2Q3N;)/R*V4&B&F'944.NNG+%O)YZ>M`R@T MT)J%-R.FD4Y?`3,;2TDN;5_Z;1``7)8R)I*6Y3D9K.3BRC6]+_1C8&5;VZY' M2R.--DJ2,_GD6D?IL'SEVZK99GG#4'#C`N10>4&>.4F$0+3BSD#2U-X_\JWR M9I-,*_K=W?KKBS4N:1IB0&1`B*'4"8P1LDXLT`Y=X[IJ>S3B=S7-2@LWTF`C M&\OA,"D5'(UL&@U.TYOD,O%F*-:7TEO?*Z2V+,7LG`_/85F*&3FRX)LXQP[1 M\MN:+.M*G8U@\/2Y2?HA2_75>@RLZ1(Z9+$#6A!K%3<2,6P6'`?-RT/OF_-O M#0#MZ;(5ZV]K^@6O`@)K+,!(<0<5U,19N?!\Q#8MKKI']\2ZM7M#1;9:8:CU M"M\FP(PX0)!EDAOBI5"LDL7BQG'`OH&BITBP([6W"J&6*WRK@&JLB1:`L(`: M)E19QF,FB<:'L'3LR+)-*GQOI^Q&L%%))N^S-/;_%W6+-Z_K$RKLG%$.<@NI M,GZ>%&0QD#05A[*AV;H)LVX4W`@4+17S=@!;QS7!1C(%'>`TJ(X'&)"VZ?6! M?8L\.X5".[IM-J,\%.-DX)++/"N2PF63=#@KZW03Y]%=//$_E@QE^5TI>SRL M^6*`'VE%N(R!T_`X28C#`5"OE MN)4<(^D7]I4$S-*F&?+[5CNM4WBTK^=&2-F#MT_P``$G-1!"&Q@@+)%82.E< MT/04=M^<34_KZSYLT.IB^Y.WGB=X8^*O\2B[*[]R?FY-TNMMU]VK*85$:*[* MZWC6^#G8>V")%J$?9JYI6+UO*ZR.C5]G/=Z:$1J![,.D=)P?K_[7\U!\_!KG M?]PD@YO5//V1C$8J?A\-5Z:X-:<86J*P!@Y#C?TG%!`J024O=8V7]?NVENL1 M=+T98W_'1SQW797$*MM[OZ(8 M:B1S+\71DI03WU^_#8I#R;)$#L&9X9A*51)9#C$33"&*+ MD^!_93VJIS.N`_A/.MUSR?SEFZQBO32`'O`\_PH?K99KL%$^3^!S MO^7],7_"U2#,Z3K_X>X^.S(.'7Z=?V'*A1XQ"4S#)!GEDGO=V$Q"4URJ](_- MA#S#V7AN676Z6?;0+L8:+I0)!AEM->54*3Y7I1+1\OWQU+KW9/381Z&Y$D&F8:G`H$;UQ^$>5Z!"B4^E./KGAW M^9SK12#=^CMFMX!UO5T5C[MV??-ELKQ]O=!U^<.2M,9;P@,V3AG03*A`P@JJ MJ$4Q1EY:L6=$Q>_&0KLNY=`IVY[9Q&9Q_:FZ?9AG(7^_JM=YC;RB)/P^^7MV M]W!W+!.+OR@!\KG^I%6%K&(3"$1/)9:T)WJ0A@IO@TPH@I[8Z%I?V+IE)A7RUF]7->_3Y;_KG*] M!G-_OZR_3>9?9G?5507_\[J^^:->PY'PJ7JL4[6NOU3+NUP8XF@[YJ0O2]H% MH(%$2GJDL*!4QYWS4\.15$K>?^(?9Q54IW1^NJ0W%*=/_\9DN:2>XRC`>'1! M*D6#VAF4BA3?U'G',9;12*M3=C_6V*DWM74`].TJ=?#`V11>?SGKB>-=?6\2 MQ+E@=.1@GQK'*49>-]@Y1(L+9_P3&AJ+S#KE>WZ)^F8'582/U7_EYK>SY6K] MY"+.KM]C*7W$HQ-`[Y5AH)E1A:Q406B[.\\\+:X9_$]0:D"Q#%&DX1P-CAT6 MF$H6<."("(9CX#OXI2AN<(S?9Q!J`!&4W=;9OL^F6/!JMJ7/G9 M:M/'XA-LZ+_5?X7%]<>;3QFW-V_Z]/1]*409,+%648H%8EHSLS-UC9?%U6K> M<>1J)+(Z-Z__>W;[=5!B__B%B5*K&'),4L<84\0+M[,+O'>E#>WP.XZ/C458 M/5/[E62'579MU]\G\UP#_OD\3N?U,=^68+U3CSW!TBA!,#54-*XH2^:`O=QD?F MCP'IFZI:31;7=\U:N-]&4=[:$MN-3B8(+@G5*N1RU,Q):IJ41VF<*O5)D7<< M$^L%^6[KJUP]+*=?)ZOJX_W&G-NX'4*NG;R"7_,?[V=;S:+`7WK^KWV\:20Y(PC3AF6V@.(`IN=/D5U:44# M\C[C5!U"W6U0M(\(?\M0,'+"1*,P"\QS&3BVS:;NB"V^`4#>9ZQI<($\H^%` MO6HV)2#&UZ%&1HNUI-Q;8J+#.B(X`;"P'-:Q5?R@UZCE&S_1Z*G_YVLW>3V9+M0-BO%R#I$>RB M8R%.9LM_3>8/F\WI]8AT.SX=_:"$"9:**<$\`DRQ982+9G9,D&+]XK*IU#?. M0VBGKRV'II-Q==VBK_)!2O;T3:#I>6LP9P[Y!DM.=6GNUMA,KNXX M.PY!]%4&;`I_`0;@']6Z;3_`8P_GWKXZ`6(2F6@][`[&8BDCD0V"@=C2^P]C ML^YZ.\G'(IF>N/WYX>YNLOS^\69CC7RJYIL>S/6_)LM-L_GFU0.LX+Q*N^+U M25^;`!WL`J.23Z;[6P$<])TFJ35`!#'J-F:)42>E! M$%9A2YE%1[=3'1"+-@K?<0]*VCOCG`F2*:,X4CJ`E;5%P[E0VN-^1.9LSRRI M!X3_'#M#65?D7WF#H$)2[RF3`@3CA,4";47O@@SB8*"TKX`&O-YL"L>.FZR^ MYFG`CP#VPK?)_`VO7=NA*5BOP(1P`@G%@L4DNM#,F!->G&K[JV\"K9GP4XBC M4\![7/:PB!>K[(I;K.KYIO/3M9W,)XMI]?EK]2R?<-!E_QGFL2U&%F<+>)G9 M9'Y5/Z9VMECM;88GSCE#V$7)N/(JV."8M#0ZYDRDB![,$>IGYELWP.$Y_OC! MI!$Q2AM#UAFJ%K3Y,7GDP;# MB'%-80\S@0>).#'-O`B3Q?64H&^RHO38!R"'J^?-F;M)LOE=SCH-F[S M?7I2F_')<>]#+OWC!$$LT*`(:^8MU25$P#J2^TO3H`=T!]ETOH$!D!T:L5[F MB\*?J^G#W'ZG.O))24A$)$'$8125X!+E4.`6"^\NH5UG/RSK%^=!=J_IYD[7 MZE,UK>"M8<'\4:U;;%Q[AB5AE/3!:66X)4(&A/UN96F-2D_`$46.>MJSN@-U M".KDLK&+7'$.WG(/59Y_+"'EG% MO!Q1'8=^B-,]MH,;\FT-^`0;8[0*1R(%]D$(*@1IY@%J7JF?]OB*"/5Z,O^% M.'(*BL/L+O5]M5Q_OYI/-D5XLX*UJ;VP_^#9-RPA234C8$=JI2-7\,5DY^MP MXG"8\U>SJTYV\G2(YJ54`V`4A6B9M2%*9DV@Q&U7BD6Y\>"E64TG1B=L0$G]^IV%Q_7E=3__]M9Z#-%9Y2UM_;Q'0;ON( M)")W3C"E?23*^0B\]SLE*Z#21.@1FC^]9D3TA/?`;&N?,/'VH,29H=I%%3EW M5`C&2'#-#*GT%Y0DU[W0WV;5:2@/&4"ZFGS/$8OVH:,?!R1CH[.*"K#X@M"> M!R=P,S-E;7%7BE'SIUB\;T2.3L)T(+8L'ZKKGR'83YC7QR0)]J+5.E#N--%: M.%`$FODQSTL=,",\Q?KA3">P#D$;OY7&]AK\81 ME,T<`VREE^/5ZX$WW0$[3)+H_2Q;LE6NVOCG?':[$5J+8VK_P"2%$A8[1X2@ MRK*<^K/S,"CA+LBYUP.%.L5VD`H6U6)6+_^HUVT4G)\_G&R0SCN)K8W!I0>_,2(1%'('1`:*FK3,"NDUVK'?B](Z.2-J M!-$C5[H!]3P.FZ,<-8EJ%"7GA'/!0(UGS-/=$I!6E48FCV^MT+NCN`>:G(SG M&:RD5E&E-\[QG8$=9%5,>D##& M*&!.)6>$*L>=U&(A(CAG\MYTTJI2#,E`8K M\(A:&@YG@76&\R`:SD\`?%A,YP_7\,Y7]7(CSQ;EC5L5+>ORBQ(8%I0880C8 M%5Y(;ARGNX-?EC?/'G>V64^*U3E%,]#E]D>);F9ZJ/3**Y].8)B`02L8$=2) MR"+H!$V*C,AU'8;*;?Q6+?^L>\^W/@\=?K[W?J(8ACJ+ZT4K7KW\:&(\1%BG M@1-ME5+",[WSE\`I4>I0/SH^\XY(=:(,!DFPO;[>7&V8S*\FL^L/BZU']]F; M[\NT/3@X"0(*K6:**F(4&#3V:*Z#I/E`I!9/9N1KVYFT]G^J/>APISU'DZ]_"@HMTX)1`UW,"_A ML\=0C'&/.Q71!4*7%3B6.K)2[ M(TQV'0EWSR*W,51E:!=>>W5H(DH1[B*A4?K<]`Q3&W8I"S&6GMGX^!S;BPJZ M=0'V,VH-W53F:@/HUVH]FT[F/[[5)768D0)A&YF6SBJG->*ZZ2#&08,Z4X>9 M']W&((F/R\ULKC?^OJMJ^?DK2*>U^_^M!R3E,-64&2>\%!H1!>QL9N]#O*`> M(]V28:^7OR.TAX\I;=YR91[67T'_^T]UW9I?+PCN?0X**$8C)=8\LBSEPYC2D(S0Q50:?KJ*-W\ M`_.H".%S<>CCPWJUGBRR&G\DD9Z-3,J@0*1V%-0L"S,.`=OM7$70KK3LQBB= M\@.SJ1SF@>/;!;I4B]%)$^><<9A'+RG8"RZ7/M_.63%7FN`Z2N=ZC]3J'NJ! MZ76$"K5G5,(X\*AX,(Q*XRF+@>^64+2L5"\?X;6-H>AT(L1GH=%!S>F-$0G! MY*B6.&CAK?6<>;.;F["DE#ZC=)D/29\B>,]"G78*T[YAR6JG`TS-(\5Y8$YC MWZ`FJ"C6O4=X9V-8$I5C/*PS<(?*ZN--+F@>Y_5?9^\TO7N1X_Q_/PU+#%/A M*`L8,VRQDCHV+?"$C]X=K#S2%2BZR,GFEJM3RDD?&K`(,J753T?(F3[%^W.;HS)\ MATGN_=^'U>/EH!P_!4@^P%I:?:D_55/X?;9I&/F4<_>E[FY/Z_NKDS$$:4F\ M"&!B6B6BY*I!VU-26FIAA)[K`=D\,JD-4PX$Y`V*9.8!_'E>;0BQN#9W.0WA M/YN_W\/S-L.3I90YF+716!E!N*&*-[/&2)J@2O#TA5^(YT^'<(+*]Z=G".&__D$1"9#F,JRCWBG@2 MC"0-`DRK4J?1"`.-;.F)O;OV!QP$^V##`?Y=C+FYV':A\4W0+1>[J]4M7=5.!+7(&/C`';RI=.P!RF<]WC=MG8L.ENW8Q,%N6M#P-B'.4=O M.8"[G6_@$I?6H1JA77S68[4,[K/1ZT47R&:-[`!K5TOTU$>GR(S%QGFM/"-. M$R7U$UK6E)[,(\SD/14`5Q.% M;^:K0"6YG)SAL^Q[I\$]!+W:YX-TDG.8`F?:(.NY8D@ZY#%O>B'"`D.B=&,[ M/D;7>]&!`3-M>L/_C`S,IORJJ^S7/0]+S!))&=.!&1.I0\$Z#*`;1@*)\F6? M^E\YFV'([-?N$!\D^W7R?>.K_U*;Z?\]S):5^3:9S;,=%>OEY\F\^EQ-07LX ML`T>\91$*!6PW%%6<2UL_8R+G8I+:>B_*O.`/I@^*?(R@[8W$0R4A#VMJNM5 M!`CSRX*1]/LDJZWK[Q]ORBA9]L04J8V&8PZ&ES>"6&E1D[P6F!*EEZ9'N"D. M21"A60=K#5LZWO M$Y`/O'3;:^]SOLQMKU`:S%&=SR2;`V+35:.ZR=B#87 MT,2DP8);:7KW3E_PQMBO+,;E..S$89B,U,R#7L(08\Y*'+BB@+2602*M_Y^] M:VMN&U?2_V@7]\LCKK.IG1FG,CF[M4\HQ:8=G94EEV1GDW^_`"72-UD2(1*B M-.=E/'9($/WU!Z#1:'1G;TM&F-:Y(`T'P_^$#&Q+1??ANM[16"`66Q0-E2@] MQ@YXZ%!"1`OA.'$R]ZK)""\\E71=]X=X:9]ARE244CE?W:Z3SOQC?I,F\^N( MV_1'Q=Z_&SB."I76$,65458S16&SVF!T M22F*AR3A#O_CJ556TG!M$SS-[\QB=9!S\NTK03,445>:26.D<8AA8AKIM#6Y MUP)R0[=/9HH.PLM^0"\]V_Z^F-]%/=QOPD=^3YN[JV^SZ=VDR]RYIY5`*2+. M.&V9=IXYPQB4K=W-7:YS:(1K_(EFPGX54"88\:$=,?DD[-!*8%A+X8@CGB,( MHWT%03.W$\>SL0O:O8;3@^E)\27DM3'EZGDW;>=AS+[WPX8`X.H,R"5 M3S`R;BZA:&36UN56%1AA:/:))L!^@"]-MA?^J]IGM06E`XEW0$N!,.JP@HPA MB91R!*#F")X3YF"N)W*$\=@G(F'_2AB7`Z@7QT_`1G)I&3(6,$N0\@C:A'3L M7LH0F'M$TSU<^U0NR"%H.!C^)1CH;F^KZ\>K6_?S^OMD?E=]B?;1U7QSKI1^ MI$/U'Y/9GJ/"+LT$8Y0SE%O,$$(.(N$IT2EBA#+'&_-^`%1RIRF(Q@6QDGDK;'/`22+@PX<_;#CV4*LE\F#Y M>"E,.P[JRZ$81T182B1!&'(GE47>-W)+6\Y\6U/,S8>-L3DAP;H!78)@?ST] M/,QJ-":S!HU/\]O%\GYR:&'3PUH(WGGO,2+Q!U,0(J.A:F0W!I6K/GV>UMDP M,)>)&US7L?X\F>XJ'_3RL0"))RG>FPINL/0&6T8:*80Q%W3.VKM>WX7Y9<-: M**AT<5]]G?RL5GOY\>K)0)3BW&&GL/8:4@!39,]&%FNS4V.,\"K0\!0Y!MDB M_JQUKL*KY>=H?6Y^J8/UUV61_/1G=;.^)K()X;^!.YB4T5K`"E)AD'+$(D:U M8U:V3F>@U/!W?RZ&;<.C7\8PWWH2%H?24]+E3I-\YYM!8TDL\)`YKCEQF#-B MVTV(1I?DQ1J8:?TB7815B_F/"'OLY=5M'<2D[E/RK'6EOUU3VNX7`U04,P&P MXQ1@@R`SJ`G>)QS"W"BA$9Y5#LZI/H%^0:G2)?06]['E[_&9Z8_J976MHJ7T M7O5B;87\6<5=4S1%VEB^SZET253U33VWC'L.$90,6@$]EL8Z!=%>8W2P<^E.Q=.DDEIZ83&$DF-' MO$.DD0*0_64(SV?7=7(>?%QAK9L22JQ*]<'W%L12=QO4MCOM#QB1QS<>XMJ- M,%$&4R@X%2D(,0@OJ$K:V&A;7'FGI/L_YK'GLU2N^S\6LX3T;Y/I/$EZ M-7].BJ&6<1\SO[-U3K^UZ`T0&8/@V$\&A*T@1A/,-+!:Q,F$PW8RH3IW,S'" M&;TD%0\.,<*D8]7@86&^G-HK\8EE-[^8FN1GFU[^^+B?S501T78RQ_FVV9E!;C>6( MT7#!!5R-E;*8FRCA0>]T@E?,D!<=9B@AV5F$L(`.$ M:]]@J27/OX#LC\@^@P!.3/8_(04=,I2*(46&QML!0)ML!;;)SPX\PRON,V-E1*Z<[ M:MMDNW]QZ;GH&=L:M;9#AQ5.W?9&``1#@0F@4@K#@`5$>TFQ1%B2].,T9UR; M$A:'9#)Z^VA@1&C+H6`"0XJD1\#3C40T"I?K#1JA=_1HG;Z[''X4E$4BFR>S M:K7IYV^+Q4W:MNP*8][R>%`(&L\PCW:"=PS%*0>"C53,2):[U1PA0?(5^C9. M^7@PC="#WQHBC M$-S-A;04UQH&$H-:O^DOT6R814TNEK5?N9%CBXX_?CA`@;BAG@@GK)9>QTE2 M-+T$4N1>B1FA6_1H/?>&8ID<-1^RX>TCP5+%G7%(<^^LA(3$I;+IO=`^U^X? MH:.QO[&>AUV9?>'J,95WW%2]/<1@_.B5@!1RSLL($I58((HI:>!AR-OALZZ= MK>'8$Z2E"'-U6]LP?RUF.T.Z7S\9)%?1T/%01>YCBI#"',TCMU^@:WC#FRJN)WTM5A&Y?.V:*N,[*?2#O?"]9'_!R3GD&G MX_IM/':-G,2RW-N3G8W7']7RV^+<:-0GM$7\'%7M<_VMFD?BSV*OUQ,LR.\E]0[I09!N-#T]%RAVGR? M+._V[)S>/QX8$DPQ2@`3GAJKA0"M5,C17!]:Y].3:.(FVE:A?EE$TTDQ_=4Q@6.%T;P%@^`LLB`6&-.?8FQ%>DNY]HND3V')99^KHZPB.6]E*2OOU^.N/ZO'[XO`ZB*5Z$30TPGGM,)161A7+ MN,EH=`"YS`VT&Z&5U?_,.%8M%O1$\,)HZQ:/58:#C M#$$*&]FT1CR3@9V3#);8!P[#P6,Q'RUK=/(MZ0.1QEV8"-D1PB!$'+*6.M,G= MTV[?K,N])2+_/I/H($"7H%O79"Y60H6$Q)X8;BQDAG#4#AB5G3=FC#X;$-I6_L]$VN MH3$OSL%#^14()%XH02UPP/)HNB+$&SEP_CT:V#VXX>QFI&.`'(?9?Y0)'SR- M&^-HYTG"G.5"Q9FXV1@+3EWNYA&.,!ZWO#W>$=VQV=:OY]`OU4/:5.5Y8RP*I4WVHOBW.'OM2D``K1E,*!T6]E)(0 M8!HL*>"YYVCP;W`6/<<@1-W(XUA]<" M49.]I1TK*T_`HL[&PS$:&@U;7V)V+%]?MA6D-3V-$GT]18QLQ;Z;K-]QW:#-!ZQ*R,\XK2B$@N2'LP*Y#VXE(M ME?$0[XA]YC&J'"'5LXR;3JT&(#AEA".CG4,&4D)YNUA#@"XH`_METOT(998@ MO)LLY]&$2Y;;H9;+1Z\$QRV2WDFFH)$&0>G;!58HK7-/T&'W6O5G9V/TA.DI M&%,/L@YTJ9\/WFF-'?>`>>P<959QV\A%3';9I.ZK^.#G5<>K=@]7<@`]!5$V M,V$'JFS>",H;"F`$2W.BF65'FX&3)@[0$7?Z[FMY]CUU3 M/^(J>E?]^73_K5I>W=:]7ET]/:X>)_,4V7;`"M6UJ:`!HS0.'@VD@S)E9,%- M$BW!K,NNSC3""LI]KUP#8STFYNU;Z3JU$VA=)I@0%P>VX\I!;W1K?PI8K`YS MB7C#X4B2R<8<%9R0BB\W$2_%Z$[&CUH*T"-,E2&,^730`!UM;SX+*=D%[3-/ M3<:>5/""CB=+N_NY!OQ[]3B]GLQ>=^_L\R)PV/]^EF@GH.^[Z816VNUA?OU/QF=ZATT=FA[>NFHO#KKNZ?*PYZ M/UA..?%2.9,X;Q630?7`J>"`(MY&M?JYW173/'.]P+V MSAG'N";1EA8$005-(R<19F\J^S.D3T<%?\23'N`LXM9[W4V[N)],=UD<6Y\/ MC@J*.%.*,\>,A5QC]$*NW$OS8Z;)/A:` M5CKNL)"#CGF'4M0\::3`VF:'R(Z/&T=J\>W=NGP0RV0RN[]?S.N5=B\?WCT; MC/"$02\@!8XJ#:VUN)5'@@LJMYRGQO?E?8X"L`0AU,W--*EC,OL\F=Y\FIO) MP_1Q,MM+CIWO!6HIA5YZ!Q0UVG`O,&WD!%KDGD*/T)'5"U'Z!+,$:;Y4CW&. MK&Z:@ZV];-G^0E"(*0B,M<)X3+R51+62&9&=,V6$M]YZH4DO*!:95*ZOG^Z? M9LE3\5&AU?T3S*%M!`VHBT88#T5@EF!4T8,@JV'C926BEQ+=X1K5;^6;H^@%O6T_!ZGT/J*QB'N ME?;AX!PW4#CGA,2$21CGV!8F_K+2],`T*7%4W+=7)1?%0M'&KTJ+?YJ_]T-^ MB1SWB^7_39:[(J`P^GX[ M5QV)=)DE[*WD/2<;[.<#(=UK1(8Z88S2'"LO4(N<J":(@P\P@1%V]1H%O?)C=0,JMSPB1'Z&DK1<0#8QYAH$$.% ML`%QOVNLUI(1R9M=,/<$Y?HR1^A>*$6<;'"++;*?5JNGZL;696D^KU>1VCYP M]P^SQ:^J25#\>3;9=>K:M:E@C(N[9@FUMH)+G/;CS4$DAP[G7JL=9UJ:>1X["?#D@(3U*:>62`Q(XB1%O#V'J1N[<>Y]79(GP?FK591W&_3^;Y@\:SV0K*UJ1#)\XY-7,>L1(W_G2.`<$_6O7CIO?7`2WCL7Y7\[' M9^\6`81X*ZB5#G!A.9`1M69%8"3;0=ZY+L"%4?04VAGL4HU=7#_55XOF-^OT MNI_FMXOE_:NU^,!+,JGA>LQ$^P/4(R;])>SZPHY++P>_&XPGP"DGE"=>8`\< M3]61A!;0:7%`@.ZN66)57?_;W>+'O]]4TS1!D/0_24;R8EZ(?PKKWGVI[NI: MS_/'/R?WVPSXCQX-BE)EE?Q_JLDR+HUV\OC1A/'1XT%*;)2"7%G+%:;(6$(:.:3*OMPT MHH.<8=G1$[!#31Q^.JN6)O;G;K'C(EU(T6A7-,(,,%1''+!=IIC\#< M0^<1'=.4F#2.P;1_1C3"?HWM?T"%EX\$#PV2SD/F,.%82L`5;_J+M+N`\Y-A M.7`$F,,I_W.SC]JQ6&Q]-K@XG3'!&?441IFI\!8W$CC&RQ4%/G,Z'(/J<+QX M7L!\_,NVP_P=3P=#*8J\]BZ%N!/+G!"JG=HTS0V^')&OOPPWCL-U:':LF7LX M/UX\'V1<^3`@SB-M"=+,`^0:290`\/Q=Z"49DH]L_QQ1L5LW===FDVWN[W?/ M!,B=P$1HXQ4&*HJ.K6EZ#"#.S1/7V>U]KEPX!LW!/!3/MW,/.1,Y[,4@+7)8 M6^FLQ@1#&+?6K=4DB"_G?CY7JO2.\6!.Y+=I73LZCL>7.UQ#+M,).C8(,4>U M-7*M+@28L'8O=\M(^#4BJ^.G_K>#B.T[`7-*+97IVA*34F&IF6ED5$AG9YD= MS_#L3\U[TACG@EIL0-IT7WJV.OMQ"9R4'%H1Y[RX%Q?`0HJYD9S&7Z.QO=>U M-="!\/7WZN9I5EW=JCAEWZ2$FM,?U5_5]=-R^CBM5NYG.A^L;M9UJNX?GM;J MO+I]QZ-]N=%Z_5!@DN&X=V78(2=]7)R0;M'D"%Q0R0\A&R_53D?!OR.!IEGF[` MI'/HO3GI]KT:B*!:>NVL8>D&)N1*^$9:+UAV*9OQ47<4G#F(Q]GJ*4'&)H*^ MWC9>/22P]J8&^?"=P`6T0$)LG&7(.P\,-XU\DOH+RH#7GZK?[AAZ`K=,3JMH M'$VOZ^3*AV3'V_I\P(!YP"2R2".G&=<`MJ/-6);K-!Y1Z,K@I.D#V#.P%7\_ M(`U-7Y\(C!I(C.%"`HJH5DX3T*`'-,Y-W#A"6EZ&%9BKN3/@O;I?/,UWN4%Z M:3]PAYU2$`"#H=!:>6];Q1&8'P8^/L:7IUJ_7,]26#$?8CT-G+\+D41S"Q+I M!<9,P_]G[UJ;W+:Q[#_:Q?OQ$<^,JYS89<=3M9]0LIIM6/)+:2<^O7U`2 MV>VV)%(0";%9ZZ02N5L`@7,/[P./>S$!7NK]"JU`50V-U[Z$V&%/H/^'!>(M MT4R"^*8@;HG45379`ZI2VPF5:;B>6(,M)29*8S`-XF?E>G,\!X\)*A_8@(PP<:#T)D6^F773" MV7:!<*6,Y1[J2"5JD4%"U',ESF:K#CC\Z]V/R%?#@9OW;;WEQN$@+ZVG"'"K M"$8QD)$0$B(TMDX02;`@5]T5ZV&F:K,IME59^;?E['.YV.G_@SCNWBT_5#:A MRI6Q+VNUKO]:E8_=H>;6K8#4[H+7@OE M%11RET^UNJ@A:U1X5=YF@O3,QZ15=@'EH.W+P1Z=UF/K/MXEW02EHLM`>(SO MA;).84R)JU%PPDZH@LRP)'E9:68X&=Q,@3Z^7Y??9NO'?3ZL>1D_MF[*7-91 MT-IAIV/<:A@W6&,D,*J1,-).2&D.0Y`N>K$O]'/PL#$M^G%G7':HM5CKDVV" M@EX08XCFR@/K!44$-C`:F;HZ-,)-E]N;Y+ZDD)5E>[2.X+,#Y--R]7E3K'_L MWZCO#]LJ^=ER'E'=,>+Y1%MM]%"/#(H#+ZWD6%`/%*&:8UFCRZV9T"&)'AAV M/B2ZE5!R4/[]NO@^*^_H@&2T@ M!L1$VU(C(#F;D)MY>Q+]DMQY("GEX.ENJ!WI^,MW@T<6.:ZJW#N*:X2,Q[:> M#]4^-9W1*$L$C8YWUXHC&[T.;\)/'E(7JIUJ%S#E5G"@`!<:<6HT1:IYC0!+ M/>HPHH0XXR9=3X+)1L`J-5\B!\\T#5`)05VU"JP51$P8[YJU"PY@:K@SH@0\ MXZ9A?[(YS\03"0_-:A%9LUK/JGU\M5[/EE_VFVEQGE_6Q>[SB5#ZHO:!(LJ8 M0YY`+[D17&"HF[>*RE0K.WYUES&L'E(BO;*K&M: MVP3$&'5"<>\0Q$H:H$4S9DRHFSA!DD6X&@;@'#Z3+=;ECQT0;Y:;[7J7]>)# MN?E7R[KPN6:!*$85!`P1AR0%<7:HCGSCORK591^_KW2#I>$>!9&7;J;*GSV; M[[+QM:[PGFL6.&#.(@,Q4UYBB3C&OIXE4F8"9JU?89]DT-789ME?6*V+\LO2 M_3W_6NGM0^;WU@#O7+.`,",<4.2@YX@PXI%E]2R]0=E./^58VNI'W"\7^_M# M-_-.Z+.#D7Y=_/LA&NRV$TP=6@=673'!D&/-!4)<.$CK71.)L4S=>Q]1KM;Q MF,#^Y9&5@\?&W'W+\W3KH!P13%)G/.9*.VV9Y?6<-=6I.:-':!=[9<`I=O6& M]*W8M6G>P79KV:%YH!1SRKGEP#D+$'?Z"5%IT!2W(?O@0`=^70EU9A/:?/Q' M6:SCL[\^OBU^%(ON5O1,!R'Z(=8HHS446#G@H3#U-I=4G$RH2N>H#&E_(KF9 MMOMU"DE6]60_`5M`J%&2&":@]0`@#QJ+(MV$XLZ^B=%%!?8$>U;Z[?;!-CM` M8'<;^VNK8+47GDK"+504,84@KN^AR&@+)I37;"#9GV+8U5C?BD\HB4^'5@$0 M[J!AEC#NO>#&0M/@QC!,79$=\V'=['Q*P_I6?,))?#JT"B3J=Z>45XK1R@-5 MGC3.+H,T53^->9#8!MEKO"J_7WZCA(88O/VZK#M0Z,CW`Q16 M.0L@),)2:#`6O'Y%%``P=4-ZA/[UH-2Y'MH;W)A,NC;$I)FWI6<$0%Y,;CQ-]2@/VTCF3FZ9`:JK5ML!!BKH05 MUEJ&D&&4ZL9(>#?%W$9Y>?(R8VK/$LEBMF>;KQ&-ZG_NWP_EC]GBIW6>ISF< M,^5=^PA`>8@\0$P2([U$3//ZZI1"U$QHY[Q'+KRT[@.AG25*W<5$E4EX\FC/ MQ:A'OAZC*,HM`II[@JCGC!GK&S]&)Y]9'&%T,1R'>@`VXY'7_4W,^6-%>;]8 M_?6/XNY+\72<4VT;B/XHSB933.@N$&4!,-XHX16UT5O!S1T[1:-QF$Y$,AS= M,@!_4V\MQ4L+F$;E[+VFU$"-.$>FN1*CN/(3NE@['+'Z0C>+,BN7LV45E#]S M32_C4L<>`O`":\Z%Y,!A2".XHGES!'.I5VF[G\&6>V8MBR^S;7'WYRLFV#"0 M)UUZ/)Z&S:R6F]6BO*N`-K/U^K&*;G:E%RHM._O%3SQ"KQY[#Q);2@B.?[1B M3$B[*ZVRQR&^AJG;!R-TSFX;9BFQI&3S$#'IK M*$/:&F<=-'4J!N4,2$UL-D)O;AQ+(OW*XQGW,J2+OV&-F"&RQ4.*."$DVBAF M+:0"6L5VF?FAHM*XUK6786;Z5##D4L(^+2]?5B:FA^<$Y;`4P&D'M4,:DLA: M7V-IX@^GLX[5#Z5.5HG)+XS!=$@5S<81WD1?'+L?78%Y&).:QU_M(+UHA^&* M7H/VECA"B?"4:/T)R/ MCHU]"B8;`9,K\F#"M">2"T(D@`H(270S'^+_OS3*P$2[0AC9R#50.13C`19. M60&,4%@SIJ,3?YAM?+$F=&ISG-3K3S99;M<<3CRW1,C/OQ:L(XX8)R0TCMCX M9A%9AX8.4I]ZOW"$RJVOH/@*^+J38%/,_^O+ZL=_SP\/JTA`FK]5!"#/"%#_ M/*C%XC"\:D/C5/QZ[NL!$(V%-AHQ&O_KM236U#.2)+D0V`B=_#1!KGK'<'!6 MN$\?SK$@_CIH@#FGP"LEHU93J-K]KD?L%)C``GT_`GLI_;K?]*0M12+A@!V%B!;;1WU+K&E;5T M0I6$^G(">X0S+VGZJP>$,,/4`4)4_".]\HXV9D]S,($J9OT*^Y)Z0)=AF_%R M=*_U@`RVA%/*O6$>&\F(T`UT7$ZIP'H_PKZD&M!EV-[*<&U^BP"\76TV^O%P M*N%#L=C)<_.U_)Y@TMH[#(`92H"5SB!OE<<2:-(@(Y+W#498,VA(8]<[T!F/ MM#T?:=2Y,AK5V26Z ME/PY^OU@O=6(@S@I*C"RQD-?!Y4QT+03NN'5@VR/9"BZ%M&\]N]MARR"1[X= M!.24..(9==)48:E@]=Z7%R#YL/4(B_3T;[E24;Q\`:?($/GRM&X&>, MV/_TV>#^6%4BF2WV%^>/L**E1:`:JJA=.9;1[=,:5E41ZCDQ)R>D/ZZ2Z&H( M-,>:FJK+#>XKN@T\QA>$(HVY$YA::`AL4/=6I,;_(UI$[I-S-X#\UL3<;<4_ MFTDB$5]V$XB)IH`#HHQGRAL*+:LWWCVE9D+*+@]9+F#HE;*X-2/K0QR/U[/R M6%=!>*45X<9);YU0%D!7'[WT&"0G:^ZN$G.GPAH=07L02Y8S8_?W\47:[J[X M-"CMV0SF MM_5JL]D?GUPM%M%^K&-`=+AG\+'81F34EUFYW&R?OKCY^/#Y?XOY]L_5$VYN M>;]:SXLJ;/]]MHF]_+'_N5JOJUV*:NGPW?IC^:U0(04<[UJ") MTQ)3J!GE6@D(,&Y\'L6GE'5P@+=A*F+-J]KW4^VDQO=?#=(2RZPT&$+";/1^ M`&WDX@%.3?!QN0>PVLX6KXVD/:%Z`X[\L=KN\7B_6I3S1[>(KT9U>[RX>]A] MZ$ZAMIX"XK:T*C/6`X3DE^/[@@48K-0E:[WFBZ" M]X08#05U&F#$A?$*U+.'GLO!X_,QF.*K:'&9JDM%_LIXO7GLSP%3\^,QQNWC M&W.@@BE%!4*82A)])X==8X4(@ZFAT2N)W_MX3:8FX]S'?QH)=#P`U'P_<``T MQ-X[Y1P14GCF;#TOCI-+K'8X()2STW/4('-C_G^D9_3`[N0%%_M_Z#M!(SHZ5!7&D`*`&\ M>9.-E:EG)I.K4TU(8>83RS,Z#Y+K_(:U5XX>K;]MJG-.,1`20>TDTHS1*)Q] M&GJHHM9I=8^'P>FIB,?/AS4W[^[?/6PWV]GR[B?*OU]MRMT!\X2:+5<](5!) M&?0$0`LM`5X1C5V-'Z-F^&#\=:16[\JRD\5<J M-D]>2"LQNS8-A!.-I`-*8.?ARDFT@^`=SV=XLX\?BS]G? M-W+8FN=?Y)"=:140$]Q!Y+`S3'B.A-<'B2GD7/L]TFSS[&)>SC4+$'C((8*" M61PC#L61Q_5,%1(3R#+5J[Q7@T&;X^V\90&I_E]23A2V0,?'08J90,H#IK$W M1#,)K&J]=-+1A#Z9_%VP_'FUWN^M/RUV-VO]5PHU`SF9/>.2YH%Y*J0TU,&BG@GD:"H$ MZE^R77AS'=A)M'D_6T=)?)R7Q7)>;**V/9D5X]S7@^.6>,H(=Y9#1J!WWM0C M)/Y]-VO5U45@'DU(%^RM=-/:'V7"`4[,?OF;EE$Z=0;'/H90^+=?%?/5E6?ZGN(O,/U#^W`&Q M$RV"@E!;QYW01%>9)#W@NIX;MFP"Z9YOH)+Z`3M))9UX](?Z:-"'8O.PJ-;K M*X#>SKYOBM6]^OY]4EM_*O5`WL^7=QV*[7>S!^:O+ADM;S[;;6Z^ZM<+'X> M0::%[_KA<1POAW;14OA%_03/H>9&ZZ@$#700"V7V.QH(00]E:Z1^0RRZ[&E= MUE'0W$&G%5721`BBPTJTJ-'01DYH(7T@EJPRPG\+S7#+G;';*`C&&$:.$VP0 M!L!6[K?9RT0`J'CK*=RA3UR]BD!H`_2\ZZ7NO<*PDIXX1`21&55E)F7#V_.-\) MY4<<2O"G2HI?"756*O5<1[,+$_LNW:D(U%(HHIP50B%%`&`UNMRZ">G)'AAV MBK.W%4J>]?SZW5\<>_=;4_)W:A^T,U59:\^<]]99+PALE(?1*O76\)C)>#/J M_+(?T+^`6<@MQR$I'_/_:NK;EM'%G_HRW<+X^XSDF=9)QU9FIJGU"* MQ=C:<40O)7O&Y].R\%940[C9#8+B6>9MNU"[IQ'6B-[1/V2PZ`54(* MB3@##BD09:(<;><<8F@$CFY/FLT)@#T.[',&P&*I-.50Q^ZIL!`R+VP]4D?Q M"`H,]J.X-@&PQV&;Q0(]*]7?Y;R(_UVTI<*A-L$K!JQ,1^1.DCA,)[3?`@!- M;A;3"_+E^N=#AP`/>[:U5#>CI"67%`AB()`J>V5C30RE[,7 MM$P/RMG+4]F@][BKJY55M$22ZSJ*VN8J]FVKH%D42FD9_2=K+8I[7,VW)RZ8 MY]X$7.`IQ:"FM#O(AZ#5Z^#4`Y%=P7AI-(G[7H:99$10`,AF]!#([-=S%[CO M&Y0PF?CV&*CX%!N5U>QL"776?__YR%P=>UL%CQFGS'CFH4%1$Q2RS=ER=!6E M.%M"G3=XL.UW/7*(BO-J:E*R=8ZZ\)GJ=Q4C'WZ`S/238COAZ\M>'E,!V-KE? M_)I2V*?=9?5T,(][<^.@F+-4IBR\G%#&)&`;JD6I-03\YYC%K76_;Q9W!?`P MYWJ;0?]15G]NG96C.;6_=>#8:T4!P2G3J2)`"@1KF=-]RIB\T!Y)U1G"@[+* MQ\WL(JX6::]Y/*OVMP[1,6:"<$N,1M0PRS5SM(`"9)Z.Z8^F`!P<>GW4(?;Z?W:X?XI]E M)M?CL,7GI9I/S>1AEDQU,5D4WPRMQ>0^KJ,@-%``"&HL="^UI$82'RJ1'0TY9#83FU&_E@T",J/Q$7XI_4_"F"Z"'G,]^ M,O\X*ZH5$F<](#K7')?,:\T08DXCQ1WUD/"4>4!RAXCTC=E?^E[3HSOY4%3+ MYX_WDWF2Q_WG<;:ZEVS_T/QP%\%*&%CMO*+I`BG7*@+;LRD9Z M"';IQPC8;'[;^`+L^P^#X0QY[^,633*1\H5R+VM)4H6ZY:*=%76ZVAQN7Q/\ M^IAX??5E[2[MBQD]U"9HBB2C!D=0Hǎ+!%@XD1G2!VZ4"RW[@'<+DJ*J8 MI#N;R;U;I!)\-2P'#,V^)A$OH;2&#%&5++$&RIHM7H;EDN<"S4L/Y.D8W0[, MR:(F;[UNMC0I;]L%[K@R!M,X>F*=<(+`[2Z/$IV;Q/8"+UN',2LG0YQ%CZN' M=9W:U2'=E^]'M(\:A]H$;X!`3E*K-=<0I>(-=#MFG'W">X%QN7W1HD-XS[K! M/7PA?ZA94%(((#0E#G*O!`"(B%I*`[-)1'\*$O6`<&9Z@E5YV%7^[2_K^K_S MV_M$YW)[]'FSOHR0V5?GQ?3N8_XPV4PE!:JSC51'L+-$O%)*''TG`J=/.FOK];YI>*TDV7 M33N^#E919+1%<5=-,).",8]JN92$/^^]4FN%[[A=/@WD(78@GQX_+XK_/,81 MNJ?-J6+#M=&>%H&JE/L11O-H!),FRL?2DPJ+%20T&J_Q$.@DS;Z^?>P$S3,Q MI?'^9V^;8"Q$EC,O-):4(BX)K>5+Q]ACNE@\59X:VVER0Y+N,"3U2[7FES\!M-_HWWXYJN0'N8021TVT"(ME?*D`RG,0I'%MV=T@ M("8L0(8+:#7R4#@0)\!&,BU`;OK>"[0AIRFV@259:`ZSPLQG995NO)IK3KWY M-AB@@$-Q;>UKG%)SCW7O,!(C2[7EA-A')H4C6O*VX\#U,1"XE3<1'D. MI,-,@%HBIOF("MCD*_,`*[)0'&B_,2WGJTRWGR?S/Z^^1%T4TS3D]^_TU77C MVM*J?8AK,5$IQPRQ0"M/`%9R(S?3`HZ4/<U>I'-HAZ#4]Y;U?8MW,7M: M!,VU<(X:R+263EE)):EEB_NX$45Z=;D:=8/F\$SQDYMBG5"[-55>F@05=UX* M8B>Q-1!9+##?S@/D](B>Q9RLWX-\R89TD-4J"GOUY?M3HP^3O],U@BZKJOQK M-K\UDX?X?PX^CSFFFR`Q$8A`R2#P*:FCC`Y#C0)4V0\C+OYB]W1B]0CS\-:I M+@:0UM]/Z=7/]&-1W23%WK:/:SS42?"8QSVF1%1Y#)".NP6`:P0PRXX_.OJ^ MZ"GN-\H?C&J]P7Q91$N_6U^]KN]..R'>ZTX#400))X&EB&!OL1&6;:(+%N3$KI[.;CY/GU8_5;'XS>Y@ M,J($85Y%IQB#V@%G+#I78W4CNR971P!GO3[[?B37Q4,]AO)IMHAZ68_M*NY= M_KB;W=Q]7*ML52NG_%(;XLW`XQ2Q1;H4B/A,=]"KWS\8%$;""`8T8!)+YP62 M6[<*6)9[-+4LCPEO'W^>1K62UG_U=,ZXI/K8WBCK;!8&`4HLXH:*#U M*BL$5D@@[#:9ZRVP<2EJXG!_TKX>\7RZ2QEM MLNYF]!:DY9`S@YQV6D@+F!;G/KL9$>>Z4G_9HUX&><6SDIE+:5A?BSLZU#=._;?':&;E^9J_?<_E//B>;VA M]H_SZ7Y6-#<*1$6+KK@UUF@D/.+$[A[!W"< M73RJDQ`=&0FX0E1!HHC2@'A=2X61RUUH+S!;3#_FKT^T.^:0^A)!WHSGM[NJ M?+R]\[.GU8]-YPPG]!G4^C:2&B>8E<`;XW`M,Q0R-[[\`L-ZAV98Y^`/?&_T M_L`;O:ZZ#EHB[JF&&$L%)%0&ZGH#3:BCN?>6E^9)_&!W0;GZR3Y;?3VXO2-3 M=6R5*1?[BPAD]QB$@-&5(P9"2J"WT''(:WFYY\-E62I3JN\+Y&,&-5Z?W`ZB MFLZI^&;5^*4J%XO?YU4QN4]C_.7`_>2I_0;HJ1"6$D0IX`XA+B,4&]F)R'[' M.AXSV2,M>U!0_^1\&=[[.-C5B#LAYXY^`X!Q>T2H)0HB0J@&S/JMZZ5]+CG; M.RER34_WV7XYVH:?..'H($C^95:M@_&/(V:K#X(T&W'KK$<&`4<*T MH5N,(P@_OF-S>73L0S.#!L:N=MOCBHNE'D.&K`#4>R,H`L3[31@RU$PT/BSJ M1]HFVGZZBUN_5/SFW?RI6"Q7=RXKY;0)D3^]\^`QL-HK1XR7#*4\*U36J#'+ M9T3;V@=]&8GKI9W1:6J*KW+7@WS+.9A-8IW\SBJ(M5\^_NA MF"^*-N;A<,-`'0,(2N!U*AP%H%9:K4&.OX7J3&7"5H/^M9RG2G=17?/;UP*T M,0/M.PF6KAI?=9[.NZ?)[< M+Y\_+:,[LBLQR3'-@X2>`.!\E`!R!C4UT;?>2".$/"&;UUGF6FOEE+UCE>7L MQ1'<%,5TX:/@ZV%MAG`]N[U;[CUO:&@6,(1QK%0X(8%RWKKH&M0CEPB.)5BZ M(@IHS[;C^$UAT!@;HH2D'@IO$)!>ZUHV8K)S7%\0CWI: ME;H%MK?M7IPWT\>;Y8;BBV_JUK?Z]I/9_^ M\W%R/_OR'`VDNEEEA_E6Z0WUT(_J)T"A#`>&(@8%-Y)'(.P6"^)&4.BZ&RJ\ MR=#?'\A#[(E>QG]_7_XUF=\4Z;SU.NJR>EJ_\VVL_]&F@X"5M,P1SKREUDGO MM,:UY#B:J1^?7CTS8B_O.H3]_(1K45>DN7DPA@KDD;3*.Y22^"CB-E)+*^R( M:A-U38.C6):%]B"OV>K1^K+ZK9I,B^OBII@]K:YKF]^S-38.D`IF@='8"6HI MUI;*>M)*C?2(*J-U2X#7[]JZ1CKKZ.FZ^#Q9%@MS-ZENXS]O_DP2ULGX&H+I MV[0-F"`;M^.K\)ET0<*CLUS+D(H@C.>PH!>V]`7TT(8H'/\R6L]N5D!N:-[W@ MV=\F",P%E`8Q39QGCL8%WM=C%H;GWH=<4"!;_\:F0X"'W5$?=CC>MRBC=71? M`8+T"DD1H935!BHI/=H:79E=U>^B5[=A'+M^-#`$(S^43\6Z>L7A27I=WM]' MT_O7I-J50_V$WH+S$AOE@3.`0XH3^_ M^5+3?S]NPJ.S3=@W?03H,94*"&(\`E@RS1&MY<=`CLC/O!P#EH]_#T9LY16O MRR\NKJJZ](EYK*H#T5@G=!DL%``2JU$<)R7:5UJ MY?QVL*MM'&;0(RT\\-YQ(%F4F]1R0]5<(J2KFG+K;9R;3W]X*O:)_X#1+%E/ M__H-9N&(QVE*N?=(,D&MPG#]]@I)RB7NOJ3%8<^S\?W=";T%R+07BC(L(LU] MBD*F;",K4PR/H(!%-ZK>G>"E1ZA[FX+1,BRKB,5C%8?Z?C;YG$I!GZLBU7># M69FM^[194#?+V=,Z%TGS6YS6?:1D=5!Q`J$BD#M"+)&;)U#:*$$:7Y>>"8-V MX:*G=!<<<9)Z%7?"G&)OK828U,@`DYWHY(+,0(]L*0=7P.#&X9R/](:U$=HA M#D7$'`B.E+'.4KA1!*2R^4EJ/QB\+#E[)$FIFO:6NLKH)1`GK%0JRDZ(LAHH MZ&I"IA$2^0]Y!P! M43^_]N[LAXWHT@3PUYICT6 MH)$&&HVSSJ\/J5%K+DMJL4_U^FV.;C;KJX_%*A997+SHP?$-.8??*`C!(H9) MDG.C*&!``$\CQ:@)G*IH36.K+A#-8D"8+3_.RW5:#CNN^#66=G59W7"RV(MH"")`$;!E(# MWKMJ#JG<@K(CI$_O[D8[D&?9DW?I"'ZJ7G7(CNP?**)AHUH+%ALQT<)YI:IR M-W&^#&Y"_F:[REFU@&;FZ8%G8LQ^$H9M>W/]X>O7^57YZ6YV5?YK]N?\]N'V M8[F^2IJZ*3_'_Q\^8-!*\X6F/LZ8SEJ.F!"$$>_\'DBJ)E2PH#M>#:.+;ECY M_B'-LJNO87:U7RN[6MW>SN_3OI<&?#S5<&&I%EQ8'[A6'!2G-FV-?92>299[ M+^$(MY0,R,26M9#%P<<^?/BZ-\?S9>KD(68=>+SPB&"CN/`00((45,D*(!*M M>>X6I!$>:.B.+^U@V\N!J74Y2R[A;.'OH\[*C^M4(6;SXXAC?>B50H*-$2+# MR@F@43C*1"-$9<$B3 M:/^94YX9A+S"PG`D,1/AY`K$9!*)#)#FQ%!"0!(2+->XP@%9.:$2$AUPHTDB M\2S<+R>1J(04(G!O(4A*$8I(ZDHN'A&=#I\ZT7:M1.)Y&%]6(A$1&M)]T=X1 MBYC006E9R>:\FM"!QH:ZK9E(/`_/X1.)C#-MM"&,!$.9=I+RRO82S]R4$\GG M:JQF(O$\1/M.)$HM-)4<)/(V3K=82Z2JWH%V$SKTUZJ^FP+9QZ2PK7U;SRJ< M>J70DE&J`HDQF?:@P0GO=M)1HFPN3<:^FMJ`)BU#.I7,,X`!(1TVADCB&(DS M;36_4NJS2^:-T-[T[I^V`WGO1-OUMUZ-CA-O%CZ.Q>BP&0XH0JI,'A4!*T6H#4Q+;JE22CJHI!(]KL7T54RC-2W78,^9 MX/9!F>KP<13W18^/T.;0*X5F*%ILKU&4+`CKJ;&ADLYS=;)2?N-IK>_CY%UQ MIR6$F^]FV,GTJ=QL%N7UO^>;[76!V\JA=YOM#38/<>:>W1_,!N6U5DB*C&=4 M22&I3Z<@%3>5G([A7",T=D^[!0KUAWK_SOBV'FE]Y_OQ\2(H!,J@&+$$+YSC MA@JVDXHK`KD9QK'O:>AJ*LN#]5*\'P$>6265I40;*3525E12(0^YAF>D-2AZ M]7W.@[;WM/.`]TOWFW16&GQ`4G,I/9&"*%"[>T2-,QI>5=)81(JQ00-9;(2)D<;JL9+,QYIL.?QKJMF;2^3P\AT\Z M`Q'1;:;@B'*$48.4K@Y>&>E\[NK))>C_7(W53#J?AVC?26?#;`@`R"/E"3$( M13>[ZAUF)G>\CS`)U*J^FP)Y:4EG"%(JT%1@3)AB$:3]QN]T\TJNFSKVI;`& M-&D9TJDDG2GG3DAO/1>$Q@C<.[J76MCL-=41VIO>_=-V(.^#:`>@V?7<_$B7 MV'WXFN2I4T9^:O=NBZ-D7J1=PM0M_9"MRG M3>R,2:=W[>HV77&^?7]WV_D@"W!/U?829$]]>FXN/GV+2O^2>EUEYVJLRC5K MN&#$16;0="D?,@P;:?G.@06J))S<<#8P6N:Y4'7L2<.6BP#:,(^8408[QKG" M0E=X!8ER*WJ,T+;T1:S5D`H:Q@(-6<=RK(8(B"%,:FM!!,<4TL$AA>-,!4%; M=CHMUK4S\\2YY\+!>CU;WFRKK-^;'V]X"2G'53^CT/`;!38.$^-"X,(+:[2Q MTE48QC!U0KOR^B+;09>H7U7ULDTKAL/O9[>G[H=__EA!)!8$8QX#'`X^]MWQ M4$E!&9G0@N(`FG^]8RL?^#[I7XH^]DYA$7488VH@!I_28V^`57WV MED\HBYFKK%4W4/9A!OZYC"YP^2D5%DEV[UW27M+3\4GER%N%QZ"001B<-]QR MPC"8G8P`"$\HB3'\'-.>'@;DVLD9Z.A[!>%&0Z`Q>DG4VHUWBXT2X>!P&H:F"'> M`U>5C3;2N0D%92WI_FT:I&6,\]R@.V(DW'NUT`T"=X282LY,)U2'G]X3ZD)\KUD8;-Q>9)L>5T[J._B+U8^RW$;&CV'Q24?M MX#L%<.F"X-*G*A$86VM#Y3HX3VUN/=JS2?:]7']9=6TV!R7(JAN59'ESU<>W M.QOF5YORN@Z;ZKY:1"=40PJ;E"`V.$Z#EY4$4D)N4>P1^FZCH%1'>FG$K.W' M/S[$P"4*GN2KQZH#K\6>2^ND""[0`()P1Q'?CPFOIN3;C8Y1[>AD%%[?(>C> MU=@"VKSQPC`:)$OW!@%AZ4AFV$=:#GN9NWMFA`>EAX]0>E=7WK+*SWNY6%2+ MD2=N3Z_[?J&UT@*KZ%''[R.//!%J+PNU4RK8VJ/B5]VKHC>[^>4T9%]>0_;\ M\;3I!)^RGZU\I$#86\:8IH8"L@3;8*I,H@]"3B"%VA&C?F8CAU!)KW%RN?Z> M;C`Z`6;:YGVUNEG._Q=%W=:&V.ZBLK.[^6:V2'^%VU3@OTZ4W>X7"\&T#YXX M4(AX3#ESNEH0\3CP[E/`?55]ZH?UXU!3+^OHCT+$4/"G,KXZ$/"S!?9:#131 M_V<(!6Z=W*RW%N1I]VJ=C=6-VR[` M&L6H\IQ9)YP6@4NRPRLB:7+7."]Q.:I]WW8_Y>9I'FE*]YQO%A#!9!%CR37!&&O%-53X4C&ER[M[Y&+.*.A! M>Q<].AZ]K&UISNV?TG/'(LM^.U(XPX%AX!P+A"2A$"?[K28,0D*)W!U-(YQ. M)CB.VE#IJ)>RJ\LQX?IZ*]QLL7WN'AXVWU;K$Y-/AU\MA/6`K426&"D`2(AD MJ#`.P"=4<79`+VP\"AST:.DP5QN.]6RI0HZB:-)`@@N6`A&:*ARHMD(0;4ZF MXSNRIZJAIO,7QO8 MS]%$K9]MVDBI]BBJ_[-<7\WORX_KZ`C]GC`XL2NV@Z\53#)OP1`3F&4,"XUIK#^]3?R,?$6QDS-^@V^EJA//:$6>'!Q7@<&2\$5)@& MJW-WN8UQ3`S)R/9&1TN:S-L7]^;;Z6((MUHL9NM[K'[3=+/:_4;0;PB=V"Z7 MU5HA!;<\QN+2&)+"[V#2Y7*/2DFD]^I_'8&-F6IMIGI'C1,]60D0=;*[RG2G+&P3J!X\0@ M4/"5G`BC"5VO=!F,;$M3[3-2O>@91@TI>;BY0A%OL(H>NP9GC>2$HU!)RKS, MK1)Q]BU.OSC9LJK:)^6V,\_ZEA7>U&NOX-0)AH1SB&F*K5(J[-UF%5CN`0OQ MBY9YM&Q/5QT$W2]]74S9;T(W";L/MU<$+SQ1,C#"G.-6B^#P3E;I",IU*N4O M7F8&WJWI:M1[`=[UW\6%J]R\\6W"%BO,/,(,5`&T=EY79)PNB4,F8]4K++9$`S M#5[<./E\=S?$.'GUV2($YH(B+*+-L0/F+5$5RD#(E.I;3F2<--/@Q8V3:F?< MAX?-_6:VO)XO;QZ?[V@/QCD]*#!R@!T6F&AA(C."QWMGE6B5FX.^F-7JRQL] MK2ESN(/AF9*_E?C?Y?SF6]J__;UWH#]<4KIKR9+Q-,9A:; MNRK/KP$Q3#<+ZX)UA!G/F-(F&ER0=N^W*#/Y',8$AVRK&K]83W7WG[3.-)"G M^K8'A<6<\(!P0-I%&A%E^#Z:]ESE3I`7DYJY7$^UL3(O;@)\*_$Q.]/;A'=F MMPHKD,")/B"`!&F(9+K2DE4F=PGR8K).ES?!=:OA88[D;?,=ORY[?'Y&2C(1 MD/,$O/1@`%FKE*'!,B,E5O+D7-CU@;QV*B2==[]UR]\L+$^+CPJ`:T2#IP1) M5&',67^%K4=_8*\V&0\>V!M6=7EU-W>=7WW]O%SO>_-S6_[[*37DGBUSK/@77V\,."" MXB$P+!G(.)(%@0IQ$B#W(HP1)CD&-^4CT>$I3_7O?TL/)Q#B+_\'4$L#!!0` M```(``.#7D?^PS$`TA(``)O0```1`!P`=G)T>"TR,#$U,#DS,"YXYF$W@QS01C]!;O]7M7UQ?'_SMMW_] MEU__K=7ZQ_GCC7?)_&B"J?0N.$82!]XSD6/O>X#%#V_(V<3[SO@/,D.M5D+E MQ4\O(O@L_#&>(`])R3HN-WYT#X[`9E`2BH^AX3^ M*)1\&?#PD/$1E&R?'*F?!TC@M#AEE$83,T$@^9&<3_$1%&I!*?X_',4_YHN2"FD)%1)1/Y/V944[SR>Z=.?L[.Q(_YH5%8&I M(,!VCOYQ>]/71CX`FWN>MCJ93!F7'EVQUA")@2:-1&N$T%3+VVIW6B>=`R]N M*S?,1U(WSKS,1L(C'$J1OFDMH`Z!AP/OJ"8_G(58;(DAC;4Q1ZKI;(LCC;46 M1U4MJ82?51+U5RNE:ZE7K<[QAFPLNF\]-E*ZK;!Q=H2XK\P-EO-E"[],0T21 M9'S>@[_=6`LY+Z!<+4`4CV>*Q\['37C4T!2/E/MVYRE/M5U&:B@FI=B<`;,+ M=^$C3WD7$VZ3G?58V8`/\S#BV(M2`E7SAYIU"NP?CMCLR&<1E7RN7-2)BV\S MT:5_M!8@ZW(3<0Y!D(8]K<5.GC#[J[6`69.A`)/:O*0TZF%S#O"+/W8>>5:( M]--:@TT!C]`9%K)V(\F1)<^;-Q&*B*^'XDX=3A94\6-K`;`F'X+XM;E(:=3# M%CB04UZ?A91(/U4Q@2AE4B/I=^G;Z930(4M>P4LUAG].!_)'//1TO/HY&46K MH]JC*6=3S"6!X"HW!=``8XZ'7PY4.-Y*0_%_^B@\A#@X+;)203'$T.,5D/A1 MJ,6X63"9(BC__>5`@+Y#G`K_TZ4*\+"N5$!"*&FR4"$:U!4*2'#85'FF'->5 M!T@$S*/7:WL*X0E*>`0F?%T?YOVJ%>/@7HXQOV`3`!]C*L@,WS`AKBE,60%% M47U[O#;/:#53KE`9.RE#BR;WVW&G_:G3;GLM[Y((/V0BXAC^R$%[&MLK@'M_ M4?!_]>(*?CU:1EVN,!+`(OU-/R^K,J%.BE11+O5_=\)B%S/3)6]36VW!A)=8 M(A**+5HR1:PTZ&G[TVG[>".#>G]):OKKWK1&0SRA08BW:=D$L-*P)^U/)^W. MAH:-*]HYNYXC0<3]\"$G2)<&H#LUVR%T],!"XA,WDSIC6?QNQ^!W-;;'AEX> MW4,T\!;X7EK!WHAFQ==PO'4A+9ZW8_"\M4RZNY[7U1*OT5/=>BS$C\>K_K>F M>=.GG;/O!0MA4L`X<#+#7FM*2=#EA-;?.RIP<<6P+P\VMXFB2)J>%`K MAL5EGIZV3]PMM+O^L53/=XC'+[=AM!4PN_56!KP*ZV7P>SNNJ-Y]3F&#L,PB M3@VSB*H>MZ-3!IA&38C4.H"@X8+ID1Q3U]BCBKQZT#H^-@Y:&9P.+@J`>]-D MJJCE!*THU=[O6$7\M0RURVZ/!I@".3P(B($#M6!QCD*5N=`?8^P:!UI1JDP& M_>JDK?M6'W2I_9NV6`+JY5&]!-:+Z09S6+/C\X]U;&$A6]6TM_"2+>ZGF&LVMV/:')S%IITU;;JH86_+ M4N5?`,O'6S9HC+FWZMM9=3L!DPNVS,^C`;!"1`'%U3B4$1S,4>Y162C&\W*`NV:<*\0I M-$[Q@+ENQRX&6:&Q[$5],"SKI1@>@,0]:-3EH?:&J+=37DEO\5D?#3ZKQ"R[Z[B,"G;W7E7D%A?VT>#"2LVSHW[L=QR, MP*6[6"(M6NVK.FV#KTI(=U2Y-;S1$D6U_^FT#?XG0=A=?Y,HP-W#%`FJ?4JG M;?`IFDR?(O;OK.%[?XDC.#+TERYC7]#FNZAE,Q4%DRA!49CP%[2GLW37;+>(_0'1P M_GWL1YQ(QZC-2&?9\OC%X`(7.-X":&^$6FZOBMRRW?&+H;<83;+O(7GMND=J M%=26K8Y?#"%;B6EV-'C3MW#4/>&\2F0)W$RW]L3W?^SRB>85-=;P5Z6TEJ'] MDR$N6[7$[GJJ!\Z"R)>/&.9U$19WV"GET4!E&<=-RS`)BI?"_(<'0'L#U.@5 MY<26,=RTZ&(TQ[YG+'3K/H*7TEK&;].22XE9=G3\?L1"3FPO4'"NG,1&T2U+SLVI3^4FF=W_9E%RTY'FJP8=E.M MW"=C-Y5WO#=6HA/W(%8IJ*F-&&;O79WN'+1 MN-.8Y09DM]W*P.5LNQTW>#+` M_$!_8.'+@;444?>8W@107U$1HKF*V?1],N!_N+79R+QY,"+[W6/OV#V M.6`31.@U_*!D//#B@E/,"0N>=,$@XLEQSJ,:DIT3UGUA%,/_PB>8^EA="EV4 MRU+F[:1:2!$)0K$07?^/B`AMA.SJ*ZF.#9,@.3VN;LC"W"YY+;4=HEG.&131;Z0 M+"_-[V0TOJ+!_?!1+3K7UUS]"OY$RKMASZ^JNV7\-U)=J1.Z>+SN/SP^C4&> M*08V_"7'6O%[`UVJNA,*.OTM6&$>;T[V(AHLBV0IU`"GJEA4_]1M"C,4XOBJ MPNX,0C[%6H_Q/LIOX69'V/(RK@NPCOSQFPFH5"(^7U;`(+Z(#:3',"ROW>U- M0I5*U)TP+LG_J?!.W;51KA9GA'>IER$$006I@%4AOE&.4:AD^PKMU44[CCBO MJ".?X^!G*6DAE[I]3(NZEI+,.$UK2.7NM.3"X>Z(8_UPJ?U=IAKGXDUPL27, M7HS5$QM>Q%?7/``NE^P"YCGJQJ,G#@'F$YG@!UTA&]XQ&!/Q(X;6`.U3,I7# M1V@N@OT)]:S?GE)5O9XZ-7'2=SO8 M-%-!^0Y[VR,9C:5D-]#BJ7BGC MO`^L0`>'I]?R-%NIHW:8_#="!Q#3UL%=I$T#Q_6GM^:?6AF_E)X$;=B[K]U<(.$N-3U47Q)1[(W/G%"'>'$O-[BO\'IC)/8V!O-.Y!1U9_KDB]$<:[TLIW M(L>$)B*YJL%,U$2YY\""WR,#S@01/0:35HV2WP]5MU8E@@;9L+VDB8UA&K!@ MKJQXK?U:/*6?QDL:#S`W(VI(CH/O^QGFW\?$'R>?Q=6;BFR87OZ>KH,0E=>M MHW(F[;S M:["M6$BI,U6?\(L\#YG_8U7%544W&+!D"K/]\;SJ6QK=A"B3TZUL\Y8A+GDT MNH!YA?Y:2WZ]P?1#`Q86W`0IIAJ8?VI@!'DUF89LCK$^X41\_?D>:-KQHD8Q M2G0KVF`9-;MI@/(`?LDL7WFQ)LI62"GAQ_/E@1>G_[=:>/3X=E))HP2 MK5U'%Q74[T(3PYPL[:)=G73A3/_>M%%LY*KNF*BK)&["NE\V/U1>>$"%U,Z2Y:BW8HV4,;_PC1`85BX*:(H6F6) M!G0T?25OINLX\>M^&%_4F\I@*?.JN6'K2"%2%L\C$JJ$OA))C.6:(HWQ/I-Y MU_=YA$+3J=3:5&]]8%(SK%(H"A(D+YJP-Y+DQ89Q(M,08X%H,$FS9Y.=H*QM M.9=N<&I%VB$,YY;3/:P>XUU_3/`L7E`>7F`NP1.IC#YQHU)I58D+!@.M+]7# M9*IV%E,EO68%#>BY!=^8)?BM2+_Z9;T=^#Y'.=/-&R$T(0. M'Z]JHE#?KCXL#A:ID)8RC1!#;1SE[JN*=XST5:>)#!4%&K?55QI\/2``H/VR M6RK*?VY`V/7`F8]Q(-1*EO)L]\-D*UTGXF=CBKU8XTYLE)NK>$?H\LY6^<]O MMIE5QOKB;IV5Z:=3R6;.-Y,\N(NQ.O0Q0/X/=3@_#1F7DLD\6)UY8TDQX`ZR$_N_'4AY"="+797D,G#D!O%_J6.HEXJ/V=S,"=2V75;.\Q M&7[[DF.4S5O=BSUBOMAJ9D:[#K)GR\15GJX6<:-]FU62 M,F_F3-@`_U5#\'XTF4!X>C_4UDLBFR?V=\2)DB)M[SH-,W72:W2Q3:MYT^YE M4&?UE,FFI9K431->[3S'N;@T^.\(A60X5PG8?CPOM@E?D[I9PK.ANE5%UD7*J'38`:.M9@/4)^Q33)[.\&$T*)*JT:=R),<86E)DT#5UJTY5;N MLNZ&H&-C:GN-\@T<1U7Z,$R`X]T!E3]\W.Z<+)FTNDP#35@1.1* M9Q`<<-7P%LDQBQ5R!6).5/A#Z!UXXQX1/@J59C(--XVKQAZ=6H02Z@(>A:CO M'8\7=D5V>C55K'OQQNTW.8JLTP`"<:ZC37W;HEI>@:ZQM,JR4-.6T!KI)>$WU3JT0:;(#B)O+=[A6 M5VJ,"`#JG?9U]5B[EC?7;_R)#0&1_03!G_\/4$L!`AX#%`````@``X->1]^> ML40G:P$`LD(:`!$`&````````0```*2!`````'9R='@M,C`Q-3`Y,S`N>&UL M550%``/ET3-6=7@+``$$)0X```0Y`0``4$L!`AX#%`````@``X->1_._.DL) M(0``T%P!`!4`&````````0```*2!`Q0````(``.#7D?#?M`] MZ4H``/N)`P`5`!@```````$```"D@`L``00E#@``!#D!``!02P$"'@,4````"``#@UY'8X0P MVTW/```#@@H`%0`8```````!````I($"V`$`=G)T>"TR,#$U,#DS,%]L86(N M>&UL550%``/ET3-6=7@+``$$)0X```0Y`0``4$L!`AX#%`````@``X->1_@Q MHO7L=0``U+P%`!4`&````````0```*2!GJ<"`'9R='@M,C`Q-3`Y,S!?<')E M+GAM;%54!0`#Y=$S5G5X"P`!!"4.```$.0$``%!+`0(>`Q0````(``.#7D?^ MPS$`TA(``)O0```1`!@```````$```"D@=D=`P!V XML 70 R38.htm IDEA: XBRL DOCUMENT v3.3.0.814
    Collaborative Arrangements Narrative (Details)
    		 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
    Oct. 26, 2015
    USD ($)
    target
    Jun. 04, 2015
    USD ($)
    Oct. 31, 2014
    USD ($)
    Apr. 30, 2011
    USD ($)
    Sep. 30, 2015
    USD ($)
    Dec. 31, 2014
    USD ($)
    Sep. 30, 2014
    USD ($)
    Mar. 31, 2013
    USD ($)
    Sep. 30, 2012
    USD ($)
    Sep. 30, 2015
    USD ($)
    payment
    Sep. 30, 2014
    USD ($)
    Dec. 31, 2014
    USD ($)
    Schedule of Collaborative Arrangement Agreements [Line Items]                        
    Collaborative revenues         $ 1,546,000   $ 33,502,000     $ 2,999,000 $ 40,846,000  
    Development milestones discount rate low end of range (percentage)   4.10%                    
    Development milestones discount rate high end of range (percentage)   5.90%                    
    Commercial milestones and royalties discount rate (percentage)   6.60%                    
    Intangible assets         284,340,000 $ 29,000,000       284,340,000   $ 29,000,000
    BioAxone Biosciences Inc                        
    Schedule of Collaborative Arrangement Agreements [Line Items]                        
    Up-front payment           $ 10,000,000            
    License fees and milestone payments (up to)     $ 90,000,000.0                  
    Purchase option, term of extension of expiration date (in years)     1 year                  
    Increase (decrease) in fair value of contingent milestone and royalty payments         (600,000)         (100,000)    
    Contingent consideration, liability         27,000,000         27,000,000    
    Parion Sciences, Inc                        
    Schedule of Collaborative Arrangement Agreements [Line Items]                        
    Up-front payment   $ 80,000,000                    
    Prior to marketing approval, time period of notice required to terminate (in days)   90 days                    
    Subsequent to marketing approval, time period of notice required to terminate (in days)   180 days                    
    Change of control prior to clinical trial, time period of notice required to terminate (in days)   30 days                    
    Term of agreement following first commercial sale (in years)   10 years                    
    Business combination, consideration transferred   $ 255,340,000                    
    Intangible assets   255,340,000                    
    Increase (decrease) in fair value of contingent milestone and royalty payments         4,500,000         2,900,000    
    Contingent consideration, liability         178,200,000         178,200,000    
    Cystic Fibrosis Foundation Therapeutics Incorporated                        
    Schedule of Collaborative Arrangement Agreements [Line Items]                        
    Collaborative funding       $ 75,000,000                
    Number of years over which funding will be made (in years)       5 years                
    Collaborative revenues         0   2,000,000     $ 0 6,500,000  
    Milestone payment made               $ 9,300,000 $ 9,300,000      
    Number of commercial milestone payments for achievement of certain sales levels for corrector compound such as VX-809 or VX-661 (in payments) | payment                   2    
    Janssen                        
    Schedule of Collaborative Arrangement Agreements [Line Items]                        
    Collaborative revenues         441,000   1,390,000     $ 1,620,000 4,262,000  
    Up-front payment                       $ 35,000,000
    Reimbursement revenue         $ 4,000,000   $ 4,300,000     $ 18,700,000 $ 4,300,000  
    Time period of notice required to terminate (in months)                   6 months    
    Additional Enac Inhibitors | Parion Sciences, Inc                        
    Schedule of Collaborative Arrangement Agreements [Line Items]                        
    Collaborative arrangement development and regulatory potential milestone payments maximum   230,000,000                    
    Enac Inhibitors in Non Cf | Parion Sciences, Inc                        
    Schedule of Collaborative Arrangement Agreements [Line Items]                        
    Collaborative arrangement development and regulatory potential milestone payments maximum   370,000,000                    
    ENaC Inhibitors in CF | Parion Sciences, Inc                        
    Schedule of Collaborative Arrangement Agreements [Line Items]                        
    Collaborative arrangement development and regulatory potential milestone payments maximum   490,000,000                    
    Collaborative arrangement regulatory potential milestone payments maximum, global filling and approval   $ 360,000,000                    
    Subsequent Event | CRISPR Therapeutics                        
    Schedule of Collaborative Arrangement Agreements [Line Items]                        
    Up-front payment $ 75,000,000.0                      
    Investment in collaborative partner, pursuant to convertible loan agreement $ 30,000,000.0                      
    Right to license, number of targets (up to) | target 6                      
    Collaborative arrangement development and regulatory potential milestone payments maximum $ 420,000,000                      
    Prior to marketing approval, time period of notice required to terminate (in days) 90 days                      
    Subsequent to marketing approval, time period of notice required to terminate (in days) 270 days                      

    XML 71 R20.htm IDEA: XBRL DOCUMENT v3.3.0.814
    Stock-based Compensation Expense
    		 9 Months Ended
    Sep. 30, 2015
    Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
    Stock-based Compensation Expense
    Stock-based Compensation Expense
    The Company issues stock options, restricted stock and restricted stock units with service conditions, which are generally the vesting periods of the awards. The Company also has issued, to certain members of senior management, restricted stock and restricted stock units that vest upon the earlier of the satisfaction of (i) a performance condition or (ii) a service condition and stock options that vest upon the earlier of the satisfaction of (a) performance conditions or (b) a service condition. In addition, the Company issued pursuant to a retention program restricted stock awards to certain members of senior management that will vest upon the satisfaction of both (i) a performance condition and (ii) a service condition. The Company also issues shares pursuant to an employee stock purchase plan ("ESPP").
    In the second quarter of 2015, the Company’s shareholders approved an amendment and restatement of the 2013 Stock and Option Plan that, among other things, increased the number of shares of common stock available for issuance under the plan by 7,800,000 shares, plus the number of shares that remained available for issuance under our 2006 Stock and Option Plan, which rolled-over into the 2013 Stock and Option Plan.
    During the three and nine months ended September 30, 2015 and 2014, the Company recognized the following stock-based compensation expense included in loss from continuing operations:
     
    Three Months Ended September 30,
     
    Nine Months Ended September 30,
     
    2015
     
    2014
     
    2015
     
    2014
     
    (in thousands)
    Stock-based compensation expense by type of award:
     
     
     
     
     
     
     
    Stock options
    $
    39,074

     
    $
    26,291

     
    $
    105,720

     
    $
    78,403

    Restricted stock and restricted stock units
    26,203

     
    18,418

     
    78,274

     
    51,431

    ESPP share issuances
    1,738

     
    1,883

     
    5,703

     
    6,231

    Less stock-based compensation expense capitalized to inventories
    (1,281
    )
     
    (456
    )
     
    (3,318
    )
     
    (905
    )
    Total stock-based compensation included in costs and expenses
    $
    65,734

     
    $
    46,136

     
    $
    186,379

     
    $
    135,160

     
     
     
     
     
     
     


    Stock-based compensation expense by line item:
     
     
     
     
     
     
     
    Research and development expenses
    $
    44,701

     
    $
    31,131

     
    $
    124,550

     
    $
    91,284

    Sales, general and administrative expenses
    21,033

     
    15,005

     
    61,829

     
    43,876

    Total stock-based compensation included in costs and expenses
    $
    65,734

     
    $
    46,136

     
    $
    186,379

     
    $
    135,160


    The following table sets forth the Company's unrecognized stock-based compensation expense, net of estimated forfeitures, by type of award and the weighted-average period over which that expense is expected to be recognized:
     
    As of September 30, 2015
     
    Unrecognized Expense,
    Net of
    Estimated Forfeitures
     
    Weighted-average
    Recognition
    Period
     
    (in thousands)
     
    (in years)
    Type of award:
     
     
     
    Stock options
    $
    197,031

     
    2.30
    Restricted stock and restricted stock units
    $
    190,786

     
    2.73
    ESPP share issuances
    $
    1,885

     
    0.44

    The following table summarizes information about stock options outstanding and exercisable at September 30, 2015:
     
     
    Options Outstanding
     
    Options Exercisable
    Range of Exercise Prices
     
    Number
    Outstanding
     
    Weighted-average
    Remaining
    Contractual Life
     
    Weighted-average
    Exercise Price
     
    Number
    Exercisable
     
    Weighted-average
    Exercise Price
     
     
    (in thousands)
     
    (in years)
     
    (per share)
     
    (in thousands)
     
    (per share)
    $18.93–$20.00
     
    138

     
    2.35
     
    $
    18.93

     
    138

     
    $
    18.93

    $20.01–$40.00
     
    2,499

     
    3.81
     
    $
    34.56

     
    2,284

     
    $
    34.36

    $40.01–$60.00
     
    2,593

     
    6.80
     
    $
    48.27

     
    1,458

     
    $
    49.52

    $60.01–$80.00
     
    1,567

     
    8.31
     
    $
    75.94

     
    551

     
    $
    74.95

    $80.01–$100.00
     
    1,932

     
    8.28
     
    $
    90.27

     
    638

     
    $
    87.16

    $100.01–$120.00
     
    1,791

     
    9.32
     
    $
    109.24

     
    201

     
    $
    109.22

    $120.01–$134.69
     
    1,505

     
    9.78
     
    $
    131.21

     
    168

     
    $
    127.52

    Total
     
    12,025

     
    7.31
     
    $
    74.90

     
    5,438

     
    $
    53.98